{"c54cb52eaf7d6bdbffd36f0e47b43d5841c2b8c7": [["IntroductionParticle counting is important and widely used in various areas from environmental (Aalto et al. 2005) to biological applications (Smolen et al. 1983; Amann et al. 1990; Yarnell et al. 1991) , such as the following: counting dust particles is required for clean room facility (Wu et al. 1989) ; counting debris particles is needed for studies of lubricating systems (Miller and Kitaljevich 2000) ; counting contaminant particles is the key factor in water purification system (Bundschuh et al. 2001; Judd and Hillis 2001) ; and counting white blood cells is essential for many biomedical diagnostic purposes such as detecting HIV infection (Yarnell et al. 1991; Kannel et al. 1992; Burnett et al. 1999; Vozarova et al. 2002) .", [["white blood cells", "ANATOMY", 549, 566], ["HIV infection", "DISEASE", 638, 651], ["white blood cells", "CELL", 549, 566], ["HIV", "ORGANISM", 638, 641], ["white blood cells", "CELL_TYPE", 549, 566], ["HIV", "SPECIES", 638, 641], ["HIV", "SPECIES", 638, 641], ["IntroductionParticle counting", "TREATMENT", 0, 29], ["environmental (Aalto et al.", "TREATMENT", 81, 108], ["counting debris particles", "PROBLEM", 307, 332], ["lubricating systems", "PROBLEM", 358, 377], ["counting contaminant particles", "PROBLEM", 410, 440], ["counting white blood cells", "TEST", 540, 566], ["HIV infection", "PROBLEM", 638, 651]]], ["The particle counting techniques have been developed further to detect single DNA molecule (Akeson et al. 1999; Kasianowicz et al. 1996) and analyze DNA contents (Sohn et al. 2000) .", [["DNA", "CELLULAR_COMPONENT", 78, 81], ["DNA", "CELLULAR_COMPONENT", 149, 152], ["DNA molecule", "PROTEIN", 78, 90], ["single DNA molecule", "PROBLEM", 71, 90], ["particle", "OBSERVATION_MODIFIER", 4, 12]]], ["However, the conventional particle counting methods rely on costly, bulky, and complex instruments and require a large amount of samples and reagents.", [["the conventional particle counting methods", "TREATMENT", 9, 51], ["a large amount of samples and reagents", "TREATMENT", 111, 149], ["large", "OBSERVATION_MODIFIER", 113, 118]]], ["These are the barriers to many particle counting applications.IntroductionMicrofluidic devices have been studied particularly in the past decade and have showed enormous potential for portable and low-cost applications, especially in medical diagnostics (Akeson et al. 1999; Burnett et al. 1999; Kannel et al. 1992; Sohn et al. 2000; Vozarova et al. 2002; Kasianowicz et al. 1996) .", [["IntroductionMicrofluidic devices", "TREATMENT", 62, 94], ["portable", "TEST", 184, 192], ["low-cost applications", "TREATMENT", 197, 218], ["Microfluidic devices", "OBSERVATION", 74, 94]]], ["Lithographic fabrication technique makes possible building inexpensive and small devices integrated with electrodes and sensors, and microfluidic control technologies such as electrokinetics (Li 2004 ) are able to control particles and liquid flow in micro-and nano-channels.", [["Li", "CHEMICAL", 192, 194], ["micro-and nano-channels", "PROTEIN", 251, 274], ["Lithographic fabrication technique", "TREATMENT", 0, 34], ["building inexpensive and small devices", "TREATMENT", 50, 88], ["electrodes and sensors", "TREATMENT", 105, 127], ["microfluidic control technologies", "TREATMENT", 133, 166], ["small devices", "OBSERVATION", 75, 88], ["liquid flow", "OBSERVATION", 236, 247]]], ["In addition, microfluidic devices are particularly useful for applications where a very small quantity of samples is available or desired.IntroductionMicrofluidics-based particle counting methods have great advantages over the conventional methods and allow the development of accurate, cheap, and portable particle counting devices.IntroductionIn this paper, we review the major advancement of microfluidic particle counting techniques: microfluidic resistive repulse sensors, nanopore sensors, capacitance counters, light-scattering and light-blocking detectors, fluorescent detectors, and micro particle image velocimetry (PIV) counters.", [["samples", "ANATOMY", 106, 113], ["samples", "CANCER", 106, 113], ["microfluidic devices", "TREATMENT", 13, 33], ["a very small quantity of samples", "PROBLEM", 81, 113], ["IntroductionMicrofluidics", "TREATMENT", 138, 163], ["the conventional methods", "TREATMENT", 223, 247], ["microfluidic resistive repulse sensors", "TEST", 438, 476], ["nanopore sensors", "TEST", 478, 494], ["capacitance counters", "TEST", 496, 516], ["fluorescent detectors", "TEST", 565, 586], ["micro particle image velocimetry (PIV) counters", "TREATMENT", 592, 639], ["microfluidic devices", "OBSERVATION", 13, 33], ["small", "OBSERVATION_MODIFIER", 88, 93]]], ["For each type of particle counters, we also explore various applications and examine the advantages and disadvantages.Coulter counterCoulter Counter perhaps is the most popular conventional method of particle counting.", [["various applications", "TREATMENT", 52, 72], ["particle counters", "OBSERVATION", 17, 34]]], ["We review this method first for two reasons: it gives a general perspective of conventional particle counting methods, and its working principle of measuring electric resistive pulse is used in some microfluidic particle counting methods.", [["conventional particle counting methods", "TREATMENT", 79, 117], ["measuring electric resistive pulse", "TREATMENT", 148, 182], ["microfluidic particle", "OBSERVATION", 199, 220]]], ["When Coulter worked for US Navy, he used this technique to count the number of plankton particles that always caused large echoes on Sonar.", [["this technique", "TREATMENT", 41, 55], ["large echoes on Sonar", "PROBLEM", 117, 138], ["large", "OBSERVATION_MODIFIER", 117, 122], ["echoes", "OBSERVATION", 123, 129]]], ["In a Coulter counter, a small aperture on the wall is immersed into a container that has particles suspended in low concentration electrolyte solution.", [["wall", "ANATOMY", 46, 50], ["wall", "TISSUE", 46, 50], ["a small aperture on the wall", "PROBLEM", 22, 50], ["low concentration electrolyte solution", "TREATMENT", 112, 150], ["small", "OBSERVATION_MODIFIER", 24, 29], ["aperture", "OBSERVATION_MODIFIER", 30, 38], ["wall", "ANATOMY_MODIFIER", 46, 50], ["low concentration", "OBSERVATION_MODIFIER", 112, 129]]], ["Two electrodes are placed: one in front and one behind the aperture, and a current path is provided by the electrolyte when an electric field is applied (Fig. 1 ) and the aperture creates a ''sensing zone.''", [["Two electrodes", "TREATMENT", 0, 14], ["an electric field", "TREATMENT", 124, 141], ["a ''sensing zone", "TREATMENT", 188, 204], ["electrodes", "OBSERVATION_MODIFIER", 4, 14], ["one", "OBSERVATION_MODIFIER", 27, 30], ["aperture", "OBSERVATION_MODIFIER", 59, 67]]], ["As a particle passes through the aperture, a volume of electrolyte, equivalent to the immersed volume of the particle is displaced from the sensing zone.", [["volume", "OBSERVATION_MODIFIER", 45, 51], ["particle", "OBSERVATION_MODIFIER", 109, 117], ["displaced", "OBSERVATION_MODIFIER", 121, 130], ["sensing", "OBSERVATION_MODIFIER", 140, 147], ["zone", "OBSERVATION_MODIFIER", 148, 152]]], ["This causes a short-term change in the impedance across the aperture.", [["a short-term change", "PROBLEM", 12, 31], ["short-term change", "OBSERVATION_MODIFIER", 14, 31]]], ["This change can be measured as a voltage pulse or a current pulse.", [["a voltage pulse", "TEST", 31, 46], ["a current pulse", "TEST", 50, 65]]], ["The pulse height is proportional to the volume of the sensed particle.", [["The pulse height", "TEST", 0, 16], ["sensed particle", "OBSERVATION", 54, 69]]], ["If a constant particle density is assumed, the pulse height is also proportional to the particle mass.", [["a constant particle density", "PROBLEM", 3, 30], ["the pulse height", "TEST", 43, 59], ["the particle mass", "PROBLEM", 84, 101], ["constant", "OBSERVATION_MODIFIER", 5, 13], ["particle", "OBSERVATION_MODIFIER", 14, 22], ["density", "OBSERVATION", 23, 30], ["particle", "OBSERVATION_MODIFIER", 88, 96], ["mass", "OBSERVATION", 97, 101]]], ["This technology thus is also called aperture technology.Coulter counterBecause the Coulter counter is simple, highly sensitive, and reliable, it is widely applied in many areas including medical instruments such as counting and analysis of blood cells (Horne et al. 2005) , protein (Kulp et al. 2004) , and viruses (Wahl-Jensen et al. 2007 ) besides detecting fine particles and pollen (DeBlois and Bean 1970) .", [["blood cells", "ANATOMY", 240, 251], ["pollen", "ANATOMY", 379, 385], ["blood cells", "CELL", 240, 251], ["pollen", "DEVELOPING_ANATOMICAL_STRUCTURE", 379, 385], ["blood cells", "CELL_TYPE", 240, 251], ["medical instruments", "TREATMENT", 187, 206], ["blood cells", "TEST", 240, 251], ["protein", "TEST", 274, 281], ["viruses", "PROBLEM", 307, 314]]], ["Before the Coulter counter was invented, complete blood counts (CBCs) were carried out manually with a telescope and static samples, which is time-consuming and inaccurate.", [["blood", "ANATOMY", 50, 55], ["samples", "ANATOMY", 124, 131], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["complete blood counts", "TEST", 41, 62], ["CBCs", "TEST", 64, 68], ["a telescope and static samples", "TEST", 101, 131]]], ["With the Coulter counter, CBCs can be done for a large amount of samples in a very short period of time.", [["CBCs", "SIMPLE_CHEMICAL", 26, 30], ["CBCs", "CELL_TYPE", 26, 30], ["CBCs", "TEST", 26, 30], ["a large amount of samples", "PROBLEM", 47, 72]]], ["When Coulter first demonstrated the Coulter counter, it could count red blood cells at a high count rate of 6,000 particles/ s, which revolutionized the science of hematology.", [["red blood cells", "ANATOMY", 68, 83], ["red blood cells", "CELL", 68, 83], ["red blood cells", "CELL_TYPE", 68, 83], ["red blood cells", "TEST", 68, 83], ["a high count rate", "TEST", 87, 104]]], ["Within a decade, literally every hospital laboratory in the US had Coulter counters, and today every modern hematology analyzer adopts the Coulter principle in some way.", [["the Coulter principle", "TREATMENT", 135, 156]]], ["Multisizer TM 4 COULTER COUNTER \u00d2 (Beckman Coulter, Fullerton, CA, USA), for example, can provide size distribution in number, volume, and surface area in one measurement of particles ranging from 0.4 to 1,600 lm in diameter.", [["surface area", "ANATOMY", 139, 151], ["volume", "TEST", 127, 133], ["surface area", "TEST", 139, 151], ["size", "OBSERVATION_MODIFIER", 98, 102], ["distribution", "OBSERVATION_MODIFIER", 103, 115], ["number", "OBSERVATION_MODIFIER", 119, 125], ["volume", "OBSERVATION_MODIFIER", 127, 133], ["surface", "OBSERVATION_MODIFIER", 139, 146], ["area", "OBSERVATION_MODIFIER", 147, 151], ["particles", "OBSERVATION_MODIFIER", 174, 183], ["1,600 lm", "OBSERVATION_MODIFIER", 204, 212], ["diameter", "OBSERVATION_MODIFIER", 216, 224]]], ["Its aperture dynamic range can reach to 1:40 by diameter and reproducibility is about 1%.", [["aperture", "OBSERVATION_MODIFIER", 4, 12], ["dynamic range", "OBSERVATION", 13, 26]]], ["Although the Coulter counter detects and analyzes particles accurately and reliably, it has still many drawbacks: bulky size, heavy weight, complexity, high power consumption, high cost, and no-portability.", [["bulky size", "PROBLEM", 114, 124], ["high power consumption", "PROBLEM", 152, 174], ["bulky", "OBSERVATION_MODIFIER", 114, 119], ["size", "OBSERVATION_MODIFIER", 120, 124], ["heavy", "OBSERVATION_MODIFIER", 126, 131], ["high power", "OBSERVATION_MODIFIER", 152, 162], ["high cost", "OBSERVATION", 176, 185]]], ["Especially during outbreak of public diseases such as severe accurate respiratory syndrome (SARS) and Influenza, there is urgent need for simple, low power, low cost, and portable particle counters.Microfluidic resistive pulse sensorsThe microfluidic resistive pulse technique applies the basic working principle of the Coulter counter to microchannels for counting micro-and sub-micron particles.", [["respiratory syndrome", "DISEASE", 70, 90], ["SARS", "DISEASE", 92, 96], ["Influenza", "DISEASE", 102, 111], ["public diseases", "PROBLEM", 30, 45], ["severe accurate respiratory syndrome", "PROBLEM", 54, 90], ["SARS", "PROBLEM", 92, 96], ["Influenza", "PROBLEM", 102, 111], ["simple, low power, low cost", "TREATMENT", 138, 165], ["Microfluidic resistive pulse sensors", "TREATMENT", 198, 234], ["The microfluidic resistive pulse technique", "TREATMENT", 234, 276], ["counting micro", "TEST", 357, 371], ["sub-micron particles", "TREATMENT", 376, 396], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["respiratory syndrome", "OBSERVATION", 70, 90], ["microfluidic resistive", "OBSERVATION", 238, 260]]], ["The resistive pulse sensor (RPS) was applied to detect submicron polystyrene beads of 90 nm inside a 0.4-0.5 mm diametric polycarbonate pore by Bean in 1970.", [["polystyrene", "CHEMICAL", 65, 76], ["polycarbonate", "CHEMICAL", 122, 135], ["submicron polystyrene beads", "TEST", 55, 82], ["mm diametric polycarbonate pore", "TREATMENT", 109, 140], ["resistive", "OBSERVATION_MODIFIER", 4, 13]]], ["DeBlois and Wesley (1977) utilized this technique in biological area Counter Amplifier + - Fig. 1 Schematic of a Coulter counter and succeeded in detecting viruses.", [["this technique", "TREATMENT", 35, 49], ["a Coulter counter", "TREATMENT", 111, 128], ["viruses", "OBSERVATION", 156, 163]]], ["After the technical advance of micro-fabrication (Rogers and Nuzzo 2005) , the RPS method has been applied to count particles moving in microchannels.", [["micro-fabrication (Rogers and Nuzzo", "TREATMENT", 31, 66], ["the RPS method", "TREATMENT", 75, 89]]], ["Many microfluidic RPS applications involve manipulating and transporting of particles by electrokinetic flow in microchannels (Jagtiani et al. 2006a, b) while some still use traditional flow control by hydraulic pressure.Microfluidic resistive pulse sensorsThe key advantages of the microfluidic RPS include label-free particle detection and simplicity without other peripheral complex instruments other than a simple electric circuit and a micro-or nano-scale sized channel.", [["micro-or nano-scale sized channel", "PROTEIN", 441, 474], ["Many microfluidic RPS applications", "TREATMENT", 0, 34], ["traditional flow control", "TREATMENT", 174, 198], ["hydraulic pressure", "TEST", 202, 220], ["Microfluidic resistive pulse sensors", "TREATMENT", 221, 257], ["the microfluidic RPS", "TREATMENT", 279, 299], ["label-free particle detection", "TREATMENT", 308, 337], ["other peripheral complex instruments", "TREATMENT", 361, 397], ["a simple electric circuit", "TREATMENT", 409, 434], ["a micro-or nano-scale sized channel", "TREATMENT", 439, 474], ["microfluidic RPS", "OBSERVATION", 5, 21], ["electrokinetic flow", "OBSERVATION", 89, 108], ["hydraulic pressure", "OBSERVATION", 202, 220]]], ["Therefore, it is mostly applicable for portable lab-on-a-chip (LOC) devices to detect biopolymers such as DNA, protein, and blood cells.", [["blood cells", "ANATOMY", 124, 135], ["DNA", "CELLULAR_COMPONENT", 106, 109], ["blood cells", "CELL", 124, 135], ["blood cells", "CELL_TYPE", 124, 135], ["portable lab", "TEST", 39, 51], ["a-chip (LOC) devices", "TREATMENT", 55, 75], ["biopolymers", "TEST", 86, 97], ["DNA, protein", "TEST", 106, 118], ["blood cells", "TEST", 124, 135], ["blood cells", "ANATOMY", 124, 135]]], ["However, the flow rate of the microfluidic RPS is small and the sensitivity of the microfluidic RPS is limited by its aperture size, resulting in poor throughput and sensitivity.", [["the flow rate", "TEST", 9, 22], ["the microfluidic RPS", "TEST", 26, 46], ["the microfluidic RPS", "TEST", 79, 99], ["sensitivity", "TEST", 166, 177], ["flow", "OBSERVATION_MODIFIER", 13, 17], ["microfluidic RPS", "OBSERVATION", 30, 46], ["small", "OBSERVATION_MODIFIER", 50, 55], ["microfluidic RPS", "OBSERVATION", 83, 99], ["aperture", "OBSERVATION_MODIFIER", 118, 126], ["size", "OBSERVATION_MODIFIER", 127, 131], ["poor", "OBSERVATION_MODIFIER", 146, 150]]], ["To overcome these shortcomings, recent researches on microfluidic RPS focus on two main issues: improving of the sensitivity and enhancing of the throughput.", [["microfluidic RPS", "TREATMENT", 53, 69], ["the sensitivity", "TEST", 109, 124], ["microfluidic RPS", "OBSERVATION", 53, 69], ["improving", "OBSERVATION_MODIFIER", 96, 105], ["enhancing", "OBSERVATION_MODIFIER", 129, 138]]], ["The RPS throughput is evaluated by particle flow rate at the aperture or the number of the counted particles at a given time.", [["The RPS throughput", "TEST", 0, 18], ["particle flow rate", "TEST", 35, 53]]], ["Its sensitivity is determined directly by the volume ratio of the detected particles and the aperture and can be adjusted by controlling the amplification gain of the electronic circuit or instrument and the noise reduction from the fluidic network and the electronic sensing system.", [["the electronic circuit", "TREATMENT", 163, 185], ["the noise reduction", "TREATMENT", 204, 223], ["fluidic network", "OBSERVATION", 233, 248]]], ["DeBlois and Bean (1970) were able to detect 90 nm polystyrene spheres, which is equivalent to minimum volume ratio of 0.06% with submicron pores etched in irradiated plastic sheet.", [["polystyrene", "CHEMICAL", 50, 61], ["90 nm polystyrene spheres", "TREATMENT", 44, 69], ["minimum volume ratio", "TREATMENT", 94, 114], ["submicron pores etched", "TREATMENT", 129, 151], ["polystyrene spheres", "OBSERVATION", 50, 69], ["irradiated plastic", "OBSERVATION", 155, 173]]], ["To improve the sensitivity, Xu et al. (2007) and Sridhar et al. (2008) used a relatively wide polydimethyl siloxane (PDMS) channel of 16 lm with metal-oxide-semiconductor-field-effect-transistor (MOS-FET).", [["polydimethyl siloxane", "CHEMICAL", 94, 115], ["metal-oxide", "CHEMICAL", 145, 156], ["polydimethyl siloxane", "CHEMICAL", 94, 115], ["PDMS", "CHEMICAL", 117, 121], ["metal-oxide", "CHEMICAL", 145, 156], ["polydimethyl siloxane", "SIMPLE_CHEMICAL", 94, 115], ["metal-oxide", "SIMPLE_CHEMICAL", 145, 156], ["a relatively wide polydimethyl siloxane (PDMS", "TREATMENT", 76, 121], ["metal-oxide", "TREATMENT", 145, 156], ["transistor (MOS-FET)", "TREATMENT", 184, 204]]], ["They detected particles by monitoring the MOSFET drain current modulation instead of the modulation in the ionic current though the sensing channel and achieved ten times smaller minimum volume ratio of 0.006% than that of DeBlois and Bean.", [["the MOSFET drain current modulation", "TREATMENT", 38, 73], ["the sensing channel", "TREATMENT", 128, 147], ["particles", "OBSERVATION_MODIFIER", 14, 23]]], ["Recently, Wu et al. (2008a, b) developed a microfluidic RPS method utilizing a mirror symmetric channel structure and a two-stage differential amplifier (Fig. 2) .", [["mirror symmetric channel structure", "PROTEIN", 79, 113], ["a microfluidic RPS method", "TREATMENT", 41, 66], ["a mirror symmetric channel structure", "TREATMENT", 77, 113], ["a two-stage differential amplifier (Fig", "TREATMENT", 118, 157]]], ["They could significantly reduce the noise and achieve a much better signal-to-noise ratio.", [["the noise", "PROBLEM", 32, 41]]], ["This sensing scheme detected 520-nm diameter polystyrene particles with a 20-lm sensing gate and improved a minimum volume ratio to as low as 0.0004%, which is about ten times more sensitive than the current commercial Coulter counter of 0.0037% (Beckman Counlter \u00d2 Multisizer TM 4).", [["polystyrene", "CHEMICAL", 45, 56], ["520-nm diameter polystyrene particles", "TREATMENT", 29, 66], ["a minimum volume ratio", "TEST", 106, 128]]], ["The principle of the symmetric dual channel design is to make noise levels for the output signals (V D1 and V D2 as indicated in Fig. 2 ) from both gate branches identical and hence the noises can be canceled by a subtraction electronic circuit.", [["V D2", "GENE_OR_GENE_PRODUCT", 108, 112], ["V D1", "PROTEIN", 99, 103], ["V D2", "PROTEIN", 108, 112], ["noise levels", "TEST", 62, 74], ["the output signals", "TEST", 79, 97], ["a subtraction electronic circuit", "TREATMENT", 212, 244], ["symmetric", "OBSERVATION_MODIFIER", 21, 30], ["dual channel", "OBSERVATION", 31, 43], ["branches", "ANATOMY_MODIFIER", 153, 161]]], ["However, ideal noise subtraction is not possible due to realistic limitation to fabricate the identical dual channels.", [["ideal noise subtraction", "TEST", 9, 32], ["not possible", "UNCERTAINTY", 36, 48], ["dual channels", "OBSERVATION", 104, 117]]], ["Furthermore, this dual channel method will not be able to detect particles when two particles pass the two apertures at the same time because the two signals with the similar amplitude will be subtracted by each other and cancelled at the second stage of differential amplifier.Microfluidic resistive pulse sensorsTo improve this microfluidic RPS method, Wu et al. (2008a, b) solved the signal cancelation problem as mentioned above by using a single sensing gate and two detecting arm channels next to the sensing gate at both ends ( Fig. 3) .", [["arm channels", "PROTEIN", 482, 494], ["this dual channel method", "TREATMENT", 13, 37], ["Microfluidic resistive pulse sensors", "TREATMENT", 278, 314], ["the signal cancelation problem", "PROBLEM", 383, 413], ["a single sensing gate", "TREATMENT", 442, 463]]], ["They coupled the RPS with laser fiber-optic fluorescence technique to demonstrate a flow cytometer LOC that is able to detect fluorescent and non-fluorescent particles simultaneously, and the RPS signal-to-noise ratio is improved significantly.", [["laser fiber-optic fluorescence technique", "TREATMENT", 26, 66], ["a flow cytometer LOC", "PROBLEM", 82, 102], ["the RPS signal", "TEST", 188, 202], ["noise ratio", "TEST", 206, 217], ["flow cytometer", "OBSERVATION", 84, 98], ["improved", "OBSERVATION_MODIFIER", 221, 229]]], ["Two-stage differential amplification is also used to further increase the signal-to-noise ratio for fluorescent signals to detect 0.9 lm fluorescent particles.", [["Two-stage differential amplification", "PROBLEM", 0, 36], ["the signal", "TEST", 70, 80], ["fluorescent signals", "TEST", 100, 119], ["stage differential", "OBSERVATION_MODIFIER", 4, 22], ["amplification", "OBSERVATION", 23, 36]]], ["This flow cytometer chip showed comparable sensitivity for detecting fluorescent and non-fluorescent particles to commercial flow cytometers with simple, cheap, and compact system on a micro glass slide.", [["This flow cytometer chip", "TEST", 0, 24], ["commercial flow cytometers", "TEST", 114, 140], ["a micro glass slide", "TREATMENT", 183, 202], ["flow cytometers", "OBSERVATION", 125, 140]]], ["Drawbacks of the method are the baseline drifting by multiple-stage differential amplification and the low throughput of using single channel detection.", [["the method", "TEST", 13, 23], ["multiple-stage differential amplification", "PROBLEM", 53, 94], ["single channel detection", "TREATMENT", 127, 151], ["stage differential", "OBSERVATION_MODIFIER", 62, 80]]], ["The throughput of a single-channel Coulter counter is proportional to the square of the diameter of the detecting aperture.", [["a single-channel Coulter counter", "TREATMENT", 18, 50], ["diameter", "OBSERVATION_MODIFIER", 88, 96]]], ["When submicron-or nanometer-size particles are to be counted, the size of the aperture has to be scaled down to submicron or nanometer in order to maintain the sensitivity.", [["nanometer-size particles", "PROBLEM", 18, 42], ["size", "OBSERVATION_MODIFIER", 28, 32], ["particles", "OBSERVATION", 33, 42], ["size", "OBSERVATION_MODIFIER", 66, 70]]], ["Otherwise, the signal-to-noise ratio will be very low.", [["noise ratio", "TEST", 25, 36], ["very low", "PROBLEM", 45, 53]]], ["While the sensitivity of the single-gate microfluidic RPS method is much higher, it requires long detecting time due to low flow rate in a microchannel and using of diluted samples to avoid multiple particles flowing together.", [["samples", "ANATOMY", 173, 180], ["low flow rate", "PROBLEM", 120, 133], ["a microchannel", "TREATMENT", 137, 151], ["diluted samples", "TREATMENT", 165, 180], ["multiple particles flowing together", "PROBLEM", 190, 225], ["multiple", "OBSERVATION_MODIFIER", 190, 198], ["particles flowing", "OBSERVATION", 199, 216]]], ["To overcome this low throughput issue, multi-counting techniques are developed.", [["multi-counting techniques", "TREATMENT", 39, 64]]], ["Carbonaro and Sohn (2005) first demonstrated the simultaneous immunoassays of two different human antigens by integrate multiple artificial pores and the RPS technique on a single chip.", [["Carbonaro", "CHEMICAL", 0, 9], ["Carbonaro", "SIMPLE_CHEMICAL", 0, 9], ["human", "ORGANISM", 92, 97], ["human antigens", "PROTEIN", 92, 106], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["the simultaneous immunoassays", "TEST", 45, 74], ["multiple artificial pores", "TREATMENT", 120, 145], ["the RPS technique", "TREATMENT", 150, 167], ["a single chip", "TREATMENT", 171, 184]]], ["Coulter and Hogg (1976) patented the particle analyzing apparatus and method with multiple sensing apertures.", [["multiple sensing apertures", "TREATMENT", 82, 108]]], ["However, it is difficult to integrate the detection circuit and independent power supply of their systems on one chip.", [["one chip", "TREATMENT", 109, 117]]], ["Zhe group (Jagtiani et al. 2006a, b) proposed a multi-aperture Coulter counter, which consists of four peripheral reservoirs and a central reservoir (Fig. 4a) .", [["a multi-aperture Coulter counter", "TREATMENT", 46, 78], ["four peripheral reservoirs", "TREATMENT", 98, 124], ["a central reservoir", "TREATMENT", 129, 148], ["peripheral", "ANATOMY_MODIFIER", 103, 113], ["reservoirs", "OBSERVATION", 114, 124], ["central reservoir", "OBSERVATION", 131, 148]]], ["Each peripheral reservoir is connected to the central reservoir through a miniature channel.", [["Each peripheral reservoir", "TREATMENT", 0, 25], ["peripheral", "ANATOMY_MODIFIER", 5, 15], ["reservoir", "OBSERVATION", 16, 25], ["central", "ANATOMY_MODIFIER", 46, 53], ["reservoir", "ANATOMY_MODIFIER", 54, 63], ["miniature channel", "OBSERVATION", 74, 91]]], ["Their results showed that the sensor can detect and count particles through its four sensing apertures simultaneously.", [["count particles", "PROBLEM", 52, 67]]], ["However, the four apertures are the maximum number of apertures that can be built in a single chip due to the configuration limit.", [["a single chip", "TREATMENT", 85, 98], ["maximum", "OBSERVATION_MODIFIER", 36, 43], ["number", "OBSERVATION_MODIFIER", 44, 50]]], ["Furthermore, Zhe group (Zhe et al. 2007) proposed different high throughput single chip counter using multiple channels, operating in parallel with single common sample reservoir and a power source (Fig. 4b) .", [["single chip counter", "TREATMENT", 76, 95], ["multiple channels", "TREATMENT", 102, 119], ["single common sample reservoir", "TREATMENT", 148, 178]]], ["This counter was capable of differentiating and counting polymethacrylate particles and Juniper pollen about three times faster than single channel counter.", [["polymethacrylate", "CHEMICAL", 57, 73], ["polymethacrylate particles", "SIMPLE_CHEMICAL", 57, 83], ["counting polymethacrylate particles", "TREATMENT", 48, 83]]], ["This Fig. 3 The schematic diagram of single channel and two detecting arm channel microfluidic differential RPS (a) and the RPS counter and fluorescent signals for 0.9 lm Nile Blue particles mixed with the 0.99 lm Dragon Green particles (b).", [["Nile Blue", "CHEMICAL", 171, 180], ["the RPS counter", "TEST", 120, 135], ["fluorescent signals", "TEST", 140, 159], ["Nile Blue particles", "TEST", 171, 190]]], ["The greater RPS peaks are the signals of the 0.99 lm non-fluorescent particles concept could be extended to multi-channel microfluidic chips in the future to improve the counting efficiency.Nanopore sensorA nanopore here is referred to as a small pore of nanometer size in an electrically insulating membrane and a nanopore resistive sensor (NRS) is a nanometer-scale Coulter counter, which uses the nanopore as an aperture to detect single molecule.", [["membrane", "ANATOMY", 300, 308], ["membrane", "CELLULAR_COMPONENT", 300, 308], ["multi-channel microfluidic chips", "TREATMENT", 108, 140], ["Nanopore sensorA nanopore", "PROBLEM", 190, 215], ["a small pore of nanometer size", "PROBLEM", 239, 269], ["an electrically insulating membrane", "TREATMENT", 273, 308], ["a nanopore resistive sensor", "TREATMENT", 313, 340], ["a nanometer-scale Coulter counter", "TREATMENT", 350, 383], ["the nanopore", "TREATMENT", 396, 408], ["greater", "OBSERVATION_MODIFIER", 4, 11], ["RPS", "OBSERVATION_MODIFIER", 12, 15], ["peaks", "OBSERVATION_MODIFIER", 16, 21], ["microfluidic chips", "OBSERVATION", 122, 140], ["counting efficiency", "OBSERVATION", 170, 189], ["small pore", "OBSERVATION_MODIFIER", 241, 251], ["nanometer", "OBSERVATION_MODIFIER", 255, 264], ["size", "OBSERVATION_MODIFIER", 265, 269], ["insulating membrane", "OBSERVATION", 289, 308]]], ["The NRS, the Coulter counter, and the RPS share the same principle for particle detection; however, the NRS has attracted many researchers since 1990s because the volumetric ratio of the NRS can be high enough to detect much smaller particles such as single molecule by the nanometer sized pores (Bezrukov et al. 1996; Kasianowicz et al. 1996; Akeson et al. 1999 ).", [["particle detection", "TEST", 71, 89], ["the volumetric ratio", "TEST", 159, 179], ["much smaller particles", "PROBLEM", 220, 242], ["nanometer", "OBSERVATION_MODIFIER", 274, 283], ["sized", "OBSERVATION_MODIFIER", 284, 289], ["pores", "OBSERVATION_MODIFIER", 290, 295]]], ["There are two types of nanopores according to the nanopore materials: synthetic and natural materials.", [["nanopores", "TREATMENT", 23, 32]]], ["A typical natural nanopore is a biological protein channel in a lipid bilayer.", [["lipid bilayer", "ANATOMY", 64, 77], ["lipid bilayer", "CELLULAR_COMPONENT", 64, 77], ["biological protein channel", "PROTEIN", 32, 58], ["a biological protein channel in a lipid bilayer", "TREATMENT", 30, 77], ["natural nanopore", "OBSERVATION", 10, 26]]], ["Bezrukov et al. (1996) demonstrated the counting of polymer molecules passing through a single alamethicin pore of 5 and 2 nm in length and diameter, respectively.", [["alamethicin", "CHEMICAL", 95, 106], ["polymer molecules", "PROTEIN", 52, 69], ["a single alamethicin pore", "TREATMENT", 86, 111], ["diameter", "OBSERVATION_MODIFIER", 140, 148]]], ["Kasianowicz et al. (1996) showed that they were able to sense single-stranded RNA and DNA through a 2.6 nm diameter ion channel in a lipid bilayer membrane.", [["lipid bilayer membrane", "ANATOMY", 133, 155], ["DNA", "CELLULAR_COMPONENT", 86, 89], ["lipid", "CELLULAR_COMPONENT", 133, 138], ["bilayer membrane", "CELLULAR_COMPONENT", 139, 155], ["single-stranded RNA", "RNA", 62, 81], ["2.6 nm diameter ion channel", "PROTEIN", 100, 127], ["a 2.6 nm diameter ion channel", "TREATMENT", 98, 127], ["a lipid bilayer membrane", "TREATMENT", 131, 155], ["2.6 nm", "OBSERVATION_MODIFIER", 100, 106], ["lipid bilayer membrane", "OBSERVATION", 133, 155]]], ["This promising result sparked many studies of DNA translocation and dynamics in biological nanopores.", [["DNA", "CELLULAR_COMPONENT", 46, 49], ["DNA translocation", "PROBLEM", 46, 63]]], ["Akeson et al. (1999) detected single DNA and RNA molecules in an a-hemolysin channel driven by an applied electric field (Fig. 5) .", [["DNA", "CELLULAR_COMPONENT", 37, 40], ["RNA molecules", "PROTEIN", 45, 58], ["a-hemolysin channel", "PROTEIN", 65, 84], ["single DNA and RNA molecules", "PROBLEM", 30, 58], ["an a-hemolysin channel", "TREATMENT", 62, 84]]], ["Since the small-sized pore can hold only one strand of DNA or RNA at a time, nucleotides within the polynucleotide must pass through the channel/pore in sequential and single-file order during the translocation.", [["pore", "ANATOMY", 22, 26], ["nucleotides", "CHEMICAL", 77, 88], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["the small-sized pore", "TREATMENT", 6, 26], ["DNA or RNA", "PROBLEM", 55, 65], ["nucleotides within the polynucleotide", "TREATMENT", 77, 114], ["the channel/pore", "TREATMENT", 133, 149], ["small", "OBSERVATION_MODIFIER", 10, 15], ["sized", "OBSERVATION_MODIFIER", 16, 21], ["pore", "OBSERVATION_MODIFIER", 22, 26]]], ["In this process, not only counting but also discriminating between pyrimidine and purine segments along a DNA or RNA molecule can be accomplished.", [["pyrimidine", "CHEMICAL", 67, 77], ["purine", "CHEMICAL", 82, 88], ["pyrimidine", "CHEMICAL", 67, 77], ["purine", "CHEMICAL", 82, 88], ["pyrimidine", "SIMPLE_CHEMICAL", 67, 77], ["purine", "SIMPLE_CHEMICAL", 82, 88], ["DNA", "CELLULAR_COMPONENT", 106, 109], ["pyrimidine and purine segments", "TREATMENT", 67, 97], ["a DNA or RNA molecule", "PROBLEM", 104, 125], ["purine segments", "OBSERVATION", 82, 97], ["RNA molecule", "OBSERVATION", 113, 125]]], ["A very important application of this research is the direct sequencing of individual DNA and RNA molecules with a nanopore.", [["DNA", "CELLULAR_COMPONENT", 85, 88], ["RNA molecules", "PROTEIN", 93, 106], ["a nanopore", "TREATMENT", 112, 122], ["very", "OBSERVATION_MODIFIER", 2, 6]]], ["In addition, nanopore method was used to measure small particles like metal ions, nucleic acids, and other types of polymers in a less than 10 nm channel (Biance et al. 2006) .Nanopore sensorThe geometrical and chemical properties of biological nanopore can be reproducibly controlled by genetic engineering.", [["nucleic acids", "CHEMICAL", 82, 95], ["metal ions", "SIMPLE_CHEMICAL", 70, 80], ["nucleic acids", "SIMPLE_CHEMICAL", 82, 95], ["nanopore method", "TREATMENT", 13, 28], ["small particles like metal ions", "PROBLEM", 49, 80], ["nucleic acids", "TEST", 82, 95], ["polymers", "TREATMENT", 116, 124], ["biological nanopore", "TREATMENT", 234, 253], ["metal ions", "OBSERVATION", 70, 80], ["nucleic acids", "OBSERVATION", 82, 95], ["geometrical", "OBSERVATION_MODIFIER", 195, 206], ["chemical properties", "OBSERVATION", 211, 230], ["biological nanopore", "OBSERVATION", 234, 253]]], ["However, the biological nanopores are not very robust and not size tunable.", [["size", "OBSERVATION_MODIFIER", 62, 66]]], ["Therefore, efforts have been made to fabricate artificial, solid-state nanopores to overcome this limitation.", [["artificial, solid-state nanopores", "TREATMENT", 47, 80]]], ["The nanopores based on synthetic material are generally made in silicon compound membranes, such like silicon nitride.", [["silicon nitride", "CHEMICAL", 102, 117], ["silicon", "CHEMICAL", 64, 71], ["silicon nitride", "CHEMICAL", 102, 117], ["silicon nitride", "SIMPLE_CHEMICAL", 102, 117], ["The nanopores", "TREATMENT", 0, 13], ["synthetic material", "TREATMENT", 23, 41], ["silicon compound membranes", "TREATMENT", 64, 90], ["silicon nitride", "TREATMENT", 102, 117], ["silicon", "OBSERVATION", 64, 71], ["compound membranes", "OBSERVATION", 72, 90], ["silicon nitride", "OBSERVATION", 102, 117]]], ["Manufacturing technique could be focused ion beam (FIB) sculpting or electron beam sculpting.", [["Manufacturing technique", "TREATMENT", 0, 23], ["ion beam (FIB) sculpting", "TREATMENT", 41, 65], ["electron beam sculpting", "TREATMENT", 69, 92]]], ["Martin group did a series of research on synthetic conical nanopores for biosensing applications (Siwy et al. 2005; Harrell et al. 2006; Wharton et al. 2007; Sexton et al. 2007 ).", [["research on synthetic conical nanopores", "TREATMENT", 29, 68]]], ["They made a conical pore with a 1.5 mm base diameter and a 40-nm tip diameter and sensed a single-stranded phage DNA of 7,250 bp and a doublestranded plasmid DNA of 6,600 bp.", [["conical pore", "ANATOMY", 12, 24], ["plasmid", "ANATOMY", 150, 157], ["DNA", "CELLULAR_COMPONENT", 113, 116], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["single-stranded phage DNA", "DNA", 91, 116], ["doublestranded plasmid DNA", "DNA", 135, 161], ["a 1.5 mm base diameter", "TREATMENT", 30, 52], ["a 40-nm tip diameter", "TREATMENT", 57, 77], ["stranded phage DNA", "TEST", 98, 116], ["bp", "TEST", 126, 128], ["a doublestranded plasmid DNA", "TEST", 133, 161]]], ["Alternatively, Ito et al. (2004) utilized a 132 nm multiwall carbon nanotube (MWNT) to detect 28-90 nm nano-particles.", [["carbon nanotube", "CHEMICAL", 61, 76], ["MWNT", "CHEMICAL", 78, 82], ["carbon", "CHEMICAL", 61, 67], ["a 132 nm multiwall carbon nanotube (MWNT", "TREATMENT", 42, 82]]], ["Synthetic nanopores are chemically and structurally stable; however, it is still hard to control the size of these nanochannels.", [["structurally", "OBSERVATION_MODIFIER", 39, 51], ["stable", "OBSERVATION_MODIFIER", 52, 58], ["size", "OBSERVATION_MODIFIER", 101, 105]]], ["Reproducing synthetic nanopores of the same size is hardly possible.", [["synthetic", "OBSERVATION_MODIFIER", 12, 21], ["nanopores", "OBSERVATION_MODIFIER", 22, 31], ["size", "OBSERVATION_MODIFIER", 44, 48], ["hardly possible", "UNCERTAINTY", 52, 67]]], ["Additionally, high manufacturing cost is another obstacle to be overcome for further development and applications of synthetic nanopore particle sensors.Microfluidic capacitance counterThe capacitance counter uses a similar principle to the Coulter counter: it measures the AC capacitance instead of DC resistance when a micron or sub-micron particle passes a sensing gate (aperture).", [["DC", "ANATOMY", 300, 302], ["DC", "CELL_TYPE", 300, 302], ["synthetic nanopore particle sensors", "TREATMENT", 117, 152], ["Microfluidic capacitance counter", "TREATMENT", 153, 185], ["The capacitance counter", "TREATMENT", 185, 208], ["the AC capacitance", "TREATMENT", 270, 288], ["a micron or sub-micron particle", "TREATMENT", 319, 350], ["a sensing gate (aperture)", "TREATMENT", 358, 383], ["high", "OBSERVATION_MODIFIER", 14, 18], ["manufacturing cost", "OBSERVATION", 19, 37]]], ["The capacitance counter is particularly useful for detecting particles in liquids of low electrical conductance because the resistance change due to the passage of a particle is difficult to measure in a poor conducting liquid (Murali et al. 2009 ).", [["The capacitance counter", "TREATMENT", 0, 23], ["low electrical conductance", "TREATMENT", 85, 111], ["the resistance change", "PROBLEM", 120, 141]]], ["In the past, the capacitance measurements have generally been used to identify bulk materials and to investigate ensembles of biological cells.", [["cells", "ANATOMY", 137, 142], ["cells", "CELL", 137, 142], ["biological cells", "CELL_TYPE", 126, 142], ["the capacitance measurements", "TEST", 13, 41], ["biological cells", "OBSERVATION", 126, 142]]], ["However, Sohn et al. (2000) employed this technique to detect and quantify the polarization responses of DNA in the nucleus of single eukaryotic cells.", [["nucleus", "ANATOMY", 116, 123], ["cells", "ANATOMY", 145, 150], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["nucleus", "CELLULAR_COMPONENT", 116, 123], ["cells", "CELL", 145, 150], ["single eukaryotic cells", "CELL_TYPE", 127, 150], ["this technique", "TREATMENT", 37, 51], ["nucleus", "ANATOMY", 116, 123], ["eukaryotic cells", "OBSERVATION", 134, 150]]], ["They built an integrated microfluidic device (Fig. 6) , and used a syringe pump to deliver the liquid to the device.", [["an integrated microfluidic device", "TREATMENT", 11, 44], ["a syringe pump", "TREATMENT", 65, 79], ["the liquid to the device", "TREATMENT", 91, 115], ["microfluidic device", "OBSERVATION", 25, 44]]], ["A capacitance bridge at a frequency of 1 kHz across the device was used to detect the capacitance change to determine the DNA content of single eukaryotic cell.", [["cell", "ANATOMY", 155, 159], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["cell", "CELL", 155, 159], ["eukaryotic cell", "CELL_TYPE", 144, 159], ["A capacitance bridge", "TREATMENT", 0, 20], ["1 kHz across the device", "TREATMENT", 39, 62], ["the capacitance change", "TREATMENT", 82, 104], ["eukaryotic cell", "OBSERVATION", 144, 159]]], ["Additionally, they demonstrated the relationship between the capacitance and the DNA content of a cell.", [["cell", "ANATOMY", 98, 102], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["cell", "CELL", 98, 102], ["the capacitance", "TREATMENT", 57, 72]]], ["Recently, Murali et al. (2009) adopted the capacitance counter to monitor of the wear debris in lubrication oil to avoid catastrophic system failure of machine in real-time.", [["lubrication oil", "ANATOMY", 96, 111], ["oil", "ORGANISM_SUBSTANCE", 108, 111], ["the capacitance counter", "TREATMENT", 39, 62], ["the wear debris in lubrication oil", "TREATMENT", 77, 111], ["catastrophic system failure", "PROBLEM", 121, 148], ["debris", "OBSERVATION", 86, 92], ["catastrophic system", "OBSERVATION", 121, 140], ["failure", "OBSERVATION", 141, 148]]], ["Unlike bulk measurement methods, they could scan each individual particle and determine the size of particles without being affected by the change of oil properties.", [["oil", "ANATOMY", 150, 153], ["oil", "ORGANISM_SUBSTANCE", 150, 153], ["bulk measurement methods", "TEST", 7, 31], ["size", "OBSERVATION_MODIFIER", 92, 96], ["particles", "OBSERVATION", 100, 109], ["oil properties", "OBSERVATION", 150, 164]]], ["Particles from 10 to 25 lm were successfully detected.", [["10 to 25 lm", "OBSERVATION_MODIFIER", 15, 26]]], ["Similar to a microfluidic RPS, the capacitance method has advantages in terms of simple sample preparation, cost, size, and robustness.", [["sample", "ANATOMY", 88, 94], ["a microfluidic RPS", "TREATMENT", 11, 29], ["the capacitance method", "TREATMENT", 31, 53], ["simple sample preparation", "TREATMENT", 81, 106], ["microfluidic RPS", "OBSERVATION", 13, 29], ["size", "OBSERVATION_MODIFIER", 114, 118]]], ["In addition, the capacitance method is sensitive to probe the polarization response of a wide range of materials both organic and inorganic to an external electric field.", [["the capacitance method", "TREATMENT", 13, 35], ["a wide range of materials", "TREATMENT", 87, 112], ["wide", "OBSERVATION_MODIFIER", 89, 93]]], ["Furthermore, it can monitor changes in DNA contents and cell-cycle kinetics so that it may serve as a medical diagnostic device to identify the presence of malignancy in very small quantities of tissue such as tumor cell and monitor in real-time of the effects of pharmacological agents on cell cycle and cell death.", [["cell", "ANATOMY", 56, 60], ["tissue", "ANATOMY", 195, 201], ["tumor cell", "ANATOMY", 210, 220], ["cell", "ANATOMY", 290, 294], ["cell", "ANATOMY", 305, 309], ["malignancy", "DISEASE", 156, 166], ["tumor", "DISEASE", 210, 215], ["death", "DISEASE", 310, 315], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["cell", "CELL", 56, 60], ["malignancy", "CANCER", 156, 166], ["tissue", "TISSUE", 195, 201], ["tumor cell", "CELL", 210, 220], ["cell", "CELL", 290, 294], ["cell", "CELL", 305, 309], ["tumor cell", "CELL_TYPE", 210, 220], ["changes in DNA contents", "PROBLEM", 28, 51], ["cell-cycle kinetics", "TREATMENT", 56, 75], ["a medical diagnostic device", "TREATMENT", 100, 127], ["malignancy", "PROBLEM", 156, 166], ["tumor cell", "PROBLEM", 210, 220], ["monitor", "TEST", 225, 232], ["pharmacological agents", "TREATMENT", 264, 286], ["cell cycle", "TREATMENT", 290, 300], ["cell death", "PROBLEM", 305, 315], ["malignancy", "OBSERVATION", 156, 166], ["very small quantities", "OBSERVATION_MODIFIER", 170, 191], ["tumor cell", "OBSERVATION", 210, 220]]], ["The capacitance method, however, has complications resulting from the charge-screening effects at the electrode-conductive liquid interface in an electronic measurement, which prevents the interpretation of the absolute capacitance value.", [["The capacitance method", "TREATMENT", 0, 22], ["complications", "PROBLEM", 37, 50], ["an electronic measurement", "TEST", 143, 168], ["the absolute capacitance value", "TEST", 207, 237], ["liquid interface", "OBSERVATION", 123, 139], ["absolute capacitance", "OBSERVATION", 211, 231]]], ["Besides, due to AC voltage and frequency required to detect the capacitance, frequency modulation controller is necessary and external support such as a syringe pump is required to deliver a liquid in a channel.", [["AC voltage", "PROBLEM", 16, 26], ["the capacitance", "TREATMENT", 60, 75], ["frequency modulation controller", "TREATMENT", 77, 108], ["external support", "TREATMENT", 126, 142], ["a syringe pump", "TREATMENT", 151, 165], ["a liquid in a channel", "TREATMENT", 189, 210]]], ["These restrictions in flow control and frequency modulation are some of the obstacles for developing compact microfluidic capacitance particle sensors.Microfluidic capacitance counter6 Light-scattering and light-blocking counters A light-scattering particle counter and a light-blocking particle counter are two similar types of light-based particle counters.", [["These restrictions in flow control", "TREATMENT", 0, 34], ["frequency modulation", "TREATMENT", 39, 59], ["developing compact microfluidic capacitance particle sensors", "TREATMENT", 90, 150], ["Microfluidic capacitance", "TEST", 151, 175], ["A light-scattering particle counter", "TREATMENT", 230, 265], ["a light-blocking particle counter", "TREATMENT", 270, 303], ["microfluidic capacitance", "OBSERVATION", 109, 133]]], ["They both use laser light sources such as laser diodes to illuminate individual particles that pass through the laser beam.", [["laser light sources", "TREATMENT", 14, 33], ["laser diodes", "TREATMENT", 42, 54]]], ["The difference between these two counters lies in how the interaction between the light and the particle is measured for counting particles.", [["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["The portion of these three components is determined by optical properties of the material composition of the particle.Microfluidic capacitance counterLight-scattering counter uses the reflected light of the particle.", [["Microfluidic capacitance counterLight-scattering counter", "TREATMENT", 118, 174], ["portion", "OBSERVATION_MODIFIER", 4, 11], ["three", "OBSERVATION_MODIFIER", 21, 26], ["components", "OBSERVATION_MODIFIER", 27, 37], ["particle", "OBSERVATION_MODIFIER", 109, 117]]], ["As shown in Fig. 7a , when the source light hits the particle, some of the light is reflected and the reflected light can be detected by a photo-detector positioned at a spot with a certain angle from the light path.", [["particle", "OBSERVATION_MODIFIER", 53, 61]]], ["The strength of detected light signal corresponds to particle size, and the number of pulses of the detected light signal is proportional to number of particles.", [["strength", "OBSERVATION_MODIFIER", 4, 12], ["particle", "OBSERVATION_MODIFIER", 53, 61], ["size", "OBSERVATION_MODIFIER", 62, 66]]], ["On the other hand, the light-blocking counter (Fig. 7b ) measures the light absorbed or reflected away from the detector by the particle.", [["the light-blocking counter", "TREATMENT", 19, 45]]], ["In this arrangement, the light is focused directly onto the detector; when the particle passes between them, and the photo-detector senses the sudden change in the light intensity by a blocking particle.", [["the sudden change", "PROBLEM", 139, 156], ["light intensity", "OBSERVATION_MODIFIER", 164, 179]]], ["It is obvious that the larger the particle, the more light it will block.", [["larger", "OBSERVATION_MODIFIER", 23, 29], ["particle", "OBSERVATION_MODIFIER", 34, 42], ["more light", "OBSERVATION_MODIFIER", 48, 58]]], ["In principle, the light-scattering counter detects light while the light-blocking counter detects the darkness.", [["the darkness", "PROBLEM", 98, 110]]], ["The light-scattering method is more sensitive than the light-blocking method.", [["The light-scattering method", "TEST", 0, 27]]], ["This is the same principle that detecting a light in a darkroom is easier than detecting a dark spot in a bright room due to the diffuse reflectance caused by solid surfaces and particles in space.", [["a dark spot", "PROBLEM", 89, 100], ["the diffuse reflectance", "PROBLEM", 125, 148], ["solid surfaces and particles in space", "PROBLEM", 159, 196], ["diffuse", "OBSERVATION_MODIFIER", 129, 136], ["solid surfaces", "OBSERVATION", 159, 173], ["particles", "OBSERVATION_MODIFIER", 178, 187]]], ["However, in order to focus and detect the scattered light at a specific angle, the light-scattering counter system normally contains more optical elements and complex electronic circuit, which makes the light-scattering counter more expensive than the light-blocking counter.", [["the light-blocking counter", "TREATMENT", 248, 274], ["scattered", "OBSERVATION_MODIFIER", 42, 51], ["more", "OBSERVATION_MODIFIER", 133, 137], ["optical elements", "OBSERVATION", 138, 154], ["complex", "OBSERVATION_MODIFIER", 159, 166], ["electronic circuit", "OBSERVATION", 167, 185]]], ["The light-blocking counter is widely used in detecting particles in water (e.g., water treatment application) while the light-scattering counter is mostly used in detecting atmospheric particles.", [["The light-blocking counter", "TREATMENT", 0, 26], ["water treatment application", "TREATMENT", 81, 108], ["the light-scattering counter", "TREATMENT", 116, 144], ["atmospheric particles", "OBSERVATION", 173, 194]]], ["The key disadvantage of these light-scattering and light-blocking counters is the low sensitivity in comparison to the Coulter counter because the sensitivity of these light-based particle counters are determined by the particle's surface area while the sensitivity of the Coulter counter is decided by the volume of the particle.", [["surface", "ANATOMY", 231, 238], ["low sensitivity", "OBSERVATION_MODIFIER", 82, 97]]], ["Pamme et al. (2003) researched the counting and sizing of particles and particle agglomerates of C-reactive protein by laser light scattering method.", [["C-reactive protein", "PROTEIN", 97, 115], ["the counting", "TEST", 31, 43], ["C-reactive protein", "TREATMENT", 97, 115], ["laser light scattering method", "TEST", 119, 148], ["particle agglomerates", "OBSERVATION", 72, 93]]], ["They detected scattering light at two different angles of 15\u00b0and 45\u00b0.", [["scattering", "OBSERVATION_MODIFIER", 14, 24], ["light", "OBSERVATION_MODIFIER", 25, 30]]], ["The experiment was carried out on a polymethyl methacrylate (PMMA) microchip which consists of three inlet channels of two buffers and one sample channel and one outlet channel.", [["polymethyl methacrylate", "CHEMICAL", 36, 59], ["PMMA", "CHEMICAL", 61, 65], ["polymethyl methacrylate", "CHEMICAL", 36, 59], ["PMMA", "CHEMICAL", 61, 65], ["polymethyl methacrylate", "SIMPLE_CHEMICAL", 36, 59], ["a polymethyl methacrylate (PMMA) microchip", "TREATMENT", 34, 76], ["three inlet channels of two buffers", "TREATMENT", 95, 130], ["outlet channel", "OBSERVATION", 162, 176]]], ["The fluid was driven by syringe pump generating a negative pressure with a flow rate of 1 ll/s to neglect the hydrostatic pressure in the inlet reservoirs.", [["fluid", "ANATOMY", 4, 9], ["fluid", "ORGANISM_SUBSTANCE", 4, 9], ["a flow rate", "TEST", 73, 84], ["the hydrostatic pressure in the inlet reservoirs", "TREATMENT", 106, 154], ["fluid", "OBSERVATION", 4, 9], ["pressure", "OBSERVATION_MODIFIER", 59, 67], ["hydrostatic pressure", "OBSERVATION", 110, 130], ["inlet reservoirs", "OBSERVATION", 138, 154]]], ["A beam splitter and an objective lens are applied to confine the He-Ne laser inside the channel to avoid scattering on the wall.", [["wall", "ANATOMY", 123, 127], ["He", "CHEMICAL", 65, 67], ["Ne", "CHEMICAL", 68, 70], ["wall", "TISSUE", 123, 127], ["A beam splitter", "TREATMENT", 0, 15], ["an objective lens", "TREATMENT", 20, 37], ["Ne laser inside the channel", "TREATMENT", 68, 95], ["beam splitter", "OBSERVATION", 2, 15], ["objective lens", "OBSERVATION", 23, 37], ["scattering", "OBSERVATION", 105, 115], ["wall", "ANATOMY_MODIFIER", 123, 127]]], ["The scattering light signals are sensed by two optical fibers and amplified by a photomultiplier tube (PMT).", [["tube", "TISSUE", 97, 101], ["a photomultiplier tube (PMT", "TREATMENT", 79, 106], ["scattering", "OBSERVATION_MODIFIER", 4, 14], ["photomultiplier tube", "OBSERVATION", 81, 101]]], ["By this method, the authors realized the particle detection of 2-9 lm.", [["the particle detection", "TEST", 37, 59]]], ["In addition, size discrimination of particles with a diameter ratio of 1:2 was achieved.", [["a diameter ratio", "TEST", 51, 67], ["size", "OBSERVATION_MODIFIER", 13, 17], ["particles", "OBSERVATION_MODIFIER", 36, 45], ["diameter", "OBSERVATION_MODIFIER", 53, 61]]], ["On the other hand, the standard deviation from the average scattering light intensity for a given particle population was high, up to 30%, and a wide laser beam led to overall lower scattering light intensity and higher background scattering from the channel walls.", [["the standard deviation", "PROBLEM", 19, 41], ["a wide laser beam", "PROBLEM", 143, 160], ["overall lower scattering light intensity", "PROBLEM", 168, 208], ["wide", "OBSERVATION_MODIFIER", 145, 149], ["overall", "OBSERVATION_MODIFIER", 168, 175], ["lower", "OBSERVATION_MODIFIER", 176, 181], ["scattering", "OBSERVATION_MODIFIER", 182, 192], ["light intensity", "OBSERVATION_MODIFIER", 193, 208], ["higher", "OBSERVATION_MODIFIER", 213, 219], ["background scattering", "OBSERVATION", 220, 241], ["channel", "ANATOMY", 251, 258], ["walls", "ANATOMY_MODIFIER", 259, 264]]], ["These cause problems for measurement of smaller particles due to the lower scattering intensity and the lower signal-to-noise ratio.", [["smaller particles", "PROBLEM", 40, 57], ["the lower scattering intensity", "PROBLEM", 65, 95], ["smaller", "OBSERVATION_MODIFIER", 40, 47], ["particles", "OBSERVATION", 48, 57], ["lower", "OBSERVATION_MODIFIER", 69, 74], ["scattering", "OBSERVATION_MODIFIER", 75, 85], ["intensity", "OBSERVATION_MODIFIER", 86, 95], ["lower", "OBSERVATION_MODIFIER", 104, 109]]], ["Xiang et al. (2005) utilized the light-blocking technique and developed a multifunctional particle detection system with embedded optical fibers in a PDMS chip to detect moving micro particles in a microchannel.", [["the light-blocking technique", "TREATMENT", 29, 57], ["a PDMS chip", "TREATMENT", 148, 159]]], ["They developed a PDMS-glass microfluidic chip with two pairs of embedded optical fibers and removed the glass cladding layer of the input and receiving fibers.", [["fibers", "ANATOMY", 152, 158], ["PDMS", "CHEMICAL", 17, 21], ["fibers", "CELL", 152, 158], ["a PDMS-glass microfluidic chip", "TREATMENT", 15, 45], ["glass microfluidic chip", "OBSERVATION", 22, 45], ["optical fibers", "OBSERVATION", 73, 87], ["glass cladding", "OBSERVATION", 104, 118]]], ["By filling the gap between the fiber and the fiber channel with PDMS, the light leakage from the fiber core and the light scattering from the fiber tips were minimized.", [["fiber", "ANATOMY", 31, 36], ["fiber", "ANATOMY", 45, 50], ["fiber", "ANATOMY", 97, 102], ["fiber", "CELLULAR_COMPONENT", 31, 36], ["PDMS", "TREATMENT", 64, 68], ["the light leakage", "PROBLEM", 70, 87], ["the fiber core", "TREATMENT", 93, 107], ["the fiber tips", "TREATMENT", 138, 152], ["fiber channel", "OBSERVATION", 45, 58], ["light", "OBSERVATION_MODIFIER", 74, 79], ["leakage", "OBSERVATION", 80, 87], ["light", "OBSERVATION_MODIFIER", 116, 121], ["scattering", "OBSERVATION_MODIFIER", 122, 132], ["fiber tips", "OBSERVATION", 142, 152]]], ["By using the two-fiber detection method, particle velocity as well as particle counting and size identification were possible.", [["particle counting", "TEST", 70, 87], ["size identification", "TEST", 92, 111], ["size", "OBSERVATION_MODIFIER", 92, 96]]], ["To get a better signal, both input and receiving fibers must be perfectly aligned.", [["fibers", "ANATOMY", 49, 55], ["fibers", "CELLULAR_COMPONENT", 49, 55], ["fibers", "TREATMENT", 49, 55]]], ["They used larger size of the receiving fiber to improve this problem.", [["the receiving fiber", "TREATMENT", 25, 44], ["larger", "OBSERVATION_MODIFIER", 10, 16], ["size", "OBSERVATION_MODIFIER", 17, 21]]], ["However, in real applications, careful handling of the fiber-embedded chip and highly controlled fiber alignment are required.", [["the fiber-embedded chip", "TREATMENT", 51, 74], ["highly controlled fiber alignment", "TREATMENT", 79, 112], ["highly", "OBSERVATION_MODIFIER", 79, 85], ["controlled", "OBSERVATION_MODIFIER", 86, 96], ["fiber alignment", "OBSERVATION", 97, 112]]], ["Schafer et al. (2009) created an all silicon and glass microfluidic device using femto-second laser ablation and anodic bonding technique and applied it for cell counting.", [["cell", "ANATOMY", 157, 161], ["silicon", "CHEMICAL", 37, 44], ["cell", "CELL", 157, 161], ["an all silicon and glass microfluidic device", "TREATMENT", 30, 74], ["femto-second laser ablation", "TREATMENT", 81, 108], ["anodic bonding technique", "TREATMENT", 113, 137], ["cell counting", "TEST", 157, 170]]], ["This microchannel fabrication needs just one-step process and shorter fabrication time by femtosecond pulse laser.", [["This microchannel fabrication", "TREATMENT", 0, 29], ["femtosecond pulse laser", "TREATMENT", 90, 113]]], ["The optical fibers for light-scattering signal detection directly contact the liquid, causing light focus on the optical detector by removing the optical free space between the detecting fiber and the channel.", [["fiber", "CELLULAR_COMPONENT", 187, 192], ["light-scattering signal detection", "TEST", 23, 56], ["free space", "OBSERVATION", 154, 164], ["channel", "ANATOMY", 201, 208]]], ["The incident light was coupled to the fiber with a 209, 0.4 NA objective, and the light was delivered through the fiber at the normal direction and collected through the fiber on the opposite side at 14\u00b0f rom the normal and then collimated by an objective and focused onto a photodiode.", [["fiber", "ANATOMY", 38, 43], ["fiber", "ANATOMY", 114, 119], ["fiber", "ANATOMY", 170, 175], ["fiber", "TISSUE", 114, 119], ["a photodiode", "TREATMENT", 273, 285], ["normal", "OBSERVATION", 127, 133], ["normal", "OBSERVATION", 213, 219]]], ["HeLa cell was detected by scattered light with the reported lowest power.", [["HeLa cell", "ANATOMY", 0, 9], ["HeLa cell", "CELL", 0, 9], ["HeLa cell", "CELL_LINE", 0, 9], ["HeLa cell", "PROBLEM", 0, 9], ["scattered", "OBSERVATION_MODIFIER", 26, 35]]], ["Conclusively, the system achieved similar particle-detecting quality with lower laser power of 2 mW and a cheaper photodiode.", [["a cheaper photodiode", "TREATMENT", 104, 124]]], ["However, this device has difficulty of controlling of the even depth and the alignment of the grooves used to guide the optic fibers, and has poorer re-productivity than PDMS chips.", [["optic fibers", "ANATOMY", 120, 132], ["optic fibers", "MULTI-TISSUE_STRUCTURE", 120, 132], ["this device", "TREATMENT", 9, 20], ["PDMS chips", "TREATMENT", 170, 180], ["grooves", "OBSERVATION_MODIFIER", 94, 101], ["optic fibers", "OBSERVATION", 120, 132]]], ["Kummrow et al. (2009) developed a microfluidic flow cytometer combined light-scattering detection and fluorescence detection in a PMMA chip with integrated optical fibers, mirrors, and electrodes for flow cytometric analysis of blood cells.", [["blood cells", "ANATOMY", 228, 239], ["PMMA", "CHEMICAL", 130, 134], ["PMMA", "CHEMICAL", 130, 134], ["blood cells", "CELL", 228, 239], ["blood cells", "CELL_TYPE", 228, 239], ["a microfluidic flow cytometer", "TEST", 32, 61], ["scattering detection", "TEST", 77, 97], ["fluorescence detection", "TEST", 102, 124], ["a PMMA chip", "TREATMENT", 128, 139], ["flow cytometric analysis", "TEST", 200, 224], ["blood cells", "TEST", 228, 239]]], ["They used ultraprecision milling technique to fabricate different flow cells featuring single-stage and two-stage cascaded hydrodynamic focusing of particles in horizontal and vertical directions by a sheath flow.", [["cells", "ANATOMY", 71, 76], ["sheath", "ANATOMY", 201, 207], ["cells", "CELL", 71, 76], ["flow cells", "CELL_TYPE", 66, 76], ["ultraprecision milling technique", "TREATMENT", 10, 42], ["different flow cells", "PROBLEM", 56, 76], ["a sheath flow", "TREATMENT", 199, 212], ["flow cells", "OBSERVATION", 66, 76], ["hydrodynamic focusing", "OBSERVATION", 123, 144], ["particles", "OBSERVATION_MODIFIER", 148, 157], ["horizontal", "OBSERVATION_MODIFIER", 161, 171], ["vertical", "OBSERVATION_MODIFIER", 176, 184], ["sheath flow", "OBSERVATION", 201, 212]]], ["As shown in Fig. 8 , the first stage decreased the diameter of the sample flow to about 30 mm, the second stage allowed to reduce the diameter down to 5 mm while maintaining stable operation for sample flow rates of up to 20 ll/min.", [["sample", "ANATOMY", 67, 73], ["sample", "ANATOMY", 195, 201], ["the sample flow", "TEST", 63, 78], ["sample flow rates", "TEST", 195, 212], ["decreased", "OBSERVATION_MODIFIER", 37, 46], ["diameter", "OBSERVATION_MODIFIER", 51, 59], ["sample", "OBSERVATION_MODIFIER", 67, 73], ["flow", "OBSERVATION_MODIFIER", 74, 78], ["30 mm", "OBSERVATION_MODIFIER", 88, 93], ["diameter", "OBSERVATION_MODIFIER", 134, 142], ["5 mm", "OBSERVATION_MODIFIER", 151, 155], ["stable", "OBSERVATION_MODIFIER", 174, 180], ["operation", "OBSERVATION", 181, 190]]], ["Inserted optic fibers were used to excite fluorescence of stained cells and to detect the axial light loss and the light scatter.", [["optic fibers", "ANATOMY", 9, 21], ["cells", "ANATOMY", 66, 71], ["optic fibers", "MULTI-TISSUE_STRUCTURE", 9, 21], ["cells", "CELL", 66, 71], ["stained cells", "CELL_TYPE", 58, 71], ["Inserted optic fibers", "TREATMENT", 0, 21], ["stained cells", "PROBLEM", 58, 71], ["the axial light loss", "PROBLEM", 86, 106], ["optic fibers", "OBSERVATION", 9, 21], ["axial light loss", "OBSERVATION", 90, 106], ["light scatter", "OBSERVATION_MODIFIER", 115, 128]]], ["Integrated mirrors were used to image the sample flow in vertical direction, thus proving the efficiency of hydrodynamic focusing in two dimensions.", [["sample", "ANATOMY", 42, 48], ["vertical", "OBSERVATION_MODIFIER", 57, 65], ["efficiency", "OBSERVATION_MODIFIER", 94, 104], ["hydrodynamic", "OBSERVATION", 108, 120], ["two dimensions", "OBSERVATION_MODIFIER", 133, 147]]], ["After passing the optical sensor the particles enter the interaction zone for impedance measurements.", [["impedance measurements", "TEST", 78, 100]]], ["Three multimode optic fibers with angles of 12\u00b0, 42\u00b0, and 145\u00b0from the incident light were used to detect the light scatter.", [["optic fibers", "ANATOMY", 16, 28], ["optic fibers", "MULTI-TISSUE_STRUCTURE", 16, 28], ["angles", "OBSERVATION_MODIFIER", 34, 40], ["light scatter", "OBSERVATION", 110, 123]]], ["The multimode optic fiber opposite to the incident light served to measure the axial light loss.", [["optic fiber", "ANATOMY", 14, 25], ["optic fiber", "MULTI-TISSUE_STRUCTURE", 14, 25], ["the axial light loss", "PROBLEM", 75, 95]]], ["An argon ion laser was used for forward light at 488 nm and for exciting the fluorescence of stained cells.", [["cells", "ANATOMY", 101, 106], ["cells", "CELL", 101, 106], ["stained cells", "CELL_TYPE", 93, 106], ["An argon ion laser", "TREATMENT", 0, 18], ["stained cells", "PROBLEM", 93, 106], ["stained cells", "OBSERVATION", 93, 106]]], ["T-helper lymphocytes labeled by monoclonal antibodies were identified by measuring side scatter and fluorescence.", [["T-helper lymphocytes", "ANATOMY", 0, 20], ["T-helper lymphocytes", "CELL", 0, 20], ["T-helper lymphocytes", "CELL_TYPE", 0, 20], ["monoclonal antibodies", "PROTEIN", 32, 53], ["monoclonal antibodies", "TEST", 32, 53], ["monoclonal antibodies", "OBSERVATION", 32, 53]]], ["Using this cytometer, mono-disperse polystyrene spheres with diameters ranging from 2 to 22 lm were detected.Fluorescence-based counterFluorescence is an optical phenomenon in which the molecular absorption of a photon triggers the emission of a photon with a longer and less energetic wavelength.", [["polystyrene", "CHEMICAL", 36, 47], ["polystyrene spheres", "SIMPLE_CHEMICAL", 36, 55], ["this cytometer", "TREATMENT", 6, 20], ["mono-disperse polystyrene spheres", "TREATMENT", 22, 55], ["diameters", "TEST", 61, 70], ["Fluorescence", "TEST", 109, 121], ["an optical phenomenon", "PROBLEM", 151, 172], ["a photon", "TREATMENT", 244, 252], ["polystyrene spheres", "OBSERVATION", 36, 55], ["diameters", "OBSERVATION_MODIFIER", 61, 70], ["optical phenomenon", "OBSERVATION", 154, 172], ["energetic wavelength", "OBSERVATION", 276, 296]]], ["The energy difference between the absorbed and emitted photons ends up as molecular rotations, vibrations, or heat.", [["The energy difference", "PROBLEM", 0, 21], ["energy difference", "OBSERVATION", 4, 21]]], ["Lin and Lee (2003) proposed a method of fluorescence detection in a micro flow cytometer without on-chip fibers.", [["fluorescence detection", "TEST", 40, 62], ["a micro flow cytometer", "TEST", 66, 88]]], ["In this system a PDMS microchip is bonded to a 150-lm-thick glass substrate.", [["PDMS", "CHEMICAL", 17, 21], ["a PDMS microchip", "TREATMENT", 15, 31], ["thick glass substrate", "PROBLEM", 54, 75], ["thick glass substrate", "OBSERVATION", 54, 75]]], ["Laser passes a filter cube and optical fiber to excite particles inside the micro-channel.", [["Laser passes a filter cube and optical fiber", "TREATMENT", 0, 44]]], ["The excited fluorescence is also detected by the same fiber and translated to electrical signals in the photo detector.", [["excited fluorescence", "OBSERVATION", 4, 24]]], ["The lock-in amplifier amplifies the electrical signal and transmits it to computer.", [["The lock-in amplifier", "TREATMENT", 0, 21]]], ["Embedding the optic fiber into the chip adds difficulty and cost to manufacturing the chip.", [["optic fiber", "ANATOMY", 14, 25], ["optic fiber", "MULTI-TISSUE_STRUCTURE", 14, 25], ["the chip", "TREATMENT", 82, 90], ["optic fiber", "OBSERVATION", 14, 25], ["difficulty", "OBSERVATION", 45, 55]]], ["In this system, however, the fiber is separated by glass substrate and the microchip is disposable.", [["fiber", "ANATOMY", 29, 34], ["fiber", "CELLULAR_COMPONENT", 29, 34], ["glass substrate", "OBSERVATION", 51, 66], ["disposable", "OBSERVATION_MODIFIER", 88, 98]]], ["In the experiments, the authors successfully detected and counted 5-20 lm fluorescent particles, white blood cells, and yeast cells.", [["white blood cells", "ANATOMY", 97, 114], ["yeast cells", "ANATOMY", 120, 131], ["white blood cells", "CELL", 97, 114], ["yeast cells", "CELL", 120, 131], ["white blood cells", "CELL_TYPE", 97, 114], ["yeast cells", "CELL_TYPE", 120, 131], ["yeast", "SPECIES", 120, 125], ["yeast", "SPECIES", 120, 125], ["white blood cells", "TEST", 97, 114], ["yeast cells", "PROBLEM", 120, 131], ["yeast cells", "OBSERVATION", 120, 131]]], ["The major advantage of this method is no embedded optic fiber.", [["optic fiber", "ANATOMY", 50, 61], ["optic fiber", "MULTI-TISSUE_STRUCTURE", 50, 61], ["this method", "TREATMENT", 23, 34]]], ["The glass substrate works as the interface between the detection fiber and fluorescent particle.", [["fiber", "CELLULAR_COMPONENT", 65, 70], ["The glass substrate", "TREATMENT", 0, 19], ["the detection fiber", "TREATMENT", 51, 70], ["glass substrate", "OBSERVATION", 4, 19], ["fluorescent particle", "OBSERVATION", 75, 95]]], ["However, the detected fluorescent signals are not constant as they depend on the distance between the optic fiber detector and particles (the particles moving closer to the detector produce stronger signals).", [["optic fiber", "ANATOMY", 102, 113]]], ["In addition, the precise alignment of the fiber and the channel is still difficult to realize.Fluorescence-based counterChen and Wang (2009) reported on-chip fluorescence detection and counting system in a PDMS microchip.", [["fiber", "ANATOMY", 42, 47], ["PDMS", "CHEMICAL", 206, 210], ["fiber", "CELLULAR_COMPONENT", 42, 47], ["Fluorescence", "TEST", 94, 106], ["a PDMS microchip", "TREATMENT", 204, 220], ["alignment", "OBSERVATION_MODIFIER", 25, 34], ["fiber", "OBSERVATION_MODIFIER", 42, 47]]], ["The fluorescence and size information of particle were characterized by combining forward scattering signal and backward fluorescence signal.", [["The fluorescence", "TEST", 0, 16], ["combining forward scattering signal and backward fluorescence signal", "PROBLEM", 72, 140], ["size", "OBSERVATION_MODIFIER", 21, 25]]], ["In the experiments, microparticles of four different sizes with diameters ranging from 3.2 to 10.2 lm were distinguished and counted.", [["microparticles", "CELL", 20, 34], ["diameters", "TEST", 64, 73], ["microparticles", "OBSERVATION_MODIFIER", 20, 34], ["four", "OBSERVATION_MODIFIER", 38, 42], ["different", "OBSERVATION_MODIFIER", 43, 52], ["sizes", "OBSERVATION_MODIFIER", 53, 58], ["diameters", "OBSERVATION_MODIFIER", 64, 73], ["ranging", "OBSERVATION_MODIFIER", 74, 81], ["3.2 to 10.2 lm", "OBSERVATION_MODIFIER", 87, 101]]], ["The relative percentage of the fluorescence-labeled particles can be analyzed by the ratio of the events of fluorescence signals to forward Fig. 8 Schematic diagram of a microfluidic system with two stage cascaded hydrodynamic focusing, integrated mirrors, optical fibers, and fluidic connection.", [["fluorescence signals", "TEST", 108, 128], ["a microfluidic system", "TREATMENT", 168, 189], ["two stage cascaded hydrodynamic focusing", "PROBLEM", 195, 235], ["percentage", "OBSERVATION_MODIFIER", 13, 23], ["hydrodynamic focusing", "OBSERVATION", 214, 235], ["fluidic connection", "OBSERVATION", 277, 295]]], ["Multimode fibers serve to detect the axial light loss or scattered light when particles pass the interaction region.", [["fibers", "ANATOMY", 10, 16], ["fibers", "CELLULAR_COMPONENT", 10, 16], ["the axial light loss", "PROBLEM", 33, 53], ["scattered", "OBSERVATION_MODIFIER", 57, 66]]], ["Orthogonal light scatter and fluorescence is collected perpendicular to the joining plane by a microscope objective scattered signals.", [["Orthogonal light scatter and fluorescence", "TEST", 0, 41], ["light", "OBSERVATION_MODIFIER", 11, 16], ["scatter", "OBSERVATION_MODIFIER", 17, 24], ["scattered", "OBSERVATION_MODIFIER", 116, 125]]], ["Similar to Lin and Lee, this system also adopted the externally installed fiber system for disposable chips.", [["disposable chips", "TREATMENT", 91, 107], ["Lin", "OBSERVATION", 11, 14]]], ["However, without a bulk lock-in amplifier, they could detect 3.2-10.2 lm particle by using an avalanche photodetector and simple electronic filter circuit.", [["an avalanche photodetector", "TREATMENT", 91, 117], ["simple electronic filter circuit", "TREATMENT", 122, 154], ["filter circuit", "OBSERVATION", 140, 154]]], ["In addition, the chip fabrication process is simpler and cheaper by only PDMS soft lithography.", [["the chip fabrication process", "TREATMENT", 13, 41], ["PDMS soft lithography", "TREATMENT", 73, 94]]], ["The same problems of inconsistent fluorescent signals caused by the distance between the photodetector and particles and the difficulty of fiber alignment still existed.Fluorescence-based counterIn general, fluorescence is the one of the most sensitive methods for particle detection; however, using this method, particles must have fluorescent characteristics and nonfluorescent particles have to be labeled with proper fluorophores.", [["inconsistent fluorescent signals", "PROBLEM", 21, 53], ["the photodetector and particles", "TREATMENT", 85, 116], ["Fluorescence", "TEST", 169, 181], ["particle detection", "TEST", 265, 283], ["this method", "TREATMENT", 300, 311], ["fluorescent characteristics and nonfluorescent particles", "PROBLEM", 333, 389], ["fluorescent signals", "OBSERVATION", 34, 53], ["fiber alignment", "OBSERVATION", 139, 154]]], ["Therefore, this technique is widely used to distinguish specific target particles from other particles, and often used in combination with other particle counting techniques (Chen and Wang 2009; Kummrow et al. 2009; Murali et al. 2009 ).Micro-PIV methodParticle image velocimetry is an optical method used to obtain instantaneous velocity measurements and related properties in fluids.", [["this technique", "TREATMENT", 11, 25], ["Micro-PIV method", "TREATMENT", 237, 253], ["Particle image velocimetry", "TEST", 253, 279], ["instantaneous velocity measurements", "TEST", 316, 351], ["PIV method", "OBSERVATION", 243, 253], ["fluids", "OBSERVATION", 378, 384]]], ["When the small seeding particles flow inside a flowing liquid, the motion of these particles is traced and computed to show the fluid flow by taking sequential images of the positions of the tracing particles.", [["fluid", "ANATOMY", 128, 133], ["the small seeding particles flow", "PROBLEM", 5, 37], ["a flowing liquid", "TREATMENT", 45, 61], ["the fluid flow", "TEST", 124, 138], ["sequential images", "TEST", 149, 166], ["small", "OBSERVATION_MODIFIER", 9, 14], ["seeding", "OBSERVATION_MODIFIER", 15, 22], ["particles flow", "OBSERVATION", 23, 37], ["flowing liquid", "OBSERVATION", 47, 61], ["fluid flow", "OBSERVATION", 128, 138]]], ["Typical PIV apparatus consists of a digital camera, a highpower laser, and an optical arrangement to convert the laser output light to a light sheet.", [["Typical PIV apparatus", "TREATMENT", 0, 21], ["a digital camera", "TREATMENT", 34, 50], ["a highpower laser", "TREATMENT", 52, 69], ["PIV apparatus", "OBSERVATION", 8, 21]]], ["A fiber-optic cable often connects the laser to the cylindrical lens setup.", [["A fiber-optic cable", "TREATMENT", 0, 19], ["the cylindrical lens setup", "TREATMENT", 48, 74], ["optic cable", "OBSERVATION", 8, 19], ["cylindrical lens setup", "OBSERVATION", 52, 74]]], ["The laser acts as a photographic flash for the digital camera, and the particles in the fluid scatter the light.", [["fluid", "ANATOMY", 88, 93], ["a photographic flash", "TEST", 18, 38], ["the digital camera", "TEST", 43, 61], ["particles", "OBSERVATION_MODIFIER", 71, 80], ["fluid scatter", "OBSERVATION", 88, 101]]], ["The scattered light is detected by the camera.", [["scattered", "OBSERVATION_MODIFIER", 4, 13], ["light", "OBSERVATION_MODIFIER", 14, 19]]], ["In the early twentieth century, German scientist Ludwig Prandtl first used particles to study fluids in a systematic manner (Goldstein 1996) , and then the rapid development of lasers and camera technology enabled flow visualization and later on quantifying the whole flow field measurement.", [["flow visualization", "TEST", 214, 232], ["the whole flow field measurement", "TEST", 258, 290]]], ["Modern PIV software continues to improve the performance of the PIV systems and their applicability to difficult flow measurements.", [["Modern PIV software", "TREATMENT", 0, 19], ["the PIV systems", "TREATMENT", 60, 75], ["PIV software", "OBSERVATION", 7, 19]]], ["Nowadays the PIV has become one of the most popular instruments for flow measurements in numerous applications.Micro-PIV methodHirono group developed the image cytometry centrifugation (ICC) to count leukocytes (Yabusaki et al. 1999 (Yabusaki et al. , 2000 and later extended their research to study theoretically and experimentally a microfluidic image cytometry by using micro-PIV flow visualization technique (Hirono et al. 2008) .", [["leukocytes", "ANATOMY", 200, 210], ["Hirono", "CHEMICAL", 127, 133], ["Hirono", "SIMPLE_CHEMICAL", 127, 133], ["leukocytes", "CELL", 200, 210], ["count leukocytes", "CELL_TYPE", 194, 210], ["the PIV", "TREATMENT", 9, 16], ["flow measurements", "TEST", 68, 85], ["Micro", "TEST", 111, 116], ["PIV method", "TREATMENT", 117, 127], ["the image cytometry centrifugation", "TEST", 150, 184], ["count leukocytes", "TEST", 194, 210], ["a microfluidic image cytometry", "TEST", 333, 363], ["micro-PIV flow visualization technique", "TREATMENT", 373, 411], ["PIV", "OBSERVATION", 13, 16], ["flow", "OBSERVATION", 68, 72]]], ["In their research, numbers and sizes of particles flowing through a microchannel were measured simultaneously by image sequence analysis.", [["a microchannel", "TEST", 66, 80], ["image sequence analysis", "TEST", 113, 136], ["sizes", "OBSERVATION_MODIFIER", 31, 36], ["particles flowing", "OBSERVATION", 40, 57]]], ["During the experiments, a dilution series of 2 lm polystyrene particle suspensions were measured and compared with the results obtained by conventional Burker-Turk hemocytometry for validation of the particle counting.", [["polystyrene", "CHEMICAL", 50, 61], ["a dilution series", "TEST", 24, 41], ["2 lm polystyrene particle suspensions", "TREATMENT", 45, 82], ["the particle counting", "TEST", 196, 217]]], ["For the particle diameter measurements, the diameters of 2, 5, 10, and 20 lm particles were measured and the results agreed well with the reference values.", [["the particle diameter measurements", "TEST", 4, 38], ["the diameters", "TEST", 40, 53], ["particle", "OBSERVATION_MODIFIER", 8, 16], ["diameter", "OBSERVATION_MODIFIER", 17, 25], ["diameters", "OBSERVATION_MODIFIER", 44, 53]]], ["This method may be used to the quantitative study of platelet aggregation in blood flow and become a powerful diagnostic tool in the future.", [["platelet", "ANATOMY", 53, 61], ["blood", "ANATOMY", 77, 82], ["platelet aggregation", "DISEASE", 53, 73], ["platelet", "CELL", 53, 61], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["the quantitative study", "TEST", 27, 49], ["platelet aggregation", "PROBLEM", 53, 73], ["blood flow", "TEST", 77, 87]]], ["The image processing procedure demands complicated computational work and microscopic instrument, resulting in high cost, additional post processing, and large system.SummaryFor counting biological or non-biological particles, a traditional Coulter counter is still the most popular device because of its high sensitivity and throughput.", [["The image processing procedure", "TREATMENT", 0, 30], ["microscopic instrument", "TEST", 74, 96], ["high cost", "PROBLEM", 111, 120], ["a traditional Coulter counter", "TREATMENT", 227, 256], ["its high sensitivity", "PROBLEM", 301, 321], ["high cost", "OBSERVATION", 111, 120], ["large", "OBSERVATION_MODIFIER", 154, 159]]], ["However, due to the increasing needs for portability and low cost in wide biological applications such as a handheld flow cytometer and a single DNA analyzer, many recent researches have focused on micro-or nano-scale particle counting devices using advanced microfluidic technologies to realize portability, low cost, and simplicity.SummaryIn this paper, among many particle counting techniques, we reviewed only those applicable in microfluidic chips.", [["DNA", "CELLULAR_COMPONENT", 145, 148], ["portability", "TREATMENT", 41, 52], ["a handheld flow cytometer", "TEST", 106, 131], ["a single DNA analyzer", "TEST", 136, 157], ["micro-or nano-scale particle counting devices", "TREATMENT", 198, 243], ["advanced microfluidic technologies", "TREATMENT", 250, 284], ["microfluidic chips", "TREATMENT", 434, 452], ["low cost", "OBSERVATION_MODIFIER", 309, 317]]], ["Microfluidic RPS has been studied and demonstrated to have significantly higher sensitivity than the commercial Coulter counter with low cost.", [["Microfluidic RPS", "TEST", 0, 16], ["significantly higher sensitivity", "PROBLEM", 59, 91]]], ["Furthermore, the RPS technique extends to nano-size by utilizing natural or synthetic nanopore to detect single DNA/RNA.", [["DNA", "CELLULAR_COMPONENT", 112, 115], ["single DNA/RNA", "RNA", 105, 119], ["the RPS technique", "TREATMENT", 13, 30], ["natural or synthetic nanopore", "TREATMENT", 65, 94], ["single DNA/RNA", "PROBLEM", 105, 119], ["size", "OBSERVATION_MODIFIER", 47, 51], ["RNA", "OBSERVATION", 116, 119]]], ["For applications in liquids of low electrical conductance, microfluidic capacitance measurement has been used instead of resistance measurement for particle counting.", [["applications in liquids", "TREATMENT", 4, 27], ["low electrical conductance", "TREATMENT", 31, 57], ["microfluidic capacitance measurement", "TREATMENT", 59, 95], ["resistance measurement", "TEST", 121, 143], ["particle counting", "TEST", 148, 165]]], ["The light-scattering and the light-blocking methods can also be applied in microfluidic chips and have a little lower sensitivity than RPS technique.", [["the light-blocking methods", "TREATMENT", 25, 51], ["microfluidic chips", "TREATMENT", 75, 93], ["RPS technique", "TEST", 135, 148], ["scattering", "OBSERVATION_MODIFIER", 10, 20]]], ["However, they are more applicable in applications involving higher density particles.", [["higher density", "OBSERVATION_MODIFIER", 60, 74], ["particles", "OBSERVATION_MODIFIER", 75, 84]]], ["Fluorescent detection has an advantage in identifying specific particles among similar sized particles because the fluorescence method has higher specificity than any other electrical measurement.", [["Fluorescent detection", "TEST", 0, 21], ["the fluorescence method", "TEST", 111, 134]]], ["Micro PIV technique can perform particle counting and analyzing the flow filed simultaneously.SummaryIn addition to the disadvantages of the individual detecting techniques described in this paper, the low throughput is a major hindrance for the applications of microfluidic particle counting methods.", [["Micro PIV technique", "TREATMENT", 0, 19], ["particle counting", "TEST", 32, 49], ["microfluidic particle counting methods", "TREATMENT", 262, 300], ["flow", "OBSERVATION", 68, 72], ["microfluidic particle", "OBSERVATION", 262, 283]]], ["A possible way to overcome this obstacle is to use multiple parallel channels; however, the number of parallel sensing microchannels can be built in single detecting chip is limited practically.", [["multiple parallel channels", "TREATMENT", 51, 77], ["parallel sensing microchannels", "TREATMENT", 102, 132]]], ["Therefore, the enhancement of the counting speed as well as stable and sensitive detection over a longer period of time is among the challenging issues.", [["enhancement", "OBSERVATION_MODIFIER", 15, 26], ["stable", "OBSERVATION_MODIFIER", 60, 66]]], ["Furthermore, in order to meet the demand of the complex analytical detection in real applications, the integration of multiple particle counting methods in a single microfluidic system should be investigated.", [["multiple particle counting methods", "TREATMENT", 118, 152], ["a single microfluidic system", "TREATMENT", 156, 184], ["multiple", "OBSERVATION_MODIFIER", 118, 126], ["particle", "OBSERVATION_MODIFIER", 127, 135]]]], "PMC7537587": [["IntroductionThe textbook depiction of the viral replication cycle1,2 contains four relatively uniform core steps: entry, replication, assembly and egress (Fig. 1a).", [["viral replication cycle1,2", "DNA", 42, 68], ["the viral replication cycle1", "TREATMENT", 38, 66], ["viral replication", "OBSERVATION", 42, 59]]], ["Innovative studies have uncovered novel and heterogeneous strategies for accomplishing each of these steps.", [["Innovative studies", "TEST", 0, 18]]], ["In this Review, we examine the phenotypic implications of both host and viral heterogeneity in shaping the viral replication cycle.", [["viral heterogeneity", "PROBLEM", 72, 91], ["viral heterogeneity", "OBSERVATION", 72, 91], ["viral replication cycle", "OBSERVATION", 107, 130]]], ["We consider several aspects of heterogeneity in hosts, including availability and post-translational modifications (PTMs) of host receptors, and variability in antiviral defences.", [["PTMs", "PROTEIN", 116, 120], ["host receptors", "PROTEIN", 125, 139], ["heterogeneity in hosts", "PROBLEM", 31, 53], ["post-translational modifications (PTMs", "TREATMENT", 82, 120], ["host receptors", "TREATMENT", 125, 139], ["antiviral defences", "OBSERVATION", 160, 178]]], ["We also discuss heterogeneity within viruses, specifically how viral polymerase fidelity, virion morphology and egress mechanisms lead to a more nuanced view of viral infection (Fig. 1b).IntroductionTechnological advances (Table 1) have been crucial for identifying how heterogeneity redefines viral replication.", [["viral infection", "DISEASE", 161, 176], ["virion", "CELLULAR_COMPONENT", 90, 96], ["viral polymerase", "PROTEIN", 63, 79], ["heterogeneity within viruses", "PROBLEM", 16, 44], ["viral polymerase fidelity", "PROBLEM", 63, 88], ["viral infection", "PROBLEM", 161, 176], ["viral replication", "TREATMENT", 294, 311], ["viruses", "OBSERVATION", 37, 44], ["viral", "OBSERVATION_MODIFIER", 161, 166], ["infection", "OBSERVATION", 167, 176]]], ["Human airway epithelial cell cultures3\u20135 are emerging as an important resource for studying the role of cellular heterogeneity during respiratory viral infections.", [["airway epithelial cell cultures3\u20135", "ANATOMY", 6, 40], ["cellular", "ANATOMY", 104, 112], ["respiratory viral infections", "DISEASE", 134, 162], ["Human", "ORGANISM", 0, 5], ["airway epithelial cell cultures3\u20135", "CELL", 6, 40], ["cellular", "CELL", 104, 112], ["Human airway epithelial cell cultures3\u20135", "CELL_LINE", 0, 40], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human airway epithelial cell cultures3\u20135", "TEST", 0, 40], ["cellular heterogeneity", "PROBLEM", 104, 126], ["respiratory viral infections", "PROBLEM", 134, 162], ["airway", "ANATOMY", 6, 12], ["epithelial cell", "OBSERVATION", 13, 28], ["cellular heterogeneity", "OBSERVATION", 104, 126], ["respiratory viral infections", "OBSERVATION", 134, 162]]], ["These cultures maintain well-differentiated patient-derived primary airway bronchial surface epithelial cells at an air\u2013liquid interface3\u20135.", [["cultures", "ANATOMY", 6, 14], ["primary airway bronchial surface epithelial cells", "ANATOMY", 60, 109], ["patient", "ORGANISM", 44, 51], ["airway bronchial surface epithelial cells", "CELL", 68, 109], ["primary airway bronchial surface epithelial cells", "CELL_TYPE", 60, 109], ["patient", "SPECIES", 44, 51], ["These cultures", "TEST", 0, 14], ["an air\u2013liquid interface3\u20135", "TREATMENT", 113, 139], ["airway bronchial", "ANATOMY", 68, 84], ["surface epithelial cells", "OBSERVATION", 85, 109]]], ["These cultures comprise ciliated, non-ciliated, goblet and basal cells, thus recapitulating the complex multicellular environment of the lung5.", [["cultures", "ANATOMY", 6, 14], ["ciliated", "ANATOMY", 24, 32], ["goblet", "ANATOMY", 48, 54], ["basal cells", "ANATOMY", 59, 70], ["lung5", "ANATOMY", 137, 142], ["goblet", "CELL", 48, 54], ["basal cells", "CELL", 59, 70], ["lung5", "GENE_OR_GENE_PRODUCT", 137, 142], ["ciliated, non-ciliated, goblet and basal cells", "CELL_TYPE", 24, 70], ["These cultures", "TEST", 0, 14], ["ciliated, non-ciliated, goblet and basal cells", "PROBLEM", 24, 70], ["non-ciliated", "OBSERVATION_MODIFIER", 34, 46], ["basal cells", "OBSERVATION", 59, 70], ["complex", "OBSERVATION_MODIFIER", 96, 103], ["multicellular environment", "OBSERVATION", 104, 129], ["lung5", "ANATOMY", 137, 142]]], ["Single-cell RNA sequencing (scRNA-seq)6\u201317 techniques reveal cell-to-cell variability in viral infections and provide important insights into the heterogeneity of transcriptional responses and viral growth.", [["cell", "ANATOMY", 61, 65], ["cell", "ANATOMY", 69, 73], ["viral infections", "DISEASE", 89, 105], ["cell", "CELL", 61, 65], ["cell", "CELL", 69, 73], ["Single-cell RNA sequencing", "TEST", 0, 26], ["scRNA", "TEST", 28, 33], ["techniques", "TEST", 43, 53], ["cell", "TEST", 61, 65], ["cell variability", "PROBLEM", 69, 85], ["viral infections", "PROBLEM", 89, 105], ["viral growth", "PROBLEM", 193, 205], ["cell", "OBSERVATION", 61, 65], ["cell variability", "OBSERVATION", 69, 85], ["viral infections", "OBSERVATION", 89, 105]]], ["Live-cell imaging and advances in single-particle tracking have also increased our understanding of heterogeneous viral infections of individual cells18.", [["Live-cell", "ANATOMY", 0, 9], ["cells", "ANATOMY", 145, 150], ["viral infections", "DISEASE", 114, 130], ["cell", "CELL", 5, 9], ["cells", "CELL", 145, 150], ["individual cells", "CELL_TYPE", 134, 150], ["cell imaging", "TEST", 5, 17], ["heterogeneous viral infections of individual cells", "PROBLEM", 100, 150], ["heterogeneous", "OBSERVATION_MODIFIER", 100, 113], ["viral infections", "OBSERVATION", 114, 130], ["cells", "OBSERVATION", 145, 150]]], ["The study of pleomorphic viruses has also benefited from technological advances.", [["The study", "TEST", 0, 9], ["pleomorphic viruses", "PROBLEM", 13, 32], ["pleomorphic viruses", "OBSERVATION", 13, 32]]], ["Historically, cryoelectron microscopy has been used to resolve the structure of homogeneous virus particles through two-dimensional averaging and single-particle reconstruction.", [["cryoelectron microscopy", "TEST", 14, 37], ["homogeneous virus particles", "PROBLEM", 80, 107], ["single-particle reconstruction", "TREATMENT", 146, 176], ["homogeneous", "OBSERVATION_MODIFIER", 80, 91], ["virus", "OBSERVATION", 92, 97]]], ["However, heterogeneous samples such as pleomorphic viruses cannot be resolved in this way.", [["samples", "ANATOMY", 23, 30], ["samples", "CANCER", 23, 30], ["heterogeneous samples", "PROBLEM", 9, 30], ["pleomorphic viruses", "PROBLEM", 39, 58], ["heterogeneous", "OBSERVATION_MODIFIER", 9, 22], ["pleomorphic", "OBSERVATION_MODIFIER", 39, 50], ["viruses", "OBSERVATION", 51, 58]]], ["Cryoelectron tomography19\u201321 and subtomogram averaging eliminated this barrier in structural biology and now enable visualization of heterogeneous virus particles.IntroductionIn this Review, we highlight the key findings of studies using the above techniques as well as other innovative studies as we dissect phenotypic heterogeneity at different steps of the viral replication cycle.", [["Cryoelectron tomography19\u201321", "TEST", 0, 28], ["subtomogram", "TEST", 33, 44], ["this barrier", "TREATMENT", 66, 78], ["heterogeneous virus particles", "PROBLEM", 133, 162], ["studies", "TEST", 224, 231], ["the above techniques", "TEST", 238, 258], ["other innovative studies", "TEST", 270, 294], ["phenotypic heterogeneity", "PROBLEM", 309, 333], ["the viral replication cycle", "TREATMENT", 356, 383], ["heterogeneous", "OBSERVATION_MODIFIER", 133, 146], ["virus particles", "OBSERVATION", 147, 162], ["viral replication", "OBSERVATION", 360, 377]]], ["Although we have restricted our discussion to recent examples relevant for human disease, we invite the reader to consider the implications of the heterogeneity discussed here on other viruses, such as environmental viruses and viruses with plant and bacterial hosts.Viral heterogeneity in receptor avidity ::: EntryViruses exploit abundant host receptors to enter into target cells, and recent studies have shown that receptor glycosylation influences avidity.", [["cells", "ANATOMY", 377, 382], ["human", "ORGANISM", 75, 80], ["EntryViruses", "SIMPLE_CHEMICAL", 311, 323], ["cells", "CELL", 377, 382], ["target cells", "CELL_TYPE", 370, 382], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["human disease", "PROBLEM", 75, 88], ["the heterogeneity", "PROBLEM", 143, 160], ["other viruses", "PROBLEM", 179, 192], ["plant and bacterial hosts", "TREATMENT", 241, 266], ["recent studies", "TEST", 388, 402], ["receptor glycosylation influences avidity", "PROBLEM", 419, 460], ["bacterial hosts", "OBSERVATION", 251, 266], ["receptor avidity", "OBSERVATION", 290, 306]]], ["Haemagglutinin (HA) of human influenza virus binds ubiquitous \u03b12,6-linked sialic acid glycan moieties on the cell surface to initiate entry into target cells, and several different cellular receptors then contribute to the entry process22.", [["cell surface", "ANATOMY", 109, 121], ["cells", "ANATOMY", 152, 157], ["cellular", "ANATOMY", 181, 189], ["Haemagglutinin", "CHEMICAL", 0, 14], ["HA", "CHEMICAL", 16, 18], ["sialic acid", "CHEMICAL", 74, 85], ["sialic acid", "CHEMICAL", 74, 85], ["Haemagglutinin", "GENE_OR_GENE_PRODUCT", 0, 14], ["HA", "GENE_OR_GENE_PRODUCT", 16, 18], ["human influenza virus", "ORGANISM", 23, 44], ["\u03b12,6-linked sialic acid", "SIMPLE_CHEMICAL", 62, 85], ["cell surface", "CELLULAR_COMPONENT", 109, 121], ["cells", "CELL", 152, 157], ["cellular", "CELL", 181, 189], ["ubiquitous \u03b12,6-linked sialic acid glycan moieties", "PROTEIN", 51, 101], ["target cells", "CELL_TYPE", 145, 157], ["cellular receptors", "PROTEIN", 181, 199], ["human", "SPECIES", 23, 28], ["influenza virus", "SPECIES", 29, 44], ["human influenza virus", "SPECIES", 23, 44], ["Haemagglutinin (HA)", "TREATMENT", 0, 19], ["human influenza virus binds", "TEST", 23, 50], ["sialic acid glycan moieties", "TREATMENT", 74, 101], ["the cell surface", "TREATMENT", 105, 121], ["the entry process", "PROBLEM", 219, 236]]], ["A recent study demonstrated that weak virion affinity for sialic acid can lead to multiple transient association and dissociation events along the cell surface, enabling the virus to travel to regions actively undergoing endocytosis and enhancing uptake into an infected cell23.", [["cell surface", "ANATOMY", 147, 159], ["sialic acid", "CHEMICAL", 58, 69], ["sialic acid", "CHEMICAL", 58, 69], ["sialic acid", "SIMPLE_CHEMICAL", 58, 69], ["cell surface", "CELLULAR_COMPONENT", 147, 159], ["A recent study", "TEST", 0, 14], ["weak virion affinity", "PROBLEM", 33, 53], ["sialic acid", "PROBLEM", 58, 69], ["multiple transient association and dissociation events", "PROBLEM", 82, 136], ["the virus", "PROBLEM", 170, 179], ["enhancing uptake into an infected cell23", "PROBLEM", 237, 277], ["enhancing", "OBSERVATION_MODIFIER", 237, 246], ["infected", "OBSERVATION", 262, 270]]], ["Interestingly, the direction of virion motion on the cell surface depends on virion morphology: movement of spherical virus particles lacks directionality, but filamentous virions travel in a straight, directed manner24.", [["virion", "ANATOMY", 32, 38], ["cell surface", "ANATOMY", 53, 65], ["virion", "ANATOMY", 77, 83], ["virions", "ANATOMY", 172, 179], ["cell surface", "CELLULAR_COMPONENT", 53, 65], ["virion", "CELLULAR_COMPONENT", 77, 83], ["manner24", "PROTEIN", 211, 219], ["spherical virus particles", "PROBLEM", 108, 133], ["virion motion", "OBSERVATION", 32, 45], ["spherical virus", "OBSERVATION", 108, 123], ["filamentous virions", "OBSERVATION", 160, 179]]], ["As discussed in the Assembly section, neuraminidase (NA) from influenza virus, which cleaves sialic acids and is required for motility23, is highly polarized on the surface of filamentous virions25.", [["surface", "ANATOMY", 165, 172], ["NA", "CHEMICAL", 53, 55], ["influenza virus", "DISEASE", 62, 77], ["sialic acids", "CHEMICAL", 93, 105], ["sialic acids", "CHEMICAL", 93, 105], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 38, 51], ["NA", "SIMPLE_CHEMICAL", 53, 55], ["influenza virus", "ORGANISM", 62, 77], ["sialic acids", "SIMPLE_CHEMICAL", 93, 105], ["motility23", "GENE_OR_GENE_PRODUCT", 126, 136], ["surface", "CELLULAR_COMPONENT", 165, 172], ["motility23", "PROTEIN", 126, 136], ["influenza virus", "SPECIES", 62, 77], ["influenza virus", "SPECIES", 62, 77], ["neuraminidase (NA)", "TREATMENT", 38, 56], ["influenza virus", "PROBLEM", 62, 77], ["sialic acids", "TEST", 93, 105], ["motility23", "TREATMENT", 126, 136], ["highly", "OBSERVATION_MODIFIER", 141, 147], ["polarized", "OBSERVATION_MODIFIER", 148, 157]]], ["Given these observations, it is tempting to speculate that the density and distribution of HA and NA molecules on a virion and the respective affinity for sialic acid binding and release may influence the movement of viruses along cell surfaces and affect virus entry.", [["cell surfaces", "ANATOMY", 231, 244], ["NA", "CHEMICAL", 98, 100], ["sialic acid", "CHEMICAL", 155, 166], ["sialic acid", "CHEMICAL", 155, 166], ["HA", "GENE_OR_GENE_PRODUCT", 91, 93], ["NA molecules", "GENE_OR_GENE_PRODUCT", 98, 110], ["virion", "CELLULAR_COMPONENT", 116, 122], ["sialic acid", "SIMPLE_CHEMICAL", 155, 166], ["cell", "CELL", 231, 235], ["HA and NA molecules", "PROTEIN", 91, 110], ["HA", "PROBLEM", 91, 93], ["NA molecules", "PROBLEM", 98, 110], ["a virion", "TREATMENT", 114, 122], ["sialic acid binding", "TREATMENT", 155, 174], ["density", "OBSERVATION", 63, 70], ["distribution", "OBSERVATION_MODIFIER", 75, 87]]], ["It is worth noting that receptor avidity is not static for influenza viruses, as evolution of the HA protein increases26 or decreases27 the affinity for \u03b12,6-linked sialic acid.", [["sialic acid", "CHEMICAL", 165, 176], ["sialic acid", "CHEMICAL", 165, 176], ["influenza viruses", "ORGANISM", 59, 76], ["HA", "GENE_OR_GENE_PRODUCT", 98, 100], ["\u03b12,6-linked sialic acid", "SIMPLE_CHEMICAL", 153, 176], ["HA protein", "PROTEIN", 98, 108], ["\u03b12,6", "PROTEIN", 153, 157], ["receptor avidity", "PROBLEM", 24, 40], ["influenza viruses", "PROBLEM", 59, 76], ["the HA protein increases26", "TREATMENT", 94, 120], ["the affinity", "TEST", 136, 148], ["sialic acid", "TEST", 165, 176]]], ["In recent years, H3N2 viruses and pandemic H1N1 viruses have caused more severe disease than previous strains28,29, which may be linked to changes in receptor avidity for long-chain branched glycans30.", [["H3N2 viruses", "DISEASE", 17, 29], ["H1N1 viruses", "DISEASE", 43, 55], ["H3N2 viruses", "ORGANISM", 17, 29], ["pandemic H1N1 viruses", "ORGANISM", 34, 55], ["pandemic H1N1 viruses", "SPECIES", 34, 55], ["H3N2 viruses", "SPECIES", 17, 29], ["pandemic H1N1 viruses", "SPECIES", 34, 55], ["H3N2 viruses", "PROBLEM", 17, 29], ["pandemic H1N1 viruses", "PROBLEM", 34, 55], ["more severe disease", "PROBLEM", 68, 87], ["previous strains", "PROBLEM", 93, 109], ["changes in receptor avidity", "PROBLEM", 139, 166], ["long-chain branched glycans", "TREATMENT", 171, 198], ["H3N2 viruses", "OBSERVATION", 17, 29], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["disease", "OBSERVATION", 80, 87]]], ["Further insight into the relationship between viral entry and virion morphology is needed to connect the role of pleomorphic viral populations in the infectivity and spread of viruses.Host heterogeneity in receptor glycosylation ::: EntryReceptor glycosylation varies between cell types and in different hosts, leading to differential receptor avidity during viral infection31\u201338.", [["cell", "ANATOMY", 276, 280], ["infection", "DISEASE", 365, 374], ["cell", "CELL", 276, 280], ["viral entry and virion morphology", "PROBLEM", 46, 79], ["pleomorphic viral populations", "PROBLEM", 113, 142], ["the infectivity", "PROBLEM", 146, 161], ["viruses", "PROBLEM", 176, 183], ["EntryReceptor glycosylation", "TREATMENT", 233, 260], ["differential receptor avidity", "PROBLEM", 322, 351], ["viral infection", "PROBLEM", 359, 374], ["pleomorphic", "OBSERVATION_MODIFIER", 113, 124], ["viral populations", "OBSERVATION", 125, 142], ["viruses", "OBSERVATION", 176, 183], ["receptor glycosylation", "OBSERVATION", 206, 228], ["cell types", "OBSERVATION", 276, 286], ["viral infection", "OBSERVATION", 359, 374]]], ["The arenavirus Lassa virus preferentially enters cells that express \u03b1-dystroglycan (\u03b1-DG) modified with long-chain matriglycans39.", [["cells", "ANATOMY", 49, 54], ["\u03b1-DG", "CHEMICAL", 84, 88], ["arenavirus Lassa virus", "ORGANISM", 4, 26], ["cells", "CELL", 49, 54], ["\u03b1-dystroglycan", "SIMPLE_CHEMICAL", 68, 82], ["\u03b1-DG", "SIMPLE_CHEMICAL", 84, 88], ["long-chain matriglycans39", "GENE_OR_GENE_PRODUCT", 104, 129], ["\u03b1-dystroglycan", "PROTEIN", 68, 82], ["\u03b1", "PROTEIN", 84, 85], ["DG", "PROTEIN", 86, 88], ["long-chain matriglycans39", "PROTEIN", 104, 129], ["arenavirus Lassa virus", "SPECIES", 4, 26], ["Lassa virus", "SPECIES", 15, 26], ["The arenavirus Lassa virus", "PROBLEM", 0, 26], ["\u03b1-dystroglycan (\u03b1-DG)", "TREATMENT", 68, 89], ["long-chain matriglycans39", "TREATMENT", 104, 129], ["arenavirus", "OBSERVATION_MODIFIER", 4, 14], ["Lassa virus", "OBSERVATION", 15, 26]]], ["Like-glycosyltransferase (LARGE) glycosylates \u03b1-DG31.", [["Like-glycosyltransferase", "GENE_OR_GENE_PRODUCT", 0, 24], ["LARGE", "GENE_OR_GENE_PRODUCT", 26, 31], ["\u03b1-DG31", "GENE_OR_GENE_PRODUCT", 46, 52], ["glycosyltransferase", "PROTEIN", 5, 24], ["LARGE", "PROTEIN", 26, 31], ["\u03b1-DG31", "PROTEIN", 46, 52], ["glycosyltransferase (LARGE) glycosylates", "TREATMENT", 5, 45], ["DG31", "TREATMENT", 48, 52]]], ["The extent to which LARGE modifies \u03b1-DG influences the avidity of Lassa virus for \u03b1-DG, and in the absence of these long-chain PTMs, Lassa virus alternatively uses TAM (Tyro3, Axl, Mer) receptors32,40.", [["\u03b1-DG", "CHEMICAL", 35, 39], ["\u03b1-DG", "CHEMICAL", 82, 86], ["TAM", "CHEMICAL", 164, 167], ["TAM", "CHEMICAL", 164, 167], ["LARGE", "GENE_OR_GENE_PRODUCT", 20, 25], ["\u03b1-DG", "SIMPLE_CHEMICAL", 35, 39], ["Lassa virus", "ORGANISM", 66, 77], ["\u03b1-DG", "SIMPLE_CHEMICAL", 82, 86], ["Lassa virus", "ORGANISM", 133, 144], ["TAM", "SIMPLE_CHEMICAL", 164, 167], ["Tyro3", "GENE_OR_GENE_PRODUCT", 169, 174], ["Axl", "GENE_OR_GENE_PRODUCT", 176, 179], ["Mer", "GENE_OR_GENE_PRODUCT", 181, 184], ["LARGE", "PROTEIN", 20, 25], ["TAM (Tyro3, Axl, Mer) receptors32,40", "PROTEIN", 164, 200], ["Lassa virus", "SPECIES", 66, 77], ["Lassa virus", "SPECIES", 66, 77], ["Lassa virus", "SPECIES", 133, 144], ["Lassa virus", "PROBLEM", 66, 77], ["\u03b1-DG", "PROBLEM", 82, 86], ["these long-chain PTMs", "TREATMENT", 110, 131], ["Lassa virus", "TREATMENT", 133, 144], ["TAM (Tyro3, Axl, Mer) receptors", "TREATMENT", 164, 195], ["LARGE", "OBSERVATION_MODIFIER", 20, 25]]], ["Population genetics data indicate positive selection of certain LARGE alleles in West Africa, a region where Lassa haemorrhagic fever is endemic31.", [["Lassa haemorrhagic fever", "DISEASE", 109, 133], ["LARGE", "GENE_OR_GENE_PRODUCT", 64, 69], ["Lassa haemorrhagic fever", "ORGANISM", 109, 133], ["LARGE alleles", "DNA", 64, 77], ["Lassa haemorrhagic fever", "SPECIES", 109, 133], ["Population genetics data", "TEST", 0, 24], ["Lassa haemorrhagic fever", "PROBLEM", 109, 133], ["positive selection", "OBSERVATION", 34, 52], ["LARGE", "OBSERVATION_MODIFIER", 64, 69], ["alleles", "OBSERVATION", 70, 77], ["Lassa", "OBSERVATION_MODIFIER", 109, 114]]], ["Therefore, population heterogeneity in \u03b1-DG glycosylation by LARGE may influence the prevalence and severity of Lassa fever.Host heterogeneity in receptor glycosylation ::: EntrySimilar findings have been reported for hepatitis C virus (HCV)34 (Fig. 2a).", [["Lassa fever", "DISEASE", 112, 123], ["hepatitis C", "DISEASE", 218, 229], ["\u03b1-DG", "SIMPLE_CHEMICAL", 39, 43], ["LARGE", "GENE_OR_GENE_PRODUCT", 61, 66], ["Lassa fever", "ORGANISM", 112, 123], ["hepatitis C virus", "ORGANISM", 218, 235], ["HCV)34", "ORGANISM", 237, 243], ["LARGE", "PROTEIN", 61, 66], ["hepatitis C virus", "SPECIES", 218, 235], ["hepatitis C virus", "SPECIES", 218, 235], ["HCV", "SPECIES", 237, 240], ["population heterogeneity", "PROBLEM", 11, 35], ["\u03b1-DG glycosylation", "TREATMENT", 39, 57], ["Lassa fever", "PROBLEM", 112, 123], ["EntrySimilar findings", "TEST", 173, 194], ["hepatitis C virus (HCV)", "PROBLEM", 218, 241], ["population", "OBSERVATION_MODIFIER", 11, 21], ["heterogeneity", "OBSERVATION_MODIFIER", 22, 35], ["LARGE", "OBSERVATION_MODIFIER", 61, 66], ["Lassa", "OBSERVATION", 112, 117], ["receptor glycosylation", "OBSERVATION", 146, 168]]], ["Glycosylation of human scavenger receptor class B type I (SR-BI), an HCV co-receptor41,42, is thought to be mediated by UDP-glucose:glycoprotein glucosyltransferase 1 (UGGT1)34.", [["UDP-glucose", "CHEMICAL", 120, 131], ["UDP", "CHEMICAL", 120, 123], ["glucose", "CHEMICAL", 124, 131], ["human", "ORGANISM", 17, 22], ["scavenger receptor class B type I", "GENE_OR_GENE_PRODUCT", 23, 56], ["SR-BI", "GENE_OR_GENE_PRODUCT", 58, 63], ["UDP-glucose:glycoprotein glucosyltransferase 1", "GENE_OR_GENE_PRODUCT", 120, 166], ["SR", "PROTEIN", 58, 60], ["HCV co-receptor41,42", "PROTEIN", 69, 89], ["UDP-glucose:glycoprotein glucosyltransferase 1 (UGGT1)34", "PROTEIN", 120, 176], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["HCV", "SPECIES", 69, 72], ["Glycosylation of human scavenger receptor class", "TREATMENT", 0, 47], ["an HCV co-receptor", "TEST", 66, 84], ["glycoprotein glucosyltransferase", "TREATMENT", 132, 164]]], ["Silencing of UGGT1 or inhibition of N-linked glycosylation of SR-BI reduces its expression, and this diminishes HCV entry34.", [["UGGT1", "CHEMICAL", 13, 18], ["UGGT1", "GENE_OR_GENE_PRODUCT", 13, 18], ["SR-BI", "GENE_OR_GENE_PRODUCT", 62, 67], ["HCV", "ORGANISM", 112, 115], ["UGGT1", "PROTEIN", 13, 18], ["SR", "PROTEIN", 62, 64], ["HCV entry34", "PROTEIN", 112, 123], ["HCV", "SPECIES", 112, 115], ["Silencing of UGGT1", "PROBLEM", 0, 18], ["N-linked glycosylation", "TREATMENT", 36, 58]]], ["SR-BI is also a receptor for high-density lipoprotein (HDL) and some individuals with high HDL levels carry the SR-BI variant T175A33, which not only interferes with removal of HDL but also disrupts SR-BI glycosylation and does not support SR-BI-mediated HCV entry43.", [["SR-BI", "GENE_OR_GENE_PRODUCT", 0, 5], ["high-density lipoprotein", "SIMPLE_CHEMICAL", 29, 53], ["HDL", "SIMPLE_CHEMICAL", 55, 58], ["HDL", "GENE_OR_GENE_PRODUCT", 91, 94], ["SR-BI", "GENE_OR_GENE_PRODUCT", 112, 117], ["HDL", "SIMPLE_CHEMICAL", 177, 180], ["SR-BI", "GENE_OR_GENE_PRODUCT", 199, 204], ["SR-BI", "GENE_OR_GENE_PRODUCT", 240, 245], ["HCV", "ORGANISM", 255, 258], ["high-density lipoprotein", "PROTEIN", 29, 53], ["HDL", "PROTEIN", 55, 58], ["HDL", "PROTEIN", 91, 94], ["HDL", "PROTEIN", 177, 180], ["HCV entry43", "PROTEIN", 255, 266], ["HCV", "SPECIES", 255, 258], ["a receptor", "TEST", 14, 24], ["some individuals", "PROBLEM", 64, 80], ["high HDL levels", "PROBLEM", 86, 101], ["the SR", "TEST", 108, 114], ["removal of HDL", "TREATMENT", 166, 180], ["density lipoprotein", "OBSERVATION", 34, 53]]], ["Therefore, allelic variants that change receptor PTMs may profoundly impact receptor avidity.", [["receptor PTMs", "PROTEIN", 40, 53], ["allelic variants", "PROBLEM", 11, 27], ["receptor PTMs", "TREATMENT", 40, 53], ["profoundly impact receptor avidity", "PROBLEM", 58, 92], ["allelic variants", "OBSERVATION", 11, 27]]], ["Future studies will be necessary to determine whether such allelic variants influence disease outcomes.Consequences of receptor heterogeneity for host range ::: EntryReceptor glycosylation can also influence the host range of a virus (Fig. 2b), as is the case for many pathogens associated with human pandemics, including influenza virus and at least two coronaviruses: severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV).", [["pandemics", "DISEASE", 301, 310], ["influenza virus", "DISEASE", 322, 337], ["acute respiratory syndrome coronavirus", "DISEASE", 377, 415], ["SARS-CoV)", "DISEASE", 417, 426], ["Middle East respiratory syndrome coronavirus", "DISEASE", 431, 475], ["human", "ORGANISM", 295, 300], ["influenza virus", "ORGANISM", 322, 337], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 370, 415], ["SARS-CoV", "ORGANISM", 417, 425], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 431, 475], ["MERS-CoV", "ORGANISM", 477, 485], ["human", "SPECIES", 295, 300], ["influenza virus", "SPECIES", 322, 337], ["human", "SPECIES", 295, 300], ["influenza virus", "SPECIES", 322, 337], ["severe acute respiratory syndrome coronavirus", "SPECIES", 370, 415], ["SARS-CoV", "SPECIES", 417, 425], ["Middle East respiratory syndrome coronavirus", "SPECIES", 431, 475], ["MERS-CoV", "SPECIES", 477, 485], ["Future studies", "TEST", 0, 14], ["such allelic variants influence disease outcomes", "PROBLEM", 54, 102], ["EntryReceptor glycosylation", "TREATMENT", 161, 188], ["a virus (Fig.", "TREATMENT", 226, 239], ["many pathogens", "PROBLEM", 264, 278], ["human pandemics", "PROBLEM", 295, 310], ["influenza virus", "PROBLEM", 322, 337], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 370, 415], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 431, 475], ["severe", "OBSERVATION_MODIFIER", 370, 376], ["acute", "OBSERVATION_MODIFIER", 377, 382], ["respiratory syndrome coronavirus", "OBSERVATION", 383, 415], ["Middle", "ANATOMY_MODIFIER", 431, 437], ["respiratory syndrome", "OBSERVATION", 443, 463]]], ["SARS-CoV and the newly emerged SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), both use angiotensin-converting enzyme 2 (ACE2) as a receptor44,45, whereas MERS-CoV uses dipeptidyl peptidase 4 (DPP4) for entry into host cells46.", [["cells", "ANATOMY", 243, 248], ["SARS", "DISEASE", 0, 4], ["coronavirus disease", "DISEASE", 66, 85], ["angiotensin", "CHEMICAL", 112, 123], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 31, 41], ["coronavirus", "ORGANISM", 66, 77], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 112, 143], ["ACE2", "GENE_OR_GENE_PRODUCT", 145, 149], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 179, 187], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 193, 215], ["DPP4", "GENE_OR_GENE_PRODUCT", 217, 221], ["host cells", "CELL", 238, 248], ["angiotensin-converting enzyme 2", "PROTEIN", 112, 143], ["ACE2", "PROTEIN", 145, 149], ["receptor44,45", "PROTEIN", 156, 169], ["MERS-CoV", "PROTEIN", 179, 187], ["dipeptidyl peptidase 4", "PROTEIN", 193, 215], ["DPP4", "PROTEIN", 217, 221], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 31, 39], ["MERS-CoV", "SPECIES", 179, 187], ["SARS", "PROBLEM", 0, 4], ["coronavirus disease", "PROBLEM", 66, 85], ["COVID", "TEST", 92, 97], ["angiotensin", "TREATMENT", 112, 123], ["a receptor", "TEST", 154, 164], ["dipeptidyl peptidase", "TREATMENT", 193, 213], ["coronavirus disease", "OBSERVATION", 66, 85]]], ["For both MERS-CoV and SARS-CoV, receptor glycosylation leads to a species barrier.", [["SARS", "DISEASE", 22, 26], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 9, 17], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 22, 30], ["MERS-CoV", "SPECIES", 9, 17], ["SARS-CoV", "SPECIES", 22, 30], ["CoV", "PROBLEM", 14, 17], ["SARS", "PROBLEM", 22, 26], ["CoV", "PROBLEM", 27, 30], ["receptor glycosylation", "TREATMENT", 32, 54], ["a species barrier", "TREATMENT", 64, 81]]], ["Bat, camel and human DPP4 orthologues, which are not glycosylated, support infection of MERS-CoV, but glycosylated DPP4 orthologues from other species do not36,37.", [["infection", "DISEASE", 75, 84], ["Bat", "GENE_OR_GENE_PRODUCT", 0, 3], ["camel", "ORGANISM", 5, 10], ["human", "ORGANISM", 15, 20], ["DPP4", "GENE_OR_GENE_PRODUCT", 21, 25], ["MERS-CoV", "ORGANISM", 88, 96], ["DPP4", "GENE_OR_GENE_PRODUCT", 115, 119], ["Bat, camel and human DPP4 orthologues", "PROTEIN", 0, 37], ["glycosylated DPP4 orthologues", "PROTEIN", 102, 131], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["MERS-CoV", "SPECIES", 88, 96], ["human DPP4 orthologues", "TEST", 15, 37], ["infection of MERS", "PROBLEM", 75, 92], ["CoV", "PROBLEM", 93, 96], ["glycosylated DPP4 orthologues", "TEST", 102, 131], ["other species", "TEST", 137, 150]]], ["Glycosylated DPP4 does not support MERS-CoV entry in cells expressing mouse, ferret, hamster and guinea pig DPP4 orthologs36,37.", [["cells", "ANATOMY", 53, 58], ["hamster", "ANATOMY", 85, 92], ["DPP4", "GENE_OR_GENE_PRODUCT", 13, 17], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 35, 43], ["cells", "CELL", 53, 58], ["mouse", "ORGANISM", 70, 75], ["ferret", "ORGANISM", 77, 83], ["hamster", "ORGANISM", 85, 92], ["guinea pig", "ORGANISM", 97, 107], ["DPP4", "GENE_OR_GENE_PRODUCT", 108, 112], ["DPP4", "PROTEIN", 13, 17], ["mouse", "SPECIES", 70, 75], ["ferret", "SPECIES", 77, 83], ["hamster", "SPECIES", 85, 92], ["guinea pig", "SPECIES", 97, 107], ["mouse", "SPECIES", 70, 75], ["ferret", "SPECIES", 77, 83], ["hamster", "SPECIES", 85, 92], ["guinea pig", "SPECIES", 97, 107], ["Glycosylated DPP4", "TREATMENT", 0, 17]]], ["Removal of DPP4 glycosylation fully restores permissivity of cells expressing mouse DPP4 and partially restores permissivity of cells expressing hamster and guinea pig DPP4 to MERS-CoV infection36,37.", [["cells", "ANATOMY", 61, 66], ["cells", "ANATOMY", 128, 133], ["hamster", "ANATOMY", 145, 152], ["infection", "DISEASE", 185, 194], ["DPP4", "GENE_OR_GENE_PRODUCT", 11, 15], ["cells", "CELL", 61, 66], ["mouse", "ORGANISM", 78, 83], ["DPP4", "GENE_OR_GENE_PRODUCT", 84, 88], ["cells", "CELL", 128, 133], ["hamster", "ORGANISM", 145, 152], ["guinea pig", "ORGANISM", 157, 167], ["DPP4", "GENE_OR_GENE_PRODUCT", 168, 172], ["MERS-CoV", "ORGANISM", 176, 184], ["DPP4", "PROTEIN", 11, 15], ["mouse DPP4", "PROTEIN", 78, 88], ["DPP4", "PROTEIN", 168, 172], ["mouse", "SPECIES", 78, 83], ["hamster", "SPECIES", 145, 152], ["guinea pig", "SPECIES", 157, 167], ["mouse", "SPECIES", 78, 83], ["hamster", "SPECIES", 145, 152], ["guinea pig", "SPECIES", 157, 167], ["MERS-CoV", "SPECIES", 176, 184], ["Removal", "TREATMENT", 0, 7], ["DPP4 glycosylation", "TREATMENT", 11, 29], ["guinea pig DPP4", "TREATMENT", 157, 172], ["CoV infection", "PROBLEM", 181, 194], ["CoV", "OBSERVATION_MODIFIER", 181, 184], ["infection", "OBSERVATION", 185, 194]]], ["SARS-CoV efficiently replicates in a wide range of animals, most prominently humans, bats and palm civets (reviewed elsewhere38).", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["humans", "ORGANISM", 77, 83], ["palm", "ORGANISM_SUBDIVISION", 94, 98], ["humans", "SPECIES", 77, 83], ["SARS-CoV", "SPECIES", 0, 8], ["humans", "SPECIES", 77, 83], ["SARS", "PROBLEM", 0, 4]]], ["A species barrier exists in mice and rats, however38.", [["mice", "ORGANISM", 28, 32], ["rats", "ORGANISM", 37, 41], ["mice", "SPECIES", 28, 32], ["rats", "SPECIES", 37, 41], ["mice", "SPECIES", 28, 32], ["A species barrier", "TREATMENT", 0, 17]]], ["This barrier has been mapped to two mutations in the ACE2 receptor, one of which introduces a glycosylation site in rat ACE2 that sterically hinders SARS-CoV infection.", [["SARS-CoV infection", "DISEASE", 149, 167], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 53, 66], ["rat", "ORGANISM", 116, 119], ["ACE2", "GENE_OR_GENE_PRODUCT", 120, 124], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 149, 157], ["ACE2 receptor", "PROTEIN", 53, 66], ["glycosylation site", "PROTEIN", 94, 112], ["rat ACE2", "PROTEIN", 116, 124], ["rat", "SPECIES", 116, 119], ["rat", "SPECIES", 116, 119], ["SARS-CoV", "SPECIES", 149, 157], ["This barrier", "TREATMENT", 0, 12], ["the ACE2 receptor", "TREATMENT", 49, 66], ["a glycosylation site", "TREATMENT", 92, 112], ["CoV infection", "PROBLEM", 154, 167], ["CoV", "OBSERVATION_MODIFIER", 154, 157], ["infection", "OBSERVATION", 158, 167]]], ["The newly emerged SARS-CoV-2 also uses ACE2 as its receptor45 and considerable interest in the receptor avidity of SARS-CoV-2 is already apparent47.", [["SARS", "DISEASE", 18, 22], ["SARS", "DISEASE", 115, 119], ["SARS-CoV-2", "ORGANISM", 18, 28], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["receptor45", "GENE_OR_GENE_PRODUCT", 51, 61], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 115, 125], ["apparent47", "GENE_OR_GENE_PRODUCT", 137, 147], ["ACE2", "PROTEIN", 39, 43], ["receptor45", "PROTEIN", 51, 61], ["apparent47", "DNA", 137, 147], ["SARS-CoV", "SPECIES", 18, 26], ["SARS-CoV", "SPECIES", 115, 123], ["ACE2", "TREATMENT", 39, 43], ["CoV", "TEST", 120, 123]]], ["Whether glycosylation or other PTMs in ACE2 or in the receptor-binding protein, spike (S), have influenced the emergence of this pandemic virus should be explored.Consequences of receptor heterogeneity for host range ::: EntryHost range is heavily influenced by the glycan specificities of influenza A viruses (IAVs) in different hosts.", [["influenza A viruses", "DISEASE", 290, 309], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["receptor-binding protein", "GENE_OR_GENE_PRODUCT", 54, 78], ["influenza A viruses", "ORGANISM", 290, 309], ["IAVs", "CANCER", 311, 315], ["PTMs", "PROTEIN", 31, 35], ["ACE2", "PROTEIN", 39, 43], ["receptor-binding protein", "PROTEIN", 54, 78], ["influenza A viruses", "SPECIES", 290, 309], ["influenza A viruses", "SPECIES", 290, 309], ["glycosylation", "PROBLEM", 8, 21], ["ACE2", "TEST", 39, 43], ["the receptor-binding protein", "TEST", 50, 78], ["this pandemic virus", "PROBLEM", 124, 143], ["influenza", "PROBLEM", 290, 299], ["influenza", "OBSERVATION", 290, 299]]], ["Most epithelial cells in the human respiratory tract preferentially express long-chain \u03b12,6-linked sialic acid glycans, whereas avian gut cells express \u03b12,3-linked sialic acids35.", [["epithelial cells", "ANATOMY", 5, 21], ["respiratory tract", "ANATOMY", 35, 52], ["gut cells", "ANATOMY", 134, 143], ["sialic acid", "CHEMICAL", 99, 110], ["sialic acid", "CHEMICAL", 99, 110], ["epithelial cells", "CELL", 5, 21], ["human", "ORGANISM", 29, 34], ["respiratory tract", "ORGAN", 35, 52], ["sialic acid glycans", "SIMPLE_CHEMICAL", 99, 118], ["gut cells", "CELL", 134, 143], ["\u03b12,3-linked sialic acids35", "SIMPLE_CHEMICAL", 152, 178], ["epithelial cells", "CELL_TYPE", 5, 21], ["avian gut cells", "CELL_TYPE", 128, 143], ["\u03b12,3-linked sialic acids35", "PROTEIN", 152, 178], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["Most epithelial cells in the human respiratory tract", "PROBLEM", 0, 52], ["linked sialic acid glycans", "PROBLEM", 92, 118], ["epithelial cells", "OBSERVATION", 5, 21], ["human", "ANATOMY_MODIFIER", 29, 34], ["respiratory tract", "ANATOMY", 35, 52], ["sialic", "ANATOMY_MODIFIER", 99, 105], ["acid glycans", "OBSERVATION", 106, 118]]], ["Correspondingly, human-origin IAV strains have higher affinity for long-chain \u03b12,6-linked sialic acids, which predominate in the human respiratory tract, and avian-origin IAV strains have higher affinity for \u03b12,3-linked sialic acids35,48,49.", [["respiratory tract", "ANATOMY", 135, 152], ["sialic acids", "CHEMICAL", 90, 102], ["sialic acids", "CHEMICAL", 220, 232], ["sialic acids", "CHEMICAL", 90, 102], ["sialic acids", "CHEMICAL", 220, 232], ["human-origin IAV strains", "ORGANISM", 17, 41], ["long-chain \u03b12,6-linked sialic acids", "SIMPLE_CHEMICAL", 67, 102], ["human", "ORGANISM", 129, 134], ["respiratory tract", "ORGANISM_SUBDIVISION", 135, 152], ["avian-origin", "ORGANISM", 158, 170], ["IAV strains", "ORGANISM", 171, 182], ["\u03b12,3-linked sialic acids", "SIMPLE_CHEMICAL", 208, 232], ["\u03b12,3-linked sialic acids35,48,49", "PROTEIN", 208, 240], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["human-origin IAV strains", "PROBLEM", 17, 41], ["higher affinity", "PROBLEM", 47, 62], ["linked sialic acids", "PROBLEM", 83, 102], ["IAV strains", "PROBLEM", 171, 182], ["sialic acids", "TEST", 220, 232], ["sialic acids", "OBSERVATION", 90, 102], ["human", "ANATOMY_MODIFIER", 129, 134], ["respiratory tract", "ANATOMY", 135, 152]]], ["As we have already seen, affinity for specific sialic acid linkages can change over time30, with consequences for disease severity.", [["sialic acid", "CHEMICAL", 47, 58], ["sialic acid", "CHEMICAL", 47, 58], ["sialic acid", "SIMPLE_CHEMICAL", 47, 58], ["specific sialic acid linkages", "TREATMENT", 38, 67], ["disease severity", "PROBLEM", 114, 130]]], ["As we continue to study and learn from past pandemics, the impact of PTMs on receptor avidity and host range must be explored.Inverse relationship between viral replication and host immunity within a cell ::: ReplicationscRNA-seq has been used to examine the viral RNA burden across single cells.", [["cell", "ANATOMY", 200, 204], ["cells", "ANATOMY", 290, 295], ["cell", "CELL", 200, 204], ["cells", "CELL", 290, 295], ["PTMs", "PROTEIN", 69, 73], ["seq", "DNA", 226, 229], ["single cells", "CELL_TYPE", 283, 295], ["PTMs on receptor avidity", "TREATMENT", 69, 93], ["viral replication", "TREATMENT", 155, 172], ["ReplicationscRNA", "TEST", 209, 225], ["the viral RNA burden across single cells", "PROBLEM", 255, 295], ["viral replication", "OBSERVATION", 155, 172], ["viral RNA", "OBSERVATION", 259, 268]]], ["This methodology revealed cell-to-cell variation in viral RNA abundance for IAVs, dengue virus, poliovirus, West Nile virus and Zika virus6,9,11,12 ranging from <0.1 to 50% of the cellular transcriptome12.", [["cell", "ANATOMY", 26, 30], ["cell", "ANATOMY", 34, 38], ["cellular", "ANATOMY", 180, 188], ["dengue", "DISEASE", 82, 88], ["cell", "CELL", 26, 30], ["cell", "CELL", 34, 38], ["IAVs", "GENE_OR_GENE_PRODUCT", 76, 80], ["dengue virus", "ORGANISM", 82, 94], ["poliovirus", "ORGANISM", 96, 106], ["West Nile virus", "ORGANISM", 108, 123], ["Zika virus", "ORGANISM", 128, 138], ["cellular", "CELL", 180, 188], ["cellular transcriptome12", "PROTEIN", 180, 204], ["dengue virus", "SPECIES", 82, 94], ["West Nile virus", "SPECIES", 108, 123], ["Zika virus", "SPECIES", 128, 138], ["dengue virus", "SPECIES", 82, 94], ["West Nile virus", "SPECIES", 108, 123], ["Zika virus", "SPECIES", 128, 138], ["This methodology", "TEST", 0, 16], ["cell", "TEST", 26, 30], ["cell variation", "PROBLEM", 34, 48], ["viral RNA abundance", "PROBLEM", 52, 71], ["IAVs", "PROBLEM", 76, 80], ["dengue virus", "PROBLEM", 82, 94], ["poliovirus", "PROBLEM", 96, 106], ["West Nile virus", "PROBLEM", 108, 123], ["Zika virus", "PROBLEM", 128, 138], ["cell variation", "OBSERVATION", 34, 48], ["viral RNA", "OBSERVATION", 52, 61]]], ["Viral infections trigger antiviral defences upon activation of interferon and downstream interferon-stimulated genes55.", [["Viral infections", "DISEASE", 0, 16], ["Viral", "ORGANISM", 0, 5], ["interferon", "GENE_OR_GENE_PRODUCT", 63, 73], ["interferon-stimulated genes55", "GENE_OR_GENE_PRODUCT", 89, 118], ["interferon", "PROTEIN", 63, 73], ["downstream interferon-stimulated genes55", "PROTEIN", 78, 118], ["Viral infections", "PROBLEM", 0, 16], ["antiviral defences", "TREATMENT", 25, 43], ["interferon", "TREATMENT", 63, 73], ["downstream interferon", "TREATMENT", 78, 99], ["infections", "OBSERVATION", 6, 16], ["antiviral defences", "OBSERVATION", 25, 43]]], ["However, scRNA-seq demonstrated that robust activation of interferon-\u03b2 (IFN\u03b2) mRNA transcripts is found in only a few cells infected with IAVs or West Nile virus6,8,12.", [["cells", "ANATOMY", 118, 123], ["interferon-\u03b2", "GENE_OR_GENE_PRODUCT", 58, 70], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 72, 76], ["cells", "CELL", 118, 123], ["IAVs", "GENE_OR_GENE_PRODUCT", 138, 142], ["West Nile virus6,8,12", "ORGANISM", 146, 167], ["scRNA-seq", "DNA", 9, 18], ["interferon-\u03b2 (IFN\u03b2) mRNA transcripts", "RNA", 58, 94], ["West Nile virus6", "SPECIES", 146, 162], ["scRNA", "TEST", 9, 14], ["interferon", "TREATMENT", 58, 68], ["mRNA transcripts", "PROBLEM", 78, 94]]], ["Defective IAV particles activate interferon expression in bulk cells56, yet individual infected cells rarely induce interferon production16,57.", [["bulk cells56", "ANATOMY", 58, 70], ["cells", "ANATOMY", 96, 101], ["IAV particles", "ORGANISM", 10, 23], ["interferon", "GENE_OR_GENE_PRODUCT", 33, 43], ["cells56", "GENE_OR_GENE_PRODUCT", 63, 70], ["cells", "CELL", 96, 101], ["interferon", "GENE_OR_GENE_PRODUCT", 116, 126], ["interferon", "PROTEIN", 33, 43], ["infected cells", "CELL_TYPE", 87, 101], ["interferon", "PROTEIN", 116, 126], ["Defective IAV particles", "PROBLEM", 0, 23], ["bulk cells56", "TEST", 58, 70], ["individual infected cells", "PROBLEM", 76, 101], ["interferon production", "PROBLEM", 116, 137], ["IAV particles", "OBSERVATION", 10, 23], ["interferon expression", "OBSERVATION", 33, 54], ["infected cells", "OBSERVATION", 87, 101]]], ["West Nile virus-infected cells exhibit several expression patterns of individual interferon-stimulated genes across single cells6.", [["cells", "ANATOMY", 25, 30], ["West Nile virus", "ORGANISM", 0, 15], ["cells", "CELL", 25, 30], ["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 81, 108], ["interferon-stimulated genes", "DNA", 81, 108], ["cells6", "DNA", 123, 129], ["Nile virus-", "SPECIES", 5, 16], ["West Nile virus", "SPECIES", 0, 15], ["West Nile virus", "PROBLEM", 0, 15], ["infected cells", "PROBLEM", 16, 30], ["individual interferon", "TREATMENT", 70, 91], ["infected cells", "OBSERVATION", 16, 30]]], ["Interferon-stimulated gene expression ranged from strongly negatively correlated to weakly positively correlated with viral RNA abundance6.", [["Interferon-stimulated gene", "GENE_OR_GENE_PRODUCT", 0, 26], ["Interferon", "PROTEIN", 0, 10], ["viral RNA abundance6", "RNA", 118, 138], ["Interferon", "TREATMENT", 0, 10], ["viral RNA abundance6", "PROBLEM", 118, 138]]], ["It is likely that use of scRNA-seq in a wide range of cell types will spur the detection of novel antiviral gene candidates with therapeutic potential6,11.", [["cell", "ANATOMY", 54, 58], ["scRNA-seq", "GENE_OR_GENE_PRODUCT", 25, 34], ["cell", "CELL", 54, 58], ["scRNA-seq", "DNA", 25, 34], ["scRNA", "TREATMENT", 25, 30], ["novel antiviral gene candidates", "TREATMENT", 92, 123], ["is likely", "UNCERTAINTY", 3, 12]]], ["Whether these observations indicate active suppression of interferon or a failure to activate interferon should be explored further.Inverse relationship between viral replication and host immunity within a cell ::: ReplicationThe scRNA-seq methodology has been indispensable in the study of incomplete or semi-infectious influenza virus particles.", [["cell", "ANATOMY", 206, 210], ["interferon", "GENE_OR_GENE_PRODUCT", 58, 68], ["interferon", "GENE_OR_GENE_PRODUCT", 94, 104], ["cell", "CELL", 206, 210], ["influenza virus", "ORGANISM", 321, 336], ["interferon", "PROTEIN", 58, 68], ["interferon", "PROTEIN", 94, 104], ["active suppression of interferon", "PROBLEM", 36, 68], ["a failure", "PROBLEM", 72, 81], ["interferon", "TREATMENT", 94, 104], ["viral replication", "TREATMENT", 161, 178], ["The scRNA", "TEST", 226, 235], ["the study", "TEST", 278, 287], ["incomplete or semi-infectious influenza virus particles", "PROBLEM", 291, 346], ["active", "OBSERVATION_MODIFIER", 36, 42], ["interferon", "OBSERVATION", 58, 68], ["viral replication", "OBSERVATION", 161, 178]]], ["The IAV genome consists of eight viral RNA segments that are not always expressed in an infected cell13,58,59.", [["cell", "ANATOMY", 97, 101], ["cell", "CELL", 97, 101], ["IAV genome", "DNA", 4, 14], ["viral RNA segments", "RNA", 33, 51], ["IAV", "SPECIES", 4, 7], ["eight viral RNA segments", "PROBLEM", 27, 51], ["IAV genome", "OBSERVATION", 4, 14], ["eight", "OBSERVATION_MODIFIER", 27, 32], ["viral RNA segments", "OBSERVATION", 33, 51], ["not always", "UNCERTAINTY", 61, 71], ["infected cell", "OBSERVATION", 88, 101]]], ["Failure to express all eight segments impairs viral mRNA transcription and the productivity of infection12,13,17,60,61.", [["infection", "DISEASE", 95, 104], ["viral mRNA", "RNA", 46, 56], ["Failure to express all eight segments impairs viral mRNA transcription", "PROBLEM", 0, 70], ["infection", "PROBLEM", 95, 104], ["infection", "OBSERVATION", 95, 104]]], ["More recently, one study coupled single-cell transcriptomics with long-read PacBio sequencing, determining that two-thirds of cells were infected with IAV variants with mutations and deletions that lead to higher levels of immune activation than the wild-type variant8.", [["cell", "ANATOMY", 40, 44], ["cells", "ANATOMY", 126, 131], ["cell", "CELL", 40, 44], ["cells", "CELL", 126, 131], ["IAV", "ORGANISM", 151, 154], ["variant8", "GENE_OR_GENE_PRODUCT", 260, 268], ["one study", "TEST", 15, 24], ["PacBio sequencing", "TEST", 76, 93], ["IAV variants", "TREATMENT", 151, 163], ["mutations and deletions", "PROBLEM", 169, 192], ["immune activation", "PROBLEM", 223, 240], ["IAV variants", "OBSERVATION", 151, 163], ["immune activation", "OBSERVATION", 223, 240]]], ["Sequencing viral genes in individual cells captures heterogeneity that has so far been overlooked and provides a unique perspective on viral species present during infection.Defective viral genomes are drivers of replicative heterogeneity ::: ReplicationMost RNA viruses produce DVGs upon replication at high multiplicity of infection7.", [["cells", "ANATOMY", 37, 42], ["infection", "DISEASE", 164, 173], ["cells", "CELL", 37, 42], ["DVGs", "GENE_OR_GENE_PRODUCT", 279, 283], ["viral genes", "DNA", 11, 22], ["viral genomes", "DNA", 184, 197], ["Sequencing viral genes in individual cells", "PROBLEM", 0, 42], ["viral species", "PROBLEM", 135, 148], ["infection", "PROBLEM", 164, 173], ["Defective viral genomes", "PROBLEM", 174, 197], ["DVGs", "PROBLEM", 279, 283], ["infection7", "PROBLEM", 325, 335], ["viral genes", "OBSERVATION", 11, 22], ["viral species", "OBSERVATION", 135, 148], ["infection", "OBSERVATION", 164, 173], ["viral genomes", "OBSERVATION", 184, 197], ["replicative heterogeneity", "OBSERVATION", 213, 238], ["high multiplicity", "OBSERVATION_MODIFIER", 304, 321]]], ["DVGs are truncated forms of the viral genome that lack essential genes and cannot replicate in the absence of a helper virus with complementing components.", [["DVGs", "GENE_OR_GENE_PRODUCT", 0, 4], ["viral genome", "DNA", 32, 44], ["the viral genome", "PROBLEM", 28, 44], ["a helper virus", "PROBLEM", 110, 124], ["truncated", "OBSERVATION", 9, 18], ["viral genome", "OBSERVATION", 32, 44], ["essential genes", "OBSERVATION", 55, 70]]], ["Two main types of DVGs exist, deletion and copy-back DVGs7,62.", [["DVGs", "GENE_OR_GENE_PRODUCT", 18, 22], ["DVGs", "DNA", 18, 22], ["deletion", "PROBLEM", 30, 38], ["copy-back DVGs", "TEST", 43, 57], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Deletion DVGs lack parts of the genome and hundreds of different variants of these have been identified from a single infection7.", [["genome", "CELLULAR_COMPONENT", 32, 38], ["DVGs", "DNA", 9, 13], ["Deletion DVGs", "PROBLEM", 0, 13], ["a single infection7", "PROBLEM", 109, 128], ["hundreds", "OBSERVATION_MODIFIER", 43, 51], ["different variants", "OBSERVATION_MODIFIER", 55, 73], ["single", "OBSERVATION_MODIFIER", 111, 117], ["infection7", "OBSERVATION", 118, 128]]], ["By contrast, copy-back DVGs are regulated by sequence-specific \u2018break points\u2019 and \u2018rejoin points\u2019 at which the polymerase detaches and rejoins the template, and thus are not stochastic in origin62.", [["the polymerase detaches", "PROBLEM", 107, 130], ["not", "UNCERTAINTY", 170, 173], ["stochastic", "OBSERVATION", 174, 184]]], ["For unknown reasons, Sendai virus DVGs are unable to interact with host factors involved in viral packaging and budding, limiting replication of these variant genomes in the absence of full-length genome complementation63,64.", [["Sendai virus DVGs", "ORGANISM", 21, 38], ["host factors", "PROTEIN", 67, 79], ["variant genomes", "DNA", 151, 166], ["full-length genome complementation63,64", "DNA", 185, 224], ["Sendai virus", "SPECIES", 21, 33], ["Sendai virus DVGs", "PROBLEM", 21, 38], ["viral packaging", "TREATMENT", 92, 107], ["viral packaging", "OBSERVATION", 92, 107]]], ["Evading or counteracting the host antiviral response is critical for productive infection and efficient replication.", [["infection", "DISEASE", 80, 89], ["productive infection", "PROBLEM", 69, 89], ["productive", "OBSERVATION_MODIFIER", 69, 79], ["infection", "OBSERVATION", 80, 89]]], ["Yet DVG production decreases infectivity by competing with full-length genomes and robustly triggering the host antiviral response.", [["DVG", "CHEMICAL", 4, 7], ["DVG", "GENE_OR_GENE_PRODUCT", 4, 7], ["full-length genomes", "DNA", 59, 78], ["DVG production", "PROBLEM", 4, 18], ["production", "OBSERVATION_MODIFIER", 8, 18], ["decreases", "OBSERVATION_MODIFIER", 19, 28], ["infectivity", "OBSERVATION_MODIFIER", 29, 40]]], ["DVGs also affect temporal variation of the host cell transcriptome61.", [["cell", "ANATOMY", 48, 52], ["DVGs", "SIMPLE_CHEMICAL", 0, 4], ["host cell", "CELL", 43, 52], ["affect", "OBSERVATION_MODIFIER", 10, 16], ["temporal", "OBSERVATION_MODIFIER", 17, 25], ["variation", "OBSERVATION_MODIFIER", 26, 35], ["host cell transcriptome61", "OBSERVATION", 43, 68]]], ["The role of DVGs during infection remains unclear but may lie in providing diversity to viral populations with high recombination or reassortment rates, or in offering a link to the development of persistent infections.Viral population diversity and implications for host fitness ::: ReplicationCross-species transmission is a major driver of viral evolution and diversity, with greater genetic heterogeneity maximizing the likelihood of host jumping.", [["DVGs", "CHEMICAL", 12, 16], ["infection", "DISEASE", 24, 33], ["infections", "DISEASE", 208, 218], ["DVGs", "GENE_OR_GENE_PRODUCT", 12, 16], ["DVGs during infection", "PROBLEM", 12, 33], ["viral populations", "PROBLEM", 88, 105], ["high recombination", "TREATMENT", 111, 129], ["persistent infections", "PROBLEM", 197, 218], ["viral evolution", "PROBLEM", 343, 358], ["greater genetic heterogeneity", "PROBLEM", 379, 408], ["host jumping", "PROBLEM", 438, 450], ["infection", "OBSERVATION", 24, 33], ["persistent", "OBSERVATION_MODIFIER", 197, 207], ["infections", "OBSERVATION", 208, 218], ["viral", "OBSERVATION", 343, 348], ["host jumping", "OBSERVATION", 438, 450]]], ["RNA virus families such as Rhabdoviridae and Picornaviridae that undergo frequent host switching are substantially less co-evolved with their hosts than double-stranded DNA viruses, which infrequently switch hosts65.", [["Rhabdoviridae", "GENE_OR_GENE_PRODUCT", 27, 40], ["Picornaviridae", "GENE_OR_GENE_PRODUCT", 45, 59], ["DNA", "CELLULAR_COMPONENT", 169, 172], ["RNA virus families", "TREATMENT", 0, 18], ["Rhabdoviridae", "TREATMENT", 27, 40], ["Picornaviridae", "TREATMENT", 45, 59], ["frequent host switching", "TREATMENT", 73, 96], ["double-stranded DNA viruses", "TREATMENT", 153, 180]]], ["This suggests that the genetic plasticity of RNA viruses allows host switching with the potential cost of reduced fitness in the original host; however, there are noteworthy exceptions to this theory, including the HCV and HIV-1 examples described at the end of this section.", [["HCV", "ORGANISM", 215, 218], ["HIV-1", "ORGANISM", 223, 228], ["HIV-1", "SPECIES", 223, 228], ["HCV", "SPECIES", 215, 218], ["HIV-1", "SPECIES", 223, 228], ["RNA viruses", "PROBLEM", 45, 56], ["reduced fitness", "PROBLEM", 106, 121], ["the HCV", "PROBLEM", 211, 218], ["this section", "TREATMENT", 262, 274], ["RNA viruses", "OBSERVATION", 45, 56]]], ["Here, we highlight recent examples of genetic heterogeneity in different viruses and examine how they impact host fitness and host jumping.Viral population diversity and implications for host fitness ::: ReplicationPopulation heterogeneity facilitates host jumping in different ways.", [["genetic heterogeneity in different viruses", "PROBLEM", 38, 80], ["ReplicationPopulation heterogeneity", "PROBLEM", 204, 239], ["different viruses", "OBSERVATION", 63, 80], ["host jumping", "OBSERVATION", 252, 264]]], ["In the arthropod-borne chikungunya virus, acquisition of the A226V mutation in the envelope protein E1 expands vector competence from the tropical mosquito vector Aedes aegypti to the Asian tiger mosquito Aedes albopictus, an invasive mosquito tolerant of both tropical and temperate climates66,67.", [["chikungunya virus", "DISEASE", 23, 40], ["arthropod-borne", "ORGANISM", 7, 22], ["chikungunya virus", "ORGANISM", 23, 40], ["A226V", "GENE_OR_GENE_PRODUCT", 61, 66], ["E1", "GENE_OR_GENE_PRODUCT", 100, 102], ["Aedes aegypti", "ORGANISM", 163, 176], ["Asian", "ORGANISM", 184, 189], ["tiger mosquito", "ORGANISM", 190, 204], ["Aedes albopictus", "ORGANISM", 205, 221], ["envelope protein E1", "PROTEIN", 83, 102], ["chikungunya virus", "SPECIES", 23, 40], ["Aedes aegypti", "SPECIES", 163, 176], ["Aedes albopictus", "SPECIES", 205, 221], ["chikungunya virus", "SPECIES", 23, 40], ["Aedes aegypti", "SPECIES", 163, 176], ["Asian tiger", "SPECIES", 184, 195], ["Aedes albopictus", "SPECIES", 205, 221], ["chikungunya virus", "PROBLEM", 23, 40], ["the A226V mutation", "PROBLEM", 57, 75], ["the envelope protein E1", "TREATMENT", 79, 102], ["invasive", "OBSERVATION_MODIFIER", 226, 234]]], ["However, the E1-A226V mutation requires lineage-specific epistatic mutations, with the Asian chikungunya virus lineage unable to adapt to Ae. albopictus68.", [["chikungunya", "DISEASE", 93, 104], ["E1", "GENE_OR_GENE_PRODUCT", 13, 15], ["A226V", "GENE_OR_GENE_PRODUCT", 16, 21], ["E1", "DNA", 13, 15], ["A226V", "PROTEIN", 16, 21], ["Asian chikungunya virus", "SPECIES", 87, 110], ["Ae.", "SPECIES", 138, 141], ["specific epistatic mutations", "PROBLEM", 48, 76], ["the Asian chikungunya virus lineage", "PROBLEM", 83, 118], ["epistatic mutations", "OBSERVATION", 57, 76]]], ["Different rabies virus (RABV) lineages also exhibit differential propensities for host jumping69.", [["rabies virus", "ORGANISM", 10, 22], ["RABV", "ORGANISM", 24, 28], ["rabies virus", "SPECIES", 10, 22], ["rabies virus", "SPECIES", 10, 22], ["RABV", "SPECIES", 24, 28], ["Different rabies virus", "PROBLEM", 0, 22], ["rabies virus", "OBSERVATION", 10, 22], ["differential", "OBSERVATION_MODIFIER", 52, 64]]], ["Dog-adapted and fox-adapted RABV lineages both show comparable rates of population heterogeneity during serial passage, yet only dog-adapted RABV efficiently replicates in both the domestic dog and the European red fox69.", [["fox", "ORGANISM", 16, 19], ["RABV", "ORGANISM", 28, 32], ["dog", "ORGANISM", 129, 132], ["RABV", "ORGANISM", 141, 145], ["dog", "ORGANISM", 190, 193], ["fox69", "GENE_OR_GENE_PRODUCT", 215, 220], ["dog", "SPECIES", 190, 193], ["RABV", "SPECIES", 28, 32], ["RABV", "SPECIES", 141, 145], ["European red fox69", "SPECIES", 202, 220], ["RABV lineages", "TREATMENT", 28, 41], ["population heterogeneity", "PROBLEM", 72, 96], ["serial passage", "TEST", 104, 118], ["domestic dog", "ANATOMY", 181, 193]]], ["These observations suggest that adaptation within certain host species can increase viral variants capable of host switching.", [["adaptation within certain host species", "PROBLEM", 32, 70], ["viral variants", "PROBLEM", 84, 98], ["host switching", "TREATMENT", 110, 124], ["host switching", "OBSERVATION", 110, 124]]], ["In addition, the acquisition of certain genetic changes through viral evolution can influence the success of a given strain in a new host.Viral population diversity and implications for host fitness ::: ReplicationThe importance of host-adaptive mutations on cross-species jumping has been examined most often for zoonotic viruses that successfully jump into human hosts, often spurring severe outbreaks that occasionally lead to widespread pandemics.", [["zoonotic viruses", "DISEASE", 314, 330], ["human", "ORGANISM", 359, 364], ["human", "SPECIES", 359, 364], ["human", "SPECIES", 359, 364], ["certain genetic changes", "PROBLEM", 32, 55], ["adaptive mutations", "PROBLEM", 237, 255], ["zoonotic viruses", "PROBLEM", 314, 330], ["spurring severe outbreaks", "PROBLEM", 378, 403], ["widespread pandemics", "PROBLEM", 430, 450], ["widespread", "OBSERVATION_MODIFIER", 430, 440], ["pandemics", "OBSERVATION", 441, 450]]], ["Wild birds are the primary reservoir for zoonotic IAVs70, and the virus can spread from birds to a wide range of hosts, which can promote viral heterogeneity and occasional spillover events to humans, as observed for H5N1, H7N9, H9N2, H6N1 and H10Nx strains.", [["H9N2", "DISEASE", 229, 233], ["Wild birds", "ORGANISM", 0, 10], ["humans", "ORGANISM", 193, 199], ["H9N2", "ORGANISM", 229, 233], ["H10Nx strains", "ORGANISM", 244, 257], ["humans", "SPECIES", 193, 199], ["H9N2", "SPECIES", 229, 233], ["humans", "SPECIES", 193, 199], ["H7N9", "SPECIES", 223, 227], ["H6N1", "SPECIES", 235, 239], ["H10Nx", "SPECIES", 244, 249], ["zoonotic IAVs", "PROBLEM", 41, 54], ["the virus", "PROBLEM", 62, 71], ["viral heterogeneity", "PROBLEM", 138, 157], ["occasional spillover events", "PROBLEM", 162, 189], ["H5N1", "PROBLEM", 217, 221], ["H7N9", "PROBLEM", 223, 227], ["H9N2", "PROBLEM", 229, 233], ["H6N1", "TREATMENT", 235, 239], ["H10Nx strains", "PROBLEM", 244, 257], ["viral heterogeneity", "OBSERVATION", 138, 157]]], ["Bats are believed to harbour more zoonotic viruses than any other animal, including RABV, Hendra virus, Nipah virus, Ebola virus, Marburg virus, hantaviruses and coronaviruses (reviewed elsewhere71,72).", [["zoonotic viruses", "DISEASE", 34, 50], ["Hendra virus", "DISEASE", 90, 102], ["Nipah virus", "DISEASE", 104, 115], ["Ebola virus", "DISEASE", 117, 128], ["Marburg virus, hantaviruses and coronaviruses", "DISEASE", 130, 175], ["Bats", "CELL", 0, 4], ["RABV", "ORGANISM", 84, 88], ["Hendra virus", "ORGANISM", 90, 102], ["Nipah virus", "ORGANISM", 104, 115], ["Ebola virus", "ORGANISM", 117, 128], ["Marburg virus", "ORGANISM", 130, 143], ["Hendra virus", "SPECIES", 90, 102], ["Nipah virus", "SPECIES", 104, 115], ["Ebola virus", "SPECIES", 117, 128], ["Marburg virus", "SPECIES", 130, 143], ["RABV", "SPECIES", 84, 88], ["Hendra virus", "SPECIES", 90, 102], ["Nipah virus", "SPECIES", 104, 115], ["Ebola virus", "SPECIES", 117, 128], ["Marburg virus", "SPECIES", 130, 143], ["RABV", "PROBLEM", 84, 88], ["Hendra virus", "PROBLEM", 90, 102], ["Nipah virus", "PROBLEM", 104, 115], ["Ebola virus", "PROBLEM", 117, 128], ["Marburg virus", "PROBLEM", 130, 143], ["hantaviruses", "PROBLEM", 145, 157], ["coronaviruses", "PROBLEM", 162, 175]]], ["Spillover events of these viruses to human hosts tends to cause severe morbidity and mortality71.", [["human", "ORGANISM", 37, 42], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["Spillover events", "PROBLEM", 0, 16], ["these viruses", "PROBLEM", 20, 33], ["severe morbidity", "PROBLEM", 64, 80], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["morbidity", "OBSERVATION", 71, 80]]], ["However, spillover of bat viruses to humans often involves an intermediate host70,73,74.", [["bat viruses", "ORGANISM", 22, 33], ["humans", "ORGANISM", 37, 43], ["humans", "SPECIES", 37, 43], ["humans", "SPECIES", 37, 43], ["spillover of bat viruses", "PROBLEM", 9, 33], ["spillover", "OBSERVATION", 9, 18], ["bat", "ANATOMY", 22, 25], ["viruses", "OBSERVATION", 26, 33]]], ["The exact reasons for the involvement of intermediate hosts remain unclear, but include barriers to infection71 such as receptor specificities described in the Entry section.", [["infection71", "GENE_OR_GENE_PRODUCT", 100, 111], ["barriers to infection71", "PROBLEM", 88, 111]]], ["Nevertheless, viral families with a wide host-tropism can accommodate viral diversity to facilitate host jumping from animal reservoirs to humans.Viral population diversity and implications for host fitness ::: ReplicationWhereas population heterogeneity widens the host range of some viruses, viral diversity in a single host is associated with persistent infections in a single host.", [["infections", "DISEASE", 357, 367], ["humans", "ORGANISM", 139, 145], ["humans", "SPECIES", 139, 145], ["humans", "SPECIES", 139, 145], ["viral diversity", "PROBLEM", 70, 85], ["some viruses", "PROBLEM", 280, 292], ["viral diversity", "PROBLEM", 294, 309], ["persistent infections", "PROBLEM", 346, 367], ["heterogeneity", "OBSERVATION_MODIFIER", 241, 254], ["widens", "OBSERVATION_MODIFIER", 255, 261], ["host range", "OBSERVATION_MODIFIER", 266, 276], ["some", "OBSERVATION_MODIFIER", 280, 284], ["viruses", "OBSERVATION", 285, 292], ["viral diversity", "OBSERVATION", 294, 309], ["single host", "OBSERVATION_MODIFIER", 315, 326], ["associated with", "UNCERTAINTY", 330, 345], ["persistent", "OBSERVATION_MODIFIER", 346, 356], ["infections", "OBSERVATION", 357, 367]]], ["Considerable within-host diversity and population structure are observed for HCV and HIV-1 (refs75\u201378).", [["HCV", "ORGANISM", 77, 80], ["HIV-1", "ORGANISM", 85, 90], ["refs75\u201378", "ORGANISM", 92, 101], ["HIV-1", "SPECIES", 85, 90], ["HCV", "SPECIES", 77, 80], ["HIV-1", "SPECIES", 85, 90], ["population structure", "PROBLEM", 39, 59], ["HCV", "PROBLEM", 77, 80], ["HIV", "TEST", 85, 88], ["host diversity", "OBSERVATION_MODIFIER", 20, 34]]], ["Viral diversity in HCV infection can enhance liver cirrhosis necessitating transplantation79, with minor variants persisting in the new liver following transplantation76.", [["liver cirrhosis", "ANATOMY", 45, 60], ["liver", "ANATOMY", 136, 141], ["HCV infection", "DISEASE", 19, 32], ["liver cirrhosis", "DISEASE", 45, 60], ["HCV", "ORGANISM", 19, 22], ["liver", "ORGAN", 45, 50], ["liver", "ORGAN", 136, 141], ["HCV", "SPECIES", 19, 22], ["Viral diversity", "PROBLEM", 0, 15], ["HCV infection", "PROBLEM", 19, 32], ["liver cirrhosis", "PROBLEM", 45, 60], ["transplantation79", "TREATMENT", 75, 92], ["minor variants", "PROBLEM", 99, 113], ["diversity", "OBSERVATION", 6, 15], ["HCV", "OBSERVATION_MODIFIER", 19, 22], ["infection", "OBSERVATION", 23, 32], ["liver", "ANATOMY", 45, 50], ["cirrhosis", "OBSERVATION", 51, 60], ["minor", "OBSERVATION_MODIFIER", 99, 104], ["variants", "OBSERVATION", 105, 113], ["new", "ANATOMY_MODIFIER", 132, 135], ["liver", "ANATOMY", 136, 141]]], ["A hallmark of HIV-1 infection is compartmentalization in different anatomical sites, triggering diversification into distinct, independently evolving subpopulations75,78,80\u201383.", [["sites", "ANATOMY", 78, 83], ["HIV-1 infection", "DISEASE", 14, 29], ["HIV-1", "ORGANISM", 14, 19], ["HIV-1", "SPECIES", 14, 19], ["HIV-1", "SPECIES", 14, 19], ["HIV-1 infection", "PROBLEM", 14, 29], ["hallmark", "OBSERVATION_MODIFIER", 2, 10], ["HIV", "OBSERVATION", 14, 17], ["infection", "OBSERVATION", 20, 29], ["anatomical sites", "OBSERVATION", 67, 83], ["distinct", "OBSERVATION_MODIFIER", 117, 125], ["subpopulation", "OBSERVATION_MODIFIER", 150, 163]]], ["HIV-1 env gene compartmentalization in cerebrospinal fluid is linked to HIV-associated dementia84,85, suggesting that genetic diversification of HIV-1 and pathogenesis and disease progression might be related.Viral population diversity and implications for host fitness ::: ReplicationFrom these examples, it is clear that population heterogeneity can have vastly different outcomes for viral fitness in different hosts.", [["cerebrospinal fluid", "ANATOMY", 39, 58], ["HIV-1", "ORGANISM", 0, 5], ["cerebrospinal fluid", "MULTI-TISSUE_STRUCTURE", 39, 58], ["HIV-1", "ORGANISM", 145, 150], ["HIV-1 env gene", "DNA", 0, 14], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 145, 150], ["HIV-1", "SPECIES", 0, 5], ["HIV", "SPECIES", 72, 75], ["HIV-1", "SPECIES", 145, 150], ["HIV", "PROBLEM", 0, 3], ["cerebrospinal fluid", "TEST", 39, 58], ["HIV", "PROBLEM", 72, 75], ["HIV", "PROBLEM", 145, 148], ["pathogenesis", "PROBLEM", 155, 167], ["disease progression", "PROBLEM", 172, 191], ["population heterogeneity", "PROBLEM", 323, 347], ["viral fitness in different hosts", "PROBLEM", 387, 419], ["cerebrospinal", "ANATOMY", 39, 52], ["fluid", "OBSERVATION", 53, 58], ["disease", "OBSERVATION", 172, 179]]], ["The examples illustrated here include a wide range of genetically plastic RNA viruses that nonetheless exhibit very different propensities for host jumping.", [["a wide range of genetically plastic RNA viruses", "PROBLEM", 38, 85], ["host jumping", "PROBLEM", 143, 155], ["plastic RNA viruses", "OBSERVATION", 66, 85]]], ["It is clear that population heterogeneity affords extreme flexibility in a virus to either co-adapt to a specific host or to host switch.Semi-infectious particles ::: AssemblyMany viruses exhibit a particle to plaque-forming unit (PFU) ratio greater than 1, suggesting that not all viral particles are equally infectious.", [["plaque", "ANATOMY", 210, 216], ["population heterogeneity", "PROBLEM", 17, 41], ["extreme flexibility", "PROBLEM", 50, 69], ["a virus", "PROBLEM", 73, 80], ["Many viruses", "PROBLEM", 175, 187], ["PFU) ratio", "TEST", 231, 241], ["all viral particles", "PROBLEM", 278, 297], ["clear", "OBSERVATION_MODIFIER", 6, 11], ["viruses", "OBSERVATION", 180, 187], ["particle", "OBSERVATION_MODIFIER", 198, 206], ["suggesting that not", "UNCERTAINTY", 258, 277], ["viral particles", "OBSERVATION", 282, 297], ["equally", "OBSERVATION_MODIFIER", 302, 309], ["infectious", "OBSERVATION", 310, 320]]], ["Particle to PFU ratios vary among virus family and type, ranging from 1 or 2 for Semliki Forest virus to as high as 107 for some HIV-1 variants96.", [["Semliki Forest virus", "ORGANISM", 81, 101], ["HIV-1", "ORGANISM", 129, 134], ["HIV-1", "SPECIES", 129, 134], ["Semliki Forest virus", "SPECIES", 81, 101], ["HIV-1", "SPECIES", 129, 134], ["Semliki Forest virus", "PROBLEM", 81, 101], ["some HIV", "TEST", 124, 132]]], ["Segmented viruses have complex packaging requirements in which a single copy of each genomic segment must be packaged to produce an infectious virion.", [["Segmented viruses", "PROBLEM", 0, 17], ["complex packaging requirements", "PROBLEM", 23, 53], ["an infectious virion", "PROBLEM", 129, 149], ["viruses", "OBSERVATION", 10, 17], ["complex", "OBSERVATION_MODIFIER", 23, 30], ["packaging requirements", "OBSERVATION", 31, 53], ["infectious", "OBSERVATION", 132, 142]]], ["Packaging of the segmented bunyavirus, Rift Valley fever virus, is thought to be random, producing virions lacking one or more segments and leading to infected cells failing to express all viral proteins97.", [["cells", "ANATOMY", 160, 165], ["Rift Valley fever", "DISEASE", 39, 56], ["bunyavirus", "ORGANISM", 27, 37], ["Rift Valley fever virus", "ORGANISM", 39, 62], ["cells", "CELL", 160, 165], ["infected cells", "CELL_TYPE", 151, 165], ["viral proteins97", "PROTEIN", 189, 205], ["Rift Valley fever virus", "SPECIES", 39, 62], ["Rift Valley fever virus", "SPECIES", 39, 62], ["the segmented bunyavirus", "PROBLEM", 13, 37], ["Rift Valley fever virus", "PROBLEM", 39, 62], ["infected cells", "PROBLEM", 151, 165], ["all viral proteins", "TEST", 185, 203], ["segmented", "OBSERVATION_MODIFIER", 17, 26], ["bunyavirus", "OBSERVATION", 27, 37], ["Rift", "OBSERVATION_MODIFIER", 39, 43], ["thought to be", "UNCERTAINTY", 67, 80], ["infected cells", "OBSERVATION", 151, 165]]], ["Meanwhile, packaging of IAVs is tightly coordinated to incorporate one copy of each segment into the majority of virions98.", [["IAVs", "GENE_OR_GENE_PRODUCT", 24, 28], ["IAVs", "PROTEIN", 24, 28], ["IAVs", "OBSERVATION", 24, 28], ["virions", "OBSERVATION", 113, 120]]], ["Despite this quality control, approximately 20% of IAV particles package fewer than eight genomic segments99, and a large number of infected cells fail to express IAV proteins from all eight segments or to replicate each segment equally58.", [["cells", "ANATOMY", 141, 146], ["IAV", "ORGANISM", 51, 54], ["cells", "CELL", 141, 146], ["IAV", "ORGANISM", 163, 166], ["genomic segments99", "DNA", 90, 108], ["infected cells", "CELL_TYPE", 132, 146], ["IAV proteins", "PROTEIN", 163, 175], ["IAV", "SPECIES", 163, 166], ["this quality control", "TREATMENT", 8, 28], ["IAV particles package", "TREATMENT", 51, 72], ["infected cells", "PROBLEM", 132, 146], ["IAV proteins", "TREATMENT", 163, 175], ["genomic segments99", "OBSERVATION", 90, 108], ["large", "OBSERVATION_MODIFIER", 116, 121], ["number", "OBSERVATION_MODIFIER", 122, 128], ["infected cells", "OBSERVATION", 132, 146], ["eight segments", "ANATOMY_MODIFIER", 185, 199], ["segment", "ANATOMY_MODIFIER", 221, 228]]], ["Viruses either lacking gene segments or unable to fully translate or replicate all eight viral gene segments are referred to broadly as \u2018semi-infectious particles\u201958.", [["viral gene segments", "DNA", 89, 108], ["Viruses", "PROBLEM", 0, 7], ["lacking gene segments", "PROBLEM", 15, 36]]], ["The origin of naturally occurring semi-infectious particles is unknown and could be a consequence of incomplete genome packaging, failed nuclear import of viral RNA segments, abortive replication or epigenetic silencing of viral RNA segments.", [["nuclear", "ANATOMY", 137, 144], ["nuclear", "CELLULAR_COMPONENT", 137, 144], ["viral RNA segments", "RNA", 155, 173], ["viral RNA segments", "RNA", 223, 241], ["naturally occurring semi-infectious particles", "PROBLEM", 14, 59], ["incomplete genome packaging", "TREATMENT", 101, 128], ["viral RNA segments", "PROBLEM", 155, 173], ["abortive replication", "TREATMENT", 175, 195], ["epigenetic silencing of viral RNA segments", "PROBLEM", 199, 241], ["semi-infectious particles", "OBSERVATION", 34, 59], ["genome packaging", "OBSERVATION", 112, 128], ["epigenetic silencing", "OBSERVATION", 199, 219], ["viral RNA segments", "OBSERVATION", 223, 241]]], ["Recently, one study demonstrated that the fitness cost of infection with semi-infectious IAV particles is reduced through complementation by incoming virions from neighbouring infected cells87.", [["virions", "ANATOMY", 150, 157], ["cells87", "ANATOMY", 185, 192], ["infection", "DISEASE", 58, 67], ["IAV", "ORGANISM", 89, 92], ["cells87", "CELL", 185, 192], ["IAV", "SPECIES", 89, 92], ["one study", "TEST", 10, 19], ["infection", "PROBLEM", 58, 67], ["semi-infectious IAV particles", "PROBLEM", 73, 102], ["incoming virions", "PROBLEM", 141, 157], ["infection", "OBSERVATION", 58, 67], ["IAV particles", "OBSERVATION", 89, 102]]], ["Semi-infectious particles are observed in IAV populations in vitro and in vivo87, and may drive viral heterogeneity within a host and, potentially, between hosts.", [["IAV", "SPECIES", 42, 45], ["Semi-infectious particles", "PROBLEM", 0, 25], ["viral heterogeneity", "PROBLEM", 96, 115], ["IAV populations", "OBSERVATION", 42, 57]]], ["Therefore, the possibility of complementation of IAV genomic segments in humans and its relationship to IAV transmission should be explored.Pleomorphic particles ::: AssemblyInfluenza virus, HIV, rubella virus, pneumoviruses and paramyxoviruses such as measles virus are all pleomorphic19,100\u2013103.", [["Influenza virus, HIV, rubella virus", "DISEASE", 174, 209], ["measles virus", "DISEASE", 253, 266], ["IAV", "ORGANISM", 49, 52], ["humans", "ORGANISM", 73, 79], ["IAV", "ORGANISM", 104, 107], ["Pleomorphic particles", "CANCER", 140, 161], ["Influenza virus", "ORGANISM", 174, 189], ["HIV", "ORGANISM", 191, 194], ["rubella virus", "ORGANISM", 196, 209], ["pneumoviruses", "CANCER", 211, 224], ["measles virus", "ORGANISM", 253, 266], ["IAV genomic segments", "DNA", 49, 69], ["humans", "SPECIES", 73, 79], ["Influenza virus", "SPECIES", 174, 189], ["HIV", "SPECIES", 191, 194], ["rubella virus", "SPECIES", 196, 209], ["measles virus", "SPECIES", 253, 266], ["IAV", "SPECIES", 49, 52], ["humans", "SPECIES", 73, 79], ["IAV", "SPECIES", 104, 107], ["Influenza virus", "SPECIES", 174, 189], ["HIV", "SPECIES", 191, 194], ["rubella virus", "SPECIES", 196, 209], ["measles virus", "SPECIES", 253, 266], ["IAV genomic segments in humans", "PROBLEM", 49, 79], ["IAV transmission", "TREATMENT", 104, 120], ["Pleomorphic particles", "TEST", 140, 161], ["AssemblyInfluenza virus", "PROBLEM", 166, 189], ["HIV", "PROBLEM", 191, 194], ["rubella virus", "PROBLEM", 196, 209], ["pneumoviruses", "PROBLEM", 211, 224], ["paramyxoviruses", "PROBLEM", 229, 244], ["measles virus", "PROBLEM", 253, 266], ["IAV genomic", "OBSERVATION", 49, 60], ["segments", "OBSERVATION_MODIFIER", 61, 69], ["IAV", "OBSERVATION", 104, 107], ["Influenza virus", "OBSERVATION", 174, 189]]], ["Rather than a strictly uniform virion structure, these viruses are highly variable in length and/or diameter and versatile in genomic packaging capacity94,104,105.", [["a strictly uniform virion structure", "PROBLEM", 12, 47], ["these viruses", "PROBLEM", 49, 62], ["genomic packaging capacity", "TEST", 126, 152], ["uniform", "OBSERVATION_MODIFIER", 23, 30], ["virion structure", "OBSERVATION", 31, 47], ["viruses", "OBSERVATION", 55, 62], ["highly", "OBSERVATION_MODIFIER", 67, 73], ["variable", "OBSERVATION_MODIFIER", 74, 82], ["length", "OBSERVATION_MODIFIER", 86, 92], ["diameter", "OBSERVATION_MODIFIER", 100, 108], ["versatile", "OBSERVATION_MODIFIER", 113, 122], ["genomic packaging", "OBSERVATION", 126, 143], ["capacity", "OBSERVATION_MODIFIER", 144, 152]]], ["Characterization of pleomorphic structures has been historically challenging, but these particles are now being resolved through cryo-electron tomography19\u201321,103.", [["pleomorphic structures", "ANATOMY", 20, 42], ["pleomorphic structures", "CANCER", 20, 42], ["pleomorphic structures", "PROBLEM", 20, 42], ["pleomorphic", "OBSERVATION", 20, 31], ["historically", "OBSERVATION_MODIFIER", 52, 64], ["challenging", "OBSERVATION_MODIFIER", 65, 76], ["particles", "OBSERVATION_MODIFIER", 88, 97]]], ["This method was recently used to resolve the helical glycoprotein arrangement of rubella virus19.Pleomorphic particles ::: AssemblyLow-fidelity assembly is intricately interwoven with host adaptation, escape from antibodies or antiviral drugs and pathogenesis.", [["rubella virus", "DISEASE", 81, 94], ["rubella virus19", "ORGANISM", 81, 96], ["Pleomorphic particles", "CANCER", 97, 118], ["antibodies", "PROTEIN", 213, 223], ["rubella virus", "SPECIES", 81, 94], ["rubella virus19", "SPECIES", 81, 96], ["This method", "TREATMENT", 0, 11], ["rubella virus", "PROBLEM", 81, 94], ["escape from antibodies", "PROBLEM", 201, 223], ["antiviral drugs", "TREATMENT", 227, 242], ["pathogenesis", "PROBLEM", 247, 259], ["antiviral drugs", "OBSERVATION", 227, 242]]], ["IAVs are highly heterogeneous in structure, with a single cell capable of producing a diverse array of particles, including spherical, ovoid and bacilliform particles and filaments of varying length and diameter102.", [["IAVs", "ANATOMY", 0, 4], ["cell", "ANATOMY", 58, 62], ["bacilliform particles", "ANATOMY", 145, 166], ["filaments", "ANATOMY", 171, 180], ["IAVs", "CANCER", 0, 4], ["cell", "CELL", 58, 62], ["filaments", "CELLULAR_COMPONENT", 171, 180], ["IAVs", "PROBLEM", 0, 4], ["a diverse array of particles", "PROBLEM", 84, 112], ["spherical, ovoid and bacilliform particles", "PROBLEM", 124, 166], ["diameter", "TEST", 203, 211], ["highly", "OBSERVATION_MODIFIER", 9, 15], ["heterogeneous", "OBSERVATION_MODIFIER", 16, 29], ["diverse", "OBSERVATION_MODIFIER", 86, 93], ["array", "OBSERVATION_MODIFIER", 94, 99], ["particles", "OBSERVATION_MODIFIER", 103, 112], ["spherical", "OBSERVATION_MODIFIER", 124, 133], ["ovoid", "OBSERVATION_MODIFIER", 135, 140], ["bacilliform particles", "OBSERVATION", 145, 166], ["filaments", "OBSERVATION_MODIFIER", 171, 180], ["varying", "OBSERVATION_MODIFIER", 184, 191], ["length", "OBSERVATION_MODIFIER", 192, 198], ["diameter", "OBSERVATION_MODIFIER", 203, 211]]], ["The filamentous morphology of IAVs has been comprehensively reviewed recently102.", [["IAVs", "ANATOMY", 30, 34], ["IAVs", "CANCER", 30, 34], ["filamentous morphology", "OBSERVATION_MODIFIER", 4, 26], ["IAVs", "OBSERVATION", 30, 34]]], ["Disruption of the actin cytoskeleton selectively impairs the budding of filamentous, but not spherical, virions102, implicating distinct mechanisms underlying the formation of each type of virion.", [["cytoskeleton", "ANATOMY", 24, 36], ["filamentous", "ANATOMY", 72, 83], ["virion", "ANATOMY", 189, 195], ["actin", "GENE_OR_GENE_PRODUCT", 18, 23], ["cytoskeleton", "CELLULAR_COMPONENT", 24, 36], ["virion", "CELLULAR_COMPONENT", 189, 195], ["actin", "PROTEIN", 18, 23], ["actin cytoskeleton selectively", "OBSERVATION", 18, 48], ["filamentous", "OBSERVATION_MODIFIER", 72, 83], ["not", "UNCERTAINTY", 89, 92], ["spherical", "OBSERVATION_MODIFIER", 93, 102], ["distinct", "OBSERVATION_MODIFIER", 128, 136], ["virion", "OBSERVATION", 189, 195]]], ["Human clinical IAV isolates are typically filamentous in morphology, but many laboratory strains, which are usually produced in embryonated eggs, produce exclusively spherical particles102.", [["eggs", "ANATOMY", 140, 144], ["Human", "ORGANISM", 0, 5], ["IAV isolates", "ORGANISM", 15, 27], ["Human", "SPECIES", 0, 5], ["Human clinical IAV isolates", "PROBLEM", 0, 27], ["many laboratory strains", "PROBLEM", 73, 96], ["filamentous", "OBSERVATION_MODIFIER", 42, 53]]], ["Further investigation of the host and viral determinants of virion morphology will be necessary to determine the factors underlying these observations.Pleomorphic particles ::: AssemblyVirion morphology may have implications for pathogenesis.", [["Pleomorphic particles", "CANCER", 151, 172], ["Further investigation", "TEST", 0, 21], ["virion morphology", "TREATMENT", 60, 77], ["pathogenesis", "PROBLEM", 229, 241], ["may have implications for", "UNCERTAINTY", 203, 228]]], ["In influenza virus, HA is enriched over NA in longer filamentous particles86, shifting the ratio of HA to NA molecules per virion and potentially impacting entry kinetics, NA activity and cleavage of sialic acids during budding.", [["influenza", "DISEASE", 3, 12], ["NA", "CHEMICAL", 106, 108], ["sialic acids", "CHEMICAL", 200, 212], ["sialic acids", "CHEMICAL", 200, 212], ["influenza virus", "ORGANISM", 3, 18], ["HA", "GENE_OR_GENE_PRODUCT", 20, 22], ["HA to NA molecules", "GENE_OR_GENE_PRODUCT", 100, 118], ["NA", "SIMPLE_CHEMICAL", 172, 174], ["sialic acids", "SIMPLE_CHEMICAL", 200, 212], ["NA molecules", "PROTEIN", 106, 118], ["influenza virus", "SPECIES", 3, 18], ["influenza virus", "SPECIES", 3, 18], ["influenza virus", "PROBLEM", 3, 18], ["HA", "PROBLEM", 20, 22], ["HA", "PROBLEM", 100, 102], ["sialic acids", "TREATMENT", 200, 212], ["influenza virus", "OBSERVATION", 3, 18]]], ["Differences in the HA to NA ratio on influenza virus particles could also influence sensitivity to NA antivirals86, and possibly antibody epitope accessibility.", [["NA", "CHEMICAL", 25, 27], ["NA", "CHEMICAL", 99, 101], ["HA", "GENE_OR_GENE_PRODUCT", 19, 21], ["NA", "SIMPLE_CHEMICAL", 25, 27], ["influenza virus", "ORGANISM", 37, 52], ["influenza virus", "SPECIES", 37, 52], ["influenza virus", "SPECIES", 37, 52], ["the HA", "PROBLEM", 15, 21], ["NA ratio", "TEST", 25, 33], ["influenza virus particles", "PROBLEM", 37, 62], ["NA antivirals", "TREATMENT", 99, 112], ["antibody epitope accessibility", "PROBLEM", 129, 159], ["possibly", "UNCERTAINTY", 120, 128], ["antibody epitope", "OBSERVATION", 129, 145]]], ["Interestingly, efficient transmission of H1N1 2009 pandemic influenza viruses correlated with NA activity and filamentous virion morphology88\u201390.", [["influenza viruses", "DISEASE", 60, 77], ["NA", "CHEMICAL", 94, 96], ["H1N1 2009 pandemic influenza viruses", "ORGANISM", 41, 77], ["pandemic influenza viruses", "SPECIES", 51, 77], ["H1N1 2009 pandemic influenza viruses", "SPECIES", 41, 77], ["H1N1", "PROBLEM", 41, 45], ["pandemic influenza viruses", "PROBLEM", 51, 77], ["NA activity", "TEST", 94, 105], ["filamentous virion morphology88\u201390", "TREATMENT", 110, 144]]], ["Further investigation of the mechanism underlying these observations is necessary.", [["Further investigation", "TEST", 0, 21]]], ["Alternatively, the glycoprotein arrangement on filamentous particles may explain differences in HA and NA activity.", [["filamentous particles", "ANATOMY", 47, 68], ["NA", "CHEMICAL", 103, 105], ["HA", "SIMPLE_CHEMICAL", 96, 98], ["NA", "SIMPLE_CHEMICAL", 103, 105], ["the glycoprotein arrangement on filamentous particles", "PROBLEM", 15, 68], ["HA", "PROBLEM", 96, 98]]], ["As described in the Entry section, NA is polarized on filamentous virions25.", [["NA", "SIMPLE_CHEMICAL", 35, 37]]], ["Whether these morphological differences impact pathogenesis remains an active area of investigation.Pleomorphic particles ::: AssemblyMeasles virus assembly also exhibits phenotypic heterogeneity, which may have consequences for clinical disease progression.", [["Pleomorphic particles", "CANCER", 100, 121], ["Measles virus", "ORGANISM", 134, 147], ["Measles virus", "SPECIES", 134, 147], ["Measles virus", "SPECIES", 134, 147], ["Measles virus", "PROBLEM", 134, 147], ["phenotypic heterogeneity", "PROBLEM", 171, 195], ["clinical disease progression", "PROBLEM", 229, 257], ["active", "OBSERVATION_MODIFIER", 71, 77], ["area", "OBSERVATION_MODIFIER", 78, 82], ["phenotypic", "OBSERVATION_MODIFIER", 171, 181], ["heterogeneity", "OBSERVATION", 182, 195]]], ["During assembly, the measles virus matrix (M) protein binds the inner surface of the plasma membrane and the cytoplasmic tails of the viral fusion (F) glycoprotein and the attachment glycoprotein haemagglutinin (H)106, and is believed to coordinate assembly107.", [["inner surface", "ANATOMY", 64, 77], ["plasma membrane", "ANATOMY", 85, 100], ["cytoplasmic", "ANATOMY", 109, 120], ["measles virus matrix (M)", "GENE_OR_GENE_PRODUCT", 21, 45], ["inner surface", "CELLULAR_COMPONENT", 64, 77], ["plasma membrane", "CELLULAR_COMPONENT", 85, 100], ["cytoplasmic tails", "CELLULAR_COMPONENT", 109, 126], ["viral fusion (F) glycoprotein", "GENE_OR_GENE_PRODUCT", 134, 163], ["measles virus matrix (M) protein", "PROTEIN", 21, 53], ["cytoplasmic tails", "PROTEIN", 109, 126], ["viral fusion (F) glycoprotein", "PROTEIN", 134, 163], ["attachment glycoprotein haemagglutinin (H)106", "PROTEIN", 172, 217], ["measles virus", "SPECIES", 21, 34], ["the measles virus matrix", "PROBLEM", 17, 41], ["the viral fusion (F) glycoprotein", "TREATMENT", 130, 163], ["the attachment glycoprotein haemagglutinin", "TREATMENT", 168, 210], ["inner", "ANATOMY_MODIFIER", 64, 69], ["plasma membrane", "ANATOMY", 85, 100], ["cytoplasmic tails", "OBSERVATION", 109, 126], ["viral fusion", "OBSERVATION", 134, 146]]], ["In rare cases, mutation or deletion of the F or H glycoprotein cytoplasmic tails accelerates measles virus dissemination through cell monolayers by the formation of syncytia and through the brain of patients suffering from subacute sclerosing panencephalitis106,108,109, a highly lethal, progressive neurological disorder resulting from persistent measles infection.", [["cytoplasmic", "ANATOMY", 63, 74], ["cell monolayers", "ANATOMY", 129, 144], ["syncytia", "ANATOMY", 165, 173], ["brain", "ANATOMY", 190, 195], ["neurological", "ANATOMY", 300, 312], ["sclerosing panencephalitis106,108,109", "DISEASE", 232, 269], ["neurological disorder", "DISEASE", 300, 321], ["measles infection", "DISEASE", 348, 365], ["F or H glycoprotein", "GENE_OR_GENE_PRODUCT", 43, 62], ["cytoplasmic", "ORGANISM_SUBSTANCE", 63, 74], ["measles virus", "ORGANISM", 93, 106], ["cell monolayers", "CELL", 129, 144], ["syncytia", "CELL", 165, 173], ["brain", "ORGAN", 190, 195], ["patients", "ORGANISM", 199, 207], ["F or H glycoprotein cytoplasmic tails", "PROTEIN", 43, 80], ["patients", "SPECIES", 199, 207], ["measles virus", "SPECIES", 93, 106], ["mutation", "PROBLEM", 15, 23], ["deletion of the F", "PROBLEM", 27, 44], ["H glycoprotein cytoplasmic tails", "PROBLEM", 48, 80], ["measles virus dissemination", "PROBLEM", 93, 120], ["cell monolayers", "TREATMENT", 129, 144], ["syncytia", "PROBLEM", 165, 173], ["subacute sclerosing panencephalitis", "PROBLEM", 223, 258], ["progressive neurological disorder", "PROBLEM", 288, 321], ["persistent measles infection", "PROBLEM", 337, 365], ["cell monolayers", "OBSERVATION", 129, 144], ["syncytia", "OBSERVATION", 165, 173], ["brain", "ANATOMY", 190, 195], ["subacute", "OBSERVATION_MODIFIER", 223, 231], ["sclerosing", "OBSERVATION_MODIFIER", 232, 242], ["panencephalitis", "OBSERVATION", 243, 258], ["progressive", "OBSERVATION_MODIFIER", 288, 299], ["neurological disorder", "OBSERVATION", 300, 321], ["persistent", "OBSERVATION_MODIFIER", 337, 347], ["measles", "OBSERVATION_MODIFIER", 348, 355], ["infection", "OBSERVATION", 356, 365]]], ["Interestingly, measles virus vaccine strains with mutations in the M protein have higher avidity for the H cytoplasmic tail, but are defective for syncytia formation.", [["cytoplasmic tail", "ANATOMY", 107, 123], ["syncytia", "ANATOMY", 147, 155], ["measles virus", "ORGANISM", 15, 28], ["syncytia", "CELL", 147, 155], ["M protein", "PROTEIN", 67, 76], ["H cytoplasmic tail", "PROTEIN", 105, 123], ["measles virus vaccine", "SPECIES", 15, 36], ["measles virus", "SPECIES", 15, 28], ["measles virus vaccine strains", "TREATMENT", 15, 44], ["mutations", "PROBLEM", 50, 59], ["the M protein", "TEST", 63, 76], ["higher avidity", "PROBLEM", 82, 96], ["the H cytoplasmic tail", "PROBLEM", 101, 123], ["syncytia formation", "PROBLEM", 147, 165], ["higher avidity", "OBSERVATION_MODIFIER", 82, 96], ["tail", "ANATOMY", 119, 123], ["defective", "OBSERVATION", 133, 142], ["syncytia", "OBSERVATION", 147, 155]]], ["Further investigation of this apparent link between the avidity of M protein for the glycoprotein cytoplasmic tails and the role of syncytia formation in disease progression is needed.Pleomorphic particles ::: AssemblyFuture studies on the role of low-fidelity assembly in the pathogenesis of other pleomorphic viruses is warranted, but lacking.", [["cytoplasmic", "ANATOMY", 98, 109], ["syncytia", "ANATOMY", 132, 140], ["pleomorphic viruses", "DISEASE", 299, 318], ["M protein", "GENE_OR_GENE_PRODUCT", 67, 76], ["cytoplasmic", "ORGANISM_SUBSTANCE", 98, 109], ["syncytia", "CELL", 132, 140], ["Pleomorphic particles", "CANCER", 184, 205], ["M protein", "PROTEIN", 67, 76], ["glycoprotein cytoplasmic tails", "PROTEIN", 85, 115], ["Further investigation", "TEST", 0, 21], ["the glycoprotein cytoplasmic tails", "TREATMENT", 81, 115], ["syncytia formation", "PROBLEM", 132, 150], ["disease progression", "PROBLEM", 154, 173], ["AssemblyFuture studies", "TEST", 210, 232], ["other pleomorphic viruses", "PROBLEM", 293, 318], ["syncytia", "OBSERVATION", 132, 140], ["pleomorphic", "OBSERVATION_MODIFIER", 299, 310], ["viruses", "OBSERVATION", 311, 318]]], ["It stands to reason that low-fidelity assembly may promote dissemination of other pleomorphic viruses.Tunnelling nanotubes promote rapid entry and egress ::: EgressA growing body of evidence suggests that viruses can bypass the extracellular environment altogether during subsequent rounds of infection.", [["extracellular", "ANATOMY", 228, 241], ["infection", "DISEASE", 293, 302], ["pleomorphic viruses", "CANCER", 82, 101], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 228, 241], ["other pleomorphic viruses", "PROBLEM", 76, 101], ["Tunnelling nanotubes", "TREATMENT", 102, 122], ["viruses", "PROBLEM", 205, 212], ["infection", "PROBLEM", 293, 302], ["pleomorphic viruses", "OBSERVATION", 82, 101], ["evidence suggests", "UNCERTAINTY", 182, 199], ["viruses", "OBSERVATION", 205, 212], ["infection", "OBSERVATION", 293, 302]]], ["For many viruses, this process involves subversion of the actin\u2013myosin cytoskeletal system through tunnelling nanotubes (TNTs).", [["cytoskeletal", "ANATOMY", 71, 83], ["actin\u2013myosin", "GENE_OR_GENE_PRODUCT", 58, 70], ["many viruses", "PROBLEM", 4, 16], ["tunnelling nanotubes (TNTs", "TREATMENT", 99, 125], ["viruses", "OBSERVATION", 9, 16], ["actin\u2013myosin cytoskeletal system", "OBSERVATION", 58, 90], ["tunnelling nanotubes", "OBSERVATION", 99, 119]]], ["TNTs are actin-rich filamentous cellular projections that facilitate intercellular exchange of cargo such as organelles, proteins and ions110.", [["cellular", "ANATOMY", 32, 40], ["intercellular", "ANATOMY", 69, 82], ["organelles", "ANATOMY", 109, 119], ["TNTs", "SIMPLE_CHEMICAL", 0, 4], ["actin", "GENE_OR_GENE_PRODUCT", 9, 14], ["filamentous cellular", "CELLULAR_COMPONENT", 20, 40], ["intercellular", "IMMATERIAL_ANATOMICAL_ENTITY", 69, 82], ["cargo", "CELLULAR_COMPONENT", 95, 100], ["organelles", "CELLULAR_COMPONENT", 109, 119], ["TNTs", "PROTEIN", 0, 4], ["actin", "PROTEIN", 9, 14]]], ["TNTs are sometimes referred to as nanotubular bridges or immunological or virological synapses, depending on the context.", [["TNTs", "SIMPLE_CHEMICAL", 0, 4], ["virological synapses", "PROBLEM", 74, 94]]], ["Interestingly, major histocompatibility complex (MHC) class I molecules are among cargo transferred along recently dispersed immunological synapses, suggesting a role for TNTs in antigen presentation111.", [["TNTs", "GENE_OR_GENE_PRODUCT", 171, 175], ["major histocompatibility complex (MHC) class I molecules", "PROTEIN", 15, 71], ["TNTs", "PROTEIN", 171, 175], ["antigen presentation111", "PROTEIN", 179, 202]]], ["Two distinct classes of TNTs have been reported that differ in size, composition and function110,112.", [["TNTs", "GENE_OR_GENE_PRODUCT", 24, 28], ["TNTs", "PROTEIN", 24, 28], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["classes", "OBSERVATION_MODIFIER", 13, 20], ["TNTs", "OBSERVATION", 24, 28], ["size", "OBSERVATION_MODIFIER", 63, 67]]], ["Thin nanotubes comprise filamentous actin (F-actin) and facilitate unidirectional cargo transfer110,112.", [["filamentous actin", "GENE_OR_GENE_PRODUCT", 24, 41], ["F-actin", "GENE_OR_GENE_PRODUCT", 43, 50], ["filamentous actin", "PROTEIN", 24, 41], ["F-actin", "PROTEIN", 43, 50], ["Thin nanotubes", "TREATMENT", 0, 14], ["filamentous actin", "OBSERVATION", 24, 41]]], ["Thick nanotubes have a diameter greater than 0.7 \u03bcm, comprise both F-actin and tubulin, and are capable of bidirectional cargo transfer110,112.", [["F-actin", "GENE_OR_GENE_PRODUCT", 67, 74], ["tubulin", "GENE_OR_GENE_PRODUCT", 79, 86], ["F-actin", "PROTEIN", 67, 74], ["tubulin", "PROTEIN", 79, 86], ["Thick nanotubes", "TEST", 0, 15], ["diameter", "OBSERVATION_MODIFIER", 23, 31], ["greater", "OBSERVATION_MODIFIER", 32, 39], ["both", "OBSERVATION_MODIFIER", 62, 66], ["F-actin", "OBSERVATION", 67, 74]]], ["The latter class, thus far reported only in macrophages, permits cargo exchange between cells tens to hundreds of microns apart111,113.", [["macrophages", "ANATOMY", 44, 55], ["cells", "ANATOMY", 88, 93], ["macrophages", "CELL", 44, 55], ["cells", "CELL", 88, 93], ["macrophages", "CELL_TYPE", 44, 55], ["macrophages", "OBSERVATION", 44, 55], ["cargo exchange", "OBSERVATION", 65, 79]]], ["TNTs form either through actin polymerization or upon disassembly of a synapse111 with lifetimes ranging from several minutes to over an hour110.Tunnelling nanotubes promote rapid entry and egress ::: EgressA broad swath of pathogenic viruses reportedly hijack TNTs, including retroviruses, herpesviruses, vaccinia virus, flaviviruses, human metapneumovirus (HMPV), measles virus and IAVs3\u20135,113\u2013123.", [["vaccinia virus", "DISEASE", 306, 320], ["human metapneumovirus", "DISEASE", 336, 357], ["measles virus", "DISEASE", 366, 379], ["IAVs3\u20135,113\u2013123", "CHEMICAL", 384, 399], ["TNTs", "SIMPLE_CHEMICAL", 0, 4], ["actin", "GENE_OR_GENE_PRODUCT", 25, 30], ["TNTs", "CANCER", 261, 265], ["retroviruses", "ORGANISM", 277, 289], ["herpesviruses", "ORGANISM", 291, 304], ["vaccinia virus", "ORGANISM", 306, 320], ["flaviviruses", "ORGANISM", 322, 334], ["human metapneumovirus", "ORGANISM", 336, 357], ["HMPV", "ORGANISM", 359, 363], ["measles virus", "ORGANISM", 366, 379], ["TNTs", "PROTEIN", 0, 4], ["actin", "PROTEIN", 25, 30], ["vaccinia virus", "SPECIES", 306, 320], ["human", "SPECIES", 336, 341], ["metapneumovirus", "SPECIES", 342, 357], ["measles virus", "SPECIES", 366, 379], ["vaccinia virus", "SPECIES", 306, 320], ["human metapneumovirus", "SPECIES", 336, 357], ["HMPV", "SPECIES", 359, 363], ["measles virus", "SPECIES", 366, 379], ["Tunnelling nanotubes", "TREATMENT", 145, 165], ["pathogenic viruses", "PROBLEM", 224, 242], ["hijack TNTs", "PROBLEM", 254, 265], ["retroviruses", "PROBLEM", 277, 289], ["herpesviruses", "PROBLEM", 291, 304], ["vaccinia virus", "TREATMENT", 306, 320], ["flaviviruses", "PROBLEM", 322, 334], ["human metapneumovirus", "PROBLEM", 336, 357], ["HMPV", "PROBLEM", 359, 363], ["measles virus", "PROBLEM", 366, 379], ["IAVs3", "TEST", 384, 389], ["pathogenic viruses", "OBSERVATION", 224, 242], ["hijack TNTs", "OBSERVATION", 254, 265], ["metapneumovirus", "OBSERVATION", 342, 357]]], ["The mechanism through which each of these viruses traverses a nanotubular bridge appears to be distinct, although the use of the actin\u2013myosin cytoskeletal machinery for trafficking along a TNT is common for many3,4,114,115.", [["cytoskeletal", "ANATOMY", 142, 154], ["actin\u2013myosin", "GENE_OR_GENE_PRODUCT", 129, 141], ["TNT", "GENE_OR_GENE_PRODUCT", 189, 192], ["these viruses", "PROBLEM", 36, 49], ["a nanotubular bridge", "TREATMENT", 60, 80], ["the actin\u2013myosin cytoskeletal machinery", "TREATMENT", 125, 164], ["a TNT", "TEST", 187, 192], ["viruses", "OBSERVATION", 42, 49], ["nanotubular bridge", "OBSERVATION", 62, 80], ["appears to be", "UNCERTAINTY", 81, 94], ["distinct", "OBSERVATION_MODIFIER", 95, 103]]], ["Retroviruses specifically traffic along the exterior surface of TNTs in a fashion that retains the classical egress step of budding from a host cell and receptor-mediated entry into the next cell.", [["exterior surface", "ANATOMY", 44, 60], ["TNTs", "ANATOMY", 64, 68], ["cell", "ANATOMY", 144, 148], ["cell", "ANATOMY", 191, 195], ["Retroviruses", "ORGANISM", 0, 12], ["exterior surface", "CELLULAR_COMPONENT", 44, 60], ["TNTs", "SIMPLE_CHEMICAL", 64, 68], ["cell", "CELL", 144, 148], ["cell", "CELL", 191, 195], ["TNTs", "PROTEIN", 64, 68], ["exterior", "OBSERVATION_MODIFIER", 44, 52], ["surface", "OBSERVATION_MODIFIER", 53, 60], ["TNTs", "OBSERVATION", 64, 68], ["host cell", "OBSERVATION", 139, 148]]], ["Murine leukaemia virus and HIV-1 bud from an infected cell and traffic unidirectionally along the outer surface of TNTs113,114,116.", [["cell", "ANATOMY", 54, 58], ["outer surface", "ANATOMY", 98, 111], ["Murine leukaemia virus", "DISEASE", 0, 22], ["Murine leukaemia virus", "ORGANISM", 0, 22], ["HIV-1", "ORGANISM", 27, 32], ["cell", "CELL", 54, 58], ["outer surface", "CELLULAR_COMPONENT", 98, 111], ["Murine", "SPECIES", 0, 6], ["HIV-1", "SPECIES", 27, 32], ["Murine leukaemia virus", "SPECIES", 0, 22], ["HIV-1", "SPECIES", 27, 32], ["Murine leukaemia virus", "PROBLEM", 0, 22], ["HIV", "PROBLEM", 27, 30], ["an infected cell", "PROBLEM", 42, 58], ["TNTs", "TEST", 115, 119], ["leukaemia virus", "OBSERVATION", 7, 22], ["infected cell", "OBSERVATION", 45, 58], ["outer", "ANATOMY_MODIFIER", 98, 103], ["surface", "ANATOMY_MODIFIER", 104, 111]]], ["Receptor-mediated binding of the murine leukaemia virus envelope glycoprotein, Env, stimulates outgrowth of a long, stable bridge between infected and uninfected cells, triggering apparent invagination through endocytosis116.", [["cells", "ANATOMY", 162, 167], ["murine leukaemia virus", "ORGANISM", 33, 55], ["Env", "GENE_OR_GENE_PRODUCT", 79, 82], ["cells", "CELL", 162, 167], ["murine leukaemia virus envelope glycoprotein", "PROTEIN", 33, 77], ["Env", "PROTEIN", 79, 82], ["infected and uninfected cells", "CELL_TYPE", 138, 167], ["murine", "SPECIES", 33, 39], ["leukaemia virus", "SPECIES", 40, 55], ["murine leukaemia virus", "SPECIES", 33, 55], ["the murine leukaemia virus envelope glycoprotein", "TREATMENT", 29, 77], ["a long, stable bridge between infected and uninfected cells", "PROBLEM", 108, 167], ["apparent invagination through endocytosis", "PROBLEM", 180, 221], ["infected", "OBSERVATION", 138, 146], ["uninfected cells", "OBSERVATION", 151, 167], ["invagination", "OBSERVATION_MODIFIER", 189, 201]]], ["TNTs are intrinsically more stable in human T cells, however, and intercellular dissemination of HIV-1 to uninfected T cells through TNTs is more efficient than that of cell-free virions113,117,118.Tunnelling nanotubes promote rapid entry and egress ::: EgressIn stark contrast to the use of TNTs by retroviruses, HMPV, IAVs and measles virus commandeer nanotubular bridges for direct transfer of viral genomic RNA across tight junctions in the host epithelium3\u20135,119.", [["T cells", "ANATOMY", 44, 51], ["intercellular", "ANATOMY", 66, 79], ["T cells", "ANATOMY", 117, 124], ["cell", "ANATOMY", 169, 173], ["tight junctions", "ANATOMY", 422, 437], ["TNTs", "SIMPLE_CHEMICAL", 0, 4], ["human", "ORGANISM", 38, 43], ["T cells", "CELL", 44, 51], ["HIV-1", "ORGANISM", 97, 102], ["T cells", "CELL", 117, 124], ["TNTs", "GENE_OR_GENE_PRODUCT", 133, 137], ["cell", "CELL", 169, 173], ["TNTs", "GENE_OR_GENE_PRODUCT", 292, 296], ["retroviruses", "ORGANISM", 300, 312], ["HMPV", "ORGANISM", 314, 318], ["IAVs", "GENE_OR_GENE_PRODUCT", 320, 324], ["measles virus", "ORGANISM", 329, 342], ["tight junctions", "CELLULAR_COMPONENT", 422, 437], ["TNTs", "PROTEIN", 0, 4], ["human T cells", "CELL_TYPE", 38, 51], ["uninfected T cells", "CELL_TYPE", 106, 124], ["TNTs", "PROTEIN", 133, 137], ["TNTs", "PROTEIN", 292, 296], ["viral genomic RNA", "RNA", 397, 414], ["human", "SPECIES", 38, 43], ["HIV-1", "SPECIES", 97, 102], ["measles virus", "SPECIES", 329, 342], ["human", "SPECIES", 38, 43], ["HIV-1", "SPECIES", 97, 102], ["HMPV", "SPECIES", 314, 318], ["measles virus", "SPECIES", 329, 342], ["HIV", "PROBLEM", 97, 100], ["cell-free virions", "TEST", 169, 186], ["Tunnelling nanotubes", "TREATMENT", 198, 218], ["TNTs", "TREATMENT", 292, 296], ["HMPV", "PROBLEM", 314, 318], ["IAVs", "TREATMENT", 320, 324], ["measles virus commandeer nanotubular bridges", "TREATMENT", 329, 373], ["viral genomic RNA", "PROBLEM", 397, 414], ["stable", "OBSERVATION_MODIFIER", 28, 34], ["viral genomic RNA", "OBSERVATION", 397, 414]]], ["HMPV phosphoprotein actively induces nanotube formation through actin polymerization and restructuring to promote cell-to-cell spread3.", [["cell", "ANATOMY", 114, 118], ["cell", "ANATOMY", 122, 126], ["HMPV", "ORGANISM", 0, 4], ["nanotube", "TISSUE", 37, 45], ["actin", "GENE_OR_GENE_PRODUCT", 64, 69], ["cell", "CELL", 114, 118], ["cell", "CELL", 122, 126], ["HMPV phosphoprotein", "PROTEIN", 0, 19], ["actin", "PROTEIN", 64, 69], ["spread3", "PROTEIN", 127, 134], ["HMPV", "SPECIES", 0, 4], ["HMPV phosphoprotein", "TREATMENT", 0, 19], ["nanotube formation", "PROBLEM", 37, 55], ["actin polymerization", "TREATMENT", 64, 84], ["nanotube formation", "OBSERVATION", 37, 55], ["actin polymerization", "OBSERVATION", 64, 84], ["promote cell", "OBSERVATION", 106, 118], ["cell spread3", "OBSERVATION", 122, 134]]], ["Intriguingly, HMPV and measles virus viral RNA and proteins traverse TNTs in lung epithelial cell lines and differentiated airway epithelial cell cultures3,5,119, suggesting that direct delivery of viral RNA into target cells occurs in the absence of classically described modes of virion egress and receptor-mediated entry.", [["lung epithelial cell lines", "ANATOMY", 77, 103], ["airway epithelial cell cultures", "ANATOMY", 123, 154], ["cells", "ANATOMY", 220, 225], ["virion", "ANATOMY", 282, 288], ["HMPV", "ORGANISM", 14, 18], ["measles virus", "ORGANISM", 23, 36], ["TNTs", "GENE_OR_GENE_PRODUCT", 69, 73], ["lung epithelial cell lines", "CELL", 77, 103], ["airway epithelial cell cultures3,5,119", "CELL", 123, 161], ["cells", "CELL", 220, 225], ["virion", "CELLULAR_COMPONENT", 282, 288], ["measles virus viral RNA", "RNA", 23, 46], ["TNTs", "PROTEIN", 69, 73], ["lung epithelial cell lines", "CELL_LINE", 77, 103], ["differentiated airway epithelial cell cultures3,5,119", "CELL_LINE", 108, 161], ["viral RNA", "RNA", 198, 207], ["target cells", "CELL_TYPE", 213, 225], ["measles virus viral", "SPECIES", 23, 42], ["HMPV", "SPECIES", 14, 18], ["measles virus", "SPECIES", 23, 36], ["HMPV", "PROBLEM", 14, 18], ["measles virus viral RNA", "PROBLEM", 23, 46], ["proteins traverse TNTs in lung epithelial cell lines", "PROBLEM", 51, 103], ["differentiated airway epithelial cell cultures", "TEST", 108, 154], ["viral RNA into target cells", "PROBLEM", 198, 225], ["HMPV", "OBSERVATION", 14, 18], ["lung", "ANATOMY", 77, 81], ["epithelial cell lines", "OBSERVATION", 82, 103], ["differentiated", "OBSERVATION_MODIFIER", 108, 122], ["airway epithelial cell cultures", "OBSERVATION", 123, 154], ["viral RNA", "OBSERVATION", 198, 207], ["target cells", "OBSERVATION", 213, 225], ["virion egress", "OBSERVATION", 282, 295]]], ["This mode of viral dissemination protects viruses from antibody neutralization during infection3.Tunnelling nanotubes promote rapid entry and egress ::: EgressTNTs thus seem to be a viable and attractive alternative mode of entry and egress for numerous viruses (Fig. 1b).", [["EgressTNTs", "GENE_OR_GENE_PRODUCT", 153, 163], ["viral dissemination protects viruses", "PROBLEM", 13, 49], ["antibody neutralization during infection3", "PROBLEM", 55, 96], ["Tunnelling nanotubes", "TREATMENT", 97, 117], ["numerous viruses", "PROBLEM", 245, 261], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["dissemination", "OBSERVATION", 19, 32], ["antibody neutralization", "OBSERVATION", 55, 78], ["seem to be", "UNCERTAINTY", 169, 179]]], ["Given that a diverse set of viruses have evolved mechanisms to traffic along TNTs, it is presumed that TNTs are widely used during viral infection.", [["viral infection", "DISEASE", 131, 146], ["TNTs", "GENE_OR_GENE_PRODUCT", 77, 81], ["TNTs", "GENE_OR_GENE_PRODUCT", 103, 107], ["TNTs", "CELL_TYPE", 77, 81], ["TNTs", "PROTEIN", 103, 107], ["a diverse set of viruses", "PROBLEM", 11, 35], ["viral infection", "PROBLEM", 131, 146], ["viruses", "OBSERVATION", 28, 35], ["viral", "OBSERVATION_MODIFIER", 131, 136], ["infection", "OBSERVATION", 137, 146]]], ["However, studies of viral trafficking along TNTs remain restricted to a small subset of cell types, frequently immortalized cell lines, some of which may not be representative of clinical disease.", [["cell", "ANATOMY", 88, 92], ["cell lines", "ANATOMY", 124, 134], ["TNTs", "GENE_OR_GENE_PRODUCT", 44, 48], ["cell", "CELL", 88, 92], ["cell lines", "CELL", 124, 134], ["TNTs", "CELL_TYPE", 44, 48], ["immortalized cell lines", "CELL_LINE", 111, 134], ["viral trafficking", "PROBLEM", 20, 37], ["a small subset of cell types", "PROBLEM", 70, 98], ["frequently immortalized cell lines", "PROBLEM", 100, 134], ["clinical disease", "PROBLEM", 179, 195], ["small subset", "OBSERVATION_MODIFIER", 72, 84], ["of cell types", "OBSERVATION", 85, 98], ["immortalized cell lines", "OBSERVATION", 111, 134], ["may not be", "UNCERTAINTY", 150, 160]]], ["Given the considerable diversity of TNTs reported across cell types, further studies of TNT formation and use in relevant models of viral pathogenesis are warranted.Tunnelling nanotubes promote rapid entry and egress ::: EgressThe use of TNTs for delivery of viral RNA to neighbouring cells by HMPV and measles virus has enormous implications for viral dissemination and suggests that TNT cargo is more diverse than previously appreciated.", [["cell", "ANATOMY", 57, 61], ["cells", "ANATOMY", 285, 290], ["TNTs", "CHEMICAL", 238, 242], ["TNTs", "GENE_OR_GENE_PRODUCT", 36, 40], ["cell", "CELL", 57, 61], ["TNT", "GENE_OR_GENE_PRODUCT", 88, 91], ["TNTs", "GENE_OR_GENE_PRODUCT", 238, 242], ["cells", "CELL", 285, 290], ["HMPV", "ORGANISM", 294, 298], ["measles virus", "ORGANISM", 303, 316], ["TNT", "GENE_OR_GENE_PRODUCT", 385, 388], ["TNTs", "PROTEIN", 36, 40], ["TNTs", "PROTEIN", 238, 242], ["viral RNA", "RNA", 259, 268], ["neighbouring cells", "CELL_TYPE", 272, 290], ["HMPV", "SPECIES", 294, 298], ["measles virus", "SPECIES", 303, 316], ["further studies", "TEST", 69, 84], ["TNT formation", "TREATMENT", 88, 101], ["viral pathogenesis", "PROBLEM", 132, 150], ["Tunnelling nanotubes", "TREATMENT", 165, 185], ["TNTs", "TREATMENT", 238, 242], ["delivery", "TREATMENT", 247, 255], ["viral RNA", "PROBLEM", 259, 268], ["HMPV", "PROBLEM", 294, 298], ["measles virus", "PROBLEM", 303, 316], ["viral dissemination", "PROBLEM", 347, 366], ["TNT cargo", "PROBLEM", 385, 394], ["considerable", "OBSERVATION_MODIFIER", 10, 22], ["diversity", "OBSERVATION_MODIFIER", 23, 32], ["across cell types", "OBSERVATION", 50, 67], ["viral dissemination", "OBSERVATION", 347, 366], ["more diverse", "OBSERVATION_MODIFIER", 398, 410]]], ["Do most viruses traffic along the exterior of TNTs, as HIV-1 does, or are intercellular TNTs widely used to evade circulating antibodies and pattern recognition receptors on cell surfaces?", [["intercellular TNTs", "ANATOMY", 74, 92], ["cell surfaces", "ANATOMY", 174, 187], ["HIV-1", "ORGANISM", 55, 60], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 141, 170], ["cell", "CELL", 174, 178], ["circulating antibodies", "PROTEIN", 114, 136], ["pattern recognition receptors", "PROTEIN", 141, 170], ["HIV-1", "SPECIES", 55, 60], ["HIV-1", "SPECIES", 55, 60], ["intercellular TNTs", "TREATMENT", 74, 92], ["circulating antibodies", "TEST", 114, 136]]], ["The answers to these questions will undoubtedly reflect the heterogeneous nature of TNTs.Cloaking of viruses in host microvesicles ::: EgressGiven the vast heterogeneity in viral replication, transmission of communities of many virus particles en masse may complement defective or incomplete genomes.", [["microvesicles", "ANATOMY", 117, 130], ["TNTs", "DISEASE", 84, 88], ["TNTs", "CANCER", 84, 88], ["microvesicles", "CELL", 117, 130], ["host microvesicles", "CELL_TYPE", 112, 130], ["the vast heterogeneity", "PROBLEM", 147, 169], ["viral replication", "TREATMENT", 173, 190], ["many virus particles", "PROBLEM", 223, 243], ["incomplete genomes", "PROBLEM", 281, 299], ["heterogeneous", "OBSERVATION_MODIFIER", 60, 73], ["viruses", "OBSERVATION", 101, 108], ["host microvesicles", "OBSERVATION", 112, 130], ["vast", "OBSERVATION_MODIFIER", 151, 155], ["heterogeneity", "OBSERVATION", 156, 169], ["viral replication", "OBSERVATION", 173, 190], ["incomplete genomes", "OBSERVATION", 281, 299]]], ["Recent work has revealed that picornaviruses package multiple viral particles into a cellular microvesicle to promote the spread of many heterogeneous virions together124.", [["cellular microvesicle", "ANATOMY", 85, 106], ["virions", "ANATOMY", 151, 158], ["cellular", "CELL", 85, 93], ["picornaviruses package multiple viral particles", "PROBLEM", 30, 77], ["a cellular microvesicle", "PROBLEM", 83, 106], ["picornaviruses", "OBSERVATION", 30, 44], ["multiple", "OBSERVATION_MODIFIER", 53, 61], ["viral particles", "OBSERVATION", 62, 77], ["cellular microvesicle", "OBSERVATION", 85, 106], ["spread", "OBSERVATION_MODIFIER", 122, 128], ["heterogeneous", "OBSERVATION_MODIFIER", 137, 150], ["virions", "OBSERVATION", 151, 158]]], ["Aggregation of enveloped viruses, such as vesicular stomatitis virus, can also facilitate the transmission of viral communities125.", [["vesicular stomatitis", "DISEASE", 42, 62], ["vesicular stomatitis virus", "ORGANISM", 42, 68], ["vesicular stomatitis virus", "SPECIES", 42, 68], ["vesicular stomatitis virus", "SPECIES", 42, 68], ["Aggregation of enveloped viruses", "PROBLEM", 0, 32], ["vesicular stomatitis virus", "PROBLEM", 42, 68], ["enveloped", "OBSERVATION_MODIFIER", 15, 24], ["viruses", "OBSERVATION", 25, 32], ["vesicular stomatitis", "OBSERVATION", 42, 62]]], ["Intriguingly, for many RNA viruses, the minimal infectious unit is the viral genome rather than a fully encapsidated and/or enveloped virion.", [["virion", "ANATOMY", 134, 140], ["minimal infectious unit", "DNA", 40, 63], ["viral genome", "DNA", 71, 83], ["many RNA viruses", "PROBLEM", 18, 34], ["the viral genome", "PROBLEM", 67, 83], ["viruses", "OBSERVATION", 27, 34], ["minimal", "OBSERVATION_MODIFIER", 40, 47], ["infectious", "OBSERVATION", 48, 58], ["viral genome", "OBSERVATION", 71, 83], ["encapsidated", "OBSERVATION", 104, 116]]], ["Although they may improve replication efficiency, proteins packaged by an RNA virus into a virion are often not essential for replication, with the exception of nucleoprotein complexes for negative-sense RNA viruses.", [["nucleoprotein complexes", "PROTEIN", 161, 184], ["replication efficiency", "PROBLEM", 26, 48], ["proteins packaged", "TREATMENT", 50, 67], ["an RNA virus", "PROBLEM", 71, 83], ["replication", "PROBLEM", 126, 137], ["nucleoprotein complexes", "TEST", 161, 184], ["sense RNA viruses", "PROBLEM", 198, 215], ["replication efficiency", "OBSERVATION", 26, 48]]], ["Historically, viruses have been classified as one of two binary types, enveloped or non-enveloped, but recent studies have indicated surprising overlap in this classification.Cloaking of viruses in host microvesicles ::: EgressMany enteroviruses, such as hepatitis A virus (HAV), were historically believed to only encapsidate their genome and undergo lytic egress as non-enveloped particles.", [["microvesicles", "ANATOMY", 203, 216], ["EgressMany enteroviruses", "DISEASE", 221, 245], ["hepatitis A virus", "DISEASE", 255, 272], ["microvesicles", "CELL", 203, 216], ["EgressMany enteroviruses", "ORGANISM", 221, 245], ["hepatitis A virus", "ORGANISM", 255, 272], ["HAV", "ORGANISM", 274, 277], ["host microvesicles", "CELL_TYPE", 198, 216], ["hepatitis A virus", "SPECIES", 255, 272], ["hepatitis A virus", "SPECIES", 255, 272], ["HAV", "SPECIES", 274, 277], ["recent studies", "TEST", 103, 117], ["EgressMany enteroviruses", "PROBLEM", 221, 245], ["hepatitis A virus", "PROBLEM", 255, 272], ["viruses", "OBSERVATION", 14, 21], ["non-enveloped", "OBSERVATION_MODIFIER", 84, 97], ["viruses", "OBSERVATION", 187, 194], ["host microvesicles", "OBSERVATION", 198, 216], ["enteroviruses", "OBSERVATION", 232, 245], ["lytic", "OBSERVATION_MODIFIER", 352, 357]]], ["Although this mode of egress may still predominate, recent work describes a duality in viral particle composition in which quasi-enveloped HAV particles acquire an envelope from extracellular vesicles and shed non-lytically from the host cell126.", [["extracellular vesicles", "ANATOMY", 178, 200], ["cell", "ANATOMY", 238, 242], ["HAV", "ORGANISM", 139, 142], ["extracellular vesicles", "CELLULAR_COMPONENT", 178, 200], ["cell126", "CELL", 238, 245], ["HAV", "SPECIES", 139, 142], ["viral particle composition", "TREATMENT", 87, 113], ["quasi-enveloped HAV particles", "PROBLEM", 123, 152], ["extracellular vesicles", "TEST", 178, 200], ["viral particle", "OBSERVATION", 87, 101], ["host cell", "OBSERVATION", 233, 242]]], ["Enveloped HAV biogenesis resembles that of exosomes in multivesicular bodies as they are decorated with host exosomal markers, including CD9 and DPP4127.", [["exosomes", "ANATOMY", 43, 51], ["multivesicular bodies", "ANATOMY", 55, 76], ["exosomal", "ANATOMY", 109, 117], ["HAV", "ORGANISM", 10, 13], ["exosomes", "CELL", 43, 51], ["multivesicular bodies", "CELLULAR_COMPONENT", 55, 76], ["CD9", "GENE_OR_GENE_PRODUCT", 137, 140], ["DPP4127", "GENE_OR_GENE_PRODUCT", 145, 152], ["exosomes", "CELL_TYPE", 43, 51], ["host exosomal markers", "PROTEIN", 104, 125], ["CD9", "PROTEIN", 137, 140], ["DPP4127", "PROTEIN", 145, 152], ["CD9", "TEST", 137, 140], ["HAV biogenesis", "OBSERVATION", 10, 24], ["exosomes", "OBSERVATION", 43, 51], ["multivesicular", "ANATOMY_MODIFIER", 55, 69], ["bodies", "ANATOMY_MODIFIER", 70, 76]]], ["Assembly of enveloped HAV also depends on at least two components of the endosomal sorting complex (ESCRT), VPS4B and ALIX126.Cloaking of viruses in host microvesicles ::: EgressMicrovesicle cloaking has emerged in recent studies as a common egress strategy for many viruses.", [["endosomal", "ANATOMY", 73, 82], ["microvesicles", "ANATOMY", 154, 167], ["HAV", "ORGANISM", 22, 25], ["endosomal", "CELLULAR_COMPONENT", 73, 82], ["ESCRT", "GENE_OR_GENE_PRODUCT", 100, 105], ["VPS4B", "GENE_OR_GENE_PRODUCT", 108, 113], ["ALIX126", "GENE_OR_GENE_PRODUCT", 118, 125], ["microvesicles", "CELL", 154, 167], ["endosomal sorting complex", "PROTEIN", 73, 98], ["ESCRT", "PROTEIN", 100, 105], ["VPS4B", "PROTEIN", 108, 113], ["ALIX126", "PROTEIN", 118, 125], ["host microvesicles", "CELL_TYPE", 149, 167], ["enveloped HAV", "PROBLEM", 12, 25], ["VPS4B", "TEST", 108, 113], ["EgressMicrovesicle cloaking", "PROBLEM", 172, 199], ["recent studies", "TEST", 215, 229], ["a common egress strategy", "TREATMENT", 233, 257], ["many viruses", "PROBLEM", 262, 274], ["enveloped", "OBSERVATION_MODIFIER", 12, 21], ["HAV", "OBSERVATION", 22, 25], ["viruses", "OBSERVATION", 138, 145], ["host microvesicles", "OBSERVATION", 149, 167], ["viruses", "OBSERVATION", 267, 274]]], ["Other members of the Picornaviridae family exhibit particle duality as well, but the mechanism of envelopment during enterovirus assembly is distinct from that of hepatoviruses128.", [["Picornaviridae", "GENE_OR_GENE_PRODUCT", 21, 35], ["enterovirus", "ORGANISM", 117, 128], ["Picornaviridae family", "PROTEIN", 21, 42], ["enterovirus", "PROBLEM", 117, 128], ["hepatoviruses", "TEST", 163, 176]]], ["Poliovirus and Coxsackievirus B3 (CVB3) are shed non-lytically through the autophagy pathway128,129.", [["Poliovirus", "ORGANISM", 0, 10], ["Coxsackievirus B3", "ORGANISM", 15, 32], ["CVB3", "ORGANISM", 34, 38], ["Coxsackievirus B3", "SPECIES", 15, 32], ["Poliovirus", "SPECIES", 0, 10], ["Coxsackievirus B3", "SPECIES", 15, 32], ["CVB3", "SPECIES", 34, 38], ["Poliovirus", "PROBLEM", 0, 10], ["Coxsackievirus B3 (CVB3", "TREATMENT", 15, 38], ["the autophagy pathway", "TEST", 71, 92]]], ["Poliovirus, CVB3 and rhinovirus are all found in phosphatidylserine-containing lipid vesicles, and the infectivity of these enveloped particles is higher than that of canonical non-enveloped particles124.", [["lipid vesicles", "ANATOMY", 79, 93], ["phosphatidylserine", "CHEMICAL", 49, 67], ["phosphatidylserine", "CHEMICAL", 49, 67], ["Poliovirus", "ORGANISM", 0, 10], ["CVB3", "ORGANISM", 12, 16], ["rhinovirus", "ORGANISM", 21, 31], ["phosphatidylserine", "SIMPLE_CHEMICAL", 49, 67], ["lipid vesicles", "CELLULAR_COMPONENT", 79, 93], ["CVB3", "SPECIES", 12, 16], ["Poliovirus", "SPECIES", 0, 10], ["CVB3", "SPECIES", 12, 16], ["Poliovirus", "PROBLEM", 0, 10], ["CVB3", "PROBLEM", 12, 16], ["rhinovirus", "PROBLEM", 21, 31], ["lipid vesicles", "TREATMENT", 79, 93], ["the infectivity of these enveloped particles", "PROBLEM", 99, 143], ["rhinovirus", "OBSERVATION", 21, 31], ["lipid vesicles", "OBSERVATION", 79, 93], ["infectivity", "OBSERVATION_MODIFIER", 103, 114], ["enveloped", "OBSERVATION_MODIFIER", 124, 133], ["particles", "OBSERVATION", 134, 143], ["higher", "OBSERVATION_MODIFIER", 147, 153]]], ["The authors of this study used innovative imaging approaches, including total-internal reflection fluorescence with super-resolution microscopy and direct stochastic optical reconstruction microscopy, to demonstrate that viral particles are packaged in microvesicles in clusters, thereby artificially increasing the multiplicity of infection124.", [["microvesicles", "ANATOMY", 253, 266], ["infection", "DISEASE", 332, 341], ["microvesicles", "CELL", 253, 266], ["microvesicles", "CELL_TYPE", 253, 266], ["this study", "TEST", 15, 25], ["innovative imaging approaches", "TEST", 31, 60], ["direct stochastic optical reconstruction microscopy", "TEST", 148, 199], ["viral particles", "PROBLEM", 221, 236], ["infection", "PROBLEM", 332, 341], ["viral particles", "OBSERVATION", 221, 236], ["increasing", "OBSERVATION_MODIFIER", 301, 311], ["multiplicity", "OBSERVATION_MODIFIER", 316, 328], ["infection", "OBSERVATION", 332, 341]]], ["Thus, it seems that the classically non-enveloped viruses of the Picornaviridae family can subvert different host processes to achieve non-lytic egress.", [["Picornaviridae", "GENE_OR_GENE_PRODUCT", 65, 79], ["non-enveloped", "OBSERVATION_MODIFIER", 36, 49], ["viruses", "OBSERVATION", 50, 57]]], ["In addition to HAV, the classically non-enveloped enteroviruses, norovirus and rotavirus, both use microvesicle cloaking for similarly enhanced infectivity130.Cloaking of viruses in host microvesicles ::: EgressEnveloped viruses such as IAVs may also hijack microvesicle assembly131.", [["microvesicle", "ANATOMY", 99, 111], ["microvesicles", "ANATOMY", 187, 200], ["enteroviruses", "DISEASE", 50, 63], ["norovirus", "DISEASE", 65, 74], ["rotavirus", "DISEASE", 79, 88], ["HAV", "ORGANISM", 15, 18], ["enteroviruses", "ORGANISM", 50, 63], ["norovirus", "ORGANISM", 65, 74], ["rotavirus", "ORGANISM", 79, 88], ["microvesicles", "CELL", 187, 200], ["EgressEnveloped viruses", "ORGANISM", 205, 228], ["IAVs", "GENE_OR_GENE_PRODUCT", 237, 241], ["host microvesicles", "CELL_TYPE", 182, 200], ["microvesicle assembly131", "PROTEIN", 258, 282], ["HAV", "SPECIES", 15, 18], ["rotavirus", "SPECIES", 79, 88], ["HAV", "PROBLEM", 15, 18], ["the classically non-enveloped enteroviruses", "PROBLEM", 20, 63], ["norovirus", "PROBLEM", 65, 74], ["rotavirus", "PROBLEM", 79, 88], ["microvesicle cloaking", "TREATMENT", 99, 120], ["similarly enhanced infectivity", "PROBLEM", 125, 155], ["EgressEnveloped viruses", "PROBLEM", 205, 228], ["IAVs", "PROBLEM", 237, 241], ["non-enveloped", "OBSERVATION_MODIFIER", 36, 49], ["enteroviruses", "OBSERVATION", 50, 63], ["norovirus", "OBSERVATION", 65, 74], ["viruses", "OBSERVATION", 171, 178], ["host microvesicles", "OBSERVATION", 182, 200], ["viruses", "OBSERVATION", 221, 228]]], ["The protein composition of the IAV virion includes over 300 host proteins, and many of these are known exosome markers, such as the tetraspanin CD9 (ref.131) identified in enveloped HAV127 (Fig. 3).", [["exosome", "ANATOMY", 103, 110], ["IAV virion", "ORGANISM", 31, 41], ["exosome", "GENE_OR_GENE_PRODUCT", 103, 110], ["tetraspanin CD9", "GENE_OR_GENE_PRODUCT", 132, 147], ["exosome markers", "PROTEIN", 103, 118], ["tetraspanin CD9", "PROTEIN", 132, 147], ["ref", "PROTEIN", 149, 152], ["the IAV virion", "TREATMENT", 27, 41], ["the tetraspanin CD9", "TREATMENT", 128, 147], ["IAV virion", "OBSERVATION", 31, 41], ["exosome markers", "OBSERVATION", 103, 118]]], ["Microvesicle assembly has therefore emerged as a common mode of egress for many virus families, from the canonically non-enveloped picornaviruses to enveloped viruses such as influenza.Cloaking of viruses in host microvesicles ::: EgressGiven that enveloped picornaviruses show higher infectivity than their non-enveloped counterparts, cloaking a virus in a microvesicle may have huge implications for entry and egress beyond particle morphology and infectivity.", [["Microvesicle", "ANATOMY", 0, 12], ["microvesicles", "ANATOMY", 213, 226], ["microvesicle", "ANATOMY", 358, 370], ["particle", "ANATOMY", 426, 434], ["influenza", "DISEASE", 175, 184], ["microvesicles", "CELL", 213, 226], ["picornaviruses", "ORGANISM", 258, 272], ["microvesicle", "CANCER", 358, 370], ["host microvesicles", "CELL_TYPE", 208, 226], ["many virus families", "PROBLEM", 75, 94], ["the canonically non-enveloped picornaviruses", "PROBLEM", 101, 145], ["influenza", "PROBLEM", 175, 184], ["enveloped picornaviruses", "PROBLEM", 248, 272], ["higher infectivity", "PROBLEM", 278, 296], ["cloaking a virus", "PROBLEM", 336, 352], ["picornaviruses", "OBSERVATION", 131, 145], ["viruses", "OBSERVATION", 159, 166], ["viruses", "OBSERVATION", 197, 204], ["host microvesicles", "OBSERVATION", 208, 226], ["picornaviruses", "OBSERVATION", 258, 272], ["higher", "OBSERVATION_MODIFIER", 278, 284], ["infectivity", "OBSERVATION_MODIFIER", 285, 296]]], ["These viral vesicles can be passively taken up by neighbouring cells through processes such as clathrin-mediated endocytosis, bypassing the requirement for a cellular receptor for entry.", [["vesicles", "ANATOMY", 12, 20], ["cells", "ANATOMY", 63, 68], ["cellular", "ANATOMY", 158, 166], ["cells", "CELL", 63, 68], ["clathrin", "GENE_OR_GENE_PRODUCT", 95, 103], ["cellular", "CELL", 158, 166], ["neighbouring cells", "CELL_TYPE", 50, 68], ["clathrin", "PROTEIN", 95, 103], ["cellular receptor", "PROTEIN", 158, 175], ["These viral vesicles", "PROBLEM", 0, 20], ["clathrin-mediated endocytosis", "PROBLEM", 95, 124], ["a cellular receptor", "TREATMENT", 156, 175], ["viral vesicles", "OBSERVATION", 6, 20], ["endocytosis", "OBSERVATION", 113, 124]]], ["In the case of picornaviruses, non-lytic egress presents a mechanism for rapid dissemination through tissues without alerting nearby cells to the presence of a pathogen upon lysis.", [["tissues", "ANATOMY", 101, 108], ["cells", "ANATOMY", 133, 138], ["picornaviruses", "ORGANISM", 15, 29], ["tissues", "TISSUE", 101, 108], ["cells", "CELL", 133, 138], ["nearby cells", "CELL_TYPE", 126, 138], ["picornaviruses", "PROBLEM", 15, 29], ["non-lytic egress", "PROBLEM", 31, 47], ["rapid dissemination through tissues", "PROBLEM", 73, 108], ["lysis", "TREATMENT", 174, 179], ["picornaviruses", "OBSERVATION", 15, 29], ["lysis", "OBSERVATION", 174, 179]]], ["Continued investigation of such possibilities remains paramount to our understanding of viral entry and egress and the development of antivirals to target these processes.Antivirals and vaccines in the face of heterogeneous entry mechanisms ::: Implications for medicineCurrent technologies make it easier than ever before to screen thousands of compounds for efficacy against viral infection and rapidly identify potential new therapeutic candidates.", [["viral infection", "DISEASE", 377, 392], ["viral entry", "PROBLEM", 88, 99], ["antivirals", "TREATMENT", 134, 144], ["Antivirals", "TREATMENT", 171, 181], ["vaccines", "TREATMENT", 186, 194], ["medicineCurrent technologies", "TREATMENT", 262, 290], ["viral infection", "PROBLEM", 377, 392], ["heterogeneous", "OBSERVATION", 210, 223]]], ["A given virus may exhibit extraordinary diversity in genomic content and particle morphology, so candidate therapeutics must be pan-protective against a heterogeneous viral population.", [["virus", "PROBLEM", 8, 13], ["extraordinary diversity in genomic content", "PROBLEM", 26, 68], ["a heterogeneous viral population", "PROBLEM", 151, 183], ["extraordinary", "OBSERVATION_MODIFIER", 26, 39], ["diversity", "OBSERVATION", 40, 49], ["genomic content", "OBSERVATION", 53, 68], ["particle morphology", "OBSERVATION_MODIFIER", 73, 92], ["heterogeneous", "OBSERVATION_MODIFIER", 153, 166], ["viral", "OBSERVATION", 167, 172]]], ["Consideration should be given to the cell type and virion morphology as well as the diversity in entry and egress processes.", [["cell", "ANATOMY", 37, 41], ["cell", "CELL", 37, 41], ["egress processes", "OBSERVATION", 107, 123]]], ["Many antiviral therapies identified to date are entry inhibitors, yet we have seen how diverse mechanisms of entry and egress enable rapid dissemination through tissues.", [["tissues", "ANATOMY", 161, 168], ["tissues", "TISSUE", 161, 168], ["Many antiviral therapies", "TREATMENT", 0, 24], ["entry inhibitors", "TREATMENT", 48, 64], ["antiviral therapies", "OBSERVATION", 5, 24], ["rapid", "OBSERVATION_MODIFIER", 133, 138], ["dissemination", "OBSERVATION", 139, 152]]], ["The use of TNTs for delivery of viral genomes to a neighbouring cell bypasses receptor-mediated entry altogether.", [["cell", "ANATOMY", 64, 68], ["TNTs", "CHEMICAL", 11, 15], ["TNTs", "GENE_OR_GENE_PRODUCT", 11, 15], ["cell", "CELL", 64, 68], ["TNTs", "PROTEIN", 11, 15], ["viral genomes", "DNA", 32, 45], ["TNTs", "TREATMENT", 11, 15], ["delivery of viral genomes", "TREATMENT", 20, 45], ["a neighbouring cell bypasses receptor", "TREATMENT", 49, 86]]], ["Therefore, entry inhibitors may prove ineffective against such infections.", [["infections", "DISEASE", 63, 73], ["entry inhibitors", "TREATMENT", 11, 27], ["such infections", "PROBLEM", 58, 73]]], ["TNTs may also facilitate viral escape from antibody neutralization, thus weakening the effectiveness of vaccination.", [["TNTs", "SIMPLE_CHEMICAL", 0, 4], ["viral escape", "PROBLEM", 25, 37], ["antibody neutralization", "PROBLEM", 43, 66], ["vaccination", "TREATMENT", 104, 115], ["viral escape", "OBSERVATION", 25, 37]]], ["Such infections may progress faster than a classical infection would, as rapid dissemination to cells hundreds of microns apart can readily occur111,113.", [["cells", "ANATOMY", 96, 101], ["infections", "DISEASE", 5, 15], ["infection", "DISEASE", 53, 62], ["cells", "CELL", 96, 101], ["Such infections", "PROBLEM", 0, 15], ["a classical infection", "PROBLEM", 41, 62], ["infections", "OBSERVATION", 5, 15], ["infection", "OBSERVATION", 53, 62]]], ["Post-entry therapeutics or combination therapies with nanotube inhibitors might prove to be more effective against such viral diseases.Dissemination of viral genomic material ::: Implications for medicineA diverse set of viruses are cloaked in host microvesicles.", [["microvesicles", "ANATOMY", 249, 262], ["viral diseases", "DISEASE", 120, 134], ["microvesicles", "CELL", 249, 262], ["host microvesicles", "CELL_TYPE", 244, 262], ["entry therapeutics", "TREATMENT", 5, 23], ["combination therapies", "TREATMENT", 27, 48], ["nanotube inhibitors", "TREATMENT", 54, 73], ["such viral diseases", "PROBLEM", 115, 134], ["medicineA diverse set of viruses", "TREATMENT", 196, 228], ["viral genomic material", "OBSERVATION", 152, 174], ["viruses", "OBSERVATION", 221, 228], ["host microvesicles", "OBSERVATION", 244, 262]]], ["Cloaked picornaviruses have higher infectivity than traditionally described non-enveloped particles and may disseminate more efficiently.", [["picornaviruses", "ORGANISM", 8, 22], ["Cloaked picornaviruses", "PROBLEM", 0, 22], ["higher infectivity", "PROBLEM", 28, 46], ["picornaviruses", "OBSERVATION", 8, 22], ["higher infectivity", "OBSERVATION_MODIFIER", 28, 46], ["non-enveloped particles", "OBSERVATION_MODIFIER", 76, 99]]], ["Cloaked particles may have other functions in addition to spreading virus particles; in the case of influenza virus, they may complement semi-infectious virus particles lacking one or more gene segments.", [["influenza", "DISEASE", 100, 109], ["influenza virus", "ORGANISM", 100, 115], ["influenza virus", "SPECIES", 100, 115], ["influenza virus", "SPECIES", 100, 115], ["other functions", "PROBLEM", 27, 42], ["spreading virus particles", "PROBLEM", 58, 83], ["influenza virus", "PROBLEM", 100, 115], ["semi-infectious virus particles", "TREATMENT", 137, 168], ["influenza virus", "OBSERVATION", 100, 115]]], ["Given that picornaviruses reportedly package multiple viral particles per microvesicle to achieve dissemination of many virions en masse124, one could envision that microvesicles promote co-infection.", [["microvesicles", "ANATOMY", 165, 178], ["co-infection", "DISEASE", 187, 199], ["picornaviruses", "ORGANISM", 11, 25], ["microvesicles", "CELL", 165, 178], ["microvesicles", "CELL_TYPE", 165, 178], ["picornaviruses", "PROBLEM", 11, 25], ["multiple viral particles", "PROBLEM", 45, 69], ["many virions en masse", "TREATMENT", 115, 136], ["co-infection", "PROBLEM", 187, 199], ["picornaviruses", "OBSERVATION", 11, 25], ["multiple", "OBSERVATION_MODIFIER", 45, 53], ["viral particles", "OBSERVATION", 54, 69], ["co-infection", "OBSERVATION", 187, 199]]], ["Interestingly, microvesicle cloaking does not increase genetic complementation or population diversity during co-infection with multiple CVB3 variants132.", [["microvesicle", "ANATOMY", 15, 27], ["CVB3", "ORGANISM", 137, 141], ["microvesicle cloaking", "PROBLEM", 15, 36], ["genetic complementation", "PROBLEM", 55, 78], ["population diversity", "PROBLEM", 82, 102], ["multiple CVB3 variants", "TEST", 128, 150], ["microvesicle cloaking", "OBSERVATION", 15, 36]]], ["This finding suggests that packaging of CVB3 into host microvesicles is highly selective.", [["microvesicles", "ANATOMY", 55, 68], ["CVB3", "ORGANISM", 40, 44], ["microvesicles", "CELL", 55, 68], ["host microvesicles", "CELL_TYPE", 50, 68], ["CVB3", "SPECIES", 40, 44], ["CVB3", "OBSERVATION", 40, 44], ["host microvesicles", "OBSERVATION", 50, 68], ["highly", "OBSERVATION_MODIFIER", 72, 78], ["selective", "OBSERVATION_MODIFIER", 79, 88]]], ["Considering that genetic reassortment is commonly reported at high multiplicity of infection during influenza virus co-infection133, further investigation will be necessary to determine whether the selectivity observed in CVB3 microvesicles applies to other viruses.", [["microvesicles", "ANATOMY", 227, 240], ["infection", "DISEASE", 83, 92], ["influenza virus co-infection", "DISEASE", 100, 128], ["influenza virus", "ORGANISM", 100, 115], ["CVB3", "ORGANISM", 222, 226], ["microvesicles", "CELL", 227, 240], ["CVB3 microvesicles", "CELL_TYPE", 222, 240], ["influenza virus", "SPECIES", 100, 115], ["influenza virus", "SPECIES", 100, 115], ["CVB3", "SPECIES", 222, 226], ["infection", "PROBLEM", 83, 92], ["influenza virus co-infection", "PROBLEM", 100, 128], ["further investigation", "TEST", 133, 154], ["CVB3 microvesicles", "TREATMENT", 222, 240], ["other viruses", "PROBLEM", 252, 265], ["infection", "OBSERVATION", 83, 92]]], ["The mechanism of such high-fidelity packaging in microvesicles is nonetheless an exciting new area of research.Heterogeneity in virion assembly may promote severe disease ::: Implications for medicinePleomorphic particles have been reported for decades, but the effect of heterogeneous assembly mechanisms on viral pathogenesis remains understudied.", [["microvesicles", "ANATOMY", 49, 62], ["virion", "ANATOMY", 128, 134], ["Pleomorphic particles", "ANATOMY", 200, 221], ["microvesicles", "CELL", 49, 62], ["virion", "CELLULAR_COMPONENT", 128, 134], ["Pleomorphic particles", "CANCER", 200, 221], ["microvesicles", "CELL_TYPE", 49, 62], ["such high-fidelity packaging in microvesicles", "PROBLEM", 17, 62], ["Heterogeneity in virion", "PROBLEM", 111, 134], ["severe disease", "PROBLEM", 156, 170], ["medicine", "TREATMENT", 192, 200], ["Pleomorphic particles", "PROBLEM", 200, 221], ["viral pathogenesis", "PROBLEM", 309, 327], ["high", "OBSERVATION_MODIFIER", 22, 26], ["fidelity packaging", "OBSERVATION", 27, 45], ["new", "OBSERVATION_MODIFIER", 90, 93], ["area", "OBSERVATION_MODIFIER", 94, 98], ["may promote", "UNCERTAINTY", 144, 155], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["disease", "OBSERVATION", 163, 170], ["heterogeneous", "OBSERVATION_MODIFIER", 272, 285], ["viral", "OBSERVATION_MODIFIER", 309, 314]]], ["An intriguing function in mucus layer penetration and clearance has been proposed for long-filament IAV particles, which are defective for genomic packaging86.", [["mucus layer", "ANATOMY", 26, 37], ["mucus layer", "TISSUE", 26, 37], ["IAV", "ORGANISM", 100, 103], ["mucus layer penetration", "PROBLEM", 26, 49], ["long-filament IAV particles", "TREATMENT", 86, 113], ["genomic packaging", "TREATMENT", 139, 156], ["mucus", "OBSERVATION", 26, 31], ["layer penetration", "OBSERVATION", 32, 49]]], ["Such a role for low-fidelity assembly of IAV particles would have clear implications for pathogenesis and may be a viable target in the development of future therapeutics.", [["IAV", "ORGANISM", 41, 44], ["IAV particles", "TREATMENT", 41, 54], ["pathogenesis", "PROBLEM", 89, 101], ["future therapeutics", "TREATMENT", 151, 170]]], ["Alternatively, the production of pleomorphic virions in a host can result in viruses with different HA to NA ratios (see Fig. 3 for an illustration).", [["pleomorphic virions", "ANATOMY", 33, 52], ["pleomorphic virions", "PROBLEM", 33, 52], ["viruses", "PROBLEM", 77, 84], ["different HA", "PROBLEM", 90, 102], ["NA ratios", "TEST", 106, 115], ["pleomorphic virions", "OBSERVATION", 33, 52], ["viruses", "OBSERVATION", 77, 84]]], ["Altered HA to NA levels on a virion could impact antibody binding and may, therefore, influence vaccine efficacy.Synergy among polymicrobial communities ::: Implications for medicineAlthough outside the scope of this Review, the contribution of diverse polymicrobial communities to the morbidity and mortality of heterogeneous viruses is a public health dilemma in need of deeper investigation.", [["NA", "CHEMICAL", 14, 16], ["polymicrobial", "DISEASE", 253, 266], ["HA", "GENE_OR_GENE_PRODUCT", 8, 10], ["Altered HA", "PROBLEM", 0, 10], ["NA levels", "TEST", 14, 23], ["a virion", "TREATMENT", 27, 35], ["impact antibody binding", "PROBLEM", 42, 65], ["influence vaccine efficacy", "TREATMENT", 86, 112], ["medicine", "TREATMENT", 174, 182], ["diverse polymicrobial communities", "PROBLEM", 245, 278], ["the morbidity", "PROBLEM", 282, 295], ["heterogeneous viruses", "PROBLEM", 313, 334], ["deeper investigation", "TEST", 373, 393], ["HA", "OBSERVATION", 8, 10], ["NA levels", "OBSERVATION_MODIFIER", 14, 23], ["polymicrobial communities", "OBSERVATION", 127, 152], ["diverse", "OBSERVATION_MODIFIER", 245, 252], ["polymicrobial", "OBSERVATION", 253, 266], ["heterogeneous", "OBSERVATION_MODIFIER", 313, 326], ["viruses", "OBSERVATION", 327, 334]]], ["Recently, a complex interplay between HIV-1 and Mycobacterium tuberculosis co-infection and TNT formation was described.", [["Mycobacterium tuberculosis co-infection", "DISEASE", 48, 87], ["HIV-1", "ORGANISM", 38, 43], ["Mycobacterium tuberculosis", "ORGANISM", 48, 74], ["TNT", "CANCER", 92, 95], ["HIV-1", "SPECIES", 38, 43], ["Mycobacterium tuberculosis", "SPECIES", 48, 74], ["HIV-1", "SPECIES", 38, 43], ["Mycobacterium tuberculosis", "SPECIES", 48, 74], ["HIV", "PROBLEM", 38, 41], ["Mycobacterium tuberculosis co-infection", "PROBLEM", 48, 87], ["TNT formation", "PROBLEM", 92, 105], ["Mycobacterium tuberculosis", "OBSERVATION", 48, 74], ["co-infection", "OBSERVATION", 75, 87]]], ["Active tuberculosis in HIV-1-infected patients is associated with elevated HIV-1 infection of macrophages found in the lungs and pleural effusions.", [["macrophages", "ANATOMY", 94, 105], ["lungs", "ANATOMY", 119, 124], ["pleural effusions", "ANATOMY", 129, 146], ["tuberculosis", "DISEASE", 7, 19], ["HIV-1-infected", "DISEASE", 23, 37], ["infection", "DISEASE", 81, 90], ["pleural effusions", "DISEASE", 129, 146], ["HIV-1", "ORGANISM", 23, 28], ["patients", "ORGANISM", 38, 46], ["HIV-1", "ORGANISM", 75, 80], ["macrophages", "CELL", 94, 105], ["lungs", "ORGAN", 119, 124], ["pleural effusions", "CANCER", 129, 146], ["macrophages", "CELL_TYPE", 94, 105], ["HIV-1", "SPECIES", 23, 28], ["patients", "SPECIES", 38, 46], ["HIV-1", "SPECIES", 75, 80], ["HIV-1", "SPECIES", 23, 28], ["HIV-1", "SPECIES", 75, 80], ["Active tuberculosis in HIV", "PROBLEM", 0, 26], ["elevated HIV", "PROBLEM", 66, 78], ["1 infection of macrophages", "PROBLEM", 79, 105], ["pleural effusions", "PROBLEM", 129, 146], ["tuberculosis", "OBSERVATION", 7, 19], ["elevated", "OBSERVATION_MODIFIER", 66, 74], ["HIV", "OBSERVATION", 75, 78], ["infection", "OBSERVATION", 81, 90], ["macrophages", "OBSERVATION", 94, 105], ["lungs", "ANATOMY", 119, 124], ["pleural", "ANATOMY", 129, 136], ["effusions", "OBSERVATION", 137, 146]]], ["Active tuberculosis skews human monocyte differentiation towards an anti-inflammatory M2 macrophage pathway and blood monocytes treated with M. tuberculosis-conditioned medium are more permissive to HIV-1 infection134.", [["monocyte", "ANATOMY", 32, 40], ["blood monocytes", "ANATOMY", 112, 127], ["tuberculosis", "DISEASE", 7, 19], ["HIV-1 infection", "DISEASE", 199, 214], ["human", "ORGANISM", 26, 31], ["monocyte", "CELL", 32, 40], ["M2 macrophage", "CELL", 86, 99], ["blood monocytes", "CELL", 112, 127], ["M. tuberculosis", "ORGANISM", 141, 156], ["HIV-1", "ORGANISM", 199, 204], ["blood monocytes", "CELL_TYPE", 112, 127], ["human", "SPECIES", 26, 31], ["M. tuberculosis", "SPECIES", 141, 156], ["HIV-1", "SPECIES", 199, 204], ["human", "SPECIES", 26, 31], ["M. tuberculosis", "SPECIES", 141, 156], ["HIV-1", "SPECIES", 199, 204], ["Active tuberculosis skews human monocyte differentiation", "PROBLEM", 0, 56], ["an anti-inflammatory M2 macrophage pathway", "TREATMENT", 65, 107], ["blood monocytes", "TEST", 112, 127], ["M. tuberculosis", "PROBLEM", 141, 156], ["HIV-1 infection", "PROBLEM", 199, 214], ["tuberculosis", "OBSERVATION", 7, 19], ["monocyte differentiation", "OBSERVATION", 32, 56], ["anti-inflammatory M2", "OBSERVATION", 68, 88]]], ["M. tuberculosis infection stimulates TNT production in human macrophages, promoting HIV-1 dissemination into macrophages134.", [["macrophages", "ANATOMY", 61, 72], ["macrophages", "ANATOMY", 109, 120], ["tuberculosis infection", "DISEASE", 3, 25], ["M. tuberculosis", "ORGANISM", 0, 15], ["TNT", "GENE_OR_GENE_PRODUCT", 37, 40], ["human", "ORGANISM", 55, 60], ["macrophages", "CELL", 61, 72], ["HIV-1", "ORGANISM", 84, 89], ["macrophages134", "CELL", 109, 123], ["human macrophages", "CELL_TYPE", 55, 72], ["macrophages", "CELL_TYPE", 109, 120], ["M. tuberculosis", "SPECIES", 0, 15], ["human", "SPECIES", 55, 60], ["HIV-1", "SPECIES", 84, 89], ["M. tuberculosis", "SPECIES", 0, 15], ["human", "SPECIES", 55, 60], ["HIV-1", "SPECIES", 84, 89], ["M. tuberculosis infection", "PROBLEM", 0, 25], ["TNT production in human macrophages", "PROBLEM", 37, 72], ["tuberculosis", "OBSERVATION", 3, 15]]], ["This particular phenotypic diversity likely contributes to M. tuberculosis-mediated exacerbation of HIV-1 morbidity and mortality.", [["tuberculosis", "DISEASE", 62, 74], ["HIV-1 morbidity", "DISEASE", 100, 115], ["M. tuberculosis", "ORGANISM", 59, 74], ["HIV-1", "ORGANISM", 100, 105], ["M. tuberculosis", "SPECIES", 59, 74], ["HIV-1", "SPECIES", 100, 105], ["M. tuberculosis", "SPECIES", 59, 74], ["HIV-1", "SPECIES", 100, 105], ["M. tuberculosis", "PROBLEM", 59, 74], ["HIV", "PROBLEM", 100, 103], ["tuberculosis", "OBSERVATION", 62, 74], ["exacerbation", "OBSERVATION_MODIFIER", 84, 96]]], ["Further study of bacterial and viral co-infection will undoubtedly reveal additional layers of phenotypic heterogeneity in these complex systems.ConclusionsAs new technologies emerge, our appreciation of phenotypic heterogeneity in the viral replication cycle grows.", [["Further study", "TEST", 0, 13], ["bacterial", "PROBLEM", 17, 26], ["viral co-infection", "PROBLEM", 31, 49], ["phenotypic heterogeneity in these complex systems", "PROBLEM", 95, 144], ["phenotypic heterogeneity", "PROBLEM", 204, 228], ["bacterial", "OBSERVATION_MODIFIER", 17, 26], ["viral co-infection", "OBSERVATION", 31, 49], ["layers", "OBSERVATION_MODIFIER", 85, 91], ["phenotypic", "OBSERVATION_MODIFIER", 95, 105], ["heterogeneity", "OBSERVATION", 106, 119], ["complex", "OBSERVATION_MODIFIER", 129, 136], ["phenotypic", "OBSERVATION_MODIFIER", 204, 214], ["heterogeneity", "OBSERVATION", 215, 228], ["viral replication", "OBSERVATION", 236, 253]]], ["From alternate egress and entry pathways to variations in genome assembly and virion morphology, these diverse replication mechanisms challenge how we classify viruses and what is considered an infectious particle.", [["viruses", "PROBLEM", 160, 167], ["an infectious particle", "PROBLEM", 191, 213], ["infectious", "OBSERVATION", 194, 204]]], ["Here, we have highlighted the use of nanotubular bridges in cell-to-cell spread, exploitation of the microvesicle secretory pathway to cloak virions and promote infection, and how low-fidelity replication can drive viral heterogeneity.", [["nanotubular", "ANATOMY", 37, 48], ["cell", "ANATOMY", 60, 64], ["cell", "ANATOMY", 68, 72], ["microvesicle", "ANATOMY", 101, 113], ["virions", "ANATOMY", 141, 148], ["infection", "DISEASE", 161, 170], ["cell", "CELL", 60, 64], ["cell", "CELL", 68, 72], ["nanotubular bridges", "TREATMENT", 37, 56], ["the microvesicle secretory pathway", "TREATMENT", 97, 131], ["cloak virions", "PROBLEM", 135, 148], ["promote infection", "PROBLEM", 153, 170], ["viral heterogeneity", "PROBLEM", 215, 234], ["infection", "OBSERVATION", 161, 170]]], ["By redefining the canonical viral replication cycle, we will be better equipped to develop antiviral therapies against the many nuances of viral replication and address adaptive evasion strategies.", [["antiviral therapies", "TREATMENT", 91, 110], ["viral replication", "TREATMENT", 139, 156], ["adaptive evasion strategies", "TREATMENT", 169, 196], ["viral replication", "OBSERVATION", 28, 45], ["viral replication", "OBSERVATION", 139, 156]]], ["Future studies examining the relationship between viral heterogeneity and disease severity are particularly needed to help refine specific antiviral targets and biosensors.", [["Future studies", "TEST", 0, 14], ["viral heterogeneity", "PROBLEM", 50, 69], ["disease severity", "PROBLEM", 74, 90], ["viral heterogeneity", "OBSERVATION", 50, 69]]], ["Investigation of heterogeneity in infections with emerging pathogens such as SARS-CoV-2 are particularly essential for combating emerging viral threats.", [["infections", "DISEASE", 34, 44], ["SARS", "DISEASE", 77, 81], ["SARS-CoV-2", "ORGANISM", 77, 87], ["SARS-CoV", "SPECIES", 77, 85], ["heterogeneity in infections", "PROBLEM", 17, 44], ["emerging pathogens", "PROBLEM", 50, 68], ["SARS", "PROBLEM", 77, 81], ["heterogeneity", "OBSERVATION_MODIFIER", 17, 30], ["infections", "OBSERVATION", 34, 44]]], ["Studies already indicate heterogeneity in SARS-CoV-2 entry mechanisms in different cell types, which ultimately determines susceptibility to antivirals like chloroquine and its derivatives135.", [["cell", "ANATOMY", 83, 87], ["SARS", "DISEASE", 42, 46], ["chloroquine", "CHEMICAL", 157, 168], ["chloroquine", "CHEMICAL", 157, 168], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["cell", "CELL", 83, 87], ["chloroquine", "SIMPLE_CHEMICAL", 157, 168], ["Studies", "TEST", 0, 7], ["heterogeneity in SARS", "PROBLEM", 25, 46], ["CoV", "PROBLEM", 47, 50], ["2 entry mechanisms", "PROBLEM", 51, 69], ["different cell types", "PROBLEM", 73, 93], ["antivirals", "TREATMENT", 141, 151], ["chloroquine", "TREATMENT", 157, 168], ["its derivatives", "TEST", 173, 188], ["heterogeneity", "OBSERVATION", 25, 38], ["SARS", "OBSERVATION", 42, 46], ["different cell types", "OBSERVATION", 73, 93]]], ["The gravity of the COVID-19 pandemic underscores the critical role of such studies in guiding global health policies.", [["the COVID", "TEST", 15, 24], ["gravity", "OBSERVATION_MODIFIER", 4, 11]]]], "PMC7151801": [["IntroductionReduced immunogenicity and thereby efficacy is an unfortunate downside to vaccines based on highly purified or synthetic antigens.", [["synthetic antigens", "PROTEIN", 123, 141], ["vaccines", "TREATMENT", 86, 94]]], ["This requires the use of vaccine adjuvants to improve vaccine immunogenicity.", [["vaccine adjuvants", "TREATMENT", 25, 42]]], ["The term adjuvant has traditionally referred to as any substance that when added to a vaccine antigen increases its immunogenicity.1 As such, the study of adjuvant action is made complicated by the wide diversity of agents including small molecule immune modulators, mineral salts, oil emulsions, and even whole viruses or bacteria.", [["oil", "ANATOMY", 282, 285], ["mineral salts", "CHEMICAL", 267, 280], ["mineral salts", "SIMPLE_CHEMICAL", 267, 280], ["oil emulsions", "SIMPLE_CHEMICAL", 282, 295], ["The term adjuvant", "TREATMENT", 0, 17], ["a vaccine antigen", "TREATMENT", 84, 101], ["the study", "TEST", 142, 151], ["adjuvant action", "TREATMENT", 155, 170], ["agents", "TREATMENT", 216, 222], ["small molecule immune modulators", "TREATMENT", 233, 265], ["mineral salts", "TREATMENT", 267, 280], ["oil emulsions", "TREATMENT", 282, 295], ["whole viruses", "PROBLEM", 306, 319], ["bacteria", "PROBLEM", 323, 331], ["small molecule immune modulators", "OBSERVATION", 233, 265]]], ["These agents all exhibit adjuvant action in vivo with no one common feature explaining this activity.", [["These agents", "TREATMENT", 0, 12], ["adjuvant action", "TREATMENT", 25, 40]]], ["Almost certainly, these compounds work through many and varied different mechanisms to enhance immune responses to coadministered antigens.", [["coadministered antigens", "PROTEIN", 115, 138], ["coadministered antigens", "TREATMENT", 115, 138]]], ["Increasing use of small protein or peptide antigens allows greater control over vaccine design and synthesis but has further exacerbated issues of poor immunogenicity.", [["small protein", "PROTEIN", 18, 31], ["small protein or peptide antigens", "TREATMENT", 18, 51], ["synthesis", "TREATMENT", 99, 108], ["further exacerbated issues", "PROBLEM", 117, 143], ["poor immunogenicity", "PROBLEM", 147, 166], ["small protein", "OBSERVATION", 18, 31], ["poor immunogenicity", "OBSERVATION_MODIFIER", 147, 166]]], ["This necessitates closer examination of how best to design vaccine delivery and adjuvant systems to maximize antigen immunogenicity, assist targeted immune delivery, and provide potent adjuvant activity.", [["closer examination", "TEST", 18, 36], ["design vaccine delivery", "TREATMENT", 52, 75], ["adjuvant systems", "TREATMENT", 80, 96], ["antigen immunogenicity", "TREATMENT", 109, 131], ["immune delivery", "TREATMENT", 149, 164], ["potent adjuvant activity", "TREATMENT", 178, 202]]]], "PMC7344953": [], "900f466e9491ca75791535e12be65ed7b820d3c6": [["AJAdherens junction ANG-1 Angiopoietin-1 APC Antigen-presenting cell AQP4AJAquaporin 4 BBB Blood-brain barrier bFGF Basic fibroblast growth factor BMEC Brain microvascular endothelial cell Cav-Introduction to BBB Structure and FunctionOver 100 years ago, a publication by Lina Stern, Professor and Head of the Department of Physiological Chemistry at the University of Geneva, coined the term \"blood-brain barrier (BBB)\" to describe the finding that systemically administered dyes are excluded from the developing mammalian brain [1] .", [["Brain microvascular endothelial cell", "ANATOMY", 152, 188], ["blood-brain barrier", "ANATOMY", 394, 413], ["brain", "ANATOMY", 524, 529], ["ANG-1 Angiopoietin-1", "GENE_OR_GENE_PRODUCT", 20, 40], ["brain", "ORGAN", 97, 102], ["microvascular endothelial cell", "CELL", 158, 188], ["blood", "ORGANISM_SUBSTANCE", 394, 399], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 400, 413], ["BBB", "MULTI-TISSUE_STRUCTURE", 415, 418], ["brain", "ORGAN", 524, 529], ["AJAdherens junction ANG-1 Angiopoietin-1 APC Antigen-presenting cell AQP4AJAquaporin 4 BBB Blood-brain barrier bFGF", "PROTEIN", 0, 115], ["ANG", "TEST", 20, 23], ["Angiopoietin", "TEST", 26, 38], ["APC Antigen", "TEST", 41, 52], ["cell AQP4AJAquaporin", "TEST", 64, 84], ["Blood", "TEST", 91, 96], ["brain barrier bFGF", "TREATMENT", 97, 115], ["Basic fibroblast growth factor BMEC", "PROBLEM", 116, 151], ["Brain microvascular endothelial cell Cav-Introduction", "TREATMENT", 152, 205], ["systemically administered dyes", "TREATMENT", 450, 480], ["brain", "ANATOMY", 97, 102], ["fibroblast growth", "OBSERVATION", 122, 139], ["microvascular endothelial cell", "OBSERVATION", 158, 188], ["brain", "ANATOMY", 400, 405], ["brain", "ANATOMY", 524, 529]]], ["Since then, physicians and scientists have appreciated the unique diffusion barrier between the blood and the brain and its stringent regulation of central nervous system (CNS) entry of molecules, immune cells, and pathogens [2] [3] [4] .", [["blood", "ANATOMY", 96, 101], ["brain", "ANATOMY", 110, 115], ["central nervous system", "ANATOMY", 148, 170], ["CNS", "ANATOMY", 172, 175], ["immune cells", "ANATOMY", 197, 209], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["brain", "ORGAN", 110, 115], ["central nervous system", "ANATOMICAL_SYSTEM", 148, 170], ["CNS", "ANATOMICAL_SYSTEM", 172, 175], ["immune cells", "CELL", 197, 209], ["immune cells", "CELL_TYPE", 197, 209], ["the unique diffusion barrier between the blood and the brain", "PROBLEM", 55, 115], ["immune cells", "TEST", 197, 209], ["pathogens", "TEST", 215, 224], ["blood", "ANATOMY", 96, 101], ["brain", "ANATOMY", 110, 115], ["central", "ANATOMY_MODIFIER", 148, 155], ["nervous system", "ANATOMY", 156, 170]]], ["The BBB occurs at the level of postcapillary venules and capillaries and is comprised of a variety of physical specializations including inter-endothelial tight and adherens junctions (TJ and AJ), endothelial cells with polarized expression of protein receptor influx and efflux transporters, and transcytosis systems limited to albumen and histones [5] .", [["BBB", "ANATOMY", 4, 7], ["postcapillary venules", "ANATOMY", 31, 52], ["capillaries", "ANATOMY", 57, 68], ["inter-endothelial tight", "ANATOMY", 137, 160], ["adherens junctions", "ANATOMY", 165, 183], ["TJ", "ANATOMY", 185, 187], ["AJ", "ANATOMY", 192, 194], ["endothelial cells", "ANATOMY", 197, 214], ["albumen", "ANATOMY", 329, 336], ["BBB", "MULTI-TISSUE_STRUCTURE", 4, 7], ["postcapillary venules", "TISSUE", 31, 52], ["capillaries", "TISSUE", 57, 68], ["inter-endothelial tight", "CELLULAR_COMPONENT", 137, 160], ["adherens junctions", "CELLULAR_COMPONENT", 165, 183], ["TJ", "CELLULAR_COMPONENT", 185, 187], ["AJ", "CELLULAR_COMPONENT", 192, 194], ["endothelial cells", "CELL", 197, 214], ["albumen", "GENE_OR_GENE_PRODUCT", 329, 336], ["postcapillary venules", "CELL_TYPE", 31, 52], ["inter-endothelial tight and adherens junctions", "CELL_TYPE", 137, 183], ["TJ", "CELL_TYPE", 185, 187], ["AJ", "CELL_TYPE", 192, 194], ["endothelial cells", "CELL_TYPE", 197, 214], ["protein receptor", "PROTEIN", 244, 260], ["efflux transporters", "PROTEIN", 272, 291], ["histones", "PROTEIN", 341, 349], ["inter-endothelial tight and adherens junctions", "TREATMENT", 137, 183], ["endothelial cells", "PROBLEM", 197, 214], ["protein receptor influx", "TREATMENT", 244, 267], ["efflux transporters", "TREATMENT", 272, 291], ["transcytosis systems", "PROBLEM", 297, 317], ["postcapillary venules", "ANATOMY", 31, 52], ["variety", "OBSERVATION_MODIFIER", 91, 98], ["adherens junctions", "OBSERVATION", 165, 183], ["endothelial cells", "ANATOMY", 197, 214]]], ["Vasculature at the BBB is enveloped by pericytes and astrocyte end feet, which leads to the development of dual basement membranes with a complicated extracellular matrix (ECM) separating blood contents from perivascular spaces within the CNS parenchyma.", [["BBB", "ANATOMY", 19, 22], ["pericytes", "ANATOMY", 39, 48], ["astrocyte end feet", "ANATOMY", 53, 71], ["basement membranes", "ANATOMY", 112, 130], ["extracellular matrix", "ANATOMY", 150, 170], ["ECM", "ANATOMY", 172, 175], ["blood", "ANATOMY", 188, 193], ["perivascular spaces", "ANATOMY", 208, 227], ["CNS parenchyma", "ANATOMY", 239, 253], ["Vasculature", "DISEASE", 0, 11], ["BBB", "MULTI-TISSUE_STRUCTURE", 19, 22], ["pericytes", "CELL", 39, 48], ["astrocyte end feet", "CELLULAR_COMPONENT", 53, 71], ["basement membranes", "CELLULAR_COMPONENT", 112, 130], ["extracellular matrix", "CELLULAR_COMPONENT", 150, 170], ["ECM", "CELLULAR_COMPONENT", 172, 175], ["blood", "ORGANISM_SUBSTANCE", 188, 193], ["perivascular spaces", "IMMATERIAL_ANATOMICAL_ENTITY", 208, 227], ["CNS parenchyma", "TISSUE", 239, 253], ["pericytes", "CELL_TYPE", 39, 48], ["dual basement membranes", "PROBLEM", 107, 130], ["a complicated extracellular matrix (ECM) separating blood contents from perivascular spaces within the CNS parenchyma", "PROBLEM", 136, 253], ["BBB", "ANATOMY", 19, 22], ["enveloped", "OBSERVATION", 26, 35], ["pericytes", "OBSERVATION", 39, 48], ["astrocyte", "ANATOMY", 53, 62], ["dual basement membranes", "OBSERVATION", 107, 130], ["complicated", "OBSERVATION_MODIFIER", 138, 149], ["extracellular matrix", "OBSERVATION", 150, 170], ["blood contents", "OBSERVATION", 188, 202], ["perivascular", "ANATOMY_MODIFIER", 208, 220], ["CNS", "ANATOMY", 239, 242], ["parenchyma", "ANATOMY_MODIFIER", 243, 253]]], ["The CNS ECM is comprised of hyaluronic acid and proteoglycans (PG), mainly chondroitin sulfate proteoglycans (CSPG) [6] .", [["CNS ECM", "ANATOMY", 4, 11], ["hyaluronic acid", "CHEMICAL", 28, 43], ["PG", "CHEMICAL", 63, 65], ["chondroitin sulfate", "CHEMICAL", 75, 94], ["CNS ECM", "CELLULAR_COMPONENT", 4, 11], ["hyaluronic acid", "SIMPLE_CHEMICAL", 28, 43], ["proteoglycans", "SIMPLE_CHEMICAL", 48, 61], ["PG", "SIMPLE_CHEMICAL", 63, 65], ["chondroitin sulfate proteoglycans", "SIMPLE_CHEMICAL", 75, 108], ["CSPG", "SIMPLE_CHEMICAL", 110, 114], ["chondroitin sulfate proteoglycans", "PROTEIN", 75, 108], ["hyaluronic acid and proteoglycans (PG", "TREATMENT", 28, 65], ["mainly chondroitin sulfate proteoglycans", "TREATMENT", 68, 108], ["CNS", "ANATOMY", 4, 7]]], ["Heparan sulfate proteoglycans (HSPG), especially the negatively charged heparan sulfate (HS), bind and sequester pro-inflammatory molecules, including the endothelial cell-derived chemokine CXCL12 ( [7] and see below), which regulates the recruitment and effector functions of leukocytes that infiltrate the CNS during neuroinflammatory diseases [8] .", [["endothelial cell", "ANATOMY", 155, 171], ["leukocytes", "ANATOMY", 277, 287], ["CNS", "ANATOMY", 308, 311], ["Heparan sulfate", "CHEMICAL", 0, 15], ["heparan sulfate", "CHEMICAL", 72, 87], ["neuroinflammatory diseases", "DISEASE", 319, 345], ["Heparan sulfate", "CHEMICAL", 0, 15], ["heparan sulfate", "CHEMICAL", 72, 87], ["Heparan sulfate proteoglycans", "GENE_OR_GENE_PRODUCT", 0, 29], ["HSPG", "GENE_OR_GENE_PRODUCT", 31, 35], ["heparan sulfate", "SIMPLE_CHEMICAL", 72, 87], ["HS", "SIMPLE_CHEMICAL", 89, 91], ["endothelial cell", "CELL", 155, 171], ["CXCL12", "GENE_OR_GENE_PRODUCT", 190, 196], ["[7]", "GENE_OR_GENE_PRODUCT", 199, 202], ["leukocytes", "CELL", 277, 287], ["CNS", "ANATOMICAL_SYSTEM", 308, 311], ["Heparan sulfate proteoglycans", "PROTEIN", 0, 29], ["HSPG", "PROTEIN", 31, 35], ["pro-inflammatory molecules", "PROTEIN", 113, 139], ["endothelial cell-derived chemokine", "PROTEIN", 155, 189], ["CXCL12", "PROTEIN", 190, 196], ["leukocytes", "CELL_TYPE", 277, 287], ["Heparan sulfate proteoglycans (HSPG)", "TREATMENT", 0, 36], ["the negatively charged heparan sulfate (HS)", "TREATMENT", 49, 92], ["bind and sequester pro-inflammatory molecules", "TREATMENT", 94, 139], ["the endothelial cell", "TREATMENT", 151, 171], ["leukocytes", "PROBLEM", 277, 287], ["infiltrate the CNS during neuroinflammatory diseases", "PROBLEM", 293, 345], ["pro-inflammatory molecules", "OBSERVATION", 113, 139], ["endothelial", "ANATOMY", 155, 166], ["CNS", "ANATOMY", 308, 311], ["neuroinflammatory diseases", "OBSERVATION", 319, 345]]], ["BBB TJ are heterodimeric proteins comprised of occludin and members of the claudin family of proteins, including claudin-3 or -5, that link to the cytoskeleton via the scaffolding and regulatory proteins ZO-1, -2, -3, and cingulin (reviewed in [9] ).", [["cytoskeleton", "ANATOMY", 147, 159], ["BBB TJ", "GENE_OR_GENE_PRODUCT", 0, 6], ["occludin", "GENE_OR_GENE_PRODUCT", 47, 55], ["claudin", "GENE_OR_GENE_PRODUCT", 75, 82], ["claudin-3", "GENE_OR_GENE_PRODUCT", 113, 122], ["-5", "GENE_OR_GENE_PRODUCT", 126, 128], ["cytoskeleton", "CELLULAR_COMPONENT", 147, 159], ["ZO-1", "GENE_OR_GENE_PRODUCT", 204, 208], ["-2", "GENE_OR_GENE_PRODUCT", 210, 212], ["-3", "GENE_OR_GENE_PRODUCT", 214, 216], ["cingulin", "GENE_OR_GENE_PRODUCT", 222, 230], ["TJ", "PROTEIN", 4, 6], ["heterodimeric proteins", "PROTEIN", 11, 33], ["occludin", "PROTEIN", 47, 55], ["claudin family", "PROTEIN", 75, 89], ["claudin-3 or -5", "PROTEIN", 113, 128], ["scaffolding and regulatory proteins", "PROTEIN", 168, 203], ["ZO-1, -2, -3", "PROTEIN", 204, 216], ["cingulin", "PROTEIN", 222, 230], ["heterodimeric proteins", "PROBLEM", 11, 33], ["claudin", "TEST", 113, 120], ["ZO", "TEST", 204, 206], ["occludin", "OBSERVATION", 47, 55]]], ["Similarly, AJ are comprised of E-cadherin proteins that link to actin filaments via \u03b1-, \u03b2-, and \u03b3-catenin.", [["AJ", "ANATOMY", 11, 13], ["filaments", "ANATOMY", 70, 79], ["AJ", "CELL", 11, 13], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 31, 41], ["actin", "GENE_OR_GENE_PRODUCT", 64, 69], ["filaments", "CELLULAR_COMPONENT", 70, 79], ["\u03b1-", "GENE_OR_GENE_PRODUCT", 84, 86], ["\u03b2-", "GENE_OR_GENE_PRODUCT", 88, 90], ["\u03b3-catenin", "GENE_OR_GENE_PRODUCT", 96, 105], ["AJ", "PROTEIN", 11, 13], ["E-cadherin proteins", "PROTEIN", 31, 50], ["actin filaments", "PROTEIN", 64, 79], ["\u03b1-, \u03b2-, and \u03b3-catenin", "PROTEIN", 84, 105], ["E-cadherin proteins", "TREATMENT", 31, 50], ["\u03b3-catenin", "TREATMENT", 96, 105]]], ["The length of actin fibers, which are regulated by the activation of RhoGTPases, controls the integrity of both AJ and TJ complexes [10] .", [["actin fibers", "ANATOMY", 14, 26], ["AJ", "ANATOMY", 112, 114], ["TJ", "ANATOMY", 119, 121], ["actin", "GENE_OR_GENE_PRODUCT", 14, 19], ["fibers", "CELLULAR_COMPONENT", 20, 26], ["RhoGTPases", "GENE_OR_GENE_PRODUCT", 69, 79], ["AJ", "GENE_OR_GENE_PRODUCT", 112, 114], ["TJ", "GENE_OR_GENE_PRODUCT", 119, 121], ["actin fibers", "PROTEIN", 14, 26], ["RhoGTPases", "PROTEIN", 69, 79], ["AJ", "PROTEIN", 112, 114], ["TJ complexes", "PROTEIN", 119, 131], ["The length of actin fibers", "TREATMENT", 0, 26], ["RhoGTPases", "TREATMENT", 69, 79], ["length", "OBSERVATION_MODIFIER", 4, 10], ["actin fibers", "OBSERVATION", 14, 26], ["both", "ANATOMY_MODIFIER", 107, 111], ["AJ", "ANATOMY", 112, 114]]], ["Activation of Rac1 promotes stabilization of TJ and AJ, while RhoA promotes destabilization.", [["TJ", "ANATOMY", 45, 47], ["AJ", "ANATOMY", 52, 54], ["Rac1", "GENE_OR_GENE_PRODUCT", 14, 18], ["TJ", "GENE_OR_GENE_PRODUCT", 45, 47], ["AJ", "GENE_OR_GENE_PRODUCT", 52, 54], ["RhoA", "GENE_OR_GENE_PRODUCT", 62, 66], ["Rac1", "PROTEIN", 14, 18], ["TJ", "PROTEIN", 45, 47], ["AJ", "PROTEIN", 52, 54], ["RhoA", "PROTEIN", 62, 66], ["TJ and AJ", "TREATMENT", 45, 54], ["Rac1", "OBSERVATION", 14, 18], ["promotes stabilization", "OBSERVATION", 19, 41], ["TJ", "ANATOMY", 45, 47], ["destabilization", "OBSERVATION", 76, 91]]], ["Junctional integrity is critical for two separate capacities of the BBB, termed \"gate\" and \"fence\" function [11] .", [["BBB", "ANATOMY", 68, 71], ["BBB", "MULTI-TISSUE_STRUCTURE", 68, 71]]], ["Gate function refers to the importance of inter-endothelial junctional complexes in limiting the movement of molecules and cells from the blood to the brain parenchyma.", [["inter-endothelial junctional complexes", "ANATOMY", 42, 80], ["cells", "ANATOMY", 123, 128], ["blood", "ANATOMY", 138, 143], ["brain parenchyma", "ANATOMY", 151, 167], ["cells", "CELL", 123, 128], ["blood", "ORGANISM_SUBSTANCE", 138, 143], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 151, 167], ["inter-endothelial junctional complexes", "PROTEIN", 42, 80], ["Gate function", "TEST", 0, 13], ["inter-endothelial junctional complexes", "PROBLEM", 42, 80], ["blood", "ANATOMY", 138, 143], ["brain", "ANATOMY", 151, 156], ["parenchyma", "ANATOMY_MODIFIER", 157, 167]]], ["RhoA activation may therefore reduce gate function and allow BBB penetration without loss of junctional proteins.", [["BBB", "ANATOMY", 61, 64], ["junctional", "ANATOMY", 93, 103], ["RhoA", "GENE_OR_GENE_PRODUCT", 0, 4], ["BBB", "MULTI-TISSUE_STRUCTURE", 61, 64], ["RhoA", "PROTEIN", 0, 4], ["junctional proteins", "PROTEIN", 93, 112], ["gate function", "PROBLEM", 37, 50], ["BBB penetration", "PROBLEM", 61, 76], ["loss of junctional proteins", "PROBLEM", 85, 112], ["junctional proteins", "OBSERVATION", 93, 112]]], ["Fence function refers to the role of TJ and AJ in the maintenance of BBB polarity, preventing the rotation and diffusion of proteins and other biomolecules within the cell membrane between abluminal and luminal surfaces.", [["TJ", "ANATOMY", 37, 39], ["AJ", "ANATOMY", 44, 46], ["BBB", "ANATOMY", 69, 72], ["cell membrane", "ANATOMY", 167, 180], ["abluminal", "ANATOMY", 189, 198], ["luminal surfaces", "ANATOMY", 203, 219], ["luminal", "CHEMICAL", 203, 210], ["TJ", "GENE_OR_GENE_PRODUCT", 37, 39], ["AJ", "GENE_OR_GENE_PRODUCT", 44, 46], ["BBB", "MULTI-TISSUE_STRUCTURE", 69, 72], ["cell membrane", "CELLULAR_COMPONENT", 167, 180], ["abluminal", "TISSUE", 189, 198], ["luminal surfaces", "CELLULAR_COMPONENT", 203, 219], ["TJ", "PROTEIN", 37, 39], ["AJ", "PROTEIN", 44, 46], ["the rotation and diffusion of proteins", "TEST", 94, 132], ["cell membrane", "OBSERVATION", 167, 180], ["abluminal", "ANATOMY_MODIFIER", 189, 198], ["luminal", "ANATOMY_MODIFIER", 203, 210], ["surfaces", "ANATOMY_MODIFIER", 211, 219]]], ["Thus, BBB permeability can also be increased without complete destruction of junctional proteins through alterations in the locations of proteins involved in transport or transcytosis.Introduction to BBB Structure and FunctionThe transcellular transport of macromolecules across endothelial barriers occurs in peripheral organs via a variety of pathways including macropinocytosis and clathrin-and caveolae-mediated endocytosis.", [["BBB", "ANATOMY", 6, 9], ["junctional", "ANATOMY", 77, 87], ["transcellular", "ANATOMY", 230, 243], ["endothelial", "ANATOMY", 279, 290], ["peripheral organs", "ANATOMY", 310, 327], ["caveolae", "ANATOMY", 398, 406], ["BBB", "MULTI-TISSUE_STRUCTURE", 6, 9], ["BBB", "MULTI-TISSUE_STRUCTURE", 200, 203], ["transcellular", "IMMATERIAL_ANATOMICAL_ENTITY", 230, 243], ["endothelial", "CELL", 279, 290], ["peripheral organs", "MULTI-TISSUE_STRUCTURE", 310, 327], ["clathrin", "GENE_OR_GENE_PRODUCT", 385, 393], ["caveolae", "CELLULAR_COMPONENT", 398, 406], ["junctional proteins", "PROTEIN", 77, 96], ["clathrin", "PROTEIN", 385, 393], ["complete destruction of junctional proteins through alterations", "PROBLEM", 53, 116], ["The transcellular transport of macromolecules across endothelial barriers", "TREATMENT", 226, 299], ["peripheral organs", "PROBLEM", 310, 327], ["macropinocytosis", "PROBLEM", 364, 380], ["clathrin", "TEST", 385, 393], ["caveolae-mediated endocytosis", "PROBLEM", 398, 427], ["destruction", "OBSERVATION", 62, 73], ["junctional proteins", "OBSERVATION", 77, 96], ["endothelial", "ANATOMY", 279, 290], ["peripheral", "ANATOMY_MODIFIER", 310, 320], ["organs", "ANATOMY", 321, 327], ["endocytosis", "OBSERVATION", 416, 427]]], ["The BBB, however, exhibits low levels of macropinocytosis and lack of clathrin expression.", [["BBB", "ANATOMY", 4, 7], ["BBB", "MULTI-TISSUE_STRUCTURE", 4, 7], ["clathrin", "GENE_OR_GENE_PRODUCT", 70, 78], ["clathrin", "PROTEIN", 70, 78], ["The BBB", "TEST", 0, 7], ["low levels of macropinocytosis", "PROBLEM", 27, 57], ["clathrin expression", "PROBLEM", 70, 89], ["low", "OBSERVATION_MODIFIER", 27, 30], ["macropinocytosis", "OBSERVATION", 41, 57], ["clathrin expression", "OBSERVATION", 70, 89]]], ["Caveolae-mediated transcytosis is strictly regulated at the BBB by the major facilitator superfamily domain-containing protein 2a (Mfsd2a), which is exclusively expressed on brain endothelial cells and induced by pericytes [12] .", [["brain endothelial cells", "ANATOMY", 174, 197], ["pericytes", "ANATOMY", 213, 222], ["Caveolae", "GENE_OR_GENE_PRODUCT", 0, 8], ["BBB", "MULTI-TISSUE_STRUCTURE", 60, 63], ["major facilitator superfamily domain-containing protein 2a", "GENE_OR_GENE_PRODUCT", 71, 129], ["Mfsd2a", "GENE_OR_GENE_PRODUCT", 131, 137], ["brain endothelial cells", "CELL", 174, 197], ["pericytes", "CELL", 213, 222], ["major facilitator superfamily domain-containing protein 2a", "PROTEIN", 71, 129], ["Mfsd2a", "PROTEIN", 131, 137], ["brain endothelial cells", "CELL_TYPE", 174, 197], ["Caveolae-mediated transcytosis", "PROBLEM", 0, 30], ["transcytosis", "OBSERVATION", 18, 30], ["brain", "ANATOMY", 174, 179], ["endothelial cells", "OBSERVATION", 180, 197]]], ["Consistently, Mfsd2a \u2212/\u2212 mice exhibit increased BBB permeability, caused by enhanced caveolae-mediated transcytosis [12] .", [["BBB", "ANATOMY", 48, 51], ["caveolae", "ANATOMY", 85, 93], ["Mfsd2a", "GENE_OR_GENE_PRODUCT", 14, 20], ["BBB", "MULTI-TISSUE_STRUCTURE", 48, 51], ["caveolae", "CELLULAR_COMPONENT", 85, 93], ["Mfsd2a", "PROTEIN", 14, 20], ["mice", "SPECIES", 25, 29], ["increased BBB permeability", "PROBLEM", 38, 64], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["BBB permeability", "OBSERVATION", 48, 64]]], ["Caveolae are flask-shaped plasma membrane invagination enriched in cholesterol and sphingolipids.", [["plasma membrane", "ANATOMY", 26, 41], ["cholesterol", "CHEMICAL", 67, 78], ["cholesterol", "CHEMICAL", 67, 78], ["sphingolipids", "CHEMICAL", 83, 96], ["Caveolae", "GENE_OR_GENE_PRODUCT", 0, 8], ["plasma", "CELLULAR_COMPONENT", 26, 32], ["membrane invagination", "CELLULAR_COMPONENT", 33, 54], ["cholesterol", "SIMPLE_CHEMICAL", 67, 78], ["sphingolipids", "SIMPLE_CHEMICAL", 83, 96], ["flask", "TEST", 13, 18], ["shaped plasma membrane invagination", "PROBLEM", 19, 54], ["sphingolipids", "TREATMENT", 83, 96], ["flask", "OBSERVATION", 13, 18], ["shaped", "OBSERVATION_MODIFIER", 19, 25], ["plasma membrane invagination", "OBSERVATION", 26, 54], ["cholesterol", "OBSERVATION_MODIFIER", 67, 78]]], ["They contain the major structural protein caveolin-1 (Cav-1), which undergoes extensive oligomerization prior to interacting with cavin-1 to form caveolae.", [["caveolae", "ANATOMY", 146, 154], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 42, 52], ["Cav-1", "GENE_OR_GENE_PRODUCT", 54, 59], ["cavin-1", "GENE_OR_GENE_PRODUCT", 130, 137], ["caveolae", "CELLULAR_COMPONENT", 146, 154], ["major structural protein caveolin-1", "PROTEIN", 17, 52], ["Cav-1", "PROTEIN", 54, 59], ["cavin-1", "PROTEIN", 130, 137], ["cavin", "TEST", 130, 135], ["protein caveolin", "OBSERVATION", 34, 50], ["caveolae", "ANATOMY", 146, 154]]], ["Genetic ablation of either Cav-1 or cavin-1 results in a complete loss of caveolae in related tissues, suggesting their essential role in caveolae formation [13, 14] .", [["caveolae", "ANATOMY", 74, 82], ["tissues", "ANATOMY", 94, 101], ["caveolae", "ANATOMY", 138, 146], ["Cav-1", "GENE_OR_GENE_PRODUCT", 27, 32], ["cavin-1", "GENE_OR_GENE_PRODUCT", 36, 43], ["caveolae", "CELLULAR_COMPONENT", 74, 82], ["tissues", "TISSUE", 94, 101], ["caveolae", "CELLULAR_COMPONENT", 138, 146], ["Cav-1", "PROTEIN", 27, 32], ["cavin-1", "PROTEIN", 36, 43], ["Genetic ablation", "TREATMENT", 0, 16], ["Cav", "TEST", 27, 30], ["cavin", "TEST", 36, 41], ["a complete loss of caveolae in related tissues", "PROBLEM", 55, 101], ["ablation", "OBSERVATION", 8, 16], ["Cav", "ANATOMY", 27, 30], ["caveolae", "OBSERVATION", 74, 82]]], ["Previous studies identified a close association between caveolae and stress fibers, a feature absent in clathrin-coated vesicles [15] .", [["caveolae", "ANATOMY", 56, 64], ["stress fibers", "ANATOMY", 69, 82], ["vesicles", "ANATOMY", 120, 128], ["caveolae", "CELLULAR_COMPONENT", 56, 64], ["stress fibers", "CELLULAR_COMPONENT", 69, 82], ["clathrin", "GENE_OR_GENE_PRODUCT", 104, 112], ["clathrin", "PROTEIN", 104, 112], ["Previous studies", "TEST", 0, 16], ["stress fibers", "OBSERVATION", 69, 82]]], ["These interactions are critical for both stabilizing and entry of caveolae at the plasma membrane and are also regulated by the small RhoGTPases, including Ras homolog gene family, member A (RhoA) and Ras-related C3 botulinum toxin substrate (Rac)-1 [15] .", [["caveolae", "ANATOMY", 66, 74], ["plasma membrane", "ANATOMY", 82, 97], ["caveolae", "CELLULAR_COMPONENT", 66, 74], ["plasma membrane", "CELLULAR_COMPONENT", 82, 97], ["RhoGTPases", "GENE_OR_GENE_PRODUCT", 134, 144], ["Ras homolog gene family, member A", "GENE_OR_GENE_PRODUCT", 156, 189], ["RhoA", "GENE_OR_GENE_PRODUCT", 191, 195], ["Ras-related C3 botulinum toxin substrate (Rac)-1", "GENE_OR_GENE_PRODUCT", 201, 249], ["RhoGTPases", "PROTEIN", 134, 144], ["Ras homolog gene family", "PROTEIN", 156, 179], ["member A", "PROTEIN", 181, 189], ["RhoA", "PROTEIN", 191, 195], ["Ras-related C3 botulinum toxin substrate", "PROTEIN", 201, 241], ["Rac", "PROTEIN", 243, 246], ["A (RhoA)", "TEST", 188, 196], ["Ras-related C3 botulinum toxin substrate", "TEST", 201, 241], ["plasma membrane", "ANATOMY", 82, 97], ["small", "OBSERVATION_MODIFIER", 128, 133]]], ["Caveolae internalization is further regulated by kinases and phosphatases.", [["Caveolae", "SIMPLE_CHEMICAL", 0, 8], ["kinases", "PROTEIN", 49, 56], ["phosphatases", "PROTEIN", 61, 73], ["Caveolae internalization", "TREATMENT", 0, 24], ["phosphatases", "TEST", 61, 73], ["internalization", "OBSERVATION", 9, 24]]], ["In general, BBB endothelial cells exhibit low level of formation of caveolae due to the effects of Mfsd2a.", [["BBB endothelial cells", "ANATOMY", 12, 33], ["caveolae", "ANATOMY", 68, 76], ["BBB endothelial cells", "CELL", 12, 33], ["caveolae", "CELLULAR_COMPONENT", 68, 76], ["Mfsd2a", "GENE_OR_GENE_PRODUCT", 99, 105], ["BBB endothelial cells", "CELL_TYPE", 12, 33], ["Mfsd2a", "PROTEIN", 99, 105], ["BBB endothelial cells", "TEST", 12, 33], ["low level of formation of caveolae", "PROBLEM", 42, 76], ["Mfsd2a", "TREATMENT", 99, 105], ["low level", "OBSERVATION_MODIFIER", 42, 51]]], ["However, levels of this protein are decreased during intracranial hemorrhage, suggesting that serum inflammatory mediators might increase BBB permeability via their effects on caveolae-mediated transcytosis.Introduction to BBB Structure and FunctionThe polarized expression of proteins at the CNS vascular barriers is also important for normal immune surveillance of the CNS.", [["intracranial", "ANATOMY", 53, 65], ["serum", "ANATOMY", 94, 99], ["BBB", "ANATOMY", 138, 141], ["caveolae", "ANATOMY", 176, 184], ["CNS vascular", "ANATOMY", 293, 305], ["CNS", "ANATOMY", 371, 374], ["intracranial hemorrhage", "DISEASE", 53, 76], ["intracranial", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 65], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["BBB", "MULTI-TISSUE_STRUCTURE", 138, 141], ["caveolae", "CELLULAR_COMPONENT", 176, 184], ["BBB", "MULTI-TISSUE_STRUCTURE", 223, 226], ["CNS vascular", "MULTI-TISSUE_STRUCTURE", 293, 305], ["CNS", "ANATOMICAL_SYSTEM", 371, 374], ["serum inflammatory mediators", "PROTEIN", 94, 122], ["this protein", "PROBLEM", 19, 31], ["intracranial hemorrhage", "PROBLEM", 53, 76], ["serum inflammatory mediators", "PROBLEM", 94, 122], ["BBB permeability", "PROBLEM", 138, 154], ["caveolae-mediated transcytosis", "PROBLEM", 176, 206], ["decreased", "OBSERVATION_MODIFIER", 36, 45], ["intracranial", "ANATOMY", 53, 65], ["hemorrhage", "OBSERVATION", 66, 76], ["inflammatory", "OBSERVATION_MODIFIER", 100, 112], ["vascular", "ANATOMY", 297, 305], ["CNS", "ANATOMY", 371, 374]]], ["There is a growing body of evidence that lymphocytes, including effector memory CD4 and CD8 T cells, normally reside within the cerebrospinal fluid (CSF) compartment [16] [17] [18] [19] [20] [21] [22] .", [["lymphocytes", "ANATOMY", 41, 52], ["effector memory CD4", "ANATOMY", 64, 83], ["CD8 T cells", "ANATOMY", 88, 99], ["cerebrospinal fluid", "ANATOMY", 128, 147], ["lymphocytes", "CELL", 41, 52], ["CD4", "GENE_OR_GENE_PRODUCT", 80, 83], ["CD8", "GENE_OR_GENE_PRODUCT", 88, 91], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 128, 147], ["CSF", "ORGANISM_SUBSTANCE", 149, 152], ["17] [18] [19] [20] [21] [22]", "SIMPLE_CHEMICAL", 172, 200], ["lymphocytes", "CELL_TYPE", 41, 52], ["effector memory CD4 and CD8 T cells", "CELL_TYPE", 64, 99], ["lymphocytes", "PROBLEM", 41, 52], ["effector memory CD4", "TEST", 64, 83], ["CD8 T cells", "TEST", 88, 99], ["the cerebrospinal fluid", "TEST", 124, 147], ["lymphocytes", "OBSERVATION", 41, 52], ["memory CD4", "OBSERVATION", 73, 83], ["cerebrospinal fluid", "ANATOMY", 128, 147]]], ["The CSF compartment includes both the subarachnoid space (SAS) and the ventricular system, the latter of which contains the choroid plexus, a plexus of microvessels with modified ependymal cells that form a barrier between its fenestrated capillaries and the CSF compartment (reviewed in [23]), which connects with lymphatics that provide mechanisms for leukocyte egress out of the CNS [24, 25] .", [["CSF compartment", "ANATOMY", 4, 19], ["subarachnoid space", "ANATOMY", 38, 56], ["ventricular system", "ANATOMY", 71, 89], ["choroid plexus", "ANATOMY", 124, 138], ["plexus", "ANATOMY", 142, 148], ["microvessels", "ANATOMY", 152, 164], ["ependymal cells", "ANATOMY", 179, 194], ["capillaries", "ANATOMY", 239, 250], ["CSF compartment", "ANATOMY", 259, 274], ["lymphatics", "ANATOMY", 315, 325], ["leukocyte", "ANATOMY", 354, 363], ["CNS", "ANATOMY", 382, 385], ["CSF compartment", "MULTI-TISSUE_STRUCTURE", 4, 19], ["subarachnoid space", "MULTI-TISSUE_STRUCTURE", 38, 56], ["ventricular system", "MULTI-TISSUE_STRUCTURE", 71, 89], ["choroid plexus", "MULTI-TISSUE_STRUCTURE", 124, 138], ["plexus", "TISSUE", 142, 148], ["microvessels", "TISSUE", 152, 164], ["ependymal cells", "CELL", 179, 194], ["fenestrated capillaries", "TISSUE", 227, 250], ["CSF compartment", "CELLULAR_COMPONENT", 259, 274], ["lymphatics", "MULTI-TISSUE_STRUCTURE", 315, 325], ["leukocyte", "CELL", 354, 363], ["CNS", "ANATOMICAL_SYSTEM", 382, 385], ["ependymal cells", "CELL_TYPE", 179, 194], ["The CSF compartment", "TEST", 0, 19], ["modified ependymal cells", "PROBLEM", 170, 194], ["leukocyte egress", "TEST", 354, 370], ["CSF", "ANATOMY", 4, 7], ["compartment", "ANATOMY_MODIFIER", 8, 19], ["both", "ANATOMY_MODIFIER", 29, 33], ["subarachnoid space", "ANATOMY", 38, 56], ["ventricular system", "ANATOMY", 71, 89], ["latter", "OBSERVATION_MODIFIER", 95, 101], ["choroid plexus", "ANATOMY", 124, 138], ["plexus", "ANATOMY", 142, 148], ["microvessels", "ANATOMY", 152, 164], ["ependymal cells", "OBSERVATION", 179, 194], ["barrier", "OBSERVATION_MODIFIER", 207, 214], ["fenestrated", "OBSERVATION_MODIFIER", 227, 238], ["capillaries", "OBSERVATION_MODIFIER", 239, 250], ["CSF compartment", "ANATOMY", 259, 274], ["lymphatics", "ANATOMY", 315, 325], ["CNS", "ANATOMY", 382, 385]]], ["The choroid plexus is the main producer of CSF, which circulates via a combination of directed bulk flow, and both pulsatile and continuous bidirectional movement at the BBB and at the borders between CSF and CNS interstitial spaces (reviewed in [26] ).", [["choroid plexus", "ANATOMY", 4, 18], ["BBB", "ANATOMY", 170, 173], ["CNS interstitial spaces", "ANATOMY", 209, 232], ["choroid plexus", "MULTI-TISSUE_STRUCTURE", 4, 18], ["CSF", "GENE_OR_GENE_PRODUCT", 43, 46], ["BBB", "MULTI-TISSUE_STRUCTURE", 170, 173], ["CSF", "GENE_OR_GENE_PRODUCT", 201, 204], ["CNS interstitial", "TISSUE", 209, 225], ["CSF", "PROTEIN", 43, 46], ["directed bulk flow", "PROBLEM", 86, 104], ["choroid plexus", "ANATOMY", 4, 18], ["main", "OBSERVATION_MODIFIER", 26, 30], ["CSF", "OBSERVATION", 43, 46], ["bulk flow", "OBSERVATION", 95, 104], ["both", "OBSERVATION_MODIFIER", 110, 114], ["pulsatile", "OBSERVATION_MODIFIER", 115, 124], ["continuous", "OBSERVATION_MODIFIER", 129, 139], ["bidirectional movement", "OBSERVATION", 140, 162], ["BBB", "ANATOMY", 170, 173], ["CSF", "OBSERVATION", 201, 204], ["CNS", "ANATOMY", 209, 212], ["interstitial", "ANATOMY_MODIFIER", 213, 225]]], ["The SAS occurs between meningeal arachnoid and pia maters and contains fenestrated capillaries where immune cells may exit the blood and migrate along abluminal surfaces into perivascular spaces within the brain parenchyma at sites with BBB specializations.", [["meningeal arachnoid", "ANATOMY", 23, 42], ["pia maters", "ANATOMY", 47, 57], ["capillaries", "ANATOMY", 83, 94], ["immune cells", "ANATOMY", 101, 113], ["blood", "ANATOMY", 127, 132], ["abluminal surfaces", "ANATOMY", 151, 169], ["perivascular spaces", "ANATOMY", 175, 194], ["brain parenchyma", "ANATOMY", 206, 222], ["sites", "ANATOMY", 226, 231], ["BBB", "ANATOMY", 237, 240], ["SAS", "DISEASE", 4, 7], ["meningeal arachnoid", "TISSUE", 23, 42], ["pia maters", "TISSUE", 47, 57], ["capillaries", "TISSUE", 83, 94], ["immune cells", "CELL", 101, 113], ["blood", "ORGANISM_SUBSTANCE", 127, 132], ["abluminal surfaces", "CELLULAR_COMPONENT", 151, 169], ["perivascular spaces", "IMMATERIAL_ANATOMICAL_ENTITY", 175, 194], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 206, 222], ["BBB specializations", "CELLULAR_COMPONENT", 237, 256], ["immune cells", "CELL_TYPE", 101, 113], ["meningeal arachnoid and pia maters", "PROBLEM", 23, 57], ["fenestrated capillaries", "PROBLEM", 71, 94], ["immune cells", "PROBLEM", 101, 113], ["the blood", "PROBLEM", 123, 132], ["meningeal arachnoid", "ANATOMY", 23, 42], ["pia maters", "OBSERVATION", 47, 57], ["fenestrated capillaries", "OBSERVATION", 71, 94], ["immune cells", "OBSERVATION", 101, 113], ["blood", "OBSERVATION_MODIFIER", 127, 132], ["abluminal", "ANATOMY_MODIFIER", 151, 160], ["surfaces", "ANATOMY_MODIFIER", 161, 169], ["perivascular", "ANATOMY_MODIFIER", 175, 187], ["brain", "ANATOMY", 206, 211], ["parenchyma", "ANATOMY_MODIFIER", 212, 222]]], ["The localization of lymphocytes along CNS vasculature is accomplished via polarized expression of chemokines, including CXCL12 [27], which promotes interactions between T and perivascular antigen-presenting cells (APCs) in the setting of neuroinfectious diseases.", [["lymphocytes", "ANATOMY", 20, 31], ["CNS vasculature", "ANATOMY", 38, 53], ["T", "ANATOMY", 169, 170], ["perivascular antigen-presenting cells", "ANATOMY", 175, 212], ["APCs", "ANATOMY", 214, 218], ["neuroinfectious diseases", "DISEASE", 238, 262], ["lymphocytes", "CELL", 20, 31], ["CNS vasculature", "MULTI-TISSUE_STRUCTURE", 38, 53], ["CXCL12", "GENE_OR_GENE_PRODUCT", 120, 126], ["T", "CELL", 169, 170], ["perivascular antigen-presenting cells", "CELL", 175, 212], ["APCs", "CELL", 214, 218], ["lymphocytes", "CELL_TYPE", 20, 31], ["chemokines", "PROTEIN", 98, 108], ["CXCL12", "PROTEIN", 120, 126], ["T and perivascular antigen-presenting cells", "CELL_TYPE", 169, 212], ["APCs", "CELL_TYPE", 214, 218], ["CXCL12", "TEST", 120, 126], ["neuroinfectious diseases", "PROBLEM", 238, 262], ["lymphocytes", "OBSERVATION", 20, 31], ["CNS", "ANATOMY_MODIFIER", 38, 41], ["vasculature", "ANATOMY", 42, 53], ["polarized", "OBSERVATION_MODIFIER", 74, 83], ["expression", "OBSERVATION_MODIFIER", 84, 94], ["perivascular", "ANATOMY", 175, 187], ["neuroinfectious diseases", "OBSERVATION", 238, 262]]], ["Infiltrating T cells express CXCR4, a G protein-coupled signaling receptor of CXCL12 that is downregulated after T cell receptor activation, which allows T cell egress out of perivascular compartments [28, 29] .", [["Infiltrating T cells", "ANATOMY", 0, 20], ["T cell", "ANATOMY", 113, 119], ["T cell", "ANATOMY", 154, 160], ["perivascular compartments", "ANATOMY", 175, 200], ["Infiltrating T cells", "CELL", 0, 20], ["CXCR4", "GENE_OR_GENE_PRODUCT", 29, 34], ["G protein", "GENE_OR_GENE_PRODUCT", 38, 47], ["CXCL12", "GENE_OR_GENE_PRODUCT", 78, 84], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 113, 128], ["T cell", "CELL", 154, 160], ["perivascular compartments", "MULTI-TISSUE_STRUCTURE", 175, 200], ["Infiltrating T cells", "CELL_TYPE", 0, 20], ["CXCR4", "PROTEIN", 29, 34], ["G protein-coupled signaling receptor", "PROTEIN", 38, 74], ["CXCL12", "PROTEIN", 78, 84], ["T cell receptor", "PROTEIN", 113, 128], ["Infiltrating T cells", "PROBLEM", 0, 20], ["CXCR4", "TEST", 29, 34], ["a G protein", "TEST", 36, 47], ["CXCL12", "TEST", 78, 84], ["T cell receptor activation", "TREATMENT", 113, 139], ["perivascular", "ANATOMY", 175, 187]]], ["The abluminal localization of CXCL12 stands in stark contrast to its expression pattern at high endothelial venules within lymph nodes, where luminal CXCL12 promotes the homeostatic circulation of lymphocytes between the blood and lymphoid compartments [30], whereas BBB CXCL12 instead limits T cell entry into the CNS parenchyma [27, 28] .", [["abluminal", "ANATOMY", 4, 13], ["endothelial venules", "ANATOMY", 96, 115], ["lymph nodes", "ANATOMY", 123, 134], ["luminal", "ANATOMY", 142, 149], ["lymphocytes", "ANATOMY", 197, 208], ["blood", "ANATOMY", 221, 226], ["lymphoid compartments", "ANATOMY", 231, 252], ["BBB", "ANATOMY", 267, 270], ["T cell", "ANATOMY", 293, 299], ["CNS parenchyma", "ANATOMY", 315, 329], ["luminal", "CHEMICAL", 142, 149], ["abluminal", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 13], ["CXCL12", "GENE_OR_GENE_PRODUCT", 30, 36], ["endothelial venules", "TISSUE", 96, 115], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 123, 134], ["CXCL12", "GENE_OR_GENE_PRODUCT", 150, 156], ["lymphocytes", "CELL", 197, 208], ["blood", "ORGANISM_SUBSTANCE", 221, 226], ["lymphoid compartments", "MULTI-TISSUE_STRUCTURE", 231, 252], ["BBB CXCL12", "GENE_OR_GENE_PRODUCT", 267, 277], ["T cell", "CELL", 293, 299], ["CNS parenchyma", "MULTI-TISSUE_STRUCTURE", 315, 329], ["CXCL12", "PROTEIN", 30, 36], ["endothelial venules", "CELL_TYPE", 96, 115], ["CXCL12", "PROTEIN", 150, 156], ["lymphocytes", "CELL_TYPE", 197, 208], ["CXCL12", "PROTEIN", 271, 277], ["high endothelial venules within lymph nodes", "PROBLEM", 91, 134], ["luminal CXCL12", "TEST", 142, 156], ["BBB CXCL12", "TEST", 267, 277], ["abluminal", "ANATOMY_MODIFIER", 4, 13], ["high", "OBSERVATION_MODIFIER", 91, 95], ["endothelial venules", "ANATOMY", 96, 115], ["lymph nodes", "OBSERVATION", 123, 134], ["luminal", "ANATOMY_MODIFIER", 142, 149], ["circulation", "OBSERVATION_MODIFIER", 182, 193], ["lymphocytes", "OBSERVATION", 197, 208], ["blood", "ANATOMY", 221, 226], ["lymphoid", "ANATOMY", 231, 239], ["CNS", "ANATOMY", 315, 318], ["parenchyma", "ANATOMY_MODIFIER", 319, 329]]], ["The level of CNS expression of CXCL12 vascular barriers is accomplished at both transcriptional and protein expression levels, the latter of which occurs via the CXCL12 scavenging receptor CXCR7 [31] .", [["CNS", "ANATOMY", 13, 16], ["vascular", "ANATOMY", 38, 46], ["CNS", "ANATOMICAL_SYSTEM", 13, 16], ["CXCL12", "GENE_OR_GENE_PRODUCT", 31, 37], ["vascular", "MULTI-TISSUE_STRUCTURE", 38, 46], ["CXCL12", "GENE_OR_GENE_PRODUCT", 162, 168], ["CXCR7", "GENE_OR_GENE_PRODUCT", 189, 194], ["CXCL12", "PROTEIN", 31, 37], ["CXCL12", "PROTEIN", 162, 168], ["CXCR7", "PROTEIN", 189, 194], ["CXCL12 vascular barriers", "TREATMENT", 31, 55], ["CNS", "ANATOMY", 13, 16]]], ["As the CXCR7 promoter contains eight NF-kB binding sites, multiple cytokines may alter the level of its expression at the BBB during neuroinflammation, including interleukin-1, -8, -17, and interferon-\u03b3.", [["BBB", "ANATOMY", 122, 125], ["neuroinflammation", "DISEASE", 133, 150], ["CXCR7", "GENE_OR_GENE_PRODUCT", 7, 12], ["NF-kB", "GENE_OR_GENE_PRODUCT", 37, 42], ["BBB", "MULTI-TISSUE_STRUCTURE", 122, 125], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 162, 175], ["-8", "GENE_OR_GENE_PRODUCT", 177, 179], ["-17", "GENE_OR_GENE_PRODUCT", 181, 184], ["interferon", "GENE_OR_GENE_PRODUCT", 190, 200], ["CXCR7 promoter", "DNA", 7, 21], ["NF-kB binding sites", "DNA", 37, 56], ["cytokines", "PROTEIN", 67, 76], ["interleukin-1, -8, -17", "PROTEIN", 162, 184], ["interferon", "PROTEIN", 190, 200], ["the CXCR7 promoter", "TREATMENT", 3, 21], ["multiple cytokines", "TREATMENT", 58, 76], ["neuroinflammation", "PROBLEM", 133, 150], ["interleukin", "TEST", 162, 173], ["interferon", "TREATMENT", 190, 200], ["multiple", "OBSERVATION_MODIFIER", 58, 66], ["cytokines", "OBSERVATION", 67, 76]]], ["Alterations in the patterns of localizing cues at the BBB could promote excessive leukocyte entry, which may lead to further alterations in the BBB functions.Cellular Constituents of the NVU Regulate BBB Formation and FunctionThe NVU is comprised of brain microvascular endothelial cells (BMECs), abluminal pericytes, and astrocyte terminal processes, known as end feet, the latter of which receive neuronal signals that modulate BBB influx and efflux transporters in response to parenchymal demands or damage [5] .", [["BBB", "ANATOMY", 54, 57], ["leukocyte", "ANATOMY", 82, 91], ["BBB", "ANATOMY", 144, 147], ["Cellular", "ANATOMY", 158, 166], ["brain microvascular endothelial cells", "ANATOMY", 250, 287], ["BMECs", "ANATOMY", 289, 294], ["abluminal pericytes", "ANATOMY", 297, 316], ["astrocyte terminal", "ANATOMY", 322, 340], ["end feet", "ANATOMY", 361, 369], ["neuronal", "ANATOMY", 399, 407], ["BBB", "ANATOMY", 430, 433], ["parenchymal", "ANATOMY", 480, 491], ["BBB", "MULTI-TISSUE_STRUCTURE", 54, 57], ["leukocyte", "CELL", 82, 91], ["BBB", "MULTI-TISSUE_STRUCTURE", 144, 147], ["NVU", "GENE_OR_GENE_PRODUCT", 187, 190], ["BBB", "MULTI-TISSUE_STRUCTURE", 200, 203], ["brain microvascular endothelial cells", "CELL", 250, 287], ["BMECs", "CELL", 289, 294], ["abluminal pericytes", "CELL", 297, 316], ["astrocyte terminal processes", "CELLULAR_COMPONENT", 322, 350], ["neuronal", "CELL", 399, 407], ["BBB", "GENE_OR_GENE_PRODUCT", 430, 433], ["parenchymal", "TISSUE", 480, 491], ["NVU", "PROTEIN", 187, 190], ["NVU", "PROTEIN", 230, 233], ["brain microvascular endothelial cells", "CELL_TYPE", 250, 287], ["BMECs", "CELL_TYPE", 289, 294], ["abluminal pericytes", "CELL_TYPE", 297, 316], ["excessive leukocyte entry", "PROBLEM", 72, 97], ["further alterations in the BBB functions", "PROBLEM", 117, 157], ["Cellular Constituents", "TEST", 158, 179], ["brain microvascular endothelial cells", "PROBLEM", 250, 287], ["abluminal pericytes, and astrocyte terminal processes", "PROBLEM", 297, 350], ["efflux transporters", "TREATMENT", 445, 464], ["parenchymal demands", "PROBLEM", 480, 499], ["damage", "PROBLEM", 503, 509], ["excessive leukocyte", "OBSERVATION", 72, 91], ["brain microvascular", "ANATOMY", 250, 269], ["endothelial cells", "OBSERVATION", 270, 287], ["abluminal pericytes", "OBSERVATION", 297, 316], ["astrocyte terminal processes", "OBSERVATION", 322, 350], ["parenchymal", "ANATOMY_MODIFIER", 480, 491]]], ["Pericapillary pericytes extend their processes along pre-and postcapillary vessels, receiving signals from BMECs, astrocytes, and neurons that induce them to form, maintain, and regulate BBB function [32] .", [["Pericapillary pericytes", "ANATOMY", 0, 23], ["postcapillary vessels", "ANATOMY", 61, 82], ["BMECs", "ANATOMY", 107, 112], ["astrocytes", "ANATOMY", 114, 124], ["neurons", "ANATOMY", 130, 137], ["BBB", "ANATOMY", 187, 190], ["Pericapillary pericytes", "CELL", 0, 23], ["postcapillary vessels", "MULTI-TISSUE_STRUCTURE", 61, 82], ["BMECs", "CELLULAR_COMPONENT", 107, 112], ["astrocytes", "CELL", 114, 124], ["neurons", "CELL", 130, 137], ["BBB", "MULTI-TISSUE_STRUCTURE", 187, 190], ["Pericapillary pericytes", "CELL_TYPE", 0, 23], ["BMECs", "CELL_TYPE", 107, 112], ["astrocytes", "CELL_TYPE", 114, 124], ["Pericapillary pericytes", "PROBLEM", 0, 23], ["pericytes", "OBSERVATION", 14, 23], ["postcapillary", "ANATOMY_MODIFIER", 61, 74], ["vessels", "ANATOMY", 75, 82]]], ["Studies in pericyte-deficient and transgenic mice with aberrant signaling between endothelial-derived platelet-derived growth factor BB (PDGF-BB) and platelet-derived growth factor receptor \u03b2 (PDGFR\u03b2) in pericytes have thus identified critical roles for these cells from embryonic development to adulthood [33] .", [["pericyte", "ANATOMY", 11, 19], ["pericytes", "ANATOMY", 204, 213], ["cells", "ANATOMY", 260, 265], ["embryonic", "ANATOMY", 271, 280], ["pericyte", "CELL", 11, 19], ["transgenic mice", "ORGANISM", 34, 49], ["endothelial-derived platelet-derived growth factor BB", "GENE_OR_GENE_PRODUCT", 82, 135], ["PDGF-BB", "GENE_OR_GENE_PRODUCT", 137, 144], ["platelet-derived growth factor receptor \u03b2", "GENE_OR_GENE_PRODUCT", 150, 191], ["PDGFR\u03b2", "GENE_OR_GENE_PRODUCT", 193, 199], ["pericytes", "CELL", 204, 213], ["cells", "CELL", 260, 265], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 271, 280], ["endothelial-derived platelet-derived growth factor BB", "PROTEIN", 82, 135], ["PDGF", "PROTEIN", 137, 141], ["BB", "PROTEIN", 142, 144], ["platelet-derived growth factor receptor \u03b2", "PROTEIN", 150, 191], ["PDGFR\u03b2", "PROTEIN", 193, 199], ["pericytes", "CELL_TYPE", 204, 213], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["Studies", "TEST", 0, 7], ["aberrant signaling between endothelial", "PROBLEM", 55, 93], ["platelet", "TEST", 102, 110], ["BB", "TEST", 133, 135], ["PDGF", "TEST", 137, 141], ["BB", "TEST", 142, 144], ["platelet", "TEST", 150, 158], ["these cells", "PROBLEM", 254, 265], ["endothelial", "ANATOMY", 82, 93]]], ["Pdgfb and Pdgfr\u03b2 homozygous knockout mice completely lack pericytes, which causes embryonic lethality via cerebral blood vessel rupture and microhemorrhages.", [["pericytes", "ANATOMY", 58, 67], ["embryonic", "ANATOMY", 82, 91], ["cerebral blood vessel", "ANATOMY", 106, 127], ["cerebral blood vessel rupture", "DISEASE", 106, 135], ["microhemorrhages", "DISEASE", 140, 156], ["Pdgfb", "GENE_OR_GENE_PRODUCT", 0, 5], ["Pdgfr\u03b2", "GENE_OR_GENE_PRODUCT", 10, 16], ["mice", "ORGANISM", 37, 41], ["pericytes", "CELL", 58, 67], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 82, 91], ["cerebral blood vessel", "MULTI-TISSUE_STRUCTURE", 106, 127], ["Pdgfb", "PROTEIN", 0, 5], ["Pdgfr\u03b2", "PROTEIN", 10, 16], ["pericytes", "CELL_TYPE", 58, 67], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["Pdgfb", "TEST", 0, 5], ["Pdgfr\u03b2 homozygous knockout mice completely lack pericytes", "PROBLEM", 10, 67], ["embryonic lethality", "PROBLEM", 82, 101], ["cerebral blood vessel rupture", "PROBLEM", 106, 135], ["microhemorrhages", "PROBLEM", 140, 156], ["lack pericytes", "OBSERVATION", 53, 67], ["embryonic lethality", "OBSERVATION", 82, 101], ["cerebral", "ANATOMY_MODIFIER", 106, 114], ["blood vessel", "ANATOMY", 115, 127], ["rupture", "OBSERVATION", 128, 135], ["microhemorrhages", "OBSERVATION", 140, 156]]], ["While Pdgfr\u03b2 +/\u2212 mice and mice with modified PDGF-BB bioavailability are viable, they exhibit reductions in pericyte coverage along vasculature, leading to poor maintenance of BBB function and increased permeability [33] .", [["pericyte", "ANATOMY", 108, 116], ["vasculature", "ANATOMY", 132, 143], ["BBB", "ANATOMY", 176, 179], ["Pdgfr\u03b2", "GENE_OR_GENE_PRODUCT", 6, 12], ["mice", "ORGANISM", 26, 30], ["PDGF-BB", "GENE_OR_GENE_PRODUCT", 45, 52], ["pericyte", "CELL", 108, 116], ["vasculature", "MULTI-TISSUE_STRUCTURE", 132, 143], ["BBB", "MULTI-TISSUE_STRUCTURE", 176, 179], ["Pdgfr\u03b2", "PROTEIN", 6, 12], ["PDGF", "PROTEIN", 45, 49], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 26, 30], ["modified PDGF-BB bioavailability", "TREATMENT", 36, 68], ["pericyte coverage", "TREATMENT", 108, 125], ["increased permeability", "PROBLEM", 193, 215], ["reductions", "OBSERVATION_MODIFIER", 94, 104], ["pericyte coverage", "OBSERVATION", 108, 125], ["vasculature", "ANATOMY", 132, 143], ["increased", "OBSERVATION_MODIFIER", 193, 202], ["permeability", "OBSERVATION_MODIFIER", 203, 215]]], ["These mice also exhibit dysregulated cerebral blood flow (CBF) leading to eventual loss of neurons in the cortex and hippocampus.", [["cerebral blood", "ANATOMY", 37, 51], ["neurons", "ANATOMY", 91, 98], ["cortex", "ANATOMY", 106, 112], ["hippocampus", "ANATOMY", 117, 128], ["dysregulated cerebral blood flow", "DISEASE", 24, 56], ["mice", "ORGANISM", 6, 10], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 37, 51], ["neurons", "CELL", 91, 98], ["cortex", "CANCER", 106, 112], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 117, 128], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["dysregulated cerebral blood flow", "PROBLEM", 24, 56], ["eventual loss of neurons in the cortex and hippocampus", "PROBLEM", 74, 128], ["dysregulated", "OBSERVATION", 24, 36], ["cerebral", "ANATOMY", 37, 45], ["blood flow", "OBSERVATION", 46, 56], ["eventual", "OBSERVATION_MODIFIER", 74, 82], ["loss", "OBSERVATION", 83, 87], ["neurons", "ANATOMY_MODIFIER", 91, 98], ["cortex", "ANATOMY_MODIFIER", 106, 112], ["hippocampus", "ANATOMY", 117, 128]]], ["These data indicate the importance of maintaining adequate pericyte numbers for proper BBB function.Cellular Constituents of the NVU Regulate BBB Formation and FunctionBoth pericytes and astrocytes are important in the preservation of BMEC TJs through the regulation of junctional proteins occludin, claudin, and ZO-1.", [["pericyte", "ANATOMY", 59, 67], ["BBB", "ANATOMY", 87, 90], ["Cellular", "ANATOMY", 100, 108], ["BBB", "ANATOMY", 142, 145], ["FunctionBoth pericytes", "ANATOMY", 160, 182], ["astrocytes", "ANATOMY", 187, 197], ["BMEC TJs", "ANATOMY", 235, 243], ["junctional", "ANATOMY", 270, 280], ["pericyte", "CELL", 59, 67], ["BBB", "MULTI-TISSUE_STRUCTURE", 87, 90], ["NVU", "GENE_OR_GENE_PRODUCT", 129, 132], ["BBB", "GENE_OR_GENE_PRODUCT", 142, 145], ["FunctionBoth pericytes", "CELL", 160, 182], ["astrocytes", "CELL", 187, 197], ["BMEC TJs", "CELL", 235, 243], ["occludin", "GENE_OR_GENE_PRODUCT", 290, 298], ["claudin", "GENE_OR_GENE_PRODUCT", 300, 307], ["ZO-1", "GENE_OR_GENE_PRODUCT", 313, 317], ["NVU", "PROTEIN", 129, 132], ["FunctionBoth pericytes", "CELL_TYPE", 160, 182], ["astrocytes", "CELL_TYPE", 187, 197], ["BMEC TJs", "CELL_TYPE", 235, 243], ["junctional proteins", "PROTEIN", 270, 289], ["occludin", "PROTEIN", 290, 298], ["claudin", "PROTEIN", 300, 307], ["ZO-1", "PROTEIN", 313, 317], ["Cellular Constituents", "TEST", 100, 121], ["FunctionBoth pericytes and astrocytes", "PROBLEM", 160, 197], ["BMEC TJs", "TREATMENT", 235, 243], ["junctional proteins occludin", "TREATMENT", 270, 298], ["claudin", "TREATMENT", 300, 307], ["BBB Formation", "OBSERVATION", 142, 155], ["FunctionBoth pericytes", "OBSERVATION", 160, 182], ["astrocytes", "ANATOMY", 187, 197], ["BMEC TJs", "OBSERVATION", 235, 243], ["junctional proteins occludin", "OBSERVATION", 270, 298]]], ["Astrocyte end feet also contact the abluminal surfaces of BMECs and enwrap neuronal synapses, enabling simultaneous modulation neuronal activity and blood flow in response to elevations in intracellular Ca 2+ levels [34, 35] .", [["Astrocyte end feet", "ANATOMY", 0, 18], ["abluminal surfaces", "ANATOMY", 36, 54], ["BMECs", "ANATOMY", 58, 63], ["neuronal synapses", "ANATOMY", 75, 92], ["neuronal", "ANATOMY", 127, 135], ["blood", "ANATOMY", 149, 154], ["intracellular", "ANATOMY", 189, 202], ["Ca", "CHEMICAL", 203, 205], ["Ca 2+", "CHEMICAL", 203, 208], ["Astrocyte", "CELL", 0, 9], ["abluminal surfaces", "CELLULAR_COMPONENT", 36, 54], ["BMECs", "CELL", 58, 63], ["neuronal synapses", "CELLULAR_COMPONENT", 75, 92], ["neuronal", "CELL", 127, 135], ["blood", "ORGANISM_SUBSTANCE", 149, 154], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 189, 202], ["Ca 2+", "SIMPLE_CHEMICAL", 203, 208], ["BMECs", "CELL_TYPE", 58, 63], ["Astrocyte end feet", "PROBLEM", 0, 18], ["enwrap neuronal synapses", "PROBLEM", 68, 92], ["blood flow", "TEST", 149, 159], ["elevations in intracellular Ca", "TEST", 175, 205], ["BMECs", "ANATOMY", 58, 63], ["elevations", "OBSERVATION_MODIFIER", 175, 185]]], ["Astrocyte end feet are also highly polarized and express specialized molecules such as Kir4.1 K + channels and aquaporin 4 (AQP4), which each regulate BBB ionic concentrations, and protein transporters such as glucose transporter-1 and P-glycoprotein, the latter of which promotes the efflux of toxic substances away from brain parenchyma [36, 37] .", [["Astrocyte end feet", "ANATOMY", 0, 18], ["BBB", "ANATOMY", 151, 154], ["brain parenchyma", "ANATOMY", 322, 338], ["K", "CHEMICAL", 94, 95], ["glucose", "CHEMICAL", 210, 217], ["K +", "CHEMICAL", 94, 97], ["glucose", "CHEMICAL", 210, 217], ["Astrocyte", "CELL", 0, 9], ["Kir4.1 K + channels", "GENE_OR_GENE_PRODUCT", 87, 106], ["aquaporin 4", "GENE_OR_GENE_PRODUCT", 111, 122], ["AQP4", "GENE_OR_GENE_PRODUCT", 124, 128], ["BBB", "GENE_OR_GENE_PRODUCT", 151, 154], ["glucose transporter-1", "GENE_OR_GENE_PRODUCT", 210, 231], ["P-glycoprotein", "GENE_OR_GENE_PRODUCT", 236, 250], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 322, 338], ["Kir4.1 K + channels", "PROTEIN", 87, 106], ["aquaporin 4", "PROTEIN", 111, 122], ["AQP4", "PROTEIN", 124, 128], ["protein transporters", "PROTEIN", 181, 201], ["glucose transporter-1", "PROTEIN", 210, 231], ["P", "PROTEIN", 236, 237], ["glycoprotein", "PROTEIN", 238, 250], ["Astrocyte end feet", "PROBLEM", 0, 18], ["Kir", "TEST", 87, 90], ["K + channels", "TREATMENT", 94, 106], ["aquaporin 4 (AQP4)", "TREATMENT", 111, 129], ["BBB ionic concentrations", "TREATMENT", 151, 175], ["protein transporters", "TEST", 181, 201], ["glucose transporter", "TEST", 210, 229], ["feet", "ANATOMY", 14, 18], ["toxic substances", "OBSERVATION", 295, 311], ["brain", "ANATOMY", 322, 327], ["parenchyma", "ANATOMY_MODIFIER", 328, 338]]], ["Astrocytes may exchange signals through gap junctions forming a functional syncytium that coordinates BBB responses and communicates with neurons [38, 39] .", [["Astrocytes", "ANATOMY", 0, 10], ["gap junctions", "ANATOMY", 40, 53], ["syncytium", "ANATOMY", 75, 84], ["BBB", "ANATOMY", 102, 105], ["neurons", "ANATOMY", 138, 145], ["Astrocytes", "CELL", 0, 10], ["gap junctions", "CELLULAR_COMPONENT", 40, 53], ["syncytium", "CELLULAR_COMPONENT", 75, 84], ["BBB", "MULTI-TISSUE_STRUCTURE", 102, 105], ["neurons", "CELL", 138, 145], ["Astrocytes", "CELL_TYPE", 0, 10], ["Astrocytes", "PROBLEM", 0, 10], ["gap junctions", "PROBLEM", 40, 53], ["a functional syncytium", "PROBLEM", 62, 84], ["functional syncytium", "OBSERVATION", 64, 84]]], ["Astrocytes critically develop and maintain BBB characteristics through the release of vascular endothelial growth factor (VEGF), glial cell line-derived neurotrophic factor (GDNF), basic fibroblast growth factor (bFGF), and angiopoietin (ANG)-1 [39, 40] , which form TJ, promote enzymatic systems, and polarize expression of transporters [41] .Cellular Constituents of the NVU Regulate BBB Formation and FunctionThe full integration of NVU responses that regulate and maintain BBB function relies on multiple signaling pathways and proteins that regulate TJ integrity, including calcium, protein kinase A, protein kinase C, G proteins, calmodulin, cAMP, and phospholipase C [42, 43] .", [["Astrocytes", "ANATOMY", 0, 10], ["BBB", "ANATOMY", 43, 46], ["TJ", "ANATOMY", 267, 269], ["Cellular", "ANATOMY", 344, 352], ["BBB", "ANATOMY", 477, 480], ["TJ", "ANATOMY", 555, 557], ["calcium", "CHEMICAL", 579, 586], ["cAMP", "CHEMICAL", 648, 652], ["calcium", "CHEMICAL", 579, 586], ["cAMP", "CHEMICAL", 648, 652], ["Astrocytes", "CELL", 0, 10], ["BBB", "MULTI-TISSUE_STRUCTURE", 43, 46], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 86, 120], ["VEGF", "GENE_OR_GENE_PRODUCT", 122, 126], ["glial cell line-derived neurotrophic factor", "GENE_OR_GENE_PRODUCT", 129, 172], ["GDNF", "GENE_OR_GENE_PRODUCT", 174, 178], ["basic fibroblast growth factor", "GENE_OR_GENE_PRODUCT", 181, 211], ["bFGF", "GENE_OR_GENE_PRODUCT", 213, 217], ["angiopoietin (ANG)-1", "GENE_OR_GENE_PRODUCT", 224, 244], ["39, 40", "SIMPLE_CHEMICAL", 246, 252], ["TJ", "GENE_OR_GENE_PRODUCT", 267, 269], ["NVU", "GENE_OR_GENE_PRODUCT", 373, 376], ["BBB", "MULTI-TISSUE_STRUCTURE", 386, 389], ["NVU", "GENE_OR_GENE_PRODUCT", 436, 439], ["BBB", "MULTI-TISSUE_STRUCTURE", 477, 480], ["TJ", "GENE_OR_GENE_PRODUCT", 555, 557], ["calcium", "SIMPLE_CHEMICAL", 579, 586], ["protein kinase A", "GENE_OR_GENE_PRODUCT", 588, 604], ["protein kinase C", "GENE_OR_GENE_PRODUCT", 606, 622], ["G proteins", "GENE_OR_GENE_PRODUCT", 624, 634], ["calmodulin", "GENE_OR_GENE_PRODUCT", 636, 646], ["cAMP", "SIMPLE_CHEMICAL", 648, 652], ["phospholipase C", "GENE_OR_GENE_PRODUCT", 658, 673], ["Astrocytes", "CELL_TYPE", 0, 10], ["vascular endothelial growth factor", "PROTEIN", 86, 120], ["VEGF", "PROTEIN", 122, 126], ["glial cell line-derived neurotrophic factor", "PROTEIN", 129, 172], ["GDNF", "PROTEIN", 174, 178], ["basic fibroblast growth factor", "PROTEIN", 181, 211], ["bFGF", "PROTEIN", 213, 217], ["angiopoietin (ANG)-1", "PROTEIN", 224, 244], ["TJ", "PROTEIN", 267, 269], ["NVU", "PROTEIN", 373, 376], ["NVU", "PROTEIN", 436, 439], ["TJ", "PROTEIN", 555, 557], ["protein kinase A", "PROTEIN", 588, 604], ["protein kinase C", "PROTEIN", 606, 622], ["G proteins", "PROTEIN", 624, 634], ["calmodulin", "PROTEIN", 636, 646], ["phospholipase C", "PROTEIN", 658, 673], ["vascular endothelial growth factor", "PROBLEM", 86, 120], ["glial cell line", "TEST", 129, 144], ["neurotrophic factor (GDNF", "PROBLEM", 153, 178], ["basic fibroblast growth factor", "PROBLEM", 181, 211], ["angiopoietin (ANG)", "TEST", 224, 242], ["Cellular Constituents", "TEST", 344, 365], ["TJ integrity", "TEST", 555, 567], ["calcium", "TEST", 579, 586], ["protein kinase", "TEST", 588, 602], ["protein kinase C", "TEST", 606, 622], ["G proteins", "TEST", 624, 634], ["calmodulin", "TEST", 636, 646], ["cAMP", "TEST", 648, 652], ["phospholipase C", "TEST", 658, 673], ["vascular endothelial", "ANATOMY", 86, 106], ["glial cell line", "OBSERVATION", 129, 144]]], ["Heterotrimeric G proteins and protein kinase C signaling pathways, in particular, act via altering intra-and/or extracellular levels of calcium, which promotes TJ integrity [44] .", [["extracellular", "ANATOMY", 112, 125], ["TJ", "ANATOMY", 160, 162], ["calcium", "CHEMICAL", 136, 143], ["calcium", "CHEMICAL", 136, 143], ["Heterotrimeric G proteins", "GENE_OR_GENE_PRODUCT", 0, 25], ["protein kinase C", "GENE_OR_GENE_PRODUCT", 30, 46], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["calcium", "SIMPLE_CHEMICAL", 136, 143], ["TJ", "CELLULAR_COMPONENT", 160, 162], ["Heterotrimeric G proteins", "PROTEIN", 0, 25], ["protein kinase C", "PROTEIN", 30, 46], ["TJ", "PROTEIN", 160, 162], ["Heterotrimeric G proteins", "TEST", 0, 25], ["protein kinase", "TEST", 30, 44], ["signaling pathways", "TEST", 47, 65], ["calcium", "TEST", 136, 143], ["G proteins", "OBSERVATION_MODIFIER", 15, 25]]], ["Phosphorylation additionally regulates transmembrane and accessory proteins of TJs.", [["transmembrane", "ANATOMY", 39, 52], ["TJs", "ANATOMY", 79, 82], ["transmembrane", "CELLULAR_COMPONENT", 39, 52], ["TJs", "GENE_OR_GENE_PRODUCT", 79, 82], ["transmembrane and accessory proteins", "PROTEIN", 39, 75], ["TJs", "CELL_TYPE", 79, 82], ["Phosphorylation", "TREATMENT", 0, 15]]], ["Both serine and threonine phosphorylation of occludin, which regulates its subcellular localization, are highly correlated with the reassembly of TJs following alterations in BBB integrity [45] The PAR3-PAR6-APKC pathway and the evolutionarily conserved signaling complex related to the Drosophila Stardust-Disc lost-Crumbs complex (equivalent to the mammalian Pals1-PATJ-Crumbs complex) [43] have also been implicated in regulation or modulation of TJ assembly.", [["subcellular", "ANATOMY", 75, 86], ["TJs", "ANATOMY", 146, 149], ["BBB", "ANATOMY", 175, 178], ["TJ", "ANATOMY", 450, 452], ["threonine", "CHEMICAL", 16, 25], ["serine", "CHEMICAL", 5, 11], ["threonine", "CHEMICAL", 16, 25], ["serine", "AMINO_ACID", 5, 11], ["threonine", "AMINO_ACID", 16, 25], ["occludin", "GENE_OR_GENE_PRODUCT", 45, 53], ["TJs", "CELLULAR_COMPONENT", 146, 149], ["BBB", "MULTI-TISSUE_STRUCTURE", 175, 178], ["PAR3", "GENE_OR_GENE_PRODUCT", 198, 202], ["PAR6", "GENE_OR_GENE_PRODUCT", 203, 207], ["APKC", "GENE_OR_GENE_PRODUCT", 208, 212], ["Disc", "GENE_OR_GENE_PRODUCT", 307, 311], ["Pals1-PATJ-Crumbs complex) [43]", "GENE_OR_GENE_PRODUCT", 361, 392], ["TJ", "GENE_OR_GENE_PRODUCT", 450, 452], ["occludin", "PROTEIN", 45, 53], ["TJs", "PROTEIN", 146, 149], ["PAR3", "PROTEIN", 198, 202], ["PAR6", "PROTEIN", 203, 207], ["APKC", "PROTEIN", 208, 212], ["evolutionarily conserved signaling complex", "PROTEIN", 229, 271], ["Drosophila Stardust-Disc lost-Crumbs complex", "PROTEIN", 287, 331], ["Pals1", "PROTEIN", 361, 366], ["PATJ", "PROTEIN", 367, 371], ["Crumbs complex", "PROTEIN", 372, 386], ["TJ", "PROTEIN", 450, 452], ["Drosophila", "SPECIES", 287, 297], ["threonine phosphorylation of occludin", "TREATMENT", 16, 53], ["BBB integrity", "TEST", 175, 188], ["The PAR3", "TEST", 194, 202], ["the evolutionarily conserved signaling complex", "PROBLEM", 225, 271], ["the Drosophila Stardust", "TEST", 283, 306], ["Disc lost", "PROBLEM", 307, 316], ["Crumbs complex", "PROBLEM", 317, 331], ["Drosophila Stardust", "OBSERVATION", 287, 306], ["Disc", "ANATOMY", 307, 311], ["Crumbs complex", "OBSERVATION", 317, 331]]], ["As PAR-complex APKC and PAR3 may be downregulated upon activation of NF-kB and, in turn, act to inhibit NF-kB-mediated signaling, these pathways may provide additional mechanisms for the alteration of BBB function during neuroinflammation.Cellular Constituents of the NVU Regulate BBB Formation and FunctionIn summary, the BBB has evolved numerous cellular, subcellular, and molecular mechanisms to stringently regulate the CNS access of solutes, molecules, cells, and pathogens.", [["BBB", "ANATOMY", 201, 204], ["Cellular", "ANATOMY", 239, 247], ["cellular", "ANATOMY", 348, 356], ["subcellular", "ANATOMY", 358, 369], ["CNS", "ANATOMY", 424, 427], ["cells", "ANATOMY", 458, 463], ["neuroinflammation", "DISEASE", 221, 238], ["PAR", "GENE_OR_GENE_PRODUCT", 3, 6], ["APKC", "GENE_OR_GENE_PRODUCT", 15, 19], ["PAR3", "GENE_OR_GENE_PRODUCT", 24, 28], ["NF-kB", "GENE_OR_GENE_PRODUCT", 69, 74], ["NF-kB", "GENE_OR_GENE_PRODUCT", 104, 109], ["BBB", "MULTI-TISSUE_STRUCTURE", 201, 204], ["BBB", "MULTI-TISSUE_STRUCTURE", 323, 326], ["cellular", "CELL", 348, 356], ["CNS", "ANATOMICAL_SYSTEM", 424, 427], ["cells", "CELL", 458, 463], ["PAR", "PROTEIN", 3, 6], ["APKC", "PROTEIN", 15, 19], ["PAR3", "PROTEIN", 24, 28], ["NF-kB", "PROTEIN", 69, 74], ["NF-kB", "PROTEIN", 104, 109], ["NF-kB", "TREATMENT", 69, 74], ["neuroinflammation", "PROBLEM", 221, 238], ["Cellular Constituents", "TEST", 239, 260], ["pathogens", "PROBLEM", 469, 478], ["numerous", "OBSERVATION_MODIFIER", 339, 347], ["cellular", "OBSERVATION", 348, 356]]], ["BBB function, however, may become dysfunctional or derailed via intrinsic and/or extrinsic effects in the setting of neuroinflammatory diseases, including those caused by autoimmune, infectious, or neurodegenerative processes.Mechanisms of BBB Disruption During Pathological ConditionsDuring CNS disease, the NVU may undergo cytoarchitectural modulations that promote BBB permeability without significant alterations in structural integrity.", [["BBB", "ANATOMY", 240, 243], ["CNS", "ANATOMY", 292, 295], ["BBB", "ANATOMY", 368, 371], ["neuroinflammatory diseases", "DISEASE", 117, 143], ["autoimmune, infectious, or neurodegenerative processes", "DISEASE", 171, 225], ["CNS disease", "DISEASE", 292, 303], ["BBB", "MULTI-TISSUE_STRUCTURE", 0, 3], ["BBB", "MULTI-TISSUE_STRUCTURE", 240, 243], ["CNS", "ANATOMICAL_SYSTEM", 292, 295], ["BBB", "MULTI-TISSUE_STRUCTURE", 368, 371], ["BBB function", "TEST", 0, 12], ["dysfunctional", "PROBLEM", 34, 47], ["extrinsic effects", "PROBLEM", 81, 98], ["neuroinflammatory diseases", "PROBLEM", 117, 143], ["autoimmune, infectious", "PROBLEM", 171, 193], ["neurodegenerative processes", "PROBLEM", 198, 225], ["BBB Disruption", "PROBLEM", 240, 254], ["CNS disease", "PROBLEM", 292, 303], ["cytoarchitectural modulations", "PROBLEM", 325, 354], ["significant alterations in structural integrity", "PROBLEM", 393, 440], ["dysfunctional", "OBSERVATION", 34, 47], ["neuroinflammatory diseases", "OBSERVATION", 117, 143], ["autoimmune", "OBSERVATION", 171, 181], ["infectious", "OBSERVATION", 183, 193], ["neurodegenerative", "OBSERVATION_MODIFIER", 198, 215], ["BBB", "ANATOMY", 240, 243], ["Disruption", "OBSERVATION", 244, 254], ["cytoarchitectural modulations", "OBSERVATION", 325, 354], ["structural integrity", "OBSERVATION", 420, 440]]], ["TJs and their associated proteins are dynamically regulated and able to undergo alterations in transcription, translation, and posttranslational modifications, subcellular localization, and protein-protein interactions in normal and diseased states.", [["TJs", "ANATOMY", 0, 3], ["subcellular", "ANATOMY", 160, 171], ["TJs", "CELL", 0, 3], ["TJs", "CELL_TYPE", 0, 3], ["subcellular localization", "TEST", 160, 184]]], ["Thus, acute and subtle changes in BBB permeability with accompanying mild elevations in CSF protein levels may occur without severe CNS symptoms.", [["BBB", "ANATOMY", 34, 37], ["CNS", "ANATOMY", 132, 135], ["BBB", "MULTI-TISSUE_STRUCTURE", 34, 37], ["CSF", "GENE_OR_GENE_PRODUCT", 88, 91], ["CNS", "ANATOMICAL_SYSTEM", 132, 135], ["CSF protein", "PROTEIN", 88, 99], ["acute and subtle changes in BBB permeability", "PROBLEM", 6, 50], ["accompanying mild elevations in CSF protein levels", "PROBLEM", 56, 106], ["severe CNS symptoms", "PROBLEM", 125, 144], ["acute", "OBSERVATION_MODIFIER", 6, 11], ["subtle", "OBSERVATION_MODIFIER", 16, 22], ["changes", "OBSERVATION", 23, 30], ["BBB permeability", "OBSERVATION", 34, 50], ["mild", "OBSERVATION_MODIFIER", 69, 73], ["elevations", "OBSERVATION", 74, 84], ["CSF protein levels", "OBSERVATION", 88, 106], ["without", "UNCERTAINTY", 117, 124], ["severe", "OBSERVATION_MODIFIER", 125, 131]]], ["Prolonged alterations in NVU structure and function, however, can lead to complete TJ disruption leading to brain edema and neural cell damage and irreversible in brain injury.", [["TJ", "ANATOMY", 83, 85], ["brain", "ANATOMY", 108, 113], ["neural cell", "ANATOMY", 124, 135], ["brain", "ANATOMY", 163, 168], ["brain edema", "DISEASE", 108, 119], ["brain injury", "DISEASE", 163, 175], ["TJ", "GENE_OR_GENE_PRODUCT", 83, 85], ["brain edema", "PATHOLOGICAL_FORMATION", 108, 119], ["neural cell", "CELL", 124, 135], ["brain", "ORGAN", 163, 168], ["Prolonged alterations in NVU structure", "PROBLEM", 0, 38], ["complete TJ disruption", "PROBLEM", 74, 96], ["brain edema", "PROBLEM", 108, 119], ["neural cell damage", "PROBLEM", 124, 142], ["irreversible in brain injury", "PROBLEM", 147, 175], ["NVU structure", "OBSERVATION", 25, 38], ["brain", "ANATOMY", 108, 113], ["edema", "OBSERVATION", 114, 119], ["neural cell damage", "OBSERVATION", 124, 142], ["irreversible", "OBSERVATION_MODIFIER", 147, 159], ["brain", "ANATOMY", 163, 168], ["injury", "OBSERVATION", 169, 175]]], ["Here, we will discuss the role of primary or secondary BBB dysfunction in the etiology, progression, and repair of neuroinflammatory diseases.BBB Disruption During CNS AutoimmunityFailure of BBB function is a critical event during the development and progression of autoimmune diseases of the CNS, including neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS).", [["BBB", "ANATOMY", 55, 58], ["CNS", "ANATOMY", 164, 167], ["CNS", "ANATOMY", 293, 296], ["neuroinflammatory diseases", "DISEASE", 115, 141], ["autoimmune diseases of the CNS", "DISEASE", 266, 296], ["neuromyelitis optica spectrum disorders", "DISEASE", 308, 347], ["NMOSD", "DISEASE", 349, 354], ["multiple sclerosis", "DISEASE", 360, 378], ["MS", "DISEASE", 380, 382], ["BBB", "MULTI-TISSUE_STRUCTURE", 55, 58], ["BBB", "MULTI-TISSUE_STRUCTURE", 142, 145], ["BBB", "MULTI-TISSUE_STRUCTURE", 191, 194], ["CNS", "ANATOMICAL_SYSTEM", 293, 296], ["secondary BBB dysfunction", "PROBLEM", 45, 70], ["repair", "TREATMENT", 105, 111], ["neuroinflammatory diseases", "PROBLEM", 115, 141], ["BBB Disruption", "PROBLEM", 142, 156], ["a critical event", "PROBLEM", 207, 223], ["autoimmune diseases", "PROBLEM", 266, 285], ["the CNS", "PROBLEM", 289, 296], ["neuromyelitis optica spectrum disorders", "PROBLEM", 308, 347], ["NMOSD", "PROBLEM", 349, 354], ["multiple sclerosis (MS)", "PROBLEM", 360, 383], ["progression", "OBSERVATION_MODIFIER", 88, 99], ["neuroinflammatory diseases", "OBSERVATION", 115, 141], ["Disruption", "OBSERVATION", 146, 156], ["progression", "OBSERVATION_MODIFIER", 251, 262], ["autoimmune", "OBSERVATION", 266, 276], ["CNS", "ANATOMY", 293, 296], ["multiple", "OBSERVATION_MODIFIER", 360, 368], ["sclerosis", "OBSERVATION", 369, 378]]], ["NMOSD are rare, relapsing immunemediated CNS disorders characterized by inflammation and demyelination of the optic nerves and spinal cord with evidence of BBB dysfunction in up to 70% of cases and two-thirds of patients exhibiting elevations in serum anti-AQP4 autoimmune IgG antibodies (classified as NMO patients) (reviewed in [46] ).", [["CNS", "ANATOMY", 41, 44], ["optic nerves", "ANATOMY", 110, 122], ["spinal cord", "ANATOMY", 127, 138], ["BBB", "ANATOMY", 156, 159], ["serum", "ANATOMY", 246, 251], ["NMOSD", "DISEASE", 0, 5], ["CNS disorders", "DISEASE", 41, 54], ["inflammation", "DISEASE", 72, 84], ["demyelination", "DISEASE", 89, 102], ["BBB dysfunction", "DISEASE", 156, 171], ["NMO", "DISEASE", 303, 306], ["optic nerves", "MULTI-TISSUE_STRUCTURE", 110, 122], ["spinal cord", "ORGAN", 127, 138], ["BBB", "MULTI-TISSUE_STRUCTURE", 156, 159], ["patients", "ORGANISM", 212, 220], ["serum", "ORGANISM_SUBSTANCE", 246, 251], ["anti-AQP4", "GENE_OR_GENE_PRODUCT", 252, 261], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 273, 287], ["patients", "ORGANISM", 307, 315], ["serum anti-AQP4 autoimmune IgG antibodies", "PROTEIN", 246, 287], ["patients", "SPECIES", 212, 220], ["patients", "SPECIES", 307, 315], ["NMOSD", "PROBLEM", 0, 5], ["relapsing immunemediated CNS disorders", "PROBLEM", 16, 54], ["inflammation", "PROBLEM", 72, 84], ["demyelination of the optic nerves and spinal cord", "PROBLEM", 89, 138], ["BBB dysfunction", "PROBLEM", 156, 171], ["elevations in serum anti-AQP4 autoimmune IgG antibodies", "PROBLEM", 232, 287], ["relapsing", "OBSERVATION_MODIFIER", 16, 25], ["CNS", "ANATOMY", 41, 44], ["inflammation", "OBSERVATION", 72, 84], ["demyelination", "OBSERVATION", 89, 102], ["optic nerves", "ANATOMY", 110, 122], ["spinal cord", "ANATOMY", 127, 138], ["evidence of", "UNCERTAINTY", 144, 155], ["BBB dysfunction", "OBSERVATION", 156, 171], ["elevations", "OBSERVATION_MODIFIER", 232, 242]]], ["While patient serum levels of anti-AQP4 IgG are not a predictive biomarker for overall disease course [47] , they are positively correlated with the extent of spinal lesions; BBB permeability, as assessed via albumin index; levels of CSF myelin basic protein concentration; and serum C3 [48] .", [["serum", "ANATOMY", 14, 19], ["spinal lesions", "ANATOMY", 159, 173], ["BBB", "ANATOMY", 175, 178], ["serum", "ANATOMY", 278, 283], ["patient", "ORGANISM", 6, 13], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["anti-AQP4 IgG", "GENE_OR_GENE_PRODUCT", 30, 43], ["spinal lesions", "PATHOLOGICAL_FORMATION", 159, 173], ["BBB", "MULTI-TISSUE_STRUCTURE", 175, 178], ["albumin", "GENE_OR_GENE_PRODUCT", 209, 216], ["CSF myelin basic protein", "GENE_OR_GENE_PRODUCT", 234, 258], ["serum", "ORGANISM_SUBSTANCE", 278, 283], ["anti-AQP4 IgG", "PROTEIN", 30, 43], ["albumin", "PROTEIN", 209, 216], ["CSF myelin basic protein", "PROTEIN", 234, 258], ["patient", "SPECIES", 6, 13], ["patient serum levels", "TEST", 6, 26], ["anti-AQP4 IgG", "TEST", 30, 43], ["spinal lesions", "PROBLEM", 159, 173], ["BBB permeability", "TEST", 175, 191], ["albumin index", "TEST", 209, 222], ["levels", "TEST", 224, 230], ["CSF myelin basic protein concentration", "TEST", 234, 272], ["serum C3", "TEST", 278, 286], ["spinal", "ANATOMY", 159, 165], ["lesions", "OBSERVATION", 166, 173]]], ["Anti-AQP4 IgG contribute to pathogenesis via effects at astrocyte end feet within the NVU, which express AQP4, and bind to the abluminal surfaces of microvessels in NMO patients, in conjunction with lesions containing complement proteins, infiltrating neutrophils and eosinophils, and loss of AQP4 [49] .", [["astrocyte end feet", "ANATOMY", 56, 74], ["NVU", "ANATOMY", 86, 89], ["abluminal surfaces", "ANATOMY", 127, 145], ["microvessels", "ANATOMY", 149, 161], ["lesions", "ANATOMY", 199, 206], ["neutrophils", "ANATOMY", 252, 263], ["eosinophils", "ANATOMY", 268, 279], ["NMO", "DISEASE", 165, 168], ["Anti-AQP4 IgG", "GENE_OR_GENE_PRODUCT", 0, 13], ["astrocyte", "CELL", 56, 65], ["NVU", "CANCER", 86, 89], ["AQP4", "GENE_OR_GENE_PRODUCT", 105, 109], ["abluminal surfaces", "TISSUE", 127, 145], ["microvessels", "TISSUE", 149, 161], ["patients", "ORGANISM", 169, 177], ["lesions", "CANCER", 199, 206], ["neutrophils", "CELL", 252, 263], ["eosinophils", "CELL", 268, 279], ["AQP4", "GENE_OR_GENE_PRODUCT", 293, 297], ["Anti-AQP4 IgG", "PROTEIN", 0, 13], ["AQP4", "PROTEIN", 105, 109], ["complement proteins", "PROTEIN", 218, 237], ["infiltrating neutrophils", "CELL_TYPE", 239, 263], ["eosinophils", "CELL_TYPE", 268, 279], ["AQP4", "PROTEIN", 293, 297], ["patients", "SPECIES", 169, 177], ["Anti-AQP4 IgG", "TREATMENT", 0, 13], ["pathogenesis", "PROBLEM", 28, 40], ["lesions", "PROBLEM", 199, 206], ["complement proteins", "TEST", 218, 237], ["infiltrating neutrophils", "PROBLEM", 239, 263], ["eosinophils", "TEST", 268, 279], ["loss of AQP4", "PROBLEM", 285, 297], ["abluminal", "ANATOMY_MODIFIER", 127, 136], ["microvessels", "ANATOMY", 149, 161], ["lesions", "OBSERVATION", 199, 206], ["infiltrating neutrophils", "OBSERVATION", 239, 263]]], ["Human data are consistent with a significant role for anti-AQP4 IgG in the pathogenesis of NMO, which is further supported by the clinical efficacy of plasma exchange and B cell depletion [50] .", [["plasma", "ANATOMY", 151, 157], ["B cell", "ANATOMY", 171, 177], ["NMO", "DISEASE", 91, 94], ["Human", "ORGANISM", 0, 5], ["anti-AQP4 IgG", "GENE_OR_GENE_PRODUCT", 54, 67], ["plasma", "ORGANISM_SUBSTANCE", 151, 157], ["B cell", "CELL", 171, 177], ["anti-AQP4 IgG", "PROTEIN", 54, 67], ["Human", "SPECIES", 0, 5], ["Human data", "TEST", 0, 10], ["anti-AQP4 IgG", "TREATMENT", 54, 67], ["NMO", "PROBLEM", 91, 94], ["plasma exchange", "TREATMENT", 151, 166], ["B cell depletion", "TREATMENT", 171, 187], ["consistent with", "UNCERTAINTY", 15, 30], ["cell depletion", "OBSERVATION", 173, 187]]], ["In animal studies, targeted deletion of AQP4 or administration of anti-AQP4 IgG-positive sera plus complement from NMO patients leads to loss of BBB integrity and impaired water homeostasis within astrocyte end feet [51] [52] [53] .", [["sera", "ANATOMY", 89, 93], ["BBB", "ANATOMY", 145, 148], ["astrocyte", "ANATOMY", 197, 206], ["NMO", "DISEASE", 115, 118], ["AQP4", "GENE_OR_GENE_PRODUCT", 40, 44], ["anti-AQP4 IgG", "GENE_OR_GENE_PRODUCT", 66, 79], ["sera", "ORGANISM_SUBSTANCE", 89, 93], ["patients", "ORGANISM", 119, 127], ["BBB", "MULTI-TISSUE_STRUCTURE", 145, 148], ["water", "SIMPLE_CHEMICAL", 172, 177], ["astrocyte", "CELL", 197, 206], ["AQP4", "PROTEIN", 40, 44], ["anti-AQP4 IgG", "PROTEIN", 66, 79], ["patients", "SPECIES", 119, 127], ["animal studies", "TEST", 3, 17], ["anti-AQP4 IgG", "TREATMENT", 66, 79], ["positive sera", "TREATMENT", 80, 93], ["loss of BBB integrity", "PROBLEM", 137, 158], ["impaired water homeostasis", "PROBLEM", 163, 189], ["astrocyte end feet", "TEST", 197, 215]]], ["Similarly, using an in vitro human BBB model administration of human anti-AQP4 IgG and complement increased the migration of granulocytes across BMECs and led to astrocyte injury and decreased transendothelial electrical resistance (TEER) [54] .", [["BBB", "ANATOMY", 35, 38], ["granulocytes", "ANATOMY", 125, 137], ["BMECs", "ANATOMY", 145, 150], ["astrocyte", "ANATOMY", 162, 171], ["transendothelial", "ANATOMY", 193, 209], ["human", "ORGANISM", 29, 34], ["BBB", "MULTI-TISSUE_STRUCTURE", 35, 38], ["human", "ORGANISM", 63, 68], ["anti-AQP4 IgG", "GENE_OR_GENE_PRODUCT", 69, 82], ["granulocytes", "CELL", 125, 137], ["BMECs", "CELL", 145, 150], ["astrocyte", "CELL", 162, 171], ["human anti-AQP4 IgG", "PROTEIN", 63, 82], ["granulocytes", "CELL_TYPE", 125, 137], ["BMECs", "CELL_TYPE", 145, 150], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 63, 68], ["an in vitro human BBB", "TREATMENT", 17, 38], ["human anti-AQP4 IgG", "TREATMENT", 63, 82], ["the migration of granulocytes across BMECs", "TREATMENT", 108, 150], ["astrocyte injury", "PROBLEM", 162, 178], ["decreased transendothelial electrical resistance", "PROBLEM", 183, 231], ["increased", "OBSERVATION_MODIFIER", 98, 107], ["migration", "OBSERVATION_MODIFIER", 112, 121], ["astrocyte injury", "OBSERVATION", 162, 178], ["decreased", "OBSERVATION_MODIFIER", 183, 192], ["transendothelial electrical resistance", "OBSERVATION", 193, 231]]], ["While the mechanism of anti-AQP4 IgG entry at the BBB, including access to astrocyte end feet, is unclear, endothelium-specific antibodies, VEGF, and matrix metalloproteinase (MMP)-9 are all elevated in NMO [52, 55] .", [["BBB", "ANATOMY", 50, 53], ["astrocyte end feet", "ANATOMY", 75, 93], ["endothelium", "ANATOMY", 107, 118], ["NMO", "DISEASE", 203, 206], ["anti-AQP4 IgG", "GENE_OR_GENE_PRODUCT", 23, 36], ["BBB", "MULTI-TISSUE_STRUCTURE", 50, 53], ["astrocyte", "CELL", 75, 84], ["endothelium", "TISSUE", 107, 118], ["VEGF", "GENE_OR_GENE_PRODUCT", 140, 144], ["matrix metalloproteinase (MMP)-9", "GENE_OR_GENE_PRODUCT", 150, 182], ["anti-AQP4 IgG", "PROTEIN", 23, 36], ["specific antibodies", "PROTEIN", 119, 138], ["VEGF", "PROTEIN", 140, 144], ["matrix metalloproteinase (MMP)-9", "PROTEIN", 150, 182], ["anti-AQP4 IgG entry", "TREATMENT", 23, 42], ["astrocyte end feet", "TEST", 75, 93], ["endothelium", "TEST", 107, 118], ["specific antibodies", "TEST", 119, 138], ["VEGF", "TEST", 140, 144], ["matrix metalloproteinase (MMP)", "TEST", 150, 180]]], ["Activation of BMECs via endothelium-specific antibodies may lead to concomitant upregulation of intercellular adhesion molecule (ICAM)-1 [52] , promoting capture of leukocytes, and secretion of TNF and VEGF.", [["BMECs", "ANATOMY", 14, 19], ["endothelium", "ANATOMY", 24, 35], ["leukocytes", "ANATOMY", 165, 175], ["BMECs", "GENE_OR_GENE_PRODUCT", 14, 19], ["endothelium", "TISSUE", 24, 35], ["intercellular adhesion molecule (ICAM)-1", "GENE_OR_GENE_PRODUCT", 96, 136], ["leukocytes", "CELL", 165, 175], ["TNF", "GENE_OR_GENE_PRODUCT", 194, 197], ["VEGF", "GENE_OR_GENE_PRODUCT", 202, 206], ["BMECs", "CELL_TYPE", 14, 19], ["intercellular adhesion molecule", "PROTEIN", 96, 127], ["ICAM", "PROTEIN", 129, 133], ["leukocytes", "CELL_TYPE", 165, 175], ["TNF", "PROTEIN", 194, 197], ["VEGF", "PROTEIN", 202, 206], ["BMECs via endothelium", "TREATMENT", 14, 35], ["specific antibodies", "TEST", 36, 55], ["intercellular adhesion molecule", "TEST", 96, 127], ["ICAM)", "TEST", 129, 134], ["leukocytes", "TEST", 165, 175], ["secretion of TNF and VEGF", "PROBLEM", 181, 206], ["intercellular adhesion", "OBSERVATION", 96, 118], ["leukocytes", "ANATOMY", 165, 175], ["TNF", "ANATOMY", 194, 197], ["VEGF", "ANATOMY", 202, 206]]], ["The release of MMP-9 from infiltrating neutrophils could play a role in the degradation of the BBB ECM [55] by allowing anti-AQP4 IgG access to astrocyte AQP4.", [["neutrophils", "ANATOMY", 39, 50], ["BBB ECM", "ANATOMY", 95, 102], ["astrocyte", "ANATOMY", 144, 153], ["MMP-9", "GENE_OR_GENE_PRODUCT", 15, 20], ["neutrophils", "CELL", 39, 50], ["BBB ECM", "CELLULAR_COMPONENT", 95, 102], ["anti-AQP4 IgG", "GENE_OR_GENE_PRODUCT", 120, 133], ["AQP4", "GENE_OR_GENE_PRODUCT", 154, 158], ["MMP-9", "PROTEIN", 15, 20], ["infiltrating neutrophils", "CELL_TYPE", 26, 50], ["anti-AQP4 IgG", "PROTEIN", 120, 133], ["astrocyte AQP4", "PROTEIN", 144, 158], ["MMP", "TEST", 15, 18], ["infiltrating neutrophils", "PROBLEM", 26, 50], ["anti-AQP4 IgG access", "TREATMENT", 120, 140], ["astrocyte AQP4", "TEST", 144, 158]]], ["Further development of animal models of NMO could help identify therapeutic targets to prevent these effects.BBB Disruption During CNS AutoimmunityThe role of BBB dysfunction in the induction and progression of MS is a subject of controversy [56] , mostly due to the lack of models that faithfully reproduce the diseases observed in patients.", [["CNS", "ANATOMY", 131, 134], ["BBB", "ANATOMY", 159, 162], ["NMO", "DISEASE", 40, 43], ["Autoimmunity", "DISEASE", 135, 147], ["MS", "DISEASE", 211, 213], ["BBB", "MULTI-TISSUE_STRUCTURE", 109, 112], ["BBB", "MULTI-TISSUE_STRUCTURE", 159, 162], ["patients", "ORGANISM", 333, 341], ["patients", "SPECIES", 333, 341], ["NMO", "PROBLEM", 40, 43], ["therapeutic targets", "TREATMENT", 64, 83], ["BBB Disruption", "PROBLEM", 109, 123], ["BBB dysfunction", "PROBLEM", 159, 174], ["the induction", "TREATMENT", 178, 191], ["MS", "PROBLEM", 211, 213], ["the lack of models", "PROBLEM", 263, 281], ["the diseases", "PROBLEM", 308, 320], ["BBB", "ANATOMY", 159, 162], ["dysfunction", "OBSERVATION", 163, 174], ["diseases", "OBSERVATION", 312, 320]]], ["MS is a heterogeneous group of demyelinating syndromes in which patients may present with a relapsing-remitting form, characterized by periods of disease exacerbation followed by recovery and remission (RRMS).", [["MS", "DISEASE", 0, 2], ["demyelinating syndromes", "DISEASE", 31, 54], ["RRMS", "DISEASE", 203, 207], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["demyelinating syndromes", "PROBLEM", 31, 54], ["a relapsing-remitting form", "PROBLEM", 90, 116], ["disease exacerbation", "PROBLEM", 146, 166], ["remission (RRMS)", "PROBLEM", 192, 208], ["heterogeneous", "OBSERVATION_MODIFIER", 8, 21], ["demyelinating syndromes", "OBSERVATION", 31, 54], ["disease", "OBSERVATION", 146, 153]]], ["RRMS may be followed by the onset of continued progression of disease (i.e., secondary-progressive (SP)MS) or a primary progressive form in which patients continue to develop neurologic deficits without remission (PPMS) [57] .", [["neurologic", "ANATOMY", 175, 185], ["RRMS", "DISEASE", 0, 4], ["secondary-progressive (SP)MS", "DISEASE", 77, 105], ["neurologic deficits", "DISEASE", 175, 194], ["PPMS", "DISEASE", 214, 218], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["RRMS", "PROBLEM", 0, 4], ["disease", "PROBLEM", 62, 69], ["progressive (SP)MS)", "PROBLEM", 87, 106], ["neurologic deficits", "PROBLEM", 175, 194], ["progression", "OBSERVATION_MODIFIER", 47, 58], ["disease", "OBSERVATION", 62, 69], ["progressive", "OBSERVATION_MODIFIER", 87, 98]]], ["The characteristic CNS lesion observed in MS patients is a focal area of inflammatory-mediated demyelination surrounding postcapillary venules within white matter [58] .", [["CNS lesion", "ANATOMY", 19, 29], ["focal area", "ANATOMY", 59, 69], ["postcapillary venules", "ANATOMY", 121, 142], ["white matter", "ANATOMY", 150, 162], ["MS", "DISEASE", 42, 44], ["demyelination", "DISEASE", 95, 108], ["CNS lesion", "PATHOLOGICAL_FORMATION", 19, 29], ["patients", "ORGANISM", 45, 53], ["postcapillary venules", "TISSUE", 121, 142], ["patients", "SPECIES", 45, 53], ["The characteristic CNS lesion", "PROBLEM", 0, 29], ["inflammatory-mediated demyelination", "PROBLEM", 73, 108], ["postcapillary venules within white matter", "PROBLEM", 121, 162], ["characteristic", "OBSERVATION_MODIFIER", 4, 18], ["CNS", "ANATOMY", 19, 22], ["lesion", "OBSERVATION", 23, 29], ["focal", "OBSERVATION_MODIFIER", 59, 64], ["area", "OBSERVATION_MODIFIER", 65, 69], ["inflammatory", "OBSERVATION", 73, 85], ["mediated", "OBSERVATION_MODIFIER", 86, 94], ["demyelination", "OBSERVATION", 95, 108], ["postcapillary", "ANATOMY_MODIFIER", 121, 134], ["venules", "ANATOMY", 135, 142], ["white matter", "OBSERVATION_MODIFIER", 150, 162]]], ["In severe cases of MS, patients may also exhibit demyelinating lesions within cortical gray matter, often adjacent to meninges.", [["lesions", "ANATOMY", 63, 70], ["cortical gray matter", "ANATOMY", 78, 98], ["meninges", "ANATOMY", 118, 126], ["MS", "DISEASE", 19, 21], ["patients", "ORGANISM", 23, 31], ["demyelinating lesions", "PATHOLOGICAL_FORMATION", 49, 70], ["cortical gray matter", "CANCER", 78, 98], ["meninges", "ORGAN", 118, 126], ["patients", "SPECIES", 23, 31], ["MS", "PROBLEM", 19, 21], ["demyelinating lesions within cortical gray matter", "PROBLEM", 49, 98], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["demyelinating", "OBSERVATION_MODIFIER", 49, 62], ["lesions", "OBSERVATION", 63, 70], ["cortical gray matter", "OBSERVATION", 78, 98], ["meninges", "ANATOMY", 118, 126]]], ["Defects in BBB function are observed in all lesions, with gadolinium extravasation observed using magnetic resonance imaging (MRI).", [["BBB", "ANATOMY", 11, 14], ["lesions", "ANATOMY", 44, 51], ["gadolinium", "CHEMICAL", 58, 68], ["gadolinium", "CHEMICAL", 58, 68], ["BBB", "MULTI-TISSUE_STRUCTURE", 11, 14], ["lesions", "PATHOLOGICAL_FORMATION", 44, 51], ["gadolinium", "SIMPLE_CHEMICAL", 58, 68], ["Defects in BBB function", "PROBLEM", 0, 23], ["all lesions", "PROBLEM", 40, 51], ["gadolinium extravasation", "PROBLEM", 58, 82], ["magnetic resonance imaging", "TEST", 98, 124], ["MRI", "TEST", 126, 129], ["BBB", "ANATOMY", 11, 14], ["all", "OBSERVATION_MODIFIER", 40, 43], ["lesions", "OBSERVATION", 44, 51]]], ["However, while frank TJ disruption is not observed in MS lesions, as assessed in early studies using electron microscopy [59] , the exact mechanisms of BBB impairment are unclear, as is the timing of these events as primary or secondary to the effects of immune cells.BBB Disruption During CNS AutoimmunityEvidence for primary causes of BBB dysfunction include altered BMEC expression of molecules involved in the stabilization of TJs, including sphingosine 1-phosphate receptor 2 (S1P2) and claudin proteins [60, 61] .", [["frank TJ", "ANATOMY", 15, 23], ["MS lesions", "ANATOMY", 54, 64], ["BBB", "ANATOMY", 152, 155], ["immune cells", "ANATOMY", 255, 267], ["CNS", "ANATOMY", 290, 293], ["BBB", "ANATOMY", 337, 340], ["BMEC", "ANATOMY", 369, 373], ["TJs", "ANATOMY", 431, 434], ["BBB impairment", "DISEASE", 152, 166], ["Autoimmunity", "DISEASE", 294, 306], ["sphingosine 1-phosphate", "CHEMICAL", 446, 469], ["sphingosine 1-phosphate", "CHEMICAL", 446, 469], ["TJ", "GENE_OR_GENE_PRODUCT", 21, 23], ["MS lesions", "PATHOLOGICAL_FORMATION", 54, 64], ["BBB", "MULTI-TISSUE_STRUCTURE", 152, 155], ["immune cells", "CELL", 255, 267], ["BBB", "MULTI-TISSUE_STRUCTURE", 268, 271], ["BBB", "MULTI-TISSUE_STRUCTURE", 337, 340], ["BMEC", "CELL", 369, 373], ["TJs", "GENE_OR_GENE_PRODUCT", 431, 434], ["sphingosine 1-phosphate receptor 2", "GENE_OR_GENE_PRODUCT", 446, 480], ["S1P2", "GENE_OR_GENE_PRODUCT", 482, 486], ["claudin", "GENE_OR_GENE_PRODUCT", 492, 499], ["TJ", "PROTEIN", 21, 23], ["immune cells", "CELL_TYPE", 255, 267], ["TJs", "PROTEIN", 431, 434], ["sphingosine 1-phosphate receptor 2", "PROTEIN", 446, 480], ["S1P2", "PROTEIN", 482, 486], ["claudin proteins", "PROTEIN", 492, 508], ["frank TJ disruption", "PROBLEM", 15, 34], ["MS lesions", "PROBLEM", 54, 64], ["electron microscopy", "TEST", 101, 120], ["BBB impairment", "PROBLEM", 152, 166], ["immune cells", "PROBLEM", 255, 267], ["BBB Disruption", "PROBLEM", 268, 282], ["primary causes", "PROBLEM", 319, 333], ["BBB dysfunction", "PROBLEM", 337, 352], ["altered BMEC expression of molecules", "PROBLEM", 361, 397], ["sphingosine 1-phosphate receptor", "TEST", 446, 478], ["claudin proteins", "TEST", 492, 508], ["frank TJ", "OBSERVATION_MODIFIER", 15, 23], ["disruption", "OBSERVATION", 24, 34], ["not observed", "UNCERTAINTY", 38, 50], ["lesions", "OBSERVATION", 57, 64], ["BBB", "ANATOMY", 152, 155], ["impairment", "OBSERVATION", 156, 166], ["immune cells", "OBSERVATION", 255, 267], ["dysfunction", "OBSERVATION", 341, 352], ["BMEC expression", "OBSERVATION", 369, 384]]], ["S1P2 is one of the five subtypes of G protein-coupled receptors (S1P1-5) that are targeted by S1P, a signaling, blood-borne sphingolipid that regulates angiogenesis, vascular stability, and permeability and may also be important in the pathogenesis of neurodegenerative diseases (reviewed in [62] ).", [["blood", "ANATOMY", 112, 117], ["vascular", "ANATOMY", 166, 174], ["S1P", "CHEMICAL", 94, 97], ["neurodegenerative diseases", "DISEASE", 252, 278], ["sphingolipid", "CHEMICAL", 124, 136], ["S1P2", "GENE_OR_GENE_PRODUCT", 0, 4], ["G protein-coupled receptors", "GENE_OR_GENE_PRODUCT", 36, 63], ["S1P1-5", "GENE_OR_GENE_PRODUCT", 65, 71], ["S1P", "GENE_OR_GENE_PRODUCT", 94, 97], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["sphingolipid", "SIMPLE_CHEMICAL", 124, 136], ["vascular", "MULTI-TISSUE_STRUCTURE", 166, 174], ["S1P2", "PROTEIN", 0, 4], ["G protein-coupled receptors", "PROTEIN", 36, 63], ["S1P1", "PROTEIN", 65, 69], ["G protein", "TEST", 36, 45], ["S1P1", "TEST", 65, 69], ["a signaling, blood-borne sphingolipid", "PROBLEM", 99, 136], ["neurodegenerative diseases", "PROBLEM", 252, 278], ["vascular", "ANATOMY", 166, 174], ["stability", "OBSERVATION_MODIFIER", 175, 184], ["may also be", "UNCERTAINTY", 207, 218], ["neurodegenerative", "OBSERVATION_MODIFIER", 252, 269], ["diseases", "OBSERVATION", 270, 278]]], ["S1P also regulates the trafficking of T and B cells within lymphoid tissues and directly suppresses TLR-mediated immune responses from T cells [63] .", [["T", "ANATOMY", 38, 39], ["B cells", "ANATOMY", 44, 51], ["lymphoid tissues", "ANATOMY", 59, 75], ["T cells", "ANATOMY", 135, 142], ["S1P", "CHEMICAL", 0, 3], ["S1P", "CHEMICAL", 0, 3], ["S1P", "GENE_OR_GENE_PRODUCT", 0, 3], ["T", "CELL", 38, 39], ["B cells", "CELL", 44, 51], ["lymphoid tissues", "TISSUE", 59, 75], ["TLR", "GENE_OR_GENE_PRODUCT", 100, 103], ["T cells", "CELL", 135, 142], ["T and B cells", "CELL_TYPE", 38, 51], ["TLR", "PROTEIN", 100, 103], ["T cells", "CELL_TYPE", 135, 142], ["lymphoid tissues", "OBSERVATION", 59, 75]]], ["At the BBB, S1P1 and S1P3 activation promote Rac1-mediated tightening of inter-endothelial junctions, while S1P2 leads to their disassembly via RhoA [64] .", [["inter-endothelial junctions", "ANATOMY", 73, 100], ["BBB", "MULTI-TISSUE_STRUCTURE", 7, 10], ["S1P1", "GENE_OR_GENE_PRODUCT", 12, 16], ["S1P3", "GENE_OR_GENE_PRODUCT", 21, 25], ["Rac1", "GENE_OR_GENE_PRODUCT", 45, 49], ["inter-endothelial junctions", "CELLULAR_COMPONENT", 73, 100], ["S1P2", "GENE_OR_GENE_PRODUCT", 108, 112], ["RhoA", "GENE_OR_GENE_PRODUCT", 144, 148], ["S1P1", "PROTEIN", 12, 16], ["S1P3", "PROTEIN", 21, 25], ["Rac1", "PROTEIN", 45, 49], ["S1P2", "PROTEIN", 108, 112], ["RhoA", "PROTEIN", 144, 148], ["S1P1", "TEST", 12, 16], ["S1P3 activation", "TREATMENT", 21, 36], ["Rac1-mediated tightening of inter-endothelial junctions", "TREATMENT", 45, 100], ["BBB", "ANATOMY", 7, 10], ["Rac1", "OBSERVATION_MODIFIER", 45, 49], ["tightening", "OBSERVATION_MODIFIER", 59, 69], ["inter-endothelial junctions", "OBSERVATION", 73, 100]]], ["In murine models of RRMS, disassembly of BBB TJs and AJs is associated with loss of polarized expression of CXCL12 with increased capture and CNS entry of CXCR4-expressing T cells [61] .", [["BBB TJs", "ANATOMY", 41, 48], ["AJs", "ANATOMY", 53, 56], ["CNS", "ANATOMY", 142, 145], ["T cells", "ANATOMY", 172, 179], ["RRMS", "DISEASE", 20, 24], ["murine", "ORGANISM", 3, 9], ["BBB TJs", "GENE_OR_GENE_PRODUCT", 41, 48], ["AJs", "CELLULAR_COMPONENT", 53, 56], ["CXCL12", "GENE_OR_GENE_PRODUCT", 108, 114], ["CNS", "ANATOMICAL_SYSTEM", 142, 145], ["CXCR4", "GENE_OR_GENE_PRODUCT", 155, 160], ["T cells", "CELL", 172, 179], ["BBB TJs", "CELL_TYPE", 41, 48], ["AJs", "CELL_TYPE", 53, 56], ["CXCL12", "PROTEIN", 108, 114], ["CXCR4", "PROTEIN", 155, 160], ["expressing T cells", "CELL_TYPE", 161, 179], ["murine", "SPECIES", 3, 9], ["RRMS", "PROBLEM", 20, 24], ["loss of polarized expression of CXCL12", "PROBLEM", 76, 114], ["increased capture", "PROBLEM", 120, 137], ["CXCR4", "TEST", 155, 160], ["RRMS", "OBSERVATION", 20, 24]]], ["Patients with MS exhibit loss of BBB polarity within white matter lesions [65] , and women with RRMS exhibit significantly higher levels of S1P2 at the NVU within hindbrain regions compared with male MS patients [61] .BBB Disruption During CNS AutoimmunityLoss of polarized expression of CXCL12 may also be the result of BMEC expression of the CXCL12 scavenger receptor CXCR7.", [["BBB", "ANATOMY", 33, 36], ["white matter lesions", "ANATOMY", 53, 73], ["hindbrain regions", "ANATOMY", 163, 180], ["CNS", "ANATOMY", 240, 243], ["BMEC", "ANATOMY", 321, 325], ["MS", "DISEASE", 14, 16], ["RRMS", "DISEASE", 96, 100], ["MS", "DISEASE", 200, 202], ["Patients", "ORGANISM", 0, 8], ["BBB", "GENE_OR_GENE_PRODUCT", 33, 36], ["white matter lesions", "CANCER", 53, 73], ["women", "ORGANISM", 85, 90], ["S1P2", "GENE_OR_GENE_PRODUCT", 140, 144], ["hindbrain", "ORGAN", 163, 172], ["patients", "ORGANISM", 203, 211], ["BBB", "MULTI-TISSUE_STRUCTURE", 218, 221], ["CXCL12", "GENE_OR_GENE_PRODUCT", 288, 294], ["BMEC", "CELL", 321, 325], ["CXCL12", "GENE_OR_GENE_PRODUCT", 344, 350], ["CXCR7", "GENE_OR_GENE_PRODUCT", 370, 375], ["S1P2", "PROTEIN", 140, 144], ["NVU", "PROTEIN", 152, 155], ["CXCL12", "PROTEIN", 288, 294], ["CXCL12 scavenger receptor", "PROTEIN", 344, 369], ["CXCR7", "PROTEIN", 370, 375], ["Patients", "SPECIES", 0, 8], ["women", "SPECIES", 85, 90], ["patients", "SPECIES", 203, 211], ["MS", "PROBLEM", 14, 16], ["loss of BBB polarity", "PROBLEM", 25, 45], ["white matter lesions", "PROBLEM", 53, 73], ["RRMS", "PROBLEM", 96, 100], ["significantly higher levels of S1P2", "PROBLEM", 109, 144], ["BBB Disruption", "PROBLEM", 218, 232], ["Disruption", "OBSERVATION", 222, 232]]], ["Studies in animal models of MS suggest that interleukin(IL)-17-secreting CD4 and \u03b3\u03b4 T cells may drive CNS autoimmunity, especially with regard to access to CNS parenchyma from perivascular spaces [66] . \u03b3\u03b4 T cells, which do not require antigen processing and major histocompatibility complex (MHC) presentation of peptide epitopes and instead may recognize lipid antigens, are also sources of IL-1 within the inflamed CNS [67, 68] .", [["CD4", "ANATOMY", 73, 76], ["\u03b3\u03b4 T cells", "ANATOMY", 81, 91], ["CNS", "ANATOMY", 102, 105], ["CNS parenchyma", "ANATOMY", 156, 170], ["perivascular spaces", "ANATOMY", 176, 195], ["\u03b3\u03b4 T cells", "ANATOMY", 203, 213], ["CNS", "ANATOMY", 418, 421], ["MS", "DISEASE", 28, 30], ["autoimmunity", "DISEASE", 106, 118], ["interleukin(IL)-17", "GENE_OR_GENE_PRODUCT", 44, 62], ["CD4", "GENE_OR_GENE_PRODUCT", 73, 76], ["\u03b3\u03b4 T cells", "CELL", 81, 91], ["CNS", "ANATOMICAL_SYSTEM", 102, 105], ["CNS parenchyma", "TISSUE", 156, 170], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 176, 188], ["\u03b3\u03b4 T cells", "CELL", 203, 213], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 259, 291], ["lipid antigens", "GENE_OR_GENE_PRODUCT", 357, 371], ["IL-1", "GENE_OR_GENE_PRODUCT", 393, 397], ["CNS", "ANATOMICAL_SYSTEM", 418, 421], ["interleukin(IL)-17", "PROTEIN", 44, 62], ["CD4 and \u03b3\u03b4 T cells", "CELL_TYPE", 73, 91], ["\u03b3\u03b4 T cells", "CELL_TYPE", 203, 213], ["major histocompatibility complex", "PROTEIN", 259, 291], ["MHC", "PROTEIN", 293, 296], ["peptide epitopes", "PROTEIN", 314, 330], ["lipid antigens", "PROTEIN", 357, 371], ["IL-1", "PROTEIN", 393, 397], ["Studies", "TEST", 0, 7], ["MS", "TEST", 28, 30], ["interleukin(IL)", "TEST", 44, 59], ["secreting CD4", "TEST", 63, 76], ["\u03b3\u03b4 T cells", "PROBLEM", 81, 91], ["CNS autoimmunity", "PROBLEM", 102, 118], ["antigen processing", "TREATMENT", 236, 254], ["peptide epitopes", "PROBLEM", 314, 330], ["lipid antigens", "PROBLEM", 357, 371], ["IL", "TEST", 393, 395], ["CNS", "ANATOMY", 156, 159], ["parenchyma", "ANATOMY_MODIFIER", 160, 170], ["perivascular", "ANATOMY_MODIFIER", 176, 188], ["inflamed CNS", "ANATOMY", 409, 421]]], ["CXCR7 reporter mice exhibit expression of the receptor along postcapillary venules, which is increased during induction of CNS autoimmune disease, leading to loss of abluminal expression of CXCL12 and increased CNS access of myelinspecific T cells [31] .", [["postcapillary venules", "ANATOMY", 61, 82], ["CNS", "ANATOMY", 123, 126], ["abluminal", "ANATOMY", 166, 175], ["CNS", "ANATOMY", 211, 214], ["myelinspecific T cells", "ANATOMY", 225, 247], ["autoimmune disease", "DISEASE", 127, 145], ["CXCR7", "GENE_OR_GENE_PRODUCT", 0, 5], ["mice", "ORGANISM", 15, 19], ["postcapillary venules", "MULTI-TISSUE_STRUCTURE", 61, 82], ["abluminal", "IMMATERIAL_ANATOMICAL_ENTITY", 166, 175], ["CXCL12", "GENE_OR_GENE_PRODUCT", 190, 196], ["myelinspecific T cells", "CELL", 225, 247], ["CXCR7", "PROTEIN", 0, 5], ["postcapillary venules", "CELL_TYPE", 61, 82], ["CXCL12", "PROTEIN", 190, 196], ["myelinspecific T cells", "CELL_TYPE", 225, 247], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["CXCR7 reporter", "TEST", 0, 14], ["the receptor along postcapillary venules", "PROBLEM", 42, 82], ["CNS autoimmune disease", "PROBLEM", 123, 145], ["abluminal expression of CXCL12", "PROBLEM", 166, 196], ["myelinspecific T cells", "PROBLEM", 225, 247], ["postcapillary venules", "ANATOMY", 61, 82], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["CNS", "ANATOMY", 123, 126], ["autoimmune disease", "OBSERVATION", 127, 145]]], ["In vivo targeting of CXCR7 in animal studies using small molecule inhibitors maintains polarized expression of CXCL12 and limits the egress of immune cells out of perivascular spaces during induction of EAE.", [["immune cells", "ANATOMY", 143, 155], ["perivascular spaces", "ANATOMY", 163, 182], ["EAE", "DISEASE", 203, 206], ["CXCR7", "GENE_OR_GENE_PRODUCT", 21, 26], ["CXCL12", "GENE_OR_GENE_PRODUCT", 111, 117], ["immune cells", "CELL", 143, 155], ["perivascular spaces", "IMMATERIAL_ANATOMICAL_ENTITY", 163, 182], ["CXCR7", "PROTEIN", 21, 26], ["CXCL12", "PROTEIN", 111, 117], ["immune cells", "CELL_TYPE", 143, 155], ["CXCR7", "TEST", 21, 26], ["animal studies", "TEST", 30, 44], ["small molecule inhibitors", "TREATMENT", 51, 76], ["CXCL12", "TEST", 111, 117], ["immune cells", "PROBLEM", 143, 155], ["immune cells", "OBSERVATION", 143, 155], ["perivascular", "ANATOMY", 163, 175]]], ["In vitro studies examining the regulation of CXCR7 expression on BMECs demonstrated that IL-17 and IL-1 increase the expression and activity of the receptor, respectively, consistent with in vivo studies demonstrating roles for these cytokines in driving neuropathology and the clinical effectiveness of therapies that target IL-17 or IL-1 in patients with autoimmune diseases [69] [70] [71] .", [["BMECs", "ANATOMY", 65, 70], ["autoimmune diseases", "DISEASE", 357, 376], ["CXCR7", "GENE_OR_GENE_PRODUCT", 45, 50], ["BMECs", "CELL", 65, 70], ["IL-17", "GENE_OR_GENE_PRODUCT", 89, 94], ["IL-1", "GENE_OR_GENE_PRODUCT", 99, 103], ["IL-17", "GENE_OR_GENE_PRODUCT", 326, 331], ["IL-1", "GENE_OR_GENE_PRODUCT", 335, 339], ["patients", "ORGANISM", 343, 351], ["CXCR7", "PROTEIN", 45, 50], ["BMECs", "CELL_TYPE", 65, 70], ["IL-17", "PROTEIN", 89, 94], ["IL-1", "PROTEIN", 99, 103], ["cytokines", "PROTEIN", 234, 243], ["IL-17", "PROTEIN", 326, 331], ["IL-1", "PROTEIN", 335, 339], ["patients", "SPECIES", 343, 351], ["vitro studies", "TEST", 3, 16], ["CXCR7 expression", "TEST", 45, 61], ["BMECs", "TEST", 65, 70], ["IL", "TEST", 89, 91], ["IL", "TREATMENT", 99, 101], ["these cytokines", "PROBLEM", 228, 243], ["therapies", "TREATMENT", 304, 313], ["target IL", "TEST", 319, 328], ["autoimmune diseases", "PROBLEM", 357, 376], ["consistent with", "UNCERTAINTY", 172, 187]]], ["Novel therapeutics targeting CXCR4 and/or CXCR7 are under development [72] and may prove beneficial for the treatment of MS.BBB Disruption During CNS AutoimmunityAlthough BBB disruption is clearly evident on gadolinium (gd)-MRI of MS patients, the notion that this is due to direct alterations in TJ protein expression has been controversial.", [["CNS", "ANATOMY", 146, 149], ["gadolinium", "CHEMICAL", 208, 218], ["MS", "DISEASE", 231, 233], ["gadolinium", "CHEMICAL", 208, 218], ["CXCR4", "GENE_OR_GENE_PRODUCT", 29, 34], ["CXCR7", "GENE_OR_GENE_PRODUCT", 42, 47], ["CNS", "ANATOMICAL_SYSTEM", 146, 149], ["BBB", "MULTI-TISSUE_STRUCTURE", 171, 174], ["gadolinium", "SIMPLE_CHEMICAL", 208, 218], ["patients", "ORGANISM", 234, 242], ["TJ", "GENE_OR_GENE_PRODUCT", 297, 299], ["CXCR4", "PROTEIN", 29, 34], ["CXCR7", "PROTEIN", 42, 47], ["TJ protein", "PROTEIN", 297, 307], ["patients", "SPECIES", 234, 242], ["CXCR4", "TEST", 29, 34], ["MS.BBB Disruption", "PROBLEM", 121, 138], ["BBB disruption", "PROBLEM", 171, 185], ["gadolinium", "TEST", 208, 218], ["MRI", "TEST", 224, 227], ["direct alterations in TJ protein expression", "PROBLEM", 275, 318], ["protein expression", "OBSERVATION", 300, 318]]], ["Early reports examining the levels of expression of claudin-5, a major component of CNS TJs, did not reveal differences in CNS specimens from patients with and without MS [73] .", [["CNS TJs", "ANATOMY", 84, 91], ["CNS specimens", "ANATOMY", 123, 136], ["MS", "DISEASE", 168, 170], ["claudin-5", "GENE_OR_GENE_PRODUCT", 52, 61], ["CNS TJs", "CELL", 84, 91], ["CNS specimens", "CANCER", 123, 136], ["patients", "ORGANISM", 142, 150], ["claudin-5", "PROTEIN", 52, 61], ["patients", "SPECIES", 142, 150], ["claudin", "TEST", 52, 59], ["CNS specimens", "TEST", 123, 136], ["CNS", "ANATOMY", 84, 87]]], ["More recently, claudin-11, which co-localizes with claudin-5 in CNS capillaries, was found to be significantly decreased in CNS tissue of MS patients and of mice with EAE [60] .", [["CNS capillaries", "ANATOMY", 64, 79], ["CNS tissue", "ANATOMY", 124, 134], ["MS", "DISEASE", 138, 140], ["EAE", "DISEASE", 167, 170], ["claudin-11", "GENE_OR_GENE_PRODUCT", 15, 25], ["claudin-5", "GENE_OR_GENE_PRODUCT", 51, 60], ["CNS capillaries", "TISSUE", 64, 79], ["CNS tissue", "TISSUE", 124, 134], ["patients", "ORGANISM", 141, 149], ["mice", "ORGANISM", 157, 161], ["claudin-11", "PROTEIN", 15, 25], ["claudin-5", "PROTEIN", 51, 60], ["patients", "SPECIES", 141, 149], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 157, 161], ["claudin", "TEST", 15, 22], ["CNS capillaries", "ANATOMY", 64, 79], ["significantly", "OBSERVATION_MODIFIER", 97, 110], ["decreased", "OBSERVATION", 111, 120], ["CNS tissue", "OBSERVATION_MODIFIER", 124, 134]]], ["Multiple studies, however, show leakage of serum proteins including fibrinogen, albumen, and IgG, into CNS parenchyma within MS lesions [74, 75] , which is consistent with the overall loss of BBB function.", [["serum", "ANATOMY", 43, 48], ["CNS parenchyma", "ANATOMY", 103, 117], ["MS lesions", "ANATOMY", 125, 135], ["BBB", "ANATOMY", 192, 195], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 68, 78], ["albumen", "GENE_OR_GENE_PRODUCT", 80, 87], ["IgG", "GENE_OR_GENE_PRODUCT", 93, 96], ["CNS parenchyma", "MULTI-TISSUE_STRUCTURE", 103, 117], ["MS lesions", "PATHOLOGICAL_FORMATION", 125, 135], ["BBB", "MULTI-TISSUE_STRUCTURE", 192, 195], ["serum proteins", "PROTEIN", 43, 57], ["fibrinogen", "PROTEIN", 68, 78], ["albumen", "PROTEIN", 80, 87], ["IgG", "PROTEIN", 93, 96], ["Multiple studies", "TEST", 0, 16], ["leakage of serum proteins", "PROBLEM", 32, 57], ["fibrinogen", "TEST", 68, 78], ["albumen", "TEST", 80, 87], ["IgG", "TEST", 93, 96], ["MS lesions", "PROBLEM", 125, 135], ["the overall loss of BBB function", "PROBLEM", 172, 204], ["leakage", "OBSERVATION", 32, 39], ["CNS", "ANATOMY", 103, 106], ["parenchyma", "ANATOMY_MODIFIER", 107, 117], ["consistent with", "UNCERTAINTY", 156, 171], ["loss", "OBSERVATION", 184, 188]]], ["Whether this extravasation is the result of loss of gate and/or fence function, the latter of which might include alterations in BMEC intracellular endocytic pathways, remains to be determined.BBB Disruption During Neuroinfectious DiseasesThe meningeal barriers, which cover the surface of the brain and spinal cord and are comprised of the dura, arachnoid, and pia maters, effectively limit the ability of a majority of bacterial, fungal, and viral pathogens to gain access to the CNS parenchyma.", [["intracellular", "ANATOMY", 134, 147], ["meningeal", "ANATOMY", 243, 252], ["surface", "ANATOMY", 279, 286], ["brain", "ANATOMY", 294, 299], ["spinal cord", "ANATOMY", 304, 315], ["dura", "ANATOMY", 341, 345], ["arachnoid", "ANATOMY", 347, 356], ["pia maters", "ANATOMY", 362, 372], ["CNS parenchyma", "ANATOMY", 482, 496], ["BMEC", "CELL", 129, 133], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 134, 147], ["BBB", "MULTI-TISSUE_STRUCTURE", 193, 196], ["surface", "CELLULAR_COMPONENT", 279, 286], ["brain", "ORGAN", 294, 299], ["spinal cord", "ORGAN", 304, 315], ["dura", "TISSUE", 341, 345], ["arachnoid", "MULTI-TISSUE_STRUCTURE", 347, 356], ["pia maters", "MULTI-TISSUE_STRUCTURE", 362, 372], ["CNS parenchyma", "MULTI-TISSUE_STRUCTURE", 482, 496], ["this extravasation", "PROBLEM", 8, 26], ["loss of gate and/or fence function", "PROBLEM", 44, 78], ["alterations in BMEC intracellular endocytic pathways", "PROBLEM", 114, 166], ["BBB Disruption", "PROBLEM", 193, 207], ["Neuroinfectious Diseases", "PROBLEM", 215, 239], ["The meningeal barriers", "PROBLEM", 239, 261], ["bacterial, fungal, and viral pathogens", "PROBLEM", 421, 459], ["extravasation", "OBSERVATION", 13, 26], ["Disruption", "OBSERVATION", 197, 207], ["meningeal", "ANATOMY", 243, 252], ["surface", "ANATOMY_MODIFIER", 279, 286], ["brain", "ANATOMY", 294, 299], ["spinal cord", "ANATOMY", 304, 315], ["dura", "ANATOMY", 341, 345], ["arachnoid", "ANATOMY", 347, 356], ["CNS", "ANATOMY", 482, 485], ["parenchyma", "ANATOMY_MODIFIER", 486, 496]]], ["Thus, only neurotropic viruses, molds, and certain parasites are able to cross the BBB and infect CNS parenchyma.", [["BBB", "ANATOMY", 83, 86], ["CNS parenchyma", "ANATOMY", 98, 112], ["neurotropic viruses", "ORGANISM", 11, 30], ["BBB", "MULTI-TISSUE_STRUCTURE", 83, 86], ["CNS parenchyma", "MULTI-TISSUE_STRUCTURE", 98, 112], ["neurotropic viruses, molds, and certain parasites", "PROBLEM", 11, 60], ["neurotropic viruses", "OBSERVATION", 11, 30], ["infect", "OBSERVATION", 91, 97]]], ["Certain bacteria that gain access to the subarachnoid space within the meninges may also enter perivascular spaces of postcapillary venule, leading to BBB disruption and parenchymal infection.", [["subarachnoid space", "ANATOMY", 41, 59], ["meninges", "ANATOMY", 71, 79], ["perivascular spaces", "ANATOMY", 95, 114], ["postcapillary venule", "ANATOMY", 118, 138], ["BBB", "ANATOMY", 151, 154], ["parenchymal", "ANATOMY", 170, 181], ["parenchymal infection", "DISEASE", 170, 191], ["subarachnoid space", "MULTI-TISSUE_STRUCTURE", 41, 59], ["meninges", "ORGAN", 71, 79], ["perivascular spaces", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 114], ["postcapillary venule", "TISSUE", 118, 138], ["BBB", "MULTI-TISSUE_STRUCTURE", 151, 154], ["parenchymal", "MULTI-TISSUE_STRUCTURE", 170, 181], ["Certain bacteria", "PROBLEM", 0, 16], ["postcapillary venule", "PROBLEM", 118, 138], ["BBB disruption", "PROBLEM", 151, 165], ["parenchymal infection", "PROBLEM", 170, 191], ["bacteria", "OBSERVATION", 8, 16], ["subarachnoid space", "ANATOMY", 41, 59], ["meninges", "ANATOMY", 71, 79], ["perivascular", "ANATOMY_MODIFIER", 95, 107], ["postcapillary venule", "OBSERVATION", 118, 138], ["BBB", "ANATOMY", 151, 154], ["disruption", "OBSERVATION", 155, 165], ["parenchymal", "ANATOMY_MODIFIER", 170, 181], ["infection", "OBSERVATION", 182, 191]]], ["However, this extent of infection occurs late in the course of bacterial meningitis and is generally associated with severe and fatal outcomes.", [["infection", "DISEASE", 24, 33], ["bacterial meningitis", "DISEASE", 63, 83], ["infection", "PROBLEM", 24, 33], ["bacterial meningitis", "PROBLEM", 63, 83], ["severe and fatal outcomes", "PROBLEM", 117, 142], ["extent", "OBSERVATION_MODIFIER", 14, 20], ["infection", "OBSERVATION", 24, 33], ["late", "OBSERVATION_MODIFIER", 41, 45], ["bacterial", "OBSERVATION_MODIFIER", 63, 72], ["meningitis", "OBSERVATION", 73, 83], ["generally associated with", "UNCERTAINTY", 91, 116], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["fatal", "OBSERVATION_MODIFIER", 128, 133], ["outcomes", "OBSERVATION", 134, 142]]], ["Here, we will delineate mechanisms of BBB disruption during neuroinfectious diseases, focusing on pathogens that infect immunocompetent hosts ( Table 1) .Induction of BBB Disruption and Parenchymal Invasion by BacteriaA variety of Gram-positive and Gram-negative bacteria display a predilection for CNS invasion, predominantly spread hematogenously within the subarachnoid space into the CSF.", [["BBB", "ANATOMY", 38, 41], ["BBB", "ANATOMY", 167, 170], ["Parenchymal", "ANATOMY", 186, 197], ["CNS", "ANATOMY", 299, 302], ["subarachnoid space", "ANATOMY", 360, 378], ["neuroinfectious diseases", "DISEASE", 60, 84], ["BBB", "MULTI-TISSUE_STRUCTURE", 38, 41], ["BBB", "MULTI-TISSUE_STRUCTURE", 167, 170], ["Gram-positive", "GENE_OR_GENE_PRODUCT", 231, 244], ["Gram", "GENE_OR_GENE_PRODUCT", 249, 253], ["CNS", "ANATOMICAL_SYSTEM", 299, 302], ["CSF", "GENE_OR_GENE_PRODUCT", 388, 391], ["BBB disruption", "PROBLEM", 38, 52], ["neuroinfectious diseases", "PROBLEM", 60, 84], ["pathogens", "PROBLEM", 98, 107], ["BBB Disruption", "PROBLEM", 167, 181], ["Parenchymal Invasion", "PROBLEM", 186, 206], ["BacteriaA variety", "TEST", 210, 227], ["Gram-positive and Gram-negative bacteria", "PROBLEM", 231, 271], ["a predilection", "PROBLEM", 280, 294], ["CNS invasion", "PROBLEM", 299, 311], ["BBB", "ANATOMY", 167, 170], ["Disruption", "OBSERVATION", 171, 181], ["Parenchymal", "ANATOMY_MODIFIER", 186, 197], ["Invasion", "OBSERVATION", 198, 206], ["negative bacteria", "OBSERVATION_MODIFIER", 254, 271], ["CNS", "ANATOMY", 299, 302], ["invasion", "OBSERVATION", 303, 311], ["predominantly", "OBSERVATION_MODIFIER", 313, 326], ["spread", "OBSERVATION_MODIFIER", 327, 333], ["subarachnoid space", "ANATOMY", 360, 378], ["CSF", "ANATOMY", 388, 391]]], ["Most bacterial infections lead to robust inflammatory responses leading to extensive neutrophilic infiltrates throughout the meninges and, if untreated, result in vasogenic edema, disruption of the BBB, coma, and death [76] .", [["neutrophilic infiltrates", "ANATOMY", 85, 109], ["meninges", "ANATOMY", 125, 133], ["vasogenic edema", "ANATOMY", 163, 178], ["BBB", "ANATOMY", 198, 201], ["bacterial infections", "DISEASE", 5, 25], ["edema", "DISEASE", 173, 178], ["disruption of the BBB", "DISEASE", 180, 201], ["coma", "DISEASE", 203, 207], ["death", "DISEASE", 213, 218], ["neutrophilic infiltrates", "PATHOLOGICAL_FORMATION", 85, 109], ["meninges", "ORGAN", 125, 133], ["vasogenic edema", "PATHOLOGICAL_FORMATION", 163, 178], ["BBB", "MULTI-TISSUE_STRUCTURE", 198, 201], ["Most bacterial infections", "PROBLEM", 0, 25], ["robust inflammatory responses", "PROBLEM", 34, 63], ["extensive neutrophilic infiltrates throughout the meninges", "PROBLEM", 75, 133], ["vasogenic edema", "PROBLEM", 163, 178], ["disruption of the BBB", "PROBLEM", 180, 201], ["coma", "PROBLEM", 203, 207], ["infections", "OBSERVATION", 15, 25], ["robust", "OBSERVATION_MODIFIER", 34, 40], ["inflammatory", "OBSERVATION", 41, 53], ["extensive", "OBSERVATION_MODIFIER", 75, 84], ["neutrophilic", "OBSERVATION_MODIFIER", 85, 97], ["infiltrates", "OBSERVATION", 98, 109], ["meninges", "ANATOMY", 125, 133], ["vasogenic", "OBSERVATION_MODIFIER", 163, 172], ["edema", "OBSERVATION", 173, 178], ["BBB", "ANATOMY", 198, 201]]], ["Although bacterial infections within the CNS generally cause meningitis and are limited to the CSF compartment, host inflammatory responses and, in some cases, bacterial products may lead to BBB disruption with bacterial invasion of the CNS parenchyma.", [["CNS", "ANATOMY", 41, 44], ["CSF compartment", "ANATOMY", 95, 110], ["BBB", "ANATOMY", 191, 194], ["CNS parenchyma", "ANATOMY", 237, 251], ["bacterial infections", "DISEASE", 9, 29], ["meningitis", "DISEASE", 61, 71], ["CNS", "ANATOMICAL_SYSTEM", 41, 44], ["CSF compartment", "MULTI-TISSUE_STRUCTURE", 95, 110], ["BBB", "MULTI-TISSUE_STRUCTURE", 191, 194], ["CNS parenchyma", "MULTI-TISSUE_STRUCTURE", 237, 251], ["bacterial infections", "PROBLEM", 9, 29], ["meningitis", "PROBLEM", 61, 71], ["the CSF compartment", "TEST", 91, 110], ["host inflammatory responses", "PROBLEM", 112, 139], ["bacterial products", "PROBLEM", 160, 178], ["BBB disruption", "PROBLEM", 191, 205], ["bacterial invasion of the CNS parenchyma", "PROBLEM", 211, 251], ["bacterial", "OBSERVATION_MODIFIER", 9, 18], ["infections", "OBSERVATION", 19, 29], ["CNS", "ANATOMY", 41, 44], ["meningitis", "OBSERVATION", 61, 71], ["inflammatory", "OBSERVATION_MODIFIER", 117, 129], ["bacterial products", "OBSERVATION", 160, 178], ["may lead to", "UNCERTAINTY", 179, 190], ["bacterial", "OBSERVATION_MODIFIER", 211, 220], ["invasion", "OBSERVATION", 221, 229], ["CNS", "ANATOMY", 237, 240], ["parenchyma", "ANATOMY_MODIFIER", 241, 251]]], ["With few exceptions, most bacteria are unable to invade neural cells, leading instead to their encapsulation by glial elements and abscess formation [77] .Induction of BBB Disruption and Parenchymal Invasion by BacteriaHere, we will discuss the specific mechanisms by which bacteria interact with subarachnoid vasculature and the molecular events that may lead to parenchymal invasion.", [["neural cells", "ANATOMY", 56, 68], ["glial elements", "ANATOMY", 112, 126], ["abscess", "ANATOMY", 131, 138], ["BBB", "ANATOMY", 168, 171], ["Parenchymal", "ANATOMY", 187, 198], ["subarachnoid vasculature", "ANATOMY", 297, 321], ["parenchymal", "ANATOMY", 364, 375], ["abscess", "DISEASE", 131, 138], ["neural cells", "CELL", 56, 68], ["glial elements", "TISSUE", 112, 126], ["abscess", "PATHOLOGICAL_FORMATION", 131, 138], ["BBB", "MULTI-TISSUE_STRUCTURE", 168, 171], ["subarachnoid vasculature", "MULTI-TISSUE_STRUCTURE", 297, 321], ["parenchymal", "TISSUE", 364, 375], ["neural cells", "CELL_TYPE", 56, 68], ["most bacteria", "PROBLEM", 21, 34], ["abscess formation", "PROBLEM", 131, 148], ["BBB Disruption", "PROBLEM", 168, 182], ["Parenchymal Invasion", "PROBLEM", 187, 207], ["subarachnoid vasculature", "PROBLEM", 297, 321], ["the molecular events", "PROBLEM", 326, 346], ["parenchymal invasion", "PROBLEM", 364, 384], ["neural cells", "OBSERVATION", 56, 68], ["glial elements", "OBSERVATION", 112, 126], ["abscess", "OBSERVATION", 131, 138], ["BBB", "ANATOMY", 168, 171], ["Disruption", "OBSERVATION", 172, 182], ["Parenchymal", "ANATOMY_MODIFIER", 187, 198], ["Invasion", "OBSERVATION", 199, 207], ["subarachnoid", "ANATOMY_MODIFIER", 297, 309], ["vasculature", "ANATOMY", 310, 321], ["may lead to", "UNCERTAINTY", 352, 363], ["parenchymal", "ANATOMY_MODIFIER", 364, 375], ["invasion", "OBSERVATION", 376, 384]]], ["TBEV (Flavivirus) Virus-induced cytokine/chemokine overproduction in the brain [172] HIV-1 (Retrovirus) Inducing lesion in brain ECs and activation of MMPs by gp120 Release of s-CD40L by Tat-induced platelet activation [135, 136, 245] HeV and NiV (Henipavirus) Syncytium formation in brain ECs.", [["brain", "ANATOMY", 73, 78], ["lesion", "ANATOMY", 113, 119], ["brain ECs", "ANATOMY", 123, 132], ["platelet", "ANATOMY", 199, 207], ["brain ECs", "ANATOMY", 284, 293], ["TBEV", "DISEASE", 0, 4], ["TBEV", "ORGANISM", 0, 4], ["Flavivirus) Virus", "ORGANISM", 6, 23], ["brain", "ORGAN", 73, 78], ["HIV-1", "ORGANISM", 85, 90], ["Retrovirus", "ORGANISM", 92, 102], ["brain ECs", "CELL", 123, 132], ["MMPs", "GENE_OR_GENE_PRODUCT", 151, 155], ["gp120", "GENE_OR_GENE_PRODUCT", 159, 164], ["CD40L", "GENE_OR_GENE_PRODUCT", 178, 183], ["Tat", "GENE_OR_GENE_PRODUCT", 187, 190], ["platelet", "CELL", 199, 207], ["HeV", "ORGANISM", 235, 238], ["NiV", "ORGANISM", 243, 246], ["brain ECs", "CELL", 284, 293], ["cytokine", "PROTEIN", 32, 40], ["chemokine", "PROTEIN", 41, 50], ["brain ECs", "CELL_TYPE", 123, 132], ["MMPs", "PROTEIN", 151, 155], ["gp120", "PROTEIN", 159, 164], ["CD40L", "PROTEIN", 178, 183], ["Tat", "PROTEIN", 187, 190], ["brain ECs", "CELL_TYPE", 284, 293], ["HIV-1", "SPECIES", 85, 90], ["TBEV", "SPECIES", 0, 4], ["HIV-1", "SPECIES", 85, 90], ["NiV", "SPECIES", 243, 246], ["TBEV (Flavivirus) Virus", "TEST", 0, 23], ["cytokine/chemokine overproduction in the brain", "PROBLEM", 32, 78], ["HIV", "TEST", 85, 88], ["Inducing lesion in brain ECs", "PROBLEM", 104, 132], ["MMPs", "TEST", 151, 155], ["gp120 Release", "TEST", 159, 172], ["s", "TEST", 176, 177], ["Tat", "TEST", 187, 190], ["platelet activation", "TEST", 199, 218], ["HeV", "TREATMENT", 235, 238], ["NiV (Henipavirus) Syncytium formation", "TREATMENT", 243, 280], ["brain", "ANATOMY", 73, 78], ["lesion", "OBSERVATION", 113, 119], ["brain", "ANATOMY", 123, 128], ["brain", "ANATOMY", 284, 289]]], ["Induction of inflammatory cytokines in the brain and peripheral tissues [129] [130] [131] VEEV (Alphavirus) Increased expression of MMP9 Monocytes infiltration and release of inflammatory cytokines [102, 105] RABV (Lyssavirus) Downregulation of TJs mediated by IFN-\u03b3 from infiltrating CD4 T cells [182] MHV3 (Coronavirus) Reduced expression of TJ and AJ proteins due to impaired production of IFN-\u03b2 by infected BMECs [111] LCMV (Arenavirus) CTL-mediated recruitment of neutrophils and monocytes into the CNS leads to vascular damage [181] Influenza A virus (Orthomyxovirus)Induction of BBB Disruption and Parenchymal Invasion by BacteriaDisruption of tight junction protein ZO-1, likely by virus-induced inflammatory cytokines [246, 247] TMEV (Cardiovirus) Degradation of TJs by perforin secreted from CD8 T cells [184] HSV-1 (Simplexvirus) Virus-induced upregulation of MMP9 [248] (continued)Induction of BBB Disruption and Parenchymal Invasion by BacteriaDisruption of the Blood-Brain Barrier During Neuroinflammatory and Neuroinfectious\u2026Induction of BBB Disruption and Parenchymal Invasion by BacteriaStreptococcus pneumoniae (aka Pneumococcus)Induction of BBB Disruption and Parenchymal Invasion by BacteriaS. pneumoniae are Gram-positive, facultative anaerobic bacteria that reside in the respiratory tract.", [["brain", "ANATOMY", 43, 48], ["peripheral tissues", "ANATOMY", 53, 71], ["Monocytes", "ANATOMY", 137, 146], ["TJs", "ANATOMY", 245, 248], ["infiltrating CD4 T cells", "ANATOMY", 272, 296], ["TJ", "ANATOMY", 344, 346], ["BMECs", "ANATOMY", 411, 416], ["neutrophils", "ANATOMY", 469, 480], ["monocytes", "ANATOMY", 485, 494], ["CNS", "ANATOMY", 504, 507], ["vascular", "ANATOMY", 517, 525], ["BBB", "ANATOMY", 586, 589], ["Parenchymal", "ANATOMY", 605, 616], ["tight junction", "ANATOMY", 651, 665], ["TJs", "ANATOMY", 772, 775], ["CD8 T cells", "ANATOMY", 802, 813], ["BBB", "ANATOMY", 906, 909], ["Parenchymal", "ANATOMY", 925, 936], ["BBB", "ANATOMY", 1053, 1056], ["Parenchymal", "ANATOMY", 1072, 1083], ["Parenchymal", "ANATOMY", 1179, 1190], ["respiratory tract", "ANATOMY", 1294, 1311], ["vascular damage", "DISEASE", 517, 532], ["brain", "ORGAN", 43, 48], ["peripheral tissues", "TISSUE", 53, 71], ["MMP9", "GENE_OR_GENE_PRODUCT", 132, 136], ["RABV", "ORGANISM", 209, 213], ["TJs", "CELL", 245, 248], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 261, 266], ["TJ", "GENE_OR_GENE_PRODUCT", 344, 346], ["AJ", "GENE_OR_GENE_PRODUCT", 351, 353], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 393, 398], ["BMECs [111] LCMV", "ORGANISM", 411, 427], ["Arenavirus", "ORGANISM", 429, 439], ["CTL", "CELL", 441, 444], ["neutrophils", "CELL", 469, 480], ["monocytes", "CELL", 485, 494], ["CNS", "ANATOMICAL_SYSTEM", 504, 507], ["vascular", "MULTI-TISSUE_STRUCTURE", 517, 525], ["Influenza A virus", "ORGANISM", 539, 556], ["BBB", "MULTI-TISSUE_STRUCTURE", 586, 589], ["ZO-1", "GENE_OR_GENE_PRODUCT", 674, 678], ["TMEV", "ORGANISM", 738, 742], ["TJs", "GENE_OR_GENE_PRODUCT", 772, 775], ["perforin", "GENE_OR_GENE_PRODUCT", 779, 787], ["CD8", "GENE_OR_GENE_PRODUCT", 802, 805], ["HSV-1", "ORGANISM", 820, 825], ["Simplexvirus) Virus", "ORGANISM", 827, 846], ["MMP9", "GENE_OR_GENE_PRODUCT", 871, 875], ["BBB", "MULTI-TISSUE_STRUCTURE", 906, 909], ["BBB", "MULTI-TISSUE_STRUCTURE", 1053, 1056], ["Parenchymal", "TISSUE", 1072, 1083], ["BacteriaStreptococcus pneumoniae", "ORGANISM", 1096, 1128], ["BBB", "MULTI-TISSUE_STRUCTURE", 1160, 1163], ["pneumoniae", "ORGANISM", 1214, 1224], ["Gram-", "GENE_OR_GENE_PRODUCT", 1229, 1234], ["respiratory tract", "ORGANISM_SUBDIVISION", 1294, 1311], ["inflammatory cytokines", "PROTEIN", 13, 35], ["MMP9", "PROTEIN", 132, 136], ["inflammatory cytokines", "PROTEIN", 175, 197], ["IFN-\u03b3", "PROTEIN", 261, 266], ["infiltrating CD4 T cells", "CELL_TYPE", 272, 296], ["TJ", "PROTEIN", 344, 346], ["AJ proteins", "PROTEIN", 351, 362], ["IFN", "PROTEIN", 393, 396], ["\u03b2", "PROTEIN", 397, 398], ["neutrophils", "CELL_TYPE", 469, 480], ["monocytes", "CELL_TYPE", 485, 494], ["tight junction protein", "PROTEIN", 651, 673], ["ZO-1", "PROTEIN", 674, 678], ["inflammatory cytokines", "PROTEIN", 704, 726], ["TJs", "PROTEIN", 772, 775], ["perforin", "PROTEIN", 779, 787], ["CD8 T cells", "CELL_TYPE", 802, 813], ["MMP9", "PROTEIN", 871, 875], ["Influenza A virus", "SPECIES", 539, 556], ["HSV-1", "SPECIES", 820, 825], ["BacteriaStreptococcus pneumoniae", "SPECIES", 1096, 1128], ["pneumoniae", "SPECIES", 1214, 1224], ["VEEV", "SPECIES", 90, 94], ["RABV", "SPECIES", 209, 213], ["Influenza A virus", "SPECIES", 539, 556], ["TMEV", "SPECIES", 738, 742], ["HSV-1", "SPECIES", 820, 825], ["BacteriaStreptococcus pneumoniae", "SPECIES", 1096, 1128], ["pneumoniae", "SPECIES", 1214, 1224], ["inflammatory cytokines in the brain", "PROBLEM", 13, 48], ["VEEV (Alphavirus", "TEST", 90, 106], ["MMP9 Monocytes infiltration", "PROBLEM", 132, 159], ["inflammatory cytokines", "TEST", 175, 197], ["RABV (Lyssavirus", "TEST", 209, 225], ["IFN", "TEST", 261, 264], ["infiltrating CD4 T cells", "PROBLEM", 272, 296], ["MHV3", "TEST", 303, 307], ["Coronavirus", "PROBLEM", 309, 320], ["Reduced expression of TJ and AJ proteins", "PROBLEM", 322, 362], ["impaired production", "PROBLEM", 370, 389], ["IFN", "TEST", 393, 396], ["infected BMECs", "PROBLEM", 402, 416], ["LCMV (Arenavirus", "TEST", 423, 439], ["CTL", "TEST", 441, 444], ["neutrophils", "TEST", 469, 480], ["monocytes", "TEST", 485, 494], ["vascular damage", "TEST", 517, 532], ["Influenza A virus (Orthomyxovirus)", "TREATMENT", 539, 573], ["BBB Disruption", "PROBLEM", 586, 600], ["Parenchymal Invasion", "PROBLEM", 605, 625], ["BacteriaDisruption", "TEST", 629, 647], ["tight junction protein ZO", "TEST", 651, 676], ["inflammatory cytokines", "PROBLEM", 704, 726], ["TMEV", "TEST", 738, 742], ["Cardiovirus", "TEST", 744, 755], ["CD8 T cells", "TEST", 802, 813], ["HSV", "TEST", 820, 823], ["Simplexvirus", "TEST", 827, 839], ["Virus", "TEST", 841, 846], ["MMP9", "TEST", 871, 875], ["BBB Disruption", "PROBLEM", 906, 920], ["Parenchymal Invasion", "PROBLEM", 925, 945], ["the Blood", "TEST", 971, 980], ["BBB Disruption", "PROBLEM", 1053, 1067], ["Parenchymal Invasion", "PROBLEM", 1072, 1092], ["BacteriaStreptococcus pneumoniae", "PROBLEM", 1096, 1128], ["aka Pneumococcus)", "TREATMENT", 1130, 1147], ["BBB Disruption", "PROBLEM", 1160, 1174], ["Parenchymal Invasion", "PROBLEM", 1179, 1199], ["BacteriaS", "PROBLEM", 1203, 1212], ["pneumoniae", "PROBLEM", 1214, 1224], ["Gram-positive", "PROBLEM", 1229, 1242], ["facultative anaerobic bacteria", "PROBLEM", 1244, 1274], ["inflammatory", "OBSERVATION_MODIFIER", 13, 25], ["cytokines", "OBSERVATION", 26, 35], ["brain", "ANATOMY", 43, 48], ["peripheral", "ANATOMY_MODIFIER", 53, 63], ["tissues", "ANATOMY", 64, 71], ["inflammatory", "OBSERVATION_MODIFIER", 175, 187], ["CNS", "ANATOMY", 504, 507], ["vascular", "ANATOMY", 517, 525], ["Parenchymal", "ANATOMY_MODIFIER", 605, 616], ["Invasion", "OBSERVATION", 617, 625], ["inflammatory", "OBSERVATION_MODIFIER", 704, 716], ["Parenchymal", "ANATOMY_MODIFIER", 925, 936], ["Invasion", "OBSERVATION", 937, 945], ["Brain", "ANATOMY", 981, 986], ["BBB", "ANATOMY", 1053, 1056], ["Disruption", "OBSERVATION", 1057, 1067], ["Parenchymal", "ANATOMY_MODIFIER", 1072, 1083], ["Invasion", "OBSERVATION", 1084, 1092], ["BacteriaStreptococcus pneumoniae", "OBSERVATION", 1096, 1128], ["Parenchymal", "ANATOMY_MODIFIER", 1179, 1190], ["Invasion", "OBSERVATION", 1191, 1199], ["facultative", "OBSERVATION_MODIFIER", 1244, 1255], ["anaerobic bacteria", "OBSERVATION", 1256, 1274], ["respiratory tract", "ANATOMY", 1294, 1311]]], ["There are over 90 serotypes of S. pneumoniae that differ in virulence and susceptibility to antimicrobials.", [["S. pneumoniae", "ORGANISM", 31, 44], ["S. pneumoniae", "SPECIES", 31, 44], ["S. pneumoniae", "SPECIES", 31, 44], ["S. pneumoniae", "PROBLEM", 31, 44], ["antimicrobials", "TREATMENT", 92, 106], ["pneumoniae", "OBSERVATION", 34, 44]]], ["Pneumococcal infections generally originate in the nasal cavities but, in young children and the elderly, may become invasive, with hematogenous spread to multiple organs including the CNS.", [["nasal cavities", "ANATOMY", 51, 65], ["organs", "ANATOMY", 164, 170], ["CNS", "ANATOMY", 185, 188], ["Pneumococcal infections", "DISEASE", 0, 23], ["nasal cavities", "MULTI-TISSUE_STRUCTURE", 51, 65], ["children", "ORGANISM", 80, 88], ["organs", "ORGAN", 164, 170], ["CNS", "ANATOMICAL_SYSTEM", 185, 188], ["children", "SPECIES", 80, 88], ["Pneumococcal infections", "PROBLEM", 0, 23], ["hematogenous spread", "PROBLEM", 132, 151], ["infections", "OBSERVATION", 13, 23], ["nasal cavities", "ANATOMY", 51, 65], ["invasive", "OBSERVATION", 117, 125], ["hematogenous", "OBSERVATION", 132, 144], ["CNS", "ANATOMY", 185, 188]]], ["Within the subarachnoid space, S. pneumoniae may adhere to fenestrated endothelium via a number of interactions between bacterial and host proteins.", [["subarachnoid space", "ANATOMY", 11, 29], ["endothelium", "ANATOMY", 71, 82], ["S. pneumoniae", "ORGANISM", 31, 44], ["endothelium", "TISSUE", 71, 82], ["bacterial and host proteins", "PROTEIN", 120, 147], ["S. pneumoniae", "SPECIES", 31, 44], ["S. pneumoniae", "SPECIES", 31, 44], ["S. pneumoniae", "PROBLEM", 31, 44], ["fenestrated endothelium", "PROBLEM", 59, 82], ["bacterial and host proteins", "PROBLEM", 120, 147], ["subarachnoid space", "ANATOMY", 11, 29], ["pneumoniae", "OBSERVATION", 34, 44], ["fenestrated endothelium", "OBSERVATION", 59, 82]]], ["Thus, the major adhesion protein of S. pneumoniae pilus-1, RrgA, binds both polymeric immunoglobulin receptor (pIgR) and platelet-associated cell adhesion molecule (PECAM)-1 on endothelial cells, while the bacterial choline-binding protein (PspC) binds only pIgR [78] .", [["endothelial cells", "ANATOMY", 177, 194], ["choline", "CHEMICAL", 216, 223], ["choline", "CHEMICAL", 216, 223], ["S. pneumoniae pilus-1", "GENE_OR_GENE_PRODUCT", 36, 57], ["RrgA", "GENE_OR_GENE_PRODUCT", 59, 63], ["polymeric immunoglobulin receptor", "GENE_OR_GENE_PRODUCT", 76, 109], ["pIgR", "GENE_OR_GENE_PRODUCT", 111, 115], ["platelet-associated cell adhesion molecule (PECAM)-1", "GENE_OR_GENE_PRODUCT", 121, 173], ["endothelial cells", "CELL", 177, 194], ["choline-binding protein", "GENE_OR_GENE_PRODUCT", 216, 239], ["PspC", "GENE_OR_GENE_PRODUCT", 241, 245], ["pIgR", "GENE_OR_GENE_PRODUCT", 258, 262], ["major adhesion protein", "PROTEIN", 10, 32], ["S. pneumoniae pilus-1", "PROTEIN", 36, 57], ["RrgA", "PROTEIN", 59, 63], ["polymeric immunoglobulin receptor", "PROTEIN", 76, 109], ["pIgR", "PROTEIN", 111, 115], ["platelet-associated cell adhesion molecule (PECAM)-1", "PROTEIN", 121, 173], ["endothelial cells", "CELL_TYPE", 177, 194], ["bacterial choline-binding protein", "PROTEIN", 206, 239], ["PspC", "PROTEIN", 241, 245], ["pIgR", "PROTEIN", 258, 262], ["S. pneumoniae pilus", "SPECIES", 36, 55], ["S. pneumoniae", "SPECIES", 36, 49], ["S. pneumoniae pilus", "TEST", 36, 55], ["polymeric immunoglobulin receptor", "TEST", 76, 109], ["platelet", "TEST", 121, 129], ["associated cell adhesion molecule", "PROBLEM", 130, 163], ["PECAM)", "TEST", 165, 171], ["endothelial cells", "TEST", 177, 194], ["the bacterial choline", "TEST", 202, 223], ["pneumoniae", "OBSERVATION", 39, 49], ["cell adhesion", "OBSERVATION", 141, 154]]], ["These interactions trigger Toll-like receptor-mediated expression of inflammatory mediators by meningeal endothelial cells including interleukins (IL)-1, -6, -10, tumor necrosis factors (TNF), and cytokine-induced neutrophil chemoattractant (CINC)-1 [79, 80] .", [["meningeal endothelial cells", "ANATOMY", 95, 122], ["tumor necrosis", "DISEASE", 163, 177], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 27, 45], ["meningeal endothelial cells", "CELL", 95, 122], ["interleukins (IL)-1", "GENE_OR_GENE_PRODUCT", 133, 152], ["-6", "GENE_OR_GENE_PRODUCT", 154, 156], ["-10", "GENE_OR_GENE_PRODUCT", 158, 161], ["tumor necrosis factors", "GENE_OR_GENE_PRODUCT", 163, 185], ["TNF", "GENE_OR_GENE_PRODUCT", 187, 190], ["neutrophil", "CELL", 214, 224], ["CINC)-1", "GENE_OR_GENE_PRODUCT", 242, 249], ["Toll-like receptor", "PROTEIN", 27, 45], ["inflammatory mediators", "PROTEIN", 69, 91], ["meningeal endothelial cells", "CELL_TYPE", 95, 122], ["interleukins (IL)-1, -6, -10", "PROTEIN", 133, 161], ["tumor necrosis factors", "PROTEIN", 163, 185], ["TNF", "PROTEIN", 187, 190], ["cytokine", "PROTEIN", 197, 205], ["neutrophil chemoattractant", "PROTEIN", 214, 240], ["CINC", "PROTEIN", 242, 246], ["inflammatory mediators", "PROBLEM", 69, 91], ["meningeal endothelial cells", "PROBLEM", 95, 122], ["interleukins (IL)", "TEST", 133, 150], ["tumor necrosis factors", "PROBLEM", 163, 185], ["TNF", "TEST", 187, 190], ["cytokine", "TEST", 197, 205], ["neutrophil chemoattractant", "TEST", 214, 240], ["CINC)", "TEST", 242, 247], ["inflammatory", "OBSERVATION", 69, 81], ["meningeal endothelial", "ANATOMY", 95, 116], ["tumor", "OBSERVATION_MODIFIER", 163, 168], ["necrosis", "OBSERVATION", 169, 177]]], ["The recruitment of neutrophils and lymphocytes heralds the onset of meningitis symptoms, including fever, photophobia, and meningismus [81] .", [["neutrophils", "ANATOMY", 19, 30], ["lymphocytes", "ANATOMY", 35, 46], ["meningitis", "DISEASE", 68, 78], ["fever", "DISEASE", 99, 104], ["photophobia", "DISEASE", 106, 117], ["meningismus", "DISEASE", 123, 134], ["neutrophils", "CELL", 19, 30], ["lymphocytes", "CELL", 35, 46], ["neutrophils", "CELL_TYPE", 19, 30], ["lymphocytes", "CELL_TYPE", 35, 46], ["neutrophils", "TEST", 19, 30], ["lymphocytes", "PROBLEM", 35, 46], ["meningitis symptoms", "PROBLEM", 68, 87], ["fever", "PROBLEM", 99, 104], ["photophobia", "PROBLEM", 106, 117], ["meningismus", "PROBLEM", 123, 134], ["recruitment", "OBSERVATION_MODIFIER", 4, 15], ["neutrophils", "ANATOMY", 19, 30], ["meningitis", "OBSERVATION", 68, 78]]], ["Untreated, inflammatory infiltrates may gain access to the CNS parenchyma via migration along venules from the meningeal compartment.", [["CNS parenchyma", "ANATOMY", 59, 73], ["venules", "ANATOMY", 94, 101], ["meningeal compartment", "ANATOMY", 111, 132], ["CNS parenchyma", "MULTI-TISSUE_STRUCTURE", 59, 73], ["venules", "MULTI-TISSUE_STRUCTURE", 94, 101], ["meningeal compartment", "MULTI-TISSUE_STRUCTURE", 111, 132], ["inflammatory infiltrates", "PROBLEM", 11, 35], ["inflammatory", "OBSERVATION_MODIFIER", 11, 23], ["infiltrates", "OBSERVATION", 24, 35], ["CNS", "ANATOMY", 59, 62], ["parenchyma", "ANATOMY_MODIFIER", 63, 73], ["migration", "OBSERVATION", 78, 87], ["venules", "ANATOMY", 94, 101], ["meningeal compartment", "ANATOMY", 111, 132]]], ["Neutrophils and macrophages secrete barrier destabilizing cytokines, IL-1, and TNF, which activate RhoA within BBB endothelial cells, which disrupts TJs [15] .", [["Neutrophils", "ANATOMY", 0, 11], ["macrophages", "ANATOMY", 16, 27], ["barrier", "ANATOMY", 36, 43], ["BBB endothelial cells", "ANATOMY", 111, 132], ["TJs", "ANATOMY", 149, 152], ["Neutrophils", "CELL", 0, 11], ["macrophages", "CELL", 16, 27], ["IL-1", "GENE_OR_GENE_PRODUCT", 69, 73], ["TNF", "GENE_OR_GENE_PRODUCT", 79, 82], ["RhoA", "GENE_OR_GENE_PRODUCT", 99, 103], ["BBB endothelial cells", "CELL", 111, 132], ["TJs", "CELLULAR_COMPONENT", 149, 152], ["Neutrophils", "CELL_TYPE", 0, 11], ["macrophages", "CELL_TYPE", 16, 27], ["cytokines", "PROTEIN", 58, 67], ["IL-1", "PROTEIN", 69, 73], ["TNF", "PROTEIN", 79, 82], ["RhoA", "PROTEIN", 99, 103], ["BBB endothelial cells", "CELL_TYPE", 111, 132], ["TJs", "CELL_TYPE", 149, 152], ["Neutrophils", "TEST", 0, 11], ["macrophages", "TEST", 16, 27], ["cytokines", "TEST", 58, 67], ["IL", "TEST", 69, 71], ["TNF", "TREATMENT", 79, 82], ["macrophages", "OBSERVATION_MODIFIER", 16, 27], ["endothelial cells", "OBSERVATION", 115, 132]]], ["In severe infections, S. pneumoniae may also gain access to the brain parenchyma, as animal studies demonstrate that pneumococcal pneumolysin may damage endothelial cell membranes or TJs [82] .Listeria monocytogenesListeria monocytogenes is a facultative intracellular bacterium that is tenfold more effective at invading the CNS other than neuroinvasive Gram-positive bacteria [83] .", [["brain parenchyma", "ANATOMY", 64, 80], ["endothelial cell membranes", "ANATOMY", 153, 179], ["TJs", "ANATOMY", 183, 186], ["intracellular", "ANATOMY", 255, 268], ["CNS", "ANATOMY", 326, 329], ["infections", "DISEASE", 10, 20], ["pneumolysin", "CHEMICAL", 130, 141], ["S. pneumoniae", "ORGANISM", 22, 35], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 64, 80], ["pneumococcal pneumolysin", "GENE_OR_GENE_PRODUCT", 117, 141], ["endothelial cell membranes", "CELLULAR_COMPONENT", 153, 179], ["TJs", "CELLULAR_COMPONENT", 183, 186], ["Listeria monocytogenes", "ORGANISM", 193, 215], ["Listeria monocytogenes", "ORGANISM", 215, 237], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 255, 268], ["CNS", "ANATOMICAL_SYSTEM", 326, 329], ["Gram-", "GENE_OR_GENE_PRODUCT", 355, 360], ["pneumococcal pneumolysin", "PROTEIN", 117, 141], ["S. pneumoniae", "SPECIES", 22, 35], ["Listeria monocytogenes", "SPECIES", 193, 215], ["Listeria monocytogenes", "SPECIES", 215, 237], ["S. pneumoniae", "SPECIES", 22, 35], ["pneumococcal", "SPECIES", 117, 129], ["Listeria monocytogenes", "SPECIES", 193, 215], ["Listeria monocytogenes", "SPECIES", 215, 237], ["severe infections", "PROBLEM", 3, 20], ["S. pneumoniae", "PROBLEM", 22, 35], ["animal studies", "TEST", 85, 99], ["pneumococcal pneumolysin", "PROBLEM", 117, 141], ["damage endothelial cell membranes", "PROBLEM", 146, 179], ["Listeria monocytogenes", "PROBLEM", 193, 215], ["Listeria monocytogenes", "PROBLEM", 215, 237], ["a facultative intracellular bacterium", "PROBLEM", 241, 278], ["neuroinvasive Gram-positive bacteria", "PROBLEM", 341, 377], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["infections", "OBSERVATION", 10, 20], ["pneumoniae", "OBSERVATION", 25, 35], ["brain", "ANATOMY", 64, 69], ["parenchyma", "ANATOMY_MODIFIER", 70, 80], ["pneumococcal", "OBSERVATION_MODIFIER", 117, 129], ["pneumolysin", "OBSERVATION", 130, 141], ["endothelial cell membranes", "OBSERVATION", 153, 179], ["monocytogenes", "OBSERVATION", 202, 215], ["monocytogenes", "OBSERVATION", 224, 237], ["facultative", "OBSERVATION_MODIFIER", 243, 254], ["intracellular bacterium", "OBSERVATION", 255, 278], ["tenfold", "OBSERVATION_MODIFIER", 287, 294], ["more effective", "OBSERVATION_MODIFIER", 295, 309], ["CNS", "ANATOMY", 326, 329]]], ["L. monocytogenes spreads hematogenously from the gastrointestinal tract after the consumption of contaminated food, gaining access to the CNS parenchyma through a variety of routes including invasion of meningeal endothelium, transportation across the BBB within infected monocyte, or retrograde migration along cranial nerve axons [84, 85] .", [["hematogenously", "ANATOMY", 25, 39], ["gastrointestinal tract", "ANATOMY", 49, 71], ["CNS parenchyma", "ANATOMY", 138, 152], ["meningeal endothelium", "ANATOMY", 203, 224], ["BBB", "ANATOMY", 252, 255], ["monocyte", "ANATOMY", 272, 280], ["cranial nerve axons", "ANATOMY", 312, 331], ["hematogenously from the gastrointestinal tract", "DISEASE", 25, 71], ["L. monocytogenes", "ORGANISM", 0, 16], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 49, 71], ["CNS parenchyma", "MULTI-TISSUE_STRUCTURE", 138, 152], ["meningeal endothelium", "TISSUE", 203, 224], ["BBB", "MULTI-TISSUE_STRUCTURE", 252, 255], ["monocyte", "CELL", 272, 280], ["cranial nerve axons", "MULTI-TISSUE_STRUCTURE", 312, 331], ["infected monocyte", "CELL_TYPE", 263, 280], ["L. monocytogenes", "SPECIES", 0, 16], ["L. monocytogenes", "SPECIES", 0, 16], ["L. monocytogenes", "PROBLEM", 0, 16], ["the gastrointestinal tract", "PROBLEM", 45, 71], ["invasion of meningeal endothelium", "TREATMENT", 191, 224], ["infected monocyte", "PROBLEM", 263, 280], ["monocytogenes", "OBSERVATION", 3, 16], ["gastrointestinal tract", "ANATOMY", 49, 71], ["CNS", "ANATOMY", 138, 141], ["parenchyma", "ANATOMY_MODIFIER", 142, 152], ["meningeal endothelium", "ANATOMY", 203, 224], ["BBB", "ANATOMY", 252, 255], ["infected monocyte", "OBSERVATION", 263, 280], ["retrograde", "OBSERVATION_MODIFIER", 285, 295], ["migration", "OBSERVATION_MODIFIER", 296, 305], ["cranial nerve", "ANATOMY", 312, 325]]], ["Bacterial proteins, including internalins (InlA and InlB), interact with host cellular receptors E-cadherin and mesenchymal-epithelial transition (MET), respectively, and are expressed by choroid plexus epithelium and brain endothelium, respectively [86] .", [["cellular", "ANATOMY", 78, 86], ["mesenchymal-epithelial", "ANATOMY", 112, 134], ["choroid plexus epithelium", "ANATOMY", 188, 213], ["brain endothelium", "ANATOMY", 218, 235], ["internalins", "GENE_OR_GENE_PRODUCT", 30, 41], ["InlA", "GENE_OR_GENE_PRODUCT", 43, 47], ["InlB", "GENE_OR_GENE_PRODUCT", 52, 56], ["host cellular receptors E-cadherin", "GENE_OR_GENE_PRODUCT", 73, 107], ["mesenchymal-epithelial transition (MET", "GENE_OR_GENE_PRODUCT", 112, 150], ["choroid plexus epithelium", "TISSUE", 188, 213], ["brain endothelium", "TISSUE", 218, 235], ["Bacterial proteins", "PROTEIN", 0, 18], ["internalins", "PROTEIN", 30, 41], ["InlA", "PROTEIN", 43, 47], ["InlB", "PROTEIN", 52, 56], ["host cellular receptors", "PROTEIN", 73, 96], ["E-cadherin", "PROTEIN", 97, 107], ["Bacterial proteins", "PROBLEM", 0, 18], ["internalins", "TEST", 30, 41], ["host cellular receptors", "TEST", 73, 96], ["proteins", "OBSERVATION", 10, 18], ["mesenchymal", "ANATOMY", 112, 123], ["epithelial transition", "OBSERVATION", 124, 145], ["choroid plexus", "ANATOMY", 188, 202], ["epithelium", "ANATOMY_MODIFIER", 203, 213], ["brain endothelium", "ANATOMY", 218, 235]]], ["Listeriolysin O (LLO), a pore forming toxin, activates NF-kB within brain endothelial cells in vitro, leading to increased expression of P-and E-selectin, ICAM-1 and VCAM-1, as well as IL-6, -8, and CCL2, which may promote the adhesion and recruitment of neutrophils and monocytes [87] .", [["pore", "ANATOMY", 25, 29], ["brain endothelial cells", "ANATOMY", 68, 91], ["neutrophils", "ANATOMY", 255, 266], ["monocytes", "ANATOMY", 271, 280], ["Listeriolysin O", "CHEMICAL", 0, 15], ["LLO", "CHEMICAL", 17, 20], ["Listeriolysin O", "CHEMICAL", 0, 15], ["LLO", "CHEMICAL", 17, 20], ["Listeriolysin O", "SIMPLE_CHEMICAL", 0, 15], ["LLO", "SIMPLE_CHEMICAL", 17, 20], ["NF-kB", "GENE_OR_GENE_PRODUCT", 55, 60], ["brain endothelial cells", "CELL", 68, 91], ["E-selectin", "GENE_OR_GENE_PRODUCT", 143, 153], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 155, 161], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 166, 172], ["IL-6", "GENE_OR_GENE_PRODUCT", 185, 189], ["-8", "GENE_OR_GENE_PRODUCT", 191, 193], ["CCL2", "GENE_OR_GENE_PRODUCT", 199, 203], ["neutrophils", "CELL", 255, 266], ["monocytes", "CELL", 271, 280], ["LLO", "PROTEIN", 17, 20], ["pore forming toxin", "PROTEIN", 25, 43], ["NF-kB", "PROTEIN", 55, 60], ["brain endothelial cells", "CELL_TYPE", 68, 91], ["P", "PROTEIN", 137, 138], ["ICAM", "PROTEIN", 155, 159], ["VCAM", "PROTEIN", 166, 170], ["CCL2", "PROTEIN", 199, 203], ["neutrophils", "CELL_TYPE", 255, 266], ["monocytes", "CELL_TYPE", 271, 280], ["a pore forming toxin", "TEST", 23, 43], ["brain endothelial cells", "TEST", 68, 91], ["P", "TEST", 137, 138], ["E", "TEST", 143, 144], ["selectin", "TEST", 145, 153], ["ICAM", "TEST", 155, 159], ["VCAM", "TEST", 166, 170], ["IL", "TEST", 185, 187], ["CCL2", "TEST", 199, 203], ["neutrophils", "TEST", 255, 266], ["monocytes", "TEST", 271, 280], ["brain", "ANATOMY", 68, 73], ["endothelial cells", "OBSERVATION", 74, 91], ["selectin", "ANATOMY", 145, 153], ["CCL2", "ANATOMY", 199, 203]]], ["Invasion and infection of brain endothelial cells with the ensuing activation of glial cells and recruitment of leukocytes in patients with severe CNS L. monocytogenes infections may lead to abscess formation or cerebritis [88] .Bacillus anthracisBacillus anthracis, a spore-forming Gram-positive bacterium, causes the disease anthrax, which has three clinical forms: cutaneous, inhalational, and gastrointestinal [89] .", [["brain endothelial cells", "ANATOMY", 26, 49], ["glial cells", "ANATOMY", 81, 92], ["leukocytes", "ANATOMY", 112, 122], ["abscess", "ANATOMY", 191, 198], ["spore", "ANATOMY", 269, 274], ["cutaneous", "ANATOMY", 368, 377], ["gastrointestinal", "ANATOMY", 397, 413], ["infection", "DISEASE", 13, 22], ["L. monocytogenes infections", "DISEASE", 151, 178], ["abscess", "DISEASE", 191, 198], ["cerebritis", "DISEASE", 212, 222], ["anthrax", "DISEASE", 327, 334], ["brain endothelial cells", "CELL", 26, 49], ["glial cells", "CELL", 81, 92], ["leukocytes", "CELL", 112, 122], ["patients", "ORGANISM", 126, 134], ["CNS L. monocytogenes", "ORGANISM", 147, 167], ["abscess", "PATHOLOGICAL_FORMATION", 191, 198], ["Bacillus anthracisBacillus anthracis", "ORGANISM", 229, 265], ["Gram", "GENE_OR_GENE_PRODUCT", 283, 287], ["cutaneous", "ORGANISM_SUBDIVISION", 368, 377], ["brain endothelial cells", "CELL_TYPE", 26, 49], ["glial cells", "CELL_TYPE", 81, 92], ["leukocytes", "CELL_TYPE", 112, 122], ["patients", "SPECIES", 126, 134], ["L. monocytogenes", "SPECIES", 151, 167], ["Bacillus anthracis", "SPECIES", 229, 247], ["Bacillus anthracis", "SPECIES", 247, 265], ["L. monocytogenes", "SPECIES", 151, 167], ["Bacillus anthracis", "SPECIES", 229, 247], ["Bacillus anthracis", "SPECIES", 247, 265], ["Invasion", "PROBLEM", 0, 8], ["infection of brain endothelial cells", "PROBLEM", 13, 49], ["glial cells", "PROBLEM", 81, 92], ["leukocytes", "PROBLEM", 112, 122], ["severe CNS L. monocytogenes infections", "PROBLEM", 140, 178], ["abscess formation", "PROBLEM", 191, 208], ["cerebritis", "PROBLEM", 212, 222], ["Bacillus anthracisBacillus anthracis", "PROBLEM", 229, 265], ["a spore-forming Gram-positive bacterium", "PROBLEM", 267, 306], ["the disease anthrax", "PROBLEM", 315, 334], ["infection", "OBSERVATION", 13, 22], ["brain", "ANATOMY", 26, 31], ["endothelial cells", "OBSERVATION", 32, 49], ["glial cells", "OBSERVATION", 81, 92], ["leukocytes", "OBSERVATION_MODIFIER", 112, 122], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["CNS", "ANATOMY", 147, 150], ["monocytogenes infections", "OBSERVATION", 154, 178], ["abscess", "OBSERVATION", 191, 198], ["cerebritis", "OBSERVATION", 212, 222], ["positive bacterium", "OBSERVATION_MODIFIER", 288, 306], ["cutaneous", "ANATOMY", 368, 377], ["gastrointestinal", "ANATOMY", 397, 413]]], ["Untreated, anthrax disseminates hematogenously to the CNS, causing fatal hemorrhagic meningitis.", [["CNS", "ANATOMY", 54, 57], ["anthrax disseminates hematogenously to the CNS", "DISEASE", 11, 57], ["hemorrhagic meningitis", "DISEASE", 73, 95], ["CNS", "ANATOMICAL_SYSTEM", 54, 57], ["anthrax", "PROBLEM", 11, 18], ["the CNS", "PROBLEM", 50, 57], ["fatal hemorrhagic meningitis", "PROBLEM", 67, 95], ["CNS", "ANATOMY", 54, 57], ["causing", "UNCERTAINTY", 59, 66], ["fatal", "OBSERVATION_MODIFIER", 67, 72], ["hemorrhagic", "OBSERVATION_MODIFIER", 73, 84], ["meningitis", "OBSERVATION", 85, 95]]], ["Anthrax toxins, such as InhA and BsIA, induce destruction of brain endothelial cell TJs, leading to increased BBB permeability and hemorrhage [90, 91] .", [["brain endothelial cell TJs", "ANATOMY", 61, 87], ["BBB", "ANATOMY", 110, 113], ["BsIA", "CHEMICAL", 33, 37], ["hemorrhage", "DISEASE", 131, 141], ["InhA", "GENE_OR_GENE_PRODUCT", 24, 28], ["BsIA", "GENE_OR_GENE_PRODUCT", 33, 37], ["brain endothelial cell TJs", "CELL", 61, 87], ["BBB", "MULTI-TISSUE_STRUCTURE", 110, 113], ["InhA", "PROTEIN", 24, 28], ["BsIA", "PROTEIN", 33, 37], ["brain endothelial cell TJs", "CELL_TYPE", 61, 87], ["Anthrax toxins", "PROBLEM", 0, 14], ["InhA and BsIA", "PROBLEM", 24, 37], ["destruction of brain endothelial cell TJs", "PROBLEM", 46, 87], ["increased BBB permeability", "PROBLEM", 100, 126], ["hemorrhage", "PROBLEM", 131, 141], ["destruction", "OBSERVATION", 46, 57], ["brain endothelial", "ANATOMY", 61, 78], ["cell TJs", "OBSERVATION", 79, 87], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["BBB", "OBSERVATION_MODIFIER", 110, 113], ["permeability", "OBSERVATION_MODIFIER", 114, 126], ["hemorrhage", "OBSERVATION", 131, 141]]], ["BsIA has also been demonstrated to act as an adherence factor for all endothelial cells and to be required for CNS infection [92] .", [["endothelial cells", "ANATOMY", 70, 87], ["CNS", "ANATOMY", 111, 114], ["BsIA", "CHEMICAL", 0, 4], ["infection", "DISEASE", 115, 124], ["BsIA", "GENE_OR_GENE_PRODUCT", 0, 4], ["endothelial cells", "CELL", 70, 87], ["CNS", "ANATOMICAL_SYSTEM", 111, 114], ["BsIA", "PROTEIN", 0, 4], ["endothelial cells", "CELL_TYPE", 70, 87], ["all endothelial cells", "PROBLEM", 66, 87], ["CNS infection", "PROBLEM", 111, 124]]], ["Finally, the anthrax toxin pXO1 downregulates innate immune responses, allowing dissemination of the pathogen throughout the CNS [93] .Haemophilus influenzaeHaemophilus influenzae is a Gram-negative bacterium that was a leading cause of childhood meningitis until its near eradication through the introduction of a the highly effective conjugate HiB vaccine [94] .", [["CNS", "ANATOMY", 125, 128], ["pXO1", "CHEMICAL", 27, 31], ["Haemophilus influenzaeHaemophilus influenzae", "DISEASE", 135, 179], ["meningitis", "DISEASE", 247, 257], ["HiB", "CHEMICAL", 346, 349], ["pXO1", "GENE_OR_GENE_PRODUCT", 27, 31], ["Haemophilus influenzaeHaemophilus influenzae", "ORGANISM", 135, 179], ["Gram-", "GENE_OR_GENE_PRODUCT", 185, 190], ["HiB", "SIMPLE_CHEMICAL", 346, 349], ["pXO1", "PROTEIN", 27, 31], ["Haemophilus influenzae", "SPECIES", 135, 157], ["Haemophilus influenzae", "SPECIES", 157, 179], ["Haemophilus influenzae", "SPECIES", 135, 157], ["Haemophilus influenzae", "SPECIES", 157, 179], ["the anthrax toxin", "TREATMENT", 9, 26], ["the pathogen", "PROBLEM", 97, 109], ["Haemophilus influenzaeHaemophilus influenzae", "PROBLEM", 135, 179], ["a Gram-negative bacterium", "PROBLEM", 183, 208], ["childhood meningitis", "PROBLEM", 237, 257], ["a the highly effective conjugate HiB vaccine", "TREATMENT", 313, 357], ["childhood", "OBSERVATION_MODIFIER", 237, 246], ["meningitis", "OBSERVATION", 247, 257]]], ["In vitro studies have implicated H. influenzae porin, OmpP2, in endothelial damage via binding to the common carboxyterminal domain of LR, and H. influenzae pili have also been shown to interact with platelet-activating factor receptor (PAFR), which are both expressed by BMECs [95, 96] .", [["endothelial", "ANATOMY", 64, 75], ["BMECs", "ANATOMY", 272, 277], ["H. influenzae porin", "ORGANISM", 33, 52], ["OmpP2", "GENE_OR_GENE_PRODUCT", 54, 59], ["endothelial", "TISSUE", 64, 75], ["LR", "GENE_OR_GENE_PRODUCT", 135, 137], ["H. influenzae pili", "ORGANISM", 143, 161], ["platelet-activating factor receptor", "GENE_OR_GENE_PRODUCT", 200, 235], ["PAFR", "GENE_OR_GENE_PRODUCT", 237, 241], ["BMECs", "GENE_OR_GENE_PRODUCT", 272, 277], ["H. influenzae porin", "PROTEIN", 33, 52], ["OmpP2", "PROTEIN", 54, 59], ["carboxyterminal domain", "PROTEIN", 109, 131], ["LR", "PROTEIN", 135, 137], ["H. influenzae pili", "PROTEIN", 143, 161], ["platelet-activating factor receptor", "PROTEIN", 200, 235], ["PAFR", "PROTEIN", 237, 241], ["BMECs", "CELL_TYPE", 272, 277], ["H. influenzae", "SPECIES", 33, 46], ["H. influenzae", "SPECIES", 143, 156], ["H. influenzae", "SPECIES", 33, 46], ["H. influenzae", "SPECIES", 143, 156], ["vitro studies", "TEST", 3, 16], ["H. influenzae porin", "PROBLEM", 33, 52], ["OmpP2", "TREATMENT", 54, 59], ["endothelial damage", "PROBLEM", 64, 82], ["LR", "TREATMENT", 135, 137], ["H. influenzae pili", "PROBLEM", 143, 161], ["platelet-activating factor receptor (PAFR", "TREATMENT", 200, 241], ["endothelial", "ANATOMY", 64, 75]]], ["In vivo studies have shown that targeting leukocyte CD11/CD18 integrins in conjunction with systemic treatment with corticosteroids reduces life-threatening CNS inflammation and prevents TJ disruption [97] , the latter of which is now standard of care in the treatment of patients with H. influenzae meningitis [98] .Neisseria meningitidisNeisseria meningitidis, a Gram-negative bacterium that may colonize the oropharynx and genital tract, causes fulminant meningococcemia and meningococcal meningitis, which often occur together [99] .", [["leukocyte", "ANATOMY", 42, 51], ["CNS", "ANATOMY", 157, 160], ["TJ", "ANATOMY", 187, 189], ["oropharynx", "ANATOMY", 411, 421], ["genital tract", "ANATOMY", 426, 439], ["corticosteroids", "CHEMICAL", 116, 131], ["inflammation", "DISEASE", 161, 173], ["H. influenzae meningitis", "DISEASE", 286, 310], ["meningococcemia", "DISEASE", 458, 473], ["meningococcal meningitis", "DISEASE", 478, 502], ["corticosteroids", "CHEMICAL", 116, 131], ["leukocyte", "CELL", 42, 51], ["CD18 integrins", "GENE_OR_GENE_PRODUCT", 57, 71], ["corticosteroids", "SIMPLE_CHEMICAL", 116, 131], ["CNS", "ANATOMICAL_SYSTEM", 157, 160], ["TJ", "GENE_OR_GENE_PRODUCT", 187, 189], ["patients", "ORGANISM", 272, 280], ["H. influenzae", "ORGANISM", 286, 299], ["Neisseria meningitidis", "ORGANISM", 317, 339], ["Neisseria meningitidis", "ORGANISM", 339, 361], ["Gram-", "GENE_OR_GENE_PRODUCT", 365, 370], ["oropharynx", "ORGAN", 411, 421], ["genital tract", "ORGANISM_SUBDIVISION", 426, 439], ["leukocyte CD11/CD18 integrins", "PROTEIN", 42, 71], ["patients", "SPECIES", 272, 280], ["H. influenzae", "SPECIES", 286, 299], ["Neisseria meningitidis", "SPECIES", 317, 339], ["Neisseria meningitidis", "SPECIES", 339, 361], ["H. influenzae", "SPECIES", 286, 299], ["Neisseria meningitidis", "SPECIES", 317, 339], ["Neisseria meningitidis", "SPECIES", 339, 361], ["vivo studies", "TEST", 3, 15], ["leukocyte CD11", "TEST", 42, 56], ["CD18 integrins", "TREATMENT", 57, 71], ["systemic treatment", "TREATMENT", 92, 110], ["corticosteroids", "TREATMENT", 116, 131], ["threatening CNS inflammation", "PROBLEM", 145, 173], ["TJ disruption", "PROBLEM", 187, 200], ["H. influenzae meningitis", "PROBLEM", 286, 310], ["Neisseria meningitidisNeisseria meningitidis", "PROBLEM", 317, 361], ["a Gram-negative bacterium", "PROBLEM", 363, 388], ["colonize the oropharynx and genital tract", "PROBLEM", 398, 439], ["fulminant meningococcemia", "PROBLEM", 448, 473], ["meningococcal meningitis", "PROBLEM", 478, 502], ["CNS", "ANATOMY", 157, 160], ["inflammation", "OBSERVATION", 161, 173], ["negative bacterium", "OBSERVATION", 370, 388], ["oropharynx", "ANATOMY", 411, 421], ["genital tract", "ANATOMY", 426, 439], ["fulminant", "OBSERVATION_MODIFIER", 448, 457], ["meningococcemia", "OBSERVATION", 458, 473], ["meningococcal", "OBSERVATION_MODIFIER", 478, 491], ["meningitis", "OBSERVATION", 492, 502]]], ["N. meningitidis adheres to host endothelial cells via pili surface proteins Opa and Opc followed by bacterial adhesin PilQ interaction with the common carboxy-terminal domain of LR [96] .", [["endothelial cells", "ANATOMY", 32, 49], ["surface", "ANATOMY", 59, 66], ["carboxy", "CHEMICAL", 151, 158], ["N. meningitidis", "ORGANISM", 0, 15], ["endothelial cells", "CELL", 32, 49], ["pili surface proteins", "GENE_OR_GENE_PRODUCT", 54, 75], ["Opa", "GENE_OR_GENE_PRODUCT", 76, 79], ["Opc", "GENE_OR_GENE_PRODUCT", 84, 87], ["PilQ", "GENE_OR_GENE_PRODUCT", 118, 122], ["host endothelial cells", "CELL_TYPE", 27, 49], ["pili surface proteins", "PROTEIN", 54, 75], ["Opa", "PROTEIN", 76, 79], ["Opc", "PROTEIN", 84, 87], ["bacterial adhesin", "PROTEIN", 100, 117], ["PilQ", "PROTEIN", 118, 122], ["common carboxy-terminal domain", "PROTEIN", 144, 174], ["LR", "PROTEIN", 178, 180], ["N. meningitidis", "SPECIES", 0, 15], ["N. meningitidis", "SPECIES", 0, 15], ["N. meningitidis", "PROBLEM", 0, 15], ["host endothelial cells via pili surface proteins Opa", "TREATMENT", 27, 79], ["the common carboxy-terminal domain of LR", "TREATMENT", 140, 180], ["meningitidis", "OBSERVATION", 3, 15], ["host endothelial cells", "OBSERVATION", 27, 49]]], ["Additional determinants of host cell binding include complex protein ACP and the autotransporter meningococcal serine protease (Msp) A [100, 101] .Neisseria meningitidisIn summary, while bacterial invasion of the CNS is primarily limited to the meningeal compartment, numerous species exhibit pili surface proteins that are able to interact with BMECs via binding to pIgR and/or LR, which lead to endothelial cell activation, with upregulation of PAFr, CD31, and/or intercellular adhesion molecules [95] .", [["cell", "ANATOMY", 32, 36], ["CNS", "ANATOMY", 213, 216], ["meningeal compartment", "ANATOMY", 245, 266], ["surface", "ANATOMY", 298, 305], ["BMECs", "ANATOMY", 346, 351], ["endothelial cell", "ANATOMY", 397, 413], ["serine", "CHEMICAL", 111, 117], ["host cell", "CELL", 27, 36], ["ACP", "GENE_OR_GENE_PRODUCT", 69, 72], ["meningococcal serine protease", "GENE_OR_GENE_PRODUCT", 97, 126], ["Neisseria meningitidis", "ORGANISM", 147, 169], ["CNS", "ANATOMICAL_SYSTEM", 213, 216], ["meningeal compartment", "MULTI-TISSUE_STRUCTURE", 245, 266], ["pili surface proteins", "GENE_OR_GENE_PRODUCT", 293, 314], ["BMECs", "GENE_OR_GENE_PRODUCT", 346, 351], ["pIgR", "GENE_OR_GENE_PRODUCT", 367, 371], ["LR", "GENE_OR_GENE_PRODUCT", 379, 381], ["endothelial cell", "CELL", 397, 413], ["PAFr", "GENE_OR_GENE_PRODUCT", 447, 451], ["CD31", "GENE_OR_GENE_PRODUCT", 453, 457], ["intercellular adhesion molecules", "GENE_OR_GENE_PRODUCT", 466, 498], ["complex protein ACP", "PROTEIN", 53, 72], ["autotransporter meningococcal serine protease", "PROTEIN", 81, 126], ["Msp", "PROTEIN", 128, 131], ["pili surface proteins", "PROTEIN", 293, 314], ["BMECs", "PROTEIN", 346, 351], ["pIgR", "PROTEIN", 367, 371], ["LR", "PROTEIN", 379, 381], ["PAFr", "PROTEIN", 447, 451], ["CD31", "PROTEIN", 453, 457], ["intercellular adhesion molecules", "PROTEIN", 466, 498], ["Neisseria meningitidis", "SPECIES", 147, 169], ["Neisseria meningitidis", "SPECIES", 147, 169], ["host cell binding", "PROBLEM", 27, 44], ["complex protein ACP", "TREATMENT", 53, 72], ["the autotransporter meningococcal serine protease", "TREATMENT", 77, 126], ["Neisseria meningitidis", "PROBLEM", 147, 169], ["bacterial invasion of the CNS", "PROBLEM", 187, 216], ["the meningeal compartment", "PROBLEM", 241, 266], ["numerous species", "PROBLEM", 268, 284], ["pili surface proteins", "PROBLEM", 293, 314], ["LR", "TREATMENT", 379, 381], ["endothelial cell activation", "PROBLEM", 397, 424], ["PAFr", "PROBLEM", 447, 451], ["CD31", "TEST", 453, 457], ["intercellular adhesion molecules", "PROBLEM", 466, 498], ["host cell binding", "OBSERVATION", 27, 44], ["meningitidis", "OBSERVATION", 157, 169], ["bacterial", "OBSERVATION_MODIFIER", 187, 196], ["invasion", "OBSERVATION", 197, 205], ["CNS", "ANATOMY", 213, 216], ["meningeal compartment", "ANATOMY", 245, 266], ["LR", "ANATOMY", 379, 381], ["endothelial cell activation", "OBSERVATION", 397, 424], ["PAFr", "ANATOMY", 447, 451]]], ["PAFr activation leads to dilation of vessels, aggregation of platelets, and increased BBB permeability, which are all terminal events during bacterial meningitis.Effects of Viruses on BBB Structure and FunctionMany neurotropic viruses with barrier disrupting properties (e.g., Japanese encephalitis virus (JEV), West Nile virus (WNV), Venezuelan equine encephalitis virus (VEEV)) enter the CNS in the absence of BBB opening, suggesting that barrier disruption results from the local virus replication in the CNS [102] [103] [104] [105] [106] .", [["vessels", "ANATOMY", 37, 44], ["platelets", "ANATOMY", 61, 70], ["BBB", "ANATOMY", 86, 89], ["barrier", "ANATOMY", 240, 247], ["CNS", "ANATOMY", 390, 393], ["CNS", "ANATOMY", 508, 511], ["meningitis", "DISEASE", 151, 161], ["Japanese encephalitis", "DISEASE", 277, 298], ["JEV", "DISEASE", 306, 309], ["Venezuelan equine encephalitis", "DISEASE", 335, 365], ["PAFr", "GENE_OR_GENE_PRODUCT", 0, 4], ["vessels", "MULTI-TISSUE_STRUCTURE", 37, 44], ["platelets", "CELL", 61, 70], ["BBB", "MULTI-TISSUE_STRUCTURE", 86, 89], ["BBB", "MULTI-TISSUE_STRUCTURE", 184, 187], ["barrier", "TISSUE", 240, 247], ["Japanese encephalitis virus", "ORGANISM", 277, 304], ["JEV", "ORGANISM", 306, 309], ["West Nile virus", "ORGANISM", 312, 327], ["WNV", "ORGANISM", 329, 332], ["Venezuelan equine encephalitis virus", "ORGANISM", 335, 371], ["VEEV", "ORGANISM", 373, 377], ["CNS", "ANATOMICAL_SYSTEM", 390, 393], ["BBB", "GENE_OR_GENE_PRODUCT", 412, 415], ["PAFr", "PROTEIN", 0, 4], ["platelets", "CELL_TYPE", 61, 70], ["Japanese encephalitis virus", "SPECIES", 277, 304], ["West Nile virus", "SPECIES", 312, 327], ["Venezuelan", "SPECIES", 335, 345], ["equine encephalitis virus", "SPECIES", 346, 371], ["Japanese encephalitis virus", "SPECIES", 277, 304], ["JEV", "SPECIES", 306, 309], ["West Nile virus", "SPECIES", 312, 327], ["WNV", "SPECIES", 329, 332], ["Venezuelan equine encephalitis virus", "SPECIES", 335, 371], ["VEEV", "SPECIES", 373, 377], ["PAFr activation", "TREATMENT", 0, 15], ["dilation of vessels", "TREATMENT", 25, 44], ["aggregation of platelets", "PROBLEM", 46, 70], ["increased BBB permeability", "PROBLEM", 76, 102], ["all terminal events", "PROBLEM", 114, 133], ["bacterial meningitis", "PROBLEM", 141, 161], ["Viruses", "PROBLEM", 173, 180], ["BBB Structure", "TREATMENT", 184, 197], ["barrier disrupting properties", "TREATMENT", 240, 269], ["Japanese encephalitis virus (JEV)", "PROBLEM", 277, 310], ["West Nile virus (WNV", "PROBLEM", 312, 332], ["Venezuelan equine encephalitis virus", "PROBLEM", 335, 371], ["barrier disruption", "PROBLEM", 441, 459], ["the local virus replication", "TREATMENT", 473, 500], ["dilation", "OBSERVATION", 25, 33], ["vessels", "ANATOMY", 37, 44], ["aggregation", "OBSERVATION_MODIFIER", 46, 57], ["platelets", "OBSERVATION_MODIFIER", 61, 70], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["BBB permeability", "OBSERVATION", 86, 102], ["terminal", "OBSERVATION_MODIFIER", 118, 126], ["bacterial", "OBSERVATION_MODIFIER", 141, 150], ["meningitis", "OBSERVATION", 151, 161], ["Viruses", "OBSERVATION", 173, 180], ["neurotropic viruses", "OBSERVATION", 215, 234], ["CNS", "ANATOMY", 390, 393]]], ["Viruses can compromise the integrity of BBB by either infecting or inducing cellular damage to the NVU or by eliciting innate and adaptive immune responses leading to neuroinflammation.", [["BBB", "ANATOMY", 40, 43], ["cellular", "ANATOMY", 76, 84], ["neuroinflammation", "DISEASE", 167, 184], ["BBB", "MULTI-TISSUE_STRUCTURE", 40, 43], ["cellular", "CELL", 76, 84], ["Viruses", "PROBLEM", 0, 7], ["inducing cellular damage", "PROBLEM", 67, 91], ["neuroinflammation", "PROBLEM", 167, 184], ["cellular damage", "OBSERVATION", 76, 91], ["neuroinflammation", "OBSERVATION", 167, 184]]], ["Thus, a combination of host and virus-related factors contributes to BBB opening during neurotropic viral infection.Virus Factors that Impact BBBInfection of mice with mouse adenovirus type-1 (MAV-1) induces BBB disruption in the absence of inflammation, suggesting that the barrier loss is primarily caused by viral infection rather than inflammatory responses [107] .", [["BBB", "ANATOMY", 69, 72], ["BBB", "ANATOMY", 208, 211], ["viral infection", "DISEASE", 100, 115], ["inflammation", "DISEASE", 241, 253], ["infection", "DISEASE", 317, 326], ["BBB", "MULTI-TISSUE_STRUCTURE", 69, 72], ["neurotropic viral", "ORGANISM", 88, 105], ["mice", "ORGANISM", 158, 162], ["mouse adenovirus type-1", "ORGANISM", 168, 191], ["MAV-1", "ORGANISM", 193, 198], ["BBB", "MULTI-TISSUE_STRUCTURE", 208, 211], ["mice", "SPECIES", 158, 162], ["mouse", "SPECIES", 168, 173], ["mice", "SPECIES", 158, 162], ["mouse adenovirus type-1", "SPECIES", 168, 191], ["host and virus", "TREATMENT", 23, 37], ["BBB opening", "PROBLEM", 69, 80], ["neurotropic viral infection", "PROBLEM", 88, 115], ["Virus Factors", "PROBLEM", 116, 129], ["mouse adenovirus type", "PROBLEM", 168, 189], ["BBB disruption", "PROBLEM", 208, 222], ["inflammation", "PROBLEM", 241, 253], ["the barrier loss", "PROBLEM", 271, 287], ["viral infection", "PROBLEM", 311, 326], ["inflammatory responses", "PROBLEM", 339, 361], ["infection", "OBSERVATION", 106, 115], ["BBB", "ANATOMY", 208, 211], ["disruption", "OBSERVATION", 212, 222], ["inflammation", "OBSERVATION", 241, 253], ["barrier loss", "OBSERVATION", 275, 287], ["viral", "OBSERVATION_MODIFIER", 311, 316], ["infection", "OBSERVATION", 317, 326]]], ["MAV-1 infects brain vascular endothelium in vivo [108] and dampens expression of TJ proteins in vitro [107] .", [["brain vascular endothelium", "ANATOMY", 14, 40], ["MAV-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["brain vascular endothelium", "TISSUE", 14, 40], ["TJ", "GENE_OR_GENE_PRODUCT", 81, 83], ["TJ proteins", "PROTEIN", 81, 92], ["MAV-1", "SPECIES", 0, 5], ["MAV", "TEST", 0, 3], ["infects", "OBSERVATION", 6, 13], ["brain", "ANATOMY_MODIFIER", 14, 19], ["vascular endothelium", "ANATOMY", 20, 40]]], ["Indeed, reduced expression of TJ and AJ proteins is a characteristic feature of BBB disruption by neurotropic viruses such as JEV, WNV, and human immunodeficiency virus type 1 (HIV-1) in vivo [104, 109, 110] .", [["BBB", "ANATOMY", 80, 83], ["human immunodeficiency virus", "DISEASE", 140, 168], ["TJ", "GENE_OR_GENE_PRODUCT", 30, 32], ["AJ", "GENE_OR_GENE_PRODUCT", 37, 39], ["BBB", "GENE_OR_GENE_PRODUCT", 80, 83], ["neurotropic viruses", "ORGANISM", 98, 117], ["JEV", "ORGANISM", 126, 129], ["WNV", "ORGANISM", 131, 134], ["human immunodeficiency virus type 1", "ORGANISM", 140, 175], ["HIV-1", "ORGANISM", 177, 182], ["TJ", "PROTEIN", 30, 32], ["AJ proteins", "PROTEIN", 37, 48], ["human immunodeficiency virus type 1", "SPECIES", 140, 175], ["HIV-1", "SPECIES", 177, 182], ["JEV", "SPECIES", 126, 129], ["WNV", "SPECIES", 131, 134], ["human immunodeficiency virus type 1", "SPECIES", 140, 175], ["HIV-1", "SPECIES", 177, 182], ["TJ and AJ proteins", "PROBLEM", 30, 48], ["BBB disruption", "PROBLEM", 80, 94], ["neurotropic viruses", "PROBLEM", 98, 117], ["JEV", "PROBLEM", 126, 129], ["WNV", "PROBLEM", 131, 134], ["human immunodeficiency virus type", "PROBLEM", 140, 173], ["HIV", "TEST", 177, 180], ["reduced", "OBSERVATION_MODIFIER", 8, 15], ["neurotropic viruses", "OBSERVATION", 98, 117]]], ["Viruses accomplish this either by downregulating transcription levels of TJ mRNA or promoting protein degradation [104, 111] .Virus Factors that Impact BBBDisruption of TJ complexes is often associated with enhanced generation of reactive oxygen species (ROS).", [["oxygen", "CHEMICAL", 239, 245], ["ROS", "CHEMICAL", 255, 258], ["oxygen", "CHEMICAL", 239, 245], ["TJ", "GENE_OR_GENE_PRODUCT", 73, 75], ["TJ", "GENE_OR_GENE_PRODUCT", 169, 171], ["reactive oxygen species", "SIMPLE_CHEMICAL", 230, 253], ["ROS", "SIMPLE_CHEMICAL", 255, 258], ["TJ mRNA", "RNA", 73, 80], ["TJ complexes", "PROTEIN", 169, 181], ["Viruses", "PROBLEM", 0, 7], ["TJ mRNA", "PROBLEM", 73, 80], ["promoting protein degradation", "PROBLEM", 84, 113], ["Virus Factors", "PROBLEM", 126, 139], ["reactive oxygen species", "PROBLEM", 230, 253], ["TJ complexes", "OBSERVATION", 169, 181], ["reactive", "OBSERVATION_MODIFIER", 230, 238], ["oxygen species", "OBSERVATION", 239, 253]]], ["Viral infection in target cells can induce mitochondrial damage or NADPH oxidase activation, resulting in robust ROS generation [112, 113] .", [["cells", "ANATOMY", 26, 31], ["mitochondrial", "ANATOMY", 43, 56], ["Viral infection", "DISEASE", 0, 15], ["NADPH", "CHEMICAL", 67, 72], ["ROS", "CHEMICAL", 113, 116], ["NADPH", "CHEMICAL", 67, 72], ["Viral", "ORGANISM", 0, 5], ["cells", "CELL", 26, 31], ["mitochondrial", "CELLULAR_COMPONENT", 43, 56], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 67, 80], ["ROS", "SIMPLE_CHEMICAL", 113, 116], ["target cells", "CELL_TYPE", 19, 31], ["NADPH oxidase", "PROTEIN", 67, 80], ["Viral infection in target cells", "PROBLEM", 0, 31], ["mitochondrial damage", "PROBLEM", 43, 63], ["NADPH oxidase activation", "PROBLEM", 67, 91], ["infection", "OBSERVATION", 6, 15], ["target cells", "OBSERVATION", 19, 31], ["mitochondrial damage", "OBSERVATION", 43, 63], ["NADPH oxidase activation", "OBSERVATION", 67, 91]]], ["While low levels of ROS are required for normal cell function, unchecked level of these reactive intermediates can exert detrimental effects.", [["cell", "ANATOMY", 48, 52], ["ROS", "CHEMICAL", 20, 23], ["ROS", "SIMPLE_CHEMICAL", 20, 23], ["cell", "CELL", 48, 52], ["these reactive intermediates", "PROBLEM", 82, 110], ["reactive", "OBSERVATION_MODIFIER", 88, 96]]], ["Indeed, ROS can target virtually all biological molecules, including lipid, protein, and nucleic acid, resulting in the release of various cytokines and proteases that damage vasculature.", [["vasculature", "ANATOMY", 175, 186], ["ROS", "CHEMICAL", 8, 11], ["nucleic acid", "CHEMICAL", 89, 101], ["ROS", "SIMPLE_CHEMICAL", 8, 11], ["lipid", "SIMPLE_CHEMICAL", 69, 74], ["nucleic acid", "SIMPLE_CHEMICAL", 89, 101], ["vasculature", "MULTI-TISSUE_STRUCTURE", 175, 186], ["cytokines", "PROTEIN", 139, 148], ["proteases", "PROTEIN", 153, 162], ["lipid, protein", "TEST", 69, 83], ["nucleic acid", "TEST", 89, 101], ["various cytokines", "TREATMENT", 131, 148]]], ["Cellular component of NVU can be a source and target of ROS.", [["Cellular", "ANATOMY", 0, 8], ["NVU", "CHEMICAL", 22, 25], ["ROS", "CHEMICAL", 56, 59], ["NVU", "GENE_OR_GENE_PRODUCT", 22, 25], ["ROS", "SIMPLE_CHEMICAL", 56, 59], ["NVU", "PROTEIN", 22, 25], ["Cellular component of NVU", "PROBLEM", 0, 25]]], ["While brain endothelial cells are highly susceptible to oxidative stress, astrocytes are less prone to such damages.", [["brain endothelial cells", "ANATOMY", 6, 29], ["astrocytes", "ANATOMY", 74, 84], ["brain endothelial cells", "CELL", 6, 29], ["astrocytes", "CELL", 74, 84], ["brain endothelial cells", "CELL_TYPE", 6, 29], ["astrocytes", "CELL_TYPE", 74, 84], ["brain endothelial cells", "TEST", 6, 29], ["brain", "ANATOMY", 6, 11], ["endothelial cells", "OBSERVATION", 12, 29]]], ["However, exposure to viral proteins (e.g., HIV-1 Nef) augments astrocyte sensitivity to redox insults [114] .", [["astrocyte", "ANATOMY", 63, 72], ["HIV-1 Nef", "ORGANISM", 43, 52], ["astrocyte", "CELL", 63, 72], ["viral proteins", "PROTEIN", 21, 35], ["Nef", "PROTEIN", 49, 52], ["HIV-1", "SPECIES", 43, 48], ["HIV-1", "SPECIES", 43, 48], ["viral proteins", "TEST", 21, 35], ["HIV", "TEST", 43, 46], ["astrocyte sensitivity", "TEST", 63, 84], ["redox insults", "TEST", 88, 101]]], ["Activation of metalloproteinases (MMPs) is one of the mechanisms by which ROS dysregulate TJ complexes [115] [116] [117] .", [["ROS", "CHEMICAL", 74, 77], ["metalloproteinases", "GENE_OR_GENE_PRODUCT", 14, 32], ["MMPs", "GENE_OR_GENE_PRODUCT", 34, 38], ["ROS", "SIMPLE_CHEMICAL", 74, 77], ["TJ", "GENE_OR_GENE_PRODUCT", 90, 92], ["metalloproteinases", "PROTEIN", 14, 32], ["MMPs", "PROTEIN", 34, 38], ["TJ complexes", "PROTEIN", 90, 102], ["metalloproteinases (MMPs)", "TREATMENT", 14, 39]]], ["Elevated levels of MMPs have been reported in brain tissue of mice infected with neurotropic viruses such as WNV, JEV, and VEEV [104, 105, 118] and in cerebrospinal fluid (CSF) of human patients infected with WNV [118] .", [["brain tissue", "ANATOMY", 46, 58], ["cerebrospinal fluid", "ANATOMY", 151, 170], ["MMPs", "GENE_OR_GENE_PRODUCT", 19, 23], ["brain tissue", "TISSUE", 46, 58], ["mice", "ORGANISM", 62, 66], ["neurotropic viruses", "ORGANISM", 81, 100], ["WNV", "ORGANISM", 109, 112], ["JEV", "ORGANISM", 114, 117], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 151, 170], ["CSF", "ORGANISM_SUBSTANCE", 172, 175], ["human", "ORGANISM", 180, 185], ["patients", "ORGANISM", 186, 194], ["MMPs", "PROTEIN", 19, 23], ["mice", "SPECIES", 62, 66], ["human", "SPECIES", 180, 185], ["patients", "SPECIES", 186, 194], ["mice", "SPECIES", 62, 66], ["WNV", "SPECIES", 109, 112], ["JEV", "SPECIES", 114, 117], ["VEEV", "SPECIES", 123, 127], ["human", "SPECIES", 180, 185], ["WNV", "SPECIES", 209, 212], ["Elevated levels of MMPs", "PROBLEM", 0, 23], ["neurotropic viruses", "PROBLEM", 81, 100], ["WNV", "PROBLEM", 109, 112], ["JEV", "PROBLEM", 114, 117], ["VEEV", "TEST", 123, 127], ["cerebrospinal fluid", "TEST", 151, 170], ["WNV", "PROBLEM", 209, 212], ["MMPs", "OBSERVATION", 19, 23], ["brain tissue", "ANATOMY", 46, 58], ["neurotropic viruses", "OBSERVATION", 81, 100], ["cerebrospinal", "ANATOMY", 151, 164], ["fluid", "OBSERVATION", 165, 170], ["infected", "OBSERVATION", 195, 203]]], ["Infected microglia and astrocytes robustly elevate the expression of MMP-2 and -9 in vitro and in vivo [119, 120] .", [["microglia", "ANATOMY", 9, 18], ["astrocytes", "ANATOMY", 23, 33], ["microglia", "CELL", 9, 18], ["astrocytes", "CELL", 23, 33], ["MMP-2", "GENE_OR_GENE_PRODUCT", 69, 74], ["-9", "GENE_OR_GENE_PRODUCT", 79, 81], ["microglia", "CELL_TYPE", 9, 18], ["astrocytes", "CELL_TYPE", 23, 33], ["MMP-2 and -9", "PROTEIN", 69, 81], ["Infected microglia and astrocytes", "PROBLEM", 0, 33], ["MMP", "TEST", 69, 72], ["microglia", "OBSERVATION", 9, 18]]], ["MMPs are known to disrupt the BBB integrity by cleaving TJ proteins, AJ proteins, and the extracellular matrix (ECM) [115] .", [["BBB", "ANATOMY", 30, 33], ["extracellular matrix", "ANATOMY", 90, 110], ["ECM", "ANATOMY", 112, 115], ["MMPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["BBB", "TISSUE", 30, 33], ["TJ", "GENE_OR_GENE_PRODUCT", 56, 58], ["AJ", "GENE_OR_GENE_PRODUCT", 69, 71], ["extracellular matrix", "CELLULAR_COMPONENT", 90, 110], ["ECM", "CELLULAR_COMPONENT", 112, 115], ["MMPs", "PROTEIN", 0, 4], ["TJ proteins", "PROTEIN", 56, 67], ["AJ proteins", "PROTEIN", 69, 80], ["extracellular matrix", "ANATOMY", 90, 110]]], ["Activity of these MMPs is controlled by regulating gene expression, activation, and inhibition mediated by endogenous tissue inhibitors of MMPs (TIMPs) [121] .", [["tissue", "ANATOMY", 118, 124], ["MMPs", "GENE_OR_GENE_PRODUCT", 18, 22], ["tissue inhibitors of MMPs", "GENE_OR_GENE_PRODUCT", 118, 143], ["TIMPs", "GENE_OR_GENE_PRODUCT", 145, 150], ["MMPs", "PROTEIN", 18, 22], ["MMPs", "PROTEIN", 139, 143], ["TIMPs", "PROTEIN", 145, 150], ["MMPs (TIMPs)", "TEST", 139, 151]]], ["Nonetheless, viral infection (e.g., HIV-1) can perturb the fine balance between MMPs and TIMPs, resulting in enhanced MMP levels and BBB leakage [122] .", [["viral infection", "DISEASE", 13, 28], ["HIV-1", "ORGANISM", 36, 41], ["MMPs", "GENE_OR_GENE_PRODUCT", 80, 84], ["TIMPs", "GENE_OR_GENE_PRODUCT", 89, 94], ["MMP", "GENE_OR_GENE_PRODUCT", 118, 121], ["MMPs", "PROTEIN", 80, 84], ["TIMPs", "PROTEIN", 89, 94], ["MMP", "PROTEIN", 118, 121], ["HIV-1", "SPECIES", 36, 41], ["HIV-1", "SPECIES", 36, 41], ["viral infection", "PROBLEM", 13, 28], ["HIV", "PROBLEM", 36, 39], ["MMPs and TIMPs", "TEST", 80, 94], ["enhanced MMP levels", "TEST", 109, 128], ["BBB leakage", "PROBLEM", 133, 144], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["infection", "OBSERVATION", 19, 28]]], ["Consistently, pharmacological blockage or genetic ablation of MMPs is reported to protect BBB integrity upon viral infection in murine models [118, 123] .Virus Factors that Impact BBBAdditionally, ROS trigger the small GTPase RhoA, PI3 kinase, and protein kinase B (PKB/Akt) signaling pathways.", [["BBB", "ANATOMY", 90, 93], ["viral infection", "DISEASE", 109, 124], ["ROS", "CHEMICAL", 197, 200], ["MMPs", "GENE_OR_GENE_PRODUCT", 62, 66], ["BBB", "MULTI-TISSUE_STRUCTURE", 90, 93], ["murine", "ORGANISM", 128, 134], ["ROS", "SIMPLE_CHEMICAL", 197, 200], ["RhoA", "GENE_OR_GENE_PRODUCT", 226, 230], ["PI3 kinase", "GENE_OR_GENE_PRODUCT", 232, 242], ["protein kinase B", "GENE_OR_GENE_PRODUCT", 248, 264], ["PKB", "GENE_OR_GENE_PRODUCT", 266, 269], ["Akt", "GENE_OR_GENE_PRODUCT", 270, 273], ["MMPs", "PROTEIN", 62, 66], ["small GTPase", "PROTEIN", 213, 225], ["RhoA", "PROTEIN", 226, 230], ["PI3 kinase", "PROTEIN", 232, 242], ["protein kinase B", "PROTEIN", 248, 264], ["PKB", "PROTEIN", 266, 269], ["Akt", "PROTEIN", 270, 273], ["murine", "SPECIES", 128, 134], ["pharmacological blockage", "PROBLEM", 14, 38], ["genetic ablation", "TREATMENT", 42, 58], ["MMPs", "PROBLEM", 62, 66], ["viral infection", "PROBLEM", 109, 124], ["murine models", "TEST", 128, 141], ["Virus Factors", "PROBLEM", 154, 167], ["the small GTPase RhoA", "TEST", 209, 230], ["PI3 kinase", "TEST", 232, 242], ["protein kinase B", "TEST", 248, 264], ["PKB", "TEST", 266, 269], ["blockage", "OBSERVATION", 30, 38], ["viral infection", "OBSERVATION", 109, 124]]], ["This results in the reorganization of the actin cytoskeleton, altered localization of TJ proteins, and consequently increased BBB permeability [124, 125] .", [["cytoskeleton", "ANATOMY", 48, 60], ["TJ", "ANATOMY", 86, 88], ["BBB", "ANATOMY", 126, 129], ["actin", "GENE_OR_GENE_PRODUCT", 42, 47], ["cytoskeleton", "CELLULAR_COMPONENT", 48, 60], ["TJ", "GENE_OR_GENE_PRODUCT", 86, 88], ["BBB", "MULTI-TISSUE_STRUCTURE", 126, 129], ["actin", "PROTEIN", 42, 47], ["TJ proteins", "PROTEIN", 86, 97], ["altered localization of TJ proteins", "PROBLEM", 62, 97], ["consequently increased BBB permeability", "PROBLEM", 103, 142], ["actin cytoskeleton", "OBSERVATION", 42, 60], ["TJ proteins", "OBSERVATION", 86, 97], ["increased", "OBSERVATION_MODIFIER", 116, 125], ["BBB", "OBSERVATION_MODIFIER", 126, 129], ["permeability", "OBSERVATION_MODIFIER", 130, 142]]], ["Furthermore, ROS can cause barrier dysfunction by activating inflammasome via signaling pathways involving mitogen-activated protein kinases (MAPK) and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) [126] .Virus Factors that Impact BBBViruses can also infect brain endothelial cells and induce syncytium resulting in vascular damage and hemorrhage [127, 128] .", [["barrier", "ANATOMY", 27, 34], ["brain endothelial cells", "ANATOMY", 276, 299], ["syncytium", "ANATOMY", 311, 320], ["vascular", "ANATOMY", 334, 342], ["ROS", "CHEMICAL", 13, 16], ["vascular damage", "DISEASE", 334, 349], ["hemorrhage", "DISEASE", 354, 364], ["ROS", "SIMPLE_CHEMICAL", 13, 16], ["barrier", "TISSUE", 27, 34], ["mitogen-activated protein kinases", "GENE_OR_GENE_PRODUCT", 107, 140], ["MAPK", "GENE_OR_GENE_PRODUCT", 142, 146], ["extracellular signal-regulated protein kinases 1", "GENE_OR_GENE_PRODUCT", 152, 200], ["2", "GENE_OR_GENE_PRODUCT", 205, 206], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 208, 214], ["BBBViruses", "GENE_OR_GENE_PRODUCT", 249, 259], ["brain endothelial cells", "CELL", 276, 299], ["syncytium", "CELL", 311, 320], ["vascular", "MULTI-TISSUE_STRUCTURE", 334, 342], ["mitogen-activated protein kinases", "PROTEIN", 107, 140], ["MAPK", "PROTEIN", 142, 146], ["extracellular signal-regulated protein kinases 1 and 2 (ERK1/2", "PROTEIN", 152, 214], ["brain endothelial cells", "CELL_TYPE", 276, 299], ["barrier dysfunction", "PROBLEM", 27, 46], ["activating inflammasome", "PROBLEM", 50, 73], ["signaling pathways", "TEST", 78, 96], ["mitogen", "TEST", 107, 114], ["activated protein kinases", "TEST", 115, 140], ["MAPK", "TEST", 142, 146], ["extracellular signal", "TEST", 152, 172], ["protein kinases", "TEST", 183, 198], ["ERK1", "TEST", 208, 212], ["Virus Factors", "PROBLEM", 223, 236], ["Impact BBBViruses", "PROBLEM", 242, 259], ["brain endothelial cells", "PROBLEM", 276, 299], ["induce syncytium", "PROBLEM", 304, 320], ["vascular damage", "PROBLEM", 334, 349], ["hemorrhage", "PROBLEM", 354, 364], ["endothelial cells", "OBSERVATION", 282, 299], ["vascular", "ANATOMY", 334, 342], ["damage", "OBSERVATION", 343, 349], ["hemorrhage", "OBSERVATION", 354, 364]]], ["For instance, Nipah and Hendra viruses (NiV and HeV, respectively) invade the CNS by infecting brain endothelial cells.", [["CNS", "ANATOMY", 78, 81], ["brain endothelial cells", "ANATOMY", 95, 118], ["Nipah", "ORGANISM", 14, 19], ["Hendra viruses", "ORGANISM", 24, 38], ["NiV", "ORGANISM", 40, 43], ["HeV", "ORGANISM", 48, 51], ["CNS", "ANATOMICAL_SYSTEM", 78, 81], ["brain endothelial cells", "CELL", 95, 118], ["brain endothelial cells", "CELL_TYPE", 95, 118], ["Nipah", "SPECIES", 14, 19], ["Hendra viruses", "SPECIES", 24, 38], ["NiV", "SPECIES", 40, 43], ["HeV", "SPECIES", 48, 51], ["Nipah", "PROBLEM", 14, 19], ["Hendra viruses", "TREATMENT", 24, 38], ["NiV", "TREATMENT", 40, 43], ["CNS", "ANATOMY", 78, 81], ["brain endothelial cells", "OBSERVATION", 95, 118]]], ["Virus infection induces syncytium in brain endothelium resulting in extensive vascular damage associated with influx of inflammatory cells [129] [130] [131] .", [["syncytium", "ANATOMY", 24, 33], ["brain endothelium", "ANATOMY", 37, 54], ["vascular", "ANATOMY", 78, 86], ["inflammatory cells", "ANATOMY", 120, 138], ["Virus infection", "DISEASE", 0, 15], ["vascular damage", "DISEASE", 78, 93], ["Virus", "ORGANISM", 0, 5], ["syncytium", "CELL", 24, 33], ["brain endothelium", "TISSUE", 37, 54], ["vascular", "MULTI-TISSUE_STRUCTURE", 78, 86], ["cells", "CELL", 133, 138], ["inflammatory cells", "CELL_TYPE", 120, 138], ["Virus infection", "PROBLEM", 0, 15], ["syncytium in brain endothelium", "PROBLEM", 24, 54], ["extensive vascular damage", "PROBLEM", 68, 93], ["inflammatory cells", "PROBLEM", 120, 138], ["infection", "OBSERVATION", 6, 15], ["brain endothelium", "ANATOMY", 37, 54], ["extensive", "OBSERVATION_MODIFIER", 68, 77], ["vascular", "ANATOMY", 78, 86], ["damage", "OBSERVATION", 87, 93], ["inflammatory cells", "OBSERVATION", 120, 138]]], ["Additionally, neurotropic viruses induce apoptosis in brain endothelial cells causing BBB dysfunction in vitro [132] .", [["brain endothelial cells", "ANATOMY", 54, 77], ["BBB", "ANATOMY", 86, 89], ["brain endothelial cells", "CELL", 54, 77], ["BBB", "MULTI-TISSUE_STRUCTURE", 86, 89], ["brain endothelial cells", "CELL_TYPE", 54, 77], ["neurotropic viruses", "PROBLEM", 14, 33], ["apoptosis in brain endothelial cells", "PROBLEM", 41, 77], ["BBB dysfunction", "PROBLEM", 86, 101], ["neurotropic viruses", "OBSERVATION", 14, 33], ["brain endothelial", "ANATOMY", 54, 71]]], ["Secretory viral proteins also trigger barrier permeability.", [["barrier", "ANATOMY", 38, 45], ["barrier", "TISSUE", 38, 45], ["Secretory viral proteins", "PROTEIN", 0, 24], ["Secretory viral proteins", "PROBLEM", 0, 24], ["viral proteins", "OBSERVATION", 10, 24], ["barrier permeability", "OBSERVATION_MODIFIER", 38, 58]]], ["For instance, HIV-1 Tat protein is actively released from the infected cells and crosses the cellular membrane [133] .", [["cells", "ANATOMY", 71, 76], ["cellular membrane", "ANATOMY", 93, 110], ["HIV-1", "ORGANISM", 14, 19], ["Tat", "GENE_OR_GENE_PRODUCT", 20, 23], ["cells", "CELL", 71, 76], ["cellular membrane", "CELLULAR_COMPONENT", 93, 110], ["HIV-1 Tat protein", "PROTEIN", 14, 31], ["infected cells", "CELL_TYPE", 62, 76], ["HIV-1", "SPECIES", 14, 19], ["HIV-1", "SPECIES", 14, 19], ["HIV", "TEST", 14, 17], ["Tat protein", "TEST", 20, 31], ["the infected cells", "PROBLEM", 58, 76], ["infected cells", "OBSERVATION", 62, 76], ["cellular membrane", "OBSERVATION", 93, 110]]], ["Intravenous injection of mice with HIV-1 Tat reduces the expression of TJ proteins in brain vasculature, partly by upregulating cyclooxygenase-2 expression [134] .", [["Intravenous", "ANATOMY", 0, 11], ["brain vasculature", "ANATOMY", 86, 103], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["mice", "ORGANISM", 25, 29], ["HIV-1", "ORGANISM", 35, 40], ["Tat", "ORGANISM", 41, 44], ["TJ", "GENE_OR_GENE_PRODUCT", 71, 73], ["brain vasculature", "MULTI-TISSUE_STRUCTURE", 86, 103], ["cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 128, 144], ["HIV-1 Tat", "PROTEIN", 35, 44], ["TJ proteins", "PROTEIN", 71, 82], ["cyclooxygenase", "PROTEIN", 128, 142], ["mice", "SPECIES", 25, 29], ["HIV-1", "SPECIES", 35, 40], ["mice", "SPECIES", 25, 29], ["HIV-1", "SPECIES", 35, 40], ["Intravenous injection of mice with HIV", "TREATMENT", 0, 38], ["TJ proteins in brain vasculature", "PROBLEM", 71, 103], ["upregulating cyclooxygenase", "TREATMENT", 115, 142], ["brain vasculature", "ANATOMY", 86, 103]]], ["Additionally, HIV-1 Tat enhances serum levels of soluble CD40L (sCD40L) by activating platelets [135, 136] , a phenomenon also observed in HIV-infected patients [137, 138] . sCD40L alters barrier permeability by increasing the expression of cell adhesion molecules on brain endothelial cells in a JNK-dependent manner [139] .", [["serum", "ANATOMY", 33, 38], ["platelets", "ANATOMY", 86, 95], ["barrier", "ANATOMY", 188, 195], ["cell", "ANATOMY", 241, 245], ["brain endothelial cells", "ANATOMY", 268, 291], ["HIV-infected", "DISEASE", 139, 151], ["HIV-1", "ORGANISM", 14, 19], ["Tat", "ORGANISM", 20, 23], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["CD40L", "GENE_OR_GENE_PRODUCT", 57, 62], ["sCD40L", "GENE_OR_GENE_PRODUCT", 64, 70], ["platelets", "CELL", 86, 95], ["HIV", "ORGANISM", 139, 142], ["patients", "ORGANISM", 152, 160], ["sCD40L", "GENE_OR_GENE_PRODUCT", 174, 180], ["barrier", "TISSUE", 188, 195], ["cell", "CELL", 241, 245], ["brain endothelial cells", "CELL", 268, 291], ["JNK", "GENE_OR_GENE_PRODUCT", 297, 300], ["HIV-1 Tat", "PROTEIN", 14, 23], ["CD40L", "PROTEIN", 57, 62], ["sCD40L", "PROTEIN", 64, 70], ["platelets", "CELL_TYPE", 86, 95], ["sCD40L", "PROTEIN", 174, 180], ["cell adhesion molecules", "PROTEIN", 241, 264], ["brain endothelial cells", "CELL_TYPE", 268, 291], ["JNK", "PROTEIN", 297, 300], ["HIV-1", "SPECIES", 14, 19], ["patients", "SPECIES", 152, 160], ["HIV-1", "SPECIES", 14, 19], ["HIV", "SPECIES", 139, 142], ["HIV", "TEST", 14, 17], ["serum levels", "TEST", 33, 45], ["soluble CD40L", "TEST", 49, 62], ["sCD40L", "TEST", 64, 70], ["activating platelets", "TEST", 75, 95], ["a phenomenon", "PROBLEM", 109, 121], ["HIV", "PROBLEM", 139, 142], ["sCD40L alters barrier permeability", "PROBLEM", 174, 208], ["cell adhesion molecules", "PROBLEM", 241, 264], ["brain endothelial cells", "TEST", 268, 291], ["barrier permeability", "OBSERVATION_MODIFIER", 188, 208], ["cell adhesion molecules", "OBSERVATION", 241, 264], ["brain endothelial", "ANATOMY", 268, 285]]], ["This culminates in enhanced leukocyte adhesion to brain endothelium leading to BBB dysfunction [135] .Virus Factors that Impact BBBIn summary, evidence indicates that neurotropic viruses can directly induce BBB permeability by disrupting TJs and AJs between brain endothelial cells.", [["leukocyte", "ANATOMY", 28, 37], ["brain endothelium", "ANATOMY", 50, 67], ["BBB", "ANATOMY", 79, 82], ["BBB", "ANATOMY", 207, 210], ["TJs", "ANATOMY", 238, 241], ["AJs", "ANATOMY", 246, 249], ["brain endothelial cells", "ANATOMY", 258, 281], ["leukocyte", "CELL", 28, 37], ["brain endothelium", "TISSUE", 50, 67], ["BBB", "MULTI-TISSUE_STRUCTURE", 79, 82], ["neurotropic viruses", "ORGANISM", 167, 186], ["BBB", "TISSUE", 207, 210], ["TJs", "CELLULAR_COMPONENT", 238, 241], ["AJs", "CELLULAR_COMPONENT", 246, 249], ["brain endothelial cells", "CELL", 258, 281], ["TJs", "CELL_TYPE", 238, 241], ["AJs", "CELL_TYPE", 246, 249], ["brain endothelial cells", "CELL_TYPE", 258, 281], ["enhanced leukocyte adhesion", "PROBLEM", 19, 46], ["BBB dysfunction", "PROBLEM", 79, 94], ["Virus Factors", "PROBLEM", 102, 115], ["neurotropic viruses", "PROBLEM", 167, 186], ["disrupting TJs and AJs between brain endothelial cells", "PROBLEM", 227, 281], ["enhanced leukocyte adhesion", "OBSERVATION", 19, 46], ["brain endothelium", "ANATOMY", 50, 67], ["brain", "ANATOMY", 258, 263], ["endothelial cells", "OBSERVATION", 264, 281]]], ["This is mainly achieved by inducing ROS generation in the CNS, which in turn activates several tyrosine kinases, MMPs, and small GTPase RhoA.", [["CNS", "ANATOMY", 58, 61], ["ROS", "CHEMICAL", 36, 39], ["tyrosine", "CHEMICAL", 95, 103], ["tyrosine", "CHEMICAL", 95, 103], ["ROS", "SIMPLE_CHEMICAL", 36, 39], ["CNS", "ANATOMICAL_SYSTEM", 58, 61], ["MMPs", "GENE_OR_GENE_PRODUCT", 113, 117], ["RhoA", "GENE_OR_GENE_PRODUCT", 136, 140], ["tyrosine kinases", "PROTEIN", 95, 111], ["MMPs", "PROTEIN", 113, 117], ["small GTPase", "PROTEIN", 123, 135], ["RhoA", "PROTEIN", 136, 140], ["inducing ROS generation in the CNS", "PROBLEM", 27, 61], ["several tyrosine kinases", "TEST", 87, 111], ["MMPs", "TEST", 113, 117], ["small GTPase RhoA", "PROBLEM", 123, 140], ["ROS generation", "OBSERVATION", 36, 50], ["CNS", "ANATOMY", 58, 61], ["several", "OBSERVATION_MODIFIER", 87, 94], ["tyrosine kinases", "OBSERVATION", 95, 111], ["small", "OBSERVATION_MODIFIER", 123, 128], ["GTPase RhoA", "OBSERVATION", 129, 140]]], ["The cumulative effect of these activities leads to the loss of BBB function.Innate Immune Responses to Viruses that Impact BBB FunctionMicrobes possess pathogen-associated molecular patterns (PAMPs) that are recognized by pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), retinoic acid-inducible gene 1 (RIG-I)-like receptors (RLRs), nucleotide oligomerization domain-like receptors (NLRs), and cytosolic DNA sensors.", [["BBB", "ANATOMY", 63, 66], ["cytosolic", "ANATOMY", 419, 428], ["nucleotide", "CHEMICAL", 358, 368], ["BBB", "MULTI-TISSUE_STRUCTURE", 63, 66], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 152, 190], ["PAMPs", "GENE_OR_GENE_PRODUCT", 192, 197], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 222, 251], ["PRRs", "GENE_OR_GENE_PRODUCT", 253, 257], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 268, 287], ["TLRs", "GENE_OR_GENE_PRODUCT", 289, 293], ["retinoic acid-inducible gene 1", "GENE_OR_GENE_PRODUCT", 296, 326], ["RIG-I)-like receptors", "GENE_OR_GENE_PRODUCT", 328, 349], ["RLRs", "GENE_OR_GENE_PRODUCT", 351, 355], ["nucleotide oligomerization domain-like receptors", "GENE_OR_GENE_PRODUCT", 358, 406], ["NLRs", "GENE_OR_GENE_PRODUCT", 408, 412], ["DNA", "CELLULAR_COMPONENT", 429, 432], ["pathogen-associated molecular patterns", "PROTEIN", 152, 190], ["PAMPs", "PROTEIN", 192, 197], ["pattern recognition receptors", "PROTEIN", 222, 251], ["PRRs", "PROTEIN", 253, 257], ["Toll-like receptors", "PROTEIN", 268, 287], ["TLRs", "PROTEIN", 289, 293], ["retinoic acid-inducible gene 1 (RIG-I)-like receptors", "PROTEIN", 296, 349], ["RLRs", "DNA", 351, 355], ["nucleotide oligomerization domain-like receptors", "PROTEIN", 358, 406], ["NLRs", "PROTEIN", 408, 412], ["cytosolic DNA sensors", "DNA", 419, 440], ["the loss of BBB function", "PROBLEM", 51, 75], ["pathogen", "PROBLEM", 152, 160], ["retinoic acid-inducible gene", "PROBLEM", 296, 324], ["nucleotide oligomerization domain", "PROBLEM", 358, 391], ["cytosolic DNA sensors", "TEST", 419, 440]]], ["These PRRs are expressed by various cell types in the CNS (reviewed in [140] ).", [["cell", "ANATOMY", 36, 40], ["CNS", "ANATOMY", 54, 57], ["PRRs", "GENE_OR_GENE_PRODUCT", 6, 10], ["cell", "CELL", 36, 40], ["CNS", "ANATOMICAL_SYSTEM", 54, 57], ["PRRs", "PROTEIN", 6, 10], ["various cell types", "OBSERVATION", 28, 46], ["CNS", "ANATOMY", 54, 57]]], ["Viruses contain single-or double-stranded RNA molecules (dsRNS and ssRNA, respectively), present either in the viral genome or generated during virus replication.", [["dsRNS", "GENE_OR_GENE_PRODUCT", 57, 62], ["single-or double-stranded RNA molecules", "RNA", 16, 55], ["dsRNS", "PROTEIN", 57, 62], ["ssRNA", "PROTEIN", 67, 72], ["viral genome", "DNA", 111, 123], ["Viruses", "PROBLEM", 0, 7], ["double-stranded RNA molecules", "TREATMENT", 26, 55], ["ssRNA", "PROBLEM", 67, 72], ["virus replication", "TREATMENT", 144, 161], ["single", "OBSERVATION_MODIFIER", 16, 22], ["ssRNA", "ANATOMY", 67, 72], ["viral genome", "OBSERVATION", 111, 123]]], ["Recognition of viral PAMPs by TLR3 (dsRNA) or TLR-7 (ssRNA) triggers signaling pathway related to NF-\u03baB, resulting in the production of pro-inflammatory cytokines and type I interferons (IFNs).", [["PAMPs", "GENE_OR_GENE_PRODUCT", 21, 26], ["TLR3", "GENE_OR_GENE_PRODUCT", 30, 34], ["TLR-7", "GENE_OR_GENE_PRODUCT", 46, 51], ["ssRNA", "GENE_OR_GENE_PRODUCT", 53, 58], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 98, 103], ["type I interferons", "GENE_OR_GENE_PRODUCT", 167, 185], ["IFNs", "GENE_OR_GENE_PRODUCT", 187, 191], ["viral PAMPs", "PROTEIN", 15, 26], ["TLR3", "PROTEIN", 30, 34], ["dsRNA", "PROTEIN", 36, 41], ["TLR-7", "PROTEIN", 46, 51], ["ssRNA", "PROTEIN", 53, 58], ["NF-\u03baB", "PROTEIN", 98, 103], ["pro-inflammatory cytokines", "PROTEIN", 136, 162], ["type I interferons", "PROTEIN", 167, 185], ["IFNs", "PROTEIN", 187, 191], ["viral PAMPs", "PROBLEM", 15, 26], ["TLR3 (dsRNA", "TREATMENT", 30, 41], ["TLR", "TEST", 46, 49], ["signaling pathway", "PROBLEM", 69, 86], ["pro-inflammatory cytokines", "PROBLEM", 136, 162], ["type I interferons (IFNs)", "TREATMENT", 167, 192], ["viral PAMPs", "OBSERVATION", 15, 26], ["pro-inflammatory cytokines", "OBSERVATION", 136, 162]]], ["Similarly, RLRs, which include RIG-I and melanoma differentiation factor (MDA)-5, are activated by dsRNA and ssRNA sequences containing 5\u2032-triphosphate [141] .", [["5\u2032-triphosphate", "CHEMICAL", 136, 151], ["5\u2032-triphosphate", "CHEMICAL", 136, 151], ["RLRs", "GENE_OR_GENE_PRODUCT", 11, 15], ["RIG-I", "GENE_OR_GENE_PRODUCT", 31, 36], ["melanoma differentiation factor (MDA)-5", "GENE_OR_GENE_PRODUCT", 41, 80], ["5\u2032-triphosphate", "SIMPLE_CHEMICAL", 136, 151], ["RLRs", "PROTEIN", 11, 15], ["RIG-I", "PROTEIN", 31, 36], ["melanoma differentiation factor (MDA)-5", "PROTEIN", 41, 80], ["ssRNA sequences", "DNA", 109, 124], ["RLRs", "TEST", 11, 15], ["RIG-I and melanoma differentiation factor", "PROBLEM", 31, 72], ["ssRNA sequences", "TEST", 109, 124], ["RIG", "OBSERVATION_MODIFIER", 31, 34], ["-I", "OBSERVATION_MODIFIER", 34, 36], ["melanoma", "OBSERVATION", 41, 49]]], ["RLR activation stimulates mitochondrial antiviral-signaling protein (MAVS), which in turn elicits the expression of inflammatory cytokines via induction of the NF-\u03baB signaling pathway.", [["mitochondrial", "ANATOMY", 26, 39], ["RLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["mitochondrial", "CELLULAR_COMPONENT", 26, 39], ["antiviral-signaling protein", "GENE_OR_GENE_PRODUCT", 40, 67], ["MAVS", "GENE_OR_GENE_PRODUCT", 69, 73], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 160, 165], ["RLR", "PROTEIN", 0, 3], ["mitochondrial antiviral-signaling protein", "PROTEIN", 26, 67], ["MAVS", "PROTEIN", 69, 73], ["inflammatory cytokines", "PROTEIN", 116, 138], ["NF-\u03baB", "PROTEIN", 160, 165], ["mitochondrial antiviral", "TREATMENT", 26, 49], ["signaling protein (MAVS)", "PROBLEM", 50, 74], ["inflammatory cytokines", "PROBLEM", 116, 138], ["the NF", "TREATMENT", 156, 162], ["mitochondrial antiviral", "OBSERVATION", 26, 49], ["inflammatory cytokines", "OBSERVATION", 116, 138]]], ["While PRRinduced expression of type I IFNs restricts virus replication in the CNS [142, 143] , enhanced production of pro-inflammatory cytokines and chemokines can lead to neuroinflammation.", [["CNS", "ANATOMY", 78, 81], ["neuroinflammation", "DISEASE", 172, 189], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 31, 42], ["CNS", "ANATOMICAL_SYSTEM", 78, 81], ["type I IFNs", "PROTEIN", 31, 42], ["pro-inflammatory cytokines", "PROTEIN", 118, 144], ["chemokines", "PROTEIN", 149, 159], ["type I IFNs restricts virus replication", "TREATMENT", 31, 70], ["pro-inflammatory cytokines", "TREATMENT", 118, 144], ["chemokines", "TREATMENT", 149, 159], ["neuroinflammation", "PROBLEM", 172, 189], ["CNS", "ANATOMY", 78, 81], ["pro-inflammatory cytokines", "OBSERVATION", 118, 144], ["neuroinflammation", "OBSERVATION", 172, 189]]], ["Studies have shown that TLR3 signaling contributes to both enhancement and protection of CNS inflammation during WNV infection in murine models [144, 145] .", [["CNS", "ANATOMY", 89, 92], ["inflammation", "DISEASE", 93, 105], ["WNV infection", "DISEASE", 113, 126], ["TLR3", "GENE_OR_GENE_PRODUCT", 24, 28], ["CNS", "ANATOMICAL_SYSTEM", 89, 92], ["WNV", "ORGANISM", 113, 116], ["murine", "ORGANISM", 130, 136], ["TLR3", "PROTEIN", 24, 28], ["murine", "SPECIES", 130, 136], ["WNV", "SPECIES", 113, 116], ["Studies", "TEST", 0, 7], ["TLR3 signaling", "PROBLEM", 24, 38], ["both enhancement", "PROBLEM", 54, 70], ["CNS inflammation", "PROBLEM", 89, 105], ["WNV infection", "PROBLEM", 113, 126], ["both", "OBSERVATION_MODIFIER", 54, 58], ["enhancement", "OBSERVATION", 59, 70], ["CNS", "ANATOMY", 89, 92], ["inflammation", "OBSERVATION", 93, 105], ["WNV", "OBSERVATION_MODIFIER", 113, 116], ["infection", "OBSERVATION", 117, 126]]], ["Similarly, TLR3 signaling has been associated with neuropathogenesis of rabies virus (RABV) in mice [146] while limiting infection of herpes simplex virus (HSV)-2 in the CNS through the activation of IFNAR signaling in astrocytes [142] .Innate Immune Responses to Viruses that Impact BBB FunctionThe NLR family is involved in the maturation of pro-inflammatory cytokines, produced by other PRRs (e.g., TLRs and RLRs) in response to viral infection.", [["CNS", "ANATOMY", 170, 173], ["astrocytes", "ANATOMY", 219, 229], ["rabies virus", "DISEASE", 72, 84], ["infection", "DISEASE", 121, 130], ["herpes simplex virus", "DISEASE", 134, 154], ["viral infection", "DISEASE", 432, 447], ["TLR3", "GENE_OR_GENE_PRODUCT", 11, 15], ["rabies virus", "ORGANISM", 72, 84], ["RABV", "ORGANISM", 86, 90], ["mice", "ORGANISM", 95, 99], ["herpes simplex virus", "ORGANISM", 134, 154], ["HSV)-2", "ORGANISM", 156, 162], ["CNS", "ANATOMICAL_SYSTEM", 170, 173], ["IFNAR", "GENE_OR_GENE_PRODUCT", 200, 205], ["astrocytes", "CELL", 219, 229], ["NLR", "GENE_OR_GENE_PRODUCT", 300, 303], ["PRRs", "GENE_OR_GENE_PRODUCT", 390, 394], ["TLRs", "GENE_OR_GENE_PRODUCT", 402, 406], ["RLRs", "GENE_OR_GENE_PRODUCT", 411, 415], ["TLR3", "PROTEIN", 11, 15], ["IFNAR", "PROTEIN", 200, 205], ["astrocytes", "CELL_TYPE", 219, 229], ["NLR family", "PROTEIN", 300, 310], ["pro-inflammatory cytokines", "PROTEIN", 344, 370], ["PRRs", "PROTEIN", 390, 394], ["TLRs", "PROTEIN", 402, 406], ["RLRs", "PROTEIN", 411, 415], ["rabies virus", "SPECIES", 72, 84], ["mice", "SPECIES", 95, 99], ["herpes simplex virus", "SPECIES", 134, 154], ["rabies virus", "SPECIES", 72, 84], ["RABV", "SPECIES", 86, 90], ["mice", "SPECIES", 95, 99], ["herpes simplex virus", "SPECIES", 134, 154], ["HSV", "SPECIES", 156, 159], ["neuropathogenesis of rabies virus", "PROBLEM", 51, 84], ["herpes simplex virus", "PROBLEM", 134, 154], ["pro-inflammatory cytokines", "PROBLEM", 344, 370], ["viral infection", "PROBLEM", 432, 447], ["herpes simplex", "OBSERVATION", 134, 148], ["CNS", "ANATOMY", 170, 173], ["viral infection", "OBSERVATION", 432, 447]]], ["Viral sensing by NLRs triggers the assembly and activation of inflammasome complex, resulting in the maturation and release of interleukin-1\u03b2 (IL-1\u03b2) and IL-18 from infected cells (reviewed in [140] ).", [["cells", "ANATOMY", 174, 179], ["NLRs", "GENE_OR_GENE_PRODUCT", 17, 21], ["inflammasome complex", "GENE_OR_GENE_PRODUCT", 62, 82], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 127, 141], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 143, 148], ["IL-18", "GENE_OR_GENE_PRODUCT", 154, 159], ["cells", "CELL", 174, 179], ["NLRs", "PROTEIN", 17, 21], ["inflammasome complex", "PROTEIN", 62, 82], ["interleukin-1\u03b2 (IL-1\u03b2", "PROTEIN", 127, 148], ["IL-18", "PROTEIN", 154, 159], ["infected cells", "CELL_TYPE", 165, 179], ["inflammasome complex", "PROBLEM", 62, 82], ["interleukin", "TEST", 127, 138], ["IL", "TEST", 143, 145], ["IL", "TEST", 154, 156], ["infected cells", "PROBLEM", 165, 179]]], ["Seemingly, IL-1\u03b2 acts in synergy with type I IFNs to suppress virus replication in cortical neurons, thus providing protection against lethal WNV infection in mice [147] .", [["cortical neurons", "ANATOMY", 83, 99], ["WNV infection", "DISEASE", 142, 155], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 11, 16], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 38, 49], ["cortical neurons", "CELL", 83, 99], ["WNV", "ORGANISM", 142, 145], ["mice", "ORGANISM", 159, 163], ["IL-1\u03b2", "PROTEIN", 11, 16], ["type I IFNs", "PROTEIN", 38, 49], ["cortical neurons", "CELL_TYPE", 83, 99], ["mice", "SPECIES", 159, 163], ["WNV", "SPECIES", 142, 145], ["mice", "SPECIES", 159, 163], ["type I IFNs", "TREATMENT", 38, 49], ["suppress virus replication", "TREATMENT", 53, 79], ["lethal WNV infection", "PROBLEM", 135, 155], ["cortical neurons", "ANATOMY", 83, 99]]], ["In contrast, enhanced production of IL-1\u03b2 is linked to neuropathology associated with JEV infection in murine models [148] .", [["neuropathology", "DISEASE", 55, 69], ["JEV infection", "DISEASE", 86, 99], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 36, 41], ["JEV", "ORGANISM", 86, 89], ["murine", "ORGANISM", 103, 109], ["IL-1\u03b2", "PROTEIN", 36, 41], ["murine", "SPECIES", 103, 109], ["JEV", "SPECIES", 86, 89], ["neuropathology", "PROBLEM", 55, 69], ["JEV infection in murine models", "PROBLEM", 86, 116], ["JEV infection", "OBSERVATION", 86, 99]]], ["IL-1\u03b2 also abrogates the protective effect of astrocytes on BBB integrity by suppressing astrocytic expression of sonic hedgehog (SHH), a protein that upregulates the expression of TJs in BMECs [149] .", [["astrocytes", "ANATOMY", 46, 56], ["BBB", "ANATOMY", 60, 63], ["TJs", "ANATOMY", 181, 184], ["BMECs", "ANATOMY", 188, 193], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["astrocytes", "CELL", 46, 56], ["BBB", "MULTI-TISSUE_STRUCTURE", 60, 63], ["sonic hedgehog", "GENE_OR_GENE_PRODUCT", 114, 128], ["SHH", "GENE_OR_GENE_PRODUCT", 130, 133], ["TJs", "GENE_OR_GENE_PRODUCT", 181, 184], ["IL-1\u03b2", "PROTEIN", 0, 5], ["astrocytes", "CELL_TYPE", 46, 56], ["sonic hedgehog", "PROTEIN", 114, 128], ["SHH", "PROTEIN", 130, 133], ["TJs", "PROTEIN", 181, 184], ["astrocytes", "PROBLEM", 46, 56], ["BBB integrity", "TREATMENT", 60, 73], ["a protein", "TREATMENT", 136, 145]]], ["Additionally, IL-1\u03b2 and IL-18 activate microglia and astrocytes to generate more inflammatory molecules potentiating inflammation.", [["microglia", "ANATOMY", 39, 48], ["astrocytes", "ANATOMY", 53, 63], ["inflammation", "DISEASE", 117, 129], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 14, 19], ["IL-18", "GENE_OR_GENE_PRODUCT", 24, 29], ["microglia", "CELL", 39, 48], ["astrocytes", "CELL", 53, 63], ["IL-1\u03b2", "PROTEIN", 14, 19], ["IL-18", "PROTEIN", 24, 29], ["microglia", "CELL_TYPE", 39, 48], ["astrocytes", "CELL_TYPE", 53, 63], ["IL", "TEST", 14, 16], ["IL", "TEST", 24, 26], ["inflammatory molecules potentiating inflammation", "PROBLEM", 81, 129], ["inflammatory", "OBSERVATION_MODIFIER", 81, 93], ["inflammation", "OBSERVATION", 117, 129]]], ["Activation of microglia is often reported during encephalitic viral infection [104, [150] [151] [152] [153] , which is regulated by IFNAR signaling in astrocytes and neurons [154] .", [["microglia", "ANATOMY", 14, 23], ["astrocytes", "ANATOMY", 151, 161], ["neurons", "ANATOMY", 166, 173], ["viral infection", "DISEASE", 62, 77], ["microglia", "CELL", 14, 23], ["IFNAR", "GENE_OR_GENE_PRODUCT", 132, 137], ["astrocytes", "CELL", 151, 161], ["neurons", "CELL", 166, 173], ["microglia", "CELL_TYPE", 14, 23], ["IFNAR", "PROTEIN", 132, 137], ["astrocytes", "CELL_TYPE", 151, 161], ["encephalitic viral infection", "PROBLEM", 49, 77]]], ["While microglia play a crucial role in viral clearance in the CNS [154] [155] [156] , uncontrolled gliosis can disrupt BBB integrity through induction of pro-inflammatory cytokines and matrix metalloproteases [153] .", [["microglia", "ANATOMY", 6, 15], ["CNS", "ANATOMY", 62, 65], ["BBB", "ANATOMY", 119, 122], ["gliosis", "DISEASE", 99, 106], ["microglia", "CELL", 6, 15], ["BBB", "MULTI-TISSUE_STRUCTURE", 119, 122], ["microglia", "CELL_TYPE", 6, 15], ["pro-inflammatory cytokines", "PROTEIN", 154, 180], ["matrix metalloproteases", "PROTEIN", 185, 208], ["uncontrolled gliosis", "PROBLEM", 86, 106], ["pro-inflammatory cytokines", "TREATMENT", 154, 180], ["matrix metalloproteases", "TEST", 185, 208], ["gliosis", "OBSERVATION", 99, 106]]], ["Similarly, astrocytes mount a strong innate immune response upon recognition of viral PAMPs via RLR and TLR signaling pathways.", [["astrocytes", "ANATOMY", 11, 21], ["astrocytes", "CELL", 11, 21], ["PAMPs", "GENE_OR_GENE_PRODUCT", 86, 91], ["RLR", "GENE_OR_GENE_PRODUCT", 96, 99], ["TLR", "GENE_OR_GENE_PRODUCT", 104, 107], ["astrocytes", "CELL_TYPE", 11, 21], ["viral PAMPs", "PROTEIN", 80, 91], ["RLR", "PROTEIN", 96, 99], ["TLR", "PROTEIN", 104, 107], ["viral PAMPs", "TREATMENT", 80, 91], ["viral PAMPs", "OBSERVATION", 80, 91]]], ["In fact, astrocytes are the main producers of type I IFNs during infection with several distinct neurotropic viruses, including La Crosse virus, rabies virus (RABV), vesicular stomatitis virus (VSV), and Theiler's murine encephalitis virus (TMEV) [157, 158] .", [["astrocytes", "ANATOMY", 9, 19], ["infection", "DISEASE", 65, 74], ["rabies virus", "DISEASE", 145, 157], ["vesicular stomatitis", "DISEASE", 166, 186], ["Theiler's murine encephalitis", "DISEASE", 204, 233], ["TMEV", "DISEASE", 241, 245], ["astrocytes", "CELL", 9, 19], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 46, 57], ["neurotropic viruses", "ORGANISM", 97, 116], ["La Crosse virus", "ORGANISM", 128, 143], ["rabies virus", "ORGANISM", 145, 157], ["RABV", "ORGANISM", 159, 163], ["vesicular stomatitis virus", "ORGANISM", 166, 192], ["VSV", "ORGANISM", 194, 197], ["Theiler's murine encephalitis virus", "ORGANISM", 204, 239], ["TMEV", "ORGANISM", 241, 245], ["astrocytes", "CELL_TYPE", 9, 19], ["type I IFNs", "PROTEIN", 46, 57], ["Crosse virus", "SPECIES", 131, 143], ["rabies virus", "SPECIES", 145, 157], ["vesicular stomatitis virus", "SPECIES", 166, 192], ["VSV", "SPECIES", 194, 197], ["Theiler", "SPECIES", 204, 211], ["murine encephalitis virus", "SPECIES", 214, 239], ["Crosse virus", "SPECIES", 131, 143], ["rabies virus", "SPECIES", 145, 157], ["RABV", "SPECIES", 159, 163], ["vesicular stomatitis virus", "SPECIES", 166, 192], ["VSV", "SPECIES", 194, 197], ["Theiler's murine encephalitis virus", "SPECIES", 204, 239], ["TMEV", "SPECIES", 241, 245], ["type I IFNs during infection", "PROBLEM", 46, 74], ["several distinct neurotropic viruses", "PROBLEM", 80, 116], ["La Crosse virus", "PROBLEM", 128, 143], ["rabies virus (RABV", "PROBLEM", 145, 163], ["vesicular stomatitis virus", "PROBLEM", 166, 192], ["Theiler's murine encephalitis virus", "PROBLEM", 204, 239], ["astrocytes", "OBSERVATION", 9, 19], ["main", "OBSERVATION_MODIFIER", 28, 32], ["neurotropic viruses", "OBSERVATION", 97, 116], ["vesicular stomatitis", "ANATOMY", 166, 186]]], ["Deletion of IFNAR signaling specifically in astrocytes results in severe encephalomyelitis and mortality during otherwise nonlethal mouse hepatitis virus (MHV) [159] .", [["astrocytes", "ANATOMY", 44, 54], ["encephalomyelitis", "DISEASE", 73, 90], ["nonlethal mouse hepatitis virus", "DISEASE", 122, 153], ["IFNAR", "GENE_OR_GENE_PRODUCT", 12, 17], ["astrocytes", "CELL", 44, 54], ["mouse hepatitis virus", "ORGANISM", 132, 153], ["IFNAR", "PROTEIN", 12, 17], ["astrocytes", "CELL_TYPE", 44, 54], ["mouse", "SPECIES", 132, 137], ["hepatitis virus", "SPECIES", 138, 153], ["mouse hepatitis virus", "SPECIES", 132, 153], ["MHV", "SPECIES", 155, 158], ["Deletion of IFNAR signaling", "PROBLEM", 0, 27], ["severe encephalomyelitis", "PROBLEM", 66, 90], ["otherwise nonlethal mouse hepatitis virus", "PROBLEM", 112, 153], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["encephalomyelitis", "OBSERVATION", 73, 90]]], ["Nonetheless, activated astrocytes can release excess amount of IP-10 during encephalitic viral infection [109] .", [["astrocytes", "ANATOMY", 23, 33], ["IP-10", "CHEMICAL", 63, 68], ["viral infection", "DISEASE", 89, 104], ["astrocytes", "CELL", 23, 33], ["IP-10", "GENE_OR_GENE_PRODUCT", 63, 68], ["encephalitic viral", "ORGANISM", 76, 94], ["activated astrocytes", "CELL_TYPE", 13, 33], ["activated astrocytes", "PROBLEM", 13, 33], ["IP", "TEST", 63, 65], ["encephalitic viral infection", "PROBLEM", 76, 104]]], ["IP-10 enhances the expression of tumor necrosis factor alpha (TNF\u03b1) in a JNK-dependent manner, leading to barrier disruption [109] .", [["barrier", "ANATOMY", 106, 113], ["IP-10", "CHEMICAL", 0, 5], ["tumor", "DISEASE", 33, 38], ["IP-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 33, 60], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 62, 66], ["JNK", "GENE_OR_GENE_PRODUCT", 73, 76], ["tumor necrosis factor alpha", "PROTEIN", 33, 60], ["TNF\u03b1", "PROTEIN", 62, 66], ["JNK", "PROTEIN", 73, 76], ["tumor necrosis", "PROBLEM", 33, 47], ["alpha (TNF\u03b1", "TEST", 55, 66], ["barrier disruption", "PROBLEM", 106, 124], ["tumor", "OBSERVATION", 33, 38], ["necrosis", "OBSERVATION_MODIFIER", 39, 47], ["alpha", "OBSERVATION_MODIFIER", 55, 60], ["dependent manner", "OBSERVATION_MODIFIER", 77, 93], ["barrier disruption", "OBSERVATION", 106, 124]]], ["Consistently, injection of mice with neutralizing antibodies against IP- 10 [109] or TNF-\u03b1 ameliorated the decrease in TJ proteins and improved BBB integrity during JEV infection [160] .Innate Immune Responses to Viruses that Impact BBB FunctionAlternatively, viral-induced inflammasome activation triggers pyroptosis, a highly inflammatory form of programmed cell death [161] .", [["TJ", "ANATOMY", 119, 121], ["BBB", "ANATOMY", 144, 147], ["cell", "ANATOMY", 360, 364], ["IP- 10", "CHEMICAL", 69, 75], ["JEV infection", "DISEASE", 165, 178], ["pyroptosis", "DISEASE", 307, 317], ["mice", "ORGANISM", 27, 31], ["IP- 10", "GENE_OR_GENE_PRODUCT", 69, 75], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 85, 90], ["TJ", "GENE_OR_GENE_PRODUCT", 119, 121], ["BBB", "MULTI-TISSUE_STRUCTURE", 144, 147], ["JEV", "ORGANISM", 165, 168], ["cell", "CELL", 360, 364], ["neutralizing antibodies", "PROTEIN", 37, 60], ["TNF", "PROTEIN", 85, 88], ["TJ proteins", "PROTEIN", 119, 130], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["JEV", "SPECIES", 165, 168], ["neutralizing antibodies", "TEST", 37, 60], ["IP", "TEST", 69, 71], ["TNF", "TEST", 85, 88], ["the decrease in TJ proteins", "PROBLEM", 103, 130], ["JEV infection", "PROBLEM", 165, 178], ["pyroptosis", "PROBLEM", 307, 317], ["programmed cell death", "PROBLEM", 349, 370], ["decrease", "OBSERVATION_MODIFIER", 107, 115], ["inflammatory", "OBSERVATION_MODIFIER", 328, 340], ["programmed cell death", "OBSERVATION", 349, 370]]], ["Although pyroptosis plays a crucial role in controlling virus spread [162] , it can cause neuronal necrosis and gliosis [163] , features associated with BBB disruption.", [["neuronal", "ANATOMY", 90, 98], ["BBB", "ANATOMY", 153, 156], ["pyroptosis", "DISEASE", 9, 19], ["neuronal necrosis", "DISEASE", 90, 107], ["gliosis", "DISEASE", 112, 119], ["neuronal", "CELL", 90, 98], ["BBB", "MULTI-TISSUE_STRUCTURE", 153, 156], ["pyroptosis", "PROBLEM", 9, 19], ["neuronal necrosis", "PROBLEM", 90, 107], ["gliosis", "PROBLEM", 112, 119], ["BBB disruption", "PROBLEM", 153, 167], ["pyroptosis", "OBSERVATION", 9, 19], ["neuronal", "ANATOMY", 90, 98], ["necrosis", "OBSERVATION", 99, 107], ["gliosis", "OBSERVATION", 112, 119], ["BBB", "ANATOMY", 153, 156], ["disruption", "OBSERVATION", 157, 167]]], ["In the CNS, inflammasome activity is regulated by mechanisms involving osteopontin (OPN) and prostaglandin D2 (PGD2), upon viral infection [164, 165] .", [["CNS", "ANATOMY", 7, 10], ["prostaglandin D2", "CHEMICAL", 93, 109], ["PGD2", "CHEMICAL", 111, 115], ["viral infection", "DISEASE", 123, 138], ["prostaglandin D2", "CHEMICAL", 93, 109], ["PGD2", "CHEMICAL", 111, 115], ["CNS", "ANATOMICAL_SYSTEM", 7, 10], ["osteopontin", "GENE_OR_GENE_PRODUCT", 71, 82], ["OPN", "GENE_OR_GENE_PRODUCT", 84, 87], ["prostaglandin D2", "GENE_OR_GENE_PRODUCT", 93, 109], ["PGD2", "GENE_OR_GENE_PRODUCT", 111, 115], ["osteopontin", "PROTEIN", 71, 82], ["OPN", "PROTEIN", 84, 87], ["osteopontin (OPN)", "TREATMENT", 71, 88], ["prostaglandin D2 (PGD2)", "PROBLEM", 93, 116], ["viral infection", "PROBLEM", 123, 138], ["CNS", "ANATOMY", 7, 10], ["inflammasome activity", "OBSERVATION", 12, 33], ["viral", "OBSERVATION_MODIFIER", 123, 128], ["infection", "OBSERVATION", 129, 138]]], ["OPN inhibits the caspase-1-dependent inflammasome activation by reducing the expression of inflammasome components in the brain [165] .", [["brain", "ANATOMY", 122, 127], ["OPN", "GENE_OR_GENE_PRODUCT", 0, 3], ["caspase-1", "GENE_OR_GENE_PRODUCT", 17, 26], ["brain", "ORGAN", 122, 127], ["OPN", "PROTEIN", 0, 3], ["caspase-1", "PROTEIN", 17, 26], ["inflammasome components", "PROTEIN", 91, 114], ["the caspase", "TEST", 13, 24], ["dependent inflammasome activation", "PROBLEM", 27, 60], ["inflammasome components in the brain", "PROBLEM", 91, 127], ["dependent", "OBSERVATION_MODIFIER", 27, 36], ["inflammasome", "OBSERVATION", 37, 49], ["inflammasome", "OBSERVATION", 91, 103], ["brain", "ANATOMY", 122, 127]]], ["However, PGD2 can exert both pro-and anti-inflammatory effects depending on the receptor involved.", [["PGD2", "CHEMICAL", 9, 13], ["PGD2", "CHEMICAL", 9, 13], ["PGD2", "SIMPLE_CHEMICAL", 9, 13], ["PGD2", "PROBLEM", 9, 13], ["both pro-and anti-inflammatory effects", "TREATMENT", 24, 62]]], ["Engagement of D-prostanoid receptor 1(DP1) on microglia by PGD2 upregulates PYDC3 (an inflammasome inhibitor), which protects against IL-1\u03b2-mediated neuroinflammation [164] .", [["microglia", "ANATOMY", 46, 55], ["PGD2", "CHEMICAL", 59, 63], ["neuroinflammation", "DISEASE", 149, 166], ["D-prostanoid receptor 1", "GENE_OR_GENE_PRODUCT", 14, 37], ["DP1", "GENE_OR_GENE_PRODUCT", 38, 41], ["microglia", "CELL", 46, 55], ["PGD2", "GENE_OR_GENE_PRODUCT", 59, 63], ["PYDC3", "GENE_OR_GENE_PRODUCT", 76, 81], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 134, 139], ["D-prostanoid receptor 1", "PROTEIN", 14, 37], ["DP1", "PROTEIN", 38, 41], ["microglia", "CELL_TYPE", 46, 55], ["PYDC3", "PROTEIN", 76, 81], ["IL-1\u03b2", "PROTEIN", 134, 139], ["D-prostanoid receptor", "TREATMENT", 14, 35], ["PGD2 upregulates PYDC3", "TREATMENT", 59, 81], ["an inflammasome inhibitor", "TREATMENT", 83, 108], ["IL", "TEST", 134, 136], ["neuroinflammation", "PROBLEM", 149, 166]]], ["Deficiency in DP1 also correlates with reduced expression of IFN-I and -III, augmenting viral titer in the brain.", [["brain", "ANATOMY", 107, 112], ["DP1", "GENE_OR_GENE_PRODUCT", 14, 17], ["IFN-I", "GENE_OR_GENE_PRODUCT", 61, 66], ["-III", "GENE_OR_GENE_PRODUCT", 71, 75], ["brain", "ORGAN", 107, 112], ["DP1", "PROTEIN", 14, 17], ["IFN-I and -III", "PROTEIN", 61, 75], ["Deficiency in DP1", "PROBLEM", 0, 17], ["IFN", "TEST", 61, 64], ["augmenting viral titer in the brain", "PROBLEM", 77, 112], ["viral titer", "OBSERVATION", 88, 99], ["brain", "ANATOMY", 107, 112]]], ["Interestingly, upon viral infections, IFNAR signaling in BMECs reduces expression of IL-1\u03b2 [15], likely via inhibition of inflammasome activity [166] .", [["BMECs", "ANATOMY", 57, 62], ["viral infections", "DISEASE", 20, 36], ["IFNAR", "GENE_OR_GENE_PRODUCT", 38, 43], ["BMECs", "PATHOLOGICAL_FORMATION", 57, 62], ["IL-1\u03b2 [15]", "GENE_OR_GENE_PRODUCT", 85, 95], ["IFNAR", "PROTEIN", 38, 43], ["BMECs", "CELL_TYPE", 57, 62], ["IL", "PROTEIN", 85, 87], ["viral infections", "PROBLEM", 20, 36], ["IFNAR signaling in BMECs", "PROBLEM", 38, 62], ["IL", "TEST", 85, 87], ["inflammasome activity", "PROBLEM", 122, 143], ["viral infections", "OBSERVATION", 20, 36]]], ["Additionally, type I IFNs act in synergy with MerTK (a member of TAM receptor tyrosine kinases) to activate Rac-1, which in turn improves TJ integrity [167] .Innate Immune Responses to Viruses that Impact BBB FunctionTaken altogether, these studies suggest that innate immunity plays a central role in restricting viral replication in the CNS.", [["TJ", "ANATOMY", 138, 140], ["CNS", "ANATOMY", 339, 342], ["TAM", "CHEMICAL", 65, 68], ["tyrosine", "CHEMICAL", 78, 86], ["TAM", "CHEMICAL", 65, 68], ["tyrosine", "CHEMICAL", 78, 86], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 14, 25], ["MerTK", "GENE_OR_GENE_PRODUCT", 46, 51], ["TAM receptor tyrosine kinases", "GENE_OR_GENE_PRODUCT", 65, 94], ["Rac-1", "GENE_OR_GENE_PRODUCT", 108, 113], ["TJ", "GENE_OR_GENE_PRODUCT", 138, 140], ["CNS", "ANATOMICAL_SYSTEM", 339, 342], ["type I IFNs", "PROTEIN", 14, 25], ["MerTK", "PROTEIN", 46, 51], ["TAM receptor tyrosine kinases", "PROTEIN", 65, 94], ["Rac-1", "PROTEIN", 108, 113], ["MerTK (a member of TAM receptor tyrosine kinases", "TREATMENT", 46, 94], ["Rac", "TEST", 108, 111], ["these studies", "TEST", 235, 248], ["restricting viral replication", "TREATMENT", 302, 331], ["viral replication", "OBSERVATION", 314, 331], ["CNS", "ANATOMY", 339, 342]]], ["This has the potential to be protective or detrimental, depending on the virus and magnitude of host immune response.", [["the virus", "PROBLEM", 69, 78]]], ["The protective effect is mainly attributed to IFNAR signaling in CNS residential cells that not only limits local virus replication but also restricts additional viral entry or leukocyte infiltration by retaining BBB integrity.Adaptive Immune Responses to Viruses that Impact BBB FunctionLeukocyte migration across the BBB requires expression of ICAM-1 and VCAM-1 on brain endothelial cells (ECs).", [["CNS residential cells", "ANATOMY", 65, 86], ["leukocyte", "ANATOMY", 177, 186], ["BBB", "ANATOMY", 213, 216], ["BBB", "ANATOMY", 319, 322], ["brain endothelial cells", "ANATOMY", 367, 390], ["ECs", "ANATOMY", 392, 395], ["IFNAR", "GENE_OR_GENE_PRODUCT", 46, 51], ["CNS residential cells", "CELL", 65, 86], ["leukocyte", "CELL", 177, 186], ["BBB", "MULTI-TISSUE_STRUCTURE", 213, 216], ["BBB", "MULTI-TISSUE_STRUCTURE", 319, 322], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 346, 352], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 357, 363], ["brain endothelial cells", "CELL", 367, 390], ["ECs", "CELL", 392, 395], ["IFNAR", "PROTEIN", 46, 51], ["CNS residential cells", "CELL_TYPE", 65, 86], ["ICAM-1", "PROTEIN", 346, 352], ["VCAM-1", "PROTEIN", 357, 363], ["brain endothelial cells", "CELL_TYPE", 367, 390], ["ECs", "CELL_TYPE", 392, 395], ["IFNAR signaling in CNS residential cells", "PROBLEM", 46, 86], ["local virus replication", "PROBLEM", 108, 131], ["leukocyte infiltration", "PROBLEM", 177, 199], ["Impact BBB FunctionLeukocyte migration", "PROBLEM", 269, 307], ["the BBB", "TEST", 315, 322], ["ICAM", "TEST", 346, 350], ["VCAM", "TEST", 357, 361], ["brain endothelial cells", "TEST", 367, 390], ["protective effect", "OBSERVATION", 4, 21], ["mainly attributed to", "UNCERTAINTY", 25, 45], ["CNS", "ANATOMY", 65, 68], ["residential cells", "OBSERVATION", 69, 86], ["leukocyte infiltration", "OBSERVATION", 177, 199], ["brain endothelial", "ANATOMY", 367, 384]]], ["As mentioned above, under normal conditions, these molecules are expressed minimally on brain ECs to restrict immune cell interaction and extravasation into the CNS.", [["brain ECs", "ANATOMY", 88, 97], ["immune cell", "ANATOMY", 110, 121], ["CNS", "ANATOMY", 161, 164], ["brain ECs", "CELL", 88, 97], ["immune cell", "CELL", 110, 121], ["CNS", "ANATOMICAL_SYSTEM", 161, 164], ["brain ECs", "CELL_TYPE", 88, 97], ["brain ECs", "TEST", 88, 97], ["immune cell interaction", "PROBLEM", 110, 133], ["extravasation into the CNS", "PROBLEM", 138, 164], ["immune cell interaction", "OBSERVATION", 110, 133], ["extravasation", "OBSERVATION", 138, 151], ["CNS", "ANATOMY", 161, 164]]], ["However, elevated expression of ICAM-1 and VCAM-1 has been frequently observed in infection with several neurotropic viruses [168] [169] [170] [171] [172] .", [["infection", "DISEASE", 82, 91], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 32, 38], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 43, 49], ["ICAM-1", "PROTEIN", 32, 38], ["VCAM-1", "PROTEIN", 43, 49], ["ICAM", "TEST", 32, 36], ["VCAM", "TEST", 43, 47], ["infection", "PROBLEM", 82, 91], ["several neurotropic viruses", "PROBLEM", 97, 124], ["infection", "OBSERVATION", 82, 91]]], ["Altered expression of these adhesion molecules mainly results from the activation of NF-\u03baB by ROS or ERK signaling pathway.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 85, 90], ["ROS", "SIMPLE_CHEMICAL", 94, 97], ["ERK", "GENE_OR_GENE_PRODUCT", 101, 104], ["adhesion molecules", "PROTEIN", 28, 46], ["NF-\u03baB", "PROTEIN", 85, 90], ["ERK", "PROTEIN", 101, 104], ["these adhesion molecules", "PROBLEM", 22, 46], ["adhesion molecules", "OBSERVATION", 28, 46]]], ["For instance, HIV-1 Tat protein induces NADPH oxidase in astrocytes, which results in the upregulation of CAMs expression via NF-\u03baB signaling [173, 174] .", [["astrocytes", "ANATOMY", 57, 67], ["NADPH", "CHEMICAL", 40, 45], ["NADPH", "CHEMICAL", 40, 45], ["HIV-1", "ORGANISM", 14, 19], ["Tat", "GENE_OR_GENE_PRODUCT", 20, 23], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 40, 53], ["astrocytes", "CELL", 57, 67], ["CAMs", "GENE_OR_GENE_PRODUCT", 106, 110], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 126, 131], ["HIV-1 Tat protein", "PROTEIN", 14, 31], ["NADPH oxidase", "PROTEIN", 40, 53], ["astrocytes", "CELL_TYPE", 57, 67], ["CAMs", "PROTEIN", 106, 110], ["NF-\u03baB", "PROTEIN", 126, 131], ["HIV-1", "SPECIES", 14, 19], ["HIV-1", "SPECIES", 14, 19], ["HIV", "TEST", 14, 17], ["Tat protein", "TEST", 20, 31], ["NADPH oxidase in astrocytes", "PROBLEM", 40, 67], ["NF", "TEST", 126, 128]]], ["Similarly, JEV infection augments ICAM-1 expression on brain endothelial cells through activation of ERK signaling pathway [171] .", [["brain endothelial cells", "ANATOMY", 55, 78], ["JEV infection", "DISEASE", 11, 24], ["JEV", "ORGANISM", 11, 14], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 34, 40], ["brain endothelial cells", "CELL", 55, 78], ["ERK", "GENE_OR_GENE_PRODUCT", 101, 104], ["ICAM", "PROTEIN", 34, 38], ["brain endothelial cells", "CELL_TYPE", 55, 78], ["ERK", "PROTEIN", 101, 104], ["JEV", "SPECIES", 11, 14], ["JEV infection augments ICAM", "PROBLEM", 11, 38], ["brain endothelial cells", "TEST", 55, 78], ["ERK signaling pathway", "TEST", 101, 122], ["JEV", "OBSERVATION_MODIFIER", 11, 14], ["infection", "OBSERVATION", 15, 24], ["brain", "ANATOMY", 55, 60], ["endothelial cells", "OBSERVATION", 61, 78]]], ["Interestingly, expression of CAMs on brain endothelium is downregulated by IFNAR signaling in astrocytes, which promotes BBB integrity during encephalitic viral infection [170] .", [["brain endothelium", "ANATOMY", 37, 54], ["astrocytes", "ANATOMY", 94, 104], ["BBB", "ANATOMY", 121, 124], ["viral infection", "DISEASE", 155, 170], ["CAMs", "GENE_OR_GENE_PRODUCT", 29, 33], ["brain endothelium", "TISSUE", 37, 54], ["IFNAR", "GENE_OR_GENE_PRODUCT", 75, 80], ["astrocytes", "CELL", 94, 104], ["BBB", "MULTI-TISSUE_STRUCTURE", 121, 124], ["CAMs", "PROTEIN", 29, 33], ["IFNAR", "PROTEIN", 75, 80], ["astrocytes", "CELL_TYPE", 94, 104], ["CAMs on brain endothelium", "PROBLEM", 29, 54], ["IFNAR signaling in astrocytes", "PROBLEM", 75, 104], ["encephalitic viral infection", "PROBLEM", 142, 170], ["CAMs", "OBSERVATION", 29, 33], ["brain endothelium", "ANATOMY", 37, 54], ["astrocytes", "ANATOMY", 94, 104], ["encephalitic", "OBSERVATION_MODIFIER", 142, 154]]], ["Additionally, IFNAR signaling in astrocytes influences the composition of inflammatory cells recruited to the CNS upon viral infection [159] .Adaptive Immune Responses to Viruses that Impact BBB FunctionAlthough immune cell infiltration is crucial for viral clearance in the CNS [147, 175, 176] , it can cause BBB disruption and neuronal damage by potentiating neuroinflammation [104] .", [["astrocytes", "ANATOMY", 33, 43], ["inflammatory cells", "ANATOMY", 74, 92], ["CNS", "ANATOMY", 110, 113], ["immune cell", "ANATOMY", 212, 223], ["CNS", "ANATOMY", 275, 278], ["BBB", "ANATOMY", 310, 313], ["neuronal", "ANATOMY", 329, 337], ["viral infection", "DISEASE", 119, 134], ["neuronal damage", "DISEASE", 329, 344], ["neuroinflammation", "DISEASE", 361, 378], ["IFNAR", "GENE_OR_GENE_PRODUCT", 14, 19], ["astrocytes", "CELL", 33, 43], ["inflammatory cells", "CELL", 74, 92], ["CNS", "ANATOMICAL_SYSTEM", 110, 113], ["immune cell", "CELL", 212, 223], ["BBB", "MULTI-TISSUE_STRUCTURE", 310, 313], ["neuronal", "CELL", 329, 337], ["IFNAR", "PROTEIN", 14, 19], ["astrocytes", "CELL_TYPE", 33, 43], ["inflammatory cells", "CELL_TYPE", 74, 92], ["IFNAR signaling in astrocytes", "PROBLEM", 14, 43], ["inflammatory cells", "PROBLEM", 74, 92], ["viral infection", "PROBLEM", 119, 134], ["immune cell infiltration", "PROBLEM", 212, 236], ["viral clearance", "TEST", 252, 267], ["BBB disruption", "PROBLEM", 310, 324], ["neuronal damage", "PROBLEM", 329, 344], ["neuroinflammation", "PROBLEM", 361, 378], ["inflammatory cells", "OBSERVATION", 74, 92], ["CNS", "ANATOMY", 110, 113], ["immune cell infiltration", "OBSERVATION", 212, 236], ["neuronal damage", "OBSERVATION", 329, 344]]], ["Studies have shown that immune cell infiltration precedes BBB disruption in mice infected with VEEV and tick-borne encephalitic virus (TBEV) [102, 172] .", [["immune cell", "ANATOMY", 24, 35], ["BBB", "ANATOMY", 58, 61], ["tick-borne encephalitic virus", "DISEASE", 104, 133], ["TBEV", "DISEASE", 135, 139], ["immune cell", "CELL", 24, 35], ["BBB", "MULTI-TISSUE_STRUCTURE", 58, 61], ["mice", "ORGANISM", 76, 80], ["VEEV", "ORGANISM", 95, 99], ["tick-borne encephalitic virus", "ORGANISM", 104, 133], ["TBEV", "ORGANISM", 135, 139], ["mice", "SPECIES", 76, 80], ["tick-borne encephalitic virus", "SPECIES", 104, 133], ["mice", "SPECIES", 76, 80], ["VEEV", "SPECIES", 95, 99], ["tick-borne encephalitic virus", "SPECIES", 104, 133], ["TBEV", "SPECIES", 135, 139], ["Studies", "TEST", 0, 7], ["immune cell infiltration", "PROBLEM", 24, 48], ["BBB disruption", "PROBLEM", 58, 72], ["VEEV", "PROBLEM", 95, 99], ["tick-borne encephalitic virus", "PROBLEM", 104, 133], ["immune cell infiltration", "OBSERVATION", 24, 48], ["BBB disruption", "OBSERVATION", 58, 72], ["infected", "OBSERVATION_MODIFIER", 81, 89]]], ["This is associated with increased expression of RANTES, CCL2, IP-10, ICAM-1, TNF-\u03b1, IL-6, and IL-1\u03b2 in brain tissues [172] .", [["brain tissues", "ANATOMY", 103, 116], ["RANTES", "GENE_OR_GENE_PRODUCT", 48, 54], ["CCL2", "GENE_OR_GENE_PRODUCT", 56, 60], ["IP-10", "GENE_OR_GENE_PRODUCT", 62, 67], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 69, 75], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 77, 82], ["IL-6", "GENE_OR_GENE_PRODUCT", 84, 88], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 94, 99], ["brain tissues", "TISSUE", 103, 116], ["RANTES", "PROTEIN", 48, 54], ["CCL2", "PROTEIN", 56, 60], ["ICAM", "PROTEIN", 69, 73], ["TNF", "PROTEIN", 77, 80], ["IL-6", "PROTEIN", 84, 88], ["IL-1\u03b2", "PROTEIN", 94, 99], ["increased expression of RANTES", "PROBLEM", 24, 54], ["CCL2", "TEST", 56, 60], ["IP", "TEST", 62, 64], ["ICAM", "TEST", 69, 73], ["TNF", "TEST", 77, 80], ["IL", "TEST", 84, 86], ["IL", "TEST", 94, 96], ["associated with", "UNCERTAINTY", 8, 23], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["expression", "OBSERVATION", 34, 44], ["RANTES", "OBSERVATION", 48, 54], ["TNF", "ANATOMY", 77, 80], ["brain tissues", "ANATOMY", 103, 116]]], ["Similarly, enhanced levels of CCL2 and RANTES have been reported in serum samples of TBE-infected human patients [177] .", [["serum samples", "ANATOMY", 68, 81], ["TBE-infected", "DISEASE", 85, 97], ["CCL2", "GENE_OR_GENE_PRODUCT", 30, 34], ["RANTES", "GENE_OR_GENE_PRODUCT", 39, 45], ["serum samples", "ORGANISM_SUBSTANCE", 68, 81], ["human", "ORGANISM", 98, 103], ["patients", "ORGANISM", 104, 112], ["CCL2", "PROTEIN", 30, 34], ["RANTES", "PROTEIN", 39, 45], ["human", "SPECIES", 98, 103], ["patients", "SPECIES", 104, 112], ["TBE", "SPECIES", 85, 88], ["human", "SPECIES", 98, 103], ["RANTES", "TEST", 39, 45], ["serum samples", "TEST", 68, 81], ["TBE", "TEST", 85, 88]]], ["Activated monocytes produce CCL2 in response to viral infections, which promotes barrier permeability via alteration in the actin cytoskeleton and localization of TJ proteins [178, 179] .", [["monocytes", "ANATOMY", 10, 19], ["barrier", "ANATOMY", 81, 88], ["cytoskeleton", "ANATOMY", 130, 142], ["viral infections", "DISEASE", 48, 64], ["monocytes", "CELL", 10, 19], ["CCL2", "GENE_OR_GENE_PRODUCT", 28, 32], ["barrier", "TISSUE", 81, 88], ["actin", "GENE_OR_GENE_PRODUCT", 124, 129], ["cytoskeleton", "CELLULAR_COMPONENT", 130, 142], ["TJ", "GENE_OR_GENE_PRODUCT", 163, 165], ["Activated monocytes", "CELL_TYPE", 0, 19], ["CCL2", "PROTEIN", 28, 32], ["actin", "PROTEIN", 124, 129], ["TJ proteins", "PROTEIN", 163, 174], ["Activated monocytes", "PROBLEM", 0, 19], ["CCL2", "PROBLEM", 28, 32], ["viral infections", "PROBLEM", 48, 64], ["TJ proteins", "TEST", 163, 174], ["monocytes", "OBSERVATION", 10, 19], ["CCL2", "OBSERVATION_MODIFIER", 28, 32], ["viral infections", "OBSERVATION", 48, 64], ["barrier permeability", "OBSERVATION_MODIFIER", 81, 101], ["actin cytoskeleton", "OBSERVATION", 124, 142]]], ["Additionally, infiltrating neutrophils and monocytes produce high levels of MMP8, which promotes myelomonocytic cell extravasation and vascular leakage upon infection with lymphocytic choriomeningitis virus (LCMV) [180] .", [["neutrophils", "ANATOMY", 27, 38], ["monocytes", "ANATOMY", 43, 52], ["myelomonocytic cell", "ANATOMY", 97, 116], ["vascular", "ANATOMY", 135, 143], ["infection", "DISEASE", 157, 166], ["lymphocytic choriomeningitis virus", "DISEASE", 172, 206], ["neutrophils", "CELL", 27, 38], ["monocytes", "CELL", 43, 52], ["MMP8", "GENE_OR_GENE_PRODUCT", 76, 80], ["myelomonocytic cell", "CELL", 97, 116], ["vascular", "MULTI-TISSUE_STRUCTURE", 135, 143], ["lymphocytic choriomeningitis virus", "ORGANISM", 172, 206], ["LCMV", "ORGANISM", 208, 212], ["infiltrating neutrophils", "CELL_TYPE", 14, 38], ["monocytes", "CELL_TYPE", 43, 52], ["MMP8", "PROTEIN", 76, 80], ["lymphocytic choriomeningitis virus", "SPECIES", 172, 206], ["lymphocytic choriomeningitis virus", "SPECIES", 172, 206], ["LCMV", "SPECIES", 208, 212], ["infiltrating neutrophils", "PROBLEM", 14, 38], ["monocytes", "TEST", 43, 52], ["high levels of MMP8", "PROBLEM", 61, 80], ["myelomonocytic cell extravasation", "PROBLEM", 97, 130], ["vascular leakage upon infection", "PROBLEM", 135, 166], ["lymphocytic choriomeningitis virus", "PROBLEM", 172, 206], ["infiltrating neutrophils", "OBSERVATION", 14, 38], ["monocytes", "OBSERVATION_MODIFIER", 43, 52], ["high levels", "OBSERVATION_MODIFIER", 61, 72], ["myelomonocytic cell extravasation", "OBSERVATION", 97, 130], ["vascular", "ANATOMY", 135, 143], ["leakage", "OBSERVATION", 144, 151], ["infection", "OBSERVATION", 157, 166], ["lymphocytic choriomeningitis", "OBSERVATION", 172, 200]]], ["Consistently, depletion of both monocytes and neutrophils in LCMV-infected mice promotes BBB integrity and prolonged survival [181] .", [["monocytes", "ANATOMY", 32, 41], ["neutrophils", "ANATOMY", 46, 57], ["BBB", "ANATOMY", 89, 92], ["monocytes", "CELL", 32, 41], ["neutrophils", "CELL", 46, 57], ["LCMV", "ORGANISM", 61, 65], ["mice", "ORGANISM", 75, 79], ["BBB", "MULTI-TISSUE_STRUCTURE", 89, 92], ["monocytes", "CELL_TYPE", 32, 41], ["neutrophils", "CELL_TYPE", 46, 57], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["monocytes", "TEST", 32, 41], ["neutrophils", "TEST", 46, 57], ["LCMV", "TEST", 61, 65], ["depletion", "OBSERVATION_MODIFIER", 14, 23], ["both monocytes", "OBSERVATION", 27, 41], ["neutrophils", "OBSERVATION_MODIFIER", 46, 57], ["LCMV", "OBSERVATION", 61, 65], ["infected", "OBSERVATION_MODIFIER", 66, 74]]], ["Notably, individual depletion of either cell type does not protect against vascular permeability.Adaptive Immune Responses to Viruses that Impact BBB FunctionAs with monocytes, infiltrating lymphocytes can also induce BBB disruption by secreting inflammatory cytokines.", [["cell", "ANATOMY", 40, 44], ["vascular", "ANATOMY", 75, 83], ["monocytes", "ANATOMY", 166, 175], ["infiltrating lymphocytes", "ANATOMY", 177, 201], ["BBB", "ANATOMY", 218, 221], ["cell", "CELL", 40, 44], ["vascular", "MULTI-TISSUE_STRUCTURE", 75, 83], ["monocytes", "CELL", 166, 175], ["lymphocytes", "CELL", 190, 201], ["BBB", "MULTI-TISSUE_STRUCTURE", 218, 221], ["monocytes", "CELL_TYPE", 166, 175], ["infiltrating lymphocytes", "CELL_TYPE", 177, 201], ["inflammatory cytokines", "PROTEIN", 246, 268], ["infiltrating lymphocytes", "PROBLEM", 177, 201], ["BBB disruption", "PROBLEM", 218, 232], ["secreting inflammatory cytokines", "PROBLEM", 236, 268], ["individual", "OBSERVATION_MODIFIER", 9, 19], ["depletion", "OBSERVATION", 20, 29], ["cell type", "OBSERVATION", 40, 49], ["vascular", "ANATOMY", 75, 83], ["permeability", "OBSERVATION", 84, 96], ["infiltrating lymphocytes", "OBSERVATION", 177, 201], ["secreting", "OBSERVATION_MODIFIER", 236, 245], ["inflammatory cytokines", "OBSERVATION", 246, 268]]], ["Infected neurons produce CXCL10, which is a chemoattractant for CD4 and CD8 T cells [176] .", [["neurons", "ANATOMY", 9, 16], ["CD4", "ANATOMY", 64, 67], ["CD8 T cells", "ANATOMY", 72, 83], ["neurons", "CELL", 9, 16], ["CXCL10", "GENE_OR_GENE_PRODUCT", 25, 31], ["CD4", "GENE_OR_GENE_PRODUCT", 64, 67], ["CD8", "GENE_OR_GENE_PRODUCT", 72, 75], ["CXCL10", "PROTEIN", 25, 31], ["CD4", "PROTEIN", 64, 67], ["CD8 T cells", "CELL_TYPE", 72, 83], ["CXCL10", "TEST", 25, 31], ["CD4", "TEST", 64, 67], ["CXCL10", "OBSERVATION", 25, 31]]], ["Upon infection with rabies virus, CD4 T cells infiltrate into the CNS and differentiate into Th1 and Th17 that produce IFN-\u03b3 and IL-17, respectively [182, 183] .", [["CD4 T cells", "ANATOMY", 34, 45], ["CNS", "ANATOMY", 66, 69], ["infection", "DISEASE", 5, 14], ["rabies virus", "ORGANISM", 20, 32], ["CD4 T cells", "CELL", 34, 45], ["CNS", "ANATOMICAL_SYSTEM", 66, 69], ["Th1", "CELL", 93, 96], ["Th17", "CELL", 101, 105], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 119, 124], ["IL-17", "GENE_OR_GENE_PRODUCT", 129, 134], ["CD4 T cells", "CELL_TYPE", 34, 45], ["Th1", "CELL_TYPE", 93, 96], ["Th17", "CELL_TYPE", 101, 105], ["IFN", "PROTEIN", 119, 122], ["IL", "PROTEIN", 129, 131], ["rabies virus", "SPECIES", 20, 32], ["infection", "PROBLEM", 5, 14], ["rabies virus", "PROBLEM", 20, 32], ["CD4 T cells infiltrate", "PROBLEM", 34, 56], ["IFN", "TEST", 119, 122], ["IL", "TEST", 129, 131], ["infection", "OBSERVATION", 5, 14], ["rabies virus", "OBSERVATION", 20, 32], ["CNS", "ANATOMY", 66, 69], ["Th1", "ANATOMY_MODIFIER", 93, 96]]], ["While IFN-\u03b3 reduces the expression of TJ proteins (i.e., occludin, claudin-5, and ZO-1), elevated levels of IL-17 disrupt TJ complexes in infected mice [182] .", [["TJ complexes", "ANATOMY", 122, 134], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 6, 11], ["TJ", "GENE_OR_GENE_PRODUCT", 38, 40], ["occludin", "GENE_OR_GENE_PRODUCT", 57, 65], ["claudin-5", "GENE_OR_GENE_PRODUCT", 67, 76], ["ZO-1", "GENE_OR_GENE_PRODUCT", 82, 86], ["IL-17", "GENE_OR_GENE_PRODUCT", 108, 113], ["TJ", "GENE_OR_GENE_PRODUCT", 122, 124], ["mice", "ORGANISM", 147, 151], ["IFN-\u03b3", "PROTEIN", 6, 11], ["TJ proteins", "PROTEIN", 38, 49], ["occludin", "PROTEIN", 57, 65], ["claudin-5", "PROTEIN", 67, 76], ["ZO-1", "PROTEIN", 82, 86], ["IL-17", "PROTEIN", 108, 113], ["TJ complexes", "PROTEIN", 122, 134], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 147, 151], ["IFN", "TEST", 6, 9], ["TJ proteins", "PROBLEM", 38, 49], ["occludin", "TEST", 57, 65], ["claudin", "TEST", 67, 74], ["elevated levels of IL", "PROBLEM", 89, 110]]], ["Consistently, blockage of IFN-\u03b3 ameliorated BBB integrity in vivo, presumably by restoring expression of TJ proteins in brain endothelial cells [182] .", [["BBB", "ANATOMY", 44, 47], ["brain endothelial cells", "ANATOMY", 120, 143], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 26, 31], ["BBB", "MULTI-TISSUE_STRUCTURE", 44, 47], ["TJ", "GENE_OR_GENE_PRODUCT", 105, 107], ["brain endothelial cells", "CELL", 120, 143], ["IFN", "PROTEIN", 26, 29], ["TJ proteins", "PROTEIN", 105, 116], ["brain endothelial cells", "CELL_TYPE", 120, 143], ["blockage of IFN", "PROBLEM", 14, 29], ["TJ proteins in brain endothelial cells", "PROBLEM", 105, 143], ["blockage", "OBSERVATION", 14, 22], ["brain endothelial", "ANATOMY", 120, 137]]], ["Administration of IFN-\u03b3-neutralizing antibody also alleviated BBB disruption in JEV-infected mice [103] .", [["BBB", "ANATOMY", 62, 65], ["JEV-infected", "DISEASE", 80, 92], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 18, 24], ["BBB", "MULTI-TISSUE_STRUCTURE", 62, 65], ["JEV", "ORGANISM", 80, 83], ["mice", "ORGANISM", 93, 97], ["IFN", "PROTEIN", 18, 21], ["\u03b3-neutralizing antibody", "PROTEIN", 22, 45], ["mice", "SPECIES", 93, 97], ["JEV", "SPECIES", 80, 83], ["mice", "SPECIES", 93, 97], ["IFN", "TEST", 18, 21], ["neutralizing antibody", "TEST", 24, 45], ["BBB disruption", "PROBLEM", 62, 76], ["JEV", "PROBLEM", 80, 83]]], ["CD8 T cells are also involved in vascular leakage during viral infection.", [["CD8 T cells", "ANATOMY", 0, 11], ["vascular", "ANATOMY", 33, 41], ["viral infection", "DISEASE", 57, 72], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["vascular", "MULTI-TISSUE_STRUCTURE", 33, 41], ["CD8 T cells", "CELL_TYPE", 0, 11], ["CD8 T cells", "TEST", 0, 11], ["vascular leakage", "PROBLEM", 33, 49], ["viral infection", "PROBLEM", 57, 72], ["vascular", "ANATOMY", 33, 41], ["leakage", "OBSERVATION", 42, 49], ["viral", "OBSERVATION_MODIFIER", 57, 62], ["infection", "OBSERVATION", 63, 72]]], ["They promote BBB disruption during infection with TMEV (Theiler's murine encephalomyelitis virus), by releasing perforin that disrupts TJ proteins [184] .", [["BBB", "ANATOMY", 13, 16], ["infection", "DISEASE", 35, 44], ["TMEV", "DISEASE", 50, 54], ["Theiler's murine encephalomyelitis", "DISEASE", 56, 90], ["BBB", "MULTI-TISSUE_STRUCTURE", 13, 16], ["TMEV", "ORGANISM", 50, 54], ["Theiler's murine encephalomyelitis virus", "ORGANISM", 56, 96], ["perforin", "GENE_OR_GENE_PRODUCT", 112, 120], ["TJ", "GENE_OR_GENE_PRODUCT", 135, 137], ["perforin", "PROTEIN", 112, 120], ["TJ proteins", "PROTEIN", 135, 146], ["TMEV", "SPECIES", 50, 54], ["Theiler", "SPECIES", 56, 63], ["murine encephalomyelitis virus", "SPECIES", 66, 96], ["TMEV", "SPECIES", 50, 54], ["Theiler's murine encephalomyelitis virus", "SPECIES", 56, 96], ["BBB disruption", "PROBLEM", 13, 27], ["infection", "PROBLEM", 35, 44], ["TMEV", "PROBLEM", 50, 54], ["Theiler's murine encephalomyelitis virus", "TREATMENT", 56, 96], ["BBB", "ANATOMY", 13, 16], ["disruption", "OBSERVATION", 17, 27], ["infection", "OBSERVATION", 35, 44]]], ["Additionally, it has been suggested that interaction of CD8 T cells with neurons upregulates VEGF, which in turn promotes barrier dysfunction by dysregulating TJ complexes [184, 185] .", [["CD8 T cells", "ANATOMY", 56, 67], ["neurons", "ANATOMY", 73, 80], ["barrier", "ANATOMY", 122, 129], ["CD8 T", "GENE_OR_GENE_PRODUCT", 56, 61], ["neurons", "CELL", 73, 80], ["VEGF", "GENE_OR_GENE_PRODUCT", 93, 97], ["barrier", "TISSUE", 122, 129], ["TJ", "GENE_OR_GENE_PRODUCT", 159, 161], ["CD8 T cells", "CELL_TYPE", 56, 67], ["VEGF", "PROTEIN", 93, 97], ["TJ complexes", "PROTEIN", 159, 171], ["CD8 T cells", "TREATMENT", 56, 67], ["neurons upregulates VEGF", "PROBLEM", 73, 97], ["barrier dysfunction", "PROBLEM", 122, 141], ["barrier dysfunction", "OBSERVATION", 122, 141]]], ["Another mechanism by which cytotoxic T cells (CTLs) can cause vascular leakage involves degradation of the basal membrane via secretion of granzyme B. This allows CTLs to extravagate across brain vasculatures [186] .", [["cytotoxic T cells", "ANATOMY", 27, 44], ["CTLs", "ANATOMY", 46, 50], ["vascular", "ANATOMY", 62, 70], ["basal membrane", "ANATOMY", 107, 121], ["CTLs", "ANATOMY", 163, 167], ["brain", "ANATOMY", 190, 195], ["cytotoxic T cells", "CELL", 27, 44], ["CTLs", "CELL", 46, 50], ["vascular", "MULTI-TISSUE_STRUCTURE", 62, 70], ["basal membrane", "CELLULAR_COMPONENT", 107, 121], ["granzyme B.", "GENE_OR_GENE_PRODUCT", 139, 150], ["brain", "ORGAN", 190, 195], ["cytotoxic T cells", "CELL_TYPE", 27, 44], ["CTLs", "CELL_TYPE", 46, 50], ["granzyme B.", "PROTEIN", 139, 150], ["CTLs", "CELL_TYPE", 163, 167], ["cytotoxic T cells", "PROBLEM", 27, 44], ["vascular leakage", "PROBLEM", 62, 78], ["vascular", "ANATOMY", 62, 70], ["leakage", "OBSERVATION", 71, 78], ["basal membrane", "ANATOMY", 107, 121]]], ["Upon extravasation, CD8 T cells release several chemoattractants (e.g., CCL2, CCL3, and CCL4), which recruit monocytes and neutrophils to the CNS, thus indirectly leading to the loss of BBB function during viral infection [181] .Adaptive Immune Responses to Viruses that Impact BBB FunctionNotably, physical interaction of infiltrating leukocytes with ICAM-1 on brain endothelium per se can promote vascular permeability by triggering generation of ROS in a NADPH oxidase and Rac-1-dependent manner [187] [188] [189] .", [["CD8 T cells", "ANATOMY", 20, 31], ["monocytes", "ANATOMY", 109, 118], ["neutrophils", "ANATOMY", 123, 134], ["CNS", "ANATOMY", 142, 145], ["BBB", "ANATOMY", 186, 189], ["infiltrating leukocytes", "ANATOMY", 323, 346], ["brain endothelium", "ANATOMY", 362, 379], ["vascular", "ANATOMY", 399, 407], ["viral infection", "DISEASE", 206, 221], ["ROS", "CHEMICAL", 449, 452], ["NADPH", "CHEMICAL", 458, 463], ["NADPH", "CHEMICAL", 458, 463], ["CD8 T", "GENE_OR_GENE_PRODUCT", 20, 25], ["CCL2", "GENE_OR_GENE_PRODUCT", 72, 76], ["CCL3", "GENE_OR_GENE_PRODUCT", 78, 82], ["CCL4", "GENE_OR_GENE_PRODUCT", 88, 92], ["monocytes", "CELL", 109, 118], ["neutrophils", "CELL", 123, 134], ["CNS", "ANATOMICAL_SYSTEM", 142, 145], ["BBB", "GENE_OR_GENE_PRODUCT", 186, 189], ["leukocytes", "CELL", 336, 346], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 352, 358], ["brain endothelium", "TISSUE", 362, 379], ["vascular", "MULTI-TISSUE_STRUCTURE", 399, 407], ["ROS", "SIMPLE_CHEMICAL", 449, 452], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 458, 471], ["Rac-1", "SIMPLE_CHEMICAL", 476, 481], ["CD8 T cells", "CELL_TYPE", 20, 31], ["chemoattractants", "PROTEIN", 48, 64], ["CCL2", "PROTEIN", 72, 76], ["CCL3", "PROTEIN", 78, 82], ["CCL4", "PROTEIN", 88, 92], ["monocytes", "CELL_TYPE", 109, 118], ["neutrophils", "CELL_TYPE", 123, 134], ["infiltrating leukocytes", "CELL_TYPE", 323, 346], ["ICAM-1", "PROTEIN", 352, 358], ["NADPH oxidase", "PROTEIN", 458, 471], ["Rac-1", "PROTEIN", 476, 481], ["extravasation", "TEST", 5, 18], ["CD8 T cells", "TEST", 20, 31], ["several chemoattractants", "TEST", 40, 64], ["CCL2", "TEST", 72, 76], ["CCL3", "TEST", 78, 82], ["monocytes", "TEST", 109, 118], ["neutrophils", "TEST", 123, 134], ["the loss of BBB function", "PROBLEM", 174, 198], ["viral infection", "PROBLEM", 206, 221], ["infiltrating leukocytes", "PROBLEM", 323, 346], ["ICAM", "TEST", 352, 356], ["a NADPH oxidase", "TEST", 456, 471], ["extravasation", "OBSERVATION", 5, 18], ["CCL4", "ANATOMY", 88, 92], ["CNS", "ANATOMY", 142, 145], ["infiltrating leukocytes", "OBSERVATION", 323, 346], ["vascular", "ANATOMY", 399, 407], ["permeability", "OBSERVATION", 408, 420]]], ["Enhanced generation of ROS activates downstream tyrosine kinases (e.g., c-Src and PYK2), resulting in phosphorylation of VE-cadherin.", [["ROS", "CHEMICAL", 23, 26], ["tyrosine", "CHEMICAL", 48, 56], ["tyrosine", "CHEMICAL", 48, 56], ["ROS", "SIMPLE_CHEMICAL", 23, 26], ["c-Src", "GENE_OR_GENE_PRODUCT", 72, 77], ["PYK2", "GENE_OR_GENE_PRODUCT", 82, 86], ["VE-cadherin", "GENE_OR_GENE_PRODUCT", 121, 132], ["tyrosine kinases", "PROTEIN", 48, 64], ["c", "PROTEIN", 72, 73], ["Src", "PROTEIN", 74, 77], ["PYK2", "PROTEIN", 82, 86], ["VE-cadherin", "PROTEIN", 121, 132], ["tyrosine kinases", "TEST", 48, 64], ["phosphorylation of VE", "TREATMENT", 102, 123], ["cadherin", "TREATMENT", 124, 132]]], ["This phosphorylation dissociates interaction of VE-cadherin with the actin cytoskeleton resulting in the disruption of adherent junctions.", [["cytoskeleton", "ANATOMY", 75, 87], ["adherent junctions", "ANATOMY", 119, 137], ["VE-cadherin", "GENE_OR_GENE_PRODUCT", 48, 59], ["actin", "GENE_OR_GENE_PRODUCT", 69, 74], ["cytoskeleton", "CELLULAR_COMPONENT", 75, 87], ["adherent junctions", "CELLULAR_COMPONENT", 119, 137], ["VE-cadherin", "PROTEIN", 48, 59], ["actin", "PROTEIN", 69, 74], ["This phosphorylation", "PROBLEM", 0, 20], ["the disruption of adherent junctions", "PROBLEM", 101, 137], ["actin cytoskeleton", "OBSERVATION", 69, 87], ["disruption", "OBSERVATION", 105, 115], ["adherent junctions", "OBSERVATION", 119, 137]]], ["Likewise, TNF\u03b1 and VEGF that are generated during viral infection [109, 120] trigger Rac-1-mediated ROS generation.", [["viral infection", "DISEASE", 50, 65], ["ROS", "CHEMICAL", 100, 103], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 10, 14], ["VEGF", "GENE_OR_GENE_PRODUCT", 19, 23], ["Rac-1", "GENE_OR_GENE_PRODUCT", 85, 90], ["ROS", "SIMPLE_CHEMICAL", 100, 103], ["TNF\u03b1", "PROTEIN", 10, 14], ["VEGF", "PROTEIN", 19, 23], ["Rac-1", "PROTEIN", 85, 90], ["TNF", "TEST", 10, 13], ["viral infection", "PROBLEM", 50, 65], ["VEGF", "ANATOMY", 19, 23]]], ["ROS in turn promotes phosphorylation and internalization of VE-cadherin, leading to barrier dysfunction [188, 190, 191] .Adaptive Immune Responses to Viruses that Impact BBB FunctionCollectively, the above studies suggest that upon viral infection, CNS residential cells release inflammatory cytokines/chemokines, which activate brain endothelium allowing immune cell infiltration.", [["barrier", "ANATOMY", 84, 91], ["CNS residential cells", "ANATOMY", 249, 270], ["brain endothelium", "ANATOMY", 329, 346], ["immune cell", "ANATOMY", 356, 367], ["ROS", "CHEMICAL", 0, 3], ["viral infection", "DISEASE", 232, 247], ["ROS", "SIMPLE_CHEMICAL", 0, 3], ["VE-cadherin", "GENE_OR_GENE_PRODUCT", 60, 71], ["barrier", "TISSUE", 84, 91], ["CNS residential cells", "CELL", 249, 270], ["brain endothelium", "TISSUE", 329, 346], ["immune cell", "CELL", 356, 367], ["VE-cadherin", "PROTEIN", 60, 71], ["CNS residential cells", "CELL_TYPE", 249, 270], ["inflammatory cytokines", "PROTEIN", 279, 301], ["chemokines", "PROTEIN", 302, 312], ["VE-cadherin", "TREATMENT", 60, 71], ["barrier dysfunction", "PROBLEM", 84, 103], ["the above studies", "TEST", 196, 213], ["viral infection", "PROBLEM", 232, 247], ["inflammatory cytokines/chemokines", "PROBLEM", 279, 312], ["immune cell infiltration", "PROBLEM", 356, 380], ["viral", "OBSERVATION_MODIFIER", 232, 237], ["infection", "OBSERVATION", 238, 247], ["brain endothelium", "ANATOMY", 329, 346], ["immune cell infiltration", "OBSERVATION", 356, 380]]], ["Infiltrating leukocytes provide microglia with costimulatory signals to eliminate infected cells.", [["Infiltrating leukocytes", "ANATOMY", 0, 23], ["microglia", "ANATOMY", 32, 41], ["cells", "ANATOMY", 91, 96], ["Infiltrating leukocytes", "CELL", 0, 23], ["microglia", "CELL", 32, 41], ["cells", "CELL", 91, 96], ["Infiltrating leukocytes", "CELL_TYPE", 0, 23], ["microglia", "CELL_TYPE", 32, 41], ["infected cells", "CELL_TYPE", 82, 96], ["Infiltrating leukocytes", "PROBLEM", 0, 23], ["costimulatory signals", "TEST", 47, 68], ["infected cells", "PROBLEM", 82, 96], ["infected cells", "OBSERVATION", 82, 96]]], ["Additionally, cytotoxic T cells can directly kill infected cells contributing to viral clearance.", [["cytotoxic T cells", "ANATOMY", 14, 31], ["cells", "ANATOMY", 59, 64], ["cytotoxic T cells", "CELL", 14, 31], ["cells", "CELL", 59, 64], ["cytotoxic T cells", "CELL_TYPE", 14, 31], ["infected cells", "CELL_TYPE", 50, 64], ["cytotoxic T cells", "PROBLEM", 14, 31], ["infected cells", "PROBLEM", 50, 64], ["viral clearance", "PROBLEM", 81, 96], ["viral clearance", "OBSERVATION", 81, 96]]], ["Nonetheless, an excessive immune cell infiltration imposes severe structural damages to the cells of NVU, leading to barrier dysfunction.Effects of Parasites on BBB Structure and FunctionAs with other pathogens, neurotropic parasites have evolved several strategies to disrupt the BBB promoting their entry into the brain.", [["immune cell", "ANATOMY", 26, 37], ["cells", "ANATOMY", 92, 97], ["barrier", "ANATOMY", 117, 124], ["BBB", "ANATOMY", 281, 284], ["brain", "ANATOMY", 316, 321], ["immune cell", "CELL", 26, 37], ["cells", "CELL", 92, 97], ["NVU", "GENE_OR_GENE_PRODUCT", 101, 104], ["barrier", "TISSUE", 117, 124], ["Parasites", "CELL", 148, 157], ["BBB", "MULTI-TISSUE_STRUCTURE", 161, 164], ["neurotropic parasites", "ORGANISM", 212, 233], ["BBB", "MULTI-TISSUE_STRUCTURE", 281, 284], ["brain", "ORGAN", 316, 321], ["an excessive immune cell infiltration", "PROBLEM", 13, 50], ["severe structural damages to the cells of NVU", "PROBLEM", 59, 104], ["barrier dysfunction", "PROBLEM", 117, 136], ["Parasites", "PROBLEM", 148, 157], ["other pathogens", "PROBLEM", 195, 210], ["neurotropic parasites", "PROBLEM", 212, 233], ["excessive", "OBSERVATION_MODIFIER", 16, 25], ["immune cell infiltration", "OBSERVATION", 26, 50], ["barrier dysfunction", "OBSERVATION", 117, 136], ["Parasites", "OBSERVATION", 148, 157], ["brain", "ANATOMY", 316, 321]]], ["These include infection and lysis of brain ECs (e.g., Toxoplasma gondii), secretion of proteases and toxins (e.g., trypanosoma and acanthamoeba), and induction of inflammatory cytokines or matrix metalloproteinases [192] .Cerebral Malaria and BBB FunctionPlasmodium falciparum, the causative agent of human cerebral malaria (HCM), is associated with disruption of BBB and severe vasculopathy.", [["brain ECs", "ANATOMY", 37, 46], ["Cerebral", "ANATOMY", 222, 230], ["cerebral", "ANATOMY", 307, 315], ["BBB", "ANATOMY", 364, 367], ["infection", "DISEASE", 14, 23], ["Toxoplasma gondii", "DISEASE", 54, 71], ["Cerebral Malaria", "DISEASE", 222, 238], ["FunctionPlasmodium falciparum", "DISEASE", 247, 276], ["cerebral malaria", "DISEASE", 307, 323], ["HCM", "DISEASE", 325, 328], ["vasculopathy", "DISEASE", 379, 391], ["brain ECs", "CELL", 37, 46], ["Toxoplasma gondii", "ORGANISM", 54, 71], ["trypanosoma", "GENE_OR_GENE_PRODUCT", 115, 126], ["acanthamoeba", "GENE_OR_GENE_PRODUCT", 131, 143], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 189, 214], ["BBB FunctionPlasmodium falciparum", "ORGANISM", 243, 276], ["human", "ORGANISM", 301, 306], ["cerebral", "ORGAN", 307, 315], ["BBB", "MULTI-TISSUE_STRUCTURE", 364, 367], ["brain ECs", "CELL_TYPE", 37, 46], ["proteases", "PROTEIN", 87, 96], ["inflammatory cytokines", "PROTEIN", 163, 185], ["matrix metalloproteinases", "PROTEIN", 189, 214], ["Toxoplasma gondii", "SPECIES", 54, 71], ["FunctionPlasmodium falciparum", "SPECIES", 247, 276], ["human", "SPECIES", 301, 306], ["Toxoplasma gondii", "SPECIES", 54, 71], ["FunctionPlasmodium falciparum", "SPECIES", 247, 276], ["human", "SPECIES", 301, 306], ["infection", "PROBLEM", 14, 23], ["lysis of brain ECs", "PROBLEM", 28, 46], ["Toxoplasma gondii", "PROBLEM", 54, 71], ["secretion of proteases", "PROBLEM", 74, 96], ["toxins", "PROBLEM", 101, 107], ["trypanosoma", "PROBLEM", 115, 126], ["acanthamoeba", "PROBLEM", 131, 143], ["inflammatory cytokines", "PROBLEM", 163, 185], ["matrix metalloproteinases", "PROBLEM", 189, 214], ["Cerebral Malaria", "PROBLEM", 222, 238], ["BBB FunctionPlasmodium falciparum", "PROBLEM", 243, 276], ["human cerebral malaria (HCM)", "PROBLEM", 301, 329], ["disruption of BBB", "PROBLEM", 350, 367], ["severe vasculopathy", "PROBLEM", 372, 391], ["infection", "OBSERVATION", 14, 23], ["brain", "ANATOMY", 37, 42], ["inflammatory", "OBSERVATION_MODIFIER", 163, 175], ["Malaria", "OBSERVATION", 231, 238], ["cerebral", "ANATOMY", 307, 315], ["malaria", "OBSERVATION", 316, 323], ["BBB", "ANATOMY", 364, 367], ["severe", "OBSERVATION_MODIFIER", 372, 378], ["vasculopathy", "OBSERVATION", 379, 391]]], ["Infection of red blood cells (RBCs) by P. falciparum induces structural changes in their membrane that make them adhesive to other cell types.", [["red blood cells", "ANATOMY", 13, 28], ["RBCs", "ANATOMY", 30, 34], ["membrane", "ANATOMY", 89, 97], ["cell", "ANATOMY", 131, 135], ["P. falciparum", "DISEASE", 39, 52], ["red blood cells", "CELL", 13, 28], ["RBCs", "CELL", 30, 34], ["P. falciparum", "ORGANISM", 39, 52], ["membrane", "CELLULAR_COMPONENT", 89, 97], ["cell", "CELL", 131, 135], ["red blood cells", "CELL_TYPE", 13, 28], ["RBCs", "CELL_TYPE", 30, 34], ["P. falciparum", "SPECIES", 39, 52], ["P. falciparum", "SPECIES", 39, 52], ["red blood cells", "TEST", 13, 28], ["RBCs", "TEST", 30, 34], ["falciparum", "PROBLEM", 42, 52], ["structural changes in their membrane", "PROBLEM", 61, 97], ["red blood cells", "OBSERVATION", 13, 28], ["cell types", "OBSERVATION", 131, 141]]], ["This results in the formation of mircoaggregates that can obstruct blood flow, leading to hypoxia, hypertension, and alteration of metabolites in the CNS [192] .", [["blood", "ANATOMY", 67, 72], ["CNS", "ANATOMY", 150, 153], ["hypoxia", "DISEASE", 90, 97], ["hypertension", "DISEASE", 99, 111], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["mircoaggregates", "PROBLEM", 33, 48], ["blood flow", "PROBLEM", 67, 77], ["hypoxia", "PROBLEM", 90, 97], ["hypertension", "PROBLEM", 99, 111], ["alteration of metabolites in the CNS", "PROBLEM", 117, 153], ["hypoxia", "OBSERVATION", 90, 97], ["hypertension", "OBSERVATION", 99, 111], ["metabolites", "OBSERVATION_MODIFIER", 131, 142]]], ["Additionally, infected RBC (iRBC) can directly interact with brain vascular endothelium and promote BBB dysfunction.", [["RBC", "ANATOMY", 23, 26], ["iRBC", "ANATOMY", 28, 32], ["brain vascular endothelium", "ANATOMY", 61, 87], ["BBB", "ANATOMY", 100, 103], ["RBC", "CELL", 23, 26], ["iRBC", "CELL", 28, 32], ["brain vascular endothelium", "TISSUE", 61, 87], ["BBB", "MULTI-TISSUE_STRUCTURE", 100, 103], ["infected RBC", "CELL_TYPE", 14, 26], ["iRBC", "CELL_TYPE", 28, 32], ["infected RBC (iRBC)", "PROBLEM", 14, 33], ["BBB dysfunction", "PROBLEM", 100, 115], ["infected RBC", "OBSERVATION", 14, 26], ["vascular endothelium", "ANATOMY", 67, 87], ["BBB dysfunction", "OBSERVATION", 100, 115]]], ["Indeed, adhesion and sequestration of iRBCs in brain vasculature are linked to the loss of BBB function in humans [193, 194] .", [["iRBCs", "ANATOMY", 38, 43], ["brain vasculature", "ANATOMY", 47, 64], ["BBB", "ANATOMY", 91, 94], ["iRBCs", "GENE_OR_GENE_PRODUCT", 38, 43], ["brain vasculature", "MULTI-TISSUE_STRUCTURE", 47, 64], ["BBB", "MULTI-TISSUE_STRUCTURE", 91, 94], ["humans", "ORGANISM", 107, 113], ["iRBCs", "PROTEIN", 38, 43], ["humans", "SPECIES", 107, 113], ["humans", "SPECIES", 107, 113], ["sequestration of iRBCs in brain vasculature", "PROBLEM", 21, 64], ["adhesion", "OBSERVATION", 8, 16], ["sequestration", "OBSERVATION", 21, 34], ["iRBCs", "OBSERVATION", 38, 43], ["brain", "ANATOMY_MODIFIER", 47, 52], ["vasculature", "ANATOMY", 53, 64], ["loss", "OBSERVATION_MODIFIER", 83, 87]]], ["In vitro studies also have shown that adherence of iRBCs to brain endothelium triggers barrier permeability via induction of apoptosis and disruption of TJ proteins (e.g., ZO-1) [195] [196] [197] .", [["iRBCs", "ANATOMY", 51, 56], ["brain endothelium", "ANATOMY", 60, 77], ["barrier", "ANATOMY", 87, 94], ["iRBCs", "CELL", 51, 56], ["brain endothelium", "TISSUE", 60, 77], ["barrier", "TISSUE", 87, 94], ["TJ", "GENE_OR_GENE_PRODUCT", 153, 155], ["ZO-1", "GENE_OR_GENE_PRODUCT", 172, 176], ["iRBCs", "CELL_TYPE", 51, 56], ["TJ proteins", "PROTEIN", 153, 164], ["vitro studies", "TEST", 3, 16], ["iRBCs", "PROBLEM", 51, 56], ["brain endothelium", "PROBLEM", 60, 77], ["barrier permeability", "TREATMENT", 87, 107], ["apoptosis", "PROBLEM", 125, 134], ["TJ proteins", "TEST", 153, 164], ["ZO", "TEST", 172, 174], ["brain endothelium", "ANATOMY", 60, 77]]], ["In mouse models of experimental cerebral malaria (ECM), BBB dysfunction correlates with platelet deposition and leukocyte arrest on the endothelium of postcapillary venules [198, 199] .", [["cerebral", "ANATOMY", 32, 40], ["ECM", "ANATOMY", 50, 53], ["BBB", "ANATOMY", 56, 59], ["platelet", "ANATOMY", 88, 96], ["leukocyte", "ANATOMY", 112, 121], ["endothelium", "ANATOMY", 136, 147], ["postcapillary venules", "ANATOMY", 151, 172], ["cerebral malaria", "DISEASE", 32, 48], ["mouse", "ORGANISM", 3, 8], ["cerebral", "ORGAN", 32, 40], ["ECM", "CELLULAR_COMPONENT", 50, 53], ["BBB", "MULTI-TISSUE_STRUCTURE", 56, 59], ["platelet", "CELL", 88, 96], ["leukocyte", "CELL", 112, 121], ["endothelium", "TISSUE", 136, 147], ["postcapillary venules", "MULTI-TISSUE_STRUCTURE", 151, 172], ["postcapillary venules", "CELL_TYPE", 151, 172], ["mouse", "SPECIES", 3, 8], ["mouse", "SPECIES", 3, 8], ["experimental cerebral malaria", "PROBLEM", 19, 48], ["BBB dysfunction", "PROBLEM", 56, 71], ["platelet deposition", "PROBLEM", 88, 107], ["leukocyte arrest", "PROBLEM", 112, 128], ["postcapillary venules", "TEST", 151, 172], ["experimental", "OBSERVATION_MODIFIER", 19, 31], ["cerebral", "ANATOMY", 32, 40], ["malaria", "OBSERVATION", 41, 48], ["dysfunction", "OBSERVATION", 60, 71], ["platelet deposition", "OBSERVATION", 88, 107], ["leukocyte arrest", "OBSERVATION", 112, 128], ["endothelium", "ANATOMY_MODIFIER", 136, 147], ["postcapillary venules", "ANATOMY", 151, 172]]], ["Activated platelets augment BBB permeability by potentiating vascular damage induced by iRBC and impairing vascular repair.", [["platelets", "ANATOMY", 10, 19], ["BBB", "ANATOMY", 28, 31], ["vascular", "ANATOMY", 61, 69], ["iRBC", "ANATOMY", 88, 92], ["vascular", "ANATOMY", 107, 115], ["vascular damage", "DISEASE", 61, 76], ["platelets", "CELL", 10, 19], ["BBB", "MULTI-TISSUE_STRUCTURE", 28, 31], ["vascular", "MULTI-TISSUE_STRUCTURE", 61, 69], ["iRBC", "CELL", 88, 92], ["vascular", "MULTI-TISSUE_STRUCTURE", 107, 115], ["Activated platelets", "CELL_TYPE", 0, 19], ["iRBC", "CELL_TYPE", 88, 92], ["Activated platelets augment BBB permeability", "TREATMENT", 0, 44], ["vascular damage", "PROBLEM", 61, 76], ["iRBC", "TEST", 88, 92], ["impairing vascular repair", "TREATMENT", 97, 122], ["vascular", "ANATOMY", 61, 69], ["damage", "OBSERVATION", 70, 76], ["vascular", "ANATOMY", 107, 115], ["repair", "OBSERVATION", 116, 122]]], ["Similarly, leukocyte arrest, along with increased production of vasoconstrictive factors, impairs venous efflux from the CNS.", [["leukocyte", "ANATOMY", 11, 20], ["venous", "ANATOMY", 98, 104], ["CNS", "ANATOMY", 121, 124], ["leukocyte arrest", "DISEASE", 11, 27], ["leukocyte", "CELL", 11, 20], ["venous", "MULTI-TISSUE_STRUCTURE", 98, 104], ["CNS", "ANATOMICAL_SYSTEM", 121, 124], ["vasoconstrictive factors", "PROTEIN", 64, 88], ["leukocyte arrest", "PROBLEM", 11, 27], ["vasoconstrictive factors", "PROBLEM", 64, 88], ["venous efflux", "PROBLEM", 98, 111], ["leukocyte arrest", "OBSERVATION", 11, 27], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["production", "OBSERVATION_MODIFIER", 50, 60], ["vasoconstrictive factors", "OBSERVATION", 64, 88], ["venous", "ANATOMY", 98, 104], ["efflux", "OBSERVATION", 105, 111], ["CNS", "ANATOMY", 121, 124]]], ["This results in enhanced intracranial hypertension, vascular leakage, and hemorrhages [200, 201] .", [["intracranial", "ANATOMY", 25, 37], ["vascular", "ANATOMY", 52, 60], ["intracranial hypertension", "DISEASE", 25, 50], ["vascular leakage", "DISEASE", 52, 68], ["hemorrhages", "DISEASE", 74, 85], ["vascular", "MULTI-TISSUE_STRUCTURE", 52, 60], ["enhanced intracranial hypertension", "PROBLEM", 16, 50], ["vascular leakage", "PROBLEM", 52, 68], ["hemorrhages", "PROBLEM", 74, 85], ["enhanced", "OBSERVATION_MODIFIER", 16, 24], ["intracranial", "OBSERVATION_MODIFIER", 25, 37], ["hypertension", "OBSERVATION", 38, 50], ["vascular", "ANATOMY", 52, 60], ["leakage", "OBSERVATION", 61, 68], ["hemorrhages", "OBSERVATION", 74, 85]]], ["Among leukocytes, antigen-specific CD8 T cells and ICAM-1 + macrophages are particularly involved in the development of ECM [198] .", [["leukocytes", "ANATOMY", 6, 16], ["CD8 T cells", "ANATOMY", 35, 46], ["ICAM-1 + macrophages", "ANATOMY", 51, 71], ["ECM", "ANATOMY", 120, 123], ["leukocytes", "CELL", 6, 16], ["antigen", "GENE_OR_GENE_PRODUCT", 18, 25], ["CD8", "GENE_OR_GENE_PRODUCT", 35, 38], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 51, 57], ["ECM", "CELLULAR_COMPONENT", 120, 123], ["leukocytes", "CELL_TYPE", 6, 16], ["CD8 T cells", "CELL_TYPE", 35, 46], ["ICAM-1", "PROTEIN", 51, 57], ["macrophages", "CELL_TYPE", 60, 71], ["Among leukocytes", "TEST", 0, 16], ["antigen", "TEST", 18, 25], ["CD8 T cells", "TEST", 35, 46], ["ICAM", "TEST", 51, 55], ["macrophages", "PROBLEM", 60, 71], ["macrophages", "ANATOMY", 60, 71]]], ["Plasmodium species upregulate the expression of ICAM-1, VCAM-1, P-, and E-selectins both in human and mice, thus promoting immune cell extravasation into the CNS [202, 203] .", [["immune cell", "ANATOMY", 123, 134], ["CNS", "ANATOMY", 158, 161], ["Plasmodium", "ORGANISM", 0, 10], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 48, 54], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 56, 62], ["P", "GENE_OR_GENE_PRODUCT", 64, 65], ["E-selectins", "GENE_OR_GENE_PRODUCT", 72, 83], ["human", "ORGANISM", 92, 97], ["mice", "ORGANISM", 102, 106], ["immune cell", "CELL", 123, 134], ["CNS", "ANATOMICAL_SYSTEM", 158, 161], ["ICAM", "PROTEIN", 48, 52], ["VCAM-1, P-, and E-selectins", "PROTEIN", 56, 83], ["human", "SPECIES", 92, 97], ["mice", "SPECIES", 102, 106], ["human", "SPECIES", 92, 97], ["mice", "SPECIES", 102, 106], ["Plasmodium species", "TEST", 0, 18], ["ICAM", "TEST", 48, 52], ["VCAM", "TEST", 56, 60], ["P", "TEST", 64, 65], ["immune cell extravasation", "OBSERVATION", 123, 148], ["CNS", "ANATOMY", 158, 161]]], ["Antigen-specific CD8 T cells trigger BBB permeability by secreting granzyme B and perforin that target TJ proteins and induce apoptosis in brain endothelial cells [204] [205] [206] .", [["CD8 T cells", "ANATOMY", 17, 28], ["BBB", "ANATOMY", 37, 40], ["TJ", "ANATOMY", 103, 105], ["brain endothelial cells", "ANATOMY", 139, 162], ["CD8", "GENE_OR_GENE_PRODUCT", 17, 20], ["BBB", "TISSUE", 37, 40], ["granzyme B", "GENE_OR_GENE_PRODUCT", 67, 77], ["perforin", "GENE_OR_GENE_PRODUCT", 82, 90], ["TJ", "GENE_OR_GENE_PRODUCT", 103, 105], ["brain endothelial cells", "CELL", 139, 162], ["CD8 T cells", "CELL_TYPE", 17, 28], ["granzyme B", "PROTEIN", 67, 77], ["perforin", "PROTEIN", 82, 90], ["TJ proteins", "PROTEIN", 103, 114], ["brain endothelial cells", "CELL_TYPE", 139, 162], ["Antigen", "TEST", 0, 7], ["BBB permeability", "TEST", 37, 53], ["secreting granzyme B", "TEST", 57, 77], ["TJ proteins", "TEST", 103, 114], ["apoptosis in brain endothelial cells", "PROBLEM", 126, 162], ["brain", "ANATOMY", 139, 144]]], ["Nonetheless, endothelial cell death is not correlated with barrier dysfunction or development of ECM in other studies [198, 199] .", [["endothelial cell", "ANATOMY", 13, 29], ["barrier", "ANATOMY", 59, 66], ["ECM", "ANATOMY", 97, 100], ["death", "DISEASE", 30, 35], ["endothelial cell", "CELL", 13, 29], ["barrier", "TISSUE", 59, 66], ["ECM", "CELLULAR_COMPONENT", 97, 100], ["endothelial cell death", "PROBLEM", 13, 35], ["barrier dysfunction", "PROBLEM", 59, 78], ["endothelial cell death", "OBSERVATION", 13, 35]]], ["Instead, BBB disruption is related to increased paracellular or transcellular transport, mediated by the interaction of leukocytes with postcapillary venules [199] .", [["paracellular", "ANATOMY", 48, 60], ["leukocytes", "ANATOMY", 120, 130], ["postcapillary venules", "ANATOMY", 136, 157], ["BBB", "MULTI-TISSUE_STRUCTURE", 9, 12], ["paracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 48, 60], ["transcellular", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 77], ["leukocytes", "CELL", 120, 130], ["postcapillary venules", "CELL", 136, 157], ["leukocytes", "CELL_TYPE", 120, 130], ["postcapillary venules", "CELL_TYPE", 136, 157], ["BBB disruption", "PROBLEM", 9, 23], ["increased paracellular or transcellular transport", "PROBLEM", 38, 87], ["disruption", "OBSERVATION", 13, 23], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["paracellular", "ANATOMY_MODIFIER", 48, 60], ["transcellular transport", "OBSERVATION", 64, 87], ["leukocytes", "OBSERVATION", 120, 130], ["postcapillary venules", "OBSERVATION", 136, 157]]], ["Furthermore, antigen-specific CD8 T cells activate brain endothelial cells by releasing IFN-\u0263 [207] , which upregulates the expression of adhesion and antigenpresenting molecules selectively on cerebrovascular ECs but not peripheral ECs [207, 208] .", [["CD8 T cells", "ANATOMY", 30, 41], ["brain endothelial cells", "ANATOMY", 51, 74], ["cerebrovascular ECs", "ANATOMY", 194, 213], ["peripheral ECs", "ANATOMY", 222, 236], ["antigen", "GENE_OR_GENE_PRODUCT", 13, 20], ["CD8", "GENE_OR_GENE_PRODUCT", 30, 33], ["brain endothelial cells", "CELL", 51, 74], ["IFN", "GENE_OR_GENE_PRODUCT", 88, 91], ["cerebrovascular ECs", "CELL", 194, 213], ["peripheral ECs", "CELL", 222, 236], ["CD8 T cells", "CELL_TYPE", 30, 41], ["brain endothelial cells", "CELL_TYPE", 51, 74], ["IFN", "PROTEIN", 88, 91], ["adhesion and antigenpresenting molecules", "PROTEIN", 138, 178], ["cerebrovascular ECs", "CELL_TYPE", 194, 213], ["peripheral ECs", "CELL_TYPE", 222, 236], ["antigen", "TEST", 13, 20], ["brain endothelial cells", "PROBLEM", 51, 74], ["adhesion", "PROBLEM", 138, 146], ["antigenpresenting molecules", "PROBLEM", 151, 178], ["cerebrovascular ECs", "TEST", 194, 213], ["peripheral ECs", "TEST", 222, 236], ["adhesion", "OBSERVATION", 138, 146]]], ["Consistently, deficiency in IFN-\u03b3 or depletion of CD8 T cells results in complete protection against ECM by preventing barrier permeability and vascular hemorrhage [207, 209] .", [["CD8 T cells", "ANATOMY", 50, 61], ["ECM", "ANATOMY", 101, 104], ["barrier", "ANATOMY", 119, 126], ["vascular", "ANATOMY", 144, 152], ["vascular hemorrhage", "DISEASE", 144, 163], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 28, 33], ["CD8 T", "GENE_OR_GENE_PRODUCT", 50, 55], ["ECM", "CELLULAR_COMPONENT", 101, 104], ["barrier", "TISSUE", 119, 126], ["vascular", "MULTI-TISSUE_STRUCTURE", 144, 152], ["IFN-\u03b3", "PROTEIN", 28, 33], ["CD8 T cells", "CELL_TYPE", 50, 61], ["deficiency in IFN", "PROBLEM", 14, 31], ["CD8 T cells", "PROBLEM", 50, 61], ["barrier permeability", "PROBLEM", 119, 139], ["vascular hemorrhage", "PROBLEM", 144, 163], ["deficiency", "OBSERVATION", 14, 24], ["barrier permeability", "OBSERVATION_MODIFIER", 119, 139], ["vascular", "ANATOMY", 144, 152], ["hemorrhage", "OBSERVATION", 153, 163]]], ["Likewise, co-infection with chikungunya virus (CHIKV) protects mice from ECM mortality by preventing pathogenic CD8 T cells from migration into the CNS [210] .ToxoplasmosisToxoplasmosis is one of the most common parasitic diseases that is caused by Toxoplasma gondii.", [["ECM", "ANATOMY", 73, 76], ["CD8 T cells", "ANATOMY", 112, 123], ["CNS", "ANATOMY", 148, 151], ["co-infection", "DISEASE", 10, 22], ["chikungunya", "DISEASE", 28, 39], ["ToxoplasmosisToxoplasmosis", "DISEASE", 159, 185], ["parasitic diseases", "DISEASE", 212, 230], ["Toxoplasma gondii", "DISEASE", 249, 266], ["chikungunya virus", "ORGANISM", 28, 45], ["CHIKV", "ORGANISM", 47, 52], ["mice", "ORGANISM", 63, 67], ["ECM", "CELLULAR_COMPONENT", 73, 76], ["CD8 T cells", "CELL", 112, 123], ["Toxoplasma gondii", "ORGANISM", 249, 266], ["CD8 T cells", "CELL_TYPE", 112, 123], ["chikungunya virus", "SPECIES", 28, 45], ["mice", "SPECIES", 63, 67], ["Toxoplasma gondii", "SPECIES", 249, 266], ["chikungunya virus", "SPECIES", 28, 45], ["CHIKV", "SPECIES", 47, 52], ["mice", "SPECIES", 63, 67], ["Toxoplasma gondii", "SPECIES", 249, 266], ["co-infection", "PROBLEM", 10, 22], ["chikungunya virus", "PROBLEM", 28, 45], ["pathogenic CD8 T cells", "PROBLEM", 101, 123], ["ToxoplasmosisToxoplasmosis", "PROBLEM", 159, 185], ["the most common parasitic diseases", "PROBLEM", 196, 230], ["Toxoplasma gondii", "PROBLEM", 249, 266], ["co-infection", "OBSERVATION", 10, 22], ["chikungunya virus", "OBSERVATION", 28, 45], ["pathogenic CD8 T cells", "OBSERVATION", 101, 123], ["CNS", "ANATOMY", 148, 151], ["Toxoplasmosis", "OBSERVATION", 172, 185], ["most common", "OBSERVATION_MODIFIER", 200, 211], ["parasitic", "OBSERVATION_MODIFIER", 212, 221], ["diseases", "OBSERVATION", 222, 230], ["caused by", "UNCERTAINTY", 239, 248], ["Toxoplasma gondii", "OBSERVATION", 249, 266]]], ["In healthy individuals, infection is either mild or asymptomatic; however, it can cause life-threatening CNS complications in developing fetus or immunocompromised patient [211] .", [["CNS", "ANATOMY", 105, 108], ["fetus", "ANATOMY", 137, 142], ["infection", "DISEASE", 24, 33], ["CNS", "ANATOMICAL_SYSTEM", 105, 108], ["fetus", "ORGAN", 137, 142], ["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 164, 171], ["infection", "PROBLEM", 24, 33], ["asymptomatic", "PROBLEM", 52, 64], ["life-threatening CNS complications", "PROBLEM", 88, 122], ["infection", "OBSERVATION", 24, 33], ["mild", "OBSERVATION_MODIFIER", 44, 48]]], ["Upon infection, T. gondii can enter CNS via Trojan horse as well as direct infection of brain endothelial cells [192, 212] .", [["CNS", "ANATOMY", 36, 39], ["brain endothelial cells", "ANATOMY", 88, 111], ["infection", "DISEASE", 5, 14], ["infection", "DISEASE", 75, 84], ["T. gondii", "ORGANISM", 16, 25], ["CNS", "ANATOMICAL_SYSTEM", 36, 39], ["Trojan horse", "ORGANISM", 44, 56], ["brain endothelial cells", "CELL", 88, 111], ["brain endothelial cells", "CELL_TYPE", 88, 111], ["T. gondii", "SPECIES", 16, 25], ["horse", "SPECIES", 51, 56], ["T. gondii", "SPECIES", 16, 25], ["Trojan horse", "SPECIES", 44, 56], ["infection", "PROBLEM", 5, 14], ["T. gondii", "PROBLEM", 16, 25], ["direct infection of brain endothelial cells", "PROBLEM", 68, 111], ["infection", "OBSERVATION", 5, 14], ["infection", "OBSERVATION", 75, 84], ["brain endothelial", "ANATOMY", 88, 105]]], ["During acute phase, the parasite induces an exacerbated inflammatory response, which then subsides during the chronic phase.", [["the parasite", "PROBLEM", 20, 32], ["an exacerbated inflammatory response", "PROBLEM", 41, 77], ["exacerbated", "OBSERVATION_MODIFIER", 44, 55], ["inflammatory response", "OBSERVATION", 56, 77], ["chronic", "OBSERVATION_MODIFIER", 110, 117]]], ["Inflammatory response upregulates expression of VCAM-1 on brain endothelium to promote migration of CD4 T cells into the CNS, which is required for controlling parasite replication [213] .", [["brain endothelium", "ANATOMY", 58, 75], ["CD4 T cells", "ANATOMY", 100, 111], ["CNS", "ANATOMY", 121, 124], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 48, 54], ["brain endothelium", "TISSUE", 58, 75], ["CD4 T cells", "CELL", 100, 111], ["CNS", "ANATOMICAL_SYSTEM", 121, 124], ["VCAM-1", "PROTEIN", 48, 54], ["CD4 T cells", "CELL_TYPE", 100, 111], ["VCAM", "TEST", 48, 52], ["brain endothelium", "TREATMENT", 58, 75], ["CD4 T cells", "TREATMENT", 100, 111], ["endothelium", "ANATOMY", 64, 75], ["migration", "OBSERVATION_MODIFIER", 87, 96], ["CNS", "ANATOMY", 121, 124]]], ["Nonetheless, sustained and intense leukocyte-endothelium interaction in postcapillary venules leads to the formation of plugging, which can interfere with blood flow and cause cerebral hypoperfusion [214, 215] .", [["leukocyte", "ANATOMY", 35, 44], ["endothelium", "ANATOMY", 45, 56], ["postcapillary venules", "ANATOMY", 72, 93], ["blood", "ANATOMY", 155, 160], ["cerebral", "ANATOMY", 176, 184], ["cerebral hypoperfusion", "DISEASE", 176, 198], ["leukocyte", "CELL", 35, 44], ["endothelium", "TISSUE", 45, 56], ["postcapillary venules", "MULTI-TISSUE_STRUCTURE", 72, 93], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["cerebral", "ORGAN", 176, 184], ["postcapillary venules", "CELL_TYPE", 72, 93], ["plugging", "PROBLEM", 120, 128], ["blood flow", "TEST", 155, 165], ["cerebral hypoperfusion", "PROBLEM", 176, 198], ["intense", "OBSERVATION_MODIFIER", 27, 34], ["leukocyte", "OBSERVATION", 35, 44], ["endothelium", "OBSERVATION", 45, 56], ["postcapillary venules", "OBSERVATION", 72, 93], ["plugging", "OBSERVATION", 120, 128], ["cerebral", "ANATOMY", 176, 184], ["hypoperfusion", "OBSERVATION", 185, 198]]], ["Additionally, T. gondii can infect, lyse, and induce structural and functional defects in brain endothelial cells [192, 215] .", [["brain endothelial cells", "ANATOMY", 90, 113], ["T. gondii", "ORGANISM", 14, 23], ["brain endothelial cells", "CELL", 90, 113], ["brain endothelial cells", "CELL_TYPE", 90, 113], ["T. gondii", "SPECIES", 14, 23], ["T. gondii", "SPECIES", 14, 23], ["T. gondii", "PROBLEM", 14, 23], ["functional defects in brain endothelial cells", "PROBLEM", 68, 113], ["functional defects", "OBSERVATION", 68, 86], ["brain endothelial", "ANATOMY", 90, 107]]], ["Furthermore, elevated levels of MMPs, inflammatory cytokines, and nitric oxide are reported during parasite infection, features associated with BBB disruption [216, 217] .TrypanosomiasisHuman African trypanosomiasis (HAT), also known as \"sleeping sickness,\" is caused by Trypanosoma brucei.", [["BBB", "ANATOMY", 144, 147], ["nitric oxide", "CHEMICAL", 66, 78], ["parasite infection", "DISEASE", 99, 117], ["TrypanosomiasisHuman African trypanosomiasis", "DISEASE", 171, 215], ["HAT", "DISEASE", 217, 220], ["sleeping sickness", "DISEASE", 238, 255], ["Trypanosoma brucei", "DISEASE", 271, 289], ["nitric oxide", "CHEMICAL", 66, 78], ["MMPs", "GENE_OR_GENE_PRODUCT", 32, 36], ["nitric oxide", "SIMPLE_CHEMICAL", 66, 78], ["BBB", "MULTI-TISSUE_STRUCTURE", 144, 147], ["TrypanosomiasisHuman African trypanosomiasis", "ORGANISM", 171, 215], ["Trypanosoma brucei", "ORGANISM", 271, 289], ["MMPs", "PROTEIN", 32, 36], ["inflammatory cytokines", "PROTEIN", 38, 60], ["Trypanosoma brucei", "SPECIES", 271, 289], ["Trypanosoma brucei", "SPECIES", 271, 289], ["elevated levels of MMPs", "PROBLEM", 13, 36], ["inflammatory cytokines", "PROBLEM", 38, 60], ["nitric oxide", "TREATMENT", 66, 78], ["parasite infection", "PROBLEM", 99, 117], ["BBB disruption", "PROBLEM", 144, 158], ["TrypanosomiasisHuman African trypanosomiasis", "PROBLEM", 171, 215], ["sleeping sickness", "PROBLEM", 238, 255], ["Trypanosoma brucei", "PROBLEM", 271, 289], ["elevated", "OBSERVATION_MODIFIER", 13, 21], ["levels", "OBSERVATION_MODIFIER", 22, 28], ["inflammatory cytokines", "OBSERVATION", 38, 60], ["nitric oxide", "OBSERVATION", 66, 78], ["parasite", "OBSERVATION_MODIFIER", 99, 107], ["infection", "OBSERVATION", 108, 117], ["Trypanosoma brucei", "OBSERVATION", 271, 289]]], ["HAT is divided into two clinical stages: during the first stage, parasite replicates in the blood and lymphatic system.", [["blood", "ANATOMY", 92, 97], ["lymphatic system", "ANATOMY", 102, 118], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["lymphatic system", "MULTI-TISSUE_STRUCTURE", 102, 118], ["blood", "ANATOMY", 92, 97], ["lymphatic system", "ANATOMY", 102, 118]]], ["This is followed by a second stage when the parasite enters and establishes infection in the CNS, which can cause meningoencephalitis [218] .", [["CNS", "ANATOMY", 93, 96], ["infection", "DISEASE", 76, 85], ["meningoencephalitis", "DISEASE", 114, 133], ["CNS", "ANATOMICAL_SYSTEM", 93, 96], ["the parasite", "PROBLEM", 40, 52], ["infection in the CNS", "PROBLEM", 76, 96], ["meningoencephalitis", "PROBLEM", 114, 133], ["parasite", "OBSERVATION", 44, 52], ["infection", "OBSERVATION", 76, 85], ["CNS", "ANATOMY", 93, 96], ["meningoencephalitis", "OBSERVATION", 114, 133]]], ["T. brucei initially enters the CNS through choroid plexus and circumventricular organs, likely by secreting a protease that degrades the basal lamina [219, 220] .", [["CNS", "ANATOMY", 31, 34], ["choroid plexus", "ANATOMY", 43, 57], ["circumventricular organs", "ANATOMY", 62, 86], ["basal lamina", "ANATOMY", 137, 149], ["T. brucei", "ORGANISM", 0, 9], ["CNS", "ANATOMICAL_SYSTEM", 31, 34], ["choroid plexus", "MULTI-TISSUE_STRUCTURE", 43, 57], ["circumventricular organs", "ORGAN", 62, 86], ["basal lamina", "CELLULAR_COMPONENT", 137, 149], ["protease", "PROTEIN", 110, 118], ["T. brucei", "SPECIES", 0, 9], ["T. brucei", "SPECIES", 0, 9], ["T. brucei", "PROBLEM", 0, 9], ["secreting a protease", "PROBLEM", 98, 118], ["brucei", "OBSERVATION", 3, 9], ["CNS", "ANATOMY", 31, 34], ["choroid plexus", "ANATOMY", 43, 57], ["circumventricular organs", "ANATOMY", 62, 86], ["basal", "ANATOMY_MODIFIER", 137, 142], ["lamina", "ANATOMY", 143, 149]]], ["During the early phase of CNS infection, production of IL-6 and IL-10 protects against neuroinflammation [221] .", [["CNS", "ANATOMY", 26, 29], ["infection", "DISEASE", 30, 39], ["neuroinflammation", "DISEASE", 87, 104], ["CNS", "ANATOMICAL_SYSTEM", 26, 29], ["IL-6", "GENE_OR_GENE_PRODUCT", 55, 59], ["IL-10", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL-6", "PROTEIN", 55, 59], ["IL-10", "PROTEIN", 64, 69], ["CNS infection", "PROBLEM", 26, 39], ["production of IL", "TREATMENT", 41, 57], ["neuroinflammation", "PROBLEM", 87, 104], ["CNS", "ANATOMY", 26, 29], ["infection", "OBSERVATION", 30, 39]]], ["However, later in disease, activated microglia and astrocytes produce high levels of inflammatory cytokines (e.g., IL-1\u03b2, CXCL-8, CCL-2, and TNF-\u03b1), which can lead to severe neuropathology [222] .", [["microglia", "ANATOMY", 37, 46], ["astrocytes", "ANATOMY", 51, 61], ["neuropathology", "DISEASE", 174, 188], ["microglia", "CELL", 37, 46], ["astrocytes", "CELL", 51, 61], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 115, 120], ["CXCL-8", "GENE_OR_GENE_PRODUCT", 122, 128], ["CCL-2", "GENE_OR_GENE_PRODUCT", 130, 135], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 141, 146], ["activated microglia", "CELL_TYPE", 27, 46], ["astrocytes", "CELL_TYPE", 51, 61], ["inflammatory cytokines", "PROTEIN", 85, 107], ["IL", "PROTEIN", 115, 117], ["CXCL-8", "PROTEIN", 122, 128], ["CCL", "PROTEIN", 130, 133], ["TNF", "PROTEIN", 141, 144], ["activated microglia and astrocytes", "TEST", 27, 61], ["inflammatory cytokines", "PROBLEM", 85, 107], ["IL", "TEST", 115, 117], ["CXCL", "TEST", 122, 126], ["CCL", "TEST", 130, 133], ["TNF", "TEST", 141, 144], ["severe neuropathology", "PROBLEM", 167, 188], ["disease", "OBSERVATION", 18, 25], ["inflammatory cytokines", "OBSERVATION", 85, 107], ["severe", "OBSERVATION_MODIFIER", 167, 173]]], ["These inflammatory cytokines upregulate the expression of cells adhesion molecules (i.e., ICAM-1, VCAM-1, and E-selectin) on brain endothelial cells, which promotes leukocyte migration into the CNS.", [["cells", "ANATOMY", 58, 63], ["brain endothelial cells", "ANATOMY", 125, 148], ["leukocyte", "ANATOMY", 165, 174], ["CNS", "ANATOMY", 194, 197], ["cells", "CELL", 58, 63], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 90, 96], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 98, 104], ["E-selectin", "GENE_OR_GENE_PRODUCT", 110, 120], ["brain endothelial cells", "CELL", 125, 148], ["leukocyte", "CELL", 165, 174], ["CNS", "ANATOMICAL_SYSTEM", 194, 197], ["inflammatory cytokines", "PROTEIN", 6, 28], ["adhesion molecules", "PROTEIN", 64, 82], ["ICAM-1", "PROTEIN", 90, 96], ["VCAM", "PROTEIN", 98, 102], ["E-selectin", "PROTEIN", 110, 120], ["brain endothelial cells", "CELL_TYPE", 125, 148], ["These inflammatory cytokines", "PROBLEM", 0, 28], ["cells adhesion molecules", "PROBLEM", 58, 82], ["ICAM", "TEST", 90, 94], ["VCAM", "TEST", 98, 102], ["brain endothelial cells", "PROBLEM", 125, 148], ["inflammatory", "OBSERVATION_MODIFIER", 6, 18], ["cells adhesion molecules", "OBSERVATION", 58, 82], ["brain endothelial", "ANATOMY", 125, 142], ["leukocyte migration", "OBSERVATION", 165, 184], ["CNS", "ANATOMY", 194, 197]]], ["Infiltrating lymphocytes are particularly involved in the entry of parasite across BBB.", [["Infiltrating lymphocytes", "ANATOMY", 0, 24], ["BBB", "ANATOMY", 83, 86], ["Infiltrating lymphocytes", "CELL", 0, 24], ["BBB", "MULTI-TISSUE_STRUCTURE", 83, 86], ["Infiltrating lymphocytes", "CELL_TYPE", 0, 24], ["Infiltrating lymphocytes", "PROBLEM", 0, 24], ["lymphocytes", "OBSERVATION", 13, 24]]], ["They secret IFN-\u03b3, which in turn activates MMP9, a protease that degrades astrocytic basement membrane allowing paracellular entry of parasite into the CNS [219] .", [["astrocytic basement membrane", "ANATOMY", 74, 102], ["paracellular", "ANATOMY", 112, 124], ["CNS", "ANATOMY", 152, 155], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 12, 17], ["MMP9", "GENE_OR_GENE_PRODUCT", 43, 47], ["astrocytic basement membrane", "CELLULAR_COMPONENT", 74, 102], ["paracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 124], ["IFN", "PROTEIN", 12, 15], ["\u03b3", "PROTEIN", 16, 17], ["MMP9", "PROTEIN", 43, 47], ["protease", "PROTEIN", 51, 59], ["MMP9", "TEST", 43, 47], ["a protease", "TREATMENT", 49, 59], ["CNS", "ANATOMY", 152, 155]]], ["Consistently, enhanced expression of MMPs is reported during Trypanosoma infection [223, 224] .", [["Trypanosoma infection", "DISEASE", 61, 82], ["MMPs", "GENE_OR_GENE_PRODUCT", 37, 41], ["MMPs", "PROTEIN", 37, 41], ["MMPs", "PROBLEM", 37, 41], ["Trypanosoma infection", "PROBLEM", 61, 82], ["MMPs", "OBSERVATION", 37, 41], ["Trypanosoma infection", "OBSERVATION", 61, 82]]], ["Additionally, IFN-\u03b3 augments the expression of CXCL-10 by astrocytes, which recruits more lymphocytes into the CNS [225] .", [["astrocytes", "ANATOMY", 58, 68], ["lymphocytes", "ANATOMY", 90, 101], ["CNS", "ANATOMY", 111, 114], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 14, 19], ["CXCL-10", "GENE_OR_GENE_PRODUCT", 47, 54], ["astrocytes", "CELL", 58, 68], ["lymphocytes", "CELL", 90, 101], ["IFN", "PROTEIN", 14, 17], ["\u03b3", "PROTEIN", 18, 19], ["CXCL-10", "PROTEIN", 47, 54], ["astrocytes", "CELL_TYPE", 58, 68], ["lymphocytes", "CELL_TYPE", 90, 101], ["IFN", "TEST", 14, 17], ["CXCL", "TEST", 47, 51], ["CNS", "ANATOMY", 111, 114]]], ["Furthermore, T. brucei releases cysteine proteases that trigger protease-activated receptors (PARs) on BMECs, thereby promoting BBB dysfunction through enhancement of intracellular calcium level [226] .", [["BMECs", "ANATOMY", 103, 108], ["BBB", "ANATOMY", 128, 131], ["intracellular", "ANATOMY", 167, 180], ["cysteine", "CHEMICAL", 32, 40], ["calcium", "CHEMICAL", 181, 188], ["cysteine", "CHEMICAL", 32, 40], ["calcium", "CHEMICAL", 181, 188], ["T. brucei", "ORGANISM", 13, 22], ["cysteine", "AMINO_ACID", 32, 40], ["protease-activated receptors", "GENE_OR_GENE_PRODUCT", 64, 92], ["PARs", "GENE_OR_GENE_PRODUCT", 94, 98], ["BMECs", "SIMPLE_CHEMICAL", 103, 108], ["BBB", "MULTI-TISSUE_STRUCTURE", 128, 131], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 167, 180], ["calcium", "SIMPLE_CHEMICAL", 181, 188], ["cysteine proteases", "PROTEIN", 32, 50], ["protease-activated receptors", "PROTEIN", 64, 92], ["PARs", "PROTEIN", 94, 98], ["BMECs", "CELL_TYPE", 103, 108], ["T. brucei", "SPECIES", 13, 22], ["T. brucei", "SPECIES", 13, 22], ["T. brucei releases cysteine proteases", "TREATMENT", 13, 50], ["protease-activated receptors (PARs", "TREATMENT", 64, 98], ["BMECs", "TREATMENT", 103, 108], ["BBB dysfunction", "PROBLEM", 128, 143], ["intracellular calcium level", "TEST", 167, 194]]], ["Interestingly, production of nitric oxide by perivascular macrophages restricts the entry of both parasites and activated T cells into the CNS by preserving BBB integrity [224] .Amoebic Encephalitis and BBB EffectsAcanthamoeba castellanii is a fatal infection of immunocompromised individuals and is associated with BBB dysfunction and has been shown to cause granulomatous encephalitis in immunocompromised patients.", [["perivascular macrophages", "ANATOMY", 45, 69], ["T cells", "ANATOMY", 122, 129], ["CNS", "ANATOMY", 139, 142], ["BBB", "ANATOMY", 157, 160], ["BBB", "ANATOMY", 316, 319], ["nitric oxide", "CHEMICAL", 29, 41], ["Encephalitis", "DISEASE", 186, 198], ["Acanthamoeba castellanii", "DISEASE", 214, 238], ["infection", "DISEASE", 250, 259], ["BBB dysfunction", "DISEASE", 316, 331], ["granulomatous encephalitis", "DISEASE", 360, 386], ["nitric oxide", "CHEMICAL", 29, 41], ["nitric oxide", "SIMPLE_CHEMICAL", 29, 41], ["perivascular macrophages", "CELL", 45, 69], ["T cells", "CELL", 122, 129], ["CNS", "ANATOMICAL_SYSTEM", 139, 142], ["BBB", "MULTI-TISSUE_STRUCTURE", 157, 160], ["Acanthamoeba castellanii", "ORGANISM", 214, 238], ["BBB", "MULTI-TISSUE_STRUCTURE", 316, 319], ["patients", "ORGANISM", 408, 416], ["perivascular macrophages", "CELL_TYPE", 45, 69], ["activated T cells", "CELL_TYPE", 112, 129], ["Acanthamoeba castellanii", "SPECIES", 214, 238], ["patients", "SPECIES", 408, 416], ["Acanthamoeba castellanii", "SPECIES", 214, 238], ["nitric oxide", "TREATMENT", 29, 41], ["perivascular macrophages", "PROBLEM", 45, 69], ["activated T cells", "TREATMENT", 112, 129], ["Amoebic Encephalitis", "PROBLEM", 178, 198], ["Acanthamoeba castellanii", "PROBLEM", 214, 238], ["a fatal infection of immunocompromised individuals", "PROBLEM", 242, 292], ["BBB dysfunction", "PROBLEM", 316, 331], ["granulomatous encephalitis", "PROBLEM", 360, 386], ["nitric oxide", "OBSERVATION", 29, 41], ["perivascular macrophages", "OBSERVATION", 45, 69], ["CNS", "ANATOMY", 139, 142], ["Encephalitis", "OBSERVATION", 186, 198], ["fatal", "OBSERVATION_MODIFIER", 244, 249], ["infection", "OBSERVATION", 250, 259], ["immunocompromised", "OBSERVATION", 263, 280], ["associated with", "UNCERTAINTY", 300, 315], ["dysfunction", "OBSERVATION", 320, 331], ["shown to cause", "UNCERTAINTY", 345, 359], ["granulomatous", "OBSERVATION_MODIFIER", 360, 373], ["encephalitis", "OBSERVATION", 374, 386], ["immunocompromised", "OBSERVATION", 390, 407]]], ["It invades the CNS through hematogenous pathway following disruption of the BBB [227] .", [["CNS", "ANATOMY", 15, 18], ["CNS", "ANATOMICAL_SYSTEM", 15, 18], ["CNS", "ANATOMY", 15, 18], ["hematogenous", "OBSERVATION", 27, 39]]], ["A. castellanii interacts with BMECs through a mannose-binding protein that is expressed on the surface of its trophozoites.", [["BMECs", "ANATOMY", 30, 35], ["surface", "ANATOMY", 95, 102], ["trophozoites", "ANATOMY", 110, 122], ["mannose", "CHEMICAL", 46, 53], ["A. castellanii", "ORGANISM", 0, 14], ["BMECs", "GENE_OR_GENE_PRODUCT", 30, 35], ["mannose", "SIMPLE_CHEMICAL", 46, 53], ["surface", "CELLULAR_COMPONENT", 95, 102], ["trophozoites", "CELL", 110, 122], ["BMECs", "PROTEIN", 30, 35], ["mannose-binding protein", "PROTEIN", 46, 69], ["A. castellanii", "SPECIES", 0, 14], ["A. castellanii", "SPECIES", 0, 14], ["a mannose-binding protein", "TREATMENT", 44, 69], ["trophozoites", "OBSERVATION", 110, 122]]], ["These interactions trigger degradation of TJ proteins (e.g., occludin and ZO-1) in a Rho kinase-dependent manner [228] .", [["TJ", "GENE_OR_GENE_PRODUCT", 42, 44], ["occludin", "GENE_OR_GENE_PRODUCT", 61, 69], ["ZO-1", "GENE_OR_GENE_PRODUCT", 74, 78], ["Rho", "GENE_OR_GENE_PRODUCT", 85, 88], ["TJ proteins", "PROTEIN", 42, 53], ["occludin", "PROTEIN", 61, 69], ["ZO-1", "PROTEIN", 74, 78], ["Rho kinase", "PROTEIN", 85, 95], ["TJ proteins", "PROBLEM", 42, 53]]], ["Additionally, parasite interaction can induce cell cycle arrest and apoptosis through activation of phosphatidylinositol 3 kinases (PI3K) and inhibition of proteins that are involved in cell cycle progression [229, 230] .", [["cell", "ANATOMY", 46, 50], ["cell", "ANATOMY", 186, 190], ["phosphatidylinositol", "CHEMICAL", 100, 120], ["cell", "CELL", 46, 50], ["phosphatidylinositol 3 kinases", "GENE_OR_GENE_PRODUCT", 100, 130], ["PI3K", "GENE_OR_GENE_PRODUCT", 132, 136], ["cell", "CELL", 186, 190], ["phosphatidylinositol 3 kinases", "PROTEIN", 100, 130], ["PI3K", "PROTEIN", 132, 136], ["parasite interaction", "PROBLEM", 14, 34], ["cell cycle arrest", "PROBLEM", 46, 63], ["apoptosis", "PROBLEM", 68, 77], ["phosphatidylinositol 3 kinases", "TREATMENT", 100, 130], ["inhibition of proteins", "TREATMENT", 142, 164], ["cell cycle arrest", "OBSERVATION", 46, 63]]], ["Similarly, cell cycle arrest and apoptosis of brain endothelial cells have been reported for Balamuthia mandrillaris, another parasite that is known to cause fatal amoebic meningoencephalitis [231] .", [["cell", "ANATOMY", 11, 15], ["brain endothelial cells", "ANATOMY", 46, 69], ["amoebic meningoencephalitis", "DISEASE", 164, 191], ["cell", "CELL", 11, 15], ["brain endothelial cells", "CELL", 46, 69], ["Balamuthia mandrillaris", "ORGANISM", 93, 116], ["brain endothelial cells", "CELL_TYPE", 46, 69], ["Balamuthia mandrillaris", "SPECIES", 93, 116], ["Balamuthia mandrillaris", "SPECIES", 93, 116], ["cell cycle arrest", "PROBLEM", 11, 28], ["apoptosis of brain endothelial cells", "PROBLEM", 33, 69], ["Balamuthia mandrillaris", "PROBLEM", 93, 116], ["fatal amoebic meningoencephalitis", "PROBLEM", 158, 191], ["cell cycle arrest", "OBSERVATION", 11, 28], ["brain", "ANATOMY", 46, 51], ["endothelial cells", "OBSERVATION", 52, 69], ["known to cause", "UNCERTAINTY", 143, 157], ["fatal", "OBSERVATION_MODIFIER", 158, 163], ["amoebic", "OBSERVATION_MODIFIER", 164, 171], ["meningoencephalitis", "OBSERVATION", 172, 191]]], ["Notably, host immune response plays a major role in the disruption of BBB during infection with A. castellanii and Naegleria fowleri [227, 232] .", [["BBB", "ANATOMY", 70, 73], ["infection", "DISEASE", 81, 90], ["BBB", "GENE_OR_GENE_PRODUCT", 70, 73], ["A. castellanii", "ORGANISM", 96, 110], ["Naegleria fowleri", "ORGANISM", 115, 132], ["A. castellanii", "SPECIES", 96, 110], ["Naegleria fowleri", "SPECIES", 115, 132], ["A. castellanii", "SPECIES", 96, 110], ["Naegleria fowleri", "SPECIES", 115, 132], ["infection", "PROBLEM", 81, 90], ["immune response", "OBSERVATION", 14, 29], ["infection", "OBSERVATION", 81, 90]]], ["Since these amoebae are relatively large in size, they elicit an amplified immune response that not only compromises the BBB integrity but also causes neuronal damage [232] .Amoebic Encephalitis and BBB EffectsNeurotropic parasites (e.g., Trypanosoma, Acanthamoeba, and Balamuthia species) are also known to produce and release a variety of proteases (e.g., cysteine and serine proteases and metalloproteinases) that target TJ proteins and the basal membrane of the BBB, leading to barrier dysfunction [233] [234] [235] [236] .", [["BBB", "ANATOMY", 121, 124], ["neuronal", "ANATOMY", 151, 159], ["TJ", "ANATOMY", 424, 426], ["basal membrane", "ANATOMY", 444, 458], ["BBB", "ANATOMY", 466, 469], ["barrier", "ANATOMY", 482, 489], ["neuronal damage", "DISEASE", 151, 166], ["Encephalitis", "DISEASE", 182, 194], ["Neurotropic parasites", "DISEASE", 210, 231], ["cysteine", "CHEMICAL", 358, 366], ["serine", "CHEMICAL", 371, 377], ["amoebae", "CELL", 12, 19], ["BBB", "MULTI-TISSUE_STRUCTURE", 121, 124], ["neuronal", "CELL", 151, 159], ["Trypanosoma, Acanthamoeba", "ORGANISM", 239, 264], ["Balamuthia species", "ORGANISM", 270, 288], ["cysteine", "AMINO_ACID", 358, 366], ["serine", "AMINO_ACID", 371, 377], ["metalloproteinases", "GENE_OR_GENE_PRODUCT", 392, 410], ["TJ", "GENE_OR_GENE_PRODUCT", 424, 426], ["basal membrane", "CELLULAR_COMPONENT", 444, 458], ["BBB", "MULTI-TISSUE_STRUCTURE", 466, 469], ["proteases", "PROTEIN", 341, 350], ["cysteine and serine proteases", "PROTEIN", 358, 387], ["metalloproteinases", "PROTEIN", 392, 410], ["TJ proteins", "PROTEIN", 424, 435], ["neuronal damage", "PROBLEM", 151, 166], ["Amoebic Encephalitis", "PROBLEM", 174, 194], ["BBB Effects", "PROBLEM", 199, 210], ["Neurotropic parasites", "TEST", 210, 231], ["Trypanosoma", "PROBLEM", 239, 250], ["Acanthamoeba", "PROBLEM", 252, 264], ["Balamuthia species", "PROBLEM", 270, 288], ["cysteine and serine proteases", "TREATMENT", 358, 387], ["metalloproteinases", "TREATMENT", 392, 410], ["target TJ proteins", "TEST", 417, 435], ["barrier dysfunction", "PROBLEM", 482, 501], ["amoebae", "OBSERVATION_MODIFIER", 12, 19], ["relatively", "OBSERVATION_MODIFIER", 24, 34], ["large", "OBSERVATION_MODIFIER", 35, 40], ["size", "OBSERVATION_MODIFIER", 44, 48], ["immune response", "OBSERVATION", 75, 90], ["neuronal damage", "OBSERVATION", 151, 166], ["Encephalitis", "OBSERVATION", 182, 194], ["Trypanosoma", "OBSERVATION_MODIFIER", 239, 250], ["basal", "ANATOMY_MODIFIER", 444, 449], ["membrane", "ANATOMY_MODIFIER", 450, 458], ["BBB", "ANATOMY", 466, 469]]], ["Proteases interact with protease-activated receptors on BMEC and stimulate calcium release from intracellular stores by activating phospholipase C (PLC) [226] .", [["BMEC", "ANATOMY", 56, 60], ["intracellular", "ANATOMY", 96, 109], ["calcium", "CHEMICAL", 75, 82], ["calcium", "CHEMICAL", 75, 82], ["protease-activated receptors", "GENE_OR_GENE_PRODUCT", 24, 52], ["BMEC", "CELL", 56, 60], ["calcium", "SIMPLE_CHEMICAL", 75, 82], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 96, 109], ["phospholipase C", "GENE_OR_GENE_PRODUCT", 131, 146], ["PLC", "GENE_OR_GENE_PRODUCT", 148, 151], ["protease-activated receptors", "PROTEIN", 24, 52], ["BMEC", "CELL_TYPE", 56, 60], ["phospholipase C", "PROTEIN", 131, 146], ["PLC", "PROTEIN", 148, 151], ["protease", "TREATMENT", 24, 32], ["activated receptors on BMEC", "TREATMENT", 33, 60], ["calcium release", "TEST", 75, 90], ["intracellular stores", "TEST", 96, 116]]], ["Increased calcium levels result in calmodulin activation of myosin light chain, which in turn augments intracellular contraction, leading to disruption of TJs between brain ECs [237] .Future PerspectivesSince the initial demonstration and appreciation of the specialized nature of the CNS microvasculature, researchers have learned that it is less an impermeable barrier and more a dynamic interface that senses and responds to the periphery.", [["intracellular", "ANATOMY", 103, 116], ["TJs", "ANATOMY", 155, 158], ["brain ECs", "ANATOMY", 167, 176], ["CNS microvasculature", "ANATOMY", 285, 305], ["calcium", "CHEMICAL", 10, 17], ["calcium", "CHEMICAL", 10, 17], ["calcium", "SIMPLE_CHEMICAL", 10, 17], ["calmodulin", "GENE_OR_GENE_PRODUCT", 35, 45], ["myosin light chain", "GENE_OR_GENE_PRODUCT", 60, 78], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 116], ["TJs", "CELL", 155, 158], ["brain ECs", "CELL", 167, 176], ["CNS microvasculature", "TISSUE", 285, 305], ["calmodulin", "PROTEIN", 35, 45], ["myosin light chain", "PROTEIN", 60, 78], ["TJs", "CELL_TYPE", 155, 158], ["brain ECs", "CELL_TYPE", 167, 176], ["Increased calcium levels", "TEST", 0, 24], ["calmodulin activation of myosin light chain", "TREATMENT", 35, 78], ["intracellular contraction", "PROBLEM", 103, 128], ["disruption of TJs between brain ECs", "PROBLEM", 141, 176], ["calcium levels", "OBSERVATION", 10, 24], ["intracellular contraction", "OBSERVATION", 103, 128], ["CNS microvasculature", "ANATOMY", 285, 305], ["impermeable", "OBSERVATION_MODIFIER", 351, 362], ["barrier", "OBSERVATION_MODIFIER", 363, 370], ["periphery", "ANATOMY_MODIFIER", 432, 441]]], ["These responses are generally neuroprotective, such as the IFNAR-mediated increase in TJ integrity during viral invasion or the stringent regulation of T cell access that can promote efficient clearance of pathogens, such as T. gondii, without excessive immunopathology.", [["TJ", "ANATOMY", 86, 88], ["T cell", "ANATOMY", 152, 158], ["IFNAR", "GENE_OR_GENE_PRODUCT", 59, 64], ["TJ", "GENE_OR_GENE_PRODUCT", 86, 88], ["T cell", "CELL", 152, 158], ["T. gondii", "ORGANISM", 225, 234], ["IFNAR", "PROTEIN", 59, 64], ["T. gondii", "SPECIES", 225, 234], ["T. gondii", "SPECIES", 225, 234], ["TJ integrity", "TREATMENT", 86, 98], ["viral invasion", "PROBLEM", 106, 120], ["T cell access", "TREATMENT", 152, 165], ["pathogens", "PROBLEM", 206, 215], ["T. gondii", "PROBLEM", 225, 234], ["excessive immunopathology", "PROBLEM", 244, 269], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["viral invasion", "OBSERVATION", 106, 120]]], ["Pathogens have evolved various mechanisms to exploit cellular and molecular processes that control the CNS access, such as the reduction in expression of ZO-1 induced by the B. anthracis edema toxin (ET).", [["cellular", "ANATOMY", 53, 61], ["CNS", "ANATOMY", 103, 106], ["cellular", "CELL", 53, 61], ["CNS", "ANATOMICAL_SYSTEM", 103, 106], ["ZO-1", "GENE_OR_GENE_PRODUCT", 154, 158], ["B. anthracis edema toxin", "ORGANISM", 174, 198], ["ZO-1", "PROTEIN", 154, 158], ["B. anthracis", "SPECIES", 174, 186], ["B. anthracis", "SPECIES", 174, 186], ["Pathogens", "PROBLEM", 0, 9], ["cellular and molecular processes", "PROBLEM", 53, 85], ["the B. anthracis edema toxin", "PROBLEM", 170, 198], ["edema", "OBSERVATION", 187, 192]]], ["Host responses, in turn, regulate immune cell infiltration into the CNS via antigen-specific events that allow leukocyte localization, interactions, and egress from perivascular spaces such that inflammation is efficiently directed at pathogen elimination.", [["immune cell", "ANATOMY", 34, 45], ["CNS", "ANATOMY", 68, 71], ["leukocyte", "ANATOMY", 111, 120], ["perivascular spaces", "ANATOMY", 165, 184], ["inflammation", "DISEASE", 195, 207], ["immune cell", "CELL", 34, 45], ["CNS", "ANATOMICAL_SYSTEM", 68, 71], ["leukocyte", "CELL", 111, 120], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 165, 177], ["immune cell infiltration", "TREATMENT", 34, 58], ["leukocyte localization", "TEST", 111, 133], ["inflammation", "PROBLEM", 195, 207], ["immune cell infiltration", "OBSERVATION", 34, 58], ["CNS", "ANATOMY", 68, 71], ["perivascular", "ANATOMY_MODIFIER", 165, 177], ["inflammation", "OBSERVATION", 195, 207]]], ["The interaction of immune cells with BMECs destabilizes junctional molecules via cytokinemediated signaling events that alter the structural properties of these cells.", [["immune cells", "ANATOMY", 19, 31], ["BMECs", "ANATOMY", 37, 42], ["junctional molecules", "ANATOMY", 56, 76], ["cells", "ANATOMY", 161, 166], ["immune cells", "CELL", 19, 31], ["BMECs", "CELL", 37, 42], ["junctional molecules", "CELLULAR_COMPONENT", 56, 76], ["cells", "CELL", 161, 166], ["immune cells", "CELL_TYPE", 19, 31], ["BMECs", "CELL_TYPE", 37, 42], ["immune cells", "PROBLEM", 19, 31], ["junctional molecules", "PROBLEM", 56, 76], ["cytokinemediated signaling events", "PROBLEM", 81, 114], ["immune cells", "OBSERVATION", 19, 31]]], ["Thus, the most severe outcomes in the context of neuroinfectious diseases that enter the CNS via the BBB arise from host inflammatory responses rather than due to direct effects of pathogens themselves.", [["CNS", "ANATOMY", 89, 92], ["BBB", "ANATOMY", 101, 104], ["CNS", "ANATOMICAL_SYSTEM", 89, 92], ["BBB", "MULTI-TISSUE_STRUCTURE", 101, 104], ["neuroinfectious diseases", "PROBLEM", 49, 73], ["host inflammatory responses", "PROBLEM", 116, 143], ["direct effects of pathogens themselves", "PROBLEM", 163, 201], ["most severe", "OBSERVATION_MODIFIER", 10, 21]]], ["This is particularly evident in the context of autoimmune diseases of the CNS where leukocytes gain inappropriate access to the CNS and cause extensive damage without acute infection.Future PerspectivesWhile we continue to improve our understanding of these processes, the challenge will be to better identify mechanisms that promote efficiency in immunemediated pathogen clearance while enhancing the CNS' own neuroprotective mechanisms.", [["CNS", "ANATOMY", 74, 77], ["leukocytes", "ANATOMY", 84, 94], ["CNS", "ANATOMY", 128, 131], ["CNS", "ANATOMY", 402, 405], ["autoimmune diseases of the CNS", "DISEASE", 47, 77], ["infection", "DISEASE", 173, 182], ["CNS", "ANATOMICAL_SYSTEM", 74, 77], ["leukocytes", "CELL", 84, 94], ["CNS", "ANATOMICAL_SYSTEM", 128, 131], ["CNS", "ANATOMICAL_SYSTEM", 402, 405], ["leukocytes", "CELL_TYPE", 84, 94], ["autoimmune diseases", "PROBLEM", 47, 66], ["the CNS", "PROBLEM", 70, 77], ["extensive damage", "PROBLEM", 142, 158], ["acute infection", "PROBLEM", 167, 182], ["immunemediated pathogen clearance", "PROBLEM", 348, 381], ["autoimmune", "OBSERVATION", 47, 57], ["CNS", "ANATOMY", 74, 77], ["CNS", "ANATOMY", 128, 131], ["extensive", "OBSERVATION_MODIFIER", 142, 151], ["damage", "OBSERVATION", 152, 158], ["without", "UNCERTAINTY", 159, 166], ["acute", "OBSERVATION_MODIFIER", 167, 172], ["infection", "OBSERVATION", 173, 182]]], ["The use of animal models of neuroinfectious diseases that focus on various aspects of these processes in conjunction with the development of methods to isolate cellular participants, such as RiboTag or single cell RNA sequencing, in conjunction with cell-specific gene deletion strategies will permit cell-type-specific evaluation of mRNA expression and protein functions during the course of in vivo pathogen invasion, infection, and clearance.", [["cellular", "ANATOMY", 160, 168], ["cell", "ANATOMY", 209, 213], ["cell", "ANATOMY", 250, 254], ["cell", "ANATOMY", 301, 305], ["neuroinfectious diseases", "DISEASE", 28, 52], ["infection", "DISEASE", 420, 429], ["cellular", "CELL", 160, 168], ["RiboTag", "GENE_OR_GENE_PRODUCT", 191, 198], ["cell", "CELL", 250, 254], ["cell", "CELL", 301, 305], ["RiboTag", "PROTEIN", 191, 198], ["participants", "SPECIES", 169, 181], ["neuroinfectious diseases", "PROBLEM", 28, 52], ["RiboTag", "TREATMENT", 191, 198], ["single cell RNA sequencing", "TREATMENT", 202, 228], ["cell-specific gene deletion strategies", "TREATMENT", 250, 288], ["specific evaluation", "TEST", 311, 330], ["mRNA expression", "PROBLEM", 334, 349], ["protein functions", "TEST", 354, 371], ["vivo pathogen invasion", "PROBLEM", 396, 418], ["infection", "PROBLEM", 420, 429], ["invasion", "OBSERVATION", 410, 418], ["infection", "OBSERVATION", 420, 429]]], ["The advent of techniques in which human-induced pluripotent stem cells (hiPSCs) can be differentiated into all members of the NVU which are then incorporated into three-dimensional, fluid-based models of the human BBB also holds promise for identifying molecular players in this process and validating results in human systems.", [["pluripotent stem cells", "ANATOMY", 48, 70], ["hiPSCs", "ANATOMY", 72, 78], ["BBB", "ANATOMY", 214, 217], ["human", "ORGANISM", 34, 39], ["pluripotent stem cells", "CELL", 48, 70], ["hiPSCs", "CELL", 72, 78], ["NVU", "GENE_OR_GENE_PRODUCT", 126, 129], ["human", "ORGANISM", 208, 213], ["BBB", "MULTI-TISSUE_STRUCTURE", 214, 217], ["human", "ORGANISM", 313, 318], ["human-induced pluripotent stem cells", "CELL_LINE", 34, 70], ["hiPSCs", "CELL_TYPE", 72, 78], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 208, 213], ["human", "SPECIES", 313, 318], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 208, 213], ["human", "SPECIES", 313, 318], ["human-induced pluripotent stem cells", "TREATMENT", 34, 70], ["pluripotent stem cells", "OBSERVATION", 48, 70]]], ["Future studies are likely to uncover novel neuroimmune pathways that may be safely targeted to prevent or treat infections of the CNS while also providing strategies for manipulating BBB function for the purposes of drug delivery or immunotherapies for noninfectious neurologic diseases.", [["CNS", "ANATOMY", 130, 133], ["BBB", "ANATOMY", 183, 186], ["neurologic", "ANATOMY", 267, 277], ["infections", "DISEASE", 112, 122], ["noninfectious neurologic diseases", "DISEASE", 253, 286], ["CNS", "ANATOMICAL_SYSTEM", 130, 133], ["BBB", "MULTI-TISSUE_STRUCTURE", 183, 186], ["Future studies", "TEST", 0, 14], ["infections of the CNS", "PROBLEM", 112, 133], ["manipulating BBB function", "PROBLEM", 170, 195], ["drug delivery", "TREATMENT", 216, 229], ["immunotherapies", "TREATMENT", 233, 248], ["noninfectious neurologic diseases", "PROBLEM", 253, 286]]]], "PMC4845017": [["ResultsA total of 183 megabats consisting of four different species were included in this study (Table 1).", [["megabats", "ANATOMY", 22, 30], ["megabats", "CANCER", 22, 30], ["four different species", "PROBLEM", 45, 67], ["this study", "TEST", 85, 95]]], ["Among these, Pteropus sp. and Dobsonia sp. were not identified at species level, but other genetically close species Pteropus hypomelanus and Dobsonia moluccensis, were included21.", [["Pteropus sp", "ORGANISM", 13, 24], ["Dobsonia sp", "ORGANISM", 30, 41], ["Pteropus hypomelanus", "ORGANISM", 117, 137], ["Dobsonia moluccensis", "ORGANISM", 142, 162], ["Pteropus hypomelanus", "SPECIES", 117, 137], ["Dobsonia moluccensis", "SPECIES", 142, 162], ["Pteropus hypomelanus", "SPECIES", 117, 137], ["Dobsonia moluccensis", "SPECIES", 142, 162], ["Dobsonia moluccensis", "PROBLEM", 142, 162], ["Pteropus sp", "OBSERVATION", 13, 24], ["Pteropus hypomelanus", "OBSERVATION", 117, 137]]], ["In an earlier study, BuV was detected from the spleen tissues and faeces of shrews9.", [["spleen tissues", "ANATOMY", 47, 61], ["faeces", "ANATOMY", 66, 72], ["BuV", "GENE_OR_GENE_PRODUCT", 21, 24], ["spleen tissues", "TISSUE", 47, 61], ["faeces", "ORGANISM_SUBDIVISION", 66, 72], ["BuV", "PROTEIN", 21, 24], ["an earlier study", "TEST", 3, 19], ["spleen", "ANATOMY", 47, 53]]], ["Therefore, we used nested-PCR targeting for the NS1 gene of BuV using 183 spleens and 96 faeces samples (faecal samples were unavailable for a subset of megabats).", [["spleens", "ANATOMY", 74, 81], ["faeces samples", "ANATOMY", 89, 103], ["faecal samples", "ANATOMY", 105, 119], ["NS1", "GENE_OR_GENE_PRODUCT", 48, 51], ["BuV", "GENE_OR_GENE_PRODUCT", 60, 63], ["spleens", "ORGAN", 74, 81], ["faecal samples", "ORGANISM_SUBSTANCE", 105, 119], ["NS1 gene", "DNA", 48, 56], ["BuV", "DNA", 60, 63], ["nested-PCR", "TREATMENT", 19, 29], ["the NS1 gene of BuV", "TREATMENT", 44, 63], ["faeces samples", "TEST", 89, 103], ["faecal samples", "TEST", 105, 119], ["a subset of megabats", "TREATMENT", 141, 161], ["spleens", "ANATOMY", 74, 81]]], ["As shown in Table 1, BuV was identified in three spleen and nine faeces specimens from Pteropus vampyrus, and one spleen specimen from Pteropus sp.", [["spleen", "ANATOMY", 49, 55], ["specimens", "ANATOMY", 72, 81], ["spleen specimen", "ANATOMY", 114, 129], ["BuV", "GENE_OR_GENE_PRODUCT", 21, 24], ["spleen", "ORGAN", 49, 55], ["faeces", "ORGANISM", 65, 71], ["Pteropus vampyrus", "CELL", 87, 104], ["spleen specimen", "MULTI-TISSUE_STRUCTURE", 114, 129], ["Pteropus sp", "ORGANISM", 135, 146], ["BuV", "PROTEIN", 21, 24], ["Pteropus vampyrus", "SPECIES", 87, 104], ["Pteropus vampyrus", "SPECIES", 87, 104], ["nine faeces specimens", "TEST", 60, 81], ["Pteropus vampyrus", "TEST", 87, 104], ["spleen", "ANATOMY", 49, 55], ["Pteropus vampyrus", "OBSERVATION", 87, 104], ["spleen", "ANATOMY", 114, 120], ["Pteropus sp", "OBSERVATION", 135, 146]]], ["Among these, one Pteropus vampyrus in Magelang was positive for BuV in both the spleen and faeces.", [["spleen", "ANATOMY", 80, 86], ["faeces", "ANATOMY", 91, 97], ["Pteropus vampyrus", "ORGANISM", 17, 34], ["Magelang", "ORGANISM", 38, 46], ["BuV", "GENE_OR_GENE_PRODUCT", 64, 67], ["spleen", "ORGAN", 80, 86], ["faeces", "ORGANISM_SUBSTANCE", 91, 97], ["BuV", "PROTEIN", 64, 67], ["Pteropus vampyrus", "SPECIES", 17, 34], ["Pteropus vampyrus", "SPECIES", 17, 34], ["one Pteropus vampyrus in Magelang", "TEST", 13, 46], ["BuV", "PROBLEM", 64, 67], ["spleen", "ANATOMY", 80, 86], ["faeces", "OBSERVATION", 91, 97]]], ["With a limited number of samples, the detection rate of BuV in spleen (2%) was lower than that in faeces (9%).ResultsBased on the nucleotide sequence identity, we tentatively grouped and named the identified BuVs into three strains: megabat bufavirus 1 (MgBuV1) originating from Pteropus vampyrus in Surabaya and Magelang (accession numbers LC085668 to LC085676), megabat bufavirus 2 (MgBuV2) from Pteropus vampyrus in Lima Puluh Kota (LC085665 and LC085666), and megabat bufavirus 3 (MgBuV3) from Pteropus sp. in Paguyaman (LC085667).", [["samples", "ANATOMY", 25, 32], ["spleen", "ANATOMY", 63, 69], ["faeces", "ANATOMY", 98, 104], ["nucleotide", "CHEMICAL", 130, 140], ["Mg", "CHEMICAL", 254, 256], ["Mg", "CHEMICAL", 385, 387], ["Mg", "CHEMICAL", 485, 487], ["nucleotide", "CHEMICAL", 130, 140], ["Mg", "CHEMICAL", 254, 256], ["Mg", "CHEMICAL", 385, 387], ["Mg", "CHEMICAL", 485, 487], ["samples", "CANCER", 25, 32], ["BuV", "GENE_OR_GENE_PRODUCT", 56, 59], ["spleen", "ORGAN", 63, 69], ["faeces", "ORGANISM_SUBSTANCE", 98, 104], ["BuVs", "GENE_OR_GENE_PRODUCT", 208, 212], ["megabat bufavirus 1", "ORGANISM", 233, 252], ["MgBuV1", "ORGANISM", 254, 260], ["Pteropus vampyrus", "ORGANISM", 279, 296], ["megabat bufavirus 2", "CELL", 364, 383], ["MgBuV2", "SIMPLE_CHEMICAL", 385, 391], ["Pteropus vampyrus", "ORGANISM", 398, 415], ["megabat bufavirus 3", "GENE_OR_GENE_PRODUCT", 464, 483], ["MgBuV3", "GENE_OR_GENE_PRODUCT", 485, 491], ["Pteropus sp.", "ORGANISM", 498, 510], ["BuV", "PROTEIN", 56, 59], ["BuVs", "DNA", 208, 212], ["Pteropus vampyrus", "SPECIES", 279, 296], ["Pteropus vampyrus", "SPECIES", 398, 415], ["Pteropus vampyrus", "SPECIES", 279, 296], ["Pteropus vampyrus", "SPECIES", 398, 415], ["Pteropus sp.", "SPECIES", 498, 510], ["the detection rate", "TEST", 34, 52], ["megabat bufavirus", "TREATMENT", 233, 250], ["megabat bufavirus", "TREATMENT", 364, 381], ["megabat bufavirus", "TREATMENT", 464, 481], ["spleen", "ANATOMY", 63, 69]]], ["The partial NS1 gene fragment of MgBuV1 showed 81\u201383% and 91\u201392% nucleotide identity to MgBuV2 and MgBuV3, respectively.", [["nucleotide", "CHEMICAL", 65, 75], ["NS1", "GENE_OR_GENE_PRODUCT", 12, 15], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 33, 39], ["MgBuV2", "GENE_OR_GENE_PRODUCT", 88, 94], ["NS1 gene fragment", "DNA", 12, 29], ["MgBuV1", "DNA", 33, 39], ["MgBuV2", "DNA", 88, 94], ["MgBuV3", "DNA", 99, 105], ["The partial NS1 gene fragment", "TEST", 0, 29], ["MgBuV1", "TEST", 33, 39], ["nucleotide identity", "TEST", 65, 84], ["MgBuV2", "TEST", 88, 94], ["MgBuV3", "TEST", 99, 105], ["partial", "OBSERVATION_MODIFIER", 4, 11], ["NS1 gene", "OBSERVATION", 12, 20], ["fragment", "OBSERVATION_MODIFIER", 21, 29]]], ["The corresponding region of MgBuV2 was 80% identical to that of MgBuV3.ResultsCurrently, DDBJ/EMBL/GenBank databases contain complete or partial nucleotide sequences of BuV from humans, nonhuman primates, shrews, rats, pigs and microbats.", [["MgBuV3", "CHEMICAL", 64, 70], ["nucleotide", "CHEMICAL", 145, 155], ["MgBuV2", "GENE_OR_GENE_PRODUCT", 28, 34], ["MgBuV3", "GENE_OR_GENE_PRODUCT", 64, 70], ["humans", "ORGANISM", 178, 184], ["nonhuman primates", "ORGANISM", 186, 203], ["shrews", "ORGANISM_SUBDIVISION", 205, 211], ["rats", "ORGANISM", 213, 217], ["pigs", "ORGANISM", 219, 223], ["microbats", "CANCER", 228, 237], ["MgBuV2", "PROTEIN", 28, 34], ["MgBuV3", "PROTEIN", 64, 70], ["DDBJ/EMBL/GenBank databases", "DNA", 89, 116], ["humans", "SPECIES", 178, 184], ["rats", "SPECIES", 213, 217], ["pigs", "SPECIES", 219, 223], ["humans", "SPECIES", 178, 184], ["pigs", "SPECIES", 219, 223], ["MgBuV2", "TEST", 28, 34], ["GenBank databases", "TEST", 99, 116], ["partial nucleotide sequences", "TEST", 137, 165], ["microbats", "TREATMENT", 228, 237], ["region", "OBSERVATION_MODIFIER", 18, 24]]], ["A phylogenetic tree was generated on the basis of the identified sequences of NS1 gene in this study and a corresponding region of the available reference sequences of protoparvoviruses including BuVs (Fig. 1).", [["NS1", "GENE_OR_GENE_PRODUCT", 78, 81], ["NS1 gene", "DNA", 78, 86], ["this study", "TEST", 90, 100], ["BuVs", "TEST", 196, 200], ["phylogenetic tree", "OBSERVATION", 2, 19], ["NS1 gene", "OBSERVATION", 78, 86]]], ["Known BuVs formed subgroups by host were distinguishable from other protoparvoviruses (groups 1\u20136, Fig. 1).", [["BuVs", "GENE_OR_GENE_PRODUCT", 6, 10], ["BuVs", "PROTEIN", 6, 10], ["Known BuVs formed subgroups", "PROBLEM", 0, 27]]], ["MgBuV1, MgBuV2 and MgBuV3 diverged from a common ancestor of known protoparvoviruses and were likely to form a distinct subgroup from other BuVs, including microbat-borne BuVs (group 7, Fig. 1).ResultsTo reveal the whole genome sequence and genetically characterise further the identified BuVs, we subjected DNA samples isolated from spleens and faeces to next-generation sequencing.", [["samples", "ANATOMY", 312, 319], ["spleens", "ANATOMY", 334, 341], ["faeces", "ANATOMY", 346, 352], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 0, 6], ["MgBuV2", "GENE_OR_GENE_PRODUCT", 8, 14], ["MgBuV3", "GENE_OR_GENE_PRODUCT", 19, 25], ["protoparvoviruses", "CANCER", 67, 84], ["BuVs", "CANCER", 140, 144], ["BuVs", "GENE_OR_GENE_PRODUCT", 289, 293], ["DNA", "CELLULAR_COMPONENT", 308, 311], ["spleens", "ORGAN", 334, 341], ["faeces", "ORGANISM_SUBSTANCE", 346, 352], ["MgBuV1", "PROTEIN", 0, 6], ["MgBuV2", "PROTEIN", 8, 14], ["MgBuV3", "PROTEIN", 19, 25], ["whole genome sequence", "DNA", 215, 236], ["BuVs", "DNA", 289, 293], ["MgBuV1", "TEST", 0, 6], ["MgBuV2", "TREATMENT", 8, 14], ["MgBuV3", "TREATMENT", 19, 25], ["known protoparvoviruses", "PROBLEM", 61, 84], ["a distinct subgroup from other BuVs", "PROBLEM", 109, 144], ["microbat", "TEST", 156, 164], ["the whole genome sequence", "TEST", 211, 236], ["DNA samples", "TEST", 308, 319], ["spleens", "ANATOMY", 334, 341]]], ["A small number of sequence reads from MgBuV1, but not MgBuV2 and MgBuV3, enabled to amplify the overlapping large fragments by PCR and determine nearly the whole genome sequence, including the complete protein-coding region.", [["fragments", "ANATOMY", 114, 123], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 38, 44], ["MgBuV2", "GENE_OR_GENE_PRODUCT", 54, 60], ["MgBuV3", "GENE_OR_GENE_PRODUCT", 65, 71], ["MgBuV1", "DNA", 38, 44], ["MgBuV2", "DNA", 54, 60], ["MgBuV3", "DNA", 65, 71], ["whole genome sequence", "DNA", 156, 177], ["protein-coding region", "DNA", 202, 223], ["MgBuV1", "TEST", 38, 44], ["MgBuV2", "TEST", 54, 60], ["MgBuV3", "TEST", 65, 71], ["the overlapping large fragments", "PROBLEM", 92, 123], ["PCR", "TEST", 127, 130], ["the whole genome sequence", "TEST", 152, 177], ["small", "OBSERVATION_MODIFIER", 2, 7], ["large", "OBSERVATION_MODIFIER", 108, 113], ["fragments", "OBSERVATION", 114, 123]]], ["The obtained genome sequence of MgBuV1 (accession number LC085675) was 4765 nt in size and encoded three complete ORFs: the non-structural protein (NS1) and the viral capsid proteins (VP1 and VP2).", [["MgBuV1", "GENE_OR_GENE_PRODUCT", 32, 38], ["NS1", "GENE_OR_GENE_PRODUCT", 148, 151], ["VP1", "GENE_OR_GENE_PRODUCT", 184, 187], ["VP2", "GENE_OR_GENE_PRODUCT", 192, 195], ["MgBuV1", "DNA", 32, 38], ["ORFs", "DNA", 114, 118], ["non-structural protein", "PROTEIN", 124, 146], ["NS1", "PROTEIN", 148, 151], ["viral capsid proteins", "PROTEIN", 161, 182], ["VP1", "PROTEIN", 184, 187], ["VP2", "PROTEIN", 192, 195], ["the non-structural protein", "TEST", 120, 146], ["the viral capsid proteins", "TEST", 157, 182], ["VP1", "TEST", 184, 187], ["VP2", "TEST", 192, 195], ["size", "OBSERVATION_MODIFIER", 82, 86], ["viral capsid proteins", "OBSERVATION", 161, 182]]], ["These proteins showed 46\u201361% amino acid sequence identities to those of other BuVs of which complete genome sequences were available (Table 2).", [["amino acid", "CHEMICAL", 29, 39], ["amino acid", "CHEMICAL", 29, 39], ["amino acid", "AMINO_ACID", 29, 39], ["BuVs", "CANCER", 78, 82], ["BuVs", "PROTEIN", 78, 82], ["genome sequences", "DNA", 101, 117], ["These proteins", "TEST", 0, 14], ["amino acid sequence", "TEST", 29, 48], ["other BuVs", "TEST", 72, 82]]], ["Parvovirus-conserved amino acid motifs were found in each viral protein of MgBuV1 (Fig. 2).", [["amino acid", "CHEMICAL", 21, 31], ["amino acid", "CHEMICAL", 21, 31], ["amino acid", "AMINO_ACID", 21, 31], ["viral protein", "PROTEIN", 58, 71], ["MgBuV1", "PROTEIN", 75, 81], ["Parvovirus", "PROBLEM", 0, 10], ["amino acid motifs", "TEST", 21, 38]]], ["NS1 contained a putative endonuclease metal coordination motif \u201cHIH\u201d and the helicase motif Walker A \u201cGPASTGKS\u201d.", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS1", "PROTEIN", 0, 3], ["putative endonuclease metal coordination motif", "PROTEIN", 16, 62], ["HIH", "PROTEIN", 64, 67], ["helicase motif", "PROTEIN", 77, 91], ["GPASTGKS", "PROTEIN", 102, 110], ["a putative endonuclease metal coordination motif", "TREATMENT", 14, 62]]], ["The VP1 of most parvovirus species possesses a phospholipase A2 (PLA2) motif that is required for viral entry22.", [["VP1", "GENE_OR_GENE_PRODUCT", 4, 7], ["parvovirus species", "ORGANISM", 16, 34], ["phospholipase A2", "GENE_OR_GENE_PRODUCT", 47, 63], ["PLA2", "GENE_OR_GENE_PRODUCT", 65, 69], ["VP1", "DNA", 4, 7], ["phospholipase A2 (PLA2) motif", "DNA", 47, 76], ["viral entry22", "PROTEIN", 98, 111], ["The VP1", "TEST", 0, 7], ["most parvovirus species", "PROBLEM", 11, 34], ["a phospholipase A2 (PLA2) motif", "TREATMENT", 45, 76], ["viral entry22", "TREATMENT", 98, 111], ["most parvovirus", "OBSERVATION_MODIFIER", 11, 26]]], ["Three potential sites responsible for the enzymatic activity of PLA2 were strictly conserved in the VP1 of MgBuV1: a calcium-binding loop site \u201cYLGPG\u201d and two catalytic sites \u201cHDLEY\u201d and \u201cD\u201d.", [["calcium", "CHEMICAL", 117, 124], ["calcium", "CHEMICAL", 117, 124], ["PLA2", "GENE_OR_GENE_PRODUCT", 64, 68], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 107, 113], ["calcium", "SIMPLE_CHEMICAL", 117, 124], ["PLA2", "PROTEIN", 64, 68], ["VP1", "PROTEIN", 100, 103], ["MgBuV1", "PROTEIN", 107, 113], ["calcium-binding loop site", "PROTEIN", 117, 142], ["YLGPG", "PROTEIN", 144, 149], ["catalytic sites", "PROTEIN", 159, 174], ["the enzymatic activity of PLA2", "PROBLEM", 38, 68], ["a calcium-binding loop site", "TREATMENT", 115, 142]]], ["The N-terminus of the VP1 and VP2 of MgBuV1 had a glycine-rich motif (G-rich) required for the cellular entry of parvovirus23.ResultsRecently, six partial genome sequences of human BuV-like parvovirus were identified from insectivorous microbats in Hungary and China1314.", [["cellular", "ANATOMY", 95, 103], ["glycine", "CHEMICAL", 50, 57], ["glycine", "CHEMICAL", 50, 57], ["VP1", "GENE_OR_GENE_PRODUCT", 22, 25], ["VP2", "GENE_OR_GENE_PRODUCT", 30, 33], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 37, 43], ["cellular", "CELL", 95, 103], ["parvovirus23", "ORGANISM", 113, 125], ["human", "ORGANISM", 175, 180], ["BuV-like parvovirus", "ORGANISM", 181, 200], ["N-terminus", "PROTEIN", 4, 14], ["VP1", "PROTEIN", 22, 25], ["VP2", "PROTEIN", 30, 33], ["MgBuV1", "PROTEIN", 37, 43], ["glycine-rich motif", "PROTEIN", 50, 68], ["human", "SPECIES", 175, 180], ["parvovirus", "SPECIES", 190, 200], ["human BuV-like parvovirus", "SPECIES", 175, 200], ["the VP1", "TEST", 18, 25], ["a glycine-rich motif (G-rich", "TREATMENT", 48, 76], ["parvovirus", "PROBLEM", 113, 123], ["human BuV", "TEST", 175, 184], ["parvovirus", "PROBLEM", 190, 200], ["parvovirus", "OBSERVATION", 190, 200]]], ["These sequences covered a partial coding region of NS1 and almost complete to complete coding regions of VP1 and VP2 (Fig. 2).", [["NS1", "GENE_OR_GENE_PRODUCT", 51, 54], ["VP1", "GENE_OR_GENE_PRODUCT", 105, 108], ["VP2", "GENE_OR_GENE_PRODUCT", 113, 116], ["NS1", "PROTEIN", 51, 54], ["coding regions", "DNA", 87, 101], ["VP1", "DNA", 105, 108], ["VP2", "DNA", 113, 116], ["a partial coding region of NS1", "TREATMENT", 24, 54], ["VP1", "TEST", 105, 108], ["VP2", "TEST", 113, 116], ["VP2", "ANATOMY", 113, 116]]], ["Therefore, using the coding region of VP2, we performed a phylogenetic analysis to infer the deeper phylogenetic relationships between these microbat-borne BuVs and megabat-borne MgBuV1 (Fig. 3).", [["VP2", "GENE_OR_GENE_PRODUCT", 38, 41], ["BuVs", "GENE_OR_GENE_PRODUCT", 156, 160], ["coding region", "DNA", 21, 34], ["VP2", "DNA", 38, 41], ["microbat-borne BuVs and megabat-borne MgBuV1", "DNA", 141, 185], ["a phylogenetic analysis", "TEST", 56, 79], ["these microbat", "TEST", 135, 149]]], ["All microbat-borne BuVs formed a single cluster (group 5, Fig. 3).", [["microbat-borne BuVs", "DNA", 4, 23], ["All microbat", "TEST", 0, 12]]], ["MgBuV1 branched from the common ancestor of human BuVs, non human primate-borne BuV (WUHARV parvovirus) and pig-borne BuV, and represented a distinct lineage of BuV (linage 4, Fig. 3).", [["MgBuV1", "CHEMICAL", 0, 6], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 0, 6], ["human", "ORGANISM", 44, 49], ["BuVs", "GENE_OR_GENE_PRODUCT", 50, 54], ["non human primate-borne BuV (WUHARV parvovirus", "ORGANISM", 56, 102], ["pig-borne BuV", "ORGANISM", 108, 121], ["MgBuV1", "PROTEIN", 0, 6], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 60, 65], ["WUHARV parvovirus", "SPECIES", 85, 102], ["pig", "SPECIES", 108, 111], ["human", "SPECIES", 44, 49], ["human primate-borne BuV (WUHARV parvovirus", "SPECIES", 60, 102], ["pig-borne BuV", "SPECIES", 108, 121], ["human BuVs", "TEST", 44, 54], ["distinct", "OBSERVATION_MODIFIER", 141, 149], ["lineage", "OBSERVATION", 150, 157]]], ["WUHARV parvovirus (linage 3, Fig. 3) fell into the cluster of human BuVs (group 2, Fig. 3), consistent with a previous study of past recombination events behind the origin of WUHARV parvovirus13.ResultsWe searched for putative recombination events on the genome of MgBuV1 using two different approaches based on sliding window analyses, one using the Bootscan approach and the second using Bayesian inference (Fig. 4A,B).", [["parvovirus", "DISEASE", 182, 192], ["WUHARV parvovirus", "ORGANISM", 0, 17], ["linage 3", "CELL", 19, 27], ["human", "ORGANISM", 62, 67], ["BuVs", "GENE_OR_GENE_PRODUCT", 68, 72], ["WUHARV parvovirus13", "ORGANISM", 175, 194], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 265, 271], ["MgBuV1", "DNA", 265, 271], ["WUHARV parvovirus", "SPECIES", 0, 17], ["human", "SPECIES", 62, 67], ["WUHARV parvovirus", "SPECIES", 0, 17], ["human", "SPECIES", 62, 67], ["WUHARV parvovirus13", "SPECIES", 175, 194], ["WUHARV parvovirus", "PROBLEM", 0, 17], ["a previous study", "TEST", 108, 124], ["past recombination events", "PROBLEM", 128, 153], ["WUHARV parvovirus", "PROBLEM", 175, 192], ["putative recombination events", "PROBLEM", 218, 247], ["MgBuV1", "TREATMENT", 265, 271], ["sliding window analyses", "TEST", 312, 335], ["the Bootscan approach", "TREATMENT", 347, 368], ["parvovirus", "OBSERVATION", 7, 17], ["origin", "ANATOMY_MODIFIER", 165, 171]]], ["Both analyses suggested a mosaic genome structure in MgBuV1 and possible recombinations among ancestors of MgBuV1, WUHARV parvovirus and porcine parvovirus Zsana, around nucleotide positions 778 to 2384 of the MgBuV1 genome (Fig. 4C).", [["nucleotide", "CHEMICAL", 170, 180], ["nucleotide", "CHEMICAL", 170, 180], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 53, 59], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 107, 113], ["WUHARV parvovirus", "ORGANISM", 115, 132], ["porcine parvovirus Zsana", "ORGANISM", 137, 161], ["mosaic genome structure", "DNA", 26, 49], ["MgBuV1", "DNA", 53, 59], ["MgBuV1", "DNA", 107, 113], ["MgBuV1 genome", "DNA", 210, 223], ["WUHARV parvovirus", "SPECIES", 115, 132], ["porcine parvovirus Zsana", "SPECIES", 137, 161], ["WUHARV parvovirus", "SPECIES", 115, 132], ["porcine parvovirus", "SPECIES", 137, 155], ["a mosaic genome structure in MgBuV1", "PROBLEM", 24, 59], ["MgBuV1", "TREATMENT", 107, 113], ["WUHARV parvovirus", "TREATMENT", 115, 132], ["porcine parvovirus Zsana", "TREATMENT", 137, 161], ["mosaic genome structure", "OBSERVATION", 26, 49]]], ["These observations were supported by independent phylogenetic trees built from five regions bordered by the inferred recombination breakpoints (Fig. 5A\u2013E).", [["Fig. 5A\u2013E", "DNA", 144, 153], ["recombination breakpoints", "OBSERVATION", 117, 142]]], ["Among the BuVs and related protoparvoviruses, MgBuV1 branched from the ancestor of porcine parvovirus Zsana in the phylogenetic tree at position 778 to 1219 (Fig. 5B) and position 1856 to 2384 (Fig. 5D).", [["MgBuV1", "CHEMICAL", 46, 52], ["BuVs", "GENE_OR_GENE_PRODUCT", 10, 14], ["protoparvoviruses", "GENE_OR_GENE_PRODUCT", 27, 44], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 46, 52], ["porcine parvovirus Zsana", "ORGANISM", 83, 107], ["BuVs", "PROTEIN", 10, 14], ["protoparvoviruses", "PROTEIN", 27, 44], ["MgBuV1", "PROTEIN", 46, 52], ["porcine parvovirus Zsana", "SPECIES", 83, 107], ["porcine parvovirus", "SPECIES", 83, 101], ["MgBuV1", "TREATMENT", 46, 52], ["porcine parvovirus Zsana", "TREATMENT", 83, 107], ["porcine parvovirus", "OBSERVATION", 83, 101], ["phylogenetic tree", "OBSERVATION", 115, 132]]], ["However, MgBuV1 branched from its ancestor WUHARV parvovirus at position 1219 to 1856 in the phylogenetic tree (Fig. 5C).", [["MgBuV1", "CHEMICAL", 9, 15], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 9, 15], ["WUHARV parvovirus", "ORGANISM", 43, 60], ["MgBuV1", "PROTEIN", 9, 15], ["WUHARV parvovirus", "SPECIES", 43, 60], ["WUHARV parvovirus", "SPECIES", 43, 60], ["MgBuV1", "TEST", 9, 15], ["tree", "ANATOMY_MODIFIER", 106, 110]]], ["In contrast, MgBuV1 formed a distinct lineage in phylogenetic trees constructed from position 2384 to 4765 (Fig. 5E).", [["MgBuV1", "CHEMICAL", 13, 19], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 13, 19], ["MgBuV1", "PROTEIN", 13, 19], ["distinct", "OBSERVATION_MODIFIER", 29, 37], ["lineage", "OBSERVATION_MODIFIER", 38, 45], ["phylogenetic trees", "OBSERVATION", 49, 67]]], ["Based on this evidence, we inferred the parsimonious origin of the mosaic genome in MgBuV1 from both recombination analyses (Fig. 4C).DiscussionSince the discovery of human BuV in 2012, its genetic divergence and worldwide distribution have been updated by a series of reports1234567.", [["human", "ORGANISM", 167, 172], ["mosaic genome", "DNA", 67, 80], ["MgBuV1", "DNA", 84, 90], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["the mosaic genome in MgBuV1", "PROBLEM", 63, 90], ["parsimonious", "OBSERVATION_MODIFIER", 40, 52], ["origin", "OBSERVATION_MODIFIER", 53, 59], ["mosaic genome", "OBSERVATION", 67, 80]]], ["Although recent studies described BuVs in nonhuman mammals, little is known about the epidemiology of animal-borne BuVs.91011121314.", [["91011121314", "CHEMICAL", 120, 131], ["BuVs", "GENE_OR_GENE_PRODUCT", 34, 38], ["BuVs", "CANCER", 115, 119], ["recent studies", "TEST", 9, 23]]], ["In this study, we report for the first time, a BuV identified in megabats.", [["megabats", "CANCER", 65, 73], ["BuV", "DNA", 47, 50], ["this study", "TEST", 3, 13]]], ["MgBuV1 is the fourth animal borne-BuV where the whole genome sequence of the protein-coding region has been determined.", [["MgBuV1", "CHEMICAL", 0, 6], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 0, 6], ["BuV", "GENE_OR_GENE_PRODUCT", 34, 37], ["MgBuV1", "DNA", 0, 6], ["fourth animal borne-BuV", "DNA", 14, 37], ["whole genome sequence", "DNA", 48, 69], ["protein-coding region", "DNA", 77, 98], ["MgBuV1", "TREATMENT", 0, 6]]], ["In addition, the detection of partial NS1 gene sequences different from MgBuV1 (called MgBuV2 and MgBuV3) indicates the presence of MgBuV1 variants.", [["NS1", "GENE_OR_GENE_PRODUCT", 38, 41], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 72, 78], ["MgBuV2", "GENE_OR_GENE_PRODUCT", 87, 93], ["MgBuV3", "GENE_OR_GENE_PRODUCT", 98, 104], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 132, 138], ["NS1 gene sequences", "DNA", 38, 56], ["MgBuV1", "PROTEIN", 72, 78], ["MgBuV2", "DNA", 87, 93], ["MgBuV3", "DNA", 98, 104], ["MgBuV1 variants", "DNA", 132, 147], ["partial NS1 gene sequences", "PROBLEM", 30, 56], ["MgBuV1", "TEST", 72, 78], ["MgBuV2", "TEST", 87, 93], ["MgBuV1 variants", "PROBLEM", 132, 147], ["MgBuV1 variants", "OBSERVATION", 132, 147]]], ["The discovery of megabat-borne BuVs facilitates a better understanding of the diversity and host-range of BuV.DiscussionMgBuV1 has a similar genome organization and is phylogenetically related to other mammalian-borne BuVs.", [["BuV.", "ORGANISM", 106, 110], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 120, 126], ["BuVs", "GENE_OR_GENE_PRODUCT", 218, 222], ["MgBuV1", "DNA", 120, 126], ["mammalian-borne BuVs", "DNA", 202, 222], ["BuV.", "SPECIES", 106, 110], ["genome organization", "OBSERVATION", 141, 160], ["borne BuVs", "OBSERVATION", 212, 222]]], ["According to the species demarcation criteria of the International Committee on Taxonomy of Viruses, parvoviruses in the same species should share >85% amino acid sequence identity in their whole NS18.", [["amino acid", "CHEMICAL", 152, 162], ["amino acid", "CHEMICAL", 152, 162], ["parvoviruses", "ORGANISM", 101, 113], ["amino acid", "AMINO_ACID", 152, 162], ["NS18", "PROTEIN", 196, 200], ["Viruses", "PROBLEM", 92, 99], ["parvoviruses", "PROBLEM", 101, 113], ["Viruses", "OBSERVATION", 92, 99]]], ["As shown in Table 2, the NS1 of MgBuV1 showed <60% identity to those of other related parvoviruses.", [["NS1", "GENE_OR_GENE_PRODUCT", 25, 28], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 32, 38], ["parvoviruses", "ORGANISM", 86, 98], ["NS1", "PROTEIN", 25, 28], ["MgBuV1", "PROTEIN", 32, 38], ["the NS1 of MgBuV1", "TEST", 21, 38], ["other related parvoviruses", "PROBLEM", 72, 98], ["parvoviruses", "OBSERVATION", 86, 98]]], ["Taken together, these results suggest that MgBuV1 is a novel species of protoparvovirus harboured by megabats.DiscussionRecently, complete or partial genome sequences of BuVs related to human BuV were identified from nonhuman primates, shrews, rats, pigs and microbats91011121314.", [["MgBuV1", "CHEMICAL", 43, 49], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 43, 49], ["protoparvovirus", "CANCER", 72, 87], ["BuVs", "GENE_OR_GENE_PRODUCT", 170, 174], ["human", "ORGANISM", 186, 191], ["BuV", "GENE_OR_GENE_PRODUCT", 192, 195], ["nonhuman", "ORGANISM", 217, 225], ["primates", "ORGANISM", 226, 234], ["shrews", "ORGANISM_SUBDIVISION", 236, 242], ["rats", "ORGANISM", 244, 248], ["pigs", "ORGANISM", 250, 254], ["microbats91011121314", "ORGANISM", 259, 279], ["MgBuV1", "PROTEIN", 43, 49], ["partial genome sequences", "DNA", 142, 166], ["BuVs", "DNA", 170, 174], ["human BuV", "DNA", 186, 195], ["human", "SPECIES", 186, 191], ["rats", "SPECIES", 244, 248], ["pigs", "SPECIES", 250, 254], ["human", "SPECIES", 186, 191], ["a novel species of protoparvovirus", "PROBLEM", 53, 87], ["human BuV", "TEST", 186, 195]]], ["However, the phylogenetic relationships among these viruses remains to be elucidated.", [["these viruses", "PROBLEM", 46, 59], ["viruses", "OBSERVATION", 52, 59]]], ["Our phylogenetic analyses covered the available sequences of these BuVs and showed a large degree of genetic divergence of BuV in the genus Protoparvovirus.", [["BuVs", "GENE_OR_GENE_PRODUCT", 67, 71], ["BuV", "GENE_OR_GENE_PRODUCT", 123, 126], ["BuVs", "DNA", 67, 71], ["BuV", "DNA", 123, 126], ["Our phylogenetic analyses", "TEST", 0, 25], ["these BuVs", "TEST", 61, 71], ["genetic divergence of BuV in the genus Protoparvovirus", "PROBLEM", 101, 155], ["large", "OBSERVATION_MODIFIER", 85, 90], ["degree", "OBSERVATION_MODIFIER", 91, 97], ["genetic divergence", "OBSERVATION", 101, 119], ["genus Protoparvovirus", "OBSERVATION", 134, 155]]], ["Both phylogenetic analyses based on NS1 and VP2 genes showed that a group of BuVs comprised host-specific lineages and megabat-borne BuVs were clearly distinguished from microbat-borne BuVs.", [["NS1", "GENE_OR_GENE_PRODUCT", 36, 39], ["VP2", "GENE_OR_GENE_PRODUCT", 44, 47], ["BuVs", "GENE_OR_GENE_PRODUCT", 77, 81], ["BuVs", "GENE_OR_GENE_PRODUCT", 133, 137], ["NS1 and VP2 genes", "DNA", 36, 53], ["BuVs", "PROTEIN", 77, 81], ["megabat-borne BuVs", "DNA", 119, 137], ["Both phylogenetic analyses", "TEST", 0, 26], ["NS1 and VP2 genes", "TEST", 36, 53]]], ["While the phylogeny of BuV is likely to be associated with their host, further studies of BuVs in animals are needed to infer the virus-host coevolution.DiscussionGenome recombination is a compelling argument to explain the evolution of a variety of viruses2425; furthermore, evidence for recombination events have been also observed in the genome of some protoparvoviruses13262728.", [["BuV", "GENE_OR_GENE_PRODUCT", 23, 26], ["BuVs", "GENE_OR_GENE_PRODUCT", 90, 94], ["BuV", "DNA", 23, 26], ["further studies", "TEST", 71, 86], ["BuVs", "TEST", 90, 94], ["a variety of viruses", "PROBLEM", 237, 257], ["recombination events", "PROBLEM", 289, 309], ["likely to be", "UNCERTAINTY", 30, 42], ["host coevolution", "OBSERVATION", 136, 152]]], ["In this study, we revealed putative recombined regions and phylogenetic incongruences across the MgBuV1 genome, suggesting genetic recombination between MgBuV1 and porcine parvovirus Zsana (event 1, Fig. 4C) and other recombination events between MgBuV1 and WUHARV parvovirus (event 2, Fig. 4C).", [["MgBuV1", "GENE_OR_GENE_PRODUCT", 97, 103], ["porcine parvovirus Zsana", "ORGANISM", 164, 188], ["WUHARV parvovirus", "ORGANISM", 258, 275], ["MgBuV1 genome", "DNA", 97, 110], ["MgBuV1", "DNA", 153, 159], ["porcine parvovirus Zsana", "SPECIES", 164, 188], ["porcine parvovirus", "SPECIES", 164, 182], ["WUHARV parvovirus", "SPECIES", 258, 275], ["this study", "TEST", 3, 13], ["putative recombined regions", "PROBLEM", 27, 54], ["phylogenetic incongruences across the MgBuV1 genome", "PROBLEM", 59, 110], ["genetic recombination between MgBuV1", "PROBLEM", 123, 159], ["porcine parvovirus Zsana", "TREATMENT", 164, 188], ["other recombination events", "PROBLEM", 212, 238], ["MgBuV1", "TEST", 247, 253], ["WUHARV parvovirus", "PROBLEM", 258, 275], ["phylogenetic incongruences", "OBSERVATION", 59, 85], ["MgBuV1 genome", "OBSERVATION", 97, 110], ["genetic recombination", "OBSERVATION", 123, 144], ["porcine parvovirus", "OBSERVATION", 164, 182]]], ["These results imply that the most common recent ancestor of MgBuV1 might have arisen from multiple recombination events.", [["MgBuV1", "CHEMICAL", 60, 66], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 60, 66], ["MgBuV1", "PROTEIN", 60, 66], ["MgBuV1", "TREATMENT", 60, 66], ["multiple recombination events", "PROBLEM", 90, 119], ["multiple", "OBSERVATION_MODIFIER", 90, 98], ["recombination events", "OBSERVATION", 99, 119]]], ["Such events also imply the occurrence of dual infection with ancestors of MgBuV1, WUHARV parvovirus and porcine parvovirus Zsana in nature.DiscussionIn conclusion, we demonstrated the presence of megabat-borne BuV, the first protoparvovirus discovered from megabats.", [["infection", "DISEASE", 46, 55], ["parvovirus", "DISEASE", 89, 99], ["parvovirus Zsana", "DISEASE", 112, 128], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 74, 80], ["WUHARV parvovirus", "ORGANISM", 82, 99], ["porcine parvovirus Zsana", "ORGANISM", 104, 128], ["BuV", "GENE_OR_GENE_PRODUCT", 210, 213], ["megabats", "CANCER", 257, 265], ["porcine parvovirus Zsana", "SPECIES", 104, 128], ["WUHARV parvovirus", "SPECIES", 82, 99], ["porcine parvovirus", "SPECIES", 104, 122], ["dual infection", "PROBLEM", 41, 55], ["MgBuV1", "TREATMENT", 74, 80], ["WUHARV parvovirus", "PROBLEM", 82, 99], ["porcine parvovirus Zsana", "TREATMENT", 104, 128], ["dual", "OBSERVATION_MODIFIER", 41, 45], ["infection", "OBSERVATION", 46, 55], ["porcine parvovirus Zsana", "OBSERVATION", 104, 128]]], ["Further genetic characterization revealed the phylogenetic distinctiveness of MgBuV1 and suggested a molecular evolution of MgBuV1 driven by multiple recombination events.", [["MgBuV1", "GENE_OR_GENE_PRODUCT", 78, 84], ["MgBuV1", "GENE_OR_GENE_PRODUCT", 124, 130], ["MgBuV1", "PROTEIN", 78, 84], ["MgBuV1", "DNA", 124, 130], ["Further genetic characterization", "TEST", 0, 32], ["MgBuV1", "PROBLEM", 124, 130], ["multiple recombination events", "PROBLEM", 141, 170]]], ["These results provide new insights into the high genetic divergence of BuV and will help us to investigate further BuV in animals.Ethics statement and sample collection ::: MethodsAll experiments involving animals were performed in accordance with the ethical guidelines of the Animal Care and Use Committee of Veterinary Teaching Hospital, Bogor Agricultural University.", [["BuV", "GENE_OR_GENE_PRODUCT", 71, 74], ["BuV", "GENE_OR_GENE_PRODUCT", 115, 118], ["BuV", "PROTEIN", 115, 118], ["Methods", "TREATMENT", 173, 180]]], ["The protocol was approved by the Animal Care and Use Committee of Veterinary Teaching Hospital, Bogor Agricultural University (permit number 05-2010 RSHP-IPB).", [["The protocol", "TREATMENT", 0, 12]]], ["Collection and exportation of samples from megabats were performed with the permission of the Directorate General of Livestock and Animal Health Services, Ministry of Agriculture, Republic of Indonesia.", [["samples", "ANATOMY", 30, 37], ["samples from megabats", "TEST", 30, 51]]], ["Faecal and spleen samples were collected from megabats at eight regions in Indonesia from 2010 to 2014.", [["Faecal", "ANATOMY", 0, 6], ["spleen samples", "ANATOMY", 11, 25], ["Faecal", "ORGANISM_SUBSTANCE", 0, 6], ["spleen samples", "CANCER", 11, 25], ["Faecal and spleen samples", "TEST", 0, 25], ["spleen", "ANATOMY", 11, 17]]], ["Some samples were used for different research projects, as reported previously21293031.", [["samples", "ANATOMY", 5, 12], ["Some samples", "TEST", 0, 12]]], ["Species were identified based on the morphological features and nucleotide sequence analysis of both mitochondrial 16S rRNA and cytochrome b as described previously21.", [["mitochondrial", "ANATOMY", 101, 114], ["nucleotide", "CHEMICAL", 64, 74], ["mitochondrial", "CELLULAR_COMPONENT", 101, 114], ["rRNA", "CELLULAR_COMPONENT", 119, 123], ["cytochrome b", "GENE_OR_GENE_PRODUCT", 128, 140], ["mitochondrial 16S rRNA", "DNA", 101, 123], ["cytochrome b", "PROTEIN", 128, 140], ["the morphological features", "TEST", 33, 59], ["nucleotide sequence analysis", "TEST", 64, 92], ["mitochondrial 16S rRNA", "TEST", 101, 123], ["cytochrome b", "TEST", 128, 140]]], ["Sample information is summarized in Table 1.Nested-PCR screening ::: MethodsFaeces suspended in RNAlater reagent (Ambion, Life Technologies, Carlsbad, CA) were subjected to DNA extraction using a High Pure Viral Nucleic Acid kit (Roche Diagnostics GmbH, Mannheim, Germany) or QIAamp Viral RNA Mini Kit (Qiagen, Valencia CA).", [["DNA", "CELLULAR_COMPONENT", 173, 176], ["MethodsFaeces", "TREATMENT", 69, 82], ["RNAlater reagent", "TREATMENT", 96, 112], ["DNA extraction", "TREATMENT", 173, 187], ["QIAamp", "TEST", 276, 282]]], ["DNA from spleen tissues was prepared using DNAzol reagent (Molecular Research Center, Cincinnati, OH) or QIAamp DNA Mini kit (Qiagen).", [["spleen tissues", "ANATOMY", 9, 23], ["DNAzol", "CHEMICAL", 43, 49], ["DNAzol", "CHEMICAL", 43, 49], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["spleen tissues", "TISSUE", 9, 23], ["DNA from spleen tissues", "PROBLEM", 0, 23], ["DNAzol reagent", "TREATMENT", 43, 57], ["QIAamp DNA Mini kit (Qiagen)", "TREATMENT", 105, 133], ["spleen", "ANATOMY", 9, 15]]], ["For nested PCR screen targeting for NS1 gene of BuV, we followed the method of Sasaki et al.9.Complete genome sequencing ::: MethodsTo determine the complete genome sequence of megabat BuV, a DNA library was prepared from the faecal-DNA samples using the Nextera XT DNA sample preparation kit (Illmina, San Diego, CA) and were sequenced on an illumina MiSeq instrument using the MiSeq Reagent Kit v3 600-cycle (Illumina) according to the manufacturer\u2019s instructions.", [["samples", "ANATOMY", 237, 244], ["NS1", "GENE_OR_GENE_PRODUCT", 36, 39], ["BuV", "GENE_OR_GENE_PRODUCT", 48, 51], ["megabat BuV", "CELL", 177, 188], ["DNA", "CELLULAR_COMPONENT", 192, 195], ["NS1 gene", "DNA", 36, 44], ["BuV", "DNA", 48, 51], ["megabat BuV", "DNA", 177, 188], ["DNA library", "DNA", 192, 203], ["nested PCR screen", "TEST", 4, 21], ["Methods", "TREATMENT", 125, 132], ["a DNA library", "TEST", 190, 203], ["the Nextera XT DNA", "TREATMENT", 251, 269], ["an illumina MiSeq instrument", "TREATMENT", 340, 368], ["the MiSeq Reagent Kit v3", "TREATMENT", 375, 399]]], ["The sequence reads homologous to known BuVs were identified by read mapping using CLC Genomics Workbench (CLC bio, Aarhus, Denmark).", [["BuVs", "GENE_OR_GENE_PRODUCT", 39, 43], ["BuVs", "DNA", 39, 43]]], ["The overlapping large fragments were amplified by conventional PCR with specific primer sets designed from each identified sequence read.", [["fragments", "ANATOMY", 22, 31], ["primer sets", "DNA", 81, 92], ["The overlapping large fragments", "PROBLEM", 0, 31], ["conventional PCR", "TEST", 50, 66], ["specific primer sets", "TEST", 72, 92], ["overlapping", "OBSERVATION_MODIFIER", 4, 15], ["large", "OBSERVATION_MODIFIER", 16, 21], ["fragments", "OBSERVATION", 22, 31]]], ["The 3\u2032 end of virus genome was amplified by the modified rapid amplification of cDNA ends as reported previously32.", [["3\u2032 end", "DNA", 4, 10], ["virus genome", "DNA", 14, 26], ["cDNA ends", "DNA", 80, 89], ["virus genome", "TREATMENT", 14, 26], ["virus genome", "OBSERVATION", 14, 26]]], ["All the amplified fragments were assembled manually into a contiguous sequence.Phylogenetic analyses ::: MethodsSequences were aligned with MAFFT33 using the FFT-NS-I method.", [["fragments", "ANATOMY", 18, 27], ["amplified fragments", "DNA", 8, 27], ["MAFFT33", "DNA", 140, 147], ["FFT", "DNA", 158, 161], ["All the amplified fragments", "PROBLEM", 0, 27], ["a contiguous sequence", "TEST", 57, 78], ["Phylogenetic analyses", "TEST", 79, 100], ["MAFFT33", "TREATMENT", 140, 147], ["the FFT-NS-I method", "TREATMENT", 154, 173], ["fragments", "OBSERVATION_MODIFIER", 18, 27]]], ["Phylogenetic inferences were performed on multiple sequence alignments with MrBayes 3.234 using a General Time Reversible model with a rate variation between sites modelled with a gamma distribution (+\u0393) with six categories and allowing for a percentage of invariable sites (+I).Recombination analyses ::: MethodsA recombination analysis was performed in Simplot 3.5.135 using the Bootscan algorithm with 200 nt window and 20 nt step under a Kimura (2-parameter) model36 and a Neighbor-Joining approach with 1000 repetitions.Recombination analyses ::: MethodsAdditionally, this study implemented a second analysis approach over the same sliding window that incorporated the power of Bayesian inference to support or reject hypotheses regarding the topology of the phylogenetic tree.", [["Bootscan algorithm", "DNA", 381, 399], ["200 nt window", "DNA", 405, 418], ["Kimura (2-parameter) model36", "DNA", 442, 470], ["Phylogenetic inferences", "PROBLEM", 0, 23], ["multiple sequence alignments", "TEST", 42, 70], ["MrBayes", "TEST", 76, 83], ["a rate variation between sites", "PROBLEM", 133, 163], ["MethodsA recombination analysis", "TEST", 306, 337], ["Simplot", "TEST", 355, 362], ["the Bootscan algorithm", "TREATMENT", 377, 399], ["200 nt window", "TREATMENT", 405, 418], ["this study", "TEST", 573, 583], ["a second analysis approach", "TREATMENT", 596, 622], ["the same sliding window", "TREATMENT", 628, 651], ["gamma distribution", "OBSERVATION", 180, 198], ["phylogenetic tree", "OBSERVATION", 764, 781]]], ["For each window, a hypothesis of the clustering of two particular sequences was tested against the null hypothesis that the cluster was less likely than those sequences independently clustering with any other under the same model parameters.", [["the null hypothesis", "PROBLEM", 95, 114]]], ["To maximize the inferential power of the approach, the marginal likelihoods of the models assuming opposite topological hypotheses were compared with the stepping stone37 sampling approach implemented in MrBayes 3.2.", [["marginal", "OBSERVATION_MODIFIER", 55, 63]]], ["Then, the difference of the calculated marginal likelihoods for both models, i.e., the model assuming a clustering and the model without the clustering, represented the Bayes factor, which usually is interpreted as supporting the first model if the difference exceeds three and strongly supportive when it exceeds five38.", [["Bayes factor", "PROTEIN", 169, 181], ["marginal", "OBSERVATION_MODIFIER", 39, 47]]], ["All hypotheses were tested under the same model assumed for the phylogenetic analyses.Recombination analyses ::: MethodsThe dataset in both analyses was composed of sequences in the BuV cluster.", [["BuV", "GENE_OR_GENE_PRODUCT", 182, 185], ["BuV cluster", "DNA", 182, 193], ["the phylogenetic analyses", "TEST", 60, 85], ["Methods", "TREATMENT", 113, 120], ["The dataset in both analyses", "TEST", 120, 148]]], ["Adopting a parsimonious approach, this study accepted only those events suggested by Bootscan that also had support from the Bayesian hypotheses testing.Nucleotide sequences ::: MethodsAll the nucleotide sequences determined in this study were deposited in the DDBJ/EMBL/GenBank databases under accession numbers LC085665\u2212LC085676.Additional InformationHow to cite this article: Sasaki, M. et al. Divergent bufavirus harboured in megabats represents a new lineage of parvoviruses.", [["megabats", "ANATOMY", 430, 438], ["nucleotide", "CHEMICAL", 193, 203], ["LC085665\u2212LC085676", "CHEMICAL", 313, 330], ["bufavirus", "CHEMICAL", 407, 416], ["nucleotide", "CHEMICAL", 193, 203], ["bufavirus", "GENE_OR_GENE_PRODUCT", 407, 416], ["megabats", "CANCER", 430, 438], ["parvoviruses", "ORGANISM", 467, 479], ["DDBJ/EMBL/GenBank databases", "DNA", 261, 288], ["this study", "TEST", 34, 44], ["the Bayesian hypotheses testing", "TEST", 121, 152], ["Nucleotide sequences", "TEST", 153, 173], ["Methods", "TREATMENT", 178, 185], ["All the nucleotide sequences", "TEST", 185, 213], ["this study", "TEST", 228, 238], ["Divergent bufavirus", "PROBLEM", 397, 416], ["a new lineage of parvoviruses", "PROBLEM", 450, 479], ["new", "OBSERVATION_MODIFIER", 452, 455], ["lineage", "OBSERVATION_MODIFIER", 456, 463], ["parvoviruses", "OBSERVATION", 467, 479]]], ["Rep.6, 24257; doi: 10.1038/srep24257 (2016).", [["Rep.6, 24257", "CHEMICAL", 0, 12]]]], "PMC7107464": [["Beetles ::: Materials and MethodsThe Southern Plains Agricultural Research Center (SPARC) starter colony of A. diaperinus was a generous gift from a colony originally isolated from a poultry farm located in Wake County, North Carolina, and maintained by Dr. D. W. Watson (North Carolina State University, Raleigh, NC).", [["colony", "ANATOMY", 149, 155], ["A. diaperinus", "ORGANISM", 108, 121], ["A. diaperinus", "SPECIES", 108, 121], ["A. diaperinus", "SPECIES", 108, 121], ["Materials", "TREATMENT", 12, 21], ["a generous gift", "TREATMENT", 126, 141], ["a colony", "PROBLEM", 147, 155]]], ["The SPARC colony was initiated and has remained in production since 2004.", [["colony", "ANATOMY", 10, 16], ["SPARC", "GENE_OR_GENE_PRODUCT", 4, 9], ["SPARC", "PROTEIN", 4, 9], ["The SPARC colony", "TREATMENT", 0, 16], ["SPARC colony", "OBSERVATION", 4, 16]]], ["Beetles were reared in 1,000-ml wheat bran (Morrison Milling Co., Denton, TX) in plastic containers (15 by 15 by 30 cm) with screen tops and held at 30\u00b0C under a photoperiod of 8:16 (L:D) h.", [["Beetles", "CELL", 0, 7], ["C", "GENE_OR_GENE_PRODUCT", 152, 153], ["wheat", "SPECIES", 32, 37], ["bran", "SPECIES", 38, 42], ["wheat", "SPECIES", 32, 37]]], ["Additionally within each cage, a 6-cm2 sponge moistened with deionized water (dH2O) and a 0.5-cm-thick slice of a medium-sized apple were replenished twice per week, and 30 ml of fishmeal (Omega Protein, Inc., Hammond, LA) was added to the wheat bran once per week.Disinfecting Agents ::: Materials and MethodsHydrogen peroxide (H2O2) (Sigma-Aldrich, St. Louis, MO), 95% ethanol (EtOH) (EMD Chemicals, Gibbstown, NJ), Tween 80 (Amresco, Solon, OH), and sodium hypochlorite (NaOCl) (Sigma-Aldrich) were diluted to working concentrations with sterile dH2O.", [["LA", "CHEMICAL", 219, 221], ["Hydrogen peroxide", "CHEMICAL", 310, 327], ["H2O2", "CHEMICAL", 329, 333], ["ethanol", "CHEMICAL", 371, 378], ["EtOH", "CHEMICAL", 380, 384], ["sodium hypochlorite", "CHEMICAL", 453, 472], ["NaOCl", "CHEMICAL", 474, 479], ["Hydrogen peroxide", "CHEMICAL", 310, 327], ["H2O2", "CHEMICAL", 329, 333], ["ethanol", "CHEMICAL", 371, 378], ["EtOH", "CHEMICAL", 380, 384], ["Tween 80", "CHEMICAL", 418, 426], ["OH", "CHEMICAL", 444, 446], ["sodium hypochlorite", "CHEMICAL", 453, 472], ["NaOCl", "CHEMICAL", 474, 479], ["apple", "ORGANISM", 127, 132], ["Hydrogen peroxide", "SIMPLE_CHEMICAL", 310, 327], ["H2O2", "SIMPLE_CHEMICAL", 329, 333], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 336, 349], ["St. Louis", "SIMPLE_CHEMICAL", 351, 360], ["ethanol", "SIMPLE_CHEMICAL", 371, 378], ["EtOH", "SIMPLE_CHEMICAL", 380, 384], ["Tween 80", "SIMPLE_CHEMICAL", 418, 426], ["Amresco", "SIMPLE_CHEMICAL", 428, 435], ["sodium hypochlorite", "SIMPLE_CHEMICAL", 453, 472], ["NaOCl", "SIMPLE_CHEMICAL", 474, 479], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 482, 495], ["wheat", "SPECIES", 240, 245], ["apple", "SPECIES", 127, 132], ["wheat", "SPECIES", 240, 245], ["a 6-cm2 sponge moistened", "TREATMENT", 31, 55], ["deionized water (dH2O)", "TREATMENT", 61, 83], ["a 0.5-cm-thick slice of a medium-sized apple", "TREATMENT", 88, 132], ["fishmeal (Omega Protein", "TREATMENT", 179, 202], ["Hammond, LA)", "TREATMENT", 210, 222], ["Materials", "TREATMENT", 289, 298], ["MethodsHydrogen peroxide", "TREATMENT", 303, 327], ["Amresco, Solon, OH)", "TREATMENT", 428, 447], ["sodium hypochlorite (NaOCl", "TREATMENT", 453, 479], ["Sigma-Aldrich)", "TREATMENT", 482, 496], ["sterile dH2O", "TREATMENT", 541, 553], ["cage", "ANATOMY", 25, 29], ["6-cm2 sponge", "OBSERVATION_MODIFIER", 33, 45], ["moistened", "OBSERVATION_MODIFIER", 46, 55]]], ["The 7.35% H2O2/0.23% peracetic acid was a commercially available formulation, SporGon (Decon Labs, Inc., Bryn Mawr, PA).Disinfecting Agents ::: Materials and MethodsThese agents were used individually or in combination to formulate and evaluate 11 disinfection protocols designed for comparison to previously described techniques or to test new combinations for increased efficacy.", [["H2O2", "CHEMICAL", 10, 14], ["peracetic acid", "CHEMICAL", 21, 35], ["SporGon", "CHEMICAL", 78, 85], ["H2O2", "CHEMICAL", 10, 14], ["peracetic acid", "CHEMICAL", 21, 35], ["H2O2", "SIMPLE_CHEMICAL", 10, 14], ["peracetic acid", "SIMPLE_CHEMICAL", 21, 35], ["SporGon", "SIMPLE_CHEMICAL", 78, 85], ["% peracetic acid", "TREATMENT", 19, 35], ["Labs", "TEST", 93, 97], ["Materials", "TREATMENT", 144, 153], ["These agents", "TREATMENT", 165, 177], ["disinfection protocols", "TREATMENT", 248, 270], ["increased efficacy", "PROBLEM", 362, 380]]], ["The protocols were grouped into EtOH (three), NaOCl (four), and H2O2 (four)-based protocols as described below.", [["EtOH", "CHEMICAL", 32, 36], ["NaOCl", "CHEMICAL", 46, 51], ["H2O2", "CHEMICAL", 64, 68], ["EtOH", "CHEMICAL", 32, 36], ["NaOCl", "CHEMICAL", 46, 51], ["H2O2", "CHEMICAL", 64, 68], ["EtOH", "SIMPLE_CHEMICAL", 32, 36], ["NaOCl", "SIMPLE_CHEMICAL", 46, 51], ["H2O2", "SIMPLE_CHEMICAL", 64, 68], ["The protocols", "TREATMENT", 0, 13], ["NaOCl", "TREATMENT", 46, 51], ["H2O2", "TREATMENT", 64, 68]]], ["All protocols were evaluated on individual beetles held and disinfected in 1.5-ml tubes covered with a sterile barrier film (Parafilm; Sigma-Aldrich).Disinfecting Agents ::: Materials and MethodsFor each protocol, the tube in which the beetle was immersed was covered by the barrier film, inverted three times, and sonicated for 2 min at 40 kHz (model 8851\u201334, Cole Parmer, Vernon Hills, IL) before the next step.", [["tube", "ANATOMY", 218, 222], ["tube", "TISSUE", 218, 222], ["All protocols", "TREATMENT", 0, 13], ["individual beetles", "TREATMENT", 32, 50], ["1.5-ml tubes", "TREATMENT", 75, 87], ["a sterile barrier film", "TREATMENT", 101, 123], ["Methods", "TREATMENT", 188, 195], ["each protocol", "TREATMENT", 199, 212], ["the tube", "TREATMENT", 214, 222], ["the barrier film", "TREATMENT", 271, 287], ["tube", "OBSERVATION", 218, 222]]], ["The beetle was transferred into a new sterile tube for each successive immersion or rinse.", [["tube", "TISSUE", 46, 50], ["a new sterile tube", "TREATMENT", 32, 50], ["each successive immersion or rinse", "TREATMENT", 55, 89], ["tube", "OBSERVATION", 46, 50]]], ["Evaporation was performed by transferring the beetle into a sterile tube, which was placed into a sterile, biosafety hood to allow the EtOH to evaporate.", [["tube", "ANATOMY", 68, 72], ["EtOH", "CHEMICAL", 135, 139], ["EtOH", "CHEMICAL", 135, 139], ["tube", "TISSUE", 68, 72], ["EtOH", "SIMPLE_CHEMICAL", 135, 139], ["Evaporation", "TREATMENT", 0, 11], ["a sterile tube", "TREATMENT", 58, 72], ["a sterile, biosafety hood", "TREATMENT", 96, 121], ["tube", "OBSERVATION", 68, 72]]], ["Sonication was used to assist in dislodging of the bacteria and to ensure uniformity of the agitation procedure for comparison of protocols.Disinfecting Agents ::: Materials and Methods", [["Sonication", "TREATMENT", 0, 10], ["the bacteria", "PROBLEM", 47, 59], ["the agitation procedure", "TREATMENT", 88, 111], ["Methods", "TREATMENT", 178, 185]]]], "5620a55a2fbb539a6be33eddcbabc2b638b3273c": [["Herausforderungen in der Seuchenkontrolle und der jetzigen Pandemie durch verzerrte VerteilungenEinleitung Die derzeitige Pandemie mit dem SARS-Coronavirus-2 illustriert, wie schwer es sein kann, einen Ausbruch zu begrenzen.", [["der Seuchenkontrolle und der jetzigen Pandemie durch verzerrte VerteilungenEinleitung Die derzeitige Pandemie mit dem SARS-Coronavirus-2 illustriert, wie schwer es sein kann, einen Ausbruch zu begrenzen", "SPECIES", 21, 223], ["Herausforderungen in der Seuchenkontrolle und der jetzigen Pandemie durch verzerrte", "TREATMENT", 0, 83], ["Coronavirus", "TEST", 144, 155]]], ["Neben der Schlagkraft der einzelnen Gesundheitssysteme und insbesondere ihrer medizinischen Exekutive, sprich Gesundheits\u00e4mter und \u00d6ffentliches Gesundheitswesen [19] , spielen die Zeitfenster von mehreren Erregereigenschaften hier eine Schl\u00fcsselrolle.", [["Neben der Schlagkraft der einzelnen Gesundheitssysteme", "TREATMENT", 0, 54]]], ["Viele Verteilungen dieser Erregereigenschaften sind aber nicht normal verteilt, sondern verzerrt; meist nach rechts oder stark nach rechts.", [["Viele", "TEST", 0, 5]]], ["In Deutschland war seiner Zeit Prof. Klaus Dietz (2008 emeritiert), vormals Direktor des Instituts f\u00fcr medizinische Biometrie der Eberhard-Karls-Universit\u00e4t T\u00fcbingen, einer der Vorreiter moderner und differenzierter Grundkonzepte der Infektionsepidemiologie.Herausforderungen in der Seuchenkontrolle und der jetzigen Pandemie durch verzerrte VerteilungenIch m\u00f6chte diese Arbeit den Eltern unserer jungen,inderPandemiesomutigen,kroatischen \u00c4rztin widmen, deren Haus im Epizentrum des soeben stattgehabten Erdbebens in der N\u00e4he von Zagreb schwer besch\u00e4digt wurde.", [["Herausforderungen in der Seuchenkontrolle und der jetzigen", "TREATMENT", 258, 316], ["kroatischen \u00c4rztin", "TREATMENT", 427, 445]]], ["Leider kommen die Plagen nicht alleine, wie diese weitere Hiobsbotschaft zeigt.Herausforderungen in der Seuchenkontrolle und der jetzigen Pandemie durch verzerrte VerteilungenIn dieser Arbeit soll dargelegt werden, wie diese verzerrten Verteilungen zu offenen Flanken in der Seuchenkontrolle, dem Infektionsschutz und dem Patientenmanagement f\u00fchren und wie damit umzugehen ist.MethodenMittels Analyse der zentralen Parameter der Seuchenkontrolle, insbesondere der Kontrollma\u00dfnahmen und des Patientenmanagements, werden die Folgen im Zusammenhang mit dem derzeitigen pandemischen Ausbruch des SARS-CoV-2 untersucht.", [["wie diese verzerrten Verteilungen zu offenen Flanken in der Seuchenkontrolle, dem Infektionsschutz und dem Patientenmanagement f\u00fchren und wie damit umzugehen", "SPECIES", 215, 372], ["insbesondere der Kontrollma\u00dfnahmen und des Patientenmanagements, werden die Folgen im Zusammenhang mit dem derzeitigen pandemischen Ausbruch des SARS-CoV-2 untersucht", "SPECIES", 447, 613], ["Herausforderungen in der Seuchenkontrolle und der jetzigen", "TREATMENT", 79, 137], ["durch verzerrte", "TREATMENT", 147, 162], ["VerteilungenIn dieser", "TREATMENT", 163, 184], ["MethodenMittels Analyse der zentralen Parameter der Seuchenkontrolle, insbesondere der Kontrollma\u00dfnahmen und des", "TREATMENT", 377, 489]]], ["Bei noch limitierter Datenlage zum derzeitigen Geschehen werden zus\u00e4tzlich Analysen aus dem SARS-Ausbruch 2002/2003 und grunds\u00e4tzliche Arbeiten aus der Infektionsepidemiologie herangezogen.", [["Bei noch limitierter Datenlage zum derzeitigen Geschehen werden zus\u00e4tzlich Analysen aus dem SARS-Ausbruch 2002/2003 und grunds\u00e4tzliche Arbeiten aus der Infektionsepidemiologie herangezogen", "SPECIES", 0, 188], ["aus dem SARS", "PROBLEM", 84, 96], ["Ausbruch", "TREATMENT", 97, 105]]], ["Die Grundparameter R0 und Tg, der Basisreproduktionskoeffizient und die Generationszeit bzw. das Serienintervall, sind \u00fcber die Infektionserreger insgesamt ebenso rechts verzerrt.", [["Die Grundparameter R0 und Tg, der Basisreproduktionskoeffizient und die Generationszeit bzw", "SPECIES", 0, 91]]], ["Das R0 reicht von pandemischen Influenzaerregern wie dem H1N1pdm2009 mit 1,6 bis hin zu Masern mit bis zu 18 [9] .", [["1,6 bis", "CHEMICAL", 73, 80], ["Das R0 reicht von pandemischen Influenzaerregern wie dem H1N1pdm2009 mit 1,6 bis hin zu Masern mit bis zu 18", "SPECIES", 0, 108]]], ["Ebenso kann die Tg von 3 Tagen f\u00fcr Influenza bis zu 50 Tagen bei der Hepatitis A reichen [3] .", [["Ebenso", "TREATMENT", 0, 6], ["Influenza bis zu", "TREATMENT", 35, 51]]], ["Da die R0 und die Tg aber f\u00fcr einen gegebenen Erreger sehr viel enger gefasst sind und meist nur durch die jeweilig verf\u00fcgbare Datenbasis und/oder der Methodik zur Berechnung von R0 und Tg voneinander abweichen mit meist engem Konfidenzintervall, sollen R0 und Tg hier nicht weiter betrachtet werden, sondern nur die Parameter (und deren Streuung), die unmittelbar f\u00fcr die Interventionsma\u00dfnahmen ma\u00dfgeblich sind.ErgebnisAlle entscheidenden Parameter sind Zeitvariablen (.", [["Da die R0 und die Tg aber f\u00fcr einen gegebenen Erreger sehr viel enger gefasst sind und meist nur durch die jeweilig verf\u00fcgbare Datenbasis und/oder der Methodik zur Berechnung von R0 und Tg voneinander abweichen mit meist engem Konfidenzintervall, sollen R0 und Tg hier nicht weiter betrachtet werden, sondern nur die Parameter (und deren Streuung", "SPECIES", 0, 346]]], ["Tab.", [["Tab", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["Der Set-point in der Betrachtung ist grunds\u00e4tzlich der Zeitpunkt der Ansteckung bzw. der \u00dcbertragung.Pr\u00e4patenzzeit (PPZ)Die sogenannte Pr\u00e4patenzzeit ist aus der Parasitologie entlehnt und bedeutet den Zeitraum zwischen Beginn der Virusausscheidung und dem Beginn der Symptome, nach dem Autor die sogenannte PPZ1, die theoretische PPZ [11, 20] .", [["der Betrachtung ist grunds\u00e4tzlich der Zeitpunkt der Ansteckung bzw", "SPECIES", 17, 83], ["Pr\u00e4patenzzeit (PPZ)Die sogenannte Pr\u00e4patenzzeit ist aus der Parasitologie entlehnt und bedeutet den Zeitraum zwischen Beginn der Virusausscheidung und dem Beginn der Symptome, nach dem Autor die sogenannte PPZ1", "SPECIES", 101, 311], ["Pr\u00e4patenzzeit (PPZ)", "TREATMENT", 101, 120], ["Die sogenannte Pr\u00e4patenzzeit ist aus der Parasitologie entlehnt", "TREATMENT", 120, 183]]], ["F\u00fcr Interventionsma\u00dfnahmen ist aber eher die nach dem Autor sogenannte PPZ2, die effektive PPZ, der Zeitraum zwischen Beginn der Erregerausscheidung und der Intervention, sprich Isolation (oder Behandlung), ma\u00dfgeblich.", [["F\u00fcr Interventionsma\u00dfnahmen ist aber eher die nach dem Autor sogenannte PPZ2, die effektive PPZ, der Zeitraum zwischen Beginn der Erregerausscheidung und der Intervention, sprich Isolation (oder Behandlung)", "SPECIES", 0, 205]]], ["Der Wirkungsgrad der Isolation (\u03b5) kann maximal 100 % betragen, wenn der Patient vor dem Einsetzen der Erregerausscheidung bereits abgesondert, bzw. isoliert wird [10] .Pr\u00e4patenzzeit (PPZ)Die PPZ ist die einzige Variable, die in dieser Betrachtung links verzerrt ist, denn die Virusausscheidung wird umso wahrscheinlicher, je n\u00e4her das Ende der Inkubationszeit kommt.", [["Pr\u00e4patenzzeit (PPZ)", "TREATMENT", 169, 188]]], ["Der Prozentsatz an Infizierten in der PPZ bezeichnet der Parameter \u03b8 [10] .", [["Der Prozentsatz an Infizierten in der PPZ bezeichnet der Parameter", "TREATMENT", 0, 66]]], ["Zusammen mit \u03b8 \u00d7 R0 f\u00fchrt das sehr leicht zu einem Wert \u00fcber 1 und somit der Verbreitung des Virus [10, 18] .", [["Zusammen mit \u03b8 \u00d7 R0 f\u00fchrt das sehr leicht zu einem Wert \u00fcber 1 und somit der Verbreitung des Virus", "SPECIES", 0, 98], ["Zusammen mit", "TREATMENT", 0, 12]]], ["Die Gr\u00f6\u00dfe von \u03b8 ist umgekehrt proportional zu \u03b5.", [["Die Gr\u00f6\u00dfe von \u03b8 ist umgekehrt proportional zu \u03b5.", "SPECIES", 0, 48]]], ["[15] .Inkubationszeit (IZ)Die Festlegung der IZ ist eine Optimierung zwischen Restrisiko oder Escape und der mit der Quarant\u00e4ne in Zeit und Personenzahl verbundenen Belastung.", [["Inkubationszeit (IZ)Die Festlegung der IZ ist eine Optimierung zwischen Restrisiko oder Escape und der mit der Quarant\u00e4ne in Zeit und Personenzahl verbundenen Belastung", "SPECIES", 6, 174], ["Inkubationszeit (IZ)", "TREATMENT", 6, 26]]], ["Die Belastung der Bev\u00f6lkerung in materiellen [4] und psychischen Belangen [2] ist nicht unerheblich, auch wenn jeder bei einer Pandemie einen \"Preis\" zu zahlen hat [12] .", [["ist nicht unerheblich", "TREATMENT", 78, 99]]], ["Im Vergleich zu Ebola mit einer Standard IZ von 21d liegt die IZ bei SARS-CoV-2 deutlich g\u00fcnstiger und in der Gr\u00f6\u00dfenordnung der Pocken mit ebenfalls 14 Tagen.", [["Im Vergleich zu Ebola mit einer Standard IZ von 21d liegt die IZ bei SARS-CoV-2 deutlich g\u00fcnstiger und in der Gr\u00f6\u00dfenordnung der Pocken mit ebenfalls", "SPECIES", 0, 148], ["Im Vergleich zu Ebola mit einer", "TREATMENT", 0, 31], ["Standard IZ von 21d liegt die", "TREATMENT", 32, 61], ["IZ bei SARS", "TEST", 62, 73], ["CoV", "TEST", 74, 77]]], ["Sp\u00e4testens aber in der Phase 3 \"mitigation\" mitZusammenfassung \u00b7 AbstractPr\u00e4v Gesundheitsf https://doi.org/10.1007/s11553-020-00775-z \u00a9 Springer-Verlag GmbH Germany, part of Springer Nature 2020Schl\u00fcsselw\u00f6rterFallmanagement \u00b7 Hospitalisierung \u00b7 Inkubationszeit \u00b7 Pr\u00e4patenzzeit \u00b7 Verteilungsfunktion \u00b7 VirusausscheidungChallenges in infectious disease control and the current pandemic by skewed distributions AbstractBackground.", [["infectious disease", "DISEASE", 332, 350], ["Pr\u00e4patenzzeit", "TREATMENT", 263, 276], ["VirusausscheidungChallenges", "TREATMENT", 301, 328], ["infectious disease control", "TREATMENT", 332, 358], ["infectious", "OBSERVATION", 332, 342]]], ["The pandemic phase 3-mitigation-by the SARS-Coronavirus-2 is currently taking on speed in Germany.", [["SARS", "DISEASE", 39, 43], ["The pandemic phase", "TEST", 0, 18]]], ["Skewed distributions of key epidemiological parameters of the virus and patient care are a challenge for the control of the outbreak as well as keeping the system functional.", [["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["the virus", "TREATMENT", 58, 67], ["a challenge", "TREATMENT", 89, 100]]], ["The skewed distributions are exclusively time related variables.", [["skewed", "OBSERVATION_MODIFIER", 4, 10], ["distributions", "OBSERVATION_MODIFIER", 11, 24]]], ["They are a handicap for outbreak control as well patient management.", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["outbreak control", "TREATMENT", 24, 40]]], ["Optimization between residual open flanks and the efforts to close them is difficult.", [["residual open flanks", "PROBLEM", 21, 41], ["residual", "OBSERVATION_MODIFIER", 21, 29], ["open", "OBSERVATION", 30, 34], ["flanks", "OBSERVATION_MODIFIER", 35, 41]]], ["The main stakeholders are the local health departments, the diagnostic laboratories, the health care infrastructure and finally the citizens in regard to the burden due to non-pharmaceutical interventions including quarantine and isolation.", [["non-pharmaceutical interventions", "TREATMENT", 172, 204], ["quarantine", "TREATMENT", 215, 225], ["isolation", "TREATMENT", 230, 239], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The duration of quarantine and isolation should urgently be shortened for health care workers (HCW) as well as people in critical infrastructure by ready (re-) testing.", [["people", "ORGANISM", 111, 117], ["people", "SPECIES", 111, 117], ["quarantine", "TREATMENT", 16, 26], ["isolation", "TREATMENT", 31, 40]]], ["Calculated risks have to be taken within a phase 3 of a pandemic to keep a system going.Challenges in infectious disease control and the current pandemic by skewed distributions AbstractConclusions.", [["infectious disease control", "TREATMENT", 102, 128], ["infectious", "OBSERVATION", 102, 112]]], ["The skewed distributions are a special challenge for infectious disease control.", [["a special challenge", "TREATMENT", 29, 48], ["infectious disease control", "TREATMENT", 53, 79], ["skewed", "OBSERVATION_MODIFIER", 4, 10], ["distributions", "OBSERVATION_MODIFIER", 11, 24]]], ["In the case of ending quarantine and isolation in phase 3 of the pandemic, they should be judged specifically in regard to the client/patient.", [["patient", "ORGANISM", 134, 141], ["patient", "SPECIES", 134, 141]]], ["Cumulative distribution functions are very helpful in this regard.KeywordsCase management \u00b7 Distribution function \u00b7 Hospitalization \u00b7 Incubation period \u00b7 Prepatency period \u00b7 Viral shedding zunehmenden Infektionen bei Krankenhausbediensteten (HCW) und Mitarbeitern in den sogenannten kritischen Infrastrukturen (KRITIS) muss der Sachverhalt differenzierter betrachtet werden.", [["Cumulative distribution functions", "TEST", 0, 33], ["Prepatency period", "TREATMENT", 154, 171], ["Viral shedding zunehmenden Infektionen bei Krankenhausbediensteten (HCW)", "TREATMENT", 174, 246]]], ["Dazu geh\u00f6ren auch die Verwaltung, Politik, medizinisches Personal (HCW) und Sicherheitskr\u00e4fte.", [["Dazu geh\u00f6ren auch die Verwaltung, Politik, medizinisches Personal (HCW) und Sicherheitskr\u00e4fte", "SPECIES", 0, 93]]], ["HCW in Quarant\u00e4ne nach R\u00fcckreise aus Risikogebieten oder bei ungesch\u00fctztem Kontakt zu einem best\u00e4tigten Fall sollten bereits nach 8-10 Tagen nachgetestet werden und bei negativem Test wieder zur T\u00e4tigkeit zugelassen werden.", [["Quarant\u00e4ne nach R\u00fcckreise aus Risikogebieten oder bei ungesch\u00fctztem Kontakt zu einem best\u00e4tigten Fall sollten bereits nach 8-10 Tagen nachgetestet werden und bei negativem", "SPECIES", 7, 178], ["bei ungesch\u00fctztem", "TREATMENT", 57, 74], ["zu einem", "TREATMENT", 83, 91], ["nach", "TEST", 125, 129]]], ["Mit einem Test am Tag 8-10 nach dem letzten Kontakt schaut man mindestens 24-48 h in die Zukunft, denn \u00fcber die PPZ im Falle eines positiven Testergebnisses lie\u00dfe sich das Ende der IZ vorwegnehmen.", [["Mit einem", "TEST", 0, 9], ["Tag", "TEST", 18, 21]]], ["Im Umkehrschluss k\u00f6nnte man damit bei einem negativen Test am Tag 8-10 auf Tag 10-12 extrapolieren und damit das Restrisiko entsprechend der kumulativen Verteilungsfunktion auf ca.", [["Im Umkehrschluss k\u00f6nnte man damit bei einem negativen Test am Tag 8-10 auf Tag 10-12 extrapolieren und damit das Restrisiko entsprechend der kumulativen Verteilungsfunktion auf ca", "SPECIES", 0, 179], ["bei einem", "TEST", 34, 43], ["Tag", "TEST", 62, 65], ["auf Tag", "TEST", 71, 78]]], ["5 bis 2 % (Risiko von 1:20 bis 1:50) begrenzen, im Vergleich zu einem Restrisiko von 1 % (1:100) bei einem Festhalten an den 14 Tagen.", [["5 bis", "CHEMICAL", 0, 5], ["von 1:20 bis 1:50) begrenzen", "SIMPLE_CHEMICAL", 18, 46], ["bis", "TEST", 2, 5], ["begrenzen", "TREATMENT", 37, 46], ["im Vergleich zu einem Restrisiko von", "TREATMENT", 48, 84]]], ["W\u00e4re die epidemiologische Lage und die verf\u00fcgbare Manpower in dem betreffenden Krankenhaus noch etwas g\u00fcnstiger und das Restrisiko von 1:20 (5 %) zu hoch, dann d\u00fcrften diese \u00dcberlegungen erst ab Tag 9 nach dem letzten Kontakt angestellt werden, mit einer Extrapolation auf Tag 11 und damit einem Restrisiko von ca.", [["W\u00e4re die epidemiologische Lage und die verf\u00fcgbare Manpower in dem betreffenden Krankenhaus noch etwas g\u00fcnstiger und das Restrisiko von 1:20 (5 %) zu hoch, dann d\u00fcrften diese \u00dcberlegungen erst ab Tag 9 nach dem letzten Kontakt angestellt werden, mit einer Extrapolation auf Tag 11 und damit einem Restrisiko von ca", "SPECIES", 0, 313], ["ab Tag", "TEST", 192, 198], ["auf Tag", "TEST", 269, 276]]], ["Dieser bedeutet, welche T\u00e4tigkeit eine Person in Quarant\u00e4ne oder Isolation aus\u00fcbt und welche Risiken f\u00fcr andere damit direkt (medizinisches und Pflege-/ Personal) und indirekt (KRITIS Personal) verbunden sind.", [["Quarant\u00e4ne oder Isolation aus\u00fcbt und welche Risiken f\u00fcr andere damit direkt (medizinisches und Pflege-/ Personal) und indirekt (KRITIS Personal) verbunden sind", "SPECIES", 49, 208]]], ["Der Brisanzgrad wird in unseren Monitorsystemen erfasst.", [["Der Brisanzgrad wird", "TREATMENT", 0, 20]]], ["Grad 1 -ohne weitere Ma\u00dfnahmen und Vorgehen wie vom RKI empfohlen [16] , Grad 2 liegt dazwischen und wird vor Ende der Quarant\u00e4ne nochmals \u00fcberpr\u00fcft, je nach Anzahl der potenziell Betroffenen und der verf\u00fcgbaren Laborkapazit\u00e4t.KeywordsDie j\u00fcngste Ma\u00dfgabe durch das RKI f\u00fcr eine De-isolierung nach 14 Tage ohne Testung muss differenzierter betrachtet werden [16] .", [["Grad 2 liegt dazwischen", "TREATMENT", 73, 96], ["je nach Anzahl", "TREATMENT", 150, 164]]], ["Auch f\u00fcr die De-Isolierung findet der Brisanzgrad in unserem Amt Anwendung und HCW bzw.", [["De-Isolierung findet der Brisanzgrad in unserem Amt Anwendung und HCW bzw", "SPECIES", 13, 86]]], ["HCW/KRITIS Mitarbeiter sollten bereits nach 8-10 Tagen nachgetestet werden.", [["KRITIS Mitarbeiter sollten bereits nach", "TREATMENT", 4, 43]]], ["Die Negativtestung hat hier den klaren Auftrag, Zeit zu gewinnen und HCW/ KRITIS Mitarbeiter m\u00f6glichst schnell, und dann immun, wieder in die Strukturen einzugliedern.", [["Die Negativtestung hat hier den klaren Auftrag, Zeit zu gewinnen und HCW/ KRITIS Mitarbeiter m\u00f6glichst schnell, und dann immun", "SPECIES", 0, 126]]], ["Die Manpower, insbesondere f\u00fcr Intensiv-und Dialysestationen, ist ein zentrales Thema.", [["Intensiv-und Dialysestationen", "TREATMENT", 31, 60], ["ist ein zentrales", "TREATMENT", 62, 79]]], ["Ob ein einmal erhobener negativer Befund in 24 h nochmals best\u00e4tigt werden soll oder kann, wird sich bei Massenproblemen gegebenenfalls \u00e4ndern m\u00fcssen.KeywordsAnderson et al. [1, 5] F\u00fcr SARS-CoV-2 wird f\u00fcr die Immunisierung der Bev\u00f6lkerung durch das Virus selbst ein \"Preis\" zu zahlen sein, vor allem in Anbetracht der Tatsache, dass der Medizin und dem \u00d6ffentlichen Gesundheitswesen zurzeit nur \"mitigation\"-M\u00f6glichkeiten inklusive der \"Mitigation\" im klinischen Verlauf durch medizinische und intensivmedizinische Ma\u00dfnahmen und dem Abfangen von Komplikationen zur Verf\u00fcgung stehen.", [["Virus selbst ein \"Preis\" zu zahlen sein, vor allem in Anbetracht der Tatsache, dass der Medizin und dem \u00d6ffentlichen Gesundheitswesen zurzeit nur \"mitigation\"-M\u00f6glichkeiten inklusive der \"Mitigation\" im klinischen Verlauf durch medizinische und intensivmedizinische Ma\u00dfnahmen und dem Abfangen von Komplikationen zur Verf\u00fcgung stehen", "SPECIES", 249, 581], ["SARS", "TEST", 185, 189], ["CoV", "TEST", 190, 193], ["die", "PROBLEM", 205, 208], ["Verlauf durch medizinische", "TREATMENT", 463, 489]]]], "200f162ff6557492747f09438f8cfcaa4551942c": [["BackgroundThere is an increasing focus on the management of care of children with complex care needs (CCNs), defined as multidimensional health and social care needs, in the presence of a recognised medical condition or where there is no unifying diagnosis [1] .", [["CCNs", "DISEASE", 102, 106], ["children", "ORGANISM", 68, 76], ["children", "SPECIES", 68, 76], ["increasing", "OBSERVATION_MODIFIER", 22, 32], ["focus", "OBSERVATION", 33, 38]]], ["This supports a child-centric approach to care within a health service that is increasingly focused on enhancing integrated care delivery.", [["enhancing integrated care delivery", "TREATMENT", 103, 137]]], ["Given the growing population of children with CCNs, little is known about the structures and processes currently in place across the EU to support the care requirements of these children and their families.", [["CCNs", "DISEASE", 46, 50], ["children", "ORGANISM", 32, 40], ["children", "ORGANISM", 178, 186], ["children", "SPECIES", 32, 40], ["children", "SPECIES", 178, 186], ["CCNs", "TREATMENT", 46, 50], ["growing", "OBSERVATION_MODIFIER", 10, 17], ["population", "OBSERVATION_MODIFIER", 18, 28]]], ["This was therefore an important area of focus within the Models of Child Health Appraised (MOCHA) project, funded by the EU under the Horizon 2020 programme.", [["important", "OBSERVATION_MODIFIER", 22, 31], ["area", "OBSERVATION_MODIFIER", 32, 36], ["focus", "OBSERVATION", 40, 45]]], ["We examined the structures and processes of care in place for children with CCNs and identified key characteristics for effective integration of care for these children at the community and acute care interface across 30 European Union (EU)/ European Economic Area (EEA) countries.", [["CCNs", "DISEASE", 76, 80], ["children", "ORGANISM", 62, 70], ["children", "ORGANISM", 160, 168], ["children", "SPECIES", 62, 70], ["children", "SPECIES", 160, 168]]], ["Three specific exemplars were chosen for examination in each of the following areas: traumatic brain injury, long-term ventilation (LTV), and intractable epilepsy.", [["brain", "ANATOMY", 95, 100], ["traumatic brain injury", "DISEASE", 85, 107], ["epilepsy", "DISEASE", 154, 162], ["brain", "ORGAN", 95, 100], ["examination", "TEST", 41, 52], ["traumatic brain injury", "PROBLEM", 85, 107], ["long-term ventilation", "TREATMENT", 109, 130], ["intractable epilepsy", "PROBLEM", 142, 162], ["traumatic", "OBSERVATION", 85, 94], ["brain", "ANATOMY", 95, 100], ["injury", "OBSERVATION", 101, 107], ["intractable", "OBSERVATION_MODIFIER", 142, 153], ["epilepsy", "OBSERVATION", 154, 162]]], ["The advisory board comprised of European medical, paediatric, and policy bodies, and civil society groups, including the youth subgroup of the European Patients' Forum [4] .", [["Patients", "ORGANISM", 152, 160], ["Patients", "SPECIES", 152, 160]]], ["This paper specifically reports on the findings on the constituents for the effective care for children assisted with LTV in the home.BackgroundIt is reported that the number of children requiring LTV has consistently increased over the last 25 years.", [["LTV", "DISEASE", 197, 200], ["children", "ORGANISM", 95, 103], ["children", "ORGANISM", 178, 186], ["children", "SPECIES", 95, 103], ["children", "SPECIES", 178, 186], ["LTV", "TREATMENT", 118, 121], ["LTV", "TREATMENT", 197, 200], ["increased", "OBSERVATION_MODIFIER", 218, 227]]], ["This is supported by a study in the United Kingdom, from 1994 to 2010 which showed a 30-fold increase in prevalence between 1994 and 2010, from 0.2-6.7 per 100,000 [5] , and more recent data available across the EU.", [["a study", "TEST", 21, 28]]], ["For example, the number of children receiving LTV at home in Canada increased from 2 in 1991 to 156 in December 2011.", [["LTV", "DISEASE", 46, 49], ["children", "ORGANISM", 27, 35], ["children", "SPECIES", 27, 35], ["LTV", "TREATMENT", 46, 49]]], ["This study found a twofold increase in the number of invasive ventilation initiations in the second 10 years, n = 45 (2001-2011) compared to the first 10 years, n = 21 (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) [8] .", [["This study", "TEST", 0, 10], ["a twofold increase", "PROBLEM", 17, 35], ["invasive ventilation initiations", "TREATMENT", 53, 85], ["twofold", "OBSERVATION_MODIFIER", 19, 26], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["number", "OBSERVATION_MODIFIER", 43, 49], ["invasive", "OBSERVATION_MODIFIER", 53, 61], ["ventilation initiations", "OBSERVATION", 62, 85]]], ["Children are reliant on LTV for a variety of reasons which may include chronic lung disease due to prematurity, congenital airway malformations, hypoventilation syndrome, neuromuscular diseases, and spinal cord injuries [9] .", [["lung", "ANATOMY", 79, 83], ["airway", "ANATOMY", 123, 129], ["neuromuscular", "ANATOMY", 171, 184], ["spinal cord", "ANATOMY", 199, 210], ["chronic lung disease", "DISEASE", 71, 91], ["prematurity", "DISEASE", 99, 110], ["congenital airway malformations", "DISEASE", 112, 143], ["hypoventilation syndrome", "DISEASE", 145, 169], ["neuromuscular diseases", "DISEASE", 171, 193], ["cord injuries", "DISEASE", 206, 219], ["Children", "ORGANISM", 0, 8], ["lung", "ORGAN", 79, 83], ["airway", "MULTI-TISSUE_STRUCTURE", 123, 129], ["cord", "ORGAN", 206, 210], ["Children", "SPECIES", 0, 8], ["chronic lung disease", "PROBLEM", 71, 91], ["prematurity", "PROBLEM", 99, 110], ["congenital airway malformations", "PROBLEM", 112, 143], ["hypoventilation syndrome", "PROBLEM", 145, 169], ["neuromuscular diseases", "PROBLEM", 171, 193], ["spinal cord injuries", "PROBLEM", 199, 219], ["chronic", "OBSERVATION_MODIFIER", 71, 78], ["lung", "ANATOMY", 79, 83], ["disease", "OBSERVATION", 84, 91], ["prematurity", "OBSERVATION", 99, 110], ["congenital", "OBSERVATION_MODIFIER", 112, 122], ["airway", "ANATOMY", 123, 129], ["malformations", "OBSERVATION", 130, 143], ["hypoventilation syndrome", "OBSERVATION", 145, 169], ["neuromuscular diseases", "OBSERVATION", 171, 193], ["spinal cord", "ANATOMY", 199, 210], ["injuries", "OBSERVATION", 211, 219]]], ["Therefore, these children often have frequent readmissions to hospital, are cared for by numerous health and social care providers, and are resource intensive in terms of care delivery at home [10] [11] [12] [13] .", [["children", "ORGANISM", 17, 25], ["children", "SPECIES", 17, 25], ["care delivery", "TREATMENT", 171, 184]]], ["Data from studies that have investigated long-term outcomes for these children are scarce; those that exists indicate reduced long-term health related quality of life [14] .", [["children", "ORGANISM", 70, 78], ["children", "SPECIES", 70, 78], ["Data from studies", "TEST", 0, 17], ["reduced", "OBSERVATION_MODIFIER", 118, 125], ["long-term", "OBSERVATION_MODIFIER", 126, 135]]], ["An examination of the structures and processes, and an exploration of the key constituents required for enhanced care, was therefore required to provide key foundational knowledge for the development of care services for these children and their families.MethodsThis was a non-experimental descriptive study with an embedded qualitative element Survey This is the first time that the care of children with CCNs was examined across the EU/EEA.", [["CCNs", "DISEASE", 406, 410], ["children", "ORGANISM", 227, 235], ["children", "ORGANISM", 392, 400], ["children", "SPECIES", 227, 235], ["children", "SPECIES", 392, 400], ["An examination", "TEST", 0, 14], ["an exploration", "TEST", 52, 66], ["a non-experimental descriptive study", "TEST", 271, 307]]], ["The Standards for Systems of Care for Children and Youth with Special Health Care Needs [15] were adapted with the permission of the Lucile Packard Foundation.", [["Children", "SPECIES", 38, 46]]], ["Detail of the adaptation of the standards for MOCHA can be found at www.childhealthservicemodels.eu The areas of care explored in this survey were: screening, assessment and referral; access to care; care coordination; community-based services; family-professional partnerships; and quality assurance.", [["screening", "TEST", 148, 157], ["assessment", "TEST", 159, 169], ["areas", "OBSERVATION_MODIFIER", 104, 109]]], ["An exemplar on LTV (Table 1 ) and related questions were provided to each participant.", [["participant", "SPECIES", 74, 85]]], ["Participants were offered an opportunity to include additional comments on key characteristics for effective integration of care for these children and their families.Data collectionData were collected by a Country Agent (CA) in each of the 30 countries between July and December 2016.", [["children", "ORGANISM", 139, 147], ["Participants", "SPECIES", 0, 12], ["children", "SPECIES", 139, 147]]], ["This was a key methodological feature of the MOCHA project, the remunerated retention in each country of a part-time CAa local expert in child health serviceswho acted as the informant for obtaining data requested by the principal scientists in the project.", [["retention", "OBSERVATION_MODIFIER", 76, 85]]], ["For more information about the country agents, please see the MOCHA website http://www.childhealthservicemodels.eu/partnerlisting/country-agents.AnalysisData were analyzed using descriptive statistics and a thematic analysis was undertaken of the free text data provided.", [["MOCHA", "DNA", 62, 67], ["a thematic analysis", "TEST", 205, 224], ["the free text data", "TEST", 243, 261]]], ["Attride-Stirling's thematic analysis network [16] was applied to the textual data.Table 1 Exemplar for child assisted by long-term ventilationMax is an 18 month old boy with a diagnosis of chronic lung disease due to bronchopulmonary dysplasia.", [["lung", "ANATOMY", 197, 201], ["bronchopulmonary dysplasia", "ANATOMY", 217, 243], ["chronic lung disease", "DISEASE", 189, 209], ["bronchopulmonary dysplasia", "DISEASE", 217, 243], ["boy", "ORGANISM", 165, 168], ["lung", "ORGAN", 197, 201], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 217, 243], ["boy", "SPECIES", 165, 168], ["Attride", "TREATMENT", 0, 7], ["the textual data", "TEST", 65, 81], ["chronic lung disease", "PROBLEM", 189, 209], ["bronchopulmonary dysplasia", "PROBLEM", 217, 243], ["chronic", "OBSERVATION_MODIFIER", 189, 196], ["lung", "ANATOMY", 197, 201], ["disease", "OBSERVATION", 202, 209], ["bronchopulmonary", "ANATOMY", 217, 233], ["dysplasia", "OBSERVATION", 234, 243]]], ["He had a diaphragmatic hernia, a gastrostomy tube placement at 3 months of age, and a Grade IV intraventricular haemorrhage requiring a cerebrospinal fluid ventricular shunt.", [["diaphragmatic", "ANATOMY", 9, 22], ["cerebrospinal", "ANATOMY", 136, 149], ["ventricular", "ANATOMY", 156, 167], ["diaphragmatic hernia", "DISEASE", 9, 29], ["intraventricular haemorrhage", "DISEASE", 95, 123], ["diaphragmatic", "ORGAN", 9, 22], ["tube", "TISSUE", 45, 49], ["cerebrospinal fluid ventricular", "MULTI-TISSUE_STRUCTURE", 136, 167], ["a diaphragmatic hernia", "PROBLEM", 7, 29], ["a gastrostomy tube placement", "TREATMENT", 31, 59], ["a Grade IV intraventricular haemorrhage", "PROBLEM", 84, 123], ["a cerebrospinal fluid ventricular shunt", "TREATMENT", 134, 173], ["diaphragmatic", "ANATOMY", 9, 22], ["hernia", "OBSERVATION", 23, 29], ["gastrostomy tube", "OBSERVATION", 33, 49], ["intraventricular", "ANATOMY_MODIFIER", 95, 111], ["haemorrhage", "OBSERVATION", 112, 123], ["cerebrospinal", "ANATOMY", 136, 149], ["fluid ventricular shunt", "OBSERVATION", 150, 173]]], ["Max has been ventilator dependent since he was born and is considered to have a life-threatening condition.", [["ventilator dependent", "PROBLEM", 13, 33], ["ventilator dependent", "OBSERVATION", 13, 33]]], ["A tracheostomy tube was placed at 6 weeks of age due to the need for ongoing ventilation.", [["tube", "TISSUE", 15, 19], ["A tracheostomy tube", "TREATMENT", 0, 19], ["ongoing ventilation", "TREATMENT", 69, 88], ["tracheostomy tube", "OBSERVATION", 2, 19]]], ["At present Max has the following: impaired pulmonary function, developmental delay in fine and gross motor skills, and speech and language difficulties.", [["pulmonary", "ANATOMY", 43, 52], ["impaired pulmonary function", "DISEASE", 34, 61], ["speech and language difficulties", "DISEASE", 119, 151], ["Max", "GENE_OR_GENE_PRODUCT", 11, 14], ["pulmonary", "ORGAN", 43, 52], ["Max", "PROTEIN", 11, 14], ["impaired pulmonary function", "PROBLEM", 34, 61], ["developmental delay", "PROBLEM", 63, 82], ["speech and language difficulties", "PROBLEM", 119, 151], ["impaired", "OBSERVATION", 34, 42], ["pulmonary", "ANATOMY", 43, 52]]], ["His prognosis for weaning off the ventilator does not seem favourable at the moment and ideally he requires the healthcare input of the following healthcare professionals: community nurses, specialist consultants (respiratory, paediatrician, neurology), community general practitioner, pharmacist, speech and language therapist, physiotherapist, occupational therapist, social worker, dentist, home care nursing team and respite care services.", [["the ventilator", "TREATMENT", 30, 44]]], ["He lives 120kms from the main children's hospital and 40kms from his nearest regional hospital which has a small paediatric unit.ResultsA total of 27 surveys were returned from a possible 30 countries (90.0%) countries.", [["He", "ORGANISM", 0, 2], ["children", "ORGANISM", 30, 38], ["children", "SPECIES", 30, 38], ["small", "OBSERVATION_MODIFIER", 107, 112]]], ["One of the 27 respondents indicated that their country did not have home LTV, therefore, responses of 26 countries (86.7%) were analysed.Structures and processes to support children assisted with LTVThe key findings from all domains surveyed are presented in Table 2 .", [["children", "ORGANISM", 173, 181], ["children", "SPECIES", 173, 181], ["home LTV", "TREATMENT", 68, 76]]], ["No country had all of the core components in place for all of the domains examined and there was therefore no discernible pattern overall in the results.", [["no discernible", "UNCERTAINTY", 107, 121]]], ["It was reported that Italy had all of the structures and processes examined in place for four of the six domains: screening, assessment and referral; access to care; community-based services; and family-professional partnerships.", [["screening", "TEST", 114, 123], ["assessment", "TEST", 125, 135]]], ["Norway reported that it had all of the structures and processes in place for three domains: screening, assessment and referral; access to care; and care coordination.", [["screening", "TEST", 92, 101], ["assessment", "TEST", 103, 113]]], ["Three countries reported that they had the structures and processes in place for two of the six domains: Estonia -screening, assessment and referral and access to care; The Netherlands -care coordination and community-based care; and Croatia -communitybased care and family-professional partnerships.", [["assessment", "TEST", 125, 135]]], ["The only similarity in this finding was that Denmark and Portugal had all core components in place for screening, assessment and referral, while the Czech Republic and Lithuania had all core components in place for access to care.Structures and processes to support children assisted with LTVFacilitators of effective integration of care at the community and secondary care interface for a child assisted with LTV Three global themes (GTs) emerged from the text provided by the CAs: 'family preparedness for transitioning Table 2 Structures and processes to support children assisted with LTVDomain and ItemNumber of countries %(n)Screening and AssessmentPolicies and procedures to support preventative screening, assessment and referral for routine developmental checks 46.2 (12) Mechanisms in place to document and communicate the results of assessments and screening to all the services who provide care to the child 46.2 (12) Mechanisms in place to support the communication of screening and assessment to parents/guardians 38.5(10)Access to CareMechanisms in place to identify all healthcare providers caring for the child 53.8 (14) Assistance with transport of the child to hospital appointments 30.8 (8) Policies or procedures in place to support the provision of linguistically appropriate information to the family 41.7 (12) Policies or procedures in place to support the provision of culturally appropriate information to the family 42.3(11)Care CoordinationPolicies and procedures in place to support care coordination 53.8 (14) Discharge Planning Coordinator in place in paediatric departments/hospitals 42.", [["children", "ORGANISM", 266, 274], ["children", "ORGANISM", 566, 574], ["children", "SPECIES", 266, 274], ["children", "SPECIES", 566, 574], ["screening", "TEST", 103, 112], ["assessment", "TEST", 114, 124], ["all core components", "TREATMENT", 182, 201], ["LTVFacilitators", "TREATMENT", 289, 304], ["LTVDomain", "TREATMENT", 589, 598], ["preventative screening", "TEST", 690, 712], ["assessment", "TEST", 714, 724], ["routine developmental checks", "TEST", 742, 770], ["assessments", "TEST", 844, 855], ["screening", "TEST", 860, 869], ["screening", "TEST", 982, 991], ["assessment", "TEST", 996, 1006], ["procedures", "TREATMENT", 1223, 1233], ["procedures", "TREATMENT", 1346, 1356], ["procedures", "TREATMENT", 1481, 1491]]], ["(11) Consultation with parents/ guardians in the development of personalised care plans 84.6 (22) Consultation with all healthcare professionals in the development of personalised care plans 73.1(19)Community Based Services and SupportsFamily advocacy groups involved in making recommendations to home and community-based services 38.5 (10) Policies in place to support paediatric palliative care and end-of-life care 65.4 (11) Access to psychological support for parents/guardians and siblings 84.6(22)Family-Professional PartnershipsFamily advocacy groups involved in the development of policies and procedures affecting the care of the child 46.2 (12) Parents/guardians included in national quality improvements 30.8 (8) Parents/guardians included in the review of patient / family information 38.5(10)Quality AssurancePolicies or procedures in place to support quality assurance for service providers 57.7 (15) Data collected on the experience of care from the perspective of the parents/guardians 30.7 (8) Data collected on the experience of care from the perspective of the siblings 11.5 (3) to home', 'coordinated pathway to specialist care' and 'legal and governance structures'.Quality AssuranceFamily preparedness for transitioning to homeQuality AssuranceThe theme 'family preparedness for transitioning to home' describes the characteristics of effective integration of care at the community and acute care interface for children assisted with LTV as parents transition to becoming the child's primary care giver in the home.", [["patient", "ORGANISM", 768, 775], ["children", "ORGANISM", 1433, 1441], ["patient", "SPECIES", 768, 775], ["children", "SPECIES", 1433, 1441], ["paediatric palliative care", "TREATMENT", 370, 396], ["Quality AssurancePolicies", "TREATMENT", 805, 830], ["procedures", "TREATMENT", 834, 844]]], ["Linguistically appropriate information was identified as a key constituent to effective individualised care, to support equity of care and optimum readiness for caring for the child at home.", [["child", "ORGANISM", 176, 181]]], ["A phased stepdown plan was identified as an appropriate way to facilitate this, whereby parents increase their input in to the clinical care of their child in an incremental manner.Quality AssuranceIf parents feel more secure, the child comes to a step down unit, where the parents share a greater part of care themselves, but know they can always call someone for support.", [["child", "ORGANISM", 150, 155], ["A phased stepdown plan", "TREATMENT", 0, 22]]], ["There are no time limits for the duration of the stay\u2026 Only when the parents feel safe and do well, and agree, the child will be discharged at home.", [["child", "ORGANISM", 115, 120], ["no", "UNCERTAINTY", 10, 12]]], ["(CA Austria)Quality AssuranceThe second OT 'discharge coordination' emerged from data from a number of countries who provided examples of support offered to enhance family preparedness for transitioning to home.", [["CA Austria)", "TREATMENT", 1, 12]]], ["In terms of specialist medical and nursing input, this refers to linking the acute care team with the community care team, to ensure the community care team would have a full picture of the clinical care needs of the child transitioning to home.", [["child", "ORGANISM", 217, 222]]], ["In addition the discharge coordinator would ideally be responsible for ensuring all the technical support is appropriately planned and in place prior to the child's discharge from hospital.Coordinated pathway to specialist servicesThis GT emerged as CAs emphasised the need for access to care for children assisted with LTV, and their families, to specialist services once discharged.", [["children", "ORGANISM", 297, 305], ["children", "SPECIES", 297, 305], ["LTV", "TREATMENT", 320, 323]]], ["Repeatedly there was concern expressed about the inequity in the provision of specialist care, in that pathways to care rarely existed.", [["specialist care", "TREATMENT", 78, 93]]], ["The GT emerged from two OTs 'access to specialist unscheduled and urgent care' and 'pathway to non-urgent care' (Fig. 2) .", [["urgent care'", "TREATMENT", 66, 78], ["non-urgent care'", "TREATMENT", 95, 111]]], ["Timely access to specialist unscheduled care was identified as critical to the safe and effective care of the child assisted with LTV.", [["child", "ORGANISM", 110, 115], ["LTV", "TREATMENT", 130, 133]]], ["The need for a pathway for care, where the parameters for access were clearly understood was identified as critical to support this.", [["care", "TREATMENT", 27, 31]]], ["In the event of a child having significant respiratory dysfunction immediate access to a PICU was identified as optimum.", [["respiratory", "ANATOMY", 43, 54], ["respiratory dysfunction", "DISEASE", 43, 66], ["significant respiratory dysfunction", "PROBLEM", 31, 66], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["respiratory dysfunction", "OBSERVATION", 43, 66]]], ["The OT 'pathway to non-urgent specialist care' emerged from four basic themes (BTs): monthly specialist home visit, psychological and psychiatric support, hospice and respite care, and complex care centres.", [["psychiatric", "DISEASE", 134, 145], ["psychiatric support", "TREATMENT", 134, 153], ["hospice", "TREATMENT", 155, 162], ["respite care", "TREATMENT", 167, 179]]], ["CAs identified a need for a clear pathway for parents to access this support in the community from healthcare, allied healthcare and social care professionals.", [["this support", "TREATMENT", 64, 76]]], ["During this visits not only the tube replacement takes place, but a set of consultations happen.", [["tube", "ANATOMY", 32, 36], ["tube", "TISSUE", 32, 36], ["the tube replacement", "TREATMENT", 28, 48], ["tube replacement", "OBSERVATION", 32, 48]]], ["(Hungary) There was considerable concern expressed about the absence of respite care available for children on LTV.", [["children", "ORGANISM", 99, 107], ["children", "SPECIES", 99, 107], ["LTV", "TREATMENT", 111, 114]]], ["An example of this was provided by the CA from Bulgaria who described what was being developed in their country:Coordinated pathway to specialist services\u2026centres for complex care for children with disabilities and chronic diseases are organisations in which medical and non-medical specialists perform at least one of the following activities: support of the families of children with disabilities and chronic diseases for prescribing and performing early diagnosis, treatment and medical and psychosocial rehabilitation; long term treatment and rehabilitation of children with Fig. 2 Emergence of global theme coordinated pathway to specialist care disabilities and chronic diseases and education of parents for home-care; providing visits of medical specialists for specialised care of children with disabilities and severe chronic diseases, who are looked after at home or at social care residential home; providing specialised palliative care for children.Legal, policy and governance structuresThe GT 'legal, policy and governance structures' emerged from four OTs: 'infrastructure', 'standards for care delivery', 'legal status' and 'advocacy' (Fig. 3) .", [["disabilities", "DISEASE", 198, 210], ["chronic diseases", "DISEASE", 215, 231], ["chronic diseases", "DISEASE", 403, 419], ["chronic diseases", "DISEASE", 668, 684], ["disabilities", "DISEASE", 803, 815], ["chronic diseases", "DISEASE", 827, 843], ["children", "ORGANISM", 184, 192], ["children", "ORGANISM", 372, 380], ["children", "ORGANISM", 565, 573], ["children", "ORGANISM", 789, 797], ["children", "ORGANISM", 952, 960], ["children", "SPECIES", 184, 192], ["children", "SPECIES", 372, 380], ["children", "SPECIES", 565, 573], ["children", "SPECIES", 789, 797], ["children", "SPECIES", 952, 960], ["chronic diseases", "PROBLEM", 215, 231], ["chronic diseases", "PROBLEM", 403, 419], ["treatment", "TREATMENT", 468, 477], ["medical and psychosocial rehabilitation", "TREATMENT", 482, 521], ["long term treatment", "TREATMENT", 523, 542], ["chronic diseases", "PROBLEM", 668, 684], ["severe chronic diseases", "PROBLEM", 820, 843], ["care delivery'", "TREATMENT", 1105, 1119], ["chronic", "OBSERVATION_MODIFIER", 215, 222], ["diseases", "OBSERVATION", 223, 231], ["severe", "OBSERVATION_MODIFIER", 820, 826], ["chronic", "OBSERVATION_MODIFIER", 827, 834], ["diseases", "OBSERVATION", 835, 843]]], ["The OT 'infrastructure' emerged from data provided by the CAs on key issues that influence the opportunities for optimum integration of care at the acute community interface.", [["acute", "OBSERVATION_MODIFIER", 148, 153]]], ["These included geographical variation in access to care, challenges with transport and difficulties with volunteer support.", [["volunteer support", "TREATMENT", 105, 122], ["geographical variation", "OBSERVATION", 15, 37]]], ["Many countries highlighted concern about inequity in access to care for children on LTV.", [["children", "ORGANISM", 72, 80], ["children", "SPECIES", 72, 80], ["LTV", "TREATMENT", 84, 87]]], ["The CAs reported that resource allocation to support care for children on LTV can vary according to funding in different geographical areas and they also highlighted that access to specialist care, to support the child transitioning to home, varied considerably between urban and rural locations.", [["children", "ORGANISM", 62, 70], ["children", "SPECIES", 62, 70], ["LTV", "TREATMENT", 74, 77]]], ["Challenges were also identified regarding the transport of children assisted with LTV regardless of the child's geographical location, with ambulances often too small for the ventilation material.", [["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67], ["LTV", "TREATMENT", 82, 85], ["the ventilation material", "TREATMENT", 171, 195]]], ["The OT 'standards of care delivery' emerged from three BTs: governance of care in the home, national strategy and data access and communication.", [["care delivery", "TREATMENT", 21, 34]]], ["The majority of CAs reported a number of challenges in governance of care in the home including lack of governance of care agencies and inadequate education of nursing and care staff to care for a child on LTV in the home.", [["CAs", "DISEASE", 16, 19], ["CAs", "OBSERVATION", 16, 19]]], ["This challenge was explained by some CAs by the fact that the number of children on LTV in their country was not very high, and thereby the experience of caring for them was limited.", [["children", "ORGANISM", 72, 80], ["children", "SPECIES", 72, 80]]], ["Lack of available clinical expertise in this area was also attributed to an overall shortage of healthcare professionals in many countries.Legal, policy and governance structuresThe majority of CAs suggested that a national strategy on the management of children assisted with LTV was required to address many of the issues raised.", [["children", "ORGANISM", 254, 262], ["children", "SPECIES", 254, 262], ["LTV", "TREATMENT", 277, 280], ["the issues", "PROBLEM", 313, 323]]], ["The consequences of the absence of such a strategy Fig. 3 Emergence of global theme legal, policy and governance structures or standards of care were explained further by a number of CAs.", [["a strategy Fig", "TREATMENT", 40, 54]]], ["This included no standardised needs-assessment or re-assessment for children and their families.", [["children", "ORGANISM", 68, 76], ["children", "SPECIES", 68, 76], ["assessment", "TEST", 36, 46]]], ["It was also highlighted in a number of CA responses that the child's legal status was important in facilitating integration of care delivery.", [["CA", "GENE_OR_GENE_PRODUCT", 39, 41], ["care delivery", "TREATMENT", 127, 140]]], ["This included where the child had official disability status and where there was a legal right established in a country affording right to long-term care for patients with respiratory problems.Legal, policy and governance structuresThe role of non-governmental organisations (NGOs) was identified as a very important facilitator for integration of care at the acute and community care interface, by virtue of the many roles they can play in supporting optimum care delivery.", [["respiratory", "ANATOMY", 172, 183], ["respiratory problems", "DISEASE", 172, 192], ["child", "ORGANISM", 24, 29], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["long-term care", "TREATMENT", 139, 153], ["respiratory problems", "PROBLEM", 172, 192], ["optimum care delivery", "TREATMENT", 452, 473], ["right", "ANATOMY_MODIFIER", 89, 94]]], ["Examples of the supportive role of NGOs included: fundraising to support state funding for care delivery; volunteers and staff from NGOs to organise and deliver care to children assisted with LTV and their families; and acting as advocates for the needs of these families.", [["volunteers", "ORGANISM", 106, 116], ["children", "ORGANISM", 169, 177], ["children", "SPECIES", 169, 177], ["care delivery", "TREATMENT", 91, 104]]], ["However, in a number of countries CAs reported no system of volunteers or charity organisations to provide care or support for children on LTV and their families.", [["children", "ORGANISM", 127, 135], ["children", "SPECIES", 127, 135]]], ["This was identified as a significant barrier to the provision of care for this population.DiscussionThe findings show that there is much to be done to enhance the care of children assisted with LTV across the EU/EEA, and indicates that health services are not yet coping with this growing number of children.", [["children", "ORGANISM", 171, 179], ["children", "ORGANISM", 299, 307], ["children", "SPECIES", 171, 179], ["children", "SPECIES", 299, 307], ["this population", "TREATMENT", 74, 89], ["significant", "OBSERVATION_MODIFIER", 25, 36]]], ["The challenges with integrated care delivery are supported internationally, often due to lack of the fundamental resources that are required to meet the needs of a growing population of children with CCNs and challenges with interagency coordination [17] [18] [19] .", [["CCNs", "DISEASE", 200, 204], ["children", "ORGANISM", 186, 194], ["children", "SPECIES", 186, 194], ["integrated care delivery", "TREATMENT", 20, 44]]], ["A further challenge identified is the persistent lack of respite care and the need for an enhanced provision of this service in the home.", [["A further challenge", "TREATMENT", 0, 19], ["respite care", "TREATMENT", 57, 69], ["persistent", "OBSERVATION_MODIFIER", 38, 48], ["lack", "OBSERVATION_MODIFIER", 49, 53]]], ["Specific care risks have been identified for this service, reflecting wider potential problems in the delivery of care at the interface of community and acute care.", [["the delivery of care", "TREATMENT", 98, 118], ["acute care", "TREATMENT", 153, 163], ["acute", "OBSERVATION_MODIFIER", 153, 158]]], ["Communication at the point of the initial referral and ongoing communication pathways, primarily regarding the documentation and handover of care, is a well-recognised challenge in literature on respite care and in wider literature on documentation and safe and effective handover practices [20] [21] [22] [23] .", [["[20] [21] [22] [23]", "SIMPLE_CHEMICAL", 291, 310], ["respite care", "TREATMENT", 195, 207]]], ["Given the variety of statutory agencies, and the reliance on NGOs, in the care of these children, there is the potential of misinterpretation or miscommunication of information.DiscussionA further challenge to enhanced integrated care is the current state of advocacy.", [["children", "ORGANISM", 88, 96], ["children", "SPECIES", 88, 96]]], ["While the majority of countries reported the involvement of the family in the development of the plan of care prior to discharge, few countries take into account the voice of the families in the development of policies or national frameworks for care delivery to these children.", [["children", "ORGANISM", 269, 277], ["children", "SPECIES", 269, 277], ["care delivery", "TREATMENT", 246, 259]]], ["Given the well-documented complexities involved in adapting to the role of the primary care giver for parents, the inclusion of the voices of these families has the opportunity to positively influence care delivery.", [["care delivery", "TREATMENT", 201, 214]]], ["There is evidence in wider literature on the care of children with CCNs that there are numerous and varied characteristics of a family that need to be understood to support family preparedness for discharge to home that goes well beyond clinical readiness to care.", [["CCNs", "DISEASE", 67, 71], ["children", "ORGANISM", 53, 61], ["children", "SPECIES", 53, 61], ["wider", "OBSERVATION_MODIFIER", 21, 26]]], ["This includes issues relating to language, culture, race and ethnicity [24] [25] [26] , family structures and support systems [27] [28] [29] and capacity for coping [30] [31] [32] .", [["culture", "TEST", 43, 50]]], ["The fact that the majority of countries do not currently collect data on the experience of care from the perspective of the parents/guardians or siblings of children assisted with LTV, suggests a persistent paternalistic health service with a limited appetite for identifying and addressing the real needs of the child and family.", [["children", "ORGANISM", 157, 165], ["child", "ORGANISM", 313, 318], ["children", "SPECIES", 157, 165], ["LTV", "TREATMENT", 180, 183]]], ["Understanding these experiences is important to identify specific ways that integration of care can be enhanced in a meaningful way.DiscussionThere is great complexity in measuring the structures and processes of complex care across 30 countries.", [["great", "OBSERVATION_MODIFIER", 151, 156], ["complexity", "OBSERVATION_MODIFIER", 157, 167]]], ["We urge caution when interpreting the data as it is always possible that some of the findings might have reflected general issues on LTV as opposed to commentary on the specific scenario presented.", [["general issues", "PROBLEM", 115, 129], ["LTV", "TREATMENT", 133, 136]]], ["Nonetheless, we consider that we received rich contextual data from the CAs, as we relied on a large number of respondents, across a large number of culturally diverse countries.", [["large", "OBSERVATION_MODIFIER", 133, 138]]], ["The perspective of children and families was not included in this part of the MOCHA project and it would be important to include this perspective in further work in this area.ConclusionsThe growing trajectory of children assisted with LTV in the home places great challenges on healthcare delivery.", [["children", "ORGANISM", 19, 27], ["children", "ORGANISM", 212, 220], ["children", "SPECIES", 19, 27], ["children", "SPECIES", 212, 220], ["LTV", "TREATMENT", 235, 238], ["healthcare delivery", "TREATMENT", 278, 297], ["growing", "OBSERVATION_MODIFIER", 190, 197], ["trajectory", "OBSERVATION_MODIFIER", 198, 208]]], ["However, prior to the MOCHA project little was known about the key constituents for effective integration of care for these children and their families.", [["children", "ORGANISM", 124, 132], ["children", "SPECIES", 124, 132]]], ["This study has begun to address this knowledge deficit.", [["This study", "TEST", 0, 10], ["this knowledge deficit", "PROBLEM", 32, 54]]], ["There are clear challenges for health services to adapt to the changing profile of the needs of the child and the family.", [["health services", "TREATMENT", 31, 46], ["clear", "OBSERVATION_MODIFIER", 10, 15]]], ["While the clinical care in the acute sector has received considerable attention the findings in this study highlight the need for an enhanced focus on the care required following discharge to the community setting and a commitment to supporting care delivery that acknowledges the complexity of contemporary child health issues and the context of the families that become their primary care givers.", [["this study", "TEST", 96, 106], ["care delivery", "TREATMENT", 245, 258]]]], "PMC7377653": [["IntroductionAcute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in critically ill patients and is defined by the acute onset of non-cardiogenic pulmonary edema, hypoxemia, and the need for mechanical ventilation [1-4].", [["respiratory", "ANATOMY", 76, 87], ["pulmonary", "ANATOMY", 176, 185], ["IntroductionAcute respiratory distress syndrome", "DISEASE", 0, 47], ["ARDS", "DISEASE", 49, 53], ["respiratory failure", "DISEASE", 76, 95], ["critically ill", "DISEASE", 99, 113], ["non-cardiogenic pulmonary edema", "DISEASE", 160, 191], ["hypoxemia", "DISEASE", 193, 202], ["patients", "ORGANISM", 114, 122], ["pulmonary", "ORGAN", 176, 185], ["patients", "SPECIES", 114, 122], ["IntroductionAcute respiratory distress syndrome", "PROBLEM", 0, 47], ["ARDS", "PROBLEM", 49, 53], ["respiratory failure", "PROBLEM", 76, 95], ["non-cardiogenic pulmonary edema", "PROBLEM", 160, 191], ["hypoxemia", "PROBLEM", 193, 202], ["mechanical ventilation", "TREATMENT", 221, 243], ["respiratory distress", "OBSERVATION", 18, 38], ["respiratory", "ANATOMY", 76, 87], ["failure", "OBSERVATION", 88, 95], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["non-cardiogenic", "OBSERVATION_MODIFIER", 160, 175], ["pulmonary", "ANATOMY", 176, 185], ["edema", "OBSERVATION", 186, 191], ["hypoxemia", "OBSERVATION", 193, 202]]], ["The pathology of ARDS is diffuse alveolar damage, such as the rapid development of capillary congestion, atelectasis, intraalveolar hemorrhaging, and alveolar edema, followed days later by hyaline-membrane formation, epithelial-cell hyperplasia, and interstitial edema [3].", [["alveolar", "ANATOMY", 33, 41], ["capillary", "ANATOMY", 83, 92], ["intraalveolar", "ANATOMY", 118, 131], ["alveolar edema", "ANATOMY", 150, 164], ["hyaline-membrane", "ANATOMY", 189, 205], ["epithelial-cell", "ANATOMY", 217, 232], ["interstitial edema", "ANATOMY", 250, 268], ["ARDS", "DISEASE", 17, 21], ["alveolar damage", "DISEASE", 33, 48], ["capillary congestion", "DISEASE", 83, 103], ["atelectasis", "DISEASE", 105, 116], ["intraalveolar hemorrhaging", "DISEASE", 118, 144], ["alveolar edema", "DISEASE", 150, 164], ["epithelial-cell hyperplasia", "DISEASE", 217, 244], ["interstitial edema", "DISEASE", 250, 268], ["alveolar", "TISSUE", 33, 41], ["capillary", "TISSUE", 83, 92], ["alveolar edema", "PATHOLOGICAL_FORMATION", 150, 164], ["hyaline-membrane", "CELLULAR_COMPONENT", 189, 205], ["epithelial-cell", "CELL", 217, 232], ["ARDS", "PROBLEM", 17, 21], ["diffuse alveolar damage", "PROBLEM", 25, 48], ["capillary congestion", "PROBLEM", 83, 103], ["atelectasis", "PROBLEM", 105, 116], ["intraalveolar hemorrhaging", "PROBLEM", 118, 144], ["alveolar edema", "PROBLEM", 150, 164], ["epithelial-cell hyperplasia", "PROBLEM", 217, 244], ["interstitial edema", "PROBLEM", 250, 268], ["ARDS", "OBSERVATION", 17, 21], ["diffuse", "OBSERVATION_MODIFIER", 25, 32], ["alveolar damage", "OBSERVATION", 33, 48], ["rapid", "OBSERVATION_MODIFIER", 62, 67], ["capillary", "OBSERVATION_MODIFIER", 83, 92], ["congestion", "OBSERVATION", 93, 103], ["atelectasis", "OBSERVATION", 105, 116], ["intraalveolar", "ANATOMY_MODIFIER", 118, 131], ["hemorrhaging", "OBSERVATION", 132, 144], ["alveolar", "ANATOMY_MODIFIER", 150, 158], ["edema", "OBSERVATION", 159, 164], ["hyaline", "OBSERVATION_MODIFIER", 189, 196], ["membrane formation", "OBSERVATION", 197, 215], ["epithelial", "ANATOMY_MODIFIER", 217, 227], ["cell hyperplasia", "OBSERVATION", 228, 244], ["interstitial", "ANATOMY_MODIFIER", 250, 262], ["edema", "OBSERVATION", 263, 268]]], ["ARDS occurs most often in the setting of pneumonia, sepsis, aspiration of gastric contents, or severe trauma and is present in roughly 10% of all patients in intensive-care units worldwide [4].", [["gastric", "ANATOMY", 74, 81], ["ARDS", "DISEASE", 0, 4], ["pneumonia", "DISEASE", 41, 50], ["sepsis", "DISEASE", 52, 58], ["aspiration of gastric contents", "DISEASE", 60, 90], ["trauma", "DISEASE", 102, 108], ["gastric", "ORGAN", 74, 81], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["ARDS", "PROBLEM", 0, 4], ["pneumonia", "PROBLEM", 41, 50], ["sepsis", "PROBLEM", 52, 58], ["aspiration of gastric contents", "PROBLEM", 60, 90], ["severe trauma", "PROBLEM", 95, 108], ["most often", "OBSERVATION_MODIFIER", 12, 22], ["pneumonia", "OBSERVATION", 41, 50], ["sepsis", "OBSERVATION", 52, 58], ["aspiration", "OBSERVATION", 60, 70], ["gastric", "ANATOMY", 74, 81], ["contents", "OBSERVATION", 82, 90], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["trauma", "OBSERVATION", 102, 108]]], ["Although much progress has been made in improving supportive care for ARDS, effective pharmacological therapies have not yet been identified, and mortality remains high at 30%-40% in most studies [4].IntroductionWe report a case of suspected virus-inducing severe ARDS treated by multimodal therapy including extracorporeal membrane oxygenation (ECMO) and immune modulation therapy that led to a favorable outcome for the patient.Case presentationA 44-year-old man felt generalized fatigue and took the day off from work.", [["extracorporeal membrane", "ANATOMY", 309, 332], ["ARDS", "DISEASE", 70, 74], ["ARDS", "DISEASE", 264, 268], ["fatigue", "DISEASE", 482, 489], ["patient", "ORGANISM", 422, 429], ["man", "ORGANISM", 461, 464], ["patient", "SPECIES", 422, 429], ["man", "SPECIES", 461, 464], ["ARDS", "PROBLEM", 70, 74], ["effective pharmacological therapies", "TREATMENT", 76, 111], ["mortality", "TEST", 146, 155], ["suspected virus", "PROBLEM", 232, 247], ["severe ARDS", "PROBLEM", 257, 268], ["multimodal therapy", "TREATMENT", 280, 298], ["extracorporeal membrane oxygenation", "TREATMENT", 309, 344], ["ECMO", "TREATMENT", 346, 350], ["immune modulation therapy", "TREATMENT", 356, 381], ["generalized fatigue", "PROBLEM", 470, 489], ["severe", "OBSERVATION_MODIFIER", 257, 263], ["ARDS", "OBSERVATION", 264, 268], ["generalized", "OBSERVATION_MODIFIER", 470, 481], ["fatigue", "OBSERVATION", 482, 489]]], ["When the son visited his house, he found the patient unconscious and called an ambulance.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52]]], ["He had no remarkable medical history.", [["no", "UNCERTAINTY", 7, 9], ["remarkable", "OBSERVATION_MODIFIER", 10, 20]]], ["He was a never\u2010smoker and drank 20 g of ethanol per day.", [["ethanol", "CHEMICAL", 40, 47], ["ethanol", "CHEMICAL", 40, 47], ["He", "ORGANISM", 0, 2], ["ethanol", "SIMPLE_CHEMICAL", 40, 47]]], ["His work zone was not located in any of the districts that were reported to have COVID-19 infections.Case presentationWhen the emergency medical technicians checked him, he had a tonic convulsive posture with severe hypoxia, and he was transported to our hospital under bag-valve-mask ventilation with high-concentration oxygen.", [["infections", "DISEASE", 90, 100], ["convulsive", "DISEASE", 185, 195], ["hypoxia", "DISEASE", 216, 223], ["oxygen", "CHEMICAL", 321, 327], ["oxygen", "CHEMICAL", 321, 327], ["oxygen", "SIMPLE_CHEMICAL", 321, 327], ["His work zone", "PROBLEM", 0, 13], ["COVID-19 infections", "PROBLEM", 81, 100], ["a tonic convulsive posture", "PROBLEM", 177, 203], ["severe hypoxia", "PROBLEM", 209, 223], ["bag-valve", "TREATMENT", 270, 279], ["mask ventilation", "TREATMENT", 280, 296], ["high-concentration oxygen", "TREATMENT", 302, 327], ["infections", "OBSERVATION", 90, 100], ["severe", "OBSERVATION_MODIFIER", 209, 215], ["hypoxia", "OBSERVATION", 216, 223], ["valve", "ANATOMY", 274, 279]]], ["On arrival, his Glasgow Coma Scale was E1V2M3.", [["Coma", "DISEASE", 24, 28], ["his Glasgow Coma Scale", "TEST", 12, 34]]], ["A physical examination revealed the following findings: blood pressure of 174/130 mmHg; heart rate of 140 beats per minute; a respiratory rate of 30 breaths per minute; SpO2 of 75% under room 15 L per minute of oxygen; and body temperature of 36.9 \u00b0C. A venous route was immediately secured, followed by endotracheal intubation.Case presentationAn arterial gas analysis revealed the following findings: pH: 7.092; PCO2: 54.2 mmHg; PO2: 54.5 mmHg; base excess -15.0 mmol/L; and lactate: 6 mmol/L. Electrocardiography revealed sinus tachycardia.", [["blood", "ANATOMY", 56, 61], ["heart", "ANATOMY", 88, 93], ["respiratory", "ANATOMY", 126, 137], ["body", "ANATOMY", 223, 227], ["venous", "ANATOMY", 254, 260], ["endotracheal", "ANATOMY", 304, 316], ["arterial", "ANATOMY", 348, 356], ["sinus", "ANATOMY", 525, 530], ["oxygen", "CHEMICAL", 211, 217], ["PO2", "CHEMICAL", 431, 434], ["lactate", "CHEMICAL", 477, 484], ["sinus tachycardia", "DISEASE", 525, 542], ["oxygen", "CHEMICAL", 211, 217], ["lactate", "CHEMICAL", 477, 484], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["heart", "ORGAN", 88, 93], ["oxygen", "SIMPLE_CHEMICAL", 211, 217], ["body", "ORGANISM_SUBDIVISION", 223, 227], ["venous route", "MULTI-TISSUE_STRUCTURE", 254, 266], ["arterial", "MULTI-TISSUE_STRUCTURE", 348, 356], ["lactate", "SIMPLE_CHEMICAL", 477, 484], ["A physical examination", "TEST", 0, 22], ["blood pressure", "TEST", 56, 70], ["heart rate", "TEST", 88, 98], ["a respiratory rate", "TEST", 124, 142], ["SpO2", "TEST", 169, 173], ["oxygen", "TREATMENT", 211, 217], ["body temperature", "TEST", 223, 239], ["A venous route", "TREATMENT", 252, 266], ["endotracheal intubation", "TREATMENT", 304, 327], ["Case presentationAn arterial gas analysis", "TEST", 328, 369], ["pH", "TEST", 403, 405], ["PCO2", "TEST", 414, 418], ["mmHg", "TEST", 425, 429], ["PO2", "TEST", 431, 434], ["mmHg", "TEST", 441, 445], ["base excess", "TEST", 447, 458], ["mmol/L", "TEST", 465, 471], ["lactate", "TEST", 477, 484], ["Electrocardiography", "TEST", 496, 515], ["sinus tachycardia", "PROBLEM", 525, 542], ["venous", "ANATOMY", 254, 260], ["endotracheal intubation", "OBSERVATION", 304, 327], ["sinus", "ANATOMY", 525, 530], ["tachycardia", "OBSERVATION", 531, 542]]], ["A chest X-ray revealed a bilateral ground-glass appearance (Figure 1).Case presentationCardiac echo showed hyper-dynamic left-ventricular wall motion.", [["chest", "ANATOMY", 2, 7], ["Cardiac", "ANATOMY", 87, 94], ["left-ventricular wall", "ANATOMY", 121, 142], ["ventricular wall", "MULTI-TISSUE_STRUCTURE", 126, 142], ["A chest X-ray", "TEST", 0, 13], ["a bilateral ground-glass appearance", "PROBLEM", 23, 58], ["Cardiac echo", "TEST", 87, 99], ["chest", "ANATOMY", 2, 7], ["bilateral", "ANATOMY_MODIFIER", 25, 34], ["ground", "OBSERVATION", 35, 41], ["glass appearance", "OBSERVATION", 42, 58], ["hyper", "OBSERVATION", 107, 112], ["left", "ANATOMY_MODIFIER", 121, 125], ["-ventricular", "ANATOMY", 125, 137], ["wall", "ANATOMY_MODIFIER", 138, 142], ["motion", "OBSERVATION", 143, 149]]], ["Whole-body CT revealed a bilateral ground-glass appearance in the ventral lung fields and bilateral consolidation in the dorsal lung fields (Figure 2).Case presentationThe pancreas was normal.", [["ventral lung", "ANATOMY", 66, 78], ["dorsal lung", "ANATOMY", 121, 132], ["pancreas", "ANATOMY", 172, 180], ["lung", "ORGAN", 74, 78], ["lung", "ORGAN", 128, 132], ["pancreas", "ORGAN", 172, 180], ["Whole-body CT", "TEST", 0, 13], ["a bilateral ground-glass appearance in the ventral lung fields", "PROBLEM", 23, 85], ["bilateral consolidation in the dorsal lung fields", "PROBLEM", 90, 139], ["bilateral", "ANATOMY_MODIFIER", 25, 34], ["ground-glass appearance", "OBSERVATION", 35, 58], ["ventral", "ANATOMY_MODIFIER", 66, 73], ["lung", "ANATOMY", 74, 78], ["fields", "ANATOMY_MODIFIER", 79, 85], ["bilateral", "ANATOMY_MODIFIER", 90, 99], ["consolidation", "OBSERVATION", 100, 113], ["dorsal", "ANATOMY_MODIFIER", 121, 127], ["lung", "ANATOMY", 128, 132], ["fields", "ANATOMY_MODIFIER", 133, 139], ["pancreas", "ANATOMY", 172, 180], ["normal", "OBSERVATION", 185, 191]]], ["The main results of a blood analysis were as follows: WBC count: 23,400/\u03bcL (neutrophil 87%, lymphocyte 6%, monocyte 6%); hemoglobin: 16.5 g/dL; platelet count: 22.0\u00d7104/\u03bcL; total protein: 7.0 g/dL; albumin: 4.3 g/dL; glucose: 177 mg/dL; HbA1C: 5.5%; total bilirubin: 1.5 mg/dL; aspartate aminotransferase: 322 IU/L; alanine aminotransferase: 79 IU/L; lactate dehydrogenase: 1,108 IU/L; blood urea nitrogen: 7.4 mg/dL; creatinine: 0.51 mg/dL; amylase: 413 (pancreas 76%) IU/L; creatine phosphokinase (CK): 44,139 IU/L; sodium: 110 mEq/L; potassium: 4.2 mEq/L; chloride: 79 mEq/L; brain natriuretic peptide: 760.1 pg/mL; C-reactive protein: 22.2 mg/dL: prothrombin time international normalized ratio: 1.02; activated partial thromboplastin time: 34.6 (26.6) seconds; fibrinogen: 242 mg/dL; D-dimer: 1.5 \u03bcg/mL; human immunodeficiency virus (HIV) antibody: negative; pneumococcal urinary antigen test: negative; legionella urinary antigen test: negative; rapid influenza diagnostic test: negative; microscopic finding of sputum: negative: and urine drug screening test: negative.", [["blood", "ANATOMY", 22, 27], ["WBC", "ANATOMY", 54, 57], ["neutrophil", "ANATOMY", 76, 86], ["lymphocyte", "ANATOMY", 92, 102], ["monocyte", "ANATOMY", 107, 115], ["platelet", "ANATOMY", 144, 152], ["blood", "ANATOMY", 386, 391], ["pancreas", "ANATOMY", 456, 464], ["brain", "ANATOMY", 579, 584], ["urinary", "ANATOMY", 877, 884], ["urinary", "ANATOMY", 920, 927], ["sputum", "ANATOMY", 1018, 1024], ["urine", "ANATOMY", 1040, 1045], ["glucose", "CHEMICAL", 217, 224], ["bilirubin", "CHEMICAL", 256, 265], ["aspartate", "CHEMICAL", 278, 287], ["alanine", "CHEMICAL", 316, 323], ["lactate", "CHEMICAL", 351, 358], ["blood urea nitrogen", "CHEMICAL", 386, 405], ["creatinine", "CHEMICAL", 418, 428], ["creatine", "CHEMICAL", 476, 484], ["sodium", "CHEMICAL", 518, 524], ["potassium", "CHEMICAL", 537, 546], ["human immunodeficiency virus", "DISEASE", 809, 837], ["glucose", "CHEMICAL", 217, 224], ["bilirubin", "CHEMICAL", 256, 265], ["aspartate", "CHEMICAL", 278, 287], ["alanine", "CHEMICAL", 316, 323], ["lactate", "CHEMICAL", 351, 358], ["urea", "CHEMICAL", 392, 396], ["nitrogen", "CHEMICAL", 397, 405], ["creatinine", "CHEMICAL", 418, 428], ["creatine", "CHEMICAL", 476, 484], ["sodium", "CHEMICAL", 518, 524], ["potassium", "CHEMICAL", 537, 546], ["chloride", "CHEMICAL", 559, 567], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["WBC", "CELL", 54, 57], ["neutrophil", "CELL", 76, 86], ["lymphocyte", "CELL", 92, 102], ["monocyte", "CELL", 107, 115], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 121, 131], ["platelet", "CELL", 144, 152], ["albumin", "GENE_OR_GENE_PRODUCT", 198, 205], ["glucose", "SIMPLE_CHEMICAL", 217, 224], ["bilirubin", "SIMPLE_CHEMICAL", 256, 265], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 278, 304], ["alanine", "AMINO_ACID", 316, 323], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 324, 340], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 351, 372], ["blood", "ORGANISM_SUBSTANCE", 386, 391], ["urea", "SIMPLE_CHEMICAL", 392, 396], ["creatinine", "SIMPLE_CHEMICAL", 418, 428], ["amylase", "GENE_OR_GENE_PRODUCT", 442, 449], ["pancreas", "ORGAN", 456, 464], ["creatine phosphokinase", "GENE_OR_GENE_PRODUCT", 476, 498], ["CK", "GENE_OR_GENE_PRODUCT", 500, 502], ["sodium", "SIMPLE_CHEMICAL", 518, 524], ["potassium", "SIMPLE_CHEMICAL", 537, 546], ["chloride", "SIMPLE_CHEMICAL", 559, 567], ["brain", "ORGAN", 579, 584], ["prothrombin", "GENE_OR_GENE_PRODUCT", 651, 662], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 724, 738], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 766, 776], ["D-dimer", "SIMPLE_CHEMICAL", 789, 796], ["human immunodeficiency virus", "ORGANISM", 809, 837], ["HIV", "ORGANISM", 839, 842], ["pneumococcal urinary antigen", "GENE_OR_GENE_PRODUCT", 864, 892], ["legionella urinary antigen", "GENE_OR_GENE_PRODUCT", 909, 935], ["sputum", "ORGANISM_SUBSTANCE", 1018, 1024], ["urine", "ORGANISM_SUBSTANCE", 1040, 1045], ["neutrophil", "CELL_TYPE", 76, 86], ["lymphocyte", "CELL_TYPE", 92, 102], ["hemoglobin", "PROTEIN", 121, 131], ["total protein", "PROTEIN", 173, 186], ["albumin", "PROTEIN", 198, 205], ["aspartate aminotransferase", "PROTEIN", 278, 304], ["alanine aminotransferase", "PROTEIN", 316, 340], ["lactate dehydrogenase", "PROTEIN", 351, 372], ["creatine phosphokinase", "PROTEIN", 476, 498], ["CK", "PROTEIN", 500, 502], ["C-reactive protein", "PROTEIN", 619, 637], ["prothrombin", "PROTEIN", 651, 662], ["fibrinogen", "PROTEIN", 766, 776], ["human", "SPECIES", 809, 814], ["immunodeficiency virus", "SPECIES", 815, 837], ["human immunodeficiency virus", "SPECIES", 809, 837], ["HIV", "SPECIES", 839, 842], ["pneumococcal", "SPECIES", 864, 876], ["a blood analysis", "TEST", 20, 36], ["WBC count", "TEST", 54, 63], ["\u03bcL", "TEST", 72, 74], ["neutrophil", "TEST", 76, 86], ["lymphocyte", "TEST", 92, 102], ["monocyte", "TEST", 107, 115], ["hemoglobin", "TEST", 121, 131], ["dL", "TEST", 140, 142], ["platelet count", "TEST", 144, 158], ["total protein", "TEST", 173, 186], ["dL", "TEST", 194, 196], ["albumin", "TEST", 198, 205], ["dL", "TEST", 213, 215], ["glucose", "TEST", 217, 224], ["HbA1C", "TEST", 237, 242], ["total bilirubin", "TEST", 250, 265], ["aspartate aminotransferase", "TEST", 278, 304], ["IU/L", "TEST", 310, 314], ["alanine aminotransferase", "TEST", 316, 340], ["IU/L", "TEST", 345, 349], ["lactate dehydrogenase", "TEST", 351, 372], ["IU", "TEST", 380, 382], ["blood urea nitrogen", "TEST", 386, 405], ["mg/dL", "TEST", 411, 416], ["creatinine", "TEST", 418, 428], ["amylase", "TEST", 442, 449], ["pancreas", "TEST", 456, 464], ["IU/L", "TEST", 470, 474], ["creatine phosphokinase", "TEST", 476, 498], ["CK", "TEST", 500, 502], ["IU", "TEST", 512, 514], ["sodium", "TEST", 518, 524], ["mEq", "TEST", 530, 533], ["potassium", "TEST", 537, 546], ["mEq", "TEST", 552, 555], ["chloride", "TEST", 559, 567], ["brain natriuretic peptide", "TEST", 579, 604], ["C-reactive protein", "TEST", 619, 637], ["prothrombin time", "TEST", 651, 667], ["ratio", "TEST", 693, 698], ["activated partial thromboplastin time", "TEST", 706, 743], ["fibrinogen", "TEST", 766, 776], ["mg/dL", "TEST", 782, 787], ["D-dimer", "TEST", 789, 796], ["\u03bcg", "TEST", 802, 804], ["human immunodeficiency virus", "TEST", 809, 837], ["HIV) antibody", "TEST", 839, 852], ["pneumococcal urinary antigen test", "TEST", 864, 897], ["legionella urinary antigen test", "TEST", 909, 940], ["rapid influenza diagnostic test", "TEST", 952, 983], ["sputum", "TEST", 1018, 1024], ["urine drug screening test", "TEST", 1040, 1065], ["main", "OBSERVATION_MODIFIER", 4, 8], ["pancreas", "ANATOMY", 456, 464], ["urinary", "ANATOMY", 877, 884], ["urinary", "ANATOMY", 920, 927]]], ["Later, \u03b2-d glucan, rheumatoid factor, and anti-neutrophil cytoplasmic antibody were all found to be negative.", [["\u03b2-d glucan", "CHEMICAL", 7, 17], ["\u03b2-d glucan", "GENE_OR_GENE_PRODUCT", 7, 17], ["rheumatoid factor", "GENE_OR_GENE_PRODUCT", 19, 36], ["anti-neutrophil cytoplasmic antibody", "GENE_OR_GENE_PRODUCT", 42, 78], ["\u03b2-d glucan", "PROTEIN", 7, 17], ["rheumatoid factor", "PROTEIN", 19, 36], ["anti-neutrophil cytoplasmic antibody", "PROTEIN", 42, 78], ["\u03b2-d glucan", "TEST", 7, 17], ["rheumatoid factor", "TEST", 19, 36], ["anti-neutrophil cytoplasmic antibody", "TEST", 42, 78], ["rheumatoid", "ANATOMY", 19, 29], ["negative", "OBSERVATION", 100, 108]]], ["He received a tentative diagnosis of pneumonia of unknown causes accompanying severe ARDS, rhabdomyolysis, and pancreatitis.Case presentationAs he showed deterioration of PaO2 [PaO2/FiO2 (P/F) = 50] and a Murray score of 3.2, he underwent mechanical ventilation under 1.0 FiO2 and 10 cmH2O with positive end-expiratory pressure (PEEP) and received indwelling venovenous ECMO (MERA centrifugal blood pump system HAS\u2010CFP; MERA NHP exelung NSH\u2010R HPO\u201023WH\u2010C; Senko Medical Instruments, Tokyo, Japan) with the right jugular vein (return side, 14 Fr) and right femoral vein (drainage side, 20 Fr) as the exit.", [["blood", "ANATOMY", 393, 398], ["right jugular vein", "ANATOMY", 505, 523], ["right femoral vein", "ANATOMY", 549, 567], ["pneumonia", "DISEASE", 37, 46], ["ARDS", "DISEASE", 85, 89], ["rhabdomyolysis", "DISEASE", 91, 105], ["pancreatitis", "DISEASE", 111, 123], ["blood", "ORGANISM_SUBSTANCE", 393, 398], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 511, 523], ["femoral vein", "MULTI-TISSUE_STRUCTURE", 555, 567], ["pneumonia", "PROBLEM", 37, 46], ["severe ARDS", "PROBLEM", 78, 89], ["rhabdomyolysis", "PROBLEM", 91, 105], ["pancreatitis", "PROBLEM", 111, 123], ["PaO2", "TEST", 171, 175], ["PaO2", "TEST", 177, 181], ["FiO2", "TEST", 182, 186], ["a Murray score", "TEST", 203, 217], ["mechanical ventilation", "TREATMENT", 239, 261], ["1.0 FiO2", "TREATMENT", 268, 276], ["positive end-expiratory pressure", "TREATMENT", 295, 327], ["PEEP", "TREATMENT", 329, 333], ["indwelling venovenous ECMO", "TREATMENT", 348, 374], ["MERA centrifugal blood pump system", "TREATMENT", 376, 410], ["right femoral vein (drainage side", "TREATMENT", 549, 582], ["pneumonia", "OBSERVATION", 37, 46], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["ARDS", "OBSERVATION", 85, 89], ["rhabdomyolysis", "OBSERVATION", 91, 105], ["pancreatitis", "OBSERVATION", 111, 123], ["right", "ANATOMY_MODIFIER", 505, 510], ["jugular vein", "ANATOMY", 511, 523], ["right", "ANATOMY_MODIFIER", 549, 554], ["femoral vein", "ANATOMY", 555, 567], ["drainage", "OBSERVATION", 569, 577]]], ["As this event occurred during the night shift, we did not attempt supine therapy before introducing venovenous ECMO.", [["supine therapy", "TREATMENT", 66, 80], ["venovenous ECMO", "TREATMENT", 100, 115]]], ["He also showed hypotension and therefore underwent infusion of noradrenalin followed by vasopressin and 200 mg of hydrocortisone.", [["hypotension", "DISEASE", 15, 26], ["noradrenalin", "CHEMICAL", 63, 75], ["vasopressin", "CHEMICAL", 88, 99], ["hydrocortisone", "CHEMICAL", 114, 128], ["noradrenalin", "CHEMICAL", 63, 75], ["hydrocortisone", "CHEMICAL", 114, 128], ["He", "ORGANISM", 0, 2], ["noradrenalin", "SIMPLE_CHEMICAL", 63, 75], ["vasopressin", "SIMPLE_CHEMICAL", 88, 99], ["hydrocortisone", "SIMPLE_CHEMICAL", 114, 128], ["hypotension", "PROBLEM", 15, 26], ["noradrenalin", "TREATMENT", 63, 75], ["vasopressin", "TREATMENT", 88, 99], ["hydrocortisone", "TREATMENT", 114, 128], ["hypotension", "OBSERVATION", 15, 26]]], ["Due to concerns of pneumonia, he received 1.5 g of meropenem and 500 mg of azithromycin in addition to an infusion of 5 g of \u03b3-globulin and 40 ml of glycyrrhizin as antibacterial and antivirus treatments respectively.Case presentationAfter the induction of ECMO, the mode of mechanical ventilation was changed to a lung rest setting (0.25 FiO2 and 5 cmH2O with PEEP).", [["lung", "ANATOMY", 315, 319], ["pneumonia", "DISEASE", 19, 28], ["meropenem", "CHEMICAL", 51, 60], ["azithromycin", "CHEMICAL", 75, 87], ["\u03b3-globulin", "CHEMICAL", 125, 135], ["glycyrrhizin", "CHEMICAL", 149, 161], ["meropenem", "CHEMICAL", 51, 60], ["azithromycin", "CHEMICAL", 75, 87], ["\u03b3-globulin", "CHEMICAL", 125, 135], ["glycyrrhizin", "CHEMICAL", 149, 161], ["meropenem", "SIMPLE_CHEMICAL", 51, 60], ["azithromycin", "SIMPLE_CHEMICAL", 75, 87], ["\u03b3-globulin", "SIMPLE_CHEMICAL", 125, 135], ["glycyrrhizin", "SIMPLE_CHEMICAL", 149, 161], ["antivirus", "SIMPLE_CHEMICAL", 183, 192], ["lung", "ORGAN", 315, 319], ["pneumonia", "PROBLEM", 19, 28], ["meropenem", "TREATMENT", 51, 60], ["azithromycin", "TREATMENT", 75, 87], ["an infusion", "TREATMENT", 103, 114], ["\u03b3-globulin", "TREATMENT", 125, 135], ["glycyrrhizin", "TREATMENT", 149, 161], ["antibacterial", "TREATMENT", 165, 178], ["antivirus treatments", "TREATMENT", 183, 203], ["ECMO", "TREATMENT", 257, 261], ["mechanical ventilation", "TREATMENT", 275, 297], ["a lung rest setting", "TREATMENT", 313, 332], ["FiO2", "TREATMENT", 339, 343], ["PEEP", "TREATMENT", 361, 365], ["pneumonia", "OBSERVATION", 19, 28], ["mechanical ventilation", "OBSERVATION", 275, 297], ["lung", "ANATOMY", 315, 319]]], ["Additional cardiac echo showed diffuse hypokinesis with a 30% ejection fraction, and troponin T became positive [207 pg/mL (normal range: <14 pg/mL)] on the first hospital day, and so he was diagnosed with myocarditis as a complication.", [["cardiac", "ANATOMY", 11, 18], ["hypokinesis", "DISEASE", 39, 50], ["myocarditis", "DISEASE", 206, 217], ["cardiac", "ORGAN", 11, 18], ["troponin T", "GENE_OR_GENE_PRODUCT", 85, 95], ["troponin T", "PROTEIN", 85, 95], ["Additional cardiac echo", "TEST", 0, 23], ["diffuse hypokinesis", "PROBLEM", 31, 50], ["troponin T", "TEST", 85, 95], ["myocarditis", "PROBLEM", 206, 217], ["a complication", "PROBLEM", 221, 235], ["cardiac", "ANATOMY", 11, 18], ["diffuse", "OBSERVATION_MODIFIER", 31, 38], ["hypokinesis", "OBSERVATION", 39, 50], ["myocarditis", "OBSERVATION", 206, 217]]], ["On the second day, his blood pressure increased, resulting in a reduction in the vasopressor administration.", [["blood", "ANATOMY", 23, 28], ["blood", "ORGANISM_SUBSTANCE", 23, 28], ["his blood pressure", "TEST", 19, 37], ["a reduction", "TREATMENT", 62, 73], ["the vasopressor administration", "TREATMENT", 77, 107], ["pressure", "OBSERVATION_MODIFIER", 29, 37], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["reduction", "OBSERVATION_MODIFIER", 64, 73], ["vasopressor administration", "OBSERVATION", 81, 107]]], ["His P/F remained under 100.", [["P", "DNA", 4, 5], ["His P/F", "TEST", 0, 7]]], ["On the third day, inflammatory data remained high, and hence azithromycin was replaced with levofloxacin.", [["azithromycin", "CHEMICAL", 61, 73], ["levofloxacin", "CHEMICAL", 92, 104], ["azithromycin", "CHEMICAL", 61, 73], ["levofloxacin", "CHEMICAL", 92, 104], ["azithromycin", "SIMPLE_CHEMICAL", 61, 73], ["levofloxacin", "SIMPLE_CHEMICAL", 92, 104], ["inflammatory data", "TEST", 18, 35], ["azithromycin", "TREATMENT", 61, 73], ["levofloxacin", "TREATMENT", 92, 104], ["inflammatory", "OBSERVATION", 18, 30], ["high", "OBSERVATION", 45, 49]]], ["However, this led to skin reddening and he was switched back to azithromycin.", [["skin", "ANATOMY", 21, 25], ["azithromycin", "CHEMICAL", 64, 76], ["azithromycin", "CHEMICAL", 64, 76], ["skin", "ORGAN", 21, 25], ["azithromycin", "SIMPLE_CHEMICAL", 64, 76], ["skin reddening", "PROBLEM", 21, 35], ["azithromycin", "TREATMENT", 64, 76], ["skin", "ANATOMY", 21, 25], ["reddening", "OBSERVATION", 26, 35]]], ["A complication of anemia, thrombocytopenia, and coagulopathy required blood transfusion.", [["blood", "ANATOMY", 70, 75], ["anemia", "DISEASE", 18, 24], ["thrombocytopenia", "DISEASE", 26, 42], ["coagulopathy", "DISEASE", 48, 60], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["A complication of anemia", "PROBLEM", 0, 24], ["thrombocytopenia", "PROBLEM", 26, 42], ["coagulopathy", "PROBLEM", 48, 60], ["blood transfusion", "TREATMENT", 70, 87], ["complication", "OBSERVATION", 2, 14], ["anemia", "OBSERVATION", 18, 24], ["thrombocytopenia", "OBSERVATION", 26, 42], ["coagulopathy", "OBSERVATION", 48, 60], ["blood transfusion", "OBSERVATION", 70, 87]]], ["A polymerase chain reaction (PCR) test for COVID-19 using sputum through the endotracheal tube without bronchoalveolar lavage (performed twice) and initial cultures of sputum, urine, and blood were all negative.Case presentationOn the fifth day, the inflammatory data remained moderate, and hence meropenem was replaced with linezolid and piperacillin/tazobactam.", [["sputum", "ANATOMY", 58, 64], ["endotracheal tube", "ANATOMY", 77, 94], ["bronchoalveolar lavage", "ANATOMY", 103, 125], ["sputum", "ANATOMY", 168, 174], ["urine", "ANATOMY", 176, 181], ["blood", "ANATOMY", 187, 192], ["meropenem", "CHEMICAL", 297, 306], ["linezolid", "CHEMICAL", 325, 334], ["piperacillin/tazobactam", "CHEMICAL", 339, 362], ["meropenem", "CHEMICAL", 297, 306], ["linezolid", "CHEMICAL", 325, 334], ["piperacillin", "CHEMICAL", 339, 351], ["tazobactam", "CHEMICAL", 352, 362], ["sputum", "ORGANISM_SUBSTANCE", 58, 64], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 77, 94], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 103, 125], ["sputum", "ORGANISM_SUBSTANCE", 168, 174], ["urine", "ORGANISM_SUBSTANCE", 176, 181], ["blood", "ORGANISM_SUBSTANCE", 187, 192], ["meropenem", "SIMPLE_CHEMICAL", 297, 306], ["linezolid", "SIMPLE_CHEMICAL", 325, 334], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 339, 362], ["COVID-19", "DNA", 43, 51], ["A polymerase chain reaction", "PROBLEM", 0, 27], ["PCR) test", "TEST", 29, 38], ["COVID", "TEST", 43, 48], ["sputum", "TEST", 58, 64], ["the endotracheal tube", "TREATMENT", 73, 94], ["bronchoalveolar lavage", "TEST", 103, 125], ["initial cultures of sputum, urine", "TEST", 148, 181], ["blood", "TEST", 187, 192], ["the inflammatory data", "TEST", 246, 267], ["meropenem", "TREATMENT", 297, 306], ["linezolid", "TREATMENT", 325, 334], ["piperacillin", "TREATMENT", 339, 351], ["tazobactam", "TREATMENT", 352, 362], ["endotracheal tube", "OBSERVATION", 77, 94], ["without", "UNCERTAINTY", 95, 102], ["bronchoalveolar lavage", "OBSERVATION", 103, 125], ["blood", "ANATOMY", 187, 192], ["inflammatory", "OBSERVATION", 250, 262], ["moderate", "OBSERVATION_MODIFIER", 277, 285]]], ["On the same day, in an attempt to withdraw ECMO, the mechanical ventilation setting was changed from 5 to 10 cmH2O for PEEP and from 0.25 to 0.4 for FiO2.", [["FiO2", "CHEMICAL", 149, 153], ["ECMO", "TREATMENT", 43, 47], ["the mechanical ventilation setting", "TREATMENT", 49, 83], ["PEEP", "TREATMENT", 119, 123], ["FiO2", "TREATMENT", 149, 153], ["mechanical ventilation", "OBSERVATION", 53, 75]]], ["This resulted in the P/F increasing to over 100.", [["the P/F", "TEST", 17, 24]]], ["After the circulation flow of ECMO was reduced from 3 to 1 L/minute, the P/F remained over 100; hence ECMO was ceased, and the cannulations were removed (Figure 3).Case presentationAs the patient was thought to require long-term mechanical ventilation, he underwent tracheostomy on the eighth hospital day.", [["patient", "ORGANISM", 188, 195], ["patient", "SPECIES", 188, 195], ["ECMO", "TREATMENT", 30, 34], ["the P/F", "TEST", 69, 76], ["ECMO", "TREATMENT", 102, 106], ["the cannulations", "TEST", 123, 139], ["long-term mechanical ventilation", "TREATMENT", 219, 251], ["tracheostomy", "TREATMENT", 266, 278], ["circulation", "OBSERVATION_MODIFIER", 10, 21], ["flow", "OBSERVATION_MODIFIER", 22, 26], ["ECMO", "OBSERVATION", 30, 34], ["long-term mechanical", "OBSERVATION_MODIFIER", 219, 239], ["tracheostomy", "OBSERVATION", 266, 278]]], ["Sedative administration was ceased, and a negative water balance was targeted by limiting the infusion volume and the use of diuretics.", [["Sedative administration", "TREATMENT", 0, 23], ["the infusion volume", "TREATMENT", 90, 109], ["diuretics", "TREATMENT", 125, 134]]], ["He showed a transient decrease in his P/F by the formation of atelectasis due to bloody sputum; however, the average P/F improved day by day.", [["bloody sputum", "ANATOMY", 81, 94], ["atelectasis", "DISEASE", 62, 73], ["atelectasis", "PATHOLOGICAL_FORMATION", 62, 73], ["a transient decrease in his P/F", "PROBLEM", 10, 41], ["atelectasis", "PROBLEM", 62, 73], ["bloody sputum", "PROBLEM", 81, 94], ["transient", "OBSERVATION_MODIFIER", 12, 21], ["decrease", "OBSERVATION_MODIFIER", 22, 30], ["atelectasis", "OBSERVATION", 62, 73], ["bloody", "OBSERVATION_MODIFIER", 81, 87], ["sputum", "OBSERVATION", 88, 94]]], ["On the 12th hospital day, his P/F exceeded 300 under 5 cmH2O for PEEP and 0.25 FiO2; hence mechanical ventilation was ceased (Figure 4).Case presentationHe recovered his ability to excrete sputum by himself, and tracheal cannulation was removed on the 13th hospital day.", [["sputum", "ANATOMY", 189, 195], ["tracheal", "ANATOMY", 212, 220], ["FiO2", "CHEMICAL", 79, 83], ["sputum", "ORGANISM_SUBSTANCE", 189, 195], ["tracheal", "ORGAN", 212, 220], ["PEEP", "TREATMENT", 65, 69], ["FiO2", "TREATMENT", 79, 83], ["mechanical ventilation", "TREATMENT", 91, 113], ["tracheal cannulation", "TREATMENT", 212, 232], ["tracheal", "ANATOMY", 212, 220], ["cannulation", "OBSERVATION", 221, 232]]], ["Even after ceasing all drugs for lung and inflammation, his pneumonia, rhabdomyolysis, and pancreatitis did not recur.", [["lung", "ANATOMY", 33, 37], ["lung and inflammation", "DISEASE", 33, 54], ["pneumonia", "DISEASE", 60, 69], ["rhabdomyolysis", "DISEASE", 71, 85], ["pancreatitis", "DISEASE", 91, 103], ["lung", "ORGAN", 33, 37], ["all drugs", "TREATMENT", 19, 28], ["lung and inflammation", "PROBLEM", 33, 54], ["his pneumonia", "PROBLEM", 56, 69], ["rhabdomyolysis", "PROBLEM", 71, 85], ["pancreatitis", "PROBLEM", 91, 103], ["lung", "ANATOMY", 33, 37], ["inflammation", "OBSERVATION", 42, 54], ["pneumonia", "OBSERVATION", 60, 69], ["rhabdomyolysis", "OBSERVATION", 71, 85], ["pancreatitis", "OBSERVATION", 91, 103]]], ["He was discharged on the 22nd day on foot.", [["foot", "ORGANISM_SUBDIVISION", 37, 41], ["foot", "ANATOMY", 37, 41]]], ["The troponin T level remained high (334 pg/mL) even after the CK level normalized, so he was followed up as an outpatient.", [["troponin T", "GENE_OR_GENE_PRODUCT", 4, 14], ["CK", "GENE_OR_GENE_PRODUCT", 62, 64], ["CK", "PROTEIN", 62, 64], ["The troponin T level", "TEST", 0, 20], ["the CK level", "TEST", 58, 70]]], ["The serum virus neutralization assay performed as a serological test using pair serum samples with a more than two-week interval for Coxsackievirus B4 showed a four-fold increase in titer (from x64 to x256).", [["serum", "ANATOMY", 4, 9], ["serum samples", "ANATOMY", 80, 93], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["serum samples", "ORGANISM_SUBSTANCE", 80, 93], ["Coxsackievirus B4", "ORGANISM", 133, 150], ["Coxsackievirus B4", "SPECIES", 133, 150], ["The serum virus neutralization assay", "TEST", 0, 36], ["a serological test", "TEST", 50, 68], ["pair serum samples", "TEST", 75, 93], ["Coxsackievirus B4", "TEST", 133, 150], ["increase", "OBSERVATION_MODIFIER", 170, 178]]], ["Finally, the troponin T level returned to the normal range and showed no subsequent complications.DiscussionRisk factors of direct lung injury involving ARDS include pneumonia (bacterial, viral, fungal, or opportunistic), aspiration of gastric contents, pulmonary contusion, inhalation injury, and near-drowning, while those of indirect lung injury involving ARDS include sepsis (non-pulmonary source), non-thoracic trauma or hemorrhagic shock, pancreatitis, major burn injury, drug overdose, transfusion of blood products, cardiopulmonary bypass, reperfusion edema after lung transplantation, and embolectomy [3,4].", [["lung", "ANATOMY", 131, 135], ["gastric", "ANATOMY", 236, 243], ["pulmonary", "ANATOMY", 254, 263], ["lung", "ANATOMY", 337, 341], ["pulmonary", "ANATOMY", 384, 393], ["blood", "ANATOMY", 508, 513], ["cardiopulmonary", "ANATOMY", 524, 539], ["lung", "ANATOMY", 572, 576], ["lung injury", "DISEASE", 131, 142], ["ARDS", "DISEASE", 153, 157], ["pneumonia", "DISEASE", 166, 175], ["bacterial, viral, fungal, or opportunistic)", "DISEASE", 177, 220], ["aspiration of gastric contents", "DISEASE", 222, 252], ["pulmonary contusion", "DISEASE", 254, 273], ["inhalation injury", "DISEASE", 275, 292], ["drowning", "DISEASE", 303, 311], ["lung injury", "DISEASE", 337, 348], ["ARDS", "DISEASE", 359, 363], ["sepsis", "DISEASE", 372, 378], ["non-thoracic trauma", "DISEASE", 403, 422], ["hemorrhagic shock", "DISEASE", 426, 443], ["pancreatitis", "DISEASE", 445, 457], ["burn injury", "DISEASE", 465, 476], ["drug overdose", "DISEASE", 478, 491], ["edema", "DISEASE", 560, 565], ["troponin T", "GENE_OR_GENE_PRODUCT", 13, 23], ["lung", "ORGAN", 131, 135], ["gastric", "ORGAN", 236, 243], ["pulmonary", "ORGAN", 254, 263], ["lung", "ORGAN", 337, 341], ["pulmonary", "ORGAN", 384, 393], ["blood", "ORGANISM_SUBSTANCE", 508, 513], ["lung", "ORGAN", 572, 576], ["troponin T", "PROTEIN", 13, 23], ["DiscussionRisk factors", "PROTEIN", 98, 120], ["the troponin T level", "TEST", 9, 29], ["subsequent complications", "PROBLEM", 73, 97], ["direct lung injury", "PROBLEM", 124, 142], ["ARDS", "PROBLEM", 153, 157], ["pneumonia", "PROBLEM", 166, 175], ["bacterial", "PROBLEM", 177, 186], ["viral", "PROBLEM", 188, 193], ["fungal", "PROBLEM", 195, 201], ["aspiration of gastric contents", "PROBLEM", 222, 252], ["pulmonary contusion", "PROBLEM", 254, 273], ["inhalation injury", "PROBLEM", 275, 292], ["near-drowning", "PROBLEM", 298, 311], ["indirect lung injury", "PROBLEM", 328, 348], ["ARDS", "PROBLEM", 359, 363], ["sepsis", "PROBLEM", 372, 378], ["non-pulmonary source", "PROBLEM", 380, 400], ["non-thoracic trauma", "PROBLEM", 403, 422], ["hemorrhagic shock", "PROBLEM", 426, 443], ["pancreatitis", "PROBLEM", 445, 457], ["major burn injury", "PROBLEM", 459, 476], ["drug overdose", "PROBLEM", 478, 491], ["transfusion of blood products", "TREATMENT", 493, 522], ["cardiopulmonary bypass", "TREATMENT", 524, 546], ["reperfusion edema", "PROBLEM", 548, 565], ["lung transplantation", "TREATMENT", 572, 592], ["embolectomy", "TREATMENT", 598, 609], ["no", "UNCERTAINTY", 70, 72], ["subsequent", "OBSERVATION_MODIFIER", 73, 83], ["complications", "OBSERVATION", 84, 97], ["lung", "ANATOMY", 131, 135], ["injury", "OBSERVATION", 136, 142], ["ARDS", "OBSERVATION", 153, 157], ["pneumonia", "OBSERVATION", 166, 175], ["fungal", "OBSERVATION_MODIFIER", 195, 201], ["gastric", "ANATOMY", 236, 243], ["contents", "OBSERVATION", 244, 252], ["pulmonary", "ANATOMY", 254, 263], ["contusion", "OBSERVATION", 264, 273], ["inhalation injury", "OBSERVATION", 275, 292], ["drowning", "OBSERVATION", 303, 311], ["lung", "ANATOMY", 337, 341], ["injury", "OBSERVATION", 342, 348], ["ARDS", "OBSERVATION", 359, 363], ["sepsis", "OBSERVATION", 372, 378], ["pulmonary", "ANATOMY", 384, 393], ["hemorrhagic", "OBSERVATION_MODIFIER", 426, 437], ["shock", "OBSERVATION", 438, 443], ["pancreatitis", "OBSERVATION", 445, 457], ["burn injury", "OBSERVATION", 465, 476], ["cardiopulmonary", "ANATOMY", 524, 539], ["bypass", "OBSERVATION", 540, 546], ["reperfusion", "OBSERVATION_MODIFIER", 548, 559], ["edema", "OBSERVATION", 560, 565], ["lung", "ANATOMY", 572, 576], ["transplantation", "OBSERVATION", 577, 592], ["embolectomy", "OBSERVATION", 598, 609]]], ["The risk factor in the present case was unspecified pneumonia, and an unspecified virus was considered the most likely cause based on the negative results of all cultures, \u03b2-D glucan, and rapid test for bacteria and influenza.", [["pneumonia", "DISEASE", 52, 61], ["\u03b2-D glucan", "CHEMICAL", 172, 182], ["influenza", "DISEASE", 216, 225], ["\u03b2-D glucan", "SIMPLE_CHEMICAL", 172, 182], ["The risk factor", "PROBLEM", 0, 15], ["pneumonia", "PROBLEM", 52, 61], ["an unspecified virus", "PROBLEM", 67, 87], ["all cultures", "TEST", 158, 170], ["D glucan", "TEST", 174, 182], ["rapid test", "TEST", 188, 198], ["bacteria", "PROBLEM", 203, 211], ["influenza", "PROBLEM", 216, 225], ["pneumonia", "OBSERVATION", 52, 61]]], ["Concerning COVID-19, while an outbreak had been reported in Tokyo at the time, our patient did not live in a COVID-19-infected district; in addition, two tests for COVID-19 were negative, and CT showed subpleural sparing with a ground-glass appearance, which is not common for COVID-19.", [["subpleural", "ANATOMY", 202, 212], ["COVID-19-infected", "DISEASE", 109, 126], ["patient", "ORGANISM", 83, 90], ["COVID-19", "ORGANISM", 109, 117], ["COVID-19", "DNA", 11, 19], ["patient", "SPECIES", 83, 90], ["COVID", "TEST", 11, 16], ["a COVID", "TEST", 107, 114], ["two tests", "TEST", 150, 159], ["COVID", "TEST", 164, 169], ["CT", "TEST", 192, 194], ["subpleural sparing", "PROBLEM", 202, 220], ["a ground-glass appearance", "PROBLEM", 226, 251], ["COVID", "TEST", 277, 282], ["subpleural", "ANATOMY", 202, 212], ["sparing", "OBSERVATION", 213, 220], ["ground-glass appearance", "OBSERVATION", 228, 251]]], ["Accordingly, the possibility of COVID-19-related pneumonia was considered to be low.", [["COVID-19", "CHEMICAL", 32, 40], ["pneumonia", "DISEASE", 49, 58], ["COVID", "TEST", 32, 37], ["pneumonia", "PROBLEM", 49, 58], ["pneumonia", "OBSERVATION", 49, 58], ["low", "OBSERVATION_MODIFIER", 80, 83]]], ["Based on our investigations for virus infection, we suspect that Coxsackievirus B4 might have been the responsible virus.", [["infection", "DISEASE", 38, 47], ["Coxsackievirus B4", "ORGANISM", 65, 82], ["Coxsackievirus B4", "SPECIES", 65, 82], ["our investigations", "TEST", 9, 27], ["virus infection", "PROBLEM", 32, 47], ["Coxsackievirus B4", "PROBLEM", 65, 82], ["the responsible virus", "PROBLEM", 99, 120], ["virus", "OBSERVATION", 115, 120]]], ["However, there are few reports concerning Coxsackievirus B infection with pulmonary involvement, and there have been no reports of ARDS induced by Coxsackievirus B4 [5].", [["pulmonary", "ANATOMY", 74, 83], ["Coxsackievirus B infection", "DISEASE", 42, 68], ["ARDS", "DISEASE", 131, 135], ["Coxsackievirus B", "ORGANISM", 42, 58], ["pulmonary", "ORGAN", 74, 83], ["Coxsackievirus B4", "ORGANISM", 147, 164], ["Coxsackievirus B", "SPECIES", 42, 58], ["Coxsackievirus B", "SPECIES", 42, 58], ["Coxsackievirus B4", "SPECIES", 147, 164], ["Coxsackievirus B infection", "PROBLEM", 42, 68], ["pulmonary involvement", "PROBLEM", 74, 95], ["ARDS", "PROBLEM", 131, 135], ["Coxsackievirus B4", "PROBLEM", 147, 164], ["few", "OBSERVATION_MODIFIER", 19, 22], ["Coxsackievirus", "OBSERVATION", 42, 56], ["infection", "OBSERVATION", 59, 68], ["pulmonary", "ANATOMY", 74, 83], ["no reports of", "UNCERTAINTY", 117, 130], ["ARDS", "OBSERVATION", 131, 135]]], ["Accordingly, this might be the first case report of severe ARDS in an adult induced by Coxsackievirus B4 infection.", [["ARDS", "DISEASE", 59, 63], ["Coxsackievirus B4 infection", "DISEASE", 87, 114], ["Coxsackievirus B4", "ORGANISM", 87, 104], ["Coxsackievirus B4", "SPECIES", 87, 104], ["severe ARDS", "PROBLEM", 52, 63], ["Coxsackievirus B4 infection", "PROBLEM", 87, 114], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["ARDS", "OBSERVATION", 59, 63], ["Coxsackievirus B4 infection", "OBSERVATION", 87, 114]]], ["As we did not perform a direct examination of a pulmonary specimen, the possibility of co-infection with multiple viruses or reactivation of Coxsackievirus B4 cannot be excluded.DiscussionThere are two main treatments for ARDS: treating the main cause of ARDS or offering supportive therapy for the severely injured lungs.", [["pulmonary specimen", "ANATOMY", 48, 66], ["lungs", "ANATOMY", 316, 321], ["co-infection", "DISEASE", 87, 99], ["ARDS", "DISEASE", 222, 226], ["ARDS", "DISEASE", 255, 259], ["pulmonary specimen", "MULTI-TISSUE_STRUCTURE", 48, 66], ["Coxsackievirus B4", "ORGANISM", 141, 158], ["lungs", "ORGAN", 316, 321], ["Coxsackievirus B4", "SPECIES", 141, 158], ["a direct examination", "TEST", 22, 42], ["a pulmonary specimen", "TEST", 46, 66], ["co-infection", "PROBLEM", 87, 99], ["multiple viruses", "PROBLEM", 105, 121], ["Coxsackievirus B4", "PROBLEM", 141, 158], ["ARDS", "PROBLEM", 222, 226], ["ARDS", "PROBLEM", 255, 259], ["supportive therapy", "TREATMENT", 272, 290], ["the severely injured lungs", "PROBLEM", 295, 321], ["pulmonary", "ANATOMY", 48, 57], ["possibility of", "UNCERTAINTY", 72, 86], ["co-infection", "OBSERVATION", 87, 99], ["multiple", "OBSERVATION_MODIFIER", 105, 113], ["viruses", "OBSERVATION", 114, 121], ["Coxsackievirus", "OBSERVATION", 141, 155], ["cannot be excluded", "UNCERTAINTY", 159, 177], ["ARDS", "OBSERVATION", 222, 226], ["ARDS", "OBSERVATION", 255, 259], ["severely", "OBSERVATION_MODIFIER", 299, 307], ["injured", "OBSERVATION", 308, 315], ["lungs", "ANATOMY", 316, 321]]], ["Supportive therapy involves oxygen and mechanical ventilation.", [["oxygen", "CHEMICAL", 28, 34], ["oxygen", "CHEMICAL", 28, 34], ["oxygen", "SIMPLE_CHEMICAL", 28, 34], ["Supportive therapy", "TREATMENT", 0, 18], ["oxygen", "TREATMENT", 28, 34], ["mechanical ventilation", "TREATMENT", 39, 61], ["mechanical ventilation", "OBSERVATION", 39, 61]]], ["According to the Berlin definition, severe ARDS requires mechanical ventilation with a high PEEP and a high concentration of oxygen.", [["ARDS", "DISEASE", 43, 47], ["oxygen", "CHEMICAL", 125, 131], ["oxygen", "CHEMICAL", 125, 131], ["oxygen", "SIMPLE_CHEMICAL", 125, 131], ["severe ARDS", "PROBLEM", 36, 47], ["mechanical ventilation", "TREATMENT", 57, 79], ["a high PEEP", "TREATMENT", 85, 96], ["a high concentration of oxygen", "TREATMENT", 101, 131], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["ARDS", "OBSERVATION", 43, 47], ["mechanical ventilation", "OBSERVATION", 57, 79]]], ["When conventional mechanical ventilation fails to improve the arterial oxygenation and/or eliminate carbon dioxide, ECMO is indicated.", [["arterial", "ANATOMY", 62, 70], ["carbon dioxide", "CHEMICAL", 100, 114], ["carbon dioxide", "CHEMICAL", 100, 114], ["ECMO", "CHEMICAL", 116, 120], ["arterial", "MULTI-TISSUE_STRUCTURE", 62, 70], ["carbon dioxide", "SIMPLE_CHEMICAL", 100, 114], ["conventional mechanical ventilation", "TREATMENT", 5, 40], ["the arterial oxygenation", "TEST", 58, 82], ["carbon dioxide", "TREATMENT", 100, 114], ["ECMO", "TREATMENT", 116, 120], ["arterial", "ANATOMY", 62, 70]]], ["Another indication is circulatory and/or cardiac failure.", [["cardiac", "ANATOMY", 41, 48], ["circulatory and/or cardiac failure", "DISEASE", 22, 56], ["cardiac", "ORGAN", 41, 48], ["cardiac failure", "PROBLEM", 41, 56], ["circulatory", "OBSERVATION", 22, 33], ["cardiac", "ANATOMY", 41, 48], ["failure", "OBSERVATION", 49, 56]]], ["The conventional ventilation mode can cause ventilator-induced lung injury, such as volutrauma, atelectrauma, and/or biotrauma.", [["lung", "ANATOMY", 63, 67], ["lung injury", "DISEASE", 63, 74], ["volutrauma", "DISEASE", 84, 94], ["atelectrauma", "DISEASE", 96, 108], ["biotrauma", "DISEASE", 117, 126], ["lung", "ORGAN", 63, 67], ["The conventional ventilation mode", "TREATMENT", 0, 33], ["lung injury", "PROBLEM", 63, 74], ["volutrauma", "PROBLEM", 84, 94], ["atelectrauma", "PROBLEM", 96, 108], ["biotrauma", "PROBLEM", 117, 126], ["lung", "ANATOMY", 63, 67], ["injury", "OBSERVATION", 68, 74]]], ["In addition, the continuous inspiration of high-concentration oxygen can also injure the lungs.", [["lungs", "ANATOMY", 89, 94], ["oxygen", "CHEMICAL", 62, 68], ["oxygen", "CHEMICAL", 62, 68], ["oxygen", "SIMPLE_CHEMICAL", 62, 68], ["lungs", "ORGAN", 89, 94], ["high-concentration oxygen", "TREATMENT", 43, 68], ["lungs", "ANATOMY", 89, 94]]], ["The induction of ECMO helps avoid such mechanical- and oxygen-induced lung injuries by using the lung rest setting, allowing patients time to recover from their lung injuries [6-8].", [["lung", "ANATOMY", 70, 74], ["lung", "ANATOMY", 97, 101], ["lung", "ANATOMY", 161, 165], ["oxygen", "CHEMICAL", 55, 61], ["lung injuries", "DISEASE", 70, 83], ["lung injuries", "DISEASE", 161, 174], ["oxygen", "CHEMICAL", 55, 61], ["oxygen", "SIMPLE_CHEMICAL", 55, 61], ["lung", "ORGAN", 70, 74], ["lung", "ORGAN", 97, 101], ["patients", "ORGANISM", 125, 133], ["lung", "ORGAN", 161, 165], ["patients", "SPECIES", 125, 133], ["ECMO", "TREATMENT", 17, 21], ["oxygen", "TREATMENT", 55, 61], ["induced lung injuries", "PROBLEM", 62, 83], ["the lung rest setting", "TREATMENT", 93, 114], ["their lung injuries", "PROBLEM", 155, 174], ["lung", "ANATOMY", 70, 74], ["injuries", "OBSERVATION", 75, 83], ["lung", "ANATOMY", 97, 101], ["lung", "ANATOMY", 161, 165], ["injuries", "OBSERVATION", 166, 174]]], ["As the present case also showed marked hypoxia despite mechanical ventilation with a high concentration of oxygen and high PEEP, ECMO was introduced, and the lung rest setting was selected.DiscussionThe severity of ARDS depends on the amount of etiologic substances with corresponding immune reactions, the duration of the appearance of specific immune cells, and the repertoire of specific immune cells that control the substances.", [["lung", "ANATOMY", 158, 162], ["immune cells", "ANATOMY", 346, 358], ["immune cells", "ANATOMY", 391, 403], ["hypoxia", "DISEASE", 39, 46], ["oxygen", "CHEMICAL", 107, 113], ["ARDS", "DISEASE", 215, 219], ["oxygen", "CHEMICAL", 107, 113], ["oxygen", "SIMPLE_CHEMICAL", 107, 113], ["lung", "ORGAN", 158, 162], ["immune cells", "CELL", 346, 358], ["immune cells", "CELL", 391, 403], ["immune cells", "CELL_TYPE", 346, 358], ["immune cells", "CELL_TYPE", 391, 403], ["marked hypoxia", "PROBLEM", 32, 46], ["mechanical ventilation", "TREATMENT", 55, 77], ["a high concentration of oxygen", "TREATMENT", 83, 113], ["high PEEP", "TREATMENT", 118, 127], ["ECMO", "TREATMENT", 129, 133], ["ARDS", "PROBLEM", 215, 219], ["corresponding immune reactions", "PROBLEM", 271, 301], ["specific immune cells", "PROBLEM", 337, 358], ["specific immune cells", "TREATMENT", 382, 403], ["marked", "OBSERVATION_MODIFIER", 32, 38], ["hypoxia", "OBSERVATION", 39, 46], ["mechanical ventilation", "OBSERVATION", 55, 77], ["high PEEP", "OBSERVATION", 118, 127], ["lung", "ANATOMY", 158, 162], ["ARDS", "OBSERVATION", 215, 219], ["immune cells", "OBSERVATION", 346, 358]]], ["Therefore, treatment with systemic immune modulators (corticosteroids and/or intravenous immunoglobulin) as soon as possible may reduce aberrant immune responses in the early stage of ARDS [9].", [["intravenous", "ANATOMY", 77, 88], ["ARDS", "DISEASE", 184, 188], ["corticosteroids", "SIMPLE_CHEMICAL", 54, 69], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 88], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 89, 103], ["intravenous immunoglobulin", "PROTEIN", 77, 103], ["systemic immune modulators", "TREATMENT", 26, 52], ["corticosteroids", "TREATMENT", 54, 69], ["intravenous immunoglobulin)", "TREATMENT", 77, 104], ["aberrant immune responses", "PROBLEM", 136, 161], ["ARDS", "PROBLEM", 184, 188], ["ARDS", "OBSERVATION", 184, 188]]], ["The results from clinical trials have often been controversial; however, the administration of steroids may shorten the duration of mechanical ventilation, duration of hospitalization, and improve oxygenation, probably because of the wide spectrum of potentially desirable effects, including anti-inflammatory, antioxidant, pulmonary vasodilator, and anti-edematous [3,4,10].", [["pulmonary", "ANATOMY", 324, 333], ["steroids", "CHEMICAL", 95, 103], ["steroids", "CHEMICAL", 95, 103], ["pulmonary", "ORGAN", 324, 333], ["steroids", "TREATMENT", 95, 103], ["mechanical ventilation", "TREATMENT", 132, 154], ["anti-inflammatory, antioxidant", "TREATMENT", 292, 322], ["pulmonary vasodilator", "TREATMENT", 324, 345], ["mechanical ventilation", "OBSERVATION", 132, 154], ["pulmonary", "ANATOMY", 324, 333]]], ["Lee et al. noted that early systemic immune modulators (corticosteroids and/or intravenous immunoglobulin) along with antibiotics or antivirals could halt the progression of pneumonia and induce a rapid recovery of pulmonary lesions in patients with ARDS [9].", [["intravenous", "ANATOMY", 79, 90], ["pulmonary lesions", "ANATOMY", 215, 232], ["pneumonia", "DISEASE", 174, 183], ["pulmonary lesions", "DISEASE", 215, 232], ["ARDS", "DISEASE", 250, 254], ["corticosteroids", "SIMPLE_CHEMICAL", 56, 71], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 90], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 91, 105], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 215, 232], ["patients", "ORGANISM", 236, 244], ["intravenous immunoglobulin", "PROTEIN", 79, 105], ["patients", "SPECIES", 236, 244], ["early systemic immune modulators", "TREATMENT", 22, 54], ["corticosteroids", "TREATMENT", 56, 71], ["intravenous immunoglobulin)", "TREATMENT", 79, 106], ["antibiotics", "TREATMENT", 118, 129], ["antivirals", "TREATMENT", 133, 143], ["pneumonia", "PROBLEM", 174, 183], ["pulmonary lesions", "PROBLEM", 215, 232], ["ARDS", "PROBLEM", 250, 254], ["early", "OBSERVATION_MODIFIER", 22, 27], ["systemic immune modulators", "OBSERVATION", 28, 54], ["pneumonia", "OBSERVATION", 174, 183], ["rapid", "OBSERVATION_MODIFIER", 197, 202], ["pulmonary", "ANATOMY", 215, 224], ["lesions", "OBSERVATION", 225, 232], ["ARDS", "OBSERVATION", 250, 254]]], ["Furthermore, macrolides also induce a broad range of immunological mechanisms that result in immunomodulatory effects; hence macrolide therapy can also help reduce mortality in patients with ARDS [11].", [["macrolides", "CHEMICAL", 13, 23], ["macrolide", "CHEMICAL", 125, 134], ["ARDS", "DISEASE", 191, 195], ["macrolides", "CHEMICAL", 13, 23], ["macrolide", "CHEMICAL", 125, 134], ["macrolides", "SIMPLE_CHEMICAL", 13, 23], ["macrolide", "SIMPLE_CHEMICAL", 125, 134], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["macrolides", "TREATMENT", 13, 23], ["immunological mechanisms", "PROBLEM", 53, 77], ["immunomodulatory effects", "PROBLEM", 93, 117], ["macrolide therapy", "TREATMENT", 125, 142], ["ARDS", "PROBLEM", 191, 195], ["ARDS", "OBSERVATION", 191, 195]]], ["Accordingly, the variety of supportive therapies offered for ARDS may explain the favorable outcome in the present case.DiscussionViral pneumonia was thought to be the most likely cause of ARDS in the present case.", [["ARDS", "DISEASE", 61, 65], ["pneumonia", "DISEASE", 136, 145], ["ARDS", "DISEASE", 189, 193], ["supportive therapies", "TREATMENT", 28, 48], ["ARDS", "PROBLEM", 61, 65], ["DiscussionViral pneumonia", "PROBLEM", 120, 145], ["ARDS", "PROBLEM", 189, 193], ["pneumonia", "OBSERVATION", 136, 145], ["thought to be the most likely", "UNCERTAINTY", 150, 179], ["ARDS", "OBSERVATION", 189, 193]]], ["Respiratory viruses are a common cause of severe pneumonia and ARDS in adults [3,12].", [["Respiratory viruses", "DISEASE", 0, 19], ["pneumonia", "DISEASE", 49, 58], ["ARDS", "DISEASE", 63, 67], ["Respiratory viruses", "PROBLEM", 0, 19], ["severe pneumonia", "PROBLEM", 42, 58], ["ARDS", "PROBLEM", 63, 67], ["viruses", "OBSERVATION", 12, 19], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["pneumonia", "OBSERVATION", 49, 58], ["ARDS", "OBSERVATION", 63, 67]]], ["Initially, the present case was suspected of having COVID-19 infection, but this diagnosis was not supported by PCR performed twice.", [["infection", "DISEASE", 61, 70], ["COVID-19 infection", "PROBLEM", 52, 70], ["PCR", "TEST", 112, 115], ["infection", "OBSERVATION", 61, 70]]], ["The percentage of patients with ARDS for which no causative organism has been identified despite bronchoalveolar lavage or PCR testing remains high (>50-60%) [4].", [["bronchoalveolar lavage", "ANATOMY", 97, 119], ["ARDS", "DISEASE", 32, 36], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["ARDS", "PROBLEM", 32, 36], ["causative organism", "PROBLEM", 50, 68], ["bronchoalveolar lavage", "TEST", 97, 119], ["PCR testing", "TEST", 123, 134], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["ARDS", "OBSERVATION", 32, 36], ["bronchoalveolar lavage", "OBSERVATION", 97, 119]]], ["Although antiviral therapy is available for some respiratory viral infections, most viruses do not have any specific treatment.", [["respiratory viral infections", "DISEASE", 49, 77], ["antiviral therapy", "TREATMENT", 9, 26], ["some respiratory viral infections", "PROBLEM", 44, 77], ["specific treatment", "TREATMENT", 108, 126], ["antiviral therapy", "OBSERVATION", 9, 26], ["viral infections", "OBSERVATION", 61, 77]]], ["One of the antivirus therapies used in the present case was glycyrrhizin.", [["glycyrrhizin", "CHEMICAL", 60, 72], ["glycyrrhizin", "CHEMICAL", 60, 72], ["antivirus", "CANCER", 11, 20], ["glycyrrhizin", "SIMPLE_CHEMICAL", 60, 72], ["the antivirus therapies", "TREATMENT", 7, 30], ["glycyrrhizin", "TREATMENT", 60, 72], ["antivirus", "OBSERVATION", 11, 20]]], ["Glycyrrhiza glabra roots contain glycyrrhizic acid (glycyrrhizin), which is effective against viruses [13].", [["roots", "ANATOMY", 19, 24], ["Glycyrrhiza glabra", "CHEMICAL", 0, 18], ["glycyrrhizic acid", "CHEMICAL", 33, 50], ["glycyrrhizin", "CHEMICAL", 52, 64], ["glycyrrhizic acid", "CHEMICAL", 33, 50], ["glycyrrhizin", "CHEMICAL", 52, 64], ["Glycyrrhiza glabra", "ORGANISM", 0, 18], ["roots", "ORGANISM", 19, 24], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 33, 50], ["glycyrrhizin", "SIMPLE_CHEMICAL", 52, 64], ["Glycyrrhiza glabra", "SPECIES", 0, 18], ["Glycyrrhiza glabra", "SPECIES", 0, 18], ["Glycyrrhiza glabra roots", "TREATMENT", 0, 24], ["glycyrrhizic acid (glycyrrhizin)", "TREATMENT", 33, 65], ["glabra roots", "OBSERVATION", 12, 24], ["glycyrrhizic acid", "OBSERVATION", 33, 50]]], ["Glycyrrhizin inhibits the growth and cytopathology of several unrelated DNA and RNA viruses while not affecting human cell activity or their ability to replicate [13].", [["cell", "ANATOMY", 118, 122], ["Glycyrrhizin", "CHEMICAL", 0, 12], ["Glycyrrhizin", "CHEMICAL", 0, 12], ["Glycyrrhizin", "SIMPLE_CHEMICAL", 0, 12], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["human", "ORGANISM", 112, 117], ["cell", "CELL", 118, 122], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["Glycyrrhizin", "TREATMENT", 0, 12], ["several unrelated DNA", "PROBLEM", 54, 75], ["RNA viruses", "PROBLEM", 80, 91], ["growth", "OBSERVATION_MODIFIER", 26, 32], ["RNA viruses", "OBSERVATION", 80, 91]]], ["Glycyrrhizin is therefore now applied in the treatment of a variety of viral infections [14].", [["Glycyrrhizin", "CHEMICAL", 0, 12], ["viral infections", "DISEASE", 71, 87], ["Glycyrrhizin", "CHEMICAL", 0, 12], ["Glycyrrhizin", "SIMPLE_CHEMICAL", 0, 12], ["Glycyrrhizin", "TREATMENT", 0, 12], ["viral infections", "PROBLEM", 71, 87], ["viral", "OBSERVATION_MODIFIER", 71, 76], ["infections", "OBSERVATION", 77, 87]]], ["Traditional Chinese medicines such as glycyrrhizin may also be effective against COVID-19 infection [15].", [["glycyrrhizin", "CHEMICAL", 38, 50], ["COVID-19", "CHEMICAL", 81, 89], ["infection", "DISEASE", 90, 99], ["glycyrrhizin", "CHEMICAL", 38, 50], ["glycyrrhizin", "SIMPLE_CHEMICAL", 38, 50], ["COVID-19", "ORGANISM", 81, 89], ["COVID-19", "SPECIES", 81, 89], ["Traditional Chinese medicines", "TREATMENT", 0, 29], ["glycyrrhizin", "TREATMENT", 38, 50], ["COVID-19 infection", "PROBLEM", 81, 99]]], ["In addition, macrolide and \u03b3-globulin can also exert an antiviral effect [16].", [["macrolide", "CHEMICAL", 13, 22], ["\u03b3-globulin", "CHEMICAL", 27, 37], ["macrolide", "CHEMICAL", 13, 22], ["\u03b3-globulin", "CHEMICAL", 27, 37], ["macrolide", "SIMPLE_CHEMICAL", 13, 22], ["\u03b3-globulin", "SIMPLE_CHEMICAL", 27, 37], ["macrolide", "TREATMENT", 13, 22], ["\u03b3-globulin", "TREATMENT", 27, 37], ["antiviral effect", "OBSERVATION", 56, 72]]], ["These unspecific antiviral therapies may be useful treatments for the main cause of ARDS, which may have resulted in the favorable outcome obtained in the present case.DiscussionThe present case showed pneumonia, pancreatitis, rhabdomyolysis, and myocarditis.", [["ARDS", "DISEASE", 84, 88], ["pneumonia", "DISEASE", 202, 211], ["pancreatitis", "DISEASE", 213, 225], ["rhabdomyolysis", "DISEASE", 227, 241], ["myocarditis", "DISEASE", 247, 258], ["These unspecific antiviral therapies", "TREATMENT", 0, 36], ["useful treatments", "TREATMENT", 44, 61], ["ARDS", "PROBLEM", 84, 88], ["pneumonia", "PROBLEM", 202, 211], ["pancreatitis", "PROBLEM", 213, 225], ["rhabdomyolysis", "PROBLEM", 227, 241], ["myocarditis", "PROBLEM", 247, 258], ["ARDS", "OBSERVATION", 84, 88], ["pneumonia", "OBSERVATION", 202, 211], ["pancreatitis", "OBSERVATION", 213, 225], ["rhabdomyolysis", "OBSERVATION", 227, 241], ["myocarditis", "OBSERVATION", 247, 258]]], ["The involvement of two pathogens (Salmonella typhi and Mycoplasma) that have been reported to accompany such complications was not found in the present case [17,18].", [["Salmonella typhi", "ORGANISM", 34, 50], ["Mycoplasma", "ORGANISM", 55, 65], ["Salmonella typhi", "SPECIES", 34, 50], ["Salmonella typhi", "SPECIES", 34, 50], ["two pathogens (Salmonella typhi", "PROBLEM", 19, 50], ["Mycoplasma", "PROBLEM", 55, 65], ["such complications", "PROBLEM", 104, 122], ["two", "OBSERVATION_MODIFIER", 19, 22], ["pathogens", "OBSERVATION_MODIFIER", 23, 32]]], ["However, cases of pneumonia, rhabdomyolysis, myocarditis, and pancreatitis induced by Coxsackievirus B4 have been reported [19-20].", [["pneumonia", "DISEASE", 18, 27], ["rhabdomyolysis", "DISEASE", 29, 43], ["myocarditis", "DISEASE", 45, 56], ["pancreatitis", "DISEASE", 62, 74], ["Coxsackievirus B4", "ORGANISM", 86, 103], ["Coxsackievirus B4", "SPECIES", 86, 103], ["pneumonia", "PROBLEM", 18, 27], ["rhabdomyolysis", "PROBLEM", 29, 43], ["myocarditis", "PROBLEM", 45, 56], ["pancreatitis", "PROBLEM", 62, 74], ["Coxsackievirus B4", "PROBLEM", 86, 103], ["pneumonia", "OBSERVATION", 18, 27], ["rhabdomyolysis", "OBSERVATION", 29, 43], ["myocarditis", "OBSERVATION", 45, 56], ["pancreatitis", "OBSERVATION", 62, 74]]], ["Accordingly, this virus may have been the causative pathogen of these complications in the present case.ConclusionsWe presented a case of suspected virus-inducing severe ARDS that was treated by multimodal therapy including ECMO and immune modulation therapy.", [["ARDS", "DISEASE", 170, 174], ["this virus", "PROBLEM", 13, 23], ["these complications", "PROBLEM", 64, 83], ["suspected virus", "PROBLEM", 138, 153], ["severe ARDS", "PROBLEM", 163, 174], ["multimodal therapy", "TREATMENT", 195, 213], ["ECMO", "TREATMENT", 224, 228], ["immune modulation therapy", "TREATMENT", 233, 258], ["complications", "OBSERVATION", 70, 83], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["ARDS", "OBSERVATION", 170, 174]]], ["The wide range of supportive therapies and unspecific antiviral therapies offered for ARDS may have resulted in the favorable outcome obtained in the present case.", [["ARDS", "DISEASE", 86, 90], ["supportive therapies", "TREATMENT", 18, 38], ["unspecific antiviral therapies", "TREATMENT", 43, 73], ["ARDS", "PROBLEM", 86, 90], ["wide", "OBSERVATION_MODIFIER", 4, 8], ["range", "OBSERVATION_MODIFIER", 9, 14]]]], "94ce3e3b40cb3eafee5f777aaa0e01f70625ddf3": [["Canonical ACE2 pathway links multiple organ damage in COVID-19SARS-CoV-2 infection down-regulates ACE2 expression and leads to the production of pro-inflammatory mediators, such as IL-6 [1] .", [["organ", "ANATOMY", 38, 43], ["organ damage", "DISEASE", 38, 50], ["infection", "DISEASE", 73, 82], ["ACE2", "GENE_OR_GENE_PRODUCT", 10, 14], ["organ", "ORGAN", 38, 43], ["COVID-19SARS", "GENE_OR_GENE_PRODUCT", 54, 66], ["CoV-2", "GENE_OR_GENE_PRODUCT", 67, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 98, 102], ["IL-6", "GENE_OR_GENE_PRODUCT", 181, 185], ["ACE2", "PROTEIN", 10, 14], ["ACE2", "PROTEIN", 98, 102], ["pro-inflammatory mediators", "PROTEIN", 145, 171], ["IL", "PROTEIN", 181, 183], ["Canonical ACE2 pathway", "PROBLEM", 0, 22], ["multiple organ damage", "PROBLEM", 29, 50], ["COVID", "TEST", 54, 59], ["CoV", "TEST", 67, 70], ["2 infection", "PROBLEM", 71, 82], ["ACE2 expression", "TREATMENT", 98, 113], ["pro-inflammatory mediators", "TREATMENT", 145, 171], ["multiple", "OBSERVATION_MODIFIER", 29, 37], ["organ", "ANATOMY", 38, 43], ["damage", "OBSERVATION", 44, 50]]], ["Angiotensin-I (Ang-I) is converted into Ang-II by the ACE in the extracellular space.", [["extracellular space", "ANATOMY", 65, 84], ["Angiotensin-I", "CHEMICAL", 0, 13], ["Ang", "CHEMICAL", 15, 18], ["Ang-II", "CHEMICAL", 40, 46], ["Angiotensin-I", "GENE_OR_GENE_PRODUCT", 0, 13], ["Ang-I", "GENE_OR_GENE_PRODUCT", 15, 20], ["Ang-II", "GENE_OR_GENE_PRODUCT", 40, 46], ["ACE", "GENE_OR_GENE_PRODUCT", 54, 57], ["extracellular space", "CELLULAR_COMPONENT", 65, 84], ["Ang-II", "PROTEIN", 40, 46], ["ACE", "PROTEIN", 54, 57], ["Angiotensin-I (Ang-I)", "TREATMENT", 0, 21], ["extracellular space", "ANATOMY", 65, 84]]], ["ACE2 is able to further cleave Ang-II to Ang(1-7), which binds MasR receptors on the cell surface and promotes anti-inflammatory, vasodilation and anti-fibrotic effects [1] .", [["cell surface", "ANATOMY", 85, 97], ["Ang-II", "CHEMICAL", 31, 37], ["Ang(1-7)", "CHEMICAL", 41, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang-II", "GENE_OR_GENE_PRODUCT", 31, 37], ["Ang(1-7", "GENE_OR_GENE_PRODUCT", 41, 48], ["MasR receptors", "GENE_OR_GENE_PRODUCT", 63, 77], ["cell surface", "CELLULAR_COMPONENT", 85, 97], ["ACE2", "PROTEIN", 0, 4], ["Ang-II", "PROTEIN", 31, 37], ["MasR receptors", "PROTEIN", 63, 77], ["ACE2", "TREATMENT", 0, 4], ["the cell surface", "TREATMENT", 81, 97], ["promotes anti-inflammatory", "TREATMENT", 102, 128], ["vasodilation and anti-fibrotic effects", "TREATMENT", 130, 168], ["anti-inflammatory", "OBSERVATION_MODIFIER", 111, 128]]], ["Since ACE2 is down-regulated during viral infection, this event will lead to the accumulation of Ang-II and binding to AT1R receptors on cellular membrane.", [["cellular membrane", "ANATOMY", 137, 154], ["viral infection", "DISEASE", 36, 51], ["Ang-II", "CHEMICAL", 97, 103], ["ACE2", "GENE_OR_GENE_PRODUCT", 6, 10], ["Ang-II", "GENE_OR_GENE_PRODUCT", 97, 103], ["AT1R receptors", "GENE_OR_GENE_PRODUCT", 119, 133], ["cellular membrane", "CELLULAR_COMPONENT", 137, 154], ["ACE2", "PROTEIN", 6, 10], ["Ang-II", "PROTEIN", 97, 103], ["AT1R receptors", "PROTEIN", 119, 133], ["ACE2", "TEST", 6, 10], ["viral infection", "PROBLEM", 36, 51], ["viral", "OBSERVATION_MODIFIER", 36, 41], ["infection", "OBSERVATION", 42, 51], ["cellular membrane", "OBSERVATION", 137, 154]]], ["AT1R signals through JAK-STAT and induces fibrosis, pro-inflammatory gene expression and vasoconstriction [2, 3] .", [["fibrosis", "DISEASE", 42, 50], ["AT1R", "GENE_OR_GENE_PRODUCT", 0, 4], ["JAK-STAT", "GENE_OR_GENE_PRODUCT", 21, 29], ["AT1R", "PROTEIN", 0, 4], ["JAK", "PROTEIN", 21, 24], ["STAT", "PROTEIN", 25, 29], ["AT1R signals", "TEST", 0, 12], ["JAK", "TEST", 21, 24], ["fibrosis", "PROBLEM", 42, 50], ["vasoconstriction", "PROBLEM", 89, 105], ["fibrosis", "OBSERVATION", 42, 50]]], ["Multiple organs express ACE2 and are target for SARS-CoV-2.", [["organs", "ANATOMY", 9, 15], ["organs", "ORGAN", 9, 15], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 48, 58], ["ACE2", "PROTEIN", 24, 28], ["SARS-CoV", "SPECIES", 48, 56], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["organs", "ANATOMY", 9, 15]]], ["As they lose ACE2-mediated protection, Ang-II signaling contributes to the pathological findings observed in COVID-19 patients, such as disseminated coagulopathy and acute tissue damage [4] .Figure 3.", [["tissue", "ANATOMY", 172, 178], ["Ang-II", "CHEMICAL", 39, 45], ["coagulopathy", "DISEASE", 149, 161], ["tissue damage", "DISEASE", 172, 185], ["ACE2", "GENE_OR_GENE_PRODUCT", 13, 17], ["Ang-II", "GENE_OR_GENE_PRODUCT", 39, 45], ["patients", "ORGANISM", 118, 126], ["tissue", "TISSUE", 172, 178], ["ACE2", "PROTEIN", 13, 17], ["Ang-II", "PROTEIN", 39, 45], ["patients", "SPECIES", 118, 126], ["ACE2", "TEST", 13, 17], ["the pathological findings", "PROBLEM", 71, 96], ["disseminated coagulopathy", "PROBLEM", 136, 161], ["acute tissue damage", "PROBLEM", 166, 185], ["disseminated", "OBSERVATION_MODIFIER", 136, 148], ["coagulopathy", "OBSERVATION", 149, 161], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["tissue", "OBSERVATION", 172, 178]]], ["Signaling pathways involved in COVID-19 pathophysiologyToll-like receptors (TLRs) 3 and TLR 7/8 recognize SARS-CoV-2 RNA and initiate the inflammatory cascade via type I and type II IFN gene expression and NF-\u03baB nuclear translocation [5, 6] .", [["nuclear", "ANATOMY", 212, 219], ["COVID-19", "GENE_OR_GENE_PRODUCT", 31, 39], ["Toll-like receptors (TLRs) 3", "GENE_OR_GENE_PRODUCT", 55, 83], ["TLR 7/8", "GENE_OR_GENE_PRODUCT", 88, 95], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 106, 116], ["type I", "GENE_OR_GENE_PRODUCT", 163, 169], ["type II IFN", "GENE_OR_GENE_PRODUCT", 174, 185], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 206, 211], ["COVID-19 pathophysiologyToll-like receptors (TLRs) 3", "PROTEIN", 31, 83], ["TLR 7/8", "PROTEIN", 88, 95], ["SARS-CoV-2 RNA", "RNA", 106, 120], ["NF-\u03baB", "PROTEIN", 206, 211], ["Signaling pathways", "PROBLEM", 0, 18], ["COVID", "TEST", 31, 36], ["TLR", "TEST", 88, 91], ["SARS", "TEST", 106, 110], ["the inflammatory cascade", "PROBLEM", 134, 158], ["type I", "PROBLEM", 163, 169], ["type II IFN gene expression", "PROBLEM", 174, 201], ["inflammatory", "OBSERVATION", 138, 150]]], ["Via NF-\u03baB, the expression of multiple pro-inflammatory genes is stimulated, including pro-IL-1\u03b2, pro-IL-18, TNF and IL-6 [7] [8] [9] .", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 4, 9], ["pro-IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 86, 95], ["pro-IL-18", "GENE_OR_GENE_PRODUCT", 97, 106], ["TNF", "GENE_OR_GENE_PRODUCT", 108, 111], ["IL-6 [7] [8] [9]", "SIMPLE_CHEMICAL", 116, 132], ["NF-\u03baB", "PROTEIN", 4, 9], ["pro-inflammatory genes", "DNA", 38, 60], ["pro-IL-1\u03b2", "PROTEIN", 86, 95], ["TNF", "PROTEIN", 108, 111], ["pro-IL", "TEST", 86, 92], ["pro-IL", "TEST", 97, 103], ["TNF", "TEST", 108, 111], ["IL", "TEST", 116, 118], ["pro-inflammatory genes", "OBSERVATION", 38, 60]]], ["The virus is also recognized by cytoplasmic NLRP3, which forms, together with ASC and caspase-1 (Casp-1), the inflammasome complex that will cleave and release mature forms of IL-1\u03b2 and IL-18 [10] .", [["cytoplasmic", "ANATOMY", 32, 43], ["cytoplasmic", "ORGANISM_SUBSTANCE", 32, 43], ["NLRP3", "GENE_OR_GENE_PRODUCT", 44, 49], ["ASC", "GENE_OR_GENE_PRODUCT", 78, 81], ["caspase-1", "GENE_OR_GENE_PRODUCT", 86, 95], ["Casp-1", "GENE_OR_GENE_PRODUCT", 97, 103], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 176, 181], ["IL-18", "GENE_OR_GENE_PRODUCT", 186, 191], ["cytoplasmic NLRP3", "PROTEIN", 32, 49], ["ASC", "PROTEIN", 78, 81], ["caspase-1", "PROTEIN", 86, 95], ["Casp-1", "PROTEIN", 97, 103], ["inflammasome complex", "PROTEIN", 110, 130], ["IL-1\u03b2", "PROTEIN", 176, 181], ["IL", "PROTEIN", 186, 188], ["The virus", "PROBLEM", 0, 9], ["cytoplasmic NLRP3", "TEST", 32, 49], ["ASC", "TEST", 78, 81], ["caspase", "TEST", 86, 93], ["Casp", "TEST", 97, 101], ["the inflammasome complex", "PROBLEM", 106, 130], ["IL", "TEST", 176, 178], ["virus", "OBSERVATION", 4, 9], ["cytoplasmic NLRP3", "OBSERVATION", 32, 49]]], ["The cytokines IL-1\u03b2, IL-18 and TNF bind to specific receptors and promote further NF-\u03baB nuclear translocation and phosphorylation of p38 MAPK, which will lead to great expression of pro-inflammatory cytokines and chemokines [11, 12] .", [["nuclear", "ANATOMY", 88, 95], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 14, 19], ["IL-18", "GENE_OR_GENE_PRODUCT", 21, 26], ["TNF", "GENE_OR_GENE_PRODUCT", 31, 34], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 82, 87], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 133, 141], ["cytokines", "PROTEIN", 4, 13], ["IL-1\u03b2", "PROTEIN", 14, 19], ["IL-18", "PROTEIN", 21, 26], ["TNF", "PROTEIN", 31, 34], ["NF-\u03baB", "PROTEIN", 82, 87], ["p38 MAPK", "PROTEIN", 133, 141], ["pro-inflammatory cytokines", "PROTEIN", 182, 208], ["chemokines", "PROTEIN", 213, 223], ["The cytokines IL", "TEST", 0, 16], ["IL", "TREATMENT", 21, 23], ["TNF bind", "TREATMENT", 31, 39], ["further NF", "TEST", 74, 84], ["phosphorylation of p38 MAPK", "TREATMENT", 114, 141], ["pro-inflammatory cytokines", "TREATMENT", 182, 208], ["pro-inflammatory cytokines", "OBSERVATION", 182, 208]]], ["IL-6, an important player in COVID-19, binds IL-6R and gp130 receptors to activate JAK/STAT-3 pathway and then contribute to the CRS observed in COVID-19 patients [13] .Figure 3.", [["CRS", "DISEASE", 129, 132], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["COVID-19", "GENE_OR_GENE_PRODUCT", 29, 37], ["IL-6R", "GENE_OR_GENE_PRODUCT", 45, 50], ["gp130", "GENE_OR_GENE_PRODUCT", 55, 60], ["JAK", "GENE_OR_GENE_PRODUCT", 83, 86], ["STAT-3", "GENE_OR_GENE_PRODUCT", 87, 93], ["patients", "ORGANISM", 154, 162], ["IL-6", "PROTEIN", 0, 4], ["COVID", "PROTEIN", 29, 34], ["IL-6R", "PROTEIN", 45, 50], ["gp130 receptors", "PROTEIN", 55, 70], ["JAK", "PROTEIN", 83, 86], ["STAT", "PROTEIN", 87, 91], ["patients", "SPECIES", 154, 162], ["binds IL", "TREATMENT", 39, 47], ["gp130 receptors", "TREATMENT", 55, 70], ["the CRS", "PROBLEM", 125, 132], ["COVID", "TEST", 145, 150]]], ["Signaling pathways involved in COVID-19 pathophysiologyThe authors apologise for any inconvenience caused to the reader.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 31, 39], ["Signaling pathways", "PROBLEM", 0, 18], ["COVID", "TEST", 31, 36]]]], "PMC7127555": [["IntroductionThe major physiological function of milk is the transport of amino acids, carbohydrates, lipids, and minerals (especially calcium) to mammalian offspring.", [["milk", "ANATOMY", 48, 52], ["amino acids", "CHEMICAL", 73, 84], ["carbohydrates, lipids, and minerals", "CHEMICAL", 86, 121], ["calcium", "CHEMICAL", 134, 141], ["amino acids", "CHEMICAL", 73, 84], ["carbohydrates", "CHEMICAL", 86, 99], ["calcium", "CHEMICAL", 134, 141], ["milk", "ORGANISM_SUBSTANCE", 48, 52], ["amino acids", "AMINO_ACID", 73, 84], ["carbohydrates", "SIMPLE_CHEMICAL", 86, 99], ["lipids", "SIMPLE_CHEMICAL", 101, 107], ["minerals", "SIMPLE_CHEMICAL", 113, 121], ["calcium", "SIMPLE_CHEMICAL", 134, 141], ["amino acids", "TREATMENT", 73, 84], ["carbohydrates", "TREATMENT", 86, 99], ["lipids, and minerals (especially calcium)", "TREATMENT", 101, 142]]], ["In addition to its nutritional importance, milk also contains a variety of molecules, which provide protection against pathogen infections or modulate immune responses.", [["milk", "ANATOMY", 43, 47], ["infections", "DISEASE", 128, 138], ["milk", "ORGANISM_SUBSTANCE", 43, 47], ["a variety of molecules", "TREATMENT", 62, 84], ["pathogen infections", "PROBLEM", 119, 138]]], ["Antibodies are the most prominent of these molecules, but other nonspecific, broad-spectrum defense substances possess antimicrobial activity as well.", [["Antibodies", "TEST", 0, 10], ["antimicrobial activity", "TREATMENT", 119, 141], ["most prominent", "OBSERVATION_MODIFIER", 19, 33], ["nonspecific", "OBSERVATION_MODIFIER", 64, 75], ["antimicrobial activity", "OBSERVATION", 119, 141]]], ["Some of these molecules can be altered to improve the antipathogenic properties of milk.", [["milk", "ANATOMY", 83, 87], ["milk", "ORGANISM_SUBSTANCE", 83, 87], ["molecules", "OBSERVATION", 14, 23]]], ["These modifications are of particular interest if no suitable vaccines are available and newborn mammals are most severely affected by the infection.", [["infection", "DISEASE", 139, 148], ["newborn mammals", "ORGANISM", 89, 104], ["suitable vaccines", "TREATMENT", 53, 70], ["the infection", "PROBLEM", 135, 148], ["infection", "OBSERVATION", 139, 148]]], ["This scenario can be the consequence of the low virulence of the pathogen, which does not elicit a major immune response in the adult host [e.g. the human respiratory syncytia virus (RSV)], or the variability of the pathogen, which evades an immune response targeted at variants encountered previously (e.g. influenza virus).", [["respiratory syncytia", "DISEASE", 155, 175], ["influenza virus", "DISEASE", 308, 323], ["human", "ORGANISM", 149, 154], ["respiratory syncytia virus", "ORGANISM", 155, 181], ["RSV", "ORGANISM", 183, 186], ["influenza virus", "ORGANISM", 308, 323], ["human", "SPECIES", 149, 154], ["respiratory syncytia virus", "SPECIES", 155, 181], ["influenza virus", "SPECIES", 308, 323], ["human respiratory syncytia virus", "SPECIES", 149, 181], ["RSV", "SPECIES", 183, 186], ["the low virulence of the pathogen", "PROBLEM", 40, 73], ["the human respiratory syncytia virus", "PROBLEM", 145, 181], ["the pathogen", "PROBLEM", 212, 224], ["influenza virus", "PROBLEM", 308, 323], ["low virulence", "OBSERVATION_MODIFIER", 44, 57], ["pathogen", "OBSERVATION", 65, 73], ["respiratory syncytia virus", "OBSERVATION", 155, 181], ["pathogen", "OBSERVATION", 216, 224]]], ["Under these circumstances, mothers do not supply protective antibodies to their offspring via placenta and milk and nonspecific defense mechanisms may be too weak to prevent disease.", [["placenta", "ANATOMY", 94, 102], ["milk", "ANATOMY", 107, 111], ["mothers", "ORGANISM", 27, 34], ["placenta", "TISSUE", 94, 102], ["milk", "ORGANISM_SUBSTANCE", 107, 111], ["protective antibodies", "PROTEIN", 49, 70], ["nonspecific defense mechanisms", "PROBLEM", 116, 146], ["disease", "PROBLEM", 174, 181], ["placenta", "ANATOMY", 94, 102]]], ["This in turn puts the offspring at an increased risk of infection, as the immune system of newborn mammals is often not sufficiently developed during the early stages of life to cope efficiently with the pathogens.", [["immune system", "ANATOMY", 74, 87], ["infection", "DISEASE", 56, 65], ["infection", "PROBLEM", 56, 65], ["the pathogens", "PROBLEM", 200, 213], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["infection", "OBSERVATION", 56, 65]]], ["Milk, which has been manipulated to contain large amounts of specific or nonspecific defense substances, may therefore provide a useful tool for disease prevention in these instances.Milk and human healthThere is convincing evidence that with regard to infant health, breast-feeding is superior to bottle-feeding Filteau, 2000, Hanson et al., 2000, Hanson, 1998.", [["breast", "ANATOMY", 268, 274], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["Milk", "ORGANISM_SUBSTANCE", 183, 187], ["human", "ORGANISM", 192, 197], ["breast", "ORGANISM_SUBDIVISION", 268, 274], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 192, 197], ["nonspecific defense substances", "PROBLEM", 73, 103], ["disease prevention", "TREATMENT", 145, 163], ["large", "OBSERVATION_MODIFIER", 44, 49], ["amounts", "OBSERVATION_MODIFIER", 50, 57], ["nonspecific", "OBSERVATION_MODIFIER", 73, 84], ["defense substances", "OBSERVATION", 85, 103], ["breast", "ANATOMY", 268, 274]]], ["Protection against infections during lactation has been demonstrated in cases of acute and prolonged diarrhea, respiratory tract infections, otitis media, urinary tract infection, neonatal septicemia, and necrotizing enterocolitis (Hanson, 1998).", [["respiratory tract", "ANATOMY", 111, 128], ["urinary tract", "ANATOMY", 155, 168], ["infections", "DISEASE", 19, 29], ["diarrhea", "DISEASE", 101, 109], ["respiratory tract infections", "DISEASE", 111, 139], ["otitis media", "DISEASE", 141, 153], ["urinary tract infection", "DISEASE", 155, 178], ["neonatal septicemia", "DISEASE", 180, 199], ["necrotizing enterocolitis", "DISEASE", 205, 230], ["urinary tract", "ORGANISM_SUBDIVISION", 155, 168], ["Protection", "TREATMENT", 0, 10], ["infections", "PROBLEM", 19, 29], ["acute and prolonged diarrhea", "PROBLEM", 81, 109], ["respiratory tract infections", "PROBLEM", 111, 139], ["otitis media", "PROBLEM", 141, 153], ["urinary tract infection", "PROBLEM", 155, 178], ["neonatal septicemia", "PROBLEM", 180, 199], ["necrotizing enterocolitis", "PROBLEM", 205, 230], ["infections", "OBSERVATION", 19, 29], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["prolonged", "OBSERVATION_MODIFIER", 91, 100], ["diarrhea", "OBSERVATION", 101, 109], ["respiratory tract", "ANATOMY", 111, 128], ["infections", "OBSERVATION", 129, 139], ["otitis", "OBSERVATION", 141, 147], ["urinary tract", "ANATOMY", 155, 168], ["infection", "OBSERVATION", 169, 178], ["septicemia", "OBSERVATION", 189, 199], ["necrotizing", "OBSERVATION_MODIFIER", 205, 216], ["enterocolitis", "OBSERVATION", 217, 230]]], ["Breast-feeding provides the newborn baby with a battery of immunologically active substances Table 1, Table 3, Table 4, Table 5.", [["Breast", "ANATOMY", 0, 6]]], ["Antibodies have been demonstrated to efficiently control a variety of pathogen-induced diseases (including malaria, Fried et al., 1998, Kassim et al., 2000), and a wide variety of virus infections (e.g. RSV, Englund, 1994, and rotavirus, Ebina et al., 1992).", [["pathogen-induced diseases", "DISEASE", 70, 95], ["malaria", "DISEASE", 107, 114], ["infections", "DISEASE", 186, 196], ["RSV", "ORGANISM", 203, 206], ["RSV", "SPECIES", 203, 206], ["Antibodies", "TEST", 0, 10], ["pathogen-induced diseases", "PROBLEM", 70, 95], ["malaria", "PROBLEM", 107, 114], ["a wide variety of virus infections", "PROBLEM", 162, 196], ["RSV", "PROBLEM", 203, 206], ["rotavirus", "PROBLEM", 227, 236], ["virus infections", "OBSERVATION", 180, 196]]], ["Lactoferrin, which is present in substantial amounts in human milk, prevents the population of the infant's gut by coliform enterobacteria and acts as an antiinflammatory immune modulator (Nuijens et al., 1996).", [["milk", "ANATOMY", 62, 66], ["gut", "ANATOMY", 108, 111], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 0, 11], ["human", "ORGANISM", 56, 61], ["milk", "ORGANISM_SUBSTANCE", 62, 66], ["gut", "ORGANISM_SUBDIVISION", 108, 111], ["Lactoferrin", "PROTEIN", 0, 11], ["human", "SPECIES", 56, 61], ["milk", "SPECIES", 62, 66], ["infant", "SPECIES", 99, 105], ["human", "SPECIES", 56, 61], ["Lactoferrin", "TREATMENT", 0, 11], ["coliform enterobacteria", "PROBLEM", 115, 138], ["an antiinflammatory immune modulator", "TREATMENT", 151, 187]]], ["Other nonspecific defense molecules enhance this protection Newburg, 1996, Labeta et al., 2000.", [["Other nonspecific defense molecules", "PROBLEM", 0, 35], ["nonspecific", "OBSERVATION_MODIFIER", 6, 17], ["defense molecules", "OBSERVATION", 18, 35]]], ["These substances are of particular importance in the newborn prior to acidification of the stomach, which provides an effective barrier to many bacterial infections of the gastrointestinal tract in later life.", [["stomach", "ANATOMY", 91, 98], ["gastrointestinal tract", "ANATOMY", 172, 194], ["infections of the gastrointestinal tract", "DISEASE", 154, 194], ["stomach", "ORGAN", 91, 98], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 172, 194], ["acidification of the stomach", "PROBLEM", 70, 98], ["many bacterial infections of the gastrointestinal tract", "PROBLEM", 139, 194], ["stomach", "ANATOMY", 91, 98], ["bacterial", "OBSERVATION_MODIFIER", 144, 153], ["infections", "OBSERVATION", 154, 164], ["gastrointestinal tract", "ANATOMY", 172, 194]]], ["In addition, there is growing evidence that the transfer of cytokines, growth factors, B-cells, and other lymphocytes from mother to offspring via milk (Zhou et al., 2000) assists the development of the infant's immune system.", [["B-cells", "ANATOMY", 87, 94], ["lymphocytes", "ANATOMY", 106, 117], ["milk", "ANATOMY", 147, 151], ["immune system", "ANATOMY", 212, 225], ["B-cells", "CELL", 87, 94], ["lymphocytes", "CELL", 106, 117], ["milk", "ORGANISM_SUBSTANCE", 147, 151], ["infant", "ORGANISM", 203, 209], ["immune system", "ANATOMICAL_SYSTEM", 212, 225], ["cytokines", "PROTEIN", 60, 69], ["growth factors", "PROTEIN", 71, 85], ["B-cells", "CELL_TYPE", 87, 94], ["lymphocytes", "CELL_TYPE", 106, 117], ["infant", "SPECIES", 203, 209], ["cytokines", "PROBLEM", 60, 69], ["growth factors", "PROBLEM", 71, 85], ["other lymphocytes", "PROBLEM", 100, 117]]], ["Babies, who are not breast-fed, are deprived of some of these defense mechanisms.", [["breast", "ANATOMY", 20, 26], ["Babies", "ORGANISM", 0, 6], ["breast", "ORGANISM_SUBDIVISION", 20, 26]]], ["The antibodies in cow's milk will be directed against bovine rather than human pathogens.", [["milk", "ANATOMY", 24, 28], ["cow", "ORGANISM", 18, 21], ["milk", "ORGANISM_SUBSTANCE", 24, 28], ["bovine", "ORGANISM", 54, 60], ["human", "ORGANISM", 73, 78], ["antibodies", "PROTEIN", 4, 14], ["cow", "SPECIES", 18, 21], ["bovine", "SPECIES", 54, 60], ["human", "SPECIES", 73, 78], ["cow", "SPECIES", 18, 21], ["bovine", "SPECIES", 54, 60], ["human", "SPECIES", 73, 78], ["The antibodies in cow's milk", "TREATMENT", 0, 28], ["human pathogens", "PROBLEM", 73, 88]]], ["Bovine lymphocytes even if they would survive the processing of milk to infant formula would be of no benefit to humans.", [["lymphocytes", "ANATOMY", 7, 18], ["milk", "ANATOMY", 64, 68], ["Bovine", "ORGANISM", 0, 6], ["lymphocytes", "CELL", 7, 18], ["milk", "ORGANISM_SUBSTANCE", 64, 68], ["humans", "ORGANISM", 113, 119], ["Bovine lymphocytes", "CELL_TYPE", 0, 18], ["Bovine", "SPECIES", 0, 6], ["humans", "SPECIES", 113, 119], ["Bovine", "SPECIES", 0, 6], ["humans", "SPECIES", 113, 119], ["Bovine lymphocytes", "PROBLEM", 0, 18], ["lymphocytes", "OBSERVATION", 7, 18]]], ["Cow's milk contains very little lactoferrin (Nuijens et al., 1996).", [["milk", "ANATOMY", 6, 10], ["milk", "ORGANISM_SUBSTANCE", 6, 10], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 32, 43], ["lactoferrin", "PROTEIN", 32, 43], ["milk", "SPECIES", 6, 10], ["Cow's milk", "TREATMENT", 0, 10], ["very", "OBSERVATION_MODIFIER", 20, 24], ["little lactoferrin", "OBSERVATION_MODIFIER", 25, 43]]], ["In addition, many babies show allergic reactions to cow's milk, with \u03b2-lactoglobulin being the major immunogen (Pecquet et al., 2000).Milk and human healthHowever, even breast-feeding fails to supply adequate protection against a variety of pathogens.", [["milk", "ANATOMY", 58, 62], ["breast", "ANATOMY", 169, 175], ["allergic reactions", "DISEASE", 30, 48], ["babies", "ORGANISM", 18, 24], ["cow", "ORGANISM", 52, 55], ["milk", "ORGANISM_SUBSTANCE", 58, 62], ["\u03b2-lactoglobulin", "GENE_OR_GENE_PRODUCT", 69, 84], ["Milk", "ORGANISM_SUBSTANCE", 134, 138], ["human", "ORGANISM", 143, 148], ["breast", "ORGANISM_SUBDIVISION", 169, 175], ["cow", "SPECIES", 52, 55], ["human", "SPECIES", 143, 148], ["cow", "SPECIES", 52, 55], ["human", "SPECIES", 143, 148], ["allergic reactions", "PROBLEM", 30, 48], ["cow's milk", "TREATMENT", 52, 62], ["\u03b2-lactoglobulin", "TREATMENT", 69, 84], ["human healthHowever", "TREATMENT", 143, 162], ["pathogens", "PROBLEM", 241, 250], ["allergic", "OBSERVATION", 30, 38], ["breast", "ANATOMY", 169, 175]]], ["This is exemplified by the frequent hospitalization of children (below the age of 6 months) infected with RSV.", [["RSV", "DISEASE", 106, 109], ["children", "ORGANISM", 55, 63], ["RSV", "ORGANISM", 106, 109], ["children", "SPECIES", 55, 63], ["RSV", "SPECIES", 106, 109], ["RSV", "PROBLEM", 106, 109], ["RSV", "OBSERVATION", 106, 109]]], ["Although the levels of maternal antibody are inversely correlated with the severity of RSV-induced disease (broncholitis and pneumonia; Lamprecht et al., 1976), most mothers transfer negligible amounts of virus-neutralizing antibodies to their children.", [["RSV-induced disease", "DISEASE", 87, 106], ["broncholitis", "DISEASE", 108, 120], ["pneumonia", "DISEASE", 125, 134], ["RSV", "ORGANISM", 87, 90], ["mothers", "ORGANISM", 166, 173], ["children", "ORGANISM", 244, 252], ["maternal antibody", "PROTEIN", 23, 40], ["neutralizing antibodies", "PROTEIN", 211, 234], ["children", "SPECIES", 244, 252], ["RSV", "SPECIES", 87, 90], ["maternal antibody", "PROBLEM", 23, 40], ["RSV", "PROBLEM", 87, 90], ["induced disease", "PROBLEM", 91, 106], ["broncholitis", "PROBLEM", 108, 120], ["pneumonia", "PROBLEM", 125, 134], ["virus", "PROBLEM", 205, 210], ["neutralizing antibodies", "TREATMENT", 211, 234], ["RSV", "OBSERVATION", 87, 90], ["pneumonia", "OBSERVATION", 125, 134]]], ["This is a consequence of the minor immune reaction that RSV elicits in adults with most infections being subacute.", [["RSV", "DISEASE", 56, 59], ["infections", "DISEASE", 88, 98], ["RSV", "ORGANISM", 56, 59], ["RSV", "SPECIES", 56, 59], ["the minor immune reaction", "PROBLEM", 25, 50], ["minor", "OBSERVATION_MODIFIER", 29, 34], ["immune reaction", "OBSERVATION", 35, 50], ["infections", "OBSERVATION", 88, 98], ["subacute", "OBSERVATION_MODIFIER", 105, 113]]], ["Available vaccines do not lead to a long-lasting immune response.", [["Available vaccines", "TREATMENT", 0, 18], ["a long-lasting immune response", "PROBLEM", 34, 64]]], ["The first RSV vaccine (using formalin-inactivated virus) even resulted in an increased incidence and severity of disease in vaccinated children (Englund, 1999).", [["formalin", "CHEMICAL", 29, 37], ["formalin", "CHEMICAL", 29, 37], ["RSV", "ORGANISM", 10, 13], ["formalin-inactivated virus", "ORGANISM", 29, 55], ["children", "ORGANISM", 135, 143], ["children", "SPECIES", 135, 143], ["RSV", "SPECIES", 10, 13], ["The first RSV vaccine", "TREATMENT", 0, 21], ["formalin-inactivated virus", "TREATMENT", 29, 55], ["disease", "PROBLEM", 113, 120], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["disease", "OBSERVATION", 113, 120]]], ["Therefore, although RSV-specific antibodies in milk are able to control RSV-induced disease, they are usually scarce.", [["milk", "ANATOMY", 47, 51], ["RSV-induced disease", "DISEASE", 72, 91], ["RSV", "ORGANISM", 20, 23], ["milk", "ORGANISM_SUBSTANCE", 47, 51], ["RSV", "ORGANISM", 72, 75], ["RSV-specific antibodies", "PROTEIN", 20, 43], ["milk", "SPECIES", 47, 51], ["RSV", "SPECIES", 20, 23], ["RSV", "SPECIES", 72, 75], ["RSV", "PROBLEM", 20, 23], ["specific antibodies in milk", "PROBLEM", 24, 51], ["RSV", "PROBLEM", 72, 75], ["disease", "PROBLEM", 84, 91], ["RSV", "OBSERVATION", 20, 23], ["disease", "OBSERVATION", 84, 91]]], ["In a scenario like this, it is obvious that the manipulation of antimicrobial substances in milk would have beneficial health effects.Immunization of mothers ::: Antibodies and antiidiotypes ::: Potential targets for manipulationMilk contains antibodies directed against a variety of pathogens that the mother has encountered during her lifetime.", [["milk", "ANATOMY", 92, 96], ["milk", "ORGANISM_SUBSTANCE", 92, 96], ["mothers", "ORGANISM", 150, 157], ["Milk", "ORGANISM_SUBSTANCE", 229, 233], ["Milk", "PROTEIN", 229, 233], ["antibodies", "PROTEIN", 243, 253], ["antimicrobial substances", "TREATMENT", 64, 88], ["manipulationMilk", "TREATMENT", 217, 233], ["antibodies", "TREATMENT", 243, 253]]], ["Some pathogens elicit a major immune response and a long-lasting immunity.", [["Some pathogens", "PROBLEM", 0, 14]]], ["Other pathogens only lead to a transient immune response.", [["Other pathogens", "PROBLEM", 0, 15], ["a transient immune response", "PROBLEM", 29, 56], ["pathogens", "OBSERVATION", 6, 15], ["transient", "OBSERVATION_MODIFIER", 31, 40], ["immune response", "OBSERVATION", 41, 56]]], ["In this case, the antibody content of human milk can be manipulated by immunizing mothers during pregnancy.", [["milk", "ANATOMY", 44, 48], ["human", "ORGANISM", 38, 43], ["milk", "ORGANISM_SUBSTANCE", 44, 48], ["mothers", "ORGANISM", 82, 89], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["the antibody content of human milk", "TREATMENT", 14, 48]]], ["This can be done as a passive immunization by infusing preparations of pathogen-specific antisera or, more frequently, as active immunization by vaccination.", [["a passive immunization", "TREATMENT", 20, 42], ["pathogen", "PROBLEM", 71, 79], ["specific antisera", "TREATMENT", 80, 97], ["active immunization", "TREATMENT", 122, 141]]], ["Vaccination in pregnancy leads to a normal immune response and no pregnancy-specific side effects have been reported Englund et al., 1998, Munoz and Englund, 2000.", [["Vaccination in pregnancy", "PROBLEM", 0, 24], ["pregnancy", "PROBLEM", 66, 75], ["specific side effects", "PROBLEM", 76, 97]]], ["This approach is particularly useful in cases (like RSV), where vaccination only leads to a short-term immune response and infants can be seriously affected by the infection.", [["infection", "DISEASE", 164, 173], ["RSV", "ORGANISM", 52, 55], ["infants", "ORGANISM", 123, 130], ["infants", "SPECIES", 123, 130], ["RSV", "SPECIES", 52, 55], ["vaccination", "TREATMENT", 64, 75], ["a short-term immune response", "PROBLEM", 90, 118], ["the infection", "PROBLEM", 160, 173], ["infection", "OBSERVATION", 164, 173]]], ["Immunization of mothers during pregnancy with RSV antigen leads to the transfer of antibodies to the offspring via placenta and colostrum and helps to prevent RSV-induced disease Englund, 1994, Englund et al., 1998.", [["placenta", "ANATOMY", 115, 123], ["colostrum", "ANATOMY", 128, 137], ["RSV antigen", "CHEMICAL", 46, 57], ["RSV", "DISEASE", 159, 162], ["mothers", "ORGANISM", 16, 23], ["RSV", "ORGANISM", 46, 49], ["placenta", "TISSUE", 115, 123], ["colostrum", "ORGANISM_SUBSTANCE", 128, 137], ["RSV", "ORGANISM", 159, 162], ["RSV antigen", "PROTEIN", 46, 57], ["antibodies", "PROTEIN", 83, 93], ["RSV", "SPECIES", 46, 49], ["RSV", "SPECIES", 159, 162], ["Immunization", "TREATMENT", 0, 12], ["RSV antigen", "PROBLEM", 46, 57], ["antibodies", "TREATMENT", 83, 93], ["placenta and colostrum", "TREATMENT", 115, 137], ["RSV", "PROBLEM", 159, 162], ["placenta", "ANATOMY", 115, 123]]], ["A potential drawback to this approach may relate to the finding that maternal antibodies can suppress the infant's own immune response to certain pathogens (Englund et al., 1998).", [["maternal antibodies", "PROTEIN", 69, 88], ["infant", "SPECIES", 106, 112], ["A potential drawback to this approach", "TREATMENT", 0, 37], ["maternal antibodies", "PROBLEM", 69, 88], ["certain pathogens", "PROBLEM", 138, 155]]], ["Therefore, careful analysis of the host\u2013pathogen interactions is required before embarking on vaccination during pregnancy.", [["careful analysis", "TEST", 11, 27], ["the host\u2013pathogen interactions", "PROBLEM", 31, 61], ["vaccination", "TREATMENT", 94, 105], ["pregnancy", "PROBLEM", 113, 122]]], ["Nevertheless, immunization during pregnancy may help to prevent a wide spectrum of diseases.Immunization of mothers ::: Antibodies and antiidiotypes ::: Potential targets for manipulationMilk can also be used as a medium for the active immunization of the neonate with antiidiotypes.", [["mothers", "ORGANISM", 108, 115], ["Milk", "ORGANISM_SUBSTANCE", 187, 191], ["neonate", "ORGANISM", 256, 263], ["immunization", "TREATMENT", 14, 26], ["a wide spectrum of diseases", "PROBLEM", 64, 91], ["manipulationMilk", "TREATMENT", 175, 191], ["the active immunization", "TREATMENT", 225, 248], ["antiidiotypes", "TREATMENT", 269, 282], ["diseases", "OBSERVATION", 83, 91]]], ["This can be achieved by immunizing mothers with pathogen-neutralizing antibodies.", [["mothers", "ORGANISM", 35, 42], ["pathogen-neutralizing antibodies", "PROTEIN", 48, 80], ["pathogen", "PROBLEM", 48, 56], ["neutralizing antibodies", "PROBLEM", 57, 80]]], ["The mother will develop an immune response against the variable region of the neutralizing antibody and transmit secondary antibodies (i.e. antiidiotypes) to the offspring via placenta and milk.", [["placenta", "ANATOMY", 176, 184], ["milk", "ANATOMY", 189, 193], ["placenta", "TISSUE", 176, 184], ["milk", "ORGANISM_SUBSTANCE", 189, 193], ["neutralizing antibody", "PROTEIN", 78, 99], ["secondary antibodies", "PROTEIN", 113, 133], ["antiidiotypes", "PROTEIN", 140, 153], ["an immune response", "PROBLEM", 24, 42], ["the neutralizing antibody", "PROBLEM", 74, 99], ["transmit secondary antibodies", "PROBLEM", 104, 133], ["antiidiotypes", "TREATMENT", 140, 153], ["neutralizing antibody", "OBSERVATION", 78, 99], ["placenta", "ANATOMY", 176, 184]]], ["The offspring's immune system will respond by generating tertiary antibodies, which recognize the same epitope as the primary neutralizing antibody.", [["immune system", "ANATOMY", 16, 29], ["immune system", "ANATOMICAL_SYSTEM", 16, 29], ["tertiary antibodies", "PROTEIN", 57, 76], ["primary neutralizing antibody", "PROTEIN", 118, 147], ["generating tertiary antibodies", "PROBLEM", 46, 76], ["neutralizing antibody", "OBSERVATION", 126, 147]]], ["The viability of such an approach has been demonstrated in animal experiments (Okamoto et al., 1989).", [["viability", "OBSERVATION_MODIFIER", 4, 13]]], ["The transfer of antiidiotypes via placenta and milk may also be a mechanism of natural immunization in humans (Hanson et al., 2000).Immunization of ruminants ::: Antibodies and antiidiotypes ::: Potential targets for manipulationImmunization during pregnancy requires a substantial financial input in terms of vaccine development and clinical testing (Englund et al., 1998), as the outcome of the vaccines is not always predictable.", [["placenta", "ANATOMY", 34, 42], ["milk", "ANATOMY", 47, 51], ["placenta", "TISSUE", 34, 42], ["milk", "ORGANISM_SUBSTANCE", 47, 51], ["humans", "ORGANISM", 103, 109], ["ruminants", "ORGANISM", 148, 157], ["humans", "SPECIES", 103, 109], ["humans", "SPECIES", 103, 109], ["antiidiotypes via placenta and milk", "TREATMENT", 16, 51], ["natural immunization", "TREATMENT", 79, 99], ["manipulationImmunization", "TREATMENT", 217, 241], ["a substantial financial input", "TREATMENT", 268, 297], ["vaccine development", "TREATMENT", 310, 329], ["clinical testing", "TEST", 334, 350], ["the vaccines", "TREATMENT", 393, 405]]], ["As an alternative, the manipulations of antimicrobial properties of milk can be carried out in ruminants.", [["milk", "ANATOMY", 68, 72], ["milk", "ORGANISM_SUBSTANCE", 68, 72], ["antimicrobial properties of milk", "TREATMENT", 40, 72]]], ["Cattle can be successfully immunized against a battery of human pathogens (Jenkins et al., 1999).", [["Cattle", "ORGANISM", 0, 6], ["human", "ORGANISM", 58, 63], ["human", "SPECIES", 58, 63], ["Cattle", "SPECIES", 0, 6], ["human", "SPECIES", 58, 63], ["human pathogens", "PROBLEM", 58, 73]]], ["Pathogen-specific antibodies can be found in substantial concentrations in bovine colostrum and milk and can be processed to provide a marketable product (Stephan et al., 1990).", [["colostrum", "ANATOMY", 82, 91], ["milk", "ANATOMY", 96, 100], ["bovine", "ORGANISM", 75, 81], ["colostrum", "ORGANISM_SUBSTANCE", 82, 91], ["milk", "ORGANISM_SUBSTANCE", 96, 100], ["Pathogen-specific antibodies", "PROTEIN", 0, 28], ["bovine", "SPECIES", 75, 81], ["colostrum", "SPECIES", 82, 91], ["bovine", "SPECIES", 75, 81], ["Pathogen", "PROBLEM", 0, 8]]], ["Cow's milk containing antibodies directed against rotavirus has been successfully used to prevent rotavirus-induced diarrhea in children (Ebina, 1996).", [["milk", "ANATOMY", 6, 10], ["diarrhea", "DISEASE", 116, 124], ["milk", "ORGANISM_SUBSTANCE", 6, 10], ["rotavirus", "ORGANISM", 50, 59], ["rotavirus", "ORGANISM", 98, 107], ["children", "ORGANISM", 128, 136], ["antibodies", "PROTEIN", 22, 32], ["children", "SPECIES", 128, 136], ["rotavirus", "SPECIES", 50, 59], ["rotavirus", "SPECIES", 98, 107], ["Cow's milk containing antibodies", "TREATMENT", 0, 32], ["rotavirus", "TREATMENT", 50, 59], ["rotavirus", "PROBLEM", 98, 107], ["diarrhea", "PROBLEM", 116, 124], ["diarrhea", "OBSERVATION", 116, 124]]], ["In another experiment, disease symptoms caused by enterotoxigenic E. coli (ETEC) were efficiently suppressed in adult volunteers by cow's milk containing ETEC-specific immunoglobulin (Freedman et al., 1998).", [["milk", "ANATOMY", 138, 142], ["enterotoxigenic E. coli", "DISEASE", 50, 73], ["ETEC", "CHEMICAL", 154, 158], ["enterotoxigenic E. coli", "ORGANISM", 50, 73], ["ETEC", "ORGANISM", 75, 79], ["volunteers", "ORGANISM", 118, 128], ["cow", "ORGANISM", 132, 135], ["milk", "ORGANISM_SUBSTANCE", 138, 142], ["ETEC", "SIMPLE_CHEMICAL", 154, 158], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 168, 182], ["immunoglobulin", "PROTEIN", 168, 182], ["E. coli", "SPECIES", 66, 73], ["cow", "SPECIES", 132, 135], ["E. coli", "SPECIES", 66, 73], ["ETEC", "SPECIES", 75, 79], ["cow", "SPECIES", 132, 135], ["disease symptoms", "PROBLEM", 23, 39], ["enterotoxigenic E. coli", "PROBLEM", 50, 73]]], ["These examples demonstrate that bovine antibodies in milk are able to control pathogen-induced diseases in humans.", [["milk", "ANATOMY", 53, 57], ["bovine", "ORGANISM", 32, 38], ["milk", "ORGANISM_SUBSTANCE", 53, 57], ["humans", "ORGANISM", 107, 113], ["bovine antibodies", "PROTEIN", 32, 49], ["bovine", "SPECIES", 32, 38], ["humans", "SPECIES", 107, 113], ["bovine", "SPECIES", 32, 38], ["humans", "SPECIES", 107, 113], ["bovine antibodies in milk", "PROBLEM", 32, 57], ["induced diseases in humans", "PROBLEM", 87, 113], ["diseases", "OBSERVATION", 95, 103]]], ["Cattle may also be immunized with pathogen-neutralizing antibodies to generate milk containing antiidiotypes, thereby providing a recombinant vaccine.Transgenesis ::: Antibodies and antiidiotypes ::: Potential targets for manipulationAlternatively, ruminants expressing pathogen-neutralizing antibodies can be generated by transgenesis.", [["milk", "ANATOMY", 79, 83], ["Cattle", "ORGANISM", 0, 6], ["milk", "ORGANISM_SUBSTANCE", 79, 83], ["pathogen-neutralizing antibodies", "PROTEIN", 34, 66], ["pathogen-neutralizing antibodies", "PROTEIN", 270, 302], ["Cattle", "SPECIES", 0, 6], ["Cattle", "SPECIES", 0, 6], ["pathogen", "PROBLEM", 34, 42], ["neutralizing antibodies", "TREATMENT", 43, 66], ["antiidiotypes", "TREATMENT", 95, 108], ["a recombinant vaccine", "TREATMENT", 128, 149], ["manipulation", "TREATMENT", 222, 234], ["neutralizing antibodies", "PROBLEM", 279, 302], ["may also be", "UNCERTAINTY", 7, 18]]], ["This has a variety of advantages.", [["variety", "OBSERVATION_MODIFIER", 11, 18]]], ["Transgenesis circumvents the problem of differences in isotype usage in milk.", [["milk", "ANATOMY", 72, 76], ["milk", "ORGANISM_SUBSTANCE", 72, 76]]], ["Cows mainly produce IgG, whereas human milk mainly contains IgA (Larson, 1992).", [["milk", "ANATOMY", 39, 43], ["Cows", "ORGANISM", 0, 4], ["IgG", "GENE_OR_GENE_PRODUCT", 20, 23], ["human", "ORGANISM", 33, 38], ["milk", "ORGANISM_SUBSTANCE", 39, 43], ["IgA", "GENE_OR_GENE_PRODUCT", 60, 63], ["IgG", "PROTEIN", 20, 23], ["IgA", "PROTEIN", 60, 63], ["Cows", "SPECIES", 0, 4], ["human", "SPECIES", 33, 38], ["milk", "SPECIES", 39, 43], ["human", "SPECIES", 33, 38], ["IgG", "OBSERVATION", 20, 23]]], ["IgG can activate complement via its Fc portion and is very potent against bacteria, whereas IgA (due to its dimeric nature) has a strongly neutralizing effect against viruses.", [["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgA", "GENE_OR_GENE_PRODUCT", 92, 95], ["IgG", "PROTEIN", 0, 3], ["Fc portion", "PROTEIN", 36, 46], ["IgA", "PROTEIN", 92, 95], ["IgG", "TEST", 0, 3], ["bacteria", "PROBLEM", 74, 82], ["IgA", "TEST", 92, 95], ["viruses", "PROBLEM", 167, 174]]], ["Humanized IgA molecules can theoretically be produced in the milk of transgenic ruminants.", [["milk", "ANATOMY", 61, 65], ["IgA", "GENE_OR_GENE_PRODUCT", 10, 13], ["milk", "ORGANISM_SUBSTANCE", 61, 65], ["Humanized IgA molecules", "PROTEIN", 0, 23], ["Humanized IgA molecules", "TREATMENT", 0, 23]]], ["The concentration of the recombinant antibody present in milk would exceed the levels of antibodies generated by vaccination by some orders of magnitude.", [["milk", "ANATOMY", 57, 61], ["milk", "ORGANISM_SUBSTANCE", 57, 61], ["recombinant antibody", "PROTEIN", 25, 45], ["antibodies", "PROTEIN", 89, 99], ["the recombinant antibody", "TREATMENT", 21, 45], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["recombinant", "OBSERVATION_MODIFIER", 25, 36], ["antibody", "OBSERVATION", 37, 45]]], ["Antibody concentrations of 10 mg/mL have been obtained in transgenic goats (Pollock et al., 1999), while the total immunoglobulin content of ruminant milk is about 1 mg/ml.", [["milk", "ANATOMY", 150, 154], ["goats", "ORGANISM", 69, 74], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 115, 129], ["ruminant", "ORGANISM", 141, 149], ["milk", "ORGANISM_SUBSTANCE", 150, 154], ["immunoglobulin", "PROTEIN", 115, 129], ["goats", "SPECIES", 69, 74], ["milk", "SPECIES", 150, 154], ["goats", "SPECIES", 69, 74], ["Antibody concentrations", "TEST", 0, 23], ["the total immunoglobulin content of ruminant milk", "TREATMENT", 105, 154]]], ["In addition, the most potent antibodies directed against a given pathogen can be selected in vitro.Transgenesis ::: Antibodies and antiidiotypes ::: Potential targets for manipulationHowever, there are also serious disadvantages of the transgenic approach.", [["antibodies", "PROTEIN", 29, 39], ["the most potent antibodies", "TREATMENT", 13, 39], ["pathogen", "PROBLEM", 65, 73], ["manipulation", "TREATMENT", 171, 183], ["the transgenic approach", "TREATMENT", 232, 255], ["serious", "OBSERVATION_MODIFIER", 207, 214]]], ["Transgenesis will lead to milk containing only one monospecific antibody directed against a single epitope (in contrast to vaccination, which leads to a whole battery of pathogen-specific antibodies).", [["milk", "ANATOMY", 26, 30], ["milk", "ORGANISM_SUBSTANCE", 26, 30], ["monospecific antibody", "PROTEIN", 51, 72], ["pathogen-specific antibodies", "PROTEIN", 170, 198], ["milk", "TREATMENT", 26, 30], ["one monospecific antibody", "TREATMENT", 47, 72], ["a single epitope (in contrast to vaccination", "TREATMENT", 90, 134], ["pathogen", "PROBLEM", 170, 178]]], ["Pathogens are often able to evade the neutralizing effect of an antibody by mutating the recognized protein domains.", [["protein domains", "PROTEIN", 100, 115], ["Pathogens", "PROBLEM", 0, 9], ["an antibody", "TEST", 61, 72]]], ["Therefore, antibodies expressed in the milk of transgenic animals will have to be selected carefully, so that they are directed against essential epitopes, which cannot be mutated without impairing infectivity (Sola et al., 1998).", [["milk", "ANATOMY", 39, 43], ["milk", "ORGANISM_SUBSTANCE", 39, 43], ["antibodies", "PROTEIN", 11, 21], ["essential epitopes", "PROTEIN", 136, 154], ["antibodies", "TREATMENT", 11, 21], ["transgenic animals", "TREATMENT", 47, 65], ["essential epitopes", "PROBLEM", 136, 154]]], ["The market for milk as a nutraceutical containing a recombinant, pathogen-neutralizing antibody may be therefore only profitable enough for some exceptional human pathogens with worldwide significance.", [["milk", "ANATOMY", 15, 19], ["milk", "ORGANISM_SUBSTANCE", 15, 19], ["human", "ORGANISM", 157, 162], ["recombinant, pathogen-neutralizing antibody", "PROTEIN", 52, 95], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 157, 162], ["milk", "TREATMENT", 15, 19], ["a nutraceutical", "TREATMENT", 23, 38], ["pathogen", "PROBLEM", 65, 73], ["neutralizing antibody", "PROBLEM", 74, 95]]], ["The biggest disadvantage of transgenic technology will be the current adverse public perception.", [["transgenic technology", "TREATMENT", 28, 49], ["biggest", "OBSERVATION_MODIFIER", 4, 11]]], ["However, the transgenic approach may find public approval in the area of animal health where it could partly obviate the need for antibiotics.Transgenesis ::: Antibodies and antiidiotypes ::: Potential targets for manipulationThe porcine coronavirus transmissible gastroenteritis virus (TGEV) illustrates the possible application of transgene-mediated modification of milk as a means to prevent disease.", [["milk", "ANATOMY", 368, 372], ["coronavirus transmissible gastroenteritis", "DISEASE", 238, 279], ["TGEV", "DISEASE", 287, 291], ["porcine coronavirus transmissible gastroenteritis virus", "ORGANISM", 230, 285], ["TGEV", "ORGANISM", 287, 291], ["milk", "ORGANISM_SUBSTANCE", 368, 372], ["porcine coronavirus transmissible gastroenteritis virus", "SPECIES", 230, 285], ["porcine coronavirus transmissible gastroenteritis virus", "SPECIES", 230, 285], ["TGEV", "SPECIES", 287, 291], ["the transgenic approach", "TREATMENT", 9, 32], ["antibiotics", "TREATMENT", 130, 141], ["manipulation", "TREATMENT", 214, 226], ["The porcine coronavirus transmissible gastroenteritis virus", "PROBLEM", 226, 285], ["transgene-mediated modification of milk", "TREATMENT", 333, 372], ["disease", "PROBLEM", 395, 402], ["porcine coronavirus", "OBSERVATION", 230, 249], ["transmissible", "OBSERVATION_MODIFIER", 250, 263], ["gastroenteritis virus", "OBSERVATION", 264, 285]]], ["TGEV causes gastroenteritis and diarrhea in pigs (Enjuanes and van der Zeijst, 1995).", [["TGEV", "DISEASE", 0, 4], ["gastroenteritis", "DISEASE", 12, 27], ["diarrhea", "DISEASE", 32, 40], ["TGEV", "ORGANISM", 0, 4], ["pigs", "ORGANISM", 44, 48], ["TGEV", "SPECIES", 0, 4], ["pigs", "SPECIES", 44, 48], ["TGEV", "SPECIES", 0, 4], ["pigs", "SPECIES", 44, 48], ["TGEV", "PROBLEM", 0, 4], ["gastroenteritis", "PROBLEM", 12, 27], ["diarrhea", "PROBLEM", 32, 40], ["gastroenteritis", "OBSERVATION", 12, 27], ["diarrhea", "OBSERVATION", 32, 40]]], ["Newborn animals are most severely affected by the infections with a mortality of up to 100%.", [["infections", "DISEASE", 50, 60], ["animals", "ORGANISM", 8, 15], ["the infections", "PROBLEM", 46, 60], ["most severely", "OBSERVATION_MODIFIER", 20, 33], ["infections", "OBSERVATION", 50, 60]]], ["Coronaviruses in general elicit an immune response that is highly strain-specific and often short-lived.", [["Coronaviruses", "PROBLEM", 0, 13]]], ["Although a variety of routes were investigated to obtain useful vaccines against TGEV, no marketable vaccine has been developed yet.", [["TGEV", "DISEASE", 81, 85], ["TGEV", "ORGANISM", 81, 85], ["TGEV", "SPECIES", 81, 85], ["TGEV", "SPECIES", 81, 85], ["useful vaccines", "TREATMENT", 57, 72], ["TGEV", "PROBLEM", 81, 85], ["marketable vaccine", "TREATMENT", 90, 108]]], ["Oral administration of neutralizing antibody has been shown to efficiently prevent TGEV infection (Torres et al., 1995).", [["Oral", "ANATOMY", 0, 4], ["TGEV infection", "DISEASE", 83, 97], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["TGEV", "ORGANISM", 83, 87], ["neutralizing antibody", "PROTEIN", 23, 44], ["TGEV", "SPECIES", 83, 87], ["Oral administration of neutralizing antibody", "TREATMENT", 0, 44], ["TGEV infection", "PROBLEM", 83, 97], ["infection", "OBSERVATION", 88, 97]]], ["Milk containing this neutralizing antibody may therefore provide a route to protecting piglets against TGEV infections Sola et al., 1998, Castilla et al., 1998.", [["TGEV infections", "DISEASE", 103, 118], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["piglets", "ORGANISM", 87, 94], ["TGEV", "ORGANISM", 103, 107], ["neutralizing antibody", "PROTEIN", 21, 42], ["piglets", "SPECIES", 87, 94], ["TGEV", "SPECIES", 103, 107], ["Milk", "TREATMENT", 0, 4], ["this neutralizing antibody", "TREATMENT", 16, 42], ["TGEV infections", "PROBLEM", 103, 118]]], ["To provide a proof of principle, a mouse model for this approach was established (Fig. 1).", [["mouse", "ORGANISM", 35, 40], ["mouse", "SPECIES", 35, 40], ["mouse", "SPECIES", 35, 40], ["a mouse model", "TREATMENT", 33, 46], ["this approach", "TREATMENT", 51, 64]]], ["Transgenic mice, which express a highly neutralizing antibody directed against a murine coronavirus (the mouse hepatitis virus MHV-JHM) in the lactating mammary gland, were generated.", [["mammary gland", "ANATOMY", 153, 166], ["hepatitis", "DISEASE", 111, 120], ["Transgenic mice", "ORGANISM", 0, 15], ["murine coronavirus", "ORGANISM", 81, 99], ["mouse hepatitis virus MHV-JHM", "ORGANISM", 105, 134], ["mammary gland", "ORGAN", 153, 166], ["mice", "SPECIES", 11, 15], ["murine", "SPECIES", 81, 87], ["coronavirus", "SPECIES", 88, 99], ["mouse", "SPECIES", 105, 110], ["hepatitis virus MHV", "SPECIES", 111, 130], ["mice", "SPECIES", 11, 15], ["murine coronavirus", "SPECIES", 81, 99], ["mouse hepatitis virus MHV-JHM", "SPECIES", 105, 134], ["a highly neutralizing antibody", "TREATMENT", 31, 61], ["a murine coronavirus", "PROBLEM", 79, 99], ["the mouse hepatitis virus MHV", "TREATMENT", 101, 130], ["JHM", "PROBLEM", 131, 134], ["lactating mammary", "ANATOMY", 143, 160], ["gland", "ANATOMY", 161, 166]]], ["Newborn mice suckling the milk of transgenic dams were fully protected against a challenge with a lethal dose (7000\u00d7LD50) of MHV-JHM.", [["milk", "ANATOMY", 26, 30], ["mice", "ORGANISM", 8, 12], ["milk", "ORGANISM_SUBSTANCE", 26, 30], ["dams", "ORGANISM", 45, 49], ["MHV-JHM", "ORGANISM", 125, 132], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["MHV", "SPECIES", 125, 128], ["a lethal dose", "TREATMENT", 96, 109]]], ["Cross-fostering experiments demonstrated that the milk-borne recombinant antibody was sufficient for this protection (Kolb et al., 2001).", [["milk", "ORGANISM_SUBSTANCE", 50, 54], ["milk-borne recombinant antibody", "PROTEIN", 50, 81], ["the milk-borne recombinant antibody", "TREATMENT", 46, 81]]], ["Although there are differences in the disease pattern elicited by MHV and TGEV and the immunoglobulin isotypes typically found in the milk of mice and pigs, these experiments demonstrate that modification of milk via a transgenic route can have a very beneficial impact on animal health.Transgenesis ::: Antibodies and antiidiotypes ::: Potential targets for manipulationCombinations of transgenesis and vaccination may provide other promising approaches for the generation of milk containing pathogen-specific antibodies.", [["milk", "ANATOMY", 134, 138], ["milk", "ANATOMY", 208, 212], ["milk", "ANATOMY", 477, 481], ["MHV", "ORGANISM", 66, 69], ["TGEV", "ORGANISM", 74, 78], ["immunoglobulin isotypes", "GENE_OR_GENE_PRODUCT", 87, 110], ["milk", "ORGANISM_SUBSTANCE", 134, 138], ["mice", "ORGANISM", 142, 146], ["pigs", "ORGANISM", 151, 155], ["milk", "ORGANISM_SUBSTANCE", 208, 212], ["milk", "ORGANISM_SUBSTANCE", 477, 481], ["immunoglobulin isotypes", "PROTEIN", 87, 110], ["pathogen-specific antibodies", "PROTEIN", 493, 521], ["milk", "SPECIES", 134, 138], ["mice", "SPECIES", 142, 146], ["pigs", "SPECIES", 151, 155], ["MHV", "SPECIES", 66, 69], ["TGEV", "SPECIES", 74, 78], ["mice", "SPECIES", 142, 146], ["pigs", "SPECIES", 151, 155], ["the disease pattern", "PROBLEM", 34, 53], ["MHV", "PROBLEM", 66, 69], ["TGEV", "PROBLEM", 74, 78], ["the immunoglobulin isotypes", "TEST", 83, 110], ["a transgenic route", "TREATMENT", 217, 235], ["manipulation", "TREATMENT", 359, 371], ["transgenesis and vaccination", "TREATMENT", 387, 415], ["the generation of milk containing pathogen", "TREATMENT", 459, 501], ["differences", "OBSERVATION_MODIFIER", 19, 30], ["disease", "OBSERVATION", 38, 45], ["MHV", "OBSERVATION_MODIFIER", 66, 69], ["immunoglobulin isotypes", "OBSERVATION", 87, 110]]], ["Cattle mainly express antibodies of the IgG isotype, whereas IgA is the predominant isotype in humans (Larson, 1992).", [["Cattle", "ORGANISM", 0, 6], ["IgG", "GENE_OR_GENE_PRODUCT", 40, 43], ["IgA", "GENE_OR_GENE_PRODUCT", 61, 64], ["humans", "ORGANISM", 95, 101], ["antibodies", "PROTEIN", 22, 32], ["IgG isotype", "PROTEIN", 40, 51], ["IgA", "PROTEIN", 61, 64], ["Cattle", "SPECIES", 0, 6], ["humans", "SPECIES", 95, 101], ["Cattle", "SPECIES", 0, 6], ["humans", "SPECIES", 95, 101], ["the IgG isotype", "PROBLEM", 36, 51], ["IgG isotype", "OBSERVATION", 40, 51], ["predominant", "OBSERVATION_MODIFIER", 72, 83], ["isotype", "OBSERVATION", 84, 91]]], ["In mice, IgG and IgA are present at roughly equal levels (Larson, 1992).", [["mice", "ORGANISM", 3, 7], ["IgG", "GENE_OR_GENE_PRODUCT", 9, 12], ["IgA", "GENE_OR_GENE_PRODUCT", 17, 20], ["IgG", "PROTEIN", 9, 12], ["IgA", "PROTEIN", 17, 20], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["IgG", "TEST", 9, 12]]], ["By overexpressing the polymeric immunoglobulin transporter in the lactating mammary gland of transgenic mice, the IgA content of murine milk could be increased twofold (De Groot et al., 2000).", [["mammary gland", "ANATOMY", 76, 89], ["milk", "ANATOMY", 136, 140], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 32, 46], ["mammary gland", "ORGAN", 76, 89], ["mice", "ORGANISM", 104, 108], ["IgA", "GENE_OR_GENE_PRODUCT", 114, 117], ["murine", "ORGANISM", 129, 135], ["milk", "ORGANISM_SUBSTANCE", 136, 140], ["polymeric immunoglobulin transporter", "PROTEIN", 22, 58], ["IgA", "PROTEIN", 114, 117], ["mice", "SPECIES", 104, 108], ["murine", "SPECIES", 129, 135], ["mice", "SPECIES", 104, 108], ["the polymeric immunoglobulin transporter", "TREATMENT", 18, 58], ["mammary gland", "ANATOMY", 76, 89], ["increased", "OBSERVATION_MODIFIER", 150, 159]]], ["A similar approach may also be used to generate cattle that are able to secrete increased amounts of IgA into milk.", [["milk", "ANATOMY", 110, 114], ["cattle", "ORGANISM", 48, 54], ["IgA", "GENE_OR_GENE_PRODUCT", 101, 104], ["milk", "ORGANISM_SUBSTANCE", 110, 114], ["IgA", "PROTEIN", 101, 104], ["cattle", "SPECIES", 48, 54], ["cattle", "SPECIES", 48, 54], ["A similar approach", "TREATMENT", 0, 18]]], ["Immunization of these transgenic cows would then lead to milk rich in pathogen-specific IgA.Transgenesis ::: Antibodies and antiidiotypes ::: Potential targets for manipulationBy using homologous recombination, researchers at Abigenix (\u3008www.abigenix.com\u3009) have replaced the murine immunoglobulin loci by their human counterparts.", [["milk", "ANATOMY", 57, 61], ["cows", "ORGANISM", 33, 37], ["milk", "ORGANISM_SUBSTANCE", 57, 61], ["IgA", "GENE_OR_GENE_PRODUCT", 88, 91], ["murine", "ORGANISM", 274, 280], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 281, 295], ["human", "ORGANISM", 310, 315], ["IgA", "PROTEIN", 88, 91], ["murine immunoglobulin loci", "DNA", 274, 300], ["cows", "SPECIES", 33, 37], ["murine", "SPECIES", 274, 280], ["human", "SPECIES", 310, 315], ["human", "SPECIES", 310, 315], ["Immunization", "TREATMENT", 0, 12], ["these transgenic cows", "TREATMENT", 16, 37], ["homologous recombination", "TREATMENT", 185, 209], ["the murine immunoglobulin loci", "TREATMENT", 270, 300]]], ["The mice will therefore respond to immunization by producing human antibodies.", [["mice", "ORGANISM", 4, 8], ["human", "ORGANISM", 61, 66], ["human antibodies", "PROTEIN", 61, 77], ["mice", "SPECIES", 4, 8], ["human", "SPECIES", 61, 66], ["mice", "SPECIES", 4, 8], ["human", "SPECIES", 61, 66], ["immunization", "TREATMENT", 35, 47]]], ["Monoclonal antibodies derived from these mice are human monoclonal antibodies and can be used therapeutically with minimal side effects.", [["mice", "ORGANISM", 41, 45], ["human", "ORGANISM", 50, 55], ["Monoclonal antibodies", "PROTEIN", 0, 21], ["human monoclonal antibodies", "PROTEIN", 50, 77], ["mice", "SPECIES", 41, 45], ["human", "SPECIES", 50, 55], ["mice", "SPECIES", 41, 45], ["human", "SPECIES", 50, 55], ["Monoclonal antibodies", "TEST", 0, 21], ["human monoclonal antibodies", "TREATMENT", 50, 77], ["minimal side effects", "PROBLEM", 115, 135]]], ["A similar approach could be taken in ruminants by using nuclear transfer techniques.", [["nuclear", "ANATOMY", 56, 63]]], ["Ruminants thus modified could be immunized against pathogens of interest and produce milk containing human antibodies.Lymphocytes ::: Potential targets for manipulationThere is growing evidence that lymphocytes are transferred from mother to offspring via milk.", [["milk", "ANATOMY", 85, 89], ["Lymphocytes", "ANATOMY", 118, 129], ["lymphocytes", "ANATOMY", 199, 210], ["milk", "ANATOMY", 256, 260], ["milk", "ORGANISM_SUBSTANCE", 85, 89], ["human", "ORGANISM", 101, 106], ["Lymphocytes", "CELL", 118, 129], ["lymphocytes", "CELL", 199, 210], ["milk", "ORGANISM_SUBSTANCE", 256, 260], ["human antibodies", "PROTEIN", 101, 117], ["Lymphocytes", "CELL_TYPE", 118, 129], ["lymphocytes", "CELL_TYPE", 199, 210], ["milk", "SPECIES", 85, 89], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["Lymphocytes", "TEST", 118, 129], ["manipulation", "TREATMENT", 156, 168], ["lymphocytes", "PROBLEM", 199, 210], ["lymphocytes", "OBSERVATION", 199, 210]]], ["In mouse experiments, B-cells carrying a reporter gene could be transferred to suckling mice via milk Zhou et al., 2000, Arvola et al., 2000.", [["B-cells", "ANATOMY", 22, 29], ["mouse", "ORGANISM", 3, 8], ["B-cells", "CELL", 22, 29], ["mice", "ORGANISM", 88, 92], ["B-cells", "CELL_TYPE", 22, 29], ["reporter gene", "DNA", 41, 54], ["mouse", "SPECIES", 3, 8], ["mice", "SPECIES", 88, 92], ["mouse", "SPECIES", 3, 8], ["mice", "SPECIES", 88, 92]]], ["Breast-feeding mothers transfer lymphocytes to their babies, which induce an immune tolerance of the baby against the mother.", [["Breast", "ANATOMY", 0, 6], ["lymphocytes", "ANATOMY", 32, 43], ["mothers", "ORGANISM", 15, 22], ["lymphocytes", "CELL", 32, 43], ["babies", "ORGANISM", 53, 59], ["baby", "ORGANISM_SUBDIVISION", 101, 105], ["lymphocytes", "CELL_TYPE", 32, 43]]], ["One well-documented consequence of this is the fact that breast-feeding mothers are often suitable organ donors for their children in later life (Hanson, 2000).", [["breast", "ANATOMY", 57, 63], ["organ", "ANATOMY", 99, 104], ["breast", "ORGANISM_SUBDIVISION", 57, 63], ["mothers", "ORGANISM", 72, 79], ["organ", "ORGAN", 99, 104], ["donors", "ORGANISM", 105, 111], ["children", "ORGANISM", 122, 130], ["children", "SPECIES", 122, 130], ["breast", "ANATOMY", 57, 63]]], ["Immunization during pregnancy may also affect the properties of these transferred immune cells.", [["immune cells", "ANATOMY", 82, 94], ["immune cells", "CELL", 82, 94], ["immune cells", "CELL_TYPE", 82, 94], ["Immunization", "TREATMENT", 0, 12]]], ["However, too little is known about lymphocyte transfer from mother to offspring to warrant direct manipulations of this process.Lactoferrin and lactoferricin ::: Potential targets for manipulationLactoferrin is a glycosylated milk protein, which is also found in other mucosal secretions and is expressed in neutrophils.", [["lymphocyte", "ANATOMY", 35, 45], ["mucosal secretions", "ANATOMY", 269, 287], ["neutrophils", "ANATOMY", 308, 319], ["lactoferricin", "CHEMICAL", 144, 157], ["lactoferricin", "CHEMICAL", 144, 157], ["lymphocyte", "CELL", 35, 45], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 128, 139], ["lactoferricin", "SIMPLE_CHEMICAL", 144, 157], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 196, 207], ["milk", "ORGANISM_SUBSTANCE", 226, 230], ["mucosal secretions", "ORGANISM_SUBSTANCE", 269, 287], ["neutrophils", "CELL", 308, 319], ["Lactoferrin", "PROTEIN", 196, 207], ["glycosylated milk protein", "PROTEIN", 213, 238], ["neutrophils", "CELL_TYPE", 308, 319], ["direct manipulations of this process", "TREATMENT", 91, 127], ["Lactoferrin", "TREATMENT", 128, 139], ["manipulationLactoferrin", "TREATMENT", 184, 207], ["a glycosylated milk protein", "TREATMENT", 211, 238], ["neutrophils", "TEST", 308, 319], ["mucosal", "ANATOMY", 269, 276], ["secretions", "OBSERVATION", 277, 287]]], ["It possesses a wide variety of antimicrobial functions (Table 3).", [["wide", "OBSERVATION_MODIFIER", 15, 19], ["variety", "OBSERVATION_MODIFIER", 20, 27], ["antimicrobial functions", "OBSERVATION", 31, 54]]], ["Its actions against viruses, bacteria, and fungi can be classified into several different modes of action.", [["viruses", "PROBLEM", 20, 27], ["bacteria", "PROBLEM", 29, 37], ["fungi", "PROBLEM", 43, 48]]], ["(1) By sequestering free iron, lactoferrin can restrict the growth of Gram-positive and Gram-negative bacteria and a variety of fungi Kuipers et al., 1999, Cirioni et al., 2000, Andersson et al., 2000.", [["iron", "CHEMICAL", 25, 29], ["iron", "CHEMICAL", 25, 29], ["free iron", "SIMPLE_CHEMICAL", 20, 29], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 31, 42], ["Gram-positive", "GENE_OR_GENE_PRODUCT", 70, 83], ["Gram-", "GENE_OR_GENE_PRODUCT", 88, 93], ["lactoferrin", "PROTEIN", 31, 42], ["sequestering free iron", "TREATMENT", 7, 29], ["lactoferrin", "TREATMENT", 31, 42], ["Gram-positive and Gram-negative bacteria", "PROBLEM", 70, 110], ["negative bacteria", "OBSERVATION", 93, 110]]], ["The bacteriostatic effects can be counteracted in vitro by addition of excess iron.", [["iron", "CHEMICAL", 78, 82], ["iron", "CHEMICAL", 78, 82], ["iron", "SIMPLE_CHEMICAL", 78, 82], ["The bacteriostatic effects", "PROBLEM", 0, 26], ["excess iron", "TREATMENT", 71, 82], ["bacteriostatic effects", "OBSERVATION", 4, 26]]], ["(2) Lactoferrin and (even more potently) its pepsin-breakdown products lactoferricin B and H (from bovine and human lactoferrin, respectively), which are derived from the N-terminus of the protein, have a bacteriocidal effect by interfering with bacterial membrane function (Hwang et al., 1998).", [["membrane", "ANATOMY", 256, 264], ["lactoferricin B", "CHEMICAL", 71, 86], ["lactoferricin B and H", "CHEMICAL", 71, 92], ["N", "CHEMICAL", 171, 172], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 4, 15], ["pepsin", "GENE_OR_GENE_PRODUCT", 45, 51], ["lactoferricin B", "SIMPLE_CHEMICAL", 71, 86], ["H", "SIMPLE_CHEMICAL", 91, 92], ["bovine", "ORGANISM", 99, 105], ["human", "ORGANISM", 110, 115], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 116, 127], ["membrane", "CELLULAR_COMPONENT", 256, 264], ["pepsin", "PROTEIN", 45, 51], ["lactoferricin B", "PROTEIN", 71, 86], ["H", "PROTEIN", 91, 92], ["human lactoferrin", "PROTEIN", 110, 127], ["N-terminus", "PROTEIN", 171, 181], ["bovine", "SPECIES", 99, 105], ["human", "SPECIES", 110, 115], ["bovine", "SPECIES", 99, 105], ["human", "SPECIES", 110, 115], ["Lactoferrin", "TREATMENT", 4, 15], ["its pepsin", "TREATMENT", 41, 51], ["breakdown products", "TREATMENT", 52, 70], ["lactoferricin B and H (from bovine and human lactoferrin", "TREATMENT", 71, 127], ["a bacteriocidal effect", "PROBLEM", 203, 225], ["bacterial membrane function", "PROBLEM", 246, 273], ["bacteriocidal effect", "OBSERVATION", 205, 225]]], ["Lactoferrin's activity against fungal infection in vitro and in vivo Kuipers et al., 1999, Bellamy et al., 1993, Wakabayashi et al., 2000 may have the same biochemical basis.", [["fungal infection", "DISEASE", 31, 47], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 0, 11], ["Lactoferrin", "PROTEIN", 0, 11], ["Lactoferrin", "TREATMENT", 0, 11], ["fungal infection", "PROBLEM", 31, 47]]], ["(3) Lactoferrin can also bind bacterial lipopolysaccharide (LPS), thereby impairing bacterial cell wall/membrane function Nuijens et al., 1996, Odell et al., 1996.", [["cell wall", "ANATOMY", 94, 103], ["membrane", "ANATOMY", 104, 112], ["lipopolysaccharide", "CHEMICAL", 40, 58], ["LPS", "CHEMICAL", 60, 63], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 4, 15], ["bacterial lipopolysaccharide", "GENE_OR_GENE_PRODUCT", 30, 58], ["LPS", "SIMPLE_CHEMICAL", 60, 63], ["membrane", "CELLULAR_COMPONENT", 104, 112], ["Lactoferrin", "PROTEIN", 4, 15], ["Lactoferrin", "TREATMENT", 4, 15], ["bacterial lipopolysaccharide (LPS)", "TEST", 30, 64], ["thereby impairing bacterial cell wall/membrane function", "PROBLEM", 66, 121], ["bacterial cell", "OBSERVATION", 84, 98], ["wall", "ANATOMY_MODIFIER", 99, 103], ["membrane function", "OBSERVATION", 104, 121]]], ["By binding free LPS or LPS bound to other proteins, it can also act as an antiinflammatory immune modulator Baveye et al., 1999, Baveye et al., 2000.", [["LPS", "CHEMICAL", 16, 19], ["LPS", "CHEMICAL", 23, 26], ["LPS", "SIMPLE_CHEMICAL", 16, 19], ["LPS", "SIMPLE_CHEMICAL", 23, 26], ["LPS bound", "PROBLEM", 23, 32], ["an antiinflammatory immune modulator", "TREATMENT", 71, 107]]], ["(4) Lactoferrin purified from milk and colostrum is able to block human cytomegalovirus (hCMV) replication as well as inhibit HIV-1-induced cytopathic effects.", [["milk", "ANATOMY", 30, 34], ["colostrum", "ANATOMY", 39, 48], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 4, 15], ["milk", "ORGANISM_SUBSTANCE", 30, 34], ["colostrum", "ORGANISM_SUBSTANCE", 39, 48], ["human cytomegalovirus", "ORGANISM", 66, 87], ["hCMV", "ORGANISM", 89, 93], ["HIV-1", "ORGANISM", 126, 131], ["Lactoferrin", "PROTEIN", 4, 15], ["milk", "SPECIES", 30, 34], ["human", "SPECIES", 66, 71], ["HIV-1", "SPECIES", 126, 131], ["human cytomegalovirus", "SPECIES", 66, 87], ["hCMV", "SPECIES", 89, 93], ["HIV-1", "SPECIES", 126, 131], ["Lactoferrin", "TREATMENT", 4, 15], ["colostrum", "TREATMENT", 39, 48], ["human cytomegalovirus (hCMV) replication", "TREATMENT", 66, 106], ["cytopathic effects", "PROBLEM", 140, 158], ["cytomegalovirus", "OBSERVATION", 72, 87], ["cytopathic", "OBSERVATION_MODIFIER", 140, 150]]], ["Negatively charged lactoferrin derivatives obtained by acylation of the amino function of lysine residues even had a fourfold stronger antiviral activity against HIV-1 but lost their anti-hCMV activity.", [["lysine", "CHEMICAL", 90, 96], ["amino", "CHEMICAL", 72, 77], ["lysine", "CHEMICAL", 90, 96], ["lactoferrin derivatives", "SIMPLE_CHEMICAL", 19, 42], ["amino", "AMINO_ACID", 72, 77], ["lysine", "AMINO_ACID", 90, 96], ["HIV-1", "ORGANISM", 162, 167], ["anti-hCMV", "CANCER", 183, 192], ["HIV-1", "SPECIES", 162, 167], ["HIV-1", "SPECIES", 162, 167], ["anti-hCMV", "SPECIES", 183, 192], ["Negatively charged lactoferrin derivatives", "TREATMENT", 0, 42], ["the amino function of lysine residues", "TREATMENT", 68, 105], ["lactoferrin derivatives", "OBSERVATION", 19, 42]]], ["Native and acylated lactoferrin strongly binds to the V3 domain of the HIV envelope protein gp120, suggesting that the shielding of this domain results in the inhibition of virus\u2013cell fusion and virus entry.", [["virus\u2013cell", "ANATOMY", 173, 183], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 20, 31], ["gp120", "GENE_OR_GENE_PRODUCT", 92, 97], ["virus\u2013cell", "GENE_OR_GENE_PRODUCT", 173, 183], ["lactoferrin", "PROTEIN", 20, 31], ["V3 domain", "PROTEIN", 54, 63], ["HIV envelope protein", "PROTEIN", 71, 91], ["gp120", "PROTEIN", 92, 97], ["HIV", "SPECIES", 71, 74], ["Native and acylated lactoferrin", "TREATMENT", 0, 31], ["the HIV envelope protein gp120", "TEST", 67, 97], ["virus\u2013cell fusion", "TREATMENT", 173, 190], ["virus entry", "PROBLEM", 195, 206], ["acylated lactoferrin", "OBSERVATION", 11, 31]]], ["Addition of positive charges to lactoferrin by amination resulted in an increased anti-hCMV activity and a loss of anti-HIV activity (Swart et al., 1998).", [["lactoferrin", "GENE_OR_GENE_PRODUCT", 32, 43], ["anti-hCMV", "CANCER", 82, 91], ["lactoferrin", "PROTEIN", 32, 43], ["anti-hCMV", "PROTEIN", 82, 91], ["lactoferrin", "TREATMENT", 32, 43], ["an increased anti-hCMV activity", "TREATMENT", 69, 100], ["a loss of anti-HIV activity", "PROBLEM", 105, 132], ["positive charges", "OBSERVATION", 12, 28], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["anti-hCMV activity", "OBSERVATION", 82, 100]]], ["(5) Lactoferrin also inhibits the entry of hepatitis virus C (HCV) into susceptible cells by direct interaction with the viral surface glycoproteins (Ikeda et al., 1998).", [["cells", "ANATOMY", 84, 89], ["surface", "ANATOMY", 127, 134], ["hepatitis virus C", "CHEMICAL", 43, 60], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 4, 15], ["hepatitis virus C", "ORGANISM", 43, 60], ["HCV", "ORGANISM", 62, 65], ["cells", "CELL", 84, 89], ["Lactoferrin", "PROTEIN", 4, 15], ["susceptible cells", "CELL_TYPE", 72, 89], ["viral surface glycoproteins", "PROTEIN", 121, 148], ["hepatitis virus C", "SPECIES", 43, 60], ["hepatitis virus", "SPECIES", 43, 58], ["HCV", "SPECIES", 62, 65], ["Lactoferrin", "TREATMENT", 4, 15], ["hepatitis virus C (HCV) into susceptible cells", "PROBLEM", 43, 89]]], ["Pilot studies in HCV-infected patients, however, only demonstrated a moderate antiviral activity in vivo (Tanaka et al., 1999).", [["HCV-infected", "DISEASE", 17, 29], ["HCV", "ORGANISM", 17, 20], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["HCV", "SPECIES", 17, 20], ["Pilot studies", "TEST", 0, 13], ["HCV", "PROBLEM", 17, 20], ["HCV", "OBSERVATION", 17, 20], ["infected", "OBSERVATION_MODIFIER", 21, 29], ["moderate", "OBSERVATION_MODIFIER", 69, 77], ["antiviral activity", "OBSERVATION", 78, 96]]], ["Whereas the antibacterial effects of lactoferrin probably reflect a natural function, the antiviral activities may be fortuitous.", [["lactoferrin", "GENE_OR_GENE_PRODUCT", 37, 48], ["lactoferrin", "PROTEIN", 37, 48], ["lactoferrin", "TREATMENT", 37, 48], ["antibacterial effects", "OBSERVATION", 12, 33], ["natural function", "OBSERVATION", 68, 84]]], ["However, lactoferrin, \u03b1-lactalbumin, and \u03b2-lactoglobulin, which can also be derivatized to yield compounds with strong anti-HIV activity (Swart et al., 1996), may provide lead structures for the development of antiviral drugs (Swart et al., 1999).Lactoferrin and lactoferricin ::: Potential targets for manipulationIn addition to its direct effects on pathogens, lactoferrin fulfills a variety of other functions.", [["\u03b1-lactalbumin", "CHEMICAL", 22, 35], ["\u03b2-lactoglobulin", "CHEMICAL", 41, 56], ["lactoferricin", "CHEMICAL", 263, 276], ["\u03b1-lactalbumin", "CHEMICAL", 22, 35], ["\u03b2-lactoglobulin", "CHEMICAL", 41, 56], ["lactoferricin", "CHEMICAL", 263, 276], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 9, 20], ["\u03b1-lactalbumin", "SIMPLE_CHEMICAL", 22, 35], ["\u03b2-lactoglobulin", "SIMPLE_CHEMICAL", 41, 56], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 247, 258], ["lactoferricin", "SIMPLE_CHEMICAL", 263, 276], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 363, 374], ["lactoferrin", "PROTEIN", 9, 20], ["lactoferrin", "PROTEIN", 363, 374], ["lactoferrin", "TREATMENT", 9, 20], ["\u03b1-lactalbumin", "TREATMENT", 22, 35], ["\u03b2-lactoglobulin", "TREATMENT", 41, 56], ["antiviral drugs", "TREATMENT", 210, 225], ["Lactoferrin", "TREATMENT", 247, 258], ["manipulationIn", "TREATMENT", 303, 317], ["pathogens", "PROBLEM", 352, 361], ["lactoferrin fulfills", "TREATMENT", 363, 383]]], ["Lactoferrin binds to a cell surface receptor (McAbee et al., 1998).", [["cell surface", "ANATOMY", 23, 35], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 0, 11], ["cell", "CELL", 23, 27], ["Lactoferrin", "PROTEIN", 0, 11], ["cell surface receptor", "PROTEIN", 23, 44], ["Lactoferrin binds", "TREATMENT", 0, 17], ["a cell surface receptor", "TREATMENT", 21, 44]]], ["It is taken up into cells and transported to the nucleus, where it binds to DNA Nuijens et al., 1996, Kanyshkova et al., 1999.", [["cells", "ANATOMY", 20, 25], ["nucleus", "ANATOMY", 49, 56], ["cells", "CELL", 20, 25], ["nucleus", "CELLULAR_COMPONENT", 49, 56], ["DNA", "CELLULAR_COMPONENT", 76, 79], ["nucleus", "ANATOMY", 49, 56]]], ["It inhibits growth of tumor cells by modulating the expression and the activity of key G1 regulatory proteins (Damiens et al., 1999) and metastasis of tumors (Iigo et al., 1999).", [["tumor cells", "ANATOMY", 22, 33], ["tumors", "ANATOMY", 151, 157], ["tumor", "DISEASE", 22, 27], ["tumors", "DISEASE", 151, 157], ["tumor cells", "CELL", 22, 33], ["tumors", "CANCER", 151, 157], ["tumor cells", "CELL_TYPE", 22, 33], ["G1 regulatory proteins", "PROTEIN", 87, 109], ["tumor cells", "PROBLEM", 22, 33], ["metastasis of tumors", "PROBLEM", 137, 157], ["growth", "OBSERVATION_MODIFIER", 12, 18], ["tumor cells", "OBSERVATION", 22, 33], ["metastasis", "OBSERVATION", 137, 147], ["tumors", "OBSERVATION", 151, 157]]], ["It also influences cellular responses to Listeria infections Moriishi et al., 1999, Valenti et al., 1999.", [["cellular", "ANATOMY", 19, 27], ["Listeria infections", "DISEASE", 41, 60], ["cellular", "CELL", 19, 27]]], ["Lactoferrin is also reported to significantly decrease the cell number of Helicobacter pylori (a suspected cause of stomach cancer) in the stomach of experimental animals (Wada et al., 1999).Lactoferrin and lactoferricin ::: Potential targets for manipulationDue to the wide variety of applications, lactoferrin has long been a prominent target for recombinant production in a variety of host organisms Krimpenfort et al., 1991, Salmon et al., 1998, Sun et al., 1999, Chong and Langridge, 2000.", [["cell", "ANATOMY", 59, 63], ["stomach cancer", "ANATOMY", 116, 130], ["stomach", "ANATOMY", 139, 146], ["Helicobacter pylori", "DISEASE", 74, 93], ["stomach cancer", "DISEASE", 116, 130], ["lactoferricin", "CHEMICAL", 207, 220], ["lactoferricin", "CHEMICAL", 207, 220], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 0, 11], ["cell", "CELL", 59, 63], ["Helicobacter pylori", "ORGANISM", 74, 93], ["stomach cancer", "CANCER", 116, 130], ["stomach", "ORGAN", 139, 146], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 191, 202], ["lactoferricin", "SIMPLE_CHEMICAL", 207, 220], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 300, 311], ["Lactoferrin", "PROTEIN", 0, 11], ["lactoferrin", "PROTEIN", 300, 311], ["Helicobacter pylori", "SPECIES", 74, 93], ["Helicobacter pylori", "SPECIES", 74, 93], ["Lactoferrin", "TREATMENT", 0, 11], ["Helicobacter pylori", "PROBLEM", 74, 93], ["stomach cancer", "PROBLEM", 116, 130], ["Lactoferrin", "TREATMENT", 191, 202], ["manipulationDue", "TREATMENT", 247, 262], ["lactoferrin", "TREATMENT", 300, 311], ["recombinant production", "PROBLEM", 349, 371], ["cell", "OBSERVATION", 59, 63], ["number", "OBSERVATION_MODIFIER", 64, 70], ["Helicobacter pylori", "OBSERVATION", 74, 93], ["stomach", "ANATOMY", 116, 123], ["cancer", "OBSERVATION", 124, 130], ["stomach", "ANATOMY", 139, 146]]], ["Milk containing high amounts of lactoferrin may be used directly as a nutraceutical to prevent or treat bacterial infections of the digestive tract.", [["digestive tract", "ANATOMY", 132, 147], ["bacterial infections of the digestive tract", "DISEASE", 104, 147], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 32, 43], ["digestive tract", "ORGANISM_SUBDIVISION", 132, 147], ["lactoferrin", "PROTEIN", 32, 43], ["Milk", "TREATMENT", 0, 4], ["lactoferrin", "TREATMENT", 32, 43], ["a nutraceutical", "TREATMENT", 68, 83], ["bacterial infections of the digestive tract", "PROBLEM", 104, 147], ["high amounts", "OBSERVATION_MODIFIER", 16, 28], ["bacterial", "OBSERVATION_MODIFIER", 104, 113], ["infections", "OBSERVATION", 114, 124], ["digestive tract", "ANATOMY", 132, 147]]], ["Lactoferrin purified from milk could serve a variety of other purposes.", [["milk", "ANATOMY", 26, 30], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 0, 11], ["milk", "ORGANISM_SUBSTANCE", 26, 30], ["Lactoferrin", "PROTEIN", 0, 11], ["Lactoferrin", "TREATMENT", 0, 11]]], ["Transgenic cattle expressing human lactoferrin have been generated (Krimpenfort et al., 1991) and the product is in clinical trials (\u3008www.pharming.com/products\u3009).Lactoferrin and lactoferricin ::: Potential targets for manipulationLactoferricin B and H are derived from lactoferrin by pepsin cleavage in the digestive tract.", [["digestive tract", "ANATOMY", 307, 322], ["lactoferricin", "CHEMICAL", 178, 191], ["Lactoferricin B", "CHEMICAL", 230, 245], ["lactoferricin", "CHEMICAL", 178, 191], ["Lactoferricin B and H", "CHEMICAL", 230, 251], ["cattle", "ORGANISM", 11, 17], ["human", "ORGANISM", 29, 34], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 35, 46], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 162, 173], ["lactoferricin", "SIMPLE_CHEMICAL", 178, 191], ["Lactoferricin B", "SIMPLE_CHEMICAL", 230, 245], ["H", "SIMPLE_CHEMICAL", 250, 251], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 269, 280], ["pepsin", "GENE_OR_GENE_PRODUCT", 284, 290], ["digestive tract", "ORGAN", 307, 322], ["human lactoferrin", "PROTEIN", 29, 46], ["lactoferrin", "PROTEIN", 269, 280], ["pepsin", "PROTEIN", 284, 290], ["cattle", "SPECIES", 11, 17], ["human", "SPECIES", 29, 34], ["cattle", "SPECIES", 11, 17], ["human", "SPECIES", 29, 34], ["Transgenic cattle expressing human lactoferrin", "TREATMENT", 0, 46], ["Lactoferrin", "TREATMENT", 162, 173], ["manipulationLactoferricin B and H", "TREATMENT", 218, 251], ["lactoferrin", "TREATMENT", 269, 280], ["digestive tract", "ANATOMY", 307, 322]]], ["The 25 amino acid lactoferricin peptide folds into a distorted antiparallel \u03b2-sheet, whereas the N-terminal 13 amino acids in the native lactoferrin adopt a \u03b1-helical structure (Hwang et al., 1998).", [["amino acid", "CHEMICAL", 7, 17], ["amino acids", "CHEMICAL", 111, 122], ["amino acid", "CHEMICAL", 7, 17], ["amino acids", "CHEMICAL", 111, 122], ["amino acid", "AMINO_ACID", 7, 17], ["amino acids", "AMINO_ACID", 111, 122], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 137, 148], ["antiparallel \u03b2-sheet", "PROTEIN", 63, 83], ["N-terminal 13 amino acids", "PROTEIN", 97, 122], ["native lactoferrin", "PROTEIN", 130, 148], ["\u03b1-helical structure", "PROTEIN", 157, 176], ["The 25 amino acid lactoferricin peptide folds", "TREATMENT", 0, 45], ["a distorted antiparallel \u03b2-sheet", "TREATMENT", 51, 83], ["the N-terminal 13 amino acids", "TREATMENT", 93, 122]]], ["The bacteriocidal effect of lactoferricin is far greater than that of native lactoferrin (Bellamy et al., 1992).", [["lactoferricin", "CHEMICAL", 28, 41], ["lactoferricin", "CHEMICAL", 28, 41], ["lactoferricin", "SIMPLE_CHEMICAL", 28, 41], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 77, 88], ["The bacteriocidal effect of lactoferricin", "TREATMENT", 0, 41]]], ["Two tryptophan residues in the bovine lactoferricin peptide are indispensable for this activity (Strom et al., 2000).", [["tryptophan", "CHEMICAL", 4, 14], ["lactoferricin", "CHEMICAL", 38, 51], ["tryptophan", "CHEMICAL", 4, 14], ["tryptophan", "AMINO_ACID", 4, 14], ["bovine", "ORGANISM", 31, 37], ["lactoferricin", "GENE_OR_GENE_PRODUCT", 38, 51], ["bovine", "SPECIES", 31, 37], ["Two tryptophan residues", "TREATMENT", 0, 23], ["the bovine lactoferricin peptide", "TREATMENT", 27, 59], ["tryptophan residues", "OBSERVATION", 4, 23]]], ["Although lactoferricin has been shown to depolarize bacterial membranes Aguilera et al., 1999, Ulvatne et al., 2001, the precise basis of its antimicrobial action remains unclear.", [["membranes", "ANATOMY", 62, 71], ["lactoferricin", "CHEMICAL", 9, 22], ["lactoferricin", "CHEMICAL", 9, 22], ["lactoferricin", "SIMPLE_CHEMICAL", 9, 22], ["lactoferricin", "TREATMENT", 9, 22], ["bacterial membranes", "PROBLEM", 52, 71]]], ["In order to induce the activity of lactoferricin in milk, the pepsin cleavage site may be engineered to be recognized by a protease, which is resident in the lactating mammary gland.", [["milk", "ANATOMY", 52, 56], ["mammary gland", "ANATOMY", 168, 181], ["lactoferricin", "CHEMICAL", 35, 48], ["lactoferricin", "CHEMICAL", 35, 48], ["lactoferricin", "SIMPLE_CHEMICAL", 35, 48], ["milk", "ORGANISM_SUBSTANCE", 52, 56], ["pepsin", "GENE_OR_GENE_PRODUCT", 62, 68], ["mammary gland", "ORGAN", 168, 181], ["pepsin", "PROTEIN", 62, 68], ["protease", "PROTEIN", 123, 131], ["lactoferricin in milk", "TREATMENT", 35, 56], ["the pepsin cleavage site", "PROBLEM", 58, 82], ["a protease", "TREATMENT", 121, 131], ["mammary gland", "ANATOMY", 168, 181]]], ["This may boost the antibacterial potency of milk and reduce the number of bacteria (especially enterobacteria, which are particularly susceptible to lactoferricin action) in milk.", [["milk", "ANATOMY", 44, 48], ["milk", "ANATOMY", 174, 178], ["lactoferricin", "CHEMICAL", 149, 162], ["lactoferricin", "CHEMICAL", 149, 162], ["milk", "ORGANISM_SUBSTANCE", 44, 48], ["lactoferricin", "SIMPLE_CHEMICAL", 149, 162], ["milk", "ORGANISM_SUBSTANCE", 174, 178], ["the antibacterial potency of milk", "TREATMENT", 15, 48], ["bacteria", "PROBLEM", 74, 82], ["enterobacteria", "PROBLEM", 95, 109], ["lactoferricin action", "TREATMENT", 149, 169], ["antibacterial potency", "OBSERVATION_MODIFIER", 19, 40], ["bacteria", "OBSERVATION_MODIFIER", 74, 82]]], ["These manipulations, however, would probably alter the processing abilities of milk.", [["milk", "ANATOMY", 79, 83], ["milk", "ORGANISM_SUBSTANCE", 79, 83]]], ["In addition, the modified milk may also have an unwanted immunogenic/allergenic effect.Casein and casein fragments ::: Potential targets for manipulationCaseins and casein fragments also display antimicrobial activities, which, however, are not very well defined (Table 4).", [["milk", "ANATOMY", 26, 30], ["milk", "ORGANISM_SUBSTANCE", 26, 30], ["Casein", "GENE_OR_GENE_PRODUCT", 87, 93], ["casein", "GENE_OR_GENE_PRODUCT", 98, 104], ["Caseins", "GENE_OR_GENE_PRODUCT", 153, 160], ["casein fragments", "SIMPLE_CHEMICAL", 165, 181], ["Casein and casein fragments", "PROTEIN", 87, 114], ["Caseins and casein fragments", "DNA", 153, 181], ["allergenic effect", "PROBLEM", 69, 86], ["manipulationCaseins and casein fragments", "TREATMENT", 141, 181], ["antimicrobial activities", "TEST", 195, 219], ["allergenic effect", "OBSERVATION", 69, 86], ["antimicrobial activities", "OBSERVATION", 195, 219]]], ["Isracidin is a chymosin cleavage product of bovine \u03b1S1 casein encompassing amino acids 1\u201323 (Fig. 2).", [["Isracidin", "CHEMICAL", 0, 9], ["amino acids", "CHEMICAL", 75, 86], ["Isracidin", "CHEMICAL", 0, 9], ["amino acids", "CHEMICAL", 75, 86], ["Isracidin", "GENE_OR_GENE_PRODUCT", 0, 9], ["chymosin", "GENE_OR_GENE_PRODUCT", 15, 23], ["bovine", "ORGANISM", 44, 50], ["\u03b1S1 casein", "GENE_OR_GENE_PRODUCT", 51, 61], ["amino acids", "AMINO_ACID", 75, 86], ["1\u201323", "AMINO_ACID", 87, 91], ["chymosin cleavage product", "PROTEIN", 15, 40], ["bovine \u03b1S1 casein", "PROTEIN", 44, 61], ["bovine", "SPECIES", 44, 50], ["Isracidin", "TREATMENT", 0, 9], ["a chymosin cleavage product", "TREATMENT", 13, 40], ["bovine \u03b1S1 casein", "TREATMENT", 44, 61], ["amino acids", "TREATMENT", 75, 86]]], ["It possesses strong antibacterial activity (at concentrations similar to that of penicillin) and was found to be effective against a variety of Gram-negative and Gram-positive bacteria (Lahov and Regelson, 1996).", [["penicillin", "CHEMICAL", 81, 91], ["penicillin", "CHEMICAL", 81, 91], ["penicillin", "SIMPLE_CHEMICAL", 81, 91], ["Gram", "GENE_OR_GENE_PRODUCT", 144, 148], ["strong antibacterial activity", "PROBLEM", 13, 42], ["penicillin", "TREATMENT", 81, 91], ["Gram", "TEST", 144, 148], ["Gram-positive bacteria", "PROBLEM", 162, 184], ["strong", "OBSERVATION_MODIFIER", 13, 19], ["antibacterial activity", "OBSERVATION", 20, 42], ["positive bacteria", "OBSERVATION", 167, 184]]], ["Surprisingly, isracidin is most potent when injected intramuscularly in vivo but only displays a modest antibacterial activity in vitro.", [["intramuscularly", "ANATOMY", 53, 68], ["isracidin", "CHEMICAL", 14, 23], ["isracidin", "CHEMICAL", 14, 23], ["isracidin", "SIMPLE_CHEMICAL", 14, 23], ["isracidin", "TREATMENT", 14, 23], ["most potent", "OBSERVATION_MODIFIER", 27, 38], ["modest", "OBSERVATION_MODIFIER", 97, 103], ["antibacterial activity", "OBSERVATION", 104, 126]]], ["This suggests that the effect of isracidin may be indirect.", [["isracidin", "CHEMICAL", 33, 42], ["isracidin", "CHEMICAL", 33, 42], ["isracidin", "SIMPLE_CHEMICAL", 33, 42], ["isracidin", "TREATMENT", 33, 42]]], ["Therefore, it is uncertain whether transgenic overexpression of an isracidin-peptide in the lactating mammary gland would increase the antibacterial potency of milk.", [["mammary gland", "ANATOMY", 102, 115], ["milk", "ANATOMY", 160, 164], ["isracidin", "CHEMICAL", 67, 76], ["isracidin", "GENE_OR_GENE_PRODUCT", 67, 76], ["mammary gland", "ORGAN", 102, 115], ["milk", "ORGANISM_SUBSTANCE", 160, 164], ["an isracidin-peptide", "TREATMENT", 64, 84], ["mammary gland", "ANATOMY", 102, 115], ["antibacterial potency", "OBSERVATION_MODIFIER", 135, 156]]], ["The chymosin cleavage sites in \u03b1S1 casein are conserved in ruminant proteins but not in other mammals, indicating that the formation of isracidin may not be essential for the well-being of mammals in vivo (Fig. 3).", [["isracidin", "CHEMICAL", 136, 145], ["isracidin", "CHEMICAL", 136, 145], ["chymosin", "GENE_OR_GENE_PRODUCT", 4, 12], ["\u03b1S1 casein", "GENE_OR_GENE_PRODUCT", 31, 41], ["isracidin", "GENE_OR_GENE_PRODUCT", 136, 145], ["chymosin cleavage sites", "DNA", 4, 27], ["\u03b1S1 casein", "PROTEIN", 31, 41], ["ruminant proteins", "PROTEIN", 59, 76], ["isracidin", "PROTEIN", 136, 145], ["The chymosin cleavage sites", "PROBLEM", 0, 27], ["isracidin", "TREATMENT", 136, 145], ["chymosin cleavage", "OBSERVATION", 4, 21], ["sites", "OBSERVATION_MODIFIER", 22, 27], ["S1", "ANATOMY", 32, 34], ["ruminant proteins", "OBSERVATION", 59, 76]]], ["Although isracidin may not augment the antibacterial properties of milk, transgenic expression may nevertheless be useful, as large-scale production of isracidin was mainly hampered by the lack of suitable production systems (the peptide had to be isolated from milk after chymosin treatment).", [["milk", "ANATOMY", 67, 71], ["milk", "ANATOMY", 262, 266], ["isracidin", "CHEMICAL", 9, 18], ["isracidin", "CHEMICAL", 152, 161], ["chymosin", "CHEMICAL", 273, 281], ["isracidin", "CHEMICAL", 9, 18], ["isracidin", "CHEMICAL", 152, 161], ["isracidin", "SIMPLE_CHEMICAL", 9, 18], ["milk", "ORGANISM_SUBSTANCE", 67, 71], ["isracidin", "SIMPLE_CHEMICAL", 152, 161], ["milk", "ORGANISM_SUBDIVISION", 262, 266], ["chymosin", "SIMPLE_CHEMICAL", 273, 281], ["isracidin", "TREATMENT", 9, 18], ["isracidin", "TREATMENT", 152, 161], ["suitable production systems", "PROBLEM", 197, 224], ["chymosin treatment", "TREATMENT", 273, 291]]], ["Production of larger amounts of isracidin in the milk of transgenic animals could be achieved either by expressing it as a peptide or by introduction of a cleavage site for a mammary-resident protease.Casein and casein fragments ::: Potential targets for manipulationTwo C-terminal pepsin fragments of bovine \u03b1S2 casein have also been shown to possess antibacterial activity (Zucht et al., 1995, Recio and Visser, 1999; Fig. 2).", [["milk", "ANATOMY", 49, 53], ["mammary", "ANATOMY", 175, 182], ["isracidin", "CHEMICAL", 32, 41], ["isracidin", "CHEMICAL", 32, 41], ["C", "CHEMICAL", 271, 272], ["isracidin", "GENE_OR_GENE_PRODUCT", 32, 41], ["milk", "ORGANISM_SUBSTANCE", 49, 53], ["Casein", "GENE_OR_GENE_PRODUCT", 201, 207], ["casein", "GENE_OR_GENE_PRODUCT", 212, 218], ["bovine", "ORGANISM", 302, 308], ["\u03b1S2 casein", "GENE_OR_GENE_PRODUCT", 309, 319], ["cleavage site", "PROTEIN", 155, 168], ["mammary-resident protease", "PROTEIN", 175, 200], ["Casein and casein fragments", "PROTEIN", 201, 228], ["C-terminal pepsin fragments", "DNA", 271, 298], ["bovine \u03b1S2 casein", "PROTEIN", 302, 319], ["bovine", "SPECIES", 302, 308], ["isracidin", "TREATMENT", 32, 41], ["a peptide", "TREATMENT", 121, 130], ["a cleavage site", "TREATMENT", 153, 168], ["manipulation", "TEST", 255, 267], ["Two C-terminal pepsin fragments of bovine \u03b1S2 casein", "TREATMENT", 267, 319], ["larger", "OBSERVATION_MODIFIER", 14, 20], ["amounts", "OBSERVATION_MODIFIER", 21, 28]]], ["The precise mechanism by which these peptides exert their bacteriocidal effect is unclear.", [["their bacteriocidal effect", "PROBLEM", 52, 78], ["bacteriocidal effect", "OBSERVATION", 58, 78]]], ["However, the \u03b1S2 casein-derived peptides share some similarities with other antibacterial peptides (Boman, 1995) and may be a component of an innate defense system of the mammary gland.Casein and casein fragments ::: Potential targets for manipulationHuman \u03ba-casein strongly inhibits binding of H. pylori to susceptible intestinal cells (Stromqvist et al., 1995).", [["mammary gland", "ANATOMY", 171, 184], ["intestinal cells", "ANATOMY", 320, 336], ["\u03ba-casein", "CHEMICAL", 257, 265], ["\u03b1S2", "GENE_OR_GENE_PRODUCT", 13, 16], ["mammary gland", "ORGAN", 171, 184], ["Casein", "GENE_OR_GENE_PRODUCT", 185, 191], ["casein", "GENE_OR_GENE_PRODUCT", 196, 202], ["Human", "ORGANISM", 251, 256], ["\u03ba-casein", "GENE_OR_GENE_PRODUCT", 257, 265], ["H. pylori", "ORGANISM", 295, 304], ["intestinal cells", "CELL", 320, 336], ["\u03b1S2 casein", "PROTEIN", 13, 23], ["Casein and casein fragments", "PROTEIN", 185, 212], ["Human \u03ba-casein", "PROTEIN", 251, 265], ["susceptible intestinal cells", "CELL_TYPE", 308, 336], ["Human", "SPECIES", 251, 256], ["H. pylori", "SPECIES", 295, 304], ["Human", "SPECIES", 251, 256], ["H. pylori", "SPECIES", 295, 304], ["manipulationHuman \u03ba-casein", "TREATMENT", 239, 265], ["H. pylori", "PROBLEM", 295, 304], ["may be", "UNCERTAINTY", 117, 123], ["innate defense system", "OBSERVATION", 142, 163], ["mammary gland", "ANATOMY", 171, 184], ["intestinal cells", "ANATOMY", 320, 336]]], ["Glycosylation of \u03ba-casein was found to be crucial for this activity.", [["\u03ba-casein", "CHEMICAL", 17, 25], ["\u03ba-casein", "CHEMICAL", 17, 25], ["\u03ba-casein", "GENE_OR_GENE_PRODUCT", 17, 25], ["\u03ba-casein", "PROTEIN", 17, 25], ["Glycosylation of \u03ba-casein", "TREATMENT", 0, 25]]], ["Casein proteins, in general, may be more difficult to manipulate than whey proteins as caseins also contribute to the generation of casein micelles.", [["Casein", "GENE_OR_GENE_PRODUCT", 0, 6], ["caseins", "GENE_OR_GENE_PRODUCT", 87, 94], ["casein micelles", "SIMPLE_CHEMICAL", 132, 147], ["Casein proteins", "PROTEIN", 0, 15], ["whey proteins", "PROTEIN", 70, 83], ["caseins", "PROTEIN", 87, 94], ["Casein proteins", "TEST", 0, 15], ["the generation of casein micelles", "PROBLEM", 114, 147]]], ["Manipulations, which disturb the micelle formation, may therefore impair the animal's ability to lactate.", [["lactate", "CHEMICAL", 97, 104], ["lactate", "CHEMICAL", 97, 104], ["lactate", "SIMPLE_CHEMICAL", 97, 104], ["Manipulations", "TREATMENT", 0, 13], ["lactate", "TEST", 97, 104]]], ["This would influence efficiency of production as well as animal welfare.Complement ::: Potential targets for manipulationThe cytotoxic activity of milk is inactivated by incubation at 56\u00b0C, suggesting that complement is a major cytotoxic factor Ogundele, 1999a, Ogundele, 1999b.", [["milk", "ANATOMY", 147, 151], ["milk", "ORGANISM_SUBSTANCE", 147, 151], ["manipulation", "TREATMENT", 109, 121], ["cytotoxic", "OBSERVATION_MODIFIER", 125, 134], ["activity", "OBSERVATION_MODIFIER", 135, 143]]], ["Complement activity, however, needs to be regulated to maintain the integrity of the mammary epithelium of the mother and the epithelium of the digestive tract in the offspring.", [["mammary epithelium", "ANATOMY", 85, 103], ["epithelium", "ANATOMY", 126, 136], ["digestive tract", "ANATOMY", 144, 159], ["Complement", "GENE_OR_GENE_PRODUCT", 0, 10], ["mammary epithelium", "TISSUE", 85, 103], ["epithelium", "TISSUE", 126, 136], ["digestive tract", "ORGAN", 144, 159], ["activity", "OBSERVATION_MODIFIER", 11, 19], ["mammary", "ANATOMY", 85, 92], ["epithelium", "ANATOMY_MODIFIER", 93, 103], ["epithelium", "ANATOMY_MODIFIER", 126, 136], ["digestive tract", "ANATOMY", 144, 159]]], ["Lactoferrin, complement protein C1, and the complement regulator CD59, which are expressed in the mammary epithelium, have been implicated in that control (Bjorge et al., 1996).", [["mammary epithelium", "ANATOMY", 98, 116], ["Lactoferrin", "GENE_OR_GENE_PRODUCT", 0, 11], ["complement protein C1", "GENE_OR_GENE_PRODUCT", 13, 34], ["CD59", "GENE_OR_GENE_PRODUCT", 65, 69], ["mammary epithelium", "TISSUE", 98, 116], ["Lactoferrin", "PROTEIN", 0, 11], ["complement protein C1", "PROTEIN", 13, 34], ["complement regulator", "PROTEIN", 44, 64], ["CD59", "PROTEIN", 65, 69], ["Lactoferrin", "TREATMENT", 0, 11], ["the complement regulator CD59", "TEST", 40, 69], ["mammary", "ANATOMY", 98, 105], ["epithelium", "ANATOMY_MODIFIER", 106, 116]]], ["Manipulation of complement proteins in milk without endangering the integrity of the mammary epithelium may be difficult.Other milk-borne molecules ::: Potential targets for manipulationOther milk-borne molecules also have antimicrobial potency (Table 5).", [["milk", "ANATOMY", 39, 43], ["mammary epithelium", "ANATOMY", 85, 103], ["complement proteins", "GENE_OR_GENE_PRODUCT", 16, 35], ["milk", "ORGANISM_SUBSTANCE", 39, 43], ["mammary epithelium", "TISSUE", 85, 103], ["milk", "ORGANISM_SUBSTANCE", 127, 131], ["milk", "ORGANISM_SUBSTANCE", 192, 196], ["complement proteins", "PROTEIN", 16, 35], ["milk-borne molecules", "PROTEIN", 127, 147], ["complement proteins in milk", "TREATMENT", 16, 43], ["manipulationOther milk", "TREATMENT", 174, 196], ["mammary", "ANATOMY", 85, 92], ["epithelium", "ANATOMY_MODIFIER", 93, 103]]], ["Milk mucin inhibits rotavirus infections in vitro and in vivo (Yolken et al., 1992), presumably by its sialic acid residues competing with natural virus receptors (Guerrero et al., 2000).", [["rotavirus infections", "DISEASE", 20, 40], ["sialic acid", "CHEMICAL", 103, 114], ["sialic acid", "CHEMICAL", 103, 114], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["mucin", "GENE_OR_GENE_PRODUCT", 5, 10], ["rotavirus", "ORGANISM", 20, 29], ["sialic acid", "SIMPLE_CHEMICAL", 103, 114], ["natural virus receptors", "PROTEIN", 139, 162], ["rotavirus", "SPECIES", 20, 29], ["Milk mucin", "PROBLEM", 0, 10], ["rotavirus infections", "PROBLEM", 20, 40], ["its sialic acid residues", "TREATMENT", 99, 123], ["natural virus receptors", "TREATMENT", 139, 162], ["rotavirus infections", "OBSERVATION", 20, 40]]], ["Tryptic fragments of bovine \u03b1-lactalbumin (Fig. 2) efficiently restrict the growth of Gram-positive bacteria (Pellegrini et al., 1999).", [["\u03b1-lactalbumin", "CHEMICAL", 28, 41], ["bovine", "ORGANISM", 21, 27], ["\u03b1-lactalbumin", "SIMPLE_CHEMICAL", 28, 41], ["Gram-", "GENE_OR_GENE_PRODUCT", 86, 91], ["bovine", "SPECIES", 21, 27], ["Tryptic fragments of bovine \u03b1-lactalbumin (Fig", "TREATMENT", 0, 46], ["Gram-positive bacteria", "PROBLEM", 86, 108]]], ["Other milk proteins have been shown to have neutralizing effects against specific pathogens (Table 5) but the protective mechanisms are not clear Labeta et al., 2000, Newburg, 1999.", [["milk", "ANATOMY", 6, 10], ["milk", "ORGANISM_SUBSTANCE", 6, 10], ["milk proteins", "PROTEIN", 6, 19], ["neutralizing effects", "PROBLEM", 44, 64], ["specific pathogens", "PROBLEM", 73, 91]]], ["Milk is also rich in oligosaccharides and glycoconjugates (Newburg, 1996).", [["Milk", "ORGANISM_SUBSTANCE", 0, 4]]], ["Many of which have been demonstrated to possess antiviral, antibacterial, or antifungal effects (see Table 2).", [["antiviral", "TREATMENT", 48, 57], ["antibacterial", "TREATMENT", 59, 72], ["antifungal effects", "TREATMENT", 77, 95]]], ["Lipids in milk have also shown antimicrobial effects, which are not well defined at present (Goldman et al., 1996).", [["milk", "ANATOMY", 10, 14], ["Lipids", "SIMPLE_CHEMICAL", 0, 6], ["milk", "ORGANISM_SUBSTANCE", 10, 14], ["Lipids in milk", "TREATMENT", 0, 14], ["antimicrobial effects", "TREATMENT", 31, 52], ["antimicrobial effects", "OBSERVATION", 31, 52]]], ["These molecules may represent components of an innate defense system of the mammary gland.", [["mammary gland", "ANATOMY", 76, 89], ["mammary gland", "ORGAN", 76, 89], ["may represent", "UNCERTAINTY", 16, 29], ["innate defense", "OBSERVATION", 47, 61], ["mammary gland", "ANATOMY", 76, 89]]], ["Synthesis of these substances, however, depends on the interplay of a number of enzymes.", [["enzymes", "PROTEIN", 80, 87], ["enzymes", "TEST", 80, 87]]], ["Manipulation of these pathways would require major efforts and may therefore not be cost-effective.Other milk-borne molecules ::: Potential targets for manipulationVarious milk proteins, which are chemically modified, are also powerful antagonists of virus infections Neurath et al., 1996, Berkhout et al., 1997.", [["infections", "DISEASE", 257, 267], ["milk", "ORGANISM_SUBSTANCE", 105, 109], ["milk", "ORGANISM_SUBSTANCE", 172, 176], ["milk-borne molecules", "PROTEIN", 105, 125], ["milk proteins", "PROTEIN", 172, 185], ["manipulationVarious milk proteins", "TREATMENT", 152, 185], ["virus infections", "PROBLEM", 251, 267]]], ["Although some of these activities are fortuitous, milk may provide a cheap source for the production for these agents.", [["milk", "ANATOMY", 50, 54], ["milk", "ORGANISM_SUBSTANCE", 50, 54], ["these agents", "TREATMENT", 105, 117]]], ["In addition, a wide variety of immunomodulatory substances are found in milk (Goldman, 2000; Table 5).", [["milk", "ANATOMY", 72, 76], ["milk", "ORGANISM_SUBSTANCE", 72, 76], ["immunomodulatory substances", "TREATMENT", 31, 58], ["wide", "OBSERVATION_MODIFIER", 15, 19], ["variety", "OBSERVATION_MODIFIER", 20, 27], ["immunomodulatory substances", "OBSERVATION", 31, 58]]], ["Examples include interleukins, transforming growth factors \u03b1 and \u03b2, or the complement regulatory protein CD59 (Bjorge et al., 1996).", [["interleukins", "GENE_OR_GENE_PRODUCT", 17, 29], ["transforming growth factors \u03b1", "GENE_OR_GENE_PRODUCT", 31, 60], ["\u03b2", "GENE_OR_GENE_PRODUCT", 65, 66], ["CD59", "GENE_OR_GENE_PRODUCT", 105, 109], ["interleukins", "PROTEIN", 17, 29], ["transforming growth factors", "PROTEIN", 31, 58], ["\u03b1", "PROTEIN", 59, 60], ["\u03b2", "PROTEIN", 65, 66], ["complement regulatory protein", "PROTEIN", 75, 104], ["CD59", "PROTEIN", 105, 109], ["interleukins", "PROBLEM", 17, 29], ["transforming growth factors", "PROBLEM", 31, 58]]], ["Some of the abovementioned molecules (e.g. lactoferrin and isracidin) also possess immune modulatory activity.", [["isracidin", "CHEMICAL", 59, 68], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 43, 54], ["isracidin", "GENE_OR_GENE_PRODUCT", 59, 68], ["lactoferrin", "PROTEIN", 43, 54], ["isracidin", "PROTEIN", 59, 68], ["lactoferrin and isracidin)", "TREATMENT", 43, 69], ["immune modulatory activity", "OBSERVATION", 83, 109]]], ["However, the importance of these factors is exemplified by the fact that TGF-\u03b2 knockout mice, which die shortly after birth, can be rescued by TGF-\u03b2 supplied by maternal sources (via placenta and milk; Letterio et al., 1994).", [["placenta", "ANATOMY", 183, 191], ["milk", "ANATOMY", 196, 200], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 73, 78], ["mice", "ORGANISM", 88, 92], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 143, 148], ["placenta", "MULTI-TISSUE_STRUCTURE", 183, 191], ["milk", "ORGANISM_SUBSTANCE", 196, 200], ["TGF-\u03b2", "PROTEIN", 73, 78], ["TGF-\u03b2", "PROTEIN", 143, 148], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92]]], ["As the precise significance of these factors is not established, they are not likely candidates for targeted manipulation.Nonmilk proteins and peptides ::: Potential targets for manipulationOther molecules with antimicrobial properties, e.g. porins, can theoretically be expressed in the milk of transgenic animals.", [["milk", "ANATOMY", 288, 292], ["porins", "GENE_OR_GENE_PRODUCT", 242, 248], ["milk", "ORGANISM_SUBSTANCE", 288, 292], ["Nonmilk proteins", "PROTEIN", 122, 138], ["targeted manipulation", "TREATMENT", 100, 121], ["manipulationOther molecules", "TREATMENT", 178, 205], ["antimicrobial properties", "TREATMENT", 211, 235], ["porins", "TREATMENT", 242, 248], ["not likely", "UNCERTAINTY", 74, 84]]], ["However, these molecules may also have a deleterious effect against the mammary epithelium of the dam or the gut epithelium of the offspring.", [["mammary epithelium", "ANATOMY", 72, 90], ["dam", "ANATOMY", 98, 101], ["gut epithelium", "ANATOMY", 109, 123], ["mammary epithelium", "TISSUE", 72, 90], ["gut epithelium", "TISSUE", 109, 123], ["deleterious", "OBSERVATION", 41, 52], ["mammary", "ANATOMY", 72, 79], ["epithelium", "ANATOMY_MODIFIER", 80, 90], ["gut", "ANATOMY", 109, 112], ["epithelium", "ANATOMY_MODIFIER", 113, 123]]], ["Therefore, these proteins or peptides would have to be expressed as preproteins, which have to be cleaved proteolytically (ideally by a pathogen-specific protease) to yield a functional toxin.ConclusionsThere are two routes for the manipulation of immunologically active, protective components of milk: vaccination and transgenesis (Table 2).", [["milk", "ANATOMY", 297, 301], ["milk", "ORGANISM_SUBSTANCE", 297, 301], ["preproteins", "PROTEIN", 68, 79], ["protease", "PROTEIN", 154, 162], ["these proteins or peptides", "PROBLEM", 11, 37], ["a pathogen-specific protease", "TREATMENT", 134, 162], ["vaccination", "TREATMENT", 303, 314]]], ["Vaccination of mothers during pregnancy requires a careful consideration of potential risks and benefits for each pathogen in question.", [["mothers", "ORGANISM", 15, 22], ["Vaccination", "TREATMENT", 0, 11], ["each pathogen", "PROBLEM", 109, 122]]], ["Vaccination of ruminants can lead to the production of milk highly enriched in antibodies directed against particular pathogens Ebina, 1996, Freedman et al., 1998.", [["milk", "ANATOMY", 55, 59], ["ruminants", "ORGANISM", 15, 24], ["milk", "ORGANISM_SUBSTANCE", 55, 59], ["antibodies", "PROTEIN", 79, 89], ["Vaccination", "TREATMENT", 0, 11], ["the production of milk", "PROBLEM", 37, 59]]], ["Since antibodies in milk are relatively stable (Schmidt, 1982), formula containing antibodies directed against a variety of pathogens can be generated and used for the prevention and treatment of infectious diseases of the digestive tract.", [["milk", "ANATOMY", 20, 24], ["digestive tract", "ANATOMY", 223, 238], ["infectious diseases of the digestive tract", "DISEASE", 196, 238], ["milk", "ORGANISM_SUBSTANCE", 20, 24], ["digestive tract", "ORGANISM_SUBDIVISION", 223, 238], ["antibodies", "PROTEIN", 6, 16], ["antibodies", "PROTEIN", 83, 93], ["milk", "SPECIES", 20, 24], ["antibodies in milk", "PROBLEM", 6, 24], ["formula containing antibodies", "TREATMENT", 64, 93], ["pathogens", "PROBLEM", 124, 133], ["infectious diseases of the digestive tract", "PROBLEM", 196, 238], ["relatively", "OBSERVATION_MODIFIER", 29, 39], ["stable", "OBSERVATION_MODIFIER", 40, 46], ["infectious", "OBSERVATION", 196, 206], ["digestive tract", "ANATOMY", 223, 238]]], ["The modified milk will have its major application in infectious diseases, which are acute but not life-threatening and do not lead to hospitalization.", [["milk", "ANATOMY", 13, 17], ["infectious diseases", "DISEASE", 53, 72], ["milk", "ORGANISM_SUBSTANCE", 13, 17], ["infectious diseases", "PROBLEM", 53, 72], ["infectious", "OBSERVATION", 53, 63], ["acute", "OBSERVATION_MODIFIER", 84, 89]]], ["In addition, the time span between the occurrence of a new pathogen (or a new variant) and the development of a vaccine may be shortened significantly by DNA vaccination.", [["DNA", "CELLULAR_COMPONENT", 154, 157], ["a new pathogen", "PROBLEM", 53, 67], ["a vaccine", "TREATMENT", 110, 119], ["new", "OBSERVATION_MODIFIER", 55, 58], ["pathogen", "OBSERVATION", 59, 67]]], ["DNA vaccines have been effective in many instances (Turnes et al., 1999) and lead to the production of pathogen-specific antibodies in colostrum and milk (Jenkins et al., 1999).", [["colostrum", "ANATOMY", 135, 144], ["milk", "ANATOMY", 149, 153], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["colostrum", "ORGANISM_SUBSTANCE", 135, 144], ["milk", "ORGANISM_SUBSTANCE", 149, 153], ["pathogen-specific antibodies", "PROTEIN", 103, 131], ["colostrum", "SPECIES", 135, 144], ["DNA vaccines", "TREATMENT", 0, 12], ["pathogen", "PROBLEM", 103, 111]]], ["Manipulation of milk by transgenesis will be useful in the veterinary field.", [["milk", "ANATOMY", 16, 20], ["milk", "ORGANISM_SUBSTANCE", 16, 20], ["Manipulation of milk", "TREATMENT", 0, 20]]], ["Milk containing either a defined, highly neutralizing antibody directed against a pathogen or a high concentration of a nonspecific defense molecule may be applied for the prevention of infectious diseases, when suitable vaccines are unavailable.", [["infectious diseases", "DISEASE", 186, 205], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["neutralizing antibody", "PROTEIN", 41, 62], ["highly neutralizing antibody", "TREATMENT", 34, 62], ["a pathogen", "PROBLEM", 80, 90], ["a nonspecific defense molecule", "PROBLEM", 118, 148], ["infectious diseases", "PROBLEM", 186, 205], ["suitable vaccines", "TREATMENT", 212, 229], ["infectious", "OBSERVATION", 186, 196]]], ["This approach, however, will be subject to a stringent cost-benefit analysis.", [["a stringent cost-benefit analysis", "TEST", 43, 76]]], ["The transgenes encoding the antipathogenic molecules will not be integrated into the conventional breeding programs but used for the generation of a herd of animals, which provides modified milk as a product (Whitelaw, 1999).ConclusionsThe modification of the immunological properties of milk by vaccination, transgenesis, or a combination of both may be a promising approach, which leads to products with a clear health benefit in the medical and veterinary field.", [["milk", "ANATOMY", 190, 194], ["milk", "ANATOMY", 288, 292], ["milk", "ORGANISM_SUBSTANCE", 190, 194], ["milk", "ORGANISM_SUBSTANCE", 288, 292], ["antipathogenic molecules", "PROTEIN", 28, 52], ["a herd of animals", "TREATMENT", 147, 164], ["vaccination", "TREATMENT", 296, 307], ["transgenesis", "TREATMENT", 309, 321]]], ["Different mammalian species employ different strategies to provide immune protection to their offspring.", [["Different mammalian species", "TREATMENT", 0, 27], ["different strategies", "TREATMENT", 35, 55], ["immune protection", "TREATMENT", 67, 84]]], ["Also, pathogens use different strategies to overcome the host's immune defenses.", [["pathogens", "PROBLEM", 6, 15], ["different strategies", "TREATMENT", 20, 40]]], ["Therefore, there will not be a single approach for the prevention of infectious diseases via immunologically modified milk, but a variety of approaches tailored to specific classes of pathogens will have to be used to turn milk into an effective disease-preventing nutraceutical.", [["milk", "ANATOMY", 118, 122], ["milk", "ANATOMY", 223, 227], ["infectious diseases", "DISEASE", 69, 88], ["milk", "ORGANISM_SUBSTANCE", 118, 122], ["milk", "ORGANISM_SUBSTANCE", 223, 227], ["a single approach", "TREATMENT", 29, 46], ["infectious diseases", "PROBLEM", 69, 88], ["immunologically modified milk", "TREATMENT", 93, 122], ["a variety of approaches", "TREATMENT", 128, 151], ["pathogens", "PROBLEM", 184, 193], ["an effective disease", "PROBLEM", 233, 253], ["nutraceutical", "TREATMENT", 265, 278], ["infectious", "OBSERVATION", 69, 79]]]], "80627ccf457f8da6f654360d4a2b2a3c17a5fa15": [["IntroductionPreterm infants are at risk of extrauterine growth restriction (EUGR) [1] , and optimal postnatal growth is important not only for survival but also for the long-term outcomes of preterm infants [2, 3] .", [["infants", "ORGANISM", 20, 27], ["infants", "ORGANISM", 199, 206], ["infants", "SPECIES", 20, 27], ["infants", "SPECIES", 199, 206], ["extrauterine growth restriction", "PROBLEM", 43, 74]]], ["Despite recent improvements in the neonatal care of preterm infants, EUGR is still prevalent among premature babies during and after the neonatal intensive care unit (NICU) stay [4] .IntroductionGrowth charts are essential tools to monitor postnatal growth of preterm infants.", [["infants", "ORGANISM", 60, 67], ["infants", "ORGANISM", 268, 275], ["infants", "SPECIES", 60, 67], ["infants", "SPECIES", 268, 275], ["postnatal growth of preterm infants", "PROBLEM", 240, 275], ["improvements", "OBSERVATION_MODIFIER", 15, 27]]], ["The American Academy of What is Known: \u2022 Preterm infants are at risk of extrauterine growth restriction (EUGR), although optimal postnatal growth is important for the long-term outcomes.Introduction\u2022 Growth charts are essential tools to monitor the postnatal growth of preterm infants.", [["infants", "ORGANISM", 49, 56], ["infants", "ORGANISM", 277, 284], ["infants", "SPECIES", 49, 56], ["infants", "SPECIES", 277, 284], ["extrauterine growth restriction", "PROBLEM", 72, 103]]], ["What is New: \u2022 EUGR of weight and length were less defined with the Intergrowth charts than the Fenton charts.Introduction\u2022 EUGR defined by the Intergrowth preterm postnatal follow-up study (PPFS) chart categorized preterm infants with morbidities more elaborately than the Fenton charts.Communicated by Daniele De LucaElectronic supplementary material The online version of this article (https://doi.org/10.1007/s00431-020-03796-0) contains supplementary material, which is available to authorized users.Communicated by Daniele De LucaPediatrics (AAP) recommended that the growth rate of normal foetuses should be used as a growth standard for preterm infants.", [["foetuses", "ANATOMY", 596, 604], ["AAP", "CHEMICAL", 548, 551], ["infants", "ORGANISM", 223, 230], ["foetuses", "ORGAN", 596, 604], ["infants", "ORGANISM", 653, 660], ["infants", "SPECIES", 223, 230], ["infants", "SPECIES", 653, 660], ["length", "TEST", 34, 40], ["morbidities", "PROBLEM", 236, 247], ["the growth rate", "TEST", 570, 585], ["New", "OBSERVATION_MODIFIER", 8, 11]]], ["Estimated foetal weight charts based on intrauterine growth had been used as references for monitoring postnatal growth [5] .", [["foetal", "ANATOMY", 10, 16], ["intrauterine", "ANATOMY", 40, 52], ["foetal", "ORGANISM_SUBDIVISION", 10, 16], ["Estimated foetal weight charts", "TEST", 0, 30], ["intrauterine growth", "PROBLEM", 40, 59]]], ["Another type of neonatal chart is based on birthweight for gestational age (GA) from various sample sizes ranging from a single hospital sample to a national population.", [["various sample sizes", "PROBLEM", 85, 105]]], ["The Fenton growth chart is one of the commonly used reference charts based on size at birth, developed from the Babson and Benda graph and several population studies [6] [7] [8] .", [["Fenton", "CHEMICAL", 4, 10], ["The Fenton growth chart", "TREATMENT", 0, 23], ["several population studies", "TEST", 139, 165], ["size", "OBSERVATION_MODIFIER", 78, 82]]], ["As it is not based on the longitudinal study, the change in weight after birth in preterm population was not included in the data of the Fenton charts.", [["Fenton", "CHEMICAL", 137, 143], ["the longitudinal study", "TEST", 22, 44], ["the change in weight", "PROBLEM", 46, 66], ["preterm population", "PROBLEM", 82, 100], ["change", "OBSERVATION_MODIFIER", 50, 56]]], ["Of the five subjects included in the project, the Preterm Postnatal Follow-up Study (PPFS), was conducted to produce standards for postnatal growth in preterm infants as a more appropriate alternative to existing references based on size-at-birth measurements.", [["infants", "ORGANISM", 159, 166], ["infants", "SPECIES", 159, 166], ["postnatal growth in preterm infants", "PROBLEM", 131, 166], ["size", "TEST", 233, 237], ["size", "OBSERVATION_MODIFIER", 233, 237]]], ["Growth charts were generated based on rigorous and standardized anthropometric measurements of selected preterm infants from the original Intergrowth-21st Project [9] .", [["infants", "ORGANISM", 112, 119], ["infants", "SPECIES", 112, 119], ["standardized anthropometric measurements", "TEST", 51, 91]]], ["However, the GA of preterm infants included in the PPFS was moderately preterm, and data for very preterm infants were obtained from the small sample size.Communicated by Daniele De LucaBased on the inherent conceptual and methodological limitations of these charts, there is currently no ideal growth standard for monitoring postnatal growth in preterm infants [10] [11] [12] .", [["infants", "ORGANISM", 27, 34], ["infants", "ORGANISM", 106, 113], ["infants", "SPECIES", 27, 34], ["infants", "SPECIES", 106, 113], ["infants", "SPECIES", 354, 361], ["moderately preterm", "PROBLEM", 60, 78], ["small", "OBSERVATION_MODIFIER", 137, 142], ["size", "OBSERVATION_MODIFIER", 150, 154]]], ["Significant deviations were found in the calculation of postnatal growth depending on the reference dataset that was used [13] .Communicated by Daniele De LucaThe objective of this study was to compare the prevalence of EUGR in extremely low GA infants who were registered in the Korean Neonatal Network (KNN) using the Fenton and PPFS charts and to investigate factors associated with EUGR by both charts.MethodsThis is a population-based study of preterm infants who were registered in the KNN between January 2013 and December 2015.", [["EUGR", "DISEASE", 220, 224], ["Fenton", "CHEMICAL", 320, 326], ["infants", "ORGANISM", 245, 252], ["infants", "ORGANISM", 457, 464], ["infants", "SPECIES", 245, 252], ["infants", "SPECIES", 457, 464], ["Significant deviations", "PROBLEM", 0, 22], ["postnatal growth", "PROBLEM", 56, 72], ["this study", "TEST", 176, 186], ["the Fenton and PPFS charts", "TREATMENT", 316, 342], ["deviations", "OBSERVATION", 12, 22]]], ["The KNN is a nationwide neonatal network based on a prospective web-based registry for very low birth weight (VLBW) infants, which covers more than 70% of the total number of VLBW infants in Korea [14] .", [["infants", "ORGANISM", 116, 123], ["infants", "SPECIES", 116, 123], ["infants", "SPECIES", 180, 187]]], ["The data in the KNN database comprises antenatal and perinatal histories, postnatal morbidities and clinical outcomes that were evaluated during and after the hospital stay using a standardised electronic casereport form.", [["postnatal morbidities", "PROBLEM", 74, 95]]], ["Among the registered population, preterm infants who were born at < 28 weeks of gestation were included.", [["infants", "ORGANISM", 41, 48], ["infants", "SPECIES", 41, 48]]], ["Infants who were born at < 24 weeks of gestation, had congenital anomalies and died or were transferred to other hospitals were excluded.", [["congenital anomalies", "DISEASE", 54, 74], ["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["congenital anomalies", "PROBLEM", 54, 74], ["congenital", "OBSERVATION_MODIFIER", 54, 64], ["anomalies", "OBSERVATION", 65, 74]]], ["For the Fenton growth charts available under 50 weeks of postmenstrual age (PMA), those who were not discharged from the hospital at 50 weeks of PMA were also excluded from the study.MethodsGestational age was calculated according to the last menstrual period.", [["Fenton", "CHEMICAL", 8, 14], ["PMA", "CHEMICAL", 145, 148], ["PMA", "SIMPLE_CHEMICAL", 145, 148], ["the study", "TEST", 173, 182]]], ["Respiratory distress syndrome (RDS) was defined by radiologic and clinical diagnosis with treatment with surfactant replacement.", [["Respiratory distress syndrome", "DISEASE", 0, 29], ["RDS", "DISEASE", 31, 34], ["surfactant", "SIMPLE_CHEMICAL", 105, 115], ["Respiratory distress syndrome", "PROBLEM", 0, 29], ["RDS", "PROBLEM", 31, 34], ["surfactant replacement", "TREATMENT", 105, 127], ["distress", "OBSERVATION", 12, 20], ["surfactant replacement", "OBSERVATION", 105, 127]]], ["Bronchopulmonary dysplasia (BPD) was defined as the need for supplemental oxygen or ventilator support at 28 days after birth [15] .", [["Bronchopulmonary dysplasia", "ANATOMY", 0, 26], ["Bronchopulmonary dysplasia", "DISEASE", 0, 26], ["BPD", "DISEASE", 28, 31], ["oxygen", "CHEMICAL", 74, 80], ["oxygen", "CHEMICAL", 74, 80], ["Bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 0, 26], ["oxygen", "SIMPLE_CHEMICAL", 74, 80], ["Bronchopulmonary dysplasia", "PROBLEM", 0, 26], ["BPD", "PROBLEM", 28, 31], ["supplemental oxygen", "TREATMENT", 61, 80], ["ventilator support", "TREATMENT", 84, 102], ["dysplasia", "OBSERVATION", 17, 26]]], ["Necrotizing enterocolitis (NEC) was defined according to Bell's criteria (stage 2 or higher) [16] .", [["Necrotizing enterocolitis", "DISEASE", 0, 25], ["NEC", "DISEASE", 27, 30], ["Necrotizing enterocolitis", "PROBLEM", 0, 25], ["NEC", "PROBLEM", 27, 30], ["Bell's criteria", "TEST", 57, 72], ["enterocolitis", "OBSERVATION", 12, 25]]], ["Intraventricular haemorrhage (IVH) was defined by the Papile criteria, using cranial ultrasonography [17] .", [["cranial", "ANATOMY", 77, 84], ["Intraventricular haemorrhage", "DISEASE", 0, 28], ["IVH", "DISEASE", 30, 33], ["Intraventricular haemorrhage (IVH", "PROBLEM", 0, 33], ["cranial ultrasonography", "TEST", 77, 100], ["haemorrhage", "OBSERVATION", 17, 28], ["IVH", "OBSERVATION", 30, 33]]], ["Retinopathy of prematurity (ROP) was defined according to the international classification of ROP [18] .MethodsPercentile and z scores of weight, length and head circumference (HC) at birth were calculated using both the Fenton growth charts and the Intergrowth-21st very preterm size charts (https://intergrowth21.tghn.org/standards-tools/) [7, 19, 20] .", [["head", "ANATOMY", 157, 161], ["Retinopathy of prematurity", "DISEASE", 0, 26], ["ROP", "DISEASE", 28, 31], ["ROP", "DISEASE", 94, 97], ["Fenton", "CHEMICAL", 221, 227], ["head", "ORGANISM_SUBDIVISION", 157, 161], ["Retinopathy of prematurity (ROP)", "PROBLEM", 0, 32], ["ROP", "TEST", 94, 97], ["weight", "TEST", 138, 144], ["length", "TEST", 146, 152], ["head circumference", "TEST", 157, 175], ["prematurity", "OBSERVATION", 15, 26]]], ["Size at discharge was also calculated using the Fenton and Intergrowth PPFS charts.", [["the Fenton", "TREATMENT", 44, 54], ["Intergrowth PPFS charts", "TREATMENT", 59, 82]]], ["Small for gestational age (SGA) was defined when weight, length and HC were less than the 10th percentile for GA [21] .", [["GA", "CHEMICAL", 110, 112], ["weight", "TEST", 49, 55], ["length", "TEST", 57, 63], ["HC", "TEST", 68, 70]]], ["The first definition of EUGR was decreased z scores of weight, length and HC > 1 at discharge compared with z scores at birth [4] .", [["weight", "TEST", 55, 61], ["length", "TEST", 63, 69], ["HC", "TEST", 74, 76]]], ["The second definition of EUGR was weight, length and HC at discharge below the 10th percentile.", [["weight", "TEST", 34, 40], ["length", "TEST", 42, 48], ["HC", "TEST", 53, 55]]], ["The need for approval was waived by the Institutional Review Board of Seoul National University Hospital.MethodsStatistical analysis was performed with STATA 12.1 (StataCorp.", [["MethodsStatistical analysis", "TEST", 105, 132], ["STATA", "TEST", 152, 157]]], ["The paired t test was used to compare z scores according to the different growth charts at birth and discharge.", [["The paired t test", "TEST", 0, 17]]], ["Cochran's Q test was used to compare the prevalence of EUGR in the study population according to the two growth charts.", [["Cochran's Q test", "TEST", 0, 16]]], ["Student's t test and Fisher's exact test were conducted to compare factors between the EUGR and non-EUGR groups defined by decreased z score > 1 at discharge according to the two growth charts.", [["Student's t test", "TEST", 0, 16], ["Fisher's exact test", "TEST", 21, 40], ["the EUGR", "TEST", 83, 91], ["decreased z score", "PROBLEM", 123, 140]]], ["Multivariate logistic regression analysis for EUGR in weight defined by decrease z score > 1 was conducted in each growth chart to determine factors associated with EUGR.", [["EUGR", "PROTEIN", 165, 169], ["Multivariate logistic regression analysis", "TEST", 0, 41], ["EUGR", "TEST", 46, 50], ["weight", "TEST", 54, 60], ["decrease z score", "TEST", 72, 88]]], ["All possible regressions were conducted with covariates based on the p value (p < 0.10) in the univariate analysis.", [["the p value", "TEST", 65, 76], ["the univariate analysis", "TEST", 91, 114], ["possible", "UNCERTAINTY", 4, 12]]], ["The variance inflation factor (VIF) was calculated to treat multicollinearity and covariates with VIF > 10 were not included in the multiple logistic regression.", [["variance inflation factor", "PROTEIN", 4, 29], ["VIF", "PROTEIN", 31, 34], ["The variance inflation factor (VIF)", "TREATMENT", 0, 35], ["multicollinearity", "PROBLEM", 60, 77], ["VIF", "TEST", 98, 101]]], ["Sensitivity analysis of multivariate linear regressions was performed for changes in z score of weight as continuous variables and provided in the supplementary materials.ResultsAmong the 5,922 preterm infants registered in the KNN database during the study period, 2,318 infants with GA < 28 weeks were selected ( Fig. 1 ).", [["infants", "ORGANISM", 202, 209], ["infants", "ORGANISM", 272, 279], ["infants", "SPECIES", 202, 209], ["infants", "SPECIES", 272, 279], ["Sensitivity analysis", "TEST", 0, 20], ["multivariate linear regressions", "PROBLEM", 24, 55], ["the study", "TEST", 248, 257]]], ["Among them, 290 infants who were born at < 24 weeks of gestation, 59 infants with a congenital anomaly and 65 infants who were not discharged until 50 weeks of PMA were excluded.", [["congenital anomaly", "DISEASE", 84, 102], ["PMA", "CHEMICAL", 160, 163], ["infants", "ORGANISM", 16, 23], ["infants", "ORGANISM", 69, 76], ["infants", "ORGANISM", 110, 117], ["PMA", "SIMPLE_CHEMICAL", 160, 163], ["infants", "SPECIES", 16, 23], ["infants", "SPECIES", 69, 76], ["infants", "SPECIES", 110, 117], ["a congenital anomaly", "PROBLEM", 82, 102]]], ["After additional exclusion of 548 infants who died or were transferred to other hospitals, 1,356 infants remained in the study population.ResultsThe GA at birth and PMA at discharge were 26.4 \u00b1 1.1 and 39.9 \u00b1 3.2 weeks (Table 1 ).", [["PMA", "CHEMICAL", 165, 168], ["infants", "ORGANISM", 34, 41], ["infants", "ORGANISM", 97, 104], ["infants", "SPECIES", 34, 41], ["infants", "SPECIES", 97, 104], ["The GA", "TEST", 145, 151], ["PMA", "TEST", 165, 168]]], ["Weights at birth and discharge were 899.6 \u00b1 189.7 and 2824.2 \u00b1 637.3 grams, respectively.", [["Weights", "TEST", 0, 7]]], ["The neonatal morbidities of the study population are provided in the supplementary materials (Table S2) .ResultsSGA of weight, length and HC at birth were more prevalent with the Intergrowth chart ( Table 2) . z-scores of weight, length and HC at birth, as well as at discharge, were lower with Intergrowth charts, except for the weight z score at discharge (Fenton \u2212 1.44 \u00b1 1.21 vs. Intergrowth \u2212 1.03 \u00b1 1.33).", [["Fenton", "CHEMICAL", 359, 365], ["the study population", "TEST", 28, 48], ["weight", "TEST", 119, 125], ["length", "TEST", 127, 133], ["HC", "TEST", 138, 140], ["z-scores", "TEST", 210, 218], ["weight", "TEST", 222, 228], ["length", "TEST", 230, 236], ["HC", "TEST", 241, 243], ["the weight z score", "PROBLEM", 326, 344], ["Fenton", "TREATMENT", 359, 365], ["Intergrowth", "TEST", 384, 395]]], ["Values are expressed as number (%) or mean \u00b1 standard deviation However, differences in z scores in all body measurements at discharge from at birth were smaller when the Intergrowth charts were used.", [["body", "ANATOMY", 104, 108], ["body", "ORGANISM_SUBDIVISION", 104, 108], ["mean \u00b1 standard deviation", "PROBLEM", 38, 63], ["z scores", "TEST", 88, 96], ["all body measurements", "TEST", 100, 121]]], ["When EUGR was defined as a decrease in z score by more than one, the prevalence of EUGR of weight, length and HC by the Fenton charts were higher than those defined by the Intergrowth charts (Fig. 2) .", [["a decrease in z score", "PROBLEM", 25, 46], ["weight", "TEST", 91, 97], ["length", "TEST", 99, 105], ["the Fenton charts", "TEST", 116, 133], ["decrease", "OBSERVATION_MODIFIER", 27, 35]]], ["EUGR defined by less than the 10th percentile at discharge of weight and length by the Fenton charts also were higher than those defined by the Intergrowth charts.", [["weight", "TEST", 62, 68], ["the Fenton charts", "TEST", 83, 100], ["less", "OBSERVATION_MODIFIER", 16, 20]]], ["However, EUGR of HC by the Fenton charts was less prevalent than that of the Intergrowth charts.ResultsInfants with EUGR defined as decreased z score > 1 according to the Intergrowth charts had lower GA (26.6 \u00b1 1.0 vs. 26.2 \u00b1 1.0 weeks, p < 0.001) and higher birthweight z score (0.0 \u00b1 1.1 vs. 0.3 \u00b1 0.8, p < 0.001) than with infants with non-EUGR (Table 3) .", [["Fenton", "CHEMICAL", 27, 33], ["infants", "ORGANISM", 326, 333], ["infants", "SPECIES", 326, 333], ["lower GA", "PROBLEM", 194, 202], ["p", "TEST", 237, 238], ["higher birthweight z score", "TEST", 252, 278]]], ["Male sex, RDS, treated PDA, IVH grade \u2265 3, NEC, ROP stage \u2265 2 and sepsis were more prevalent in the EUGR group.ResultsWhen EUGR was defined as decreased z core > 1 by the Fenton charts, GA was lower (26.6 \u00b1 1.1 vs. 26.3 \u00b1 1.0 weeks, p < 0.001) and birthweight z score was higher in the EUGR group (\u2212 0.1 \u00b1 1.0 vs. 0.3 \u00b1 0.9, p < 0.001) ( Table 4 ).", [["RDS", "DISEASE", 10, 13], ["IVH", "DISEASE", 28, 31], ["NEC", "DISEASE", 43, 46], ["ROP", "DISEASE", 48, 51], ["sepsis", "DISEASE", 66, 72], ["EUGR", "CANCER", 100, 104], ["RDS", "PROBLEM", 10, 13], ["IVH grade \u2265 3", "PROBLEM", 28, 41], ["NEC", "PROBLEM", 43, 46], ["ROP stage \u2265 2", "PROBLEM", 48, 61], ["sepsis", "PROBLEM", 66, 72], ["GA", "TEST", 186, 188], ["p", "TEST", 233, 234], ["birthweight z score", "TEST", 248, 267], ["RDS", "OBSERVATION", 10, 13], ["NEC", "OBSERVATION_MODIFIER", 43, 46], ["ROP", "OBSERVATION_MODIFIER", 48, 51], ["sepsis", "OBSERVATION", 66, 72], ["more prevalent", "OBSERVATION_MODIFIER", 78, 92]]], ["There were more cases of maternal hypertension in the non-EUGR group.", [["hypertension", "DISEASE", 34, 46], ["non-EUGR", "CANCER", 54, 62], ["maternal hypertension", "PROBLEM", 25, 46], ["hypertension", "OBSERVATION", 34, 46]]], ["RDS, treated PDA, IVH, NEC and ROP were more prevalent in the EUGR group.ResultsMultivariate logistic regression was conducted to find associated factors with EUGR.", [["RDS", "DISEASE", 0, 3], ["IVH", "DISEASE", 18, 21], ["NEC", "DISEASE", 23, 26], ["ROP", "DISEASE", 31, 34], ["EUGR", "CANCER", 62, 66], ["EUGR", "PROTEIN", 159, 163], ["RDS", "PROBLEM", 0, 3], ["PDA", "PROBLEM", 13, 16], ["IVH", "PROBLEM", 18, 21], ["NEC", "PROBLEM", 23, 26], ["ROP", "PROBLEM", 31, 34], ["PDA", "OBSERVATION_MODIFIER", 13, 16], ["IVH", "OBSERVATION", 18, 21], ["NEC", "OBSERVATION_MODIFIER", 23, 26]]], ["When EUGR was defined by decreased z score > 1 based on the Intergrowth charts, lower GA, higher birthweight z-score, male sex, high grade IVH, NEC and longer duration of parenteral nutrition (PN) were associated with EUGR (goodness of fit, p = 0.426) ( Table 5 ).", [["parenteral", "ANATOMY", 171, 181], ["IVH", "DISEASE", 139, 142], ["NEC", "DISEASE", 144, 147], ["decreased z score", "PROBLEM", 25, 42], ["lower GA", "PROBLEM", 80, 88], ["high grade IVH", "PROBLEM", 128, 142], ["NEC", "PROBLEM", 144, 147], ["parenteral nutrition (PN", "TREATMENT", 171, 195], ["EUGR", "TEST", 218, 222], ["high grade", "OBSERVATION_MODIFIER", 128, 138], ["IVH", "OBSERVATION", 139, 142], ["NEC", "OBSERVATION", 144, 147]]], ["When the same definition of EUGR was made by the Fenton charts, higher birthweight z score, treated PDA, and longer duration of PN were associated with EUGR (goodness of fit, p = 0.286).DiscussionThe present study explored the prevalence and associated factors of EUGR in extremely low GA infants.", [["EUGR", "DISEASE", 264, 268], ["infants", "ORGANISM", 289, 296], ["infants", "SPECIES", 289, 296], ["higher birthweight z score", "PROBLEM", 64, 90], ["PDA", "PROBLEM", 100, 103], ["PN", "TREATMENT", 128, 130], ["EUGR", "TEST", 152, 156], ["The present study", "TEST", 196, 213]]], ["EUGR defined as a > 1 decrease in z score in weight, length and HC as well as EUGR defined as <10th percentile at discharge in weight and length were more prevalent based on the Fenton charts.", [["weight", "TEST", 45, 51], ["length", "TEST", 53, 59], ["HC", "TEST", 64, 66], ["EUGR", "TEST", 78, 82], ["weight", "TEST", 127, 133], ["length", "TEST", 138, 144], ["decrease", "OBSERVATION_MODIFIER", 22, 30]]], ["When EUGR was defined as a > 1 decrease in z score in weight, the multivariate analysis showed that lower GA, higher birthweight z score, male sex, IVH, NEC, and longer duration of PN were associated with EUGR by the Intergrowth charts, whereas EUGR by the Fenton charts showed association with higher birthweight z score, treated PDA and longer duration of PN.DiscussionEUGR is a prevalent phenomenon during NICU stay in preterm infants.", [["IVH", "DISEASE", 148, 151], ["NEC", "DISEASE", 153, 156], ["Fenton", "CHEMICAL", 257, 263], ["infants", "ORGANISM", 430, 437], ["infants", "SPECIES", 430, 437], ["a > 1 decrease in z score in weight", "PROBLEM", 25, 60], ["the multivariate analysis", "TEST", 62, 87], ["lower GA", "PROBLEM", 100, 108], ["higher birthweight z score", "PROBLEM", 110, 136], ["IVH", "PROBLEM", 148, 151], ["NEC", "PROBLEM", 153, 156], ["PN", "TREATMENT", 181, 183], ["the Fenton charts", "TEST", 253, 270], ["higher birthweight z score", "PROBLEM", 295, 321], ["PDA", "PROBLEM", 331, 334], ["PN", "TREATMENT", 358, 360], ["IVH", "OBSERVATION", 148, 151], ["NEC", "OBSERVATION", 153, 156]]], ["Clark et al. defined EUGR as below the 10th percentile at the time of discharge according to an intrauterine growth chart and reported the incidence of EUGR in weight and length at discharge to be 28% and 34% among preterm infants born at 23-34 weeks GA [21] .", [["infants", "ORGANISM", 223, 230], ["infants", "SPECIES", 223, 230], ["EUGR", "TEST", 21, 25], ["length", "TEST", 171, 177]]], ["Vermont Oxford Network study reported that EUGR below the 10th percentile of weight by the Fenton growth chart occurred in half of VLBW infants [22] .", [["Fenton", "CHEMICAL", 91, 97], ["infants", "SPECIES", 136, 143]]], ["The definition of EUGR as the change in z scores also has been used, and a study using the Fenton chart reported the prevalence of EUGR during NICU admission in preterm infants born at GA of 22-32 weeks as 47% in 2005 and 38% in 2012 [4, 23] .", [["EUGR", "DISEASE", 131, 135], ["infants", "ORGANISM", 169, 176], ["infants", "SPECIES", 169, 176], ["the change in z scores", "PROBLEM", 26, 48], ["a study", "TEST", 73, 80]]], ["EUGR defined by the Fenton chart in the present study seemed higher than those reports, but the study population was less mature in our study compared with those in the aforementioned studies.DiscussionStudies comparing the Fenton and Intergrowth charts reported that EUGR for weight and length were less prevalent with the Intergrowth charts, as shown in the current study [24, 25] .", [["Fenton", "CHEMICAL", 20, 26], ["Fenton", "CHEMICAL", 224, 230], ["Fenton", "SIMPLE_CHEMICAL", 224, 230], ["the study population", "TEST", 92, 112], ["our study", "TEST", 132, 141], ["the aforementioned studies", "TEST", 165, 191], ["weight", "TEST", 277, 283], ["length", "TEST", 288, 294], ["the current study", "TEST", 356, 373]]], ["To evaluate the appropriateness of the growth charts in defining EUGR, the comparison of long-term outcomes should be required, which was not investigated in the previous studies or in our study either.", [["the previous studies", "TEST", 158, 178], ["our study", "TEST", 185, 194]]], ["Rather, noted factors or morbidities associated with growth restriction in preterm infants such as low GA, IVH and NEC were associated with EUGR when defined according to the Intergrowth charts, but when defined by the Fenton charts, although treated PDA was associated with EUGR, low GA, IVH and NEC were not associated with EUGR [4, 21] .", [["GA", "CHEMICAL", 103, 105], ["IVH", "DISEASE", 107, 110], ["NEC", "DISEASE", 115, 118], ["IVH", "DISEASE", 289, 292], ["NEC", "DISEASE", 297, 300], ["infants", "ORGANISM", 83, 90], ["infants", "SPECIES", 83, 90], ["morbidities", "PROBLEM", 25, 36], ["growth restriction in preterm infants", "PROBLEM", 53, 90], ["low GA", "PROBLEM", 99, 105], ["IVH", "PROBLEM", 107, 110], ["NEC", "PROBLEM", 115, 118], ["PDA", "PROBLEM", 251, 254], ["EUGR", "PROBLEM", 275, 279], ["low GA", "PROBLEM", 281, 287], ["IVH", "PROBLEM", 289, 292], ["NEC", "PROBLEM", 297, 300], ["IVH", "OBSERVATION", 107, 110], ["NEC", "OBSERVATION", 115, 118], ["IVH", "OBSERVATION", 289, 292]]], ["Linear regression analysis showed that NEC was associated with decreased weight z score at discharge by Fenton charts, but more factors were associated with EUGR when it was defined by the Intergrowth charts (Table S3) .DiscussionGrowth charts based on foetal growth standards or crosssectional size-at-birth measurements by GA should be used prudently because growth in utero and ex utero is not comparable due to different biological processes as well as environmental and nutritional aspects.", [["NEC", "DISEASE", 39, 42], ["GA", "CHEMICAL", 325, 327], ["foetal", "ORGANISM_SUBDIVISION", 253, 259], ["GA", "SIMPLE_CHEMICAL", 325, 327], ["Linear regression analysis", "TEST", 0, 26], ["NEC", "PROBLEM", 39, 42], ["decreased weight z score", "PROBLEM", 63, 87], ["growth in utero and ex utero", "PROBLEM", 361, 389], ["different biological processes", "PROBLEM", 415, 445], ["NEC", "OBSERVATION", 39, 42], ["size", "OBSERVATION_MODIFIER", 295, 299]]], ["There have been concerns on the overestimation of EUGR in preterm infants because efforts to avoid EUGR such as aggressive nutritional support could lead to unfavourable outcomes later in life including insulin resistance [26, 27] .", [["infants", "ORGANISM", 66, 73], ["insulin", "GENE_OR_GENE_PRODUCT", 203, 210], ["infants", "SPECIES", 66, 73], ["EUGR in preterm infants", "TREATMENT", 50, 73], ["EUGR", "TREATMENT", 99, 103], ["aggressive nutritional support", "TREATMENT", 112, 142], ["insulin resistance", "TEST", 203, 221]]], ["Intergrowth PPFS charts could be better standards for preterm infants because they were made during the postnatal period based on regular follow-up of preterm infants without adverse perinatal factors that could affect postnatal growth.", [["infants", "ORGANISM", 62, 69], ["infants", "ORGANISM", 159, 166], ["infants", "SPECIES", 62, 69], ["infants", "SPECIES", 159, 166], ["adverse perinatal factors", "PROBLEM", 175, 200], ["postnatal growth", "PROBLEM", 219, 235]]], ["As a result, the growth centiles in the PPFS charts were lower across the entire GA range than those in growth charts based on measurements at birth [9] .DiscussionThere are several limitations to our study.", [["the growth centiles", "TEST", 13, 32], ["the PPFS charts", "TEST", 36, 51], ["our study", "TEST", 197, 206]]], ["First, as only body sizes at birth and at discharge were registered in the database, information on growth patterns such as weight loss during first few days after birth and body sizes at specified timing (i.e. PMA 36 weeks) was not provided.", [["body", "ANATOMY", 15, 19], ["body", "ANATOMY", 174, 178], ["weight loss", "DISEASE", 124, 135], ["PMA", "CHEMICAL", 211, 214], ["body", "ORGANISM_SUBDIVISION", 15, 19], ["body", "ORGANISM_SUBDIVISION", 174, 178], ["weight loss", "PROBLEM", 124, 135], ["birth and body sizes", "TREATMENT", 164, 184]]], ["Moreover, a quarter of eligible infants with gestational age < 28 weeks were excluded because they died or were transferred to other hospitals [24, 25] .", [["infants", "ORGANISM", 32, 39], ["infants", "SPECIES", 32, 39]]], ["The other limitation was that long-term outcomes of growth and neurodevelopment were not investigated in the present study.", [["the present study", "TEST", 105, 122], ["long-term", "OBSERVATION_MODIFIER", 30, 39]]], ["Even though the prevalence of SGA and EUGR was changed by new growth charts, the more appropriate charts in extremely preterm infants could not be determined without long-term outcomes of the study population.", [["SGA", "DISEASE", 30, 33], ["infants", "ORGANISM", 126, 133], ["infants", "SPECIES", 126, 133], ["SGA", "PROBLEM", 30, 33], ["the study population", "TEST", 188, 208]]], ["However, this study analysed a large study population of nationwide registered data of preterm infants to evaluate the prevalence of EUGR and associated factors by the Fenton charts and the Intergrowth charts.ConclusionsEUGR of weight and length were less prevalent with the Intergrowth charts than with the Fenton charts.", [["EUGR", "DISEASE", 133, 137], ["Fenton", "CHEMICAL", 308, 314], ["infants", "ORGANISM", 95, 102], ["infants", "SPECIES", 95, 102], ["this study", "TEST", 9, 19], ["a large study", "TEST", 29, 42], ["nationwide registered data", "TEST", 57, 83], ["EUGR", "PROBLEM", 133, 137], ["weight", "TEST", 228, 234], ["length", "TEST", 239, 245], ["the Fenton charts", "TREATMENT", 304, 321]]], ["More morbidities associated with growth restriction of weight were found when EUGR is defined by the Intergrowth charts.", [["More morbidities", "PROBLEM", 0, 16], ["growth restriction of weight", "PROBLEM", 33, 61]]], ["Despite the differences between two charts, we cannot conclude that one tool is better than the other, and further validation of Intergrowth charts with long-term outcome studies for extremely low GA infants might be required.Compliance with ethical standardsConflict of interest The authors declare that they have no conflict of interest.", [["infants", "ORGANISM", 200, 207], ["infants", "SPECIES", 200, 207], ["outcome studies", "TEST", 163, 178], ["extremely low GA infants", "PROBLEM", 183, 207], ["ethical standards", "TREATMENT", 242, 259]]], ["Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.Compliance with ethical standardsInformed consent Informed consent was obtained from all individual participants included in the study.Compliance with ethical standardsAbbreviations EUGR, extrauterine growth restriction; NICU, Neonatal intensive care unit; AAP, American Academy of Pediatrics; PPFS, Preterm Postnatal Follow-up Study; KNN, Korean Neonatal Network; VLBW, very low birth weight; PMA, postmenstrual age; RDS, respiratory distress syndrome; BPD, bronchopulmonary dysplasia; NEC, necrotizing enterocolitis; IVH, intraventricular haemorrhage; ROP, retinopathy of prematurity; HC, Head circumference; PN, parenteral nutrition; PDA, patent ductus arteriosus; GA, gestational age; SGA, small for gestational age", [["bronchopulmonary dysplasia", "ANATOMY", 585, 611], ["intraventricular", "ANATOMY", 650, 666], ["parenteral", "ANATOMY", 741, 751], ["RDS", "DISEASE", 544, 547], ["respiratory distress syndrome", "DISEASE", 549, 578], ["BPD", "DISEASE", 580, 583], ["bronchopulmonary dysplasia", "DISEASE", 585, 611], ["NEC", "DISEASE", 613, 616], ["necrotizing enterocolitis", "DISEASE", 618, 643], ["IVH", "DISEASE", 645, 648], ["intraventricular haemorrhage", "DISEASE", 650, 678], ["ROP", "DISEASE", 680, 683], ["retinopathy of prematurity", "DISEASE", 685, 711], ["HC", "DISEASE", 713, 715], ["patent ductus arteriosus", "DISEASE", 768, 792], ["SGA", "DISEASE", 815, 818], ["human", "ORGANISM", 64, 69], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 585, 611], ["ductus arteriosus", "MULTI-TISSUE_STRUCTURE", 775, 792], ["human", "SPECIES", 64, 69], ["participants", "SPECIES", 70, 82], ["participants", "SPECIES", 226, 238], ["human", "SPECIES", 64, 69], ["Ethical approval", "TREATMENT", 0, 16], ["ethical standards", "TREATMENT", 142, 159], ["the study", "TEST", 251, 260], ["ethical standards", "TREATMENT", 277, 294], ["very low birth weight", "PROBLEM", 497, 518], ["RDS", "PROBLEM", 544, 547], ["respiratory distress syndrome", "PROBLEM", 549, 578], ["BPD", "PROBLEM", 580, 583], ["bronchopulmonary dysplasia", "PROBLEM", 585, 611], ["NEC", "PROBLEM", 613, 616], ["necrotizing enterocolitis", "PROBLEM", 618, 643], ["IVH", "PROBLEM", 645, 648], ["intraventricular haemorrhage", "PROBLEM", 650, 678], ["ROP", "PROBLEM", 680, 683], ["retinopathy", "PROBLEM", 685, 696], ["prematurity", "PROBLEM", 700, 711], ["PN", "TREATMENT", 737, 739], ["parenteral nutrition", "TREATMENT", 741, 761], ["PDA", "PROBLEM", 763, 766], ["patent ductus arteriosus", "PROBLEM", 768, 792], ["SGA", "PROBLEM", 815, 818], ["respiratory distress", "OBSERVATION", 549, 569], ["bronchopulmonary", "ANATOMY", 585, 601], ["dysplasia", "OBSERVATION", 602, 611], ["necrotizing", "OBSERVATION_MODIFIER", 618, 629], ["enterocolitis", "OBSERVATION", 630, 643], ["IVH", "OBSERVATION", 645, 648], ["intraventricular", "ANATOMY", 650, 666], ["haemorrhage", "OBSERVATION", 667, 678], ["retinopathy", "OBSERVATION", 685, 696], ["prematurity", "OBSERVATION", 700, 711], ["Head", "ANATOMY", 717, 721], ["patent", "OBSERVATION", 768, 774], ["ductus arteriosus", "ANATOMY", 775, 792], ["small", "OBSERVATION_MODIFIER", 820, 825]]]]}